02055000000000409000450099100020000070000020000270600020000470100020000609100090
00081300025000174210018000421510019000602300025000790350010001044800056001140300
01900170930000400189117000800193085000500201935001000206032000600216036000700222
04200020022920000020023106500090023312200030024204800140024504800140025904800240
02730430052002970430052003490430052004015400388004535400402008415400396012435410
00601639#1#0#i#1#20110408#Revista de Saúde Pública#Rev Saude Publica#Rev. saúde 
pública#Journal of Public Health#0034-8910#Faculdade de Saúde Pública da Univers
idade de São Paulo#Rev. Saúde Pública#RSP#vancouv#decs#0034-8910#ahead#201150#1#
0#20110000#23#^les^hSumario#^lpt^hSumário#^len^hTable of Contents#^les^tRev. Saú
de Pública^nno.ahead^cSão Paulo^a2011#^lpt^tRev. Saúde Pública^nno.ahead^cSão Pa
ulo^a2011#^len^tRev. Saúde Pública^nno.ahead^cSão Paulo^a2011#^t<a rel="license"
 href="http://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Common
s License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/
80x15.png" /></a> Todo el contenido de esta revista, excepto dónde está identifi
cado, est&#225; bajo una <a rel="license" href="http://creativecommons.org/licen
ses/by-nc/3.0/">Licencia Creative Commons</a>^les#^t<a rel="license" href="http:
//creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons License" s
tyle="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80x15.png" /
></a> Todo o conteúdo deste periódico, exceto onde est&#225 identificado, est&#2
25; licenciado sob uma <a rel="license" href="http://creativecommons.org/license
s/by-nc/3.0/">Licen&#231;a Creative Commons</a>^lpt#^t<a rel="license" href="htt
p://creativecommons.org/licenses/by-nc/3.0/"><img alt="Creative Commons License"
 style="border-width:0" src="http://i.creativecommons.org/l/by-nc/3.0/80x15.png"
 /></a> All the contents of this journal, except where otherwise noted, is licen
sed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc/3.0
/">Creative Commons Attribution License</a>^len#BY-NC##
00276000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00400102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#o#1#1#arti
cle#1#20110321#104726#2036.htm#162##
07205000000000733000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000400095121000300099049000300102158000300105030001900108
03200060012706500090013301400070014203500100014922300090015901200920016801201010
02600120087003610100031004480100035004790100039005140100042005530700130005950700
05500725070008900780070009300869083158800962085001002550085004302560085003002603
08500380263308500460267108316960271708500100441308500420442308500260446508500340
44910850040045250831677045650850010062420850044062520850030062960850039063260850
04706365117000806412072000306420112000906423111001006432114000906442113001106451
002000906462#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#h#2#1#
article#1#oa#pt#br1.1#1#4.0#TAB#14#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l
0#0034-8910#20110325#Estudo exploratório de custos e conseqüências do pré-natal 
no Programa Saúde da Família^lpt#An exploratory study of the costs and consequen
ces of prenatal care in the Family Health Program^len#Estudio exploratorio de co
stos y consecuencias del prenatal en Salud de la Familia^les#^rND^1A01^nSuely Ar
ruda^sVidal#^rND^1A01^nIsabella Chagas^sSamico#^rND^1A02 A03^nPaulo Germano de^s
Frias#^rND^1A04^nZulmira Maria de Araújo^sHartz#Instituto de Medicina Integral P
rof. Fernando Figueira^iA01^1Grupo de Pesquisa de Gestão e Avaliação em Saúde^cR
ecife^sPE^pBrasil#Secretaria de Saúde do Recife^iA02^cRecife^sPE^pBrasil#Univers
idade Federal de Pernambuco^iA03^1Centro de Ciências da Saúde^cRecife^sPE^pBrasi
l#Universidade Nova de Lisboa^iA04^1Instituto de Higiene e Medicina Tropical^cLi
sboa^pPortugal#^lpt^aOBJETIVO: Avaliar custos e conseqüências da assistência pré
-natal na morbimortalidade perinatal. MÉTODOS: Estudo avaliativo com dois tipos 
de análise - de implantação e de eficiência, realizado em 11 Unidades de Saúde d
a Família do Recife, PE, em 2006. Os custos foram apurados pela técnica activity
-based costing e a razão de custo-efetividade foi calculada para cada conseqüênc
ia. As fontes de dados foram sistemas de informação do Ministério da Saúde e pla
nilhas de custos da Secretaria de Saúde do Recife e do Instituto de Medicina Int
egral Prof. Fernando Figueira. As unidades de saúde com pré-natal implantado ou 
parcial foram comparadas quanto ao seu custo-efetividade e resultados perinatais
. RESULTADOS: Em 64% das unidades, o pré-natal estava implantado com custo médio
 total de R$ 39.226,88 e variação de R$ 3.841,87 a R$ 8.765,02 por Unidade de Sa
úde. Nas unidades parcialmente implantadas (36%), o custo médio total foi de R$ 
30.092,61 (R$ 4.272,12 a R$ 11.774,68). O custo médio por gestante foi de R$ 196
,13 com pré-natal implantado e R$ 150,46 no parcial. Encontrou-se maior proporçã
o de baixo peso ao nascer, sífilis congênita, óbitos perinatais e fetais no grup
o parcialmente implantado. CONCLUSÕES: Pré-natal é custo-efetivo para várias con
seqüências estudadas. Os efeitos adversos medidos pelos indicadores de saúde for
am menores nas unidades com pré-natal implantado. O custo médio no grupo parcial
mente implantado foi mais elevado, sugerindo possível desperdício de recursos, u
ma vez que a produtividade das equipes é insuficiente para a capacidade instalad
a.#^ddecs^i1#^tm^lpt^kAvaliação de Custo-Efetividade^i1#^tm^lpt^kCuidado Pré-Nat
al^i1#^tm^lpt^kPrograma Saúde da Família^i1#^tm^lpt^kEstudos de Avaliação como A
ssunto^i1#^len^aOBJECTIVE: To assess costs and consequences of prenatal care on 
perinatal morbidity and mortality. METHODS: Evaluation study using two types of 
analysis: implementation and efficiency analysis, carried out at 11 Family Healt
h Units in the Recife, Northeastern Brazil, in 2006. The costs were calculated b
y means of the activity-based costing technique and the cost-effectiveness ratio
 was calculated for each consequence. Data sources were information systems of t
he Ministry of Health and worksheets of costs provided by the Health Department 
of Recife and Instituto de Medicina Integral Prof. Fernando Figueira. Healthcare
 units with implemented or partially implemented prenatal care were compared in 
terms of their cost-effectiveness and perinatal results. RESULTS: In 64% of the 
units, prenatal care was implemented with a mean total cost of R$ 39,226.88 and 
variation of R$ 3,841,87 to R$ 8,765.02 per healthcare unit. In the units with p
artially implemented prenatal care (36%), the mean total cost was R$ 30,092.61 (
R$ 4,272.12 to R$ 11,774.68). The mean cost per pregnant woman was R$ 196.13 wit
h implemented prenatal care and R$ 150.46 with partially implemented prenatal ca
re. A higher proportion of low birth weight, congenital syphilis, perinatal and 
fetal deaths was found in the partially implemented group. CONCLUSIONS: Prenatal
 care is cost-effective for several studied consequences. The adverse effects me
asured by the health indicators were lower in the units with implemented prenata
l care. The mean cost in the partially implemented group was higher, which sugge
sts a possible waste of resources, as the teams' productivity is insufficient fo
r the installed capacity.#^ddecs^i2#^tm^len^kCost-Effectiveness Evaluation^i2#^t
m^len^kPrenatal Care^i2#^tm^len^kFamily Health Program^i2#^tm^len^kEvaluation St
udies as Topic^i2#^les^aOBJETIVO: Evaluar costos y consecuencias de la asistenci
a prenatal en la morbimortalidad perinatal. MÉTODOS: Estudio evaluativo con dos 
tipos de análisis: de implantación y de eficiencia, realizado en 11 Unidades de 
Salud de la Familia de Recife, Sureste de Brasil, en 2006. Los costos fueron mej
orados por la técnica activity-based costing y la razón de costo-efectividad fue
 calculada para cada consecuencia. Las fuentes de datos fueron sistemas de infor
mación del Ministerio de la Salud y planillas de costos de la Secretaria de la S
alud de Recife y del Instituto de Medicina Integral Prof. Fernando Figueira. Las
 unidades de salud con prenatal implantado o parcial fueron comparadas con relac
ión a su costo-efectividad y resultados perinatales. RESULTADOS: En 64% de las u
nidades, el prenatal estaba implantado con costo promedio total de R$ 39.226,88 
y variación de R$ 3.841,87 a R$ 8.765,02 por unidad de salud. En las unidades pa
rcialmente implantadas (36%), el costo promedio total fue de R$ 30.092,61 (R$ 4.
272,12 a R$ 11.774,68). El costo promedio por gestante fue de R$ 196,13 con pren
atal implantado y R$ 150,46 en el parcial. Se encontró mayor proporción de bajo 
peso al nacer, sífilis congénita, óbitos perinatales y fetales en el grupo parci
almente implantado. CONCLUSIONES: El prenatal es costo-efectivo para varias cons
ecuencias estudiadas. Los efectos adversos medidos por los indicadores de salud 
fueron menores en las unidades con prenatal implantado. El costo promedio en el 
grupo parcialmente implantado fue más elevado, sugiriendo posible desperdicio de
 recursos, dado que la productividad de los equipos es suficiente para la capaci
dad instalada.#^ddecs^i3#^tm^les^kAvaliación de Costo-Efectividad^i3#^tm^les^kAt
ención Prenatal^i3#^tm^les^kPrograma de Salud Familiar^i3#^tm^les^kEstudios de E
valuación como Asunto^i3#vancouv#21#20100218#18/2/2010#20101018#18/10/2010#2036.
htm##
07317000000000733000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000400095121000300099049000300102158000300105030001900108
03200060012706500090013301400070014203500100014922300090015901200990016801201080
02670120094003750100031004690100035005000100039005350100042005740700130006160700
05500746070008900801070009300890083161600983085001002599085004302609085003002652
08500380268208500460272008317240276608500100449008500420450008500260454208500340
45680850040046020831712046420850010063540850044063640850030064080850039064380850
04706477117000806524072000306532112000906535111001006544114000906554113001106563
002000906574#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#f#3#1#
article#1#oa#pt#br1.1#1#4.0#TAB#14#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l
0#0034-8910#20110325#<b>Estudo exploratório de custos e conseqüências do pré-nat
al no Programa Saúde da Família</b>^lpt#<b>An exploratory study of the costs and
 consequences of prenatal care in the Family Health Program</b>^len#<b>Estudio e
xploratorio de costos y consecuencias del prenatal en Salud de la Familia</b>^le
s#^rND^1A01^nSuely Arruda^sVidal#^rND^1A01^nIsabella Chagas^sSamico#^rND^1A02 A0
3^nPaulo Germano de^sFrias#^rND^1A04^nZulmira Maria de Araújo^sHartz#Instituto d
e Medicina Integral Prof. Fernando Figueira^iA01^1Grupo de Pesquisa de Gestão e 
Avaliação em Saúde^cRecife^sPE^pBrasil#Secretaria de Saúde do Recife^iA02^cRecif
e^sPE^pBrasil#Universidade Federal de Pernambuco^iA03^1Centro de Ciências da Saú
de^cRecife^sPE^pBrasil#Universidade Nova de Lisboa^iA04^1Instituto de Higiene e 
Medicina Tropical^cLisboa^pPortugal#^lpt^a<b>OBJETIVO:</b> Avaliar custos e cons
eqüências da assistência pré-natal na morbimortalidade perinatal. <b>MÉTODOS:</b
> Estudo avaliativo com dois tipos de análise - de implantação e de eficiência, 
realizado em 11 Unidades de Saúde da Família do Recife, PE, em 2006. Os custos f
oram apurados pela técnica activity-based costing e a razão de custo-efetividade
 foi calculada para cada conseqüência. As fontes de dados foram sistemas de info
rmação do Ministério da Saúde e planilhas de custos da Secretaria de Saúde do Re
cife e do Instituto de Medicina Integral Prof. Fernando Figueira. As unidades de
 saúde com pré-natal implantado ou parcial foram comparadas quanto ao seu custo-
efetividade e resultados perinatais. <b>RESULTADOS:</b> Em 64% das unidades, o p
ré-natal estava implantado com custo médio total de R$ 39.226,88 e variação de R
$ 3.841,87 a R$ 8.765,02 por Unidade de Saúde. Nas unidades parcialmente implant
adas (36%), o custo médio total foi de R$ 30.092,61 (R$ 4.272,12 a R$ 11.774,68)
. O custo médio por gestante foi de R$ 196,13 com pré-natal implantado e R$ 150,
46 no parcial. Encontrou-se maior proporção de baixo peso ao nascer, sífilis con
gênita, óbitos perinatais e fetais no grupo parcialmente implantado. <b>CONCLUSÕ
ES:</b> Pré-natal é custo-efetivo para várias conseqüências estudadas. Os efeito
s adversos medidos pelos indicadores de saúde foram menores nas unidades com pré
-natal implantado. O custo médio no grupo parcialmente implantado foi mais eleva
do, sugerindo possível desperdício de recursos, uma vez que a produtividade das 
equipes é insuficiente para a capacidade instalada.#^ddecs^i1#^tm^lpt^kAvaliação
 de Custo-Efetividade^i1#^tm^lpt^kCuidado Pré-Natal^i1#^tm^lpt^kPrograma Saúde d
a Família^i1#^tm^lpt^kEstudos de Avaliação como Assunto^i1#^len^a<b>OBJECTIVE:</
b> To assess costs and consequences of prenatal care on perinatal morbidity and 
mortality. <b>METHODS:</b> Evaluation study using two types of analysis: impleme
ntation and efficiency analysis, carried out at 11 Family Health Units in the Re
cife, Northeastern Brazil, in 2006. The costs were calculated by means of the ac
tivity-based costing technique and the cost-effectiveness ratio was calculated f
or each consequence. Data sources were information systems of the Ministry of He
alth and worksheets of costs provided by the Health Department of Recife and Ins
tituto de Medicina Integral Prof. Fernando Figueira. Healthcare units with imple
mented or partially implemented prenatal care were compared in terms of their co
st-effectiveness and perinatal results. <b>RESULTS:</b> In 64% of the units, pre
natal care was implemented with a mean total cost of R$ 39,226.88 and variation 
of R$ 3,841,87 to R$ 8,765.02 per healthcare unit. In the units with partially i
mplemented prenatal care (36%), the mean total cost was R$ 30,092.61 (R$ 4,272.1
2 to R$ 11,774.68). The mean cost per pregnant woman was R$ 196.13 with implemen
ted prenatal care and R$ 150.46 with partially implemented prenatal care. A high
er proportion of low birth weight, congenital syphilis, perinatal and fetal deat
hs was found in the partially implemented group. <b>CONCLUSIONS:</b> Prenatal ca
re is cost-effective for several studied consequences. The adverse effects measu
red by the health indicators were lower in the units with implemented prenatal c
are. The mean cost in the partially implemented group was higher, which suggests
 a possible waste of resources, as the teams' productivity is insufficient for t
he installed capacity.#^ddecs^i2#^tm^len^kCost-Effectiveness Evaluation^i2#^tm^l
en^kPrenatal Care^i2#^tm^len^kFamily Health Program^i2#^tm^len^kEvaluation Studi
es as Topic^i2#^les^a<b>OBJETIVO:</b> Evaluar costos y consecuencias de la asist
encia prenatal en la morbimortalidad perinatal. <b>MÉTODOS: </b>Estudio evaluati
vo con dos tipos de análisis: de implantación y de eficiencia, realizado en 11 U
nidades de Salud de la Familia de Recife, Sureste de Brasil, en 2006. Los costos
 fueron mejorados por la técnica <i>activity-based costing</i> y la razón de cos
to-efectividad fue calculada para cada consecuencia. Las fuentes de datos fueron
 sistemas de información del Ministerio de la Salud y planillas de costos de la 
Secretaria de la Salud de Recife y del Instituto de Medicina Integral Prof. Fern
ando Figueira. Las unidades de salud con prenatal implantado o parcial fueron co
mparadas con relación a su costo-efectividad y resultados perinatales. <b>RESULT
ADOS: </b>En 64% de las unidades, el prenatal estaba implantado con costo promed
io total de R$ 39.226,88 y variación de R$ 3.841,87 a R$ 8.765,02 por unidad de 
salud. En las unidades parcialmente implantadas (36%), el costo promedio total f
ue de R$ 30.092,61 (R$ 4.272,12 a R$ 11.774,68). El costo promedio por gestante 
fue de R$ 196,13 con prenatal implantado y R$ 150,46 en el parcial. Se encontró 
mayor proporción de bajo peso al nacer, sífilis congénita, óbitos perinatales y 
fetales en el grupo parcialmente implantado. <b>CONCLUSIONES: </b>El prenatal es
 costo-efectivo para varias consecuencias estudiadas. Los efectos adversos medid
os por los indicadores de salud fueron menores en las unidades con prenatal impl
antado. El costo promedio en el grupo parcialmente implantado fue más elevado, s
ugiriendo posible desperdicio de recursos, dado que la productividad de los equi
pos es suficiente para la capacidad instalada.#^ddecs^i3#^tm^les^kAvaliación de 
Costo-Efectividad^i3#^tm^les^kAtención Prenatal^i3#^tm^les^kPrograma de Salud Fa
miliar^i3#^tm^les^kEstudios de Evaluación como Asunto^i3#vancouv#21#20100218#18/
2/2010#20101018#18/10/2010#2036.htm##
07385000000000757000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098038000400102121000300106049000300109158000300112
03000190011503200060013406500090014001400070014903500100015622300090016601200920
01750120101002670120087003680100031004550100035004860100039005210100042005600700
13200602070005700734070009100791070009500882083160600977085001002583085004302593
08500300263608500380266608500460270408317100275008500100446008500420447008500260
45120850034045380850040045720831697046120850010063090850044063190850030063630850
03906393085004706432117000806479072000306487112000906490111001006499114000906509
113001106518002000906529008008906538#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2036.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#tab#14#nd#nd#Rev. saú
de pública#ahead#20110000#^f0^l0#0034-8910#20110325#Estudo exploratório de custo
s e conseqüências do pré-natal no Programa Saúde da Família^lpt#An exploratory s
tudy of the costs and consequences of prenatal care in the Family Health Program
^len#Estudio exploratorio de costos y consecuencias del prenatal en Salud de la 
Familia^les#^rND^1A01^nSuely Arruda^sVidal#^rND^1A01^nIsabella Chagas^sSamico#^r
ND^1A02 A03^nPaulo Germano de^sFrias#^rND^1A04^nZulmira Maria de Araújo^sHartz#^
iA01^1Instituto de Medicina Integral Prof. Fernando Figueira^2Grupo de Pesquisa 
de Gestão e Avaliação em Saúde^cRecife^sPE^pBrasil#^iA02^1Secretaria de Saúde do
 Recife^cRecife^sPE^pBrasil#^iA03^1Universidade Federal de Pernambuco^2Centro de
 Ciências da Saúde^cRecife^sPE^pBrasil#^iA04^1Universidade Nova de Lisboa^2Insti
tuto de Higiene e Medicina Tropical^cLisboa^pPortugal#^lpt^aOBJETIVO: Avaliar cu
stos e conseqüências da assistência pré-natal na morbimortalidade perinatal. MÉT
ODOS: Estudo avaliativo com dois tipos de análise - de implantação e de eficiênc
ia, realizado em 11 Unidades de Saúde da Família do Recife, PE, em 2006. Os cust
os foram apurados pela técnica activity-based costing e a razão de custo-efetivi
dade foi calculada para cada conseqüência. As fontes de dados foram sistemas de 
informação do Ministério da Saúde e planilhas de custos da Secretaria de Saúde d
o Recife e do Instituto de Medicina Integral Prof. Fernando Figueira. As unidade
s de saúde com pré-natal implantado ou parcial foram comparadas quanto ao seu cu
sto-efetividade e resultados perinatais. RESULTADOS: Em 64 por cento das unidade
s, o pré-natal estava implantado com custo médio total de R$ 39.226,88 e variaçã
o de R$ 3.841,87 a R$ 8.765,02 por Unidade de Saúde. Nas unidades parcialmente i
mplantadas (36 por cento), o custo médio total foi de R$ 30.092,61 (R$ 4.272,12 
a R$ 11.774,68). O custo médio por gestante foi de R$ 196,13 com pré-natal impla
ntado e R$ 150,46 no parcial. Encontrou-se maior proporção de baixo peso ao nasc
er, sífilis congênita, óbitos perinatais e fetais no grupo parcialmente implanta
do. CONCLUSÕES: Pré-natal é custo-efetivo para várias conseqüências estudadas. O
s efeitos adversos medidos pelos indicadores de saúde foram menores nas unidades
 com pré-natal implantado. O custo médio no grupo parcialmente implantado foi ma
is elevado, sugerindo possível desperdício de recursos, uma vez que a produtivid
ade das equipes é insuficiente para a capacidade instalada.#^ddecs^i1#^tm^lpt^kA
valiação de Custo-Efetividade^i1#^tm^lpt^kCuidado Pré-Natal^i1#^tm^lpt^kPrograma
 Saúde da Família^i1#^tm^lpt^kEstudos de Avaliação como Assunto^i1#^len^aOBJECTI
VE: To assess costs and consequences of prenatal care on perinatal morbidity and
 mortality. METHODS: Evaluation study using two types of analysis: implementatio
n and efficiency analysis, carried out at 11 Family Health Units in the Recife, 
Northeastern Brazil, in 2006. The costs were calculated by means of the activity
-based costing technique and the cost-effectiveness ratio was calculated for eac
h consequence. Data sources were information systems of the Ministry of Health a
nd worksheets of costs provided by the Health Department of Recife and Instituto
 de Medicina Integral Prof. Fernando Figueira. Healthcare units with implemented
 or partially implemented prenatal care were compared in terms of their cost-eff
ectiveness and perinatal results. RESULTS: In 64 percent of the units, prenatal 
care was implemented with a mean total cost of R$ 39,226.88 and variation of R$ 
3,841,87 to R$ 8,765.02 per healthcare unit. In the units with partially impleme
nted prenatal care (36 percent), the mean total cost was R$ 30,092.61 (R$ 4,272.
12 to R$ 11,774.68). The mean cost per pregnant woman was R$ 196.13 with impleme
nted prenatal care and R$ 150.46 with partially implemented prenatal care. A hig
her proportion of low birth weight, congenital syphilis, perinatal and fetal dea
ths was found in the partially implemented group. CONCLUSIONS: Prenatal care is 
cost-effective for several studied consequences. The adverse effects measured by
 the health indicators were lower in the units with implemented prenatal care. T
he mean cost in the partially implemented group was higher, which suggests a pos
sible waste of resources, as the teams' productivity is insufficient for the ins
talled capacity.#^ddecs^i2#^tm^len^kCost-Effectiveness Evaluation^i2#^tm^len^kPr
enatal Care^i2#^tm^len^kFamily Health Program^i2#^tm^len^kEvaluation Studies as 
Topic^i2#^les^aOBJETIVO: Evaluar costos y consecuencias de la asistencia prenata
l en la morbimortalidad perinatal. MÉTODOS: Estudio evaluativo con dos tipos de 
análisis: de implantación y de eficiencia, realizado en 11 Unidades de Salud de 
la Familia de Recife, Sureste de Brasil, en 2006. Los costos fueron mejorados po
r la técnica activity-based costing y la razón de costo-efectividad fue calculad
a para cada consecuencia. Las fuentes de datos fueron sistemas de información de
l Ministerio de la Salud y planillas de costos de la Secretaria de la Salud de R
ecife y del Instituto de Medicina Integral Prof. Fernando Figueira. Las unidades
 de salud con prenatal implantado o parcial fueron comparadas con relación a su 
costo-efectividad y resultados perinatales. RESULTADOS: En 64 por ciento de las 
unidades, el prenatal estaba implantado con costo promedio total de R$ 39.226,88
 y variación de R$ 3.841,87 a R$ 8.765,02 por unidad de salud. En las unidades p
arcialmente implantadas (36 por ciento), el costo promedio total fue de R$ 30.09
2,61 (R$ 4.272,12 a R$ 11.774,68). El costo promedio por gestante fue de R$ 196,
13 con prenatal implantado y R$ 150,46 en el parcial. Se encontró mayor proporci
ón de bajo peso al nacer, sífilis congénita, óbitos perinatales y fetales en el 
grupo parcialmente implantado. CONCLUSIONES: El prenatal es costo-efectivo para 
varias consecuencias estudiadas. Los efectos adversos medidos por los indicadore
s de salud fueron menores en las unidades con prenatal implantado. El costo prom
edio en el grupo parcialmente implantado fue más elevado, sugiriendo posible des
perdicio de recursos, dado que la productividad de los equipos es suficiente par
a la capacidad instalada.#^ddecs^i3#^tm^les^kAvaliación de Costo-Efectividad^i3#
^tm^les^kAtención Prenatal^i3#^tm^les^kPrograma de Salud Familiar^i3#^tm^les^kEs
tudios de Evaluación como Asunto^i3#vancouv#21#20100218#18/2/2010#20101018#18/10
/2010#2036.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=
S0034-89102011005000014##
00474000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704024000079002000900319#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#5#1#article#137#<p><a name="top"
></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Estudo    ex
plorat&oacute;rio de custos e conseq&uuml;&ecirc;ncias do pr&eacute;-natal    no
 Programa Sa&uacute;de da Fam&iacute;lia</b></font></p>     ^cY#2036.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#6#2#article#137#<p>&nbsp;</p>   
  ^cY#2036.htm##
00409000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704017500079002000900254#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#7#3#article#137#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Estudio exploratorio    de cos
tos y consecuencias del prenatal en Salud de la Familia</b></font></p>     ^cY#2
036.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#8#4#article#137#<p>&nbsp;</p>   
  ^cY#2036.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#9#5#article#137#<p>&nbsp;</p>   
  ^cY#2036.htm##
00490000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704025500080002000900335#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#10#6#article#137#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Suely Arruda    Vidal<sup>I</
sup>; Isabella Chagas Samico<sup>I</sup>; Paulo Germano de Frias<sup>II,    III<
/sup>; Zulmira Maria de Ara&uacute;jo Hartz<sup>IV</sup></b></font></p>     ^cY#
2036.htm##
00476000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704024100080002000900321#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#11#7#article#137#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Grupo    de Pesquisa
 de Gest&atilde;o e Avalia&ccedil;&atilde;o em Sa&uacute;de. Instituto    de Med
icina Integral Prof. Fernando Figueira. Recife, PE, Brasil    ^cY#2036.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704008400080002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#12#8#article#137#<br>   <sup>II<
/sup>Secretaria de Sa&uacute;de do Recife. Recife, PE, Brasil    ^cY#2036.htm##
00465000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704023000080002000900310#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#13#9#article#137#<br>   <sup>III
</sup>Programa de P&oacute;s-Gradua&ccedil;&atilde;o em Sa&uacute;de    da Crian
&ccedil;a e do Adolescente. Centro de Ci&ecirc;ncias da Sa&uacute;de.    Univers
idade Federal de Pernambuco. Recife, PE, Brasil    ^cY#2036.htm##
00366000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704013000081002000900211#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#14#10#article#137#<br>   <sup>IV
</sup>Instituto de Higiene e Medicina Tropical. Universidade Nova de    Lisboa. 
Lisboa, Portugal</font></p>     ^cY#2036.htm##
00380000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014400081002000900225#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#15#11#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecir
c;ncia    | Correspondence</a></font></p>     ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#16#12#article#137#<p>&nbsp;</p> 
    ^cY#2036.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704004400081002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#17#13#article#137#<p>&nbsp;</p> 
<hr size="1" noshade>     ^cY#2036.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#18#14#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^c
Y#2036.htm##
00440000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020400081002000900285#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#19#15#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Avaliar cus
tos e conseq&uuml;&ecirc;ncias da assist&ecirc;ncia pr&eacute;-natal    na morbi
mortalidade perinatal.    ^cY#2036.htm##
01010000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704077400081002000900855#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#20#16#article#137#<br>   <b>M&Ea
cute;TODOS:</b> Estudo avaliativo com dois tipos de an&aacute;lise -    de impla
nta&ccedil;&atilde;o e de efici&ecirc;ncia, realizado em 11 Unidades    de Sa&ua
cute;de da Fam&iacute;lia do Recife, PE, em 2006. Os custos foram apurados    pe
la t&eacute;cnica activity-based costing e a raz&atilde;o de custo-efetividade  
  foi calculada para cada conseq&uuml;&ecirc;ncia. As fontes de dados foram sist
emas    de informa&ccedil;&atilde;o do Minist&eacute;rio da Sa&uacute;de e plani
lhas    de custos da Secretaria de Sa&uacute;de do Recife e do Instituto de Medi
cina    Integral Prof. Fernando Figueira. As unidades de sa&uacute;de com pr&eac
ute;-natal    implantado ou parcial foram comparadas quanto ao seu custo-efetivi
dade e resultados    perinatais.    ^cY#2036.htm##
00873000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704063700081002000900718#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#21#17#article#137#<br>   <b>RESU
LTADOS:</b> Em 64% das unidades, o pr&eacute;-natal estava implantado    com cus
to m&eacute;dio total de R$ 39.226,88 e varia&ccedil;&atilde;o de R$    3.841,87
 a R$ 8.765,02 por Unidade de Sa&uacute;de. Nas unidades parcialmente    implant
adas (36%), o custo m&eacute;dio total foi de R$ 30.092,61 (R$ 4.272,12    a R$ 
11.774,68). O custo m&eacute;dio por gestante foi de R$ 196,13 com pr&eacute;-na
tal    implantado e R$ 150,46 no parcial. Encontrou-se maior propor&ccedil;&atil
de;o    de baixo peso ao nascer, s&iacute;filis cong&ecirc;nita, &oacute;bitos p
erinatais    e fetais no grupo parcialmente implantado.    ^cY#2036.htm##
00741000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704050500081002000900586#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#22#18#article#137#<br>   <b>CONC
LUS&Otilde;ES:</b> Pr&eacute;-natal &eacute; custo-efetivo para v&aacute;rias   
 conseq&uuml;&ecirc;ncias estudadas. Os efeitos adversos medidos pelos indicador
es    de sa&uacute;de foram menores nas unidades com pr&eacute;-natal implantado
.    O custo m&eacute;dio no grupo parcialmente implantado foi mais elevado, sug
erindo    poss&iacute;vel desperd&iacute;cio de recursos, uma vez que a produtiv
idade    das equipes &eacute; insuficiente para a capacidade instalada.</font></
p>     ^cY#2036.htm##
00532000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704029600081002000900377#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#23#19#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> Avalia&
ccedil;&atilde;o de Custo-Efetividade. Cuidado Pr&eacute;-Natal.    Programa Sa&
uacute;de da Fam&iacute;lia. Estudos de Avalia&ccedil;&atilde;o    como Assunto.
</font></p> <hr size="1" noshade>     ^cY#2036.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#24#20#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^
cY#2036.htm##
00419000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018300081002000900264#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#25#21#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Evaluar cos
tos y consecuencias de la asistencia prenatal en la morbimortalidad    perinatal
.    ^cY#2036.htm##
00987000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704075100081002000900832#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#26#22#article#137#<br>   <b>M&Ea
cute;TODOS: </b> Estudio evaluativo con dos tipos de an&aacute;lisis:    de impl
antaci&oacute;n y de eficiencia, realizado en 11 Unidades de Salud de    la Fami
lia de Recife, Sureste de Brasil, en 2006. Los costos fueron mejorados    por la
 t&eacute;cnica <i>activity-based costing</i> y la raz&oacute;n de costo-efectiv
idad    fue calculada para cada consecuencia. Las fuentes de datos fueron sistem
as de    informaci&oacute;n del Ministerio de la Salud y planillas de costos de 
la Secretaria    de la Salud de Recife y del Instituto de Medicina Integral Prof
. Fernando Figueira.    Las unidades de salud con prenatal implantado o parcial 
fueron comparadas con    relaci&oacute;n a su costo-efectividad y resultados per
inatales.    ^cY#2036.htm##
00848000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704061200081002000900693#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#27#23#article#137#<br>   <b>RESU
LTADOS: </b> En 64% de las unidades, el prenatal estaba implantado con    costo 
promedio total de R$ 39.226,88 y variaci&oacute;n de R$ 3.841,87 a R$    8.765,0
2 por unidad de salud. En las unidades parcialmente implantadas (36%),    el cos
to promedio total fue de R$ 30.092,61 (R$ 4.272,12 a R$ 11.774,68). El    costo 
promedio por gestante fue de R$ 196,13 con prenatal implantado y R$ 150,46    en
 el parcial. Se encontr&oacute; mayor proporci&oacute;n de bajo peso al nacer,  
  s&iacute;filis cong&eacute;nita, &oacute;bitos perinatales y fetales en el gru
po    parcialmente implantado.    ^cY#2036.htm##
00687000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704045100081002000900532#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#28#24#article#137#<br>   <b>CONC
LUSIONES: </b> El prenatal es costo-efectivo para varias consecuencias    estudi
adas. Los efectos adversos medidos por los indicadores de salud fueron    menore
s en las unidades con prenatal implantado. El costo promedio en el grupo    parc
ialmente implantado fue m&aacute;s elevado, sugiriendo posible desperdicio    de
 recursos, dado que la productividad de los equipos es suficiente para la    cap
acidad instalada.</font></p>     ^cY#2036.htm##
00505000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704026900081002000900350#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#29#25#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:    </b> Avalia
ci&oacute;n de Costo-Efectividad. Atenci&oacute;n Prenatal. Programa    de Salud
 Familiar. Estudios de Evaluaci&oacute;n como Asunto.</font></p> <hr size="1" no
shade>     ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#30#26#article#137#<p>&nbsp;</p> 
    ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#31#27#article#137#<p>&nbsp;</p> 
    ^cY#2036.htm##
00350000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011400081002000900195#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#32#28#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b>
</font></p>     ^cY#2036.htm##
00577000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034100081002000900422#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#33#29#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A economia da sa&uacute;de    a
valia a rela&ccedil;&atilde;o entre os custos e os efeitos de diferentes interve
n&ccedil;&otilde;es    para determinar a mais eficiente, que ofere&ccedil;a melh
or rendimento e aloca&ccedil;&atilde;o    dos recursos.<sup>4</sup></font></p>  
   ^cY#2036.htm##
01118000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704088200081002000900963#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#34#30#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Esse tipo de avalia&ccedil;&ati
lde;o    na &aacute;rea da sa&uacute;de j&aacute; foi alvo de cr&iacute;tica na 
d&eacute;cada    de 1970-80, como um artif&iacute;cio para racionamento de despe
sa. Entretanto,    segundo Hartz &amp; Pouvourville,<sup>14</sup> o processo de 
racionaliza&ccedil;&atilde;o    de custos tem outras aplica&ccedil;&otilde;es e 
seus resultados podem evitar    o subfinanciamento de algumas a&ccedil;&otilde;e
s, considerando seus efeitos.    &Eacute; necess&aacute;rio que se promova a efi
ci&ecirc;ncia dos recursos p&uacute;blicos,    por princ&iacute;pio de justi&cce
dil;a, e isso n&atilde;o exclui a possibilidade    de redu&ccedil;&atilde;o de i
nvestimentos em interven&ccedil;&otilde;es para    as quais ainda n&atilde;o h&a
acute; comprova&ccedil;&atilde;o de efetividade.</font></p>     ^cY#2036.htm##
01074000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704083800081002000900919#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#35#31#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">H&aacute; quatro    t&eacute;cn
icas ou tipos de an&aacute;lise econ&ocirc;mica de sa&uacute;de,    com procedim
entos para apura&ccedil;&atilde;o de custos similares, mas que se    diferenciam
 entre si pelas medidas das conseq&uuml;&ecirc;ncias. No custo-benef&iacute;cio,
    custos e efeitos s&atilde;o mensurados em unidades monet&aacute;rias; no cus
to-utilidade,    o resultado &eacute; medido em unidades de utilidade, como o <i
>quality-adjusted    life year</i> (QALY); no custo-efetividade, o efeito &uacut
e;nico &eacute; expresso    em unidades naturais (casos evitados); e na an&aacut
e;lise de minimiza&ccedil;&atilde;o    de custos, compara-se o custo de duas int
erven&ccedil;&otilde;es com resultados    similares e custos diferentes.<sup>8</
sup></font></p>     ^cY#2036.htm##
01189000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704095300081002000901034#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#36#32#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">H&aacute; uma variante    da an
&aacute;lise de custo-efetividade, denominada de custos e conseq&uuml;&ecirc;nci
as,<sup>4</sup>    proposta pelo Centers for Disease Control (CDC), em que a vis
ualiza&ccedil;&atilde;o    da interven&ccedil;&atilde;o pelos gestores &eacute; 
mais eficiente e pr&aacute;tica.    A utiliza&ccedil;&atilde;o dos resultados no
 planejamento visa atender &agrave;s    necessidades da popula&ccedil;&atilde;o,
 levando em conta seus valores e suas    prefer&ecirc;ncias.<sup>5</sup> &Eacute
; considerada por Coast<sup>7</sup> a    melhor alternativa para a tomada de dec
is&atilde;o, tendo como principal vantagem    disponibilizar um cen&aacute;rio d
e op&ccedil;&otilde;es, incluindo recursos    empregados, efeitos prevenidos pel
a interven&ccedil;&atilde;o, al&eacute;m de    permitir agregar informa&ccedil;&
otilde;es quantitativas e qualitativas.</font></p>     ^cY#2036.htm##
00870000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704063400081002000900715#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#37#33#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A aten&ccedil;&atilde;o    pr&e
acute;-natal &eacute; uma a&ccedil;&atilde;o program&aacute;tica consolidada    
no Brasil desde 1984. A aten&ccedil;&atilde;o &agrave; gesta&ccedil;&atilde;o   
 de baixo risco &eacute; conduzida pelas equipes de sa&uacute;de da fam&iacute;l
ia,    com base no manual t&eacute;cnico do Programa Nacional de Humaniza&ccedil
;&atilde;o    do Pr&eacute;-Natal e Nascimento (PHPN),<a href="#backa">ª</a> que
 faz parte    da Pol&iacute;tica Nacional de Sa&uacute;de da Mulher.<a name="top
b"></a><a href="#backb"><sup>b</sup></a></font></p>     ^cY#2036.htm##
00603000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704036700081002000900448#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#38#34#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A escolha pela    aten&ccedil;&
atilde;o pr&eacute;-natal foi feita pelo desafio nacional de reduzir    a morbim
ortalidade perinatal, ainda elevada no Brasil, e as a&ccedil;&otilde;es    mater
no-infantis s&atilde;o custo-efetivas, como mostrado em estudos internacionais.<
sup>1,9</sup></font></p>     ^cY#2036.htm##
00461000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704022500081002000900306#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#39#35#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O presente trabalho    teve por
 objetivo avaliar os custos e as conseq&uuml;&ecirc;ncias do pr&eacute;-natal   
 na morbimortalidade perinatal.</font></p>     ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#40#36#article#137#<p>&nbsp;</p> 
    ^cY#2036.htm##
00340000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010400081002000900185#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#41#37#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p
>     ^cY#2036.htm##
00471000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704023500081002000900316#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#42#38#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Pesquisa avaliativa    com dois
 tipos de an&aacute;lise<sup>8</sup> de implanta&ccedil;&atilde;o (tipo    dois)
 e de rendimentos ou de efici&ecirc;ncia.</font></p>     ^cY#2036.htm##
00846000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704061000081002000900691#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#43#39#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudo realizado    no Recife, 
PE, com 17 Equipes de Sa&uacute;de da Fam&iacute;lia (ESF), lotadas    em 11 Uni
dades de da Fam&iacute;lia (USF) de tr&ecirc;s distritos sanit&aacute;rios.    E
ssas USF integram o Programa de Extens&atilde;o Comunit&aacute;ria do Instituto 
   de Medicina Integral Prof. Fernando Figueira - PEC/IMIP, administradas em par
ceria    com a Secretaria Municipal de Sa&uacute;de, e prestam assist&ecirc;ncia
 &agrave;    sa&uacute;de de aproximadamente 60.000 habitantes.<a href="#backc">
<sup>c</sup></a></font></p>     ^cY#2036.htm##
00971000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704073500081002000900816#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#44#40#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Para avaliar o    grau de impla
nta&ccedil;&atilde;o, adotou-se a abordagem sist&ecirc;mica de    Donabedian, a 
qual trabalha com tr&ecirc;s componentes: estrutura, processo    e resultado,<su
p>15</sup> este &uacute;ltimo como <i>proxy</i> da efetividade.    Baseada nessa
 abordagem, procedeu-se inicialmente &agrave; avalia&ccedil;&atilde;o    normati
va, tomando como par&acirc;metro de boas pr&aacute;ticas as normas do    manual 
t&eacute;cnico do PHPN.<a href="#backa">ª</a> Esse tipo de avalia&ccedil;&atilde
;o    confronta a realidade emp&iacute;rica com as normas estabelecidas e atribu
i    o grau de ader&ecirc;ncia &agrave;s normas.<sup>11</sup></font></p>     ^cY
#2036.htm##
01147000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704091100081002000900992#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#45#41#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Aplicou-se um question&aacute;r
io    &agrave;s ESF em maio e junho de 2007 com perguntas fechadas acerca dos re
cursos    materiais, insumos, pessoal e treinamento (estrutura) e das pr&aacute;
ticas    da assist&ecirc;ncia pr&eacute;-natal (processo). A consolida&ccedil;&a
tilde;o    dessa etapa normativa fez-se mediante as respostas das ESF. Atribuiu-
se peso    cinco para as quest&otilde;es referentes &agrave; estrutura e dez &ag
rave;s    relativas ao processo de trabalho, totalizando 100 pontos, e calculou-
se o percentual    de acertos de cada ESF. Foram classificadas em pr&eacute;-nat
al implantado (cumprimento    de 76% a 100% dos par&acirc;metros estabelecidos n
o manual t&eacute;cnico);    parcialmente implantado (entre 51% e 75,9%); incipi
ente (entre 26% e 50,9%);    ou sem implanta&ccedil;&atilde;o (<u><</u> 25%).</f
ont></p>     ^cY#2036.htm##
00683000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704044700081002000900528#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#46#42#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O grau de implanta&ccedil;&atil
de;o    do pr&eacute;-natal foi relacionado aos resultados perinatais medidos po
r indicadores    de sa&uacute;de. O poder explicativo dessa an&aacute;lise estev
e na coer&ecirc;ncia    das rela&ccedil;&otilde;es entre os efeitos encontrados 
e o grau de adequa&ccedil;&atilde;o    da estrutura e funcionamento do programa.
<sup>10</sup></font></p>     ^cY#2036.htm##
01204000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704096800081002000901049#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#47#43#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os indicadores    relativos &ag
rave; sa&uacute;de da crian&ccedil;a foram: &oacute;bitos neonatais,    fetais e
 perinatais do tri&ecirc;nio 2004-2006 e condi&ccedil;&otilde;es tra&ccedil;ador
as,    como:<sup>13</sup> t&eacute;tano neonatal, s&iacute;filis cong&ecirc;nita
, baixo    peso ao nascer (abaixo de 2.500 g); nascidos vivos sem assist&ecirc;n
cia pr&eacute;-natal    e com menos de quatro consultas pr&eacute;-natal no ano 
de 2006. Essas informa&ccedil;&otilde;es    foram obtidas dos Sistemas de Inform
a&ccedil;&atilde;o: sobre Nascidos Vivos    (Sinasc), Mortalidade (Sim), Agravos
 de Notifica&ccedil;&atilde;o (Sinan), obtidos    da Secretaria de Sa&uacute;de 
do Recife; e do Sistema de Informa&ccedil;&atilde;o    Hospitalar (SIH) obtido n
a Secretaria Estadual de Sa&uacute;de. Todos os eventos    foram identificados p
elo nome da m&atilde;e e seu endere&ccedil;o completo.</font></p>     ^cY#2036.h
tm##
00985000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704074900081002000900830#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#48#44#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    de efici&ec
irc;ncia empregou a alternativa de custos e conseq&uuml;&ecirc;ncias,<sup>4</sup
>    tipo custo-efetividade pela medida dos efeitos em unidades naturais.<sup>8<
/sup>    Para isso, adotou-se a t&eacute;cnica <i>Basic Assessment Scheme for In
tervention    Costs and Consequences Methodology</i> (Basicc), recomendada pelo 
CDC, que incorpora    os princ&iacute;pios da medicina baseada em evid&ecirc;nci
as para programas    de sa&uacute;de p&uacute;blica na avalia&ccedil;&atilde;o d
e programas de preven&ccedil;&atilde;o<sup>9</sup>    e permite avaliar efeitos 
adversos causados ou prevenidos pela interven&ccedil;&atilde;o.<sup>4</sup></fon
t></p>     ^cY#2036.htm##
00711000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704047500081002000900556#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#49#45#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A apura&ccedil;&atilde;o    dos
 custos realizou-se segundo a t&eacute;cnica <i>activity-based costing</i>    (A
BC) na perspectiva do setor p&uacute;blico, escolhida pela maior aproxima&ccedil
;&atilde;o    dos custos &agrave;s atividades. Utiliza apenas os custos diretos 
(fixos e vari&aacute;veis)    envolvidos na atividade, calculados mediante direc
ionadores espec&iacute;ficos.<sup>2</sup></font></p>     ^cY#2036.htm##
01339000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704110300081002000901184#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#50#46#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os direcionadores    de assist&
ecirc;ncia analisados foram consultas de pr&eacute;-natal e n&uacute;mero    de 
gestantes. Al&eacute;m do atendimento por m&eacute;dico e/ou enfermeiro,    fora
m inclu&iacute;dos solicita&ccedil;&atilde;o de exames, aferi&ccedil;&atilde;o  
  do peso e press&atilde;o arterial pela t&eacute;cnica de enfermagem, atividade
s    educativas e visitas domiciliares pelos agentes de sa&uacute;de. Para o c&a
acute;lculo    da fra&ccedil;&atilde;o de outros custos diretos concernentes ao 
pr&eacute;-natal    relativos a aluguel, &aacute;gua, luz, telefone, manuten&cce
dil;&atilde;o, limpeza    e conserva&ccedil;&atilde;o e loca&ccedil;&atilde;o de
 m&atilde;o de obra, foi    selecionado o direcionador "turnos de atendimento de
 pr&eacute;-natal" de cada    ESF. N&atilde;o se contabilizou o custo de implant
a&ccedil;&atilde;o das unidades    nem com treinamento de pessoal e taxa de depr
ecia&ccedil;&atilde;o, por se tratar    de um per&iacute;odo curto, equivalente 
a uma gesta&ccedil;&atilde;o.</font></p>     ^cY#2036.htm##
00693000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704045700081002000900538#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#51#47#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As planilhas de    custos com v
alores monet&aacute;rios gastos por USF foram obtidas na Secretaria    de Sa&uac
ute;de do Recife<a name="topd"></a><a href="#backd"><sup>d</sup></a>    e no Ins
tituto de Medicina Integral Prof. Fernando Figueira,<a name="tope"></a><a href="
#backe"><sup>e</sup></a>    referentes ao &uacute;ltimo trimestre de 2006 e prim
eiro trimestre de 2007.</font></p>     ^cY#2036.htm##
00710000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704047400081002000900555#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#52#48#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As informa&ccedil;&otilde;es   
 relativas &agrave; assist&ecirc;ncia foram retiradas dos relat&oacute;rios do  
  Siab, que disponibiliza os dados desagregados por ESF: "S&eacute;rie Hist&oacu
te;rica    das Informa&ccedil;&otilde;es de Sa&uacute;de (SSA2)" e "S&eacute;rie
 Hist&oacute;rica    da Produ&ccedil;&atilde;o (PMA2)", ano 2006, emitidos pela 
Secretaria de Sa&uacute;de    do Recife.</font></p>     ^cY#2036.htm##
00683000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704044700081002000900528#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#53#49#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As conseq&uuml;&ecirc;ncias    
(efeitos) utilizadas na an&aacute;lise de efici&ecirc;ncia foram os mesmos indic
adores    e condi&ccedil;&otilde;es tra&ccedil;adoras selecionadas na an&aacute;
lise de    implanta&ccedil;&atilde;o, excetuando-se "aus&ecirc;ncia de pr&eacute
;-natal    e n&uacute;mero de nascidos vivos com menos de quatro consultas pr&ea
cute;-natal".</font></p>     ^cY#2036.htm##
00761000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704052500081002000900606#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#54#50#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Para a an&aacute;lise    de cus
tos e conseq&uuml;&ecirc;ncia, agruparam-se as USF conforme o grau de    implant
a&ccedil;&atilde;o e procedeu-se da mesma forma com os custos e com os    indica
dores, agregando-os por grupo. A raz&atilde;o de custo-efetividade foi    calcul
ada dividindo-se a diferen&ccedil;a de custos pela diferen&ccedil;a de    cada c
onseq&uuml;&ecirc;ncia entre os grupos com melhor e pior grau de implanta&ccedil
;&atilde;o.</font></p>     ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#55#51#article#137#<p>&nbsp;</p> 
    ^cY#2036.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010000081002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#56#52#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>   
  ^cY#2036.htm##
00813000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704057700081002000900658#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#57#53#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A <a href="/img/revistas/rsp/20
11nahead/2036t01.jpg">Tabela    1</a> apresenta o grau (%) de implanta&ccedil;&a
tilde;o de estrutura e processo    e os indicadores de efeitos, &agrave; exce&cc
edil;&atilde;o dos n&uacute;meros    de &oacute;bitos em n&uacute;meros absoluto
s. As USF foram classificadas em    dois grupos: com pr&eacute;-natal implantado
, denominado GI, que congregou sete    USF (64% do total), e as quatro restantes
 (36%) classificadas em grupo parcialmente    implantado (GPI).</font></p>     ^
cY#2036.htm##
00582000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034600081002000900427#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#58#54#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O n&uacute;mero    de nascidos 
vivos registrados no Sinasc na &aacute;rea de abrang&ecirc;ncia    foi de 440 no
 grupo GI e 344 no GPI. Cerca de 5% das m&atilde;es dos nascidos    vivos n&atil
de;o tiveram consulta pr&eacute;-natal, a maioria pertencente ao    GPI.</font><
/p>     ^cY#2036.htm##
00613000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704037700081002000900458#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#59#55#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Oito casos de s&iacute;filis   
 cong&ecirc;nita foram notificados ao Sinan e um caso foi recuperado do SIH,    
a maioria nas &aacute;reas do GPI. N&atilde;o houve registro de casos de t&eacut
e;tano    neonatal no per&iacute;odo (<a href="/img/revistas/rsp/2011nahead/2036
t01.jpg">Tabela 1</a>).</font></p>     ^cY#2036.htm##
00563000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704032700081002000900408#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#60#56#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os custos m&eacute;dios    mens
ais com os profissionais nas ESF, proporcionais aos atendimentos do pr&eacute;-n
atal,    variaram de R$ 381,45 (Distrito Sanit&aacute;rio I) a R$ 1.287,72 (Dist
rito    IV, dados n&atilde;o apresentados em tabela).</font></p>     ^cY#2036.ht
m##
00893000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704065700081002000900738#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#61#57#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Na composi&ccedil;&atilde;o    
de custos (<a href="/img/revistas/rsp/2011nahead/2036t02.jpg">Tabela 2</a>), os 
valores relacionados    diretamente &agrave; assist&ecirc;ncia da gestante tiver
am maior participa&ccedil;&atilde;o    (R$ 63.433,47; 92,1%). A fra&ccedil;&atil
de;o m&eacute;dia atribu&iacute;da    ao pr&eacute;-natal relativa aos custos co
m aluguel, &aacute;gua, energia, telefone,    manuten&ccedil;&atilde;o de equipa
mentos, limpeza e conserva&ccedil;&atilde;o    e loca&ccedil;&atilde;o de m&atil
de;o de obra foi de R$ 5.482,85 no per&iacute;odo    analisado.</font></p>     ^
cY#2036.htm##
00799000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704056300081002000900644#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#62#58#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O custo m&eacute;dio    total d
o pr&eacute;-natal na perspectiva do SUS foi de R$ 39.226,88 no GI, com    varia
&ccedil;&atilde;o de R$ 3.841,87 a R$ 8.765,02, e no GPI, de R$ 30.092,61    (R$
 4.272,12 a R$ 11.774,68) (<a href="/img/revistas/rsp/2011nahead/2036t02.jpg">Ta
bela 2</a>). Para    o Sistema &Uacute;nico de Sa&uacute;de, o custo m&eacute;di
o do pr&eacute;-natal    por gestante do GI foi de R$ 196,13 e no GPI, de R$ 150
,46 (dados n&atilde;o    apresentados em tabela).</font></p>     ^cY#2036.htm##
00749000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051300081002000900594#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#63#59#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os coeficientes    de mortalida
de neonatal e perinatal, a propor&ccedil;&atilde;o de baixo peso    ao nascer e 
a incid&ecirc;ncia da s&iacute;filis cong&ecirc;nita foram maiores    nas USF GP
I, que tamb&eacute;m apresentaram custos m&eacute;dios maiores. O    pr&eacute;-
natal por USF custou, em m&eacute;dia, R$ 5.603,84 no grupo GI e    R$ 7.523,15 
no grupo GPI (<a href="/img/revistas/rsp/2011nahead/2036t03.jpg">Tabela 3</a>).<
/font></p>     ^cY#2036.htm##
00796000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704056000081002000900641#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#64#60#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Para a preven&ccedil;&atilde;o 
   do baixo peso ao nascer &eacute; necess&aacute;rio investimento da ordem de  
  R$ 3.761,58, em m&eacute;dia, nas USF do grupo GPI; para a redu&ccedil;&atilde
;o    da s&iacute;filis cong&ecirc;nita, de R$ 2.283,57 (<a href="/img/revistas/
rsp/2011nahead/2036t03.jpg">Tabela    3</a>). Para a mortalidade perinatal, a ra
z&atilde;o de custo-efetividade mostrou    que poderiam ser evitados quatro even
tos com investimento de R$ 2.455,45 no    GPI.</font></p>     ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#65#61#article#137#<p>&nbsp;</p> 
    ^cY#2036.htm##
00342000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010600081002000900187#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#66#62#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font><
/p>     ^cY#2036.htm##
00810000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704057400081002000900655#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#67#63#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os resultados apontam    que o 
pr&eacute;-natal &eacute; custo-efetivo para v&aacute;rias conseq&uuml;&ecirc;nc
ias    estudadas. Os efeitos adversos medidos pelos indicadores de sa&uacute;de 
foram    menores no grupo de unidades com pr&eacute;-natal implantado. O custo m
&eacute;dio    no grupo parcialmente implantado foi mais elevado, sugerindo poss
&iacute;vel    desperd&iacute;cio de recursos, uma vez que a produtividade das e
quipes &eacute;    insuficiente para a capacidade instalada.</font></p>     ^cY#
2036.htm##
01018000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704078200081002000900863#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#68#64#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A escolha pela    abordagem de 
custos e conseq&uuml;&ecirc;ncias utilizando a metodologia Basicc    do CDC base
ou-se na facilidade de aplica&ccedil;&atilde;o para tomada de decis&atilde;o    
e na cr&iacute;tica &agrave;s an&aacute;lises de custo-efetividade e custo-utili
dade.    No primeiro caso, o gestor precisa analisar e julgar v&aacute;rios efei
tos em    vez de um s&oacute; e, no segundo, h&aacute; dificuldade de entendimen
to pleno    da medida "custo por QALY ganho". Al&eacute;m disso, a compreens&ati
lde;o da    teoria econ&ocirc;mica que ap&oacute;ia a compara&ccedil;&atilde;o d
e custos    e efeitos n&atilde;o &eacute; f&aacute;cil para quem n&atilde;o &eac
ute; economista.<sup>7</sup></font></p>     ^cY#2036.htm##
01009000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704077300081002000900854#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#69#65#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    de implanta
&ccedil;&atilde;o foi feita previamente &agrave; de efici&ecirc;ncia    devido &
agrave; depend&ecirc;ncia de comprova&ccedil;&atilde;o da efetividade    nas ava
lia&ccedil;&otilde;es econ&ocirc;micas, para ent&atilde;o estabelecer    rela&cc
edil;&atilde;o entre custos e efeitos.<sup>6</sup> Da mesma forma, a    interven
&ccedil;&atilde;o deve estar comprovadamente implantada, porque, sem    conhecim
ento do grau de implanta&ccedil;&atilde;o, a avalia&ccedil;&atilde;o    pode ser
 in&oacute;cua ou levar &agrave; interpreta&ccedil;&atilde;o err&ocirc;nea    so
bre sua efetividade, ao que Contandriopoulos et al<sup>8</sup> denominaram    de
 erro do tipo dois.</font></p>     ^cY#2036.htm##
01148000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704091200081002000900993#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#70#66#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O uso da t&eacute;cnica    ABC 
permite maior aproxima&ccedil;&atilde;o dos custos &agrave;s atividades,    calc
ulados por meio de direcionadores espec&iacute;ficos, e, assim, identifica    it
ens que consomem mais recursos financeiros; no presente estudo, as equipes    e 
as a&ccedil;&otilde;es. Isso se torna particularmente importante no setor    p&u
acute;blico, considerando a Lei Complementar 101,<a name="topf"></a><a href="#ba
ckf"><sup>f</sup></a>    que disp&otilde;e sobre normas relativas ao controle de
 custos e &agrave; avalia&ccedil;&atilde;o    dos resultados dos programas finan
ciados com recursos do or&ccedil;amento p&uacute;blico.    Mas o uso dessa t&eac
ute;cnica s&oacute; &eacute; poss&iacute;vel em locais    com um sistema de apur
a&ccedil;&atilde;o de custos estruturado, como o munic&iacute;pio    estudado.</
font></p>     ^cY#2036.htm##
01171000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704093500081002000901016#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#71#67#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">H&aacute; escassez    de estudo
s na &aacute;rea de economia da sa&uacute;de no Brasil. Seus resultados    s&ati
lde;o pouco usados e, mesmo no n&iacute;vel internacional, raramente &eacute;   
 utilizado para subsidiar o planejamento<sup>21</sup> e a tomada de decis&atilde
;o.    Coast<sup>7</sup> justifica essa assertiva pelo conhecimento insatisfat&o
acute;rio    acerca dos m&eacute;todos, ao que se acrescenta o incipiente grau d
e institucionaliza&ccedil;&atilde;o    da cultura avaliativa das pol&iacute;tica
s p&uacute;blicas na realidade brasileira.    N&atilde;o se identificou, at&eacu
te; o momento, nas bases eletr&ocirc;nicas    pesquisadas (SciELO, Lilacs, PubMe
d) um estudo econ&ocirc;mico brasileiro que    comparasse uma mesma interven&cce
dil;&atilde;o com diferentes graus de implanta&ccedil;&atilde;o,    como abordad
o no presente estudo.</font></p>     ^cY#2036.htm##
01067000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704083100081002000900912#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#72#68#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A implanta&ccedil;&atilde;o    
de a&ccedil;&otilde;es b&aacute;sicas de sa&uacute;de da crian&ccedil;a em Perna
mbuco    foi analisada em estudos anteriores, como o de Bezerra et al.<sup>3</su
p> Da    mesma forma, foram realizados estudos sobre a efetividade da estrat&eac
ute;gia    de sa&uacute;de da fam&iacute;lia sobre a mortalidade infantil<sup>16
</sup>    e sobre a efici&ecirc;ncia do modelo de sa&uacute;de da fam&iacute;lia
 em rela&ccedil;&atilde;o    ao tradicional. Neste &uacute;ltimo estudo, alguns 
indicadores mostraram-se    melhores, como oferta de servi&ccedil;os, medido pel
o n&uacute;mero de atendimentos    ou de acesso/utiliza&ccedil;&atilde;o, julgad
o pela cobertura vacinal.<a name="topg"></a><a href="#backg"><sup>g</sup></a></f
ont></p>     ^cY#2036.htm##
01029000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079300081002000900874#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#73#69#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Para Darmstadt    et al,<sup>9<
/sup> interven&ccedil;&otilde;es para melhoria da sa&uacute;de    materna inclue
m a efetividade da vacina&ccedil;&atilde;o antitet&acirc;nica,    da detec&ccedi
l;&atilde;o e tratamento de s&iacute;filis e de bacteri&uacute;ria    assintom&a
acute;tica no pr&eacute;-natal. Segundo a Organiza&ccedil;&atilde;o    Mundial d
a Sa&uacute;de, quase 3/4 das mortes maternas ocorridas em pa&iacute;ses    pobr
es s&atilde;o evit&aacute;veis, 26% com o pr&eacute;-natal e 48% com a amplia&cc
edil;&atilde;o    do acesso aos cuidados obst&eacute;tricos de qualidade. Esses 
aspectos consumiram    30% e 26% dos recursos financeiros do Programa Maternidad
e Segura, respectivamente.<sup>15</sup></font></p>     ^cY#2036.htm##
01439000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704120300081002000901284#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#74#70#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Adam et al<sup>1</sup>    avali
aram o custo-efetividade de atividades pr&oacute;prias do pr&eacute;-natal    no
s pa&iacute;ses pobres da &Aacute;frica Subsaariana e do sudeste asi&aacute;tico
.    Identificaram como mais custo-efetivas na aten&ccedil;&atilde;o prim&aacute
;ria    a vacina&ccedil;&atilde;o antitet&acirc;nica; o <i>screening</i> e trata
mento    para bacteri&uacute;ria assintom&aacute;tica e para s&iacute;filis; <i>
screening</i>    para pr&eacute;-ecl&acirc;mpsia, mediante aferi&ccedil;&atilde;
o da press&atilde;o    arterial, detec&ccedil;&atilde;o de protein&uacute;ria e 
exist&ecirc;ncia de    servi&ccedil;o de refer&ecirc;ncia para tratamento. Contu
do, para evitar cerca    de 50% das mortes neonatais e maternas, seria necess&aa
cute;rio que, afora essas    atividades, outras relacionadas ao parto, puerp&eac
ute;rio e &agrave; assist&ecirc;ncia    neonatal imediata tivessem 95% de cobert
ura populacional. Note-se que todas    essas atividades est&atilde;o incorporada
s ao pr&eacute;-natal no Brasil e constam    do manual t&eacute;cnico do Minist&
eacute;rio da Sa&uacute;de.<a href="#backa">ª</a></font></p>     ^cY#2036.htm##
00828000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704059200081002000900673#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#75#71#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A cobertura pr&eacute;-natal   
 no Recife para quatro ou mais consultas alcan&ccedil;ou 88,3%.<a href="#backc">
<sup>c</sup></a>    (Nas &aacute;reas de abrang&ecirc;ncia das USF pesquisadas, 
mesmo no pior cen&aacute;rio    (GPI), a cobertura pr&eacute;-natal foi semelhan
te &agrave; m&eacute;dia do    Recife. Isso sugere que as ESF precisam seguir as
 normas de assist&ecirc;ncia    com envolvimento de toda a equipe, fazer busca a
tiva de gestantes faltosas e    acompanh&aacute;-las com visitas domiciliares.</
font></p>     ^cY#2036.htm##
00873000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704063700081002000900718#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#76#72#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Outro indicativo    de falha no
 pr&eacute;-natal &eacute; a ocorr&ecirc;ncia de s&iacute;filis cong&ecirc;nita,
    mais freq&uuml;ente no grupo GPI, resultado coerente com o grau de implanta&
ccedil;&atilde;o.    Esse resultado sinaliza a necessidade de mais empenho das E
SF no acompanhamento    das gestantes acometidas por essa infec&ccedil;&atilde;o
 sexualmente transmiss&iacute;vel    para garantir o tratamento completo forneci
do pelo SUS ao casal. Esse tratamento    tem baixo custo e boa rela&ccedil;&atil
de;o de custo-efetividade por caso evitado.</font></p>     ^cY#2036.htm##
00999000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704076300081002000900844#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#77#73#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Em 2006, 8,2% dos    nascidos v
ivos no Brasil eram de baixo peso, incluindo os rec&eacute;m-nascido    pr&eacut
e;-termo e pequenos para idade gestacional.<a href="#backc"><sup>c</sup></a>    
Essa ocorr&ecirc;ncia est&aacute; associada &agrave; aus&ecirc;ncia e/ou inadequ
a&ccedil;&atilde;o    da assist&ecirc;ncia pr&eacute;-natal<sup>18, 19</sup> e f
oi mais freq&uuml;ente    (10,2%) nas &aacute;reas com GPI, acima da m&eacute;di
a nacional.<a href="#backc"><sup>c</sup></a>    Para reduzir a propor&ccedil;&at
ilde;o de baixo peso nesse grupo e na m&eacute;dia    do Pa&iacute;s, seria nece
ss&aacute;rio mais investimento nas ESF, conforme    a raz&atilde;o de custo-efe
tividade.</font></p>     ^cY#2036.htm##
01081000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704084500081002000900926#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#78#74#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As crian&ccedil;as    de baixo 
peso ao nascer s&atilde;o mais vulner&aacute;veis &agrave;s doen&ccedil;as    e 
ao &oacute;bito; al&eacute;m disso, o custo da hospitaliza&ccedil;&atilde;o    v
aria inversamente com o peso ao nascer.<sup>12, 20</sup> Em 2001, um estudo    r
ealizado nos Estados Unidos comparou o custo m&eacute;dio da hospitaliza&ccedil;
&atilde;o    de crian&ccedil;a pr&eacute;-termo/baixo peso ao nascer com os RN d
e peso normal,    o que correspondeu a US$ 15.800 e US$ 600, respectivamente.<su
p>20</sup> Outra    pesquisa conduzida na Gr&eacute;cia, em 2004, verificou que 
o custo m&eacute;dio    para o governo com RN pesando entre 1.001 e 1.500 g em u
nidades p&uacute;blicas    de cuidados intensivos neonatais foi de US$ 10.438.<s
up>12</sup></font></p>     ^cY#2036.htm##
00877000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704064100081002000900722#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#79#75#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o &eacute;    inten&cc
edil;&atilde;o debater a necessidade dessas unidades, o que se poderia    fazer 
a menor custo, para evitar a demanda excessiva desses servi&ccedil;os.    Afora 
o maior valor, h&aacute; custos intang&iacute;veis, haja vista que os    beb&eci
rc;s de baixo peso apresentam maior risco de &oacute;bito neonatal evit&aacute;v
el,    segundo classifica&ccedil;&atilde;o de Malta et al,<sup>17</sup> relacion
ados    &agrave; falha na assist&ecirc;ncia pr&eacute;-natal e ao manejo do part
o e    do per&iacute;odo neonatal.<sup>19</sup></font></p>     ^cY#2036.htm##
00736000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704050000081002000900581#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#80#76#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A falha da assist&ecirc;ncia   
 pr&eacute;-natal tamb&eacute;m repercutiu nas taxas de mortalidade perinatal   
 e neonatal, maiores no grupo GPI. A semelhan&ccedil;a nas taxas entre os grupos
    pode ser explicada pela pequena diferen&ccedil;a de pontos para a classifica
&ccedil;&atilde;o    do grau de implanta&ccedil;&atilde;o do pr&eacute;-natal en
tre as unidades que,    no geral, foram bem pontuadas, exceto uma.</font></p>   
  ^cY#2036.htm##
01158000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704092200081002000901003#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#81#77#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">N&atilde;o foi    poss&iacute;v
el estabelecer efeitos do pr&eacute;-natal sobre a sa&uacute;de    da mulher pel
os indicadores selecionados, pois n&atilde;o ocorreu &oacute;bito    materno nas
 &aacute;reas sob an&aacute;lise no tri&ecirc;nio 2004-2006. Por    outro lado, 
houve problemas na identifica&ccedil;&atilde;o das hospitaliza&ccedil;&otilde;es
    por complica&ccedil;&otilde;es da gravidez no SIH, tais como hipertens&atild
e;o    arterial (primeira causa de morte materna), diabetes gestacional e infec&
ccedil;&atilde;o    do trato urin&aacute;rio. H&aacute; possibilidade de importa
nte sub-registro,    uma vez que foram localizadas tr&ecirc;s hospitaliza&ccedil
;&otilde;es por pr&eacute;-ecl&acirc;mpsia    grave (USF 8, 9 e 10) e um parto c
om ecl&acirc;mpsia (USF 1) por falha no preenchimento    do endere&ccedil;o da g
estante.</font></p>     ^cY#2036.htm##
00829000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704059300081002000900674#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#82#78#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A indisponibilidade    desses i
ndicadores de sa&uacute;de da mulher e custos decorrentes talvez seja    a maior
 limita&ccedil;&atilde;o do presente trabalho, provavelmente, com vi&eacute;s   
 de subestima&ccedil;&atilde;o da magnitude dos diferenciais de efetividade entr
e    GI e GPI. As incertezas sobre a confiabilidade dos sistemas de informa&cced
il;&atilde;o    podem ter desviado para mais os custos do pr&eacute;-natal naque
las unidades    que registraram menos, outra limita&ccedil;&atilde;o do estudo.<
/font></p>     ^cY#2036.htm##
00675000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704043900081002000900520#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#83#79#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">&Eacute; poss&iacute;vel    que
 haja potenciais vieses de sele&ccedil;&atilde;o e informa&ccedil;&atilde;o,    
pela forma de identifica&ccedil;&atilde;o dos efeitos, mediante os endere&ccedil
;os    das &aacute;reas de cobertura das USF fornecidos pelos agentes de sa&uacu
te;de    que, de forma involunt&aacute;ria, podem ter sido suprimidos ou incompl
etos.</font></p>     ^cY#2036.htm##
00583000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034700081002000900428#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#84#80#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O modelo constru&iacute;do    p
oder&aacute; ser aplicado para o universo das equipes de sa&uacute;de da fam&iac
ute;lia    do Recife ou ser adaptado para outras a&ccedil;&otilde;es e outros co
ntextos,    de acordo com as etapas preconizadas no m&eacute;todo Basicc.</font>
</p>     ^cY#2036.htm##
01185000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704094900081002000901030#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#85#81#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">No tocante &agrave;    generali
za&ccedil;&atilde;o, os resultados n&atilde;o podem ser extrapolados    para out
ros locais, pelas diferentes caracter&iacute;sticas das comunidades,    da produ
tividade dos profissionais das equipes, assim como da organiza&ccedil;&atilde;o 
   do sistema de aten&ccedil;&atilde;o &agrave; sa&uacute;de e dos pre&ccedil;os
    dos insumos, incluindo sal&aacute;rios. S&atilde;o ainda relevantes os fator
es    relativos &agrave; unidade de custo associado a um recurso e &agrave; medi
da    de efetividade, e todas essas caracter&iacute;sticas t&ecirc;m rela&ccedil
;&atilde;o    temporal. Contudo, para o munic&iacute;pio do Recife, os resultado
s podem representar    boa estimativa para o setor p&uacute;blico, quanto &agrav
e; a&ccedil;&atilde;o    program&aacute;tica conduzida pelas ESF, e ser &uacute;
teis para orientar decis&otilde;es.</font></p>     ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#86#82#article#137#<p>&nbsp;</p> 
    ^cY#2036.htm##
00343000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010700081002000900188#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#87#83#article#137#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font>
</p>     ^cY#2036.htm##
00572000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704032200083002000900405#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#88#84#article#137#1#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Adam T, Lim   
 SS, Mehta S, Bhutta ZA, Fogstad H, Mathai M, et al. Cost effectiveness analysis
    of strategies for maternal and neonatal health in developing countries. <i>B
MJ.</i>    2005; 331(7525):1107. DOI:10.1136/bmj.331.7525.1107</font></p>     ^c
Y#2036.htm##
00538000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704028800083002000900371#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#89#85#article#137#2#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Beulke R, Bert
&oacute;    DJ. Gest&atilde;o de custos e resultado na sa&uacute;de: hospitais, 
cl&iacute;nicas,    laborat&oacute;rios e cong&ecirc;neres. 3. ed. rev. atual. a
mpl. S&atilde;o    Paulo: Saraiva; 2005.    ^cY#2036.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#90#86#article#137#</font></p>   
  ^cY#2036.htm##
00649000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704039900083002000900482#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#91#87#article#137#3#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Bezerra LCA,  
  Frias PG, Vidal SA, Macedo VC, Vanderlei LC. Aleitamento materno: avalia&ccedi
l;&atilde;o    da implanta&ccedil;&atilde;o do programa em unidades b&aacute;sic
as de sa&uacute;de    do Recife, Pernambuco (2002). <i>Cienc Saude Coletiva</i>.
 2007;12(5):1309-17.    DOI:10.1590/S1413-81232007000500029</font></p>     ^cY#2
036.htm##
00645000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704039500083002000900478#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#92#88#article#137#4#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Brousselle A, 
   Lachaine J, Contandriopoulos AP. L'&eacute;valuation &eacute;conomique: In:  
  Brousselle A, Champagne F, Contandriopoulos A-P, Hartz Z. Concepts et m&eacute
;thodes    d'&eacute;valuation des interventions. Montr&eacute;al: Les Presses d
e l&acute;Universit&eacute;    de Montr&eacute;al; 2009. p.187-224.    ^cY#2036.
htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#93#89#article#137#</font></p>   
  ^cY#2036.htm##
00522000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704027200083002000900355#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#94#90#article#137#5#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Centers for   
 Disease Control and Prevention - CDC. Assessing the effectiveness of disease   
 and injury prevention programs: costs and consequences. <i>MMWR Recomm Rep.</i>
    1995;44(RR-10):1-10.    ^cY#2036.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#95#91#article#137#</font></p>   
  ^cY#2036.htm##
00488000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704023800083002000900321#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#96#92#article#137#6#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Clyne G, Edwar
ds    R. Understanding economic evaluations: a guide for health and human servic
es.    <i>Can J Program Evaluation</i>. 2002;17(3 Special Issue):1-23.    ^cY#20
36.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#97#93#article#137#</font></p>   
  ^cY#2036.htm##
00483000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704023300083002000900316#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#98#94#article#137#7#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Coast J. Is   
 economic evaluation in touch with society&acute;s health values? <i>BMJ.</i>   
 2004;329(7476):1233-6. DOI:10.1136/bmj.329.7476.1233</font></p>     ^cY#2036.ht
m##
00711000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704046100083002000900544#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#99#95#article#137#8#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Contandriopoul
os    A-P, Champagne F, Denis J-L, Hartz ZMA, Pineault R. A avalia&ccedil;&atild
e;o    na &aacute;rea da sa&uacute;de: conceitos e m&eacute;todos. In: Hartz ZMA
, organizador.    Avalia&ccedil;&atilde;o em sa&uacute;de: dos modelos conceitua
is &agrave; pr&aacute;tica    na an&aacute;lise da implanta&ccedil;&atilde;o de 
programas. Rio de Janeiro:    Fiocruz; 1997. p.29-47.    ^cY#2036.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704002000082002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#100#96#article#137#</font></p>  
   ^cY#2036.htm##
00564000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704031300084002000900397#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#101#97#article#137#9
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Darmstadt GI,
    Bhutta ZA, Cousens S, Adam T, Walker N, Bernis L. Evidence-based, cost-effec
tive    interventions: how many newborn babies can we save? <i>Lancet</i>. 2005;
365(9463):977-88.    DOI:10.1016/S0140-6736(05)71088-6</font></p>     ^cY#2036.h
tm##
00638000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000300082704038600085002000900471#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#102#98#article#137#1
0#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Denis J-L, 
   Champagne F. An&aacute;lise de implanta&ccedil;&atilde;o de programas. In: Ha
rtz    ZMA, organizador. Avalia&ccedil;&atilde;o em sa&uacute;de: dos modelos co
nceituais    &agrave; pr&aacute;tica na an&aacute;lise da implanta&ccedil;&atild
e;o de programas.    Rio de Janeiro: Fiocruz; 1997. p.49-88.    ^cY#2036.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704002000082002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#103#99#article#137#</font></p>  
   ^cY#2036.htm##
00423000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704017000086002000900256#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#104#100#article#137#
11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Donabedian
    A. The quality of care. How can it be assessed? <i>JAMA.</i> 1988;260(12):17
43-8.    ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#105#101#article#137#</font></p> 
    ^cY#2036.htm##
00552000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029900086002000900385#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#106#102#article#137#
12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Geitona M,
    Hatzikou M, Hatzistamatiou Z, Anastasiadou A, Theodoratou TD. The economic b
urden    of treating neonates in Intensive Care Units in Greece. <i>Cost Eff Res
our Alloc.</i>    2007;5:9. DOI:10.1186/1478-7547-5-9.    ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#107#103#article#137#</font></p> 
    ^cY#2036.htm##
00772000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704051900086002000900605#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#108#104#article#137#
13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Hartz ZMA,
    Champagne F, Contandriopoulos A-P, Leal MC. Avalia&ccedil;&atilde;o do progr
ama    materno-infantil: an&aacute;lise de implanta&ccedil;&atilde;o em sistemas
 locais    de sa&uacute;de no Nordeste do Brasil. In: Hartz ZMA, organizador. Av
alia&ccedil;&atilde;o    em sa&uacute;de: dos modelos conceituais &agrave; pr&aa
cute;tica na an&aacute;lise    de implanta&ccedil;&atilde;o de programas. Rio de
 Janeiro: Fiocruz, 1997. p.89-131.    ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#109#105#article#137#</font></p> 
    ^cY#2036.htm##
00499000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704024600086002000900332#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#110#106#article#137#
14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Hartz ZMA,
    Pouvourville G. Avalia&ccedil;&atilde;o dos programas de sa&uacute;de: a efi
ci&ecirc;ncia    em quest&atilde;o. <i>Cienc Saude Coletiva.</i> 1998;3(1):68-82
.    ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#111#107#article#137#</font></p> 
    ^cY#2036.htm##
00501000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704024800086002000900334#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#112#108#article#137#
15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Jowett M. 
Safe    motherhood interventions in low-income countries: an economic justificat
ion    and evidence of cost effectiveness. <i>Health Policy.</i> 2000;53(3):201-
28.    ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#113#109#article#137#</font></p> 
    ^cY#2036.htm##
00560000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704030700086002000900393#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#114#110#article#137#
16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Macinko J,
    Guanais FC, Souza MFM. An evaluation of impact of the Family Health Program 
   on infant mortality in Brazil, 1990-2002. <i>J Epidemiol Community Health.</i
>    2006;60(1):13-9. DOI:10.1136/jech.2005.038323</font></p>     ^cY#2036.htm##
00584000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704033100086002000900417#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#115#111#article#137#
17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Malta DC, 
Duarte    EC, Almeida MF, Dias MAS, Morais Neto OL, Moura L, et al. Lista de cau
sas de    mortes evit&aacute;veis por interven&ccedil;&otilde;es do Sistema &Uac
ute;nico    de Sa&uacute;de do Brasil. <i>Epidemiol Serv Saude</i>. 2007;16(4):2
33-44.    ^cY#2036.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#116#112#article#137#</font></p> 
    ^cY#2036.htm##
00536000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028300086002000900369#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#117#113#article#137#
18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Minuci EG,
    Almeida MF. Diferenciais intra-urbanos de peso ao nascer no munic&iacute;pio
    de S&atilde;o Paulo. <i>Rev Saude Publica</i>. 2009;43(2):256-66. DOI: 10.15
90/S0034-89102009005000011</font></p>     ^cY#2036.htm##
00585000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704033200086002000900418#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#118#114#article#137#
19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Ribeiro AM
,    Guimar&atilde;es MJ, Lima MC, Sarinho SW, Coutinho SB. Fatores de risco par
a    mortalidade neonatal em crian&ccedil;as com baixo peso ao nascer. <i>Rev Sa
ude    Publica</i>. 2009;43(2):246-255. DOI:10.1590/S0034-89102009005000004</fon
t></p>     ^cY#2036.htm##
00573000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704032000086002000900406#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#119#115#article#137#
20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Russell RB
,    Green NS, Steiner CA, Meikle S, Howse JL, Poschman K, et al. Cost of hospit
alization    for preterm and low birth weigth infants in the United States. <i>P
ediatrics</i>.    2007;120(1);e1-9. DOI: 10.1542/peds.2006-2386</font></p>     ^
cY#2036.htm##
00582000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704032900086002000900415#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#120#116#article#137#
21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Sancho LG,
    Vargens JMC. Avalia&ccedil;&atilde;o econ&ocirc;mica em sa&uacute;de na esfe
ra    de aten&ccedil;&atilde;o local &agrave; sa&uacute;de. <i>Cienc Saude Colet
iva</i>.    2009;14(Supl 1):1513-21. DOI:10.1590/S1413-81232009000800025</font><
/p>     ^cY#2036.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#121#117#article#137#<p>&nbsp;</p
>     ^cY#2036.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#122#118#article#137#<p>&nbsp;</p
>     ^cY#2036.htm##
00454000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021600083002000900299#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#123#119#article#137#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#
top"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    <b> Cor
respond&ecirc;ncia | Correspondence:    ^cY#2036.htm##
00276000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003800083002000900121#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#124#120#article#137#<br>   </b> 
Suely Arruda Vidal    ^cY#2036.htm##
00307000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704006900083002000900152#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#125#121#article#137#<br>   Insti
tuto de Medicina Integral Prof. Fernando Figueira    ^cY#2036.htm##
00285000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004700083002000900130#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#126#122#article#137#<br>   Rua d
os Coelhos, 300 - Boa Vista    ^cY#2036.htm##
00281000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004300083002000900126#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#127#123#article#137#<br>   50070
-550 Recife, PE, Brasil    ^cY#2036.htm##
00329000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704009100083002000900174#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#128#124#article#137#<br>   E-mai
l: <a href="mailto:suely@imip.org.br">suely@imip.org.br</a></font></p>     ^cY#2
036.htm##
00328000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704009000083002000900173#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#129#125#article#137#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Recebido: 18/2/2010    ^cY#20
36.htm##
00285000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004700083002000900130#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#130#126#article#137#<br>   Aprov
ado: 18/10/2010</font></p>     ^cY#2036.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#131#127#article#137#<p>&nbsp;</p
>     ^cY#2036.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#132#128#article#137#<p>&nbsp;</p
>     ^cY#2036.htm##
00441000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704020300083002000900286#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#133#129#article#137#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo baseado    na tese de 
doutorado de Vidal SA apresentada ao Instituto de Medicina Integral    Prof. Fer
nando Figueira em 2010.    ^cY#2036.htm##
00313000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704007500083002000900158#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#134#130#article#137#<br>   Os au
tores declaram n&atilde;o haver conflitos de interesse.    ^cY#2036.htm##
00770000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704053200083002000900615#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#135#131#article#137#<br>   <a na
me="backa"></a>a Minist&eacute;rio da Sa&uacute;de. Secretaria de Aten&ccedil;&a
tilde;o    &agrave; Sa&uacute;de. Departamento de A&ccedil;&otilde;es Program&aa
cute;ticas    Estrat&eacute;gicas. &Aacute;rea T&eacute;cnica de Sa&uacute;de da
 Mulher. Pr&eacute;-natal    e puerp&eacute;rio: aten&ccedil;&atilde;o qualifica
da e humanizada: manual t&eacute;cnico.    3.ed.rev. Bras&iacute;lia, DF; 2006. 
(S&eacute;rie A. Normas e Manuais T&eacute;cnicos.    S&eacute;rie Direitos Sexu
ais e Direitos Reprodutivos, 5).    ^cY#2036.htm##
00482000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704024400083002000900327#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#136#132#article#137#<br>   <a na
me="backb"></a><a href="#topb">b</a> -Minist&eacute;rio da Sa&uacute;de.    Secr
etaria de Pol&iacute;ticas de Sa&uacute;de. Programa de humaniza&ccedil;&atilde;
o    no pr&eacute;-natal e nascimento. Bras&iacute;lia,DF; 2000.    ^cY#2036.htm
##
00433000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704019500083002000900278#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#137#133#article#137#<br>   <a na
me="backc"></a>c Instituto de Medicina Integral Prof Fernando Figueira.    Relat
&oacute;rio interno do Programa de Extens&atilde;o Comunit&aacute;ria do    IMIP
. Recife; 2006.    ^cY#2036.htm##
00394000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704015600083002000900239#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#138#134#article#137#<br>   <a na
me="backd"></a><a href="#topd">d</a> Secretaria de Sa&uacute;de do Recife.    Re
lat&oacute;rio do CC/DAS, emitido em 10 de maio de 2007.    ^cY#2036.htm##
00433000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704019500083002000900278#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#139#135#article#137#<br>   <a na
me="backe"></a><a href="#tope">e</a> Instituto de Medicina Integral Prof.    Fer
nando Figueira. Relat&oacute;rio do Setor de Controladoria do IMIP, emitido    e
m maio de 2007.    ^cY#2036.htm##
00704000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704046600083002000900549#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#140#136#article#137#<br>   <a na
me="backf"></a><a href="#topf">f</a> Brasil. Presid&ecirc;ncia da Rep&uacute;bli
ca.    Lei Complementar 101, de 4 de maio de 2000. Cap&iacute;tulo II, Se&ccedil
;&atilde;o    II Lei de diretrizes or&ccedil;ament&aacute;rias, Art. 4 &#91;Inte
rnet&#93;.    &#91;citado 2010 jul&#93;. Dispon&iacute;vel em: <a href="http://w
ww.planalto.gov.br/ccivil_03/Leis/LCP/Lcp101.htm" target="_blank">http://www.pla
nalto.gov.br/ccivil_03/Leis/LCP/Lcp101.htm</a>    ^cY#2036.htm##
00676000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704043800083002000900521#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2036.htm#S#p#141#137#article#137#<br>   <a na
me="backg"></a><a href="#topg">g</a> Castro JD. A utiliza&ccedil;&atilde;o    do
 sistema de custeio por absor&ccedil;&atilde;o para avaliar os custos da aten&cc
edil;&atilde;o    b&aacute;sica de sa&uacute;de: reformula&ccedil;&otilde;es e a
primoramentos    metodol&oacute;gicos &#91;tese de doutorado&#93;. Campinas: Fac
uldade de Ci&ecirc;ncias    M&eacute;dicas da Universidade Estadual de Campinas;
 2000.</font></p>     ^cY#2036.htm##
00713000000000349000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100014000820100014000960100
01500110010001700125010001700142010001600159810000600175012010300181030000500284
71000020028906500090029106400050030003100040030503200050030901400050031423700260
0319865000900345002000900354#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
036.htm#S#c#142#1#article#21#1#^rND^sAdam^nT#^rND^sLim^nSS#^rND^sMehta^nS#^rND^s
Bhutta^nZA#^rND^sFogstad^nH#^rND^sMathai^nM#et al#Cost effectiveness analysis of
 strategies for maternal and neonatal health in developing countries^len#BMJ.#2#
20050000#2005#331#7525#1107#10.1136/bmj.331.7525.1107#20110000#2036.htm##
00510000000000253000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800160016000820160016000980180
09000114063000200204066001000206062000800216065000900224064000500233865000900238
002000900247#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#c#143#
2#article#21#2#^rND^sBeulke^nR#^rND^sBertó^nDJ#Gestão de custos e resultado na s
aúde: hospitais, clínicas, laboratórios e congêneres^lpt#3#São Paulo#Saraiva#200
50000#2005#20110000#2036.htm##
00716000000000325000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100019000820100016001010100
01600117010001700133010002000150012012000170030002100290710000200311065000900313
06400050032203100030032703200020033001400080033223700320034086500090037200200090
0381#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#c#144#3#articl
e#21#3#^rND^sBezerra^nLCA#^rND^sFrias^nPG#^rND^sVidal^nSA#^rND^sMacedo^nVC#^rND^
sVanderlei^nLC#Aleitamento materno: avaliação da implantação do programa em unid
ades básicas de saúde do Recife, Pernambuco (2002)^lpt#Cienc Saude Coletiva#2#20
070000#2007#12#5#1309-17#10.1590/S1413-81232007000500029#20110000#2036.htm##
00728000000000325000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100020000820100018001020100
02700120012002800147016002000175016001900195016002800214016001500242018005600257
06600090031306200400032206500090036206400050037101400080037686500090038400200090
0393#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#c#145#4#articl
e#21#4#^rND^sBrousselle^nA#^rND^sLachaine^nJ#^rND^sContandriopoulos^nAP#L'évalua
tion économique^lfr#^rND^sBrousselle^nA#^rND^sChampagne^nF#^rND^sContandriopoulo
s^nA-P#^rND^sHartz^nZ#Concepts et méthodes d'évaluation des interventions^lfr#Mo
ntréal#Les Presses de l´Université de Montréal#20090000#2009#187-224#20110000#20
36.htm##
00564000000000265000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100056000820120098001380300
01700236710000200253065000900255064000500264031000300269032000300272014000500275
865000900280002000900289#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.
htm#S#c#146#5#article#21#5#^rND^sCenters for Disease Control and Prevention -^nC
DC#Assessing the effectiveness of disease and injury prevention programs: costs 
and consequences^len#MMWR Recomm Rep.#2#19950000#1995#44#10#1-10#20110000#2036.h
tm##
00539000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100015000820100017000970120
07800114030002500192710000200217065000900219064000500228031000300233032000200236
014000500238865000900243002000900252#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2036.htm#S#c#147#6#article#21#6#^rND^sClyne^nG#^rND^sEdwards^nR#Understan
ding economic evaluations: a guide for health and human services^len#Can J Progr
am Evaluation#2#20020000#2002#17#3#1-23#20110000#2036.htm##
00522000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100015000820120066000970300
00500163710000200168065000900170064000500179031000400184032000500188014000700193
237002600200865000900226002000900235#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2036.htm#S#c#148#7#article#21#7#^rND^sCoast^nJ#Is economic evaluation in 
touch with society´s health values?^len#BMJ.#2#20040000#2004#329#7476#1233-6#10.
1136/bmj.329.7476.1233#20110000#2036.htm##
00724000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100028000820100019001100100
01700129010001700146010001800163012005400181016001700235018009700252066001500349
062000800364065000900372064000500381014000600386865000900392002000900401#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#c#149#8#article#21#8#^rND^
sContandriopoulos^nA-P#^rND^sChampagne^nF#^rND^sDenis^nJ-L#^rND^sHartz^nZMA#^rND
^sPineault^nR#A avaliação na área da saúde: conceitos e métodos^lpt#^rND^sHartz^
nZMA#Avaliação em saúde: dos modelos conceituais à prática na análise da implant
ação de programas^lpt#Rio de Janeiro#Fiocruz#19970000#1997#29-47#20110000#2036.h
tm##
00721000000000349000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100020000820100017001020100
01700119010001400136010001600150010001600166012008700182030000700269065000900276
06400050028503100040029003200050029401400070029923700300030686500090033600200090
0345035001000354801000700364#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
036.htm#S#c#150#9#article#21#9#^rND^sDarmstadt^nGI#^rND^sBhutta^nZA#^rND^sCousen
s^nS#^rND^sAdam^nT#^rND^sWalker^nN#^rND^sBernis^nL#Evidence-based, cost-effectiv
e interventions: how many newborn babies can we save?^len#Lancet#20050000#2005#3
65#9463#977-88#10.1016/S0140-6736(05)71088-6#20110000#2036.htm#0099-5355#Lancet#
#
00613000000000277000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100019001010120
04000120016001700160018009700177066001500274062000800289065000900297064000500306
014000600311865000900317002000900326#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2036.htm#S#c#151#10#article#21#10#^rND^sDenis^nJ-L#^rND^sChampagne^nF#Aná
lise de implantação de programas^lpt#^rND^sHartz^nZMA#Avaliação em saúde: dos mo
delos conceituais à prática na análise da implantação de programas^lpt#Rio de Ja
neiro#Fiocruz#19970000#1997#49-88#20110000#2036.htm##
00473000000000265000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100020000840120049001040300
00600153710000200159065000900161064000500170031000400175032000300179014000700182
865000900189002000900198#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.
htm#S#c#152#11#article#21#11#^rND^sDonabedian^nA#The quality of care: How can it
 be assessed?^len#JAMA.#2#19880000#1988#260#12#1743-8#20110000#2036.htm##
00663000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100018001010100
02400119010002200143010002200165012007900187030002300266710000200289065000900291
064000500300031000200305014000200307237002200309865000900331002000900340#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#c#153#12#article#21#12#^rN
D^sGeitona^nM#^rND^sHatzikou^nM#^rND^sHatzistamatiou^nZ#^rND^sAnastasiadou^nA#^r
ND^sTheodoratou^nTD#The economic burden of treating neonates in Intensive Care U
nits in Greece^len#Cost Eff Resour Alloc.#2#20070000#2007#5#9#10.1186/1478-7547-
5-9#20110000#2036.htm##
00758000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100019001010100
02800120010001500148012011700163016001700280018009700297066001500394062000800409
065000900417064000500426014000700431865000900438002000900447#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2036.htm#S#c#154#13#article#21#13#^rND^sHartz^nZM
A#^rND^sChampagne^nF#^rND^sContandriopoulos^nA-P#^rND^sLeal^nMC#Avaliação do pro
grama materno-infantil: análise de implantação em sistemas locais de saúde no No
rdeste do Brasil^lpt#^rND^sHartz^nZMA#Avaliação em saúde: dos modelos conceituai
s à prática na análise de implantação de programas^lpt#Rio de Janeiro#Fiocruz#19
970000#1997#89-131#20110000#2036.htm##
00529000000000277000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100022001010120
06200123030002200185710000200207065000900209064000500218031000200223032000200225
014000600227865000900233002000900242#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2036.htm#S#c#155#14#article#21#14#^rND^sHartz^nZMA#^rND^sPouvourville^nG#
Avaliação dos programas de saúde: a eficiência em questão^lpt#Cienc Saude Coleti
va.#2#19980000#1998#3#1#68-82#20110000#2036.htm##
00547000000000265000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840120120001000300
01500220710000200235065000900237064000500246031000300251032000200254014000700256
865000900263002000900272#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.
htm#S#c#156#15#article#21#15#^rND^sJowett^nM#Safe motherhood interventions in lo
w-income countries: an economic justification and evidence of cost effectiveness
^len#Health Policy.#2#20000000#2000#53#3#201-28#20110000#2036.htm##
00635000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100018001010100
01700119012009800136030003000234710000200264065000900266064000500275031000300280
032000200283014000500285237002500290865000900315002000900324#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2036.htm#S#c#157#16#article#21#16#^rND^sMacinko^n
J#^rND^sGuanais^nFC#^rND^sSouza^nMFM#An evaluation of impact of the Family Healt
h Program on infant mortality in Brazil, 1990-2002^len#J Epidemiol Community Hea
lth.#2#20060000#2006#60#1#13-9#10.1136/jech.2005.038323#20110000#2036.htm##
00692000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100017001000100
01800117010001600135010002200151010001500173810000600188012009300194030002100287
71000020030806500090031006400050031903100030032403200020032701400070032986500090
0336002000900345#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#c#
158#17#article#21#17#^rND^sMalta^nDC#^rND^sDuarte^nEC#^rND^sAlmeida^nMF#^rND^sDi
as^nMAS#^rND^sMorais Neto^nOL#^rND^sMoura^nL#et al#Lista de causas de mortes evi
táveis por intervenções do Sistema Único de Saúde do Brasil^lpt#Epidemiol Serv S
aude#2#20070000#2007#16#4#233-44#20110000#2036.htm##
00618000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100018001010120
07500119030001800194065000900212064000500221031000300226032000200229014000700231
237003200238865000900270002000900279035001000288801001800298#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2036.htm#S#c#159#18#article#21#18#^rND^sMinuci^nE
G#^rND^sAlmeida^nMF#Diferenciais intra-urbanos de peso ao nascer no município de
 São Paulo^lpt#Rev Saude Publica#20090000#2009#43#2#256-66#10.1590/S0034-8910200
9005000011#20110000#2036.htm#0034-8910#Rev Saude Publica##
00719000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100020001020100
01500122010001800137010001900155012008400174030001800258065000900276064000500285
03100030029003200020029301400080029523700320030386500090033500200090034403500100
0353801001800363#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2036.htm#S#c#
160#19#article#21#19#^rND^sRibeiro^nAM#^rND^sGuimarães^nMJ#^rND^sLima^nMC#^rND^s
Sarinho^nSW#^rND^sCoutinho^nSB#Fatores de risco para mortalidade neonatal em cri
anças com baixo peso ao nascer^lpt#Rev Saude Publica#20090000#2009#43#2#246-255#
10.1590/S0034-89102009005000004#20110000#2036.htm#0034-8910#Rev Saude Publica##
00742000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100016001020100
01800118010001600136010001600152010001800168810000600186012009000192030001100282
06500090029306400050030203100040030703200020031101400050031323700230031886500090
0341002000900350035001000359801001100369#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2036.htm#S#c#161#20#article#21#20#^rND^sRussell^nRB#^rND^sGreen^nNS#^
rND^sSteiner^nCA#^rND^sMeikle^nS#^rND^sHowse^nJL#^rND^sPoschman^nK#et al#Cost of
 hospitalization for preterm and low birth weigth infants in the United States^l
en#Pediatrics#20070000#2007#120#1#e1-9#10.1542/peds.2006-2386#20110000#2036.htm#
0031-4005#Pediatrics##
00580000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100019001010120
06800120030002100188710000200209065000900211064000500220031000300225032000400228
014000800232237003200240865000900272002000900281#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2036.htm#S#c#162#21#article#21#21#^rND^sSancho^nLG#^rND^sVarg
ens^nJMC#Avaliação econômica em saúde na esfera de atenção local à saúde^lpt#Cie
nc Saude Coletiva#2#20090000#2009#14#^s1#1513-21#10.1590/S1413-81232009000800025
#20110000#2036.htm##
00276000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00400102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#o#1#1#arti
cle#1#20110325#111828#2403.htm#170##
07710000000000793000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000400095121000300099049000300102158000300105030001900108
03200060012706500090013301400070014203500100014922300090015901200780016801200860
02460120094003320100047004260100039004730100046005120100036005580100037005940100
04000631010003600671070014600707070009400853070010500947070010701052070007901159
08316980123808500100293608500370294608500460298308500280302908500310305708316920
30880850010047800850036047900850033048260850028048590850031048870831777049180850
01006695085003606705085004606741085003106787085003406818058000506852117000806857
072000306865112000906868111001006877114000906887113001106896002000906907#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#h#2#1#article#1#oa#pt#br1.
1#1#4.0#TAB#15#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0#0034-8910#20110401
#Judicialização do acesso a medicamentos no Estado de Minas Gerais, Brasil^lpt#J
udicialization of access to medicines in Minas Gerais state, Southeastern Brazil
^len#Judicialización del acceso a medicamentos en el Estado de Minas Gerais, Sur
este de Brasil^les#^rND^1A01 A02^nMarina Amaral de Ávila^sMachado#^rND^1A02^nFra
ncisco de Assis^sAcurcio#^rND^1A03 A04^nCristina Mariano Ruas^sBrandão#^rND^1A05
^nDaniel Resende^sFaleiros#^rND^1A05^nAugusto Afonso^sGuerra Jr#^rND^1A04^nMariâ
ngela Leal^sCherchiglia#^rND^1A04^nEli Iola Gurgel^sAndrade#Universidade Federal
 de Minas Gerais^iA01^1Faculdade de Farmácia^2Programa de Pós-Graduação em Ciênc
ias Farmacêuticas^cBelo Horizonte^sMG^pBrasil#UFMG^iA02^1Faculdade de Farmácia^2
Departamento de Farmácia Social^cBelo Horizonte^sMG^pBrasil#UFMG^iA03^1Faculdade
 de Medicina^2Programa de Pós-Graduação em Saúde Pública^cBelo Horizonte^sMG^pBr
asil#UFMG^iA04^1Faculdade de Medicina^2Departamento de Medicina Preventiva e Soc
ial^cBelo Horizonte^sMG^pBrasil#Secretaria de Estado de Saúde de Minas Gerais^iA
05^cBelo Horizonte^sMG^pBrasil#^lpt^aOBJETIVO: Analisar o perfil dos requerentes
 e dos medicamentos pleiteados em ações judiciais. MÉTODOS: Estudo descritivo so
bre 827 processos judiciais com 1.777 pedidos de medicamentos de 2005 a 2006 no 
Estado de Minas Gerais. Avaliaram-se os tipos de atendimento no sistema de saúde
 e a representação dos autores junto ao Poder Judiciário. Os medicamentos foram 
descritos segundo registro na Agência Nacional de Vigilância Sanitária, essencia
lidade, inclusão programática no Sistema Único de Saúde e evidências de eficácia
. RESULTADOS: Mais de 70% dos autores foram atendidos no sistema privado de saúd
e e 60,3% foram representados por advogados particulares. O diagnóstico mais fre
qüente foi o de artrite reumatóide (23,1%) e os imunossupressores foram os medic
amentos mais solicitados (principalmente adalimumabe e etanercepte). Aproximadam
ente 5% dos medicamentos pleiteados não eram registrados na Agência, 19,6% estav
am presentes na Relação Nacional de Medicamentos Essenciais, 24,3% compunham o P
rograma de Medicamentos de Alto Custo e 53,9% apresentavam evidência consistente
 de eficácia. Dentre os medicamentos não disponíveis no sistema público, 79,0% a
presentavam alternativa terapêutica nos programas de assistência farmacêutica. C
ONCLUSÕES: O fenômeno da judicialização na saúde pode indicar falhas do sistema 
público de saúde, uma vez que há solicitações de medicamentos constantes de suas
 listas. Todavia, constitui um obstáculo para a prática do uso racional de medic
amentos e para a consolidação das premissas da Política Nacional de Medicamentos
, principalmente quando são solicitados medicamentos sem comprovação de eficácia
 e não padronizados pelo Sistema Único de Saúde.#^ddecs^i1#^tm^lpt^kAssistência 
Farmacêutica^i1#^tm^lpt^kPolítica Nacional de Medicamentos^i1#^tm^lpt^kDireito à
 saúde^i1#^tm^lpt^kDecisões judiciais^i1#^len^aOBJECTIVE: To analyze the profile
 of claimants and medicines demanded in lawsuits. METHODS: Descriptive study tha
t examined 827 lawsuits with 1,777 demands of access to medicines in the period 
between July 2005 and June 2006 in the state of Minas Gerais, Southeastern Brazi
l. There were examined the type of health care provided to claimants and their a
ttorneyship. The medicines were described based on the following: drug registrat
ion at the National Health Surveillance Agency (Anvisa); wheter they were essent
ial medicines; supply in the Brazilian Health System programs; and evidence of d
rug efficacy. RESULTS: More than 70% of the claimants were provided care in the 
private health system and 60.3% hired private lawyers. The most common diagnosis
 of claimants was rheumatoid arthritis (23.1%) and the immunosuppressant agents 
were the most frequent demand medicines (mainly adalimumab and etanercept). Appr
oximately 5% of the medicines demanded were not registered at Anvisa, 19.6% were
 included in the Brazilian List of Essential Medicine, 24.3% were included in th
e High-Cost Drug Program and 53.9% showed consistent evidence of efficacy. Among
 the medicines that were not available in Brazilian Health System, 79.0% had the
rapeutic alternatives in drug programs. CONCLUSIONS: The phenomenon of judiciali
zation of health in Brazil can point out failures in the public health system as
 some medicines demanded are included in its lists. However, it is a barrier for
 rational drug use and application of the National Drug Policy guidelines, espec
ially when there are demanded medicines with no evidence of efficacy and that ar
e not included in Brazilian Health System standards.#^ddecs^i2#^tm^len^kPharmace
utical Services^i2#^tm^len^kNational Drug Policy^i2#^tm^len^kRight to Health^i2#
^tm^len^kJudicial Decisions^i2#^les^aOBJETIVO: Analizar el perfil de los require
ntes y de los medicamentos pleiteados en acciones judiciales. MÉTODOS: Estudio d
escriptivo sobre 827 procesos judiciales con 1.777 pedidos de medicamentos de 20
05 a 2006 en el Estado de Minas Gerais, Sureste de Brasil. Se evaluaron los tipo
s de asistencia en el sistema de salud y la representación de los autores junto 
al Poder Judicial. Los medicamentos fueron descritos según registro en la Agenci
a Nacional de Vigilancia Sanitaria, esencialidad, inclusión programática en el S
istema Único de Salud y evidencias de eficiencia. RESULTADOS: Más de 70% de los 
autores fueron atendidos en el sistema privado de salud y 60,3% fueron represent
ados por abogados particulares. El diagnóstico más frecuente fue el de artritis 
reumatoidea (23,1%) y los inmunosupresores fueron los más solicitados (principal
mente adalimumabe y etanercepte). Aproximadamente 5% de los medicamentos pleitea
dos no eran registrados en la Agencia, 19,6% estaban presentes en la Relación Na
cional de Medicamentos Esenciales, 24,3% componían el Programa de Medicamentos d
e Alto Costo y 53,9% presentaban evidencia consistente de eficiencia. Entre los 
medicamentos no disponibles en el sistema público, 79,0% presentaban alternativa
 terapéutica en los programas de asistencia farmacéutica. CONCLUSIONES: El fenóm
eno de la judicialización en la salud puede indicar fallas del sistema público d
e salud, dado que hay solicitudes de medicamentos constantes de sus listas. Aún 
constituye un obstáculo para la práctica del uso racional de medicamentos y para
 la consolidación de las premisas de la Política Nacional de Medicamentos, princ
ipalmente cuando son solicitados medicamentos sin comprobación de eficiencia y n
o estandarizados por el Sistema Único de Salud.#^ddecs^i3#^tm^les^kServicios Far
macéuticos^i3#^tm^les^kPolítica Nacional de Medicamentos^i3#^tm^les^kDerecho a l
a Salud^i3#^tm^les^kDecisiones Judiciales^i3#GPFE#vancouv#15#20100630#30/6/2010#
20101114#14/11/2010#2403.htm##
07815000000000793000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000400095121000300099049000300102158000300105030001900108
03200060012706500090013301400070014203500100014922300090015901200850016801200930
02530120101003460100047004470100039004940100046005330100036005790100037006150100
04000652010003600692070014600728070009400874070010500968070010701073070007901180
08317260125908500100298508500370299508500460303208500280307808500310310608317200
31370850010048570850036048670850033049030850028049360850031049640831805049950850
01006800085003606810085004606846085003106892085003406923058000506957117000806962
072000306970112000906973111001006982114000906992113001107001002000907012#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#f#3#1#article#1#oa#pt#br1.
1#1#4.0#TAB#15#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0#0034-8910#20110401
#<b>Judicialização do acesso a medicamentos no Estado de Minas Gerais, Brasil</b
>^lpt#<b>Judicialization of access to medicines in Minas Gerais state, Southeast
ern Brazil</b>^len#<b>Judicialización del acceso a medicamentos en el Estado de 
Minas Gerais, Sureste de Brasil</b>^les#^rND^1A01 A02^nMarina Amaral de Ávila^sM
achado#^rND^1A02^nFrancisco de Assis^sAcurcio#^rND^1A03 A04^nCristina Mariano Ru
as^sBrandão#^rND^1A05^nDaniel Resende^sFaleiros#^rND^1A05^nAugusto Afonso^sGuerr
a Jr#^rND^1A04^nMariângela Leal^sCherchiglia#^rND^1A04^nEli Iola Gurgel^sAndrade
#Universidade Federal de Minas Gerais^iA01^1Faculdade de Farmácia^2Programa de P
ós-Graduação em Ciências Farmacêuticas^cBelo Horizonte^sMG^pBrasil#UFMG^iA02^1Fa
culdade de Farmácia^2Departamento de Farmácia Social^cBelo Horizonte^sMG^pBrasil
#UFMG^iA03^1Faculdade de Medicina^2Programa de Pós-Graduação em Saúde Pública^cB
elo Horizonte^sMG^pBrasil#UFMG^iA04^1Faculdade de Medicina^2Departamento de Medi
cina Preventiva e Social^cBelo Horizonte^sMG^pBrasil#Secretaria de Estado de Saú
de de Minas Gerais^iA05^cBelo Horizonte^sMG^pBrasil#^lpt^a<b>OBJETIVO:</b> Anali
sar o perfil dos requerentes e dos medicamentos pleiteados em ações judiciais. <
b>MÉTODOS:</b> Estudo descritivo sobre 827 processos judiciais com 1.777 pedidos
 de medicamentos de 2005 a 2006 no Estado de Minas Gerais. Avaliaram-se os tipos
 de atendimento no sistema de saúde e a representação dos autores junto ao Poder
 Judiciário. Os medicamentos foram descritos segundo registro na Agência Naciona
l de Vigilância Sanitária, essencialidade, inclusão programática no Sistema Únic
o de Saúde e evidências de eficácia. <b>RESULTADOS:</b> Mais de 70% dos autores 
foram atendidos no sistema privado de saúde e 60,3% foram representados por advo
gados particulares. O diagnóstico mais freqüente foi o de artrite reumatóide (23
,1%) e os imunossupressores foram os medicamentos mais solicitados (principalmen
te adalimumabe e etanercepte). Aproximadamente 5% dos medicamentos pleiteados nã
o eram registrados na Agência, 19,6% estavam presentes na Relação Nacional de Me
dicamentos Essenciais, 24,3% compunham o Programa de Medicamentos de Alto Custo 
e 53,9% apresentavam evidência consistente de eficácia. Dentre os medicamentos n
ão disponíveis no sistema público, 79,0% apresentavam alternativa terapêutica no
s programas de assistência farmacêutica. <b>CONCLUSÕES:</b> O fenômeno da judici
alização na saúde pode indicar falhas do sistema público de saúde, uma vez que h
á solicitações de medicamentos constantes de suas listas. Todavia, constitui um 
obstáculo para a prática do uso racional de medicamentos e para a consolidação d
as premissas da Política Nacional de Medicamentos, principalmente quando são sol
icitados medicamentos sem comprovação de eficácia e não padronizados pelo Sistem
a Único de Saúde.#^ddecs^i1#^tm^lpt^kAssistência Farmacêutica^i1#^tm^lpt^kPolíti
ca Nacional de Medicamentos^i1#^tm^lpt^kDireito à saúde^i1#^tm^lpt^kDecisões jud
iciais^i1#^len^a<b>OBJECTIVE:</b> To analyze the profile of claimants and medici
nes demanded in lawsuits. <b>METHODS:</b> Descriptive study that examined 827 la
wsuits with 1,777 demands of access to medicines in the period between July 2005
 and June 2006 in the state of Minas Gerais, Southeastern Brazil. There were exa
mined the type of health care provided to claimants and their attorneyship. The 
medicines were described based on the following: drug registration at the Nation
al Health Surveillance Agency (Anvisa); wheter they were essential medicines; su
pply in the Brazilian Health System programs; and evidence of drug efficacy. <b>
RESULTS:</b> More than 70% of the claimants were provided care in the private he
alth system and 60.3% hired private lawyers. The most common diagnosis of claima
nts was rheumatoid arthritis (23.1%) and the immunosuppressant agents were the m
ost frequent demand medicines (mainly adalimumab and etanercept). Approximately 
5% of the medicines demanded were not registered at Anvisa, 19.6% were included 
in the Brazilian List of Essential Medicine, 24.3% were included in the High-Cos
t Drug Program and 53.9% showed consistent evidence of efficacy. Among the medic
ines that were not available in Brazilian Health System, 79.0% had therapeutic a
lternatives in drug programs. <b>CONCLUSIONS:</b> The phenomenon of judicializat
ion of health in Brazil can point out failures in the public health system as so
me medicines demanded are included in its lists. However, it is a barrier for ra
tional drug use and application of the National Drug Policy guidelines, especial
ly when there are demanded medicines with no evidence of efficacy and that are n
ot included in Brazilian Health System standards.#^ddecs^i2#^tm^len^kPharmaceuti
cal Services^i2#^tm^len^kNational Drug Policy^i2#^tm^len^kRight to Health^i2#^tm
^len^kJudicial Decisions^i2#^les^a<b>OBJETIVO:</b> Analizar el perfil de los req
uirentes y de los medicamentos pleiteados en acciones judiciales. <b>MÉTODOS:</b
> Estudio descriptivo sobre 827 procesos judiciales con 1.777 pedidos de medicam
entos de 2005 a 2006 en el Estado de Minas Gerais, Sureste de Brasil. Se evaluar
on los tipos de asistencia en el sistema de salud y la representación de los aut
ores junto al Poder Judicial. Los medicamentos fueron descritos según registro e
n la Agencia Nacional de Vigilancia Sanitaria, esencialidad, inclusión programát
ica en el Sistema Único de Salud y evidencias de eficiencia. <b>RESULTADOS:</b> 
Más de 70% de los autores fueron atendidos en el sistema privado de salud y 60,3
% fueron representados por abogados particulares. El diagnóstico más frecuente f
ue el de artritis reumatoidea (23,1%) y los inmunosupresores fueron los más soli
citados (principalmente adalimumabe y etanercepte). Aproximadamente 5% de los me
dicamentos pleiteados no eran registrados en la Agencia, 19,6% estaban presentes
 en la Relación Nacional de Medicamentos Esenciales, 24,3% componían el Programa
 de Medicamentos de Alto Costo y 53,9% presentaban evidencia consistente de efic
iencia. Entre los medicamentos no disponibles en el sistema público, 79,0% prese
ntaban alternativa terapéutica en los programas de asistencia farmacéutica. <b>C
ONCLUSIONES:</b> El fenómeno de la judicialización en la salud puede indicar fal
las del sistema público de salud, dado que hay solicitudes de medicamentos const
antes de sus listas. Aún constituye un obstáculo para la práctica del uso racion
al de medicamentos y para la consolidación de las premisas de la Política Nacion
al de Medicamentos, principalmente cuando son solicitados medicamentos sin compr
obación de eficiencia y no estandarizados por el Sistema Único de Salud.#^ddecs^
i3#^tm^les^kServicios Farmacéuticos^i3#^tm^les^kPolítica Nacional de Medicamento
s^i3#^tm^les^kDerecho a la Salud^i3#^tm^les^kDecisiones Judiciales^i3#GPFE#vanco
uv#15#20100630#30/6/2010#20101114#14/11/2010#2403.htm##
08052000000000817000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098038000400102121000300106049000300109158000300112
03000190011503200060013406500090014001400070014903500100015622300090016601200780
01750120086002530120094003390100047004330100039004800100046005190100036005650100
04100601010004000642010003600682070014800718070009600866070010700962070010901069
07000810117808317700125908500100302908500370303908500460307608500280312208500310
31500831748031810850010049290850036049390850033049750850028050080850031050360831
85705067085001006924085003606934085004606970085003107016085003407047058000507081
11700080708607200030709411200090709711100100710611400090711611300110712500200090
7136008008907145#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#l#
4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#tab#15#nd#nd#Rev. saúde pública#ahead#201
10000#^f0^l0#0034-8910#20110401#Judicialização do acesso a medicamentos no Estad
o de Minas Gerais, Brasil^lpt#Judicialization of access to medicines in Minas Ge
rais state, Southeastern Brazil^len#Judicialización del acceso a medicamentos en
 el Estado de Minas Gerais, Sureste de Brasil^les#^rND^1A01 A02^nMarina Amaral d
e Ávila^sMachado#^rND^1A02^nFrancisco de Assis^sAcurcio#^rND^1A03 A04^nCristina 
Mariano Ruas^sBrandão#^rND^1A05^nDaniel Resende^sFaleiros#^rND^1A05^nAugusto Afo
nso^sGuerra Júnior#^rND^1A04^nMariângela Leal^sCherchiglia#^rND^1A04^nEli Iola G
urgel^sAndrade#^iA01^1Universidade Federal de Minas Gerais^2Faculdade de Farmáci
a^3Programa de Pós-Graduação em Ciências Farmacêuticas^cBelo Horizonte^sMG^pBras
il#^iA02^1UFMG^2Faculdade de Farmácia^3Departamento de Farmácia Social^cBelo Hor
izonte^sMG^pBrasil#^iA03^1UFMG^2Faculdade de Medicina^3Programa de Pós-Graduação
 em Saúde Pública^cBelo Horizonte^sMG^pBrasil#^iA04^1UFMG^2Faculdade de Medicina
^3Departamento de Medicina Preventiva e Social^cBelo Horizonte^sMG^pBrasil#^iA05
^1Secretaria de Estado de Saúde de Minas Gerais^cBelo Horizonte^sMG^pBrasil#^lpt
^aOBJETIVO: Analisar o perfil dos requerentes e dos medicamentos pleiteados em a
ções judiciais. MÉTODOS: Estudo descritivo sobre 827 processos judiciais com 1.7
77 pedidos de medicamentos de 2005 a 2006 no Estado de Minas Gerais. Avaliaram-s
e os tipos de atendimento no sistema de saúde e a representação dos autores junt
o ao Poder Judiciário. Os medicamentos foram descritos segundo registro na Agênc
ia Nacional de Vigilância Sanitária, essencialidade, inclusão programática no Si
stema Único de Saúde e evidências de eficácia. RESULTADOS: Mais de 70 por cento 
dos autores foram atendidos no sistema privado de saúde e 60,3 por cento foram r
epresentados por advogados particulares. O diagnóstico mais freqüente foi o de a
rtrite reumatóide (23,1 por cento) e os imunossupressores foram os medicamentos 
mais solicitados (principalmente adalimumabe e etanercepte). Aproximadamente 5 p
or cento dos medicamentos pleiteados não eram registrados na Agência, 19,6 por c
ento estavam presentes na Relação Nacional de Medicamentos Essenciais, 24,3 por 
cento compunham o Programa de Medicamentos de Alto Custo e 53,9 por cento aprese
ntavam evidência consistente de eficácia. Dentre os medicamentos não disponíveis
 no sistema público, 79,0 por cento apresentavam alternativa terapêutica nos pro
gramas de assistência farmacêutica. CONCLUSÕES: O fenômeno da judicialização na 
saúde pode indicar falhas do sistema público de saúde, uma vez que há solicitaçõ
es de medicamentos constantes de suas listas. Todavia, constitui um obstáculo pa
ra a prática do uso racional de medicamentos e para a consolidação das premissas
 da Política Nacional de Medicamentos, principalmente quando são solicitados med
icamentos sem comprovação de eficácia e não padronizados pelo Sistema Único de S
aúde.#^ddecs^i1#^tm^lpt^kAssistência Farmacêutica^i1#^tm^lpt^kPolítica Nacional 
de Medicamentos^i1#^tm^lpt^kDireito à saúde^i1#^tm^lpt^kDecisões judiciais^i1#^l
en^aOBJECTIVE: To analyze the profile of claimants and medicines demanded in law
suits. METHODS: Descriptive study that examined 827 lawsuits with 1,777 demands 
of access to medicines in the period between July 2005 and June 2006 in the stat
e of Minas Gerais, Southeastern Brazil. There were examined the type of health c
are provided to claimants and their attorneyship. The medicines were described b
ased on the following: drug registration at the National Health Surveillance Age
ncy (Anvisa); wheter they were essential medicines; supply in the Brazilian Heal
th System programs; and evidence of drug efficacy. RESULTS: More than 70 percent
 of the claimants were provided care in the private health system and 60.3 perce
nt hired private lawyers. The most common diagnosis of claimants was rheumatoid 
arthritis (23.1 percent) and the immunosuppressant agents were the most frequent
 demand medicines (mainly adalimumab and etanercept). Approximately 5 percent of
 the medicines demanded were not registered at Anvisa, 19.6 percent were include
d in the Brazilian List of Essential Medicine, 24.3 percent were included in the
 High-Cost Drug Program and 53.9 percent showed consistent evidence of efficacy.
 Among the medicines that were not available in Brazilian Health System, 79.0 pe
rcent had therapeutic alternatives in drug programs. CONCLUSIONS: The phenomenon
 of judicialization of health in Brazil can point out failures in the public hea
lth system as some medicines demanded are included in its lists. However, it is 
a barrier for rational drug use and application of the National Drug Policy guid
elines, especially when there are demanded medicines with no evidence of efficac
y and that are not included in Brazilian Health System standards.#^ddecs^i2#^tm^
len^kPharmaceutical Services^i2#^tm^len^kNational Drug Policy^i2#^tm^len^kRight 
to Health^i2#^tm^len^kJudicial Decisions^i2#^les^aOBJETIVO: Analizar el perfil d
e los requirentes y de los medicamentos pleiteados en acciones judiciales. MÉTOD
OS: Estudio descriptivo sobre 827 procesos judiciales con 1.777 pedidos de medic
amentos de 2005 a 2006 en el Estado de Minas Gerais, Sureste de Brasil. Se evalu
aron los tipos de asistencia en el sistema de salud y la representación de los a
utores junto al Poder Judicial. Los medicamentos fueron descritos según registro
 en la Agencia Nacional de Vigilancia Sanitaria, esencialidad, inclusión program
ática en el Sistema Único de Salud y evidencias de eficiencia. RESULTADOS: Más d
e 70 por ciento de los autores fueron atendidos en el sistema privado de salud y
 60,3 por ciento fueron representados por abogados particulares. El diagnóstico 
más frecuente fue el de artritis reumatoidea (23,1 por ciento) y los inmunosupre
sores fueron los más solicitados (principalmente adalimumabe y etanercepte). Apr
oximadamente 5 por ciento de los medicamentos pleiteados no eran registrados en 
la Agencia, 19,6 por ciento estaban presentes en la Relación Nacional de Medicam
entos Esenciales, 24,3 por ciento componían el Programa de Medicamentos de Alto 
Costo y 53,9 por ciento presentaban evidencia consistente de eficiencia. Entre l
os medicamentos no disponibles en el sistema público, 79,0 por ciento presentaba
n alternativa terapéutica en los programas de asistencia farmacéutica. CONCLUSIO
NES: El fenómeno de la judicialización en la salud puede indicar fallas del sist
ema público de salud, dado que hay solicitudes de medicamentos constantes de sus
 listas. Aún constituye un obstáculo para la práctica del uso racional de medica
mentos y para la consolidación de las premisas de la Política Nacional de Medica
mentos, principalmente cuando son solicitados medicamentos sin comprobación de e
ficiencia y no estandarizados por el Sistema Único de Salud.#^ddecs^i3#^tm^les^k
Servicios Farmacéuticos^i3#^tm^les^kPolítica Nacional de Medicamentos^i3#^tm^les
^kDerecho a la Salud^i3#^tm^les^kDecisiones Judiciales^i3#GPFE#vancouv#15#201006
30#30/6/2010#20101114#14/11/2010#2403.htm#Internet^ihttp://www.scielo.br/scielo.
php?script=sci_arttext&pid=S0034-89102011005000015##
00432000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704019800079002000900277#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#5#1#article#151#<p><a name="top"
></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Judicializa&
ccedil;&atilde;o    do acesso a medicamentos no Estado de Minas Gerais, Brasil</
b></font></p>     ^cY#2403.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#6#2#article#151#<p>&nbsp;</p>   
  ^cY#2403.htm##
00408000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704017400079002000900253#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#7#3#article#151#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Judicialization    of access t
o medicines in Minas Gerais state, Southeastern Brazil</b></font></p>     ^cY#24
03.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#8#4#article#151#<p>&nbsp;</p>   
  ^cY#2403.htm##
00423000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704018900079002000900268#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#9#5#article#151#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Judicializaci&oacute;n    del 
acceso a medicamentos en el Estado de Minas Gerais, Sureste de Brasil</b></font>
</p>     ^cY#2403.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#10#6#article#151#<p>&nbsp;</p>  
   ^cY#2403.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#11#7#article#151#<p>&nbsp;</p>  
   ^cY#2403.htm##
00648000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704041300080002000900493#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#12#8#article#151#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Marina Amaral    de &Aacute;v
ila Machado<sup>I, II</sup>; Francisco de Assis Acurcio<sup>II</sup>;    Cristin
a Mariano Ruas Brand&atilde;o<sup>III, IV</sup>; Daniel Resende Faleiros<sup>V</
sup>;    Augusto Afonso Guerra Jr<sup>V</sup>; Mari&acirc;ngela Leal Cherchiglia
<sup>IV</sup>;    Eli Iola Gurgel Andrade<sup>IV</sup></b></font></p>     ^cY#24
03.htm##
00514000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704027900080002000900359#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#13#9#article#151#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Programa    de P&oac
ute;s-Gradua&ccedil;&atilde;o em Ci&ecirc;ncias Farmac&ecirc;uticas.    Faculdad
e de Farm&aacute;cia. Universidade Federal de Minas Gerais (UFMG). Belo    Horiz
onte, MG, Brasil    ^cY#2403.htm##
00369000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704013300081002000900214#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#14#10#article#151#<br>   <sup>II
</sup>Departamento de Farm&aacute;cia Social. Faculdade de Farm&aacute;cia.    U
FMG. Belo Horizonte, MG, Brasil    ^cY#2403.htm##
00402000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704016600081002000900247#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#15#11#article#151#<br>   <sup>II
I</sup>Programa de P&oacute;s-Gradua&ccedil;&atilde;o em Sa&uacute;de    P&uacut
e;blica. Faculdade de Medicina. UFMG. Belo Horizonte, MG, Brasil    ^cY#2403.htm
##
00368000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704013200081002000900213#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#16#12#article#151#<br>   <sup>IV
</sup>Departamento de Medicina Preventiva e Social. Faculdade de Medicina.    UF
MG. Belo Horizonte, MG, Brasil    ^cY#2403.htm##
00358000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704012200081002000900203#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#17#13#article#151#<br>   <sup>V<
/sup>Secretaria de Estado de Sa&uacute;de de Minas Gerais. Belo Horizonte,    MG
, Brasil</font></p>     ^cY#2403.htm##
00380000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014400081002000900225#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#18#14#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecir
c;ncia    | Correspondence</a></font></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#19#15#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704004400081002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#20#16#article#151#<p>&nbsp;</p> 
<hr size="1" noshade>     ^cY#2403.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#21#17#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^c
Y#2403.htm##
00427000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704019100081002000900272#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#22#18#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analisar o 
perfil dos requerentes e dos medicamentos pleiteados em a&ccedil;&otilde;es    j
udiciais.    ^cY#2403.htm##
00801000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704056500081002000900646#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#23#19#article#151#<br>   <b>M&Ea
cute;TODOS:</b> Estudo descritivo sobre 827 processos judiciais com 1.777    ped
idos de medicamentos de 2005 a 2006 no Estado de Minas Gerais. Avaliaram-se    o
s tipos de atendimento no sistema de sa&uacute;de e a representa&ccedil;&atilde;
o    dos autores junto ao Poder Judici&aacute;rio. Os medicamentos foram descrit
os    segundo registro na Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacut
e;ria,    essencialidade, inclus&atilde;o program&aacute;tica no Sistema &Uacute
;nico    de Sa&uacute;de e evid&ecirc;ncias de efic&aacute;cia.    ^cY#2403.htm#
#
01109000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704087300081002000900954#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#24#20#article#151#<br>   <b>RESU
LTADOS:</b> Mais de 70% dos autores foram atendidos no sistema privado    de sa&
uacute;de e 60,3% foram representados por advogados particulares. O diagn&oacute
;stico    mais freq&uuml;ente foi o de artrite reumat&oacute;ide (23,1%) e os im
unossupressores    foram os medicamentos mais solicitados (principalmente adalim
umabe e etanercepte).    Aproximadamente 5% dos medicamentos pleiteados n&atilde
;o eram registrados na    Ag&ecirc;ncia, 19,6% estavam presentes na Rela&ccedil;
&atilde;o Nacional de    Medicamentos Essenciais, 24,3% compunham o Programa de 
Medicamentos de Alto    Custo e 53,9% apresentavam evid&ecirc;ncia consistente d
e efic&aacute;cia. Dentre    os medicamentos n&atilde;o dispon&iacute;veis no si
stema p&uacute;blico, 79,0%    apresentavam alternativa terap&ecirc;utica nos pr
ogramas de assist&ecirc;ncia    farmac&ecirc;utica.    ^cY#2403.htm##
00893000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704065700081002000900738#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#25#21#article#151#<br>   <b>CONC
LUS&Otilde;ES:</b> O fen&ocirc;meno da judicializa&ccedil;&atilde;o na    sa&uac
ute;de pode indicar falhas do sistema p&uacute;blico de sa&uacute;de,    uma vez
 que h&aacute; solicita&ccedil;&otilde;es de medicamentos constantes    de suas 
listas. Todavia, constitui um obst&aacute;culo para a pr&aacute;tica    do uso r
acional de medicamentos e para a consolida&ccedil;&atilde;o das premissas    da 
Pol&iacute;tica Nacional de Medicamentos, principalmente quando s&atilde;o    so
licitados medicamentos sem comprova&ccedil;&atilde;o de efic&aacute;cia e    n&a
tilde;o padronizados pelo Sistema &Uacute;nico de Sa&uacute;de.</font></p>     ^
cY#2403.htm##
00505000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704026900081002000900350#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#26#22#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> Assist&
ecirc;ncia Farmac&ecirc;utica. Pol&iacute;tica Nacional de Medicamentos.    Dire
ito &agrave; sa&uacute;de. Decis&otilde;es judiciais.</font></p> <hr size="1" no
shade>     ^cY#2403.htm##
00334000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009800081002000900179#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#27#23#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     
^cY#2403.htm##
00399000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704016300081002000900244#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#28#24#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To analyze
 the profile of claimants and medicines demanded in lawsuits.    ^cY#2403.htm##
00799000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704056300081002000900644#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#29#25#article#151#<br>   <b>METH
ODS:</b> Descriptive study that examined 827 lawsuits with 1,777 demands    of a
ccess to medicines in the period between July 2005 and June 2006 in the    state
 of Minas Gerais, Southeastern Brazil. There were examined the type of    health
 care provided to claimants and their attorneyship. The medicines were    descri
bed based on the following: drug registration at the National Health Surveillanc
e    Agency (Anvisa); wheter they were essential medicines; supply in the Brazil
ian    Health System programs; and evidence of drug efficacy.    ^cY#2403.htm##
00947000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704071100081002000900792#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#30#26#article#151#<br>   <b>RESU
LTS:</b> More than 70% of the claimants were provided care in the private    hea
lth system and 60.3% hired private lawyers. The most common diagnosis of    clai
mants was rheumatoid arthritis (23.1%) and the immunosuppressant agents    were 
the most frequent demand medicines (mainly adalimumab and etanercept).    Approx
imately 5% of the medicines demanded were not registered at Anvisa, 19.6%    wer
e included in the Brazilian List of Essential Medicine, 24.3% were included    i
n the High-Cost Drug Program and 53.9% showed consistent evidence of efficacy.  
  Among the medicines that were not available in Brazilian Health System, 79.0% 
   had therapeutic alternatives in drug programs.    ^cY#2403.htm##
00697000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704046100081002000900542#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#31#27#article#151#<br>   <b>CONC
LUSIONS:</b> The phenomenon of judicialization of health in Brazil can    point 
out failures in the public health system as some medicines demanded are    inclu
ded in its lists. However, it is a barrier for rational drug use and application
    of the National Drug Policy guidelines, especially when there are demanded m
edicines    with no evidence of efficacy and that are not included in Brazilian 
Health System    standards.</font></p>     ^cY#2403.htm##
00451000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704021500081002000900296#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#32#28#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:    </b> Pharmac
eutical Services. National Drug Policy. Right to Health. Judicial    Decisions.<
/font></p> <hr size="1" noshade>     ^cY#2403.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#33#29#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^
cY#2403.htm##
00424000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018800081002000900269#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#34#30#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analizar el
 perfil de los requirentes y de los medicamentos pleiteados en acciones    judic
iales.    ^cY#2403.htm##
00785000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704054900081002000900630#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#35#31#article#151#<br>   <b>M&Ea
cute;TODOS:</b> Estudio descriptivo sobre 827 procesos judiciales con    1.777 p
edidos de medicamentos de 2005 a 2006 en el Estado de Minas Gerais, Sureste    d
e Brasil. Se evaluaron los tipos de asistencia en el sistema de salud y la    re
presentaci&oacute;n de los autores junto al Poder Judicial. Los medicamentos    
fueron descritos seg&uacute;n registro en la Agencia Nacional de Vigilancia    S
anitaria, esencialidad, inclusi&oacute;n program&aacute;tica en el Sistema    &U
acute;nico de Salud y evidencias de eficiencia.    ^cY#2403.htm##
01075000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704083900081002000900920#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#36#32#article#151#<br>   <b>RESU
LTADOS:</b> M&aacute;s de 70% de los autores fueron atendidos en el sistema    p
rivado de salud y 60,3% fueron representados por abogados particulares. El    di
agn&oacute;stico m&aacute;s frecuente fue el de artritis reumatoidea (23,1%)    
y los inmunosupresores fueron los m&aacute;s solicitados (principalmente adalimu
mabe    y etanercepte). Aproximadamente 5% de los medicamentos pleiteados no era
n registrados    en la Agencia, 19,6% estaban presentes en la Relaci&oacute;n Na
cional de Medicamentos    Esenciales, 24,3% compon&iacute;an el Programa de Medi
camentos de Alto Costo    y 53,9% presentaban evidencia consistente de eficienci
a. Entre los medicamentos    no disponibles en el sistema p&uacute;blico, 79,0% 
presentaban alternativa terap&eacute;utica    en los programas de asistencia far
mac&eacute;utica.    ^cY#2403.htm##
00827000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704059100081002000900672#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#37#33#article#151#<br>   <b>CONC
LUSIONES:</b> El fen&oacute;meno de la judicializaci&oacute;n en la salud    pue
de indicar fallas del sistema p&uacute;blico de salud, dado que hay solicitudes 
   de medicamentos constantes de sus listas. A&uacute;n constituye un obst&aacut
e;culo    para la pr&aacute;ctica del uso racional de medicamentos y para la con
solidaci&oacute;n    de las premisas de la Pol&iacute;tica Nacional de Medicamen
tos, principalmente    cuando son solicitados medicamentos sin comprobaci&oacute
;n de eficiencia y    no estandarizados por el Sistema &Uacute;nico de Salud.</f
ont></p>     ^cY#2403.htm##
00485000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704024900081002000900330#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#38#34#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:    </b> Servic
ios Farmac&eacute;uticos. Pol&iacute;tica Nacional de Medicamentos.    Derecho a
 la Salud. Decisiones Judiciales.</font></p> <hr size="1" noshade>     ^cY#2403.
htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#39#35#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#40#36#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00350000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011400081002000900195#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#41#37#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b>
</font></p>     ^cY#2403.htm##
01503000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704126700081002000901348#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#42#38#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A judicializa&ccedil;&atilde;o 
   da sa&uacute;de &eacute; um fen&ocirc;meno que pode prejudicar a execu&ccedil
;&atilde;o    de pol&iacute;ticas de sa&uacute;de no &acirc;mbito do Sistema &Ua
cute;nico    de Sa&uacute;de (SUS), uma vez que o cumprimento de determina&ccedi
l;&otilde;es    judiciais para fornecimento de medicamentos, insumos e servi&cce
dil;os de sa&uacute;de    acarreta gastos elevados e n&atilde;o programados. Em 
2005, o Governo Federal    gastou diretamente R$ 2,5 milh&otilde;es com aquisi&c
cedil;&atilde;o de medicamentos    solicitados pela via judicial e foi citado co
mo r&eacute;u em 387 processos.    Em 2007, o gasto passou para R$ 15 milh&otild
e;es destinados ao atendimento    de aproximadamente tr&ecirc;s mil a&ccedil;&ot
ilde;es. Em 2008, as despesas    alcan&ccedil;aram R$ 52 milh&otilde;es.<sup><a 
name="topa"></a><a href="#backa">a</a>,<a name="topb"></a><a href="#backb">b</a>
</sup>    O Estado de Minas Gerais gastou nesses anos, respectivamente, R$ 8,5 m
ilh&otilde;es,    R$ 22,8 milh&otilde;es e R$ 42,5 milh&otilde;es com o cumprime
nto de processos    judiciais na &aacute;rea da sa&uacute;de.<a name="topc"></a>
<a href="#backc"><sup>c</sup></a></font></p>     ^cY#2403.htm##
01102000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704086600081002000900947#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#43#39#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O Conselho Nacional    de Secre
t&aacute;rios de Sa&uacute;de divulgou em 2004 que a&ccedil;&otilde;es    judici
ais para fornecimento de medicamentos excepcionais ocorreram de forma    freq&uu
ml;ente em 18 estados brasileiros, tendo como principais raz&otilde;es    a falt
a de medicamentos, o n&atilde;o cumprimento de crit&eacute;rios de protocolos   
 cl&iacute;nicos e a solicita&ccedil;&atilde;o de medicamentos n&atilde;o padron
izados.<a name="topd"></a><a href="#backd"><sup>d</sup></a>    Medicamentos disp
on&iacute;veis na rede de aten&ccedil;&atilde;o b&aacute;sica    e outros sem re
gistro na Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria    (Anvisa
) ou sem evid&ecirc;ncias de efic&aacute;cia tamb&eacute;m s&atilde;o    pleitea
dos dessa forma.<sup>10,14</sup></font></p>     ^cY#2403.htm##
01561000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704132500081002000901406#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#44#40#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O SUS tem como    uma de suas a
tribui&ccedil;&otilde;es executar a&ccedil;&otilde;es de assist&ecirc;ncia    te
rap&ecirc;utica integral. A Pol&iacute;tica Nacional de Medicamentos (PNM)<a nam
e="tope"></a><a href="#backe"><sup>e</sup></a>    foi elaborada para garantir o 
acesso da popula&ccedil;&atilde;o a medicamentos    seguros, eficazes e de quali
dade, e para promover seu uso racional. Contudo,    pacientes t&ecirc;m recorrid
o ao Poder Judici&aacute;rio, e o uso desse mecanismo    para o recebimento de m
edicamentos pode acarretar preju&iacute;zos &agrave;    eq&uuml;idade na sa&uacu
te;de.<sup>14</sup> A PNM determina as responsabilidades    de cada esfera do go
verno no &acirc;mbito da assist&ecirc;ncia farmac&ecirc;utica    e o processo de
 judicializa&ccedil;&atilde;o da sa&uacute;de desconsidera essa    normatiza&cce
dil;&atilde;o. O munic&iacute;pio &eacute; freq&uuml;entemente    obrigado a for
necer medicamentos do Programa de Medicamentos de Dispensa&ccedil;&atilde;o    E
xcepcional,<a name="topf"></a><a href="#backf"><sup>f</sup></a> que s&atilde;o  
  de responsabilidade da gest&atilde;o estadual, e esta, por sua vez, &eacute;  
  compelida a fornecer medicamentos da aten&ccedil;&atilde;o b&aacute;sica.<sup>
10,14</sup></font></p>     ^cY#2403.htm##
01016000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704078000081002000900861#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#45#41#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Poucos estudos    publicados av
aliam o fen&ocirc;meno recente da judicializa&ccedil;&atilde;o    no &acirc;mbit
o da sa&uacute;de p&uacute;blica, e isso requer melhor compreens&atilde;o    par
a seu adequado enfrentamento. No &acirc;mbito das a&ccedil;&otilde;es interposta
s    contra o Minist&eacute;rio da Sa&uacute;de entre janeiro de 2003 e agosto d
e    2005, o Estado de Minas Gerais foi identificado como o de maior volume de d
emandas    judiciais por medicamentos no Pa&iacute;s.<a name="topg"></a><a href=
"#backg"><sup>g</sup></a>    O presente trabalho teve como objetivo descrever o 
perfil dos requerentes e    dos medicamentos pleiteados por a&ccedil;&otilde;es 
judiciais contra o Estado.</font></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#46#42#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00340000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010400081002000900185#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#47#43#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p
>     ^cY#2403.htm##
00806000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704057000081002000900651#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#48#44#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudo descritivo    de process
os judiciais com demandas de medicamentos interpostos contra o Estado    de Mina
s Gerais de julho de 2005 a junho de 2006. A coleta de dados foi realizada    po
r equipe treinada, utilizando question&aacute;rio estruturado previamente    tes
tado. Os dados foram obtidos na Procuradoria Geral do Estado de Minas Gerais    
em Belo Horizonte e nas regionais de Juiz de Fora, Uberl&acirc;ndia, Divin&oacut
e;polis    e Passos, de novembro de 2006 a maio de 2007.</font></p>     ^cY#2403
.htm##
01216000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704098000081002000901061#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#49#45#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As vari&aacute;veis    pesquisa
das foram: n&uacute;mero do processo; patrono da a&ccedil;&atilde;o,<a name="top
h"></a><a href="#backh"><sup>h</sup></a>    sexo, idade, ocupa&ccedil;&atilde;o,
 munic&iacute;pio de resid&ecirc;ncia e    representa&ccedil;&atilde;o do autor 
no Poder Judici&aacute;rio; nome do m&eacute;dico    prescritor; origem do atend
imento de sa&uacute;de (p&uacute;blico e privado);    munic&iacute;pio do estabe
lecimento de sa&uacute;de em que ocorreu o atendimento;    diagn&oacute;stico re
lativo ao autor do pedido; nome, forma farmac&ecirc;utica    e concentra&ccedil;
&atilde;o do(s) medicamento(s) solicitado(s). A representa&ccedil;&atilde;o    n
o Poder Judici&aacute;rio foi classificada em: escrit&oacute;rio de advocacia,  
  Defensoria P&uacute;blica, Minist&eacute;rio P&uacute;blico, N&uacute;cleo de 
   Assist&ecirc;ncia Judici&aacute;ria e Juizado Especial Federal.</font></p>   
  ^cY#2403.htm##
00586000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035000081002000900431#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#50#46#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os medicamentos    foram classi
ficados segundo o Sistema Anat&ocirc;mico e Terap&ecirc;utico Qu&iacute;mico    
(c&oacute;digo ATC),<a name="topi"></a><a href="#backi"><sup>i</sup></a> registr
o    na Anvisa, essencialidade e inclus&atilde;o program&aacute;tica no SUS.</fo
nt></p>     ^cY#2403.htm##
00894000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704065800081002000900739#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#51#47#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As informa&ccedil;&otilde;es   
 sobre registro dos medicamentos no Brasil foram obtidas no banco de dados de   
 medicamentos e hemoderivados da Anvisa.<a name="topj"></a><a href="#backj"><sup
>j</sup></a>    A essencialidade foi avaliada segundo a presen&ccedil;a na Rela&
ccedil;&atilde;o    Nacional de Medicamentos Essenciais (Rename) de 2006 e na li
sta modelo de medicamentos    essenciais da Organiza&ccedil;&atilde;o Mundial de
 Sa&uacute;de (OMS) de 2007.<a name="topk"></a><a href="#backk"><sup>k</sup></a>
<sup>,</sup><a name="topl"></a><a href="#backl"><sup>l</sup></a></font></p>     
^cY#2403.htm##
00937000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704070100081002000900782#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#52#48#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os medicamentos    foram classi
ficados quanto &agrave; presen&ccedil;a em listas padronizadas dos    programas 
da Secretaria de Estado de Sa&uacute;de de Minas Gerais (SES/MG)<a name="topm"><
/a><a href="#backm"><sup>m</sup></a>    da seguinte forma: (1) Programa de Medic
amentos de Alto Custo (PMAC);<a name="topn"></a><a href="#backn"><sup>n</sup></a
>    (2) medicamentos do componente de Assist&ecirc;ncia Farmac&ecirc;utica B&aa
cute;sica;    (3) programas estrat&eacute;gicos; (4) n&atilde;o pertencente a ne
nhum programa    da SES/MG (n&atilde;o inclu&iacute;do em nenhuma classifica&cce
dil;&atilde;o    anterior).</font></p>     ^cY#2403.htm##
00672000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704043600081002000900517#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#53#49#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Para os medicamentos    da cate
goria 4, verificou-se a exist&ecirc;ncia de alternativas terap&ecirc;uticas    n
os programas de assist&ecirc;ncia farmac&ecirc;utica da SES/MG (categorias    1 
a 3). Medicamentos com o mesmo c&oacute;digo ATC n&iacute;vel 3 (subgrupo    far
macol&oacute;gico) foram considerados alternativas terap&ecirc;uticas entre    s
i.</font></p>     ^cY#2403.htm##
00715000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704047900081002000900560#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#54#50#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Realizou-se an&aacute;lise    d
e evid&ecirc;ncias cient&iacute;ficas de efic&aacute;cia para os medicamentos   
 por meio de pesquisa de revis&otilde;es sistem&aacute;ticas no banco de dados  
  do Centro Cochrane do Brasil<a name="topo"></a><a href="#backo">º</a> e dados 
   em literatura especializada,<sup>2</sup> relacionando os medicamentos com os 
   diagn&oacute;sticos relativos aos autores.</font></p>     ^cY#2403.htm##
00768000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704053200081002000900613#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#55#51#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os dados foram    sumarizados. 
Distribui&ccedil;&otilde;es de freq&uuml;&ecirc;ncia foram apresentadas    para 
vari&aacute;veis categ&oacute;ricas e medidas de tend&ecirc;ncia central,    par
a vari&aacute;veis cont&iacute;nuas. O <i>software</i> Excel<sup>&reg;</sup>    
vers&atilde;o 2003 foi empregado para a constru&ccedil;&atilde;o do banco de    
dados e o EpiInfo<sup>&reg;</sup> vers&atilde;o 3.4.3 para a an&aacute;lise    e
stat&iacute;stica.</font></p>     ^cY#2403.htm##
00471000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704023500081002000900316#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#56#52#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O projeto de pesquisa    foi ap
rovado pelo Comit&ecirc; de &Eacute;tica em Pesquisa da Universidade Federal    
de Minas Gerais (parecer nº ETIC 292/08).</font></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#57#53#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010000081002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#58#54#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>   
  ^cY#2403.htm##
01131000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704089500081002000900976#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#59#55#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Dos 873 processos    judiciais 
com demandas de medicamentos no per&iacute;odo estudado, 820 (93,9%)    foram an
alisados. Dentre os n&atilde;o investigados, dez (1,1%) estavam com    procurado
res, oito (0,9%) n&atilde;o foram encontrados nos arquivos da Procuradoria    em
 Belo Horizonte, 29 (3,3%) encontravam-se em outras cidades e n&atilde;o se    o
btiveram informa&ccedil;&otilde;es sobre seis (0,7%). Um processo com oito    au
tores foi desmembrado para fins de an&aacute;lise. Logo, 827 processos foram    
considerados para an&aacute;lise e resultaram em 1.777 pedidos de medicamentos, 
   correspondentes a 381 itens diferentes. Os processos apresentaram em m&eacute
;dia    2,1 pedidos (desvio-padr&atilde;o 2,2, amplitude = 1 a 16), 66,3% contin
ham    apenas um medicamento e 16,0%, quatro ou mais pedidos.</font></p>     ^cY
#2403.htm##
00925000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704068900081002000900770#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#60#56#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Dentre os processos    com info
rma&ccedil;&otilde;es dispon&iacute;veis (<a href="#t1">Tabela 1</a>),    60,2% 
dos autores eram do sexo feminino, 35,4% apresentavam 60 anos ou mais,    e a id
ade m&eacute;dia era de 48,2 anos (desvio-padr&atilde;o 22,3, amplitude    = 1 a
 94). Aproximadamente 63% residiam no interior de Minas Gerais, 37,4% eram    ap
osentados ou pensionistas, 20,8% eram donas de casa. O diagn&oacute;stico    mai
s freq&uuml;ente foi o de artrite reumat&oacute;ide (23,1%), seguido pelo    de 
diabetes <i>mellitus</i> tipo 1 (6,5%) e hipertens&atilde;o arterial sist&ecirc;
mica    (5,5%).</font></p>     ^cY#2403.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#61#57#article#151#<p><a name="t1
"></a></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#62#58#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#63#59#article#151#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2403t01.jpg"></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#64#60#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00940000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704070400081002000900785#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#65#61#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O munic&iacute;pio    de atendi
mento m&eacute;dico estava identificado em 545 processos, dos quais    metade co
rrespondia ao interior do estado e 47,9% &agrave; capital mineira.    A origem d
o atendimento foi identificada em 535 processos: 70,5% receberam aten&ccedil;&at
ilde;o    no sistema privado de sa&uacute;de e 25,8% no SUS (<a href="#t1">Tabel
a 1</a>).    Na rede particular, dez m&eacute;dicos assistiram 106 autores de pr
ocessos (28,1%    de 377 pacientes) e um profissional destacou-se pelo cuidado d
e 84 pessoas (22,3%,    n = 377). Os 217 m&eacute;dicos restantes atenderam 271 
pacientes (71,9%, n    = 377).</font></p>     ^cY#2403.htm##
00786000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704055000081002000900631#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#66#62#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Mais da metade    dos autores d
os processos foi representada por advogados particulares e 23,1%    pela Defenso
ria P&uacute;blica (n = 785) (<a href="#t1">Tabela 1</a>). Dentre    os escrit&o
acute;rios de advocacia, dez foram respons&aacute;veis por 304 processos    (64,
3%, n = 473), dois escrit&oacute;rios com representa&ccedil;&atilde;o em    155 
processos, e outro em 77, enquanto 140 advogados apresentaram 169 a&ccedil;&otil
de;es    judiciais (35,7%, n = 473).</font></p>     ^cY#2403.htm##
01306000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704107000081002000901151#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#67#63#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Conforme classifica&ccedil;&ati
lde;o    do grupo anat&ocirc;mico principal do c&oacute;digo ATC, 21,4% dos medi
camentos    (n = 1.777) eram do sistema nervoso; 18,3% do sistema cardiovascular
; 16,4%    agentes antineopl&aacute;sicos e imunomoduladores; 15,6% do trato ali
mentar    e metabolismo; 5,7% do sistema hematopoi&eacute;tico; 4,7% do sistema 
respirat&oacute;rio;    4,7% do sistema m&uacute;sculo-esquel&eacute;tico; 3,9% 
horm&ocirc;nios sist&ecirc;micos    - exceto horm&ocirc;nios sexuais e insulina 
-; 2,1% antiinfecciosos de uso sist&ecirc;mico;    1,5% de &oacute;rg&atilde;os 
sensoriais; 1,4% do sistema geniturin&aacute;rio    e horm&ocirc;nios sexuais; 0
,5% produtos antiparasit&aacute;rios; 0,3% do grupo    V, que inclui medicamento
s n&atilde;o classificados nos outros grupos; 0,2%    prepara&ccedil;&otilde;es 
dermatol&oacute;gicas; 3,3% n&atilde;o foram classificados    por falta de infor
ma&ccedil;&atilde;o ou por n&atilde;o possu&iacute;rem c&oacute;digo    ATC.</fo
nt></p>     ^cY#2403.htm##
00628000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704039200081002000900473#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#68#64#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Imunossupressores    foi o subg
rupo farmacol&oacute;gico mais solicitado (13,6%), majoritariamente    represent
ado pelo adalimumabe (155 pedidos) e etanercepte (50 pedidos), requeridos    pri
ncipalmente para o tratamento de artrite reumat&oacute;ide e espondilite    anqu
ilosante (<a href="#t2">Tabela 2</a>).</font></p>     ^cY#2403.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#69#65#article#151#<p><a name="t2
"></a></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#70#66#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#71#67#article#151#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2403t02.jpg"></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#72#68#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00704000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704046800081002000900549#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#73#69#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Aproximadamente    5% dos medic
amentos n&atilde;o continham registro na Anvisa, 19,6% estavam presentes    na R
ename e 11,1% eram essenciais, de acordo com a lista da OMS. Quase um quarto    
compunha o PMAC, 10,9% eram do componente b&aacute;sico, 3,5% eram dos Programas
    Estrat&eacute;gicos e 56,7% n&atilde;o pertenciam a nenhum programa da SES/M
G    (<a href="#t3">Tabela 3</a>).</font></p>     ^cY#2403.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#74#70#article#151#<p><a name="t3
"></a></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#75#71#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#76#72#article#151#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2403t03.jpg"></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#77#73#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00633000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704039700081002000900478#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#78#74#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Dos 1.008 medicamentos    n&ati
lde;o inclu&iacute;dos em programas da SES/MG, observou-se exist&ecirc;ncia    d
e alternativa terap&ecirc;utica para 79,0% e falta de alternativas para 16,9%.  
  A an&aacute;lise n&atilde;o foi realizada para 4,1% dos medicamentos que n&ati
lde;o    possu&iacute;am c&oacute;digo ATC.</font></p>     ^cY#2403.htm##
01187000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704095100081002000901032#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#79#75#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A pesquisa por    evid&ecirc;nc
ias cient&iacute;ficas de efic&aacute;cia foi realizada para os    1.675 medicam
entos relativos aos casos em que havia relato do diagn&oacute;stico    no proces
so judicial. Havia evid&ecirc;ncia consistente de efic&aacute;cia para    53,9% 
dos medicamentos, a evid&ecirc;ncia era limitada para 7,3% e n&atilde;o    havia
 evid&ecirc;ncia comprovada para 3,7%. Nenhuma informa&ccedil;&atilde;o    foi e
ncontrada nas fontes utilizadas na an&aacute;lise de efic&aacute;cia para    33,
4% dos medicamentos pesquisados. Os compostos de vitaminas, isoladas ou em    co
mbina&ccedil;&atilde;o (20,7%, n = 58), predominaram entre os medicamentos    se
m evid&ecirc;ncia comprovada de efic&aacute;cia. Dos 559 medicamentos sem    inf
orma&ccedil;&otilde;es sobre evid&ecirc;ncia, 5,4% eram associa&ccedil;&otilde;e
s    de dois ou mais f&aacute;rmacos.</font></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#80#76#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00342000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010600081002000900187#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#81#77#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font><
/p>     ^cY#2403.htm##
00975000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704073900081002000900820#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#82#78#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Grande parte dos    pacientes q
ue ingressaram no Poder Judici&aacute;rio e solicitaram medicamentos    ao gesto
r estadual do SUS em Minas Gerais foi atendida no sistema privado de    sa&uacut
e;de e procurou servi&ccedil;os particulares de advocacia. Em Santa    Catarina,
 entre 2003 e 2004, 56% dos atendimentos foram feitos em servi&ccedil;os    priv
ados de sa&uacute;de e 59% das a&ccedil;&otilde;es foram conduzidas por    escri
t&oacute;rios de advocacia.<sup>12</sup> No munic&iacute;pio de S&atilde;o    Pa
ulo, SP, os servi&ccedil;os particulares de advocacia tamb&eacute;m predominaram
    entre solicitantes: 54% em 2005 e 74% em 2006.<sup>4,14</sup></font></p>    
 ^cY#2403.htm##
00984000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704074800081002000900829#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#83#79#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Esses resultados    sugerem que
 os pacientes que recorrem ao Poder Judici&aacute;rio podem ter melhores    cond
i&ccedil;&otilde;es socioecon&ocirc;micas, considerando que podem arcar    com a
s despesas processuais e podem ter maior conhecimento de seus direitos.    Essa 
hip&oacute;tese corrobora estudos que constataram maior propor&ccedil;&atilde;o 
   de processos oriundos de pacientes com menor grau de exclus&atilde;o social.<
sup>4,14</sup>    Dessa forma, a judicializa&ccedil;&atilde;o da sa&uacute;de po
deria agravar    a iniq&uuml;idade no acesso &agrave; sa&uacute;de de um sistema
 j&aacute; marcado    por desigualdades socioecon&ocirc;micas.<sup>5</sup></font
></p>     ^cY#2403.htm##
02091000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704185500081002000901936#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#84#80#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Pequena quantidade    de advoga
dos e m&eacute;dicos da rede particular predominou em muitas a&ccedil;&otilde;es
,    principalmente de pedidos de etanercepte e adalimumabe, medicamentos regist
rados    no Brasil em 2003. O primeiro &eacute; considerado inova&ccedil;&atilde
;o terap&ecirc;utica,    pois figura como f&aacute;rmaco inaugurativo de seu gru
po, apesar de acrescentar    pouco &agrave; pr&aacute;tica terap&ecirc;utica, de
pendendo da indica&ccedil;&atilde;o.    O adalimumabe &eacute; um f&aacute;rmaco
 adicional ao grupo terap&ecirc;utico    e avalia-se que tamb&eacute;m n&atilde;
o traz contribui&ccedil;&otilde;es significativas    &agrave; terapia.<a name="t
opp"></a><a href="#backp"><sup>p</sup></a> Os dois    f&aacute;rmacos somaram 20
5 solicita&ccedil;&otilde;es (24,8% dos 827 processos)    e passaram a ser conte
mplados no PMAC (protocolo da artrite reumat&oacute;ide)    a partir de outubro 
de 2006, ou seja, ap&oacute;s o per&iacute;odo em que foram    demandados. Essa 
concentra&ccedil;&atilde;o de m&eacute;dicos e de advogados    pode sugerir a ex
ist&ecirc;ncia de interesses al&eacute;m da prote&ccedil;&atilde;o    e recupera
&ccedil;&atilde;o da sa&uacute;de do paciente e a conquista de seu    direito ao
 tratamento. Essas a&ccedil;&otilde;es podem representar interesses    daqueles 
que comercializam medicamentos novos e financeiramente inacess&iacute;veis    &a
grave; popula&ccedil;&atilde;o em geral.<sup>3,8</sup> O SUS, que possui a    at
ribui&ccedil;&atilde;o de garantir a todos o direito &agrave; sa&uacute;de,    t
ornou-se um grande mercado consumidor para os novos lan&ccedil;amentos da ind&ua
cute;stria    farmac&ecirc;utica, que nem sempre atendem &agrave;s necessidades 
sanit&aacute;rias    da popula&ccedil;&atilde;o.<sup>13</sup></font></p>     ^cY
#2403.htm##
00843000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704060700081002000900688#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#85#81#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Aproximadamente    56% dos medi
camentos n&atilde;o estavam inclu&iacute;dos em programas do SUS,    e a maioria
 n&atilde;o &eacute; classificada como medicamento essencial. Estudos    com foc
o na judicializa&ccedil;&atilde;o mostram maior quantidade de medicamentos    es
senciais e/ou dispon&iacute;veis no SUS;<sup>10,14</sup> por&eacute;m, pesquisas
    realizadas em S&atilde;o Paulo<sup>4</sup> e Santa Catarina<sup>12</sup> ind
icam    predom&iacute;nio de medicamentos n&atilde;o dispensados pelo sistema p&
uacute;blico.</font></p>     ^cY#2403.htm##
01780000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704154400081002000901625#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#86#82#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">No presente estudo,    observou
-se expressiva inclus&atilde;o dos medicamentos solicitados no PMAC    (cerca de
 um quarto do total), tend&ecirc;ncia constatada em outros estudos.<sup>4,10,12<
/sup>    Tais medicamentos s&atilde;o caros, o que pode ser a principal motiva&c
cedil;&atilde;o    dos pacientes para o ingresso de a&ccedil;&otilde;es judiciai
s. Al&eacute;m    disso, o acesso a eles pelo programa exige o cumprimento dos c
rit&eacute;rios    de inclus&atilde;o dos Protocolos Cl&iacute;nicos e Diretrize
s Terap&ecirc;uticas    do Minist&eacute;rio da Sa&uacute;de e de alguns tr&acir
c;mites das Secretarias    Estaduais de Sa&uacute;de. Caso esses crit&eacute;rio
s n&atilde;o sejam atendidos,    o medicamento n&atilde;o &eacute; liberado. Ade
mais, o processo de libera&ccedil;&atilde;o    pode se delongar e &eacute; poss&
iacute;vel que o paciente prefira obt&ecirc;-lo    de forma mais r&aacute;pida p
ela via judicial. Soma-se a isso o fato de que    alguns medicamentos foram soli
citados para doen&ccedil;as diversas daquelas    contempladas no programa, o que
, <i>a priori,</i> configura impedimento ao fornecimento    do medicamento. Pere
ira et al<sup>12</sup> afirmam que alguns pacientes procuram    a via administra
tiva para obter os medicamentos do PMAC, mas, devido &agrave;    documenta&ccedi
l;&atilde;o incompleta ou ao n&atilde;o cumprimento dos crit&eacute;rios,    o p
edido &eacute; negado, o que os leva a recorrer &agrave; via judicial.</font></p
>     ^cY#2403.htm##
00661000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704042500081002000900506#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#87#83#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Outras raz&otilde;es    para pe
didos de medicamentos presentes nos programas do SUS podem ser a sua    falta na
s farm&aacute;cias por falhas no gerenciamento da assist&ecirc;ncia    farmac&ec
irc;utica e o desconhecimento das listas oficiais de medicamentos do    sistema 
p&uacute;blico por parte dos prescritores e requerentes.<sup>4,14</sup></font></
p>     ^cY#2403.htm##
00969000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704073300081002000900814#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#88#84#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A requisi&ccedil;&atilde;o    d
e v&aacute;rios medicamentos em um mesmo processo judicial pode decorrer da    s
olicita&ccedil;&atilde;o judicial de todos os medicamentos prescritos ao pacient
e    quando pelo menos um n&atilde;o &eacute; dispensado pelo SUS, independentem
ente    da disponibilidade dos demais.<sup>11</sup> Isso pode explicar a ocorr&e
circ;ncia    de medicamentos inclu&iacute;dos em programas do SUS nesses process
os,<sup>4</sup>    especialmente os medicamentos da aten&ccedil;&atilde;o b&aacu
te;sica, mais acess&iacute;veis    por serem dispensados sem a necessidade de cu
mprir crit&eacute;rios de protocolos    espec&iacute;ficos.</font></p>     ^cY#2
403.htm##
01374000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704113800081002000901219#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#89#85#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Entre os medicamentos    n&atil
de;o dispon&iacute;veis em programas da SES/MG, aproximadamente 80% possu&iacute
;am    alternativa terap&ecirc;utica na rede p&uacute;blica, valor pr&oacute;xim
o ao    encontrado em pesquisa na cidade de S&atilde;o Paulo, em que 73% possu&i
acute;am    substitutos na rela&ccedil;&atilde;o municipal de medicamentos essen
ciais e    em programas do SUS.<sup>14</sup> N&atilde;o se pode afirmar que todo
s os pacientes    seriam beneficiados com as alternativas dispon&iacute;veis no 
SUS. Seria necess&aacute;rio    avaliar cada caso com base na hist&oacute;ria cl
&iacute;nica do paciente e em    sua experi&ecirc;ncia com medicamentos (ocorr&e
circ;ncia de falha terap&ecirc;utica,    alergias e rea&ccedil;&otilde;es advers
as). Entretanto, a disponibilidade de    alternativas terap&ecirc;uticas mostra 
que a gest&atilde;o do SUS n&atilde;o    &eacute; omissa na efetiva&ccedil;&atil
de;o do acesso a medicamentos, cujas    pol&iacute;ticas p&uacute;blicas s&atild
e;o abrangentes a v&aacute;rias &aacute;reas    da sa&uacute;de.</font></p>     
^cY#2403.htm##
00955000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704071900081002000900800#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#90#86#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A pesquisa mostrou    que peque
na propor&ccedil;&atilde;o dos medicamentos n&atilde;o possu&iacute;a    registr
o na Anvisa, resultado coerente com outros estudos.<sup>12,14</sup> O    gefitin
ibe, solicitado duas vezes para c&acirc;ncer de pulm&atilde;o, n&atilde;o    tin
ha registro e sua evid&ecirc;ncia de efic&aacute;cia &eacute; limitada. Segundo 
   Machado,<sup>7</sup> uma decis&atilde;o judicial que obriga o poder p&uacute;
blico    a adquirir um medicamento n&atilde;o regulamentado no Brasil "transform
a o Judici&aacute;rio    muito mais num vocalizador de minorias privilegiadas do
 que num parceiro dos    'grupos marginais'".</font></p>     ^cY#2403.htm##
01734000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704149800081002000901579#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#91#87#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O resultado da    an&aacute;lis
e de efic&aacute;cia mostrou evid&ecirc;ncia para 53,9% dos medicamentos.    Ass
im, a judicializa&ccedil;&atilde;o excessiva pode ser um obst&aacute;culo    par
a a consolida&ccedil;&atilde;o da PNM, que objetiva garantir &agrave; popula&cce
dil;&atilde;o    medicamentos eficazes, seguros e de qualidade por meio da promo
&ccedil;&atilde;o    do uso racional de medicamentos. Medicamentos de efic&aacut
e;cia duvidosa tamb&eacute;m    foram encontrados por Vieira &amp; Zucchi<sup>14
</sup> ao analisarem os antineopl&aacute;sicos    requeridos no munic&iacute;pio
 de S&atilde;o Paulo. No presente estudo, compostos    de vitaminas predominaram
 entre os medicamentos sem evid&ecirc;ncia comprovada    de efic&aacute;cia nas 
doen&ccedil;as para as quais foram indicados. Embora    a efic&aacute;cia de v&a
acute;rias vitaminas analisadas esteja atestada pela    literatura, esses produt
os s&atilde;o comumente utilizados sem necessidade e    de forma irracional, com
o observado neste estudo, por estarem associados a um    estilo de vida saud&aac
ute;vel e &agrave; recupera&ccedil;&atilde;o da disposi&ccedil;&atilde;o    para
 as atividades di&aacute;rias. Laporte &amp; Capella<sup>6</sup> j&aacute;    al
ertavam na d&eacute;cada de 1980 que medicamentos sem provas de efic&aacute;cia 
   n&atilde;o podem ser considerados meros placebos e que seu uso pode ser preju
dicial    aos pacientes.</font></p>     ^cY#2403.htm##
01074000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704083800081002000900919#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#92#88#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A baixa freq&uuml;&ecirc;ncia  
  da essencialidade dos medicamentos requisitados sugere que a judicializa&ccedi
l;&atilde;o    contraria as prioridades em sa&uacute;de p&uacute;blica do Brasil
. Os medicamentos    essenciais s&atilde;o selecionados com base em crit&eacute;
rios de efic&aacute;cia,    seguran&ccedil;a e relev&acirc;ncia p&uacute;blica d
e forma a satisfazer as    principais necessidades sanit&aacute;rias da popula&c
cedil;&atilde;o,<sup>15</sup>    e a Rename deve orientar a prescri&ccedil;&atil
de;o e o abastecimento de medicamentos    no SUS. Como adverte Carvalho,<sup>3</
sup> a falta de crit&eacute;rios na sele&ccedil;&atilde;o    de medicamentos pod
e causar danos s&eacute;rios aos usu&aacute;rios que pretendiam    ser beneficia
dos.</font></p>     ^cY#2403.htm##
01289000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704105300081002000901134#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#93#89#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Desse modo, o perfil    de medi
camentos requeridos parece n&atilde;o corresponder &agrave;s necessidades    col
etivas na forma com que s&atilde;o contempladas pelas pol&iacute;ticas p&uacute;
blicas    de sa&uacute;de, ou seja, o que &eacute; predominantemente demandado n
a Justi&ccedil;a    &eacute; fruto de necessidades individuais. Por&eacute;m, qu
ando o Estado formula    essas pol&iacute;ticas, pretende garantir na pr&aacute;
tica o direito &agrave;    sa&uacute;de universal e integral que preconiza a Con
stitui&ccedil;&atilde;o    da Rep&uacute;blica e reduzir iniq&uuml;idades. Para 
isso, o Estado seleciona    quais servi&ccedil;os e a&ccedil;&otilde;es ser&atil
de;o priorizados com base    nos recursos dispon&iacute;veis e nas melhores evid
&ecirc;ncias de efic&aacute;cia,    seguran&ccedil;a e custo-efetividade. Como r
elembram Ferraz &amp; Vieira:<sup>5</sup>    "a necessidade individual &eacute; 
claramente insuficiente como crit&eacute;rio    alocativo".</font></p>     ^cY#2
403.htm##
01931000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704169500081002000901776#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#94#90#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A judicializa&ccedil;&atilde;o,
    por interferir demasiadamente nas pol&iacute;ticas de sa&uacute;de, transfor
mou-se    em press&atilde;o para a incorpora&ccedil;&atilde;o de medicamentos pe
lo setor    p&uacute;blico. Messeder et al<sup>10</sup> identificaram rela&ccedi
l;&atilde;o    entre o aumento de a&ccedil;&otilde;es judiciais que requisitam m
edicamentos    e sua a incorpora&ccedil;&atilde;o pelo SUS. Isso ocorreu clarame
nte com os    medicamentos para a aids<a name="topq"></a><a href="#backq"><sup>q
</sup></a>    e parece ter acontecido com a insulina glargina, incorporada pela 
SES/MG em    outubro de 2005, com o adalimumabe e o etanercepte, inclu&iacute;do
s no PMAC    em outubro de 2006, e com os medicamentos bosentana e sildenafil, c
ontemplados    em programas da SES/MG em outubro de 2009. Esse mecanismo de pres
s&atilde;o    pode gerar efeitos positivos, uma vez que induz a atualiza&ccedil;
&atilde;o    dos programas/protocolos que precisam acompanhar o desenvolvimento 
de novos    conhecimentos sobre as pr&aacute;ticas terap&ecirc;uticas. Por outro
 lado, a    gest&atilde;o p&uacute;blica pode perceber que &eacute; mais oportun
o e vi&aacute;vel    programar a aquisi&ccedil;&atilde;o e distribui&ccedil;&ati
lde;o de determinados    medicamentos do que atender &agrave;s liminares judicia
is. Entretanto, ao incorpor&aacute;-los    &agrave; rotina da assist&ecirc;ncia 
farmac&ecirc;utica sob press&atilde;o,    existe o risco de faz&ecirc;-lo de for
ma n&atilde;o atenta a crit&eacute;rios    como efic&aacute;cia, seguran&ccedil;
a e prioridades sanit&aacute;rias da popula&ccedil;&atilde;o.</font></p>     ^cY
#2403.htm##
00843000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704060700081002000900688#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#95#91#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A falta de informa&ccedil;&otil
de;es    em alguns processos dificultou a an&aacute;lise dos dados. Essa lacuna 
decorre    do acesso apenas &agrave;s c&oacute;pias dos documentos originais, al
&eacute;m    da aus&ecirc;ncia de dados espec&iacute;ficos dos autores, prescri&
ccedil;&atilde;o,    relat&oacute;rio m&eacute;dico ou outras informa&ccedil;&ot
ilde;es em muitos    processos. Entretanto, considera-se que os dados dispon&iac
ute;veis para as    an&aacute;lises foram suficientes para atender aos objetivos
 da pesquisa.</font></p>     ^cY#2403.htm##
01239000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704100300081002000901084#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#96#92#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As a&ccedil;&otilde;es    judic
iais que pretendem determinado medicamento s&atilde;o legitimadas com o    argum
ento do direito inviol&aacute;vel &agrave; sa&uacute;de, a despeito de    quest&
otilde;es pol&iacute;ticas e or&ccedil;ament&aacute;rias.<sup>8</sup>    Dessa f
orma, a sa&uacute;de &eacute; reduzida ao acesso a medicamentos, exames,    cons
ultas, &agrave; aus&ecirc;ncia de doen&ccedil;as, desconhecendo que a garantia  
  da sa&uacute;de envolve fatores sociais, econ&ocirc;micos e ambientais diverso
s,    al&eacute;m de a&ccedil;&otilde;es e servi&ccedil;os integrais de promo&cc
edil;&atilde;o,    prote&ccedil;&atilde;o e recupera&ccedil;&atilde;o da sa&uacu
te;de. A judicializa&ccedil;&atilde;o    da sa&uacute;de inverte essa l&oacute;g
ica quando desconsidera as pol&iacute;ticas    p&uacute;blicas e, conseq&uuml;en
temente, os princ&iacute;pios do SUS de universalidade,    integralidade e eq&uu
ml;idade.</font></p>     ^cY#2403.htm##
01512000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704127600081002000901357#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#97#93#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O ingresso de a&ccedil;&otilde;
es    judiciais &eacute; uma das formas que os cidad&atilde;os encontraram para 
garantir    seus direitos. Portanto, &eacute; leg&iacute;tima a a&ccedil;&atilde
;o judicial    reivindicando um medicamento contemplado nas pol&iacute;ticas p&u
acute;blicas    elaboradas pelo Poder Executivo e eventualmente n&atilde;o dispo
n&iacute;vel    no SUS, pois objetiva garantir um direito fundamental. Considera
r esse caso    como "judicializa&ccedil;&atilde;o" &eacute; desqualificar a atua
&ccedil;&atilde;o    judicial, pressupondo que o Poder Judici&aacute;rio est&aac
ute; interferindo    indevidamente na atua&ccedil;&atilde;o de outro poder.<sup>
9</sup> Entretanto,    o que se observa &eacute; um processo de judicializa&cced
il;&atilde;o excessiva,    que se manifesta pela prolifera&ccedil;&atilde;o de d
ecis&otilde;es que condenam    o Poder P&uacute;blico ao custeio de tratamentos 
irracionais e remetem ao gestor    a responsabilidade da decis&atilde;o de aloca
&ccedil;&atilde;o de recursos que,    muitas vezes, contradiz o princ&iacute;pio
 da eq&uuml;idade em sa&uacute;de    e o acesso &agrave; assist&ecirc;ncia &agra
ve; sa&uacute;de de qualidade.<sup>1</sup></font></p>     ^cY#2403.htm##
00846000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704061000081002000900691#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#98#94#article#151#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Assim, mesmo que    a judiciali
za&ccedil;&atilde;o indique, em certas circunst&acirc;ncias, falhas    a serem s
anadas no sistema de sa&uacute;de, ela tende a se constituir predominantemente  
  em um est&iacute;mulo &agrave; medicaliza&ccedil;&atilde;o e em um obst&aacute
;culo    para o uso racional de medicamentos. Essa pr&aacute;tica prejudica a co
nsolida&ccedil;&atilde;o    das premissas da PNM e leva a uma desarticula&ccedil
;&atilde;o nas a&ccedil;&otilde;es    e servi&ccedil;os de Assist&ecirc;ncia Far
mac&ecirc;utica.</font></p>     ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#99#95#article#151#<p>&nbsp;</p> 
    ^cY#2403.htm##
00341000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704010400082002000900186#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#100#96#article#151#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="3"><b>AGRADECIMENTOS</b></font></
p>     ^cY#2403.htm##
00951000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704071400082002000900796#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#101#97#article#151#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">&Agrave; Procuradoria    Geral
 do Estado de Minas Gerais, pelo apoio log&iacute;stico e por permitir    o aces
so aos processos judiciais. Aos Grupos de Pesquisa em Farmacoepidemiologia    (G
PFE), do Departamento de Farm&aacute;cia Social, e em Economia da Sa&uacute;de  
  (GPES), do Departamento de Medicina Preventiva e Social, ambos da Universidade
    Federal de Minas Gerais, pelo apoio log&iacute;stico ao desenvolvimento do t
rabalho.    &Agrave; Isabella Vitral Pinto (bolsista de inicia&ccedil;&atilde;o 
cient&iacute;fica    do GPFE), pela participa&ccedil;&atilde;o na coleta de dado
s e desenvolvimento    do banco de dados.</font></p>     ^cY#2403.htm##
00259000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704002200082002000900104#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#102#98#article#151#<p>&nbsp;</p>
     ^cY#2403.htm##
00344000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704010700082002000900189#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#103#99#article#151#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font
></p>     ^cY#2403.htm##
00683000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704043100085002000900516#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#104#100#article#151#
1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Andrade EIG,
    Machado CD, Faleiros DR, Szuster DAC, Guerra Jr AA, Silva GD, et al. A judic
ializa&ccedil;&atilde;o    da sa&uacute;de e a pol&iacute;tica nacional de assis
t&ecirc;ncia farmac&ecirc;utica    no Brasil: gest&atilde;o da cl&iacute;nica e 
medicaliza&ccedil;&atilde;o da    justi&ccedil;a. <i>Rev Med Minas Gerais.</i> 2
008;18(4 Supl 4):S46-S50.    ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#105#101#article#151#</font></p> 
    ^cY#2403.htm##
00454000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704020200085002000900287#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#106#102#article#151#
2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. British Medi
cal    Journal. Evid&ecirc;ncia cl&iacute;nica: conciso. 11. ed. Bolner AR, trad
utor.    Porto Alegre: Artmed; 2005.    ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#107#103#article#151#</font></p> 
    ^cY#2403.htm##
00491000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704023900085002000900324#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#108#104#article#151#
3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Carvalho G. 
   Sa&uacute;de: o tudo para todos que sonhamos e o tudo que nos impingem os que
    lucram com ela. <i>Rev Cent Bras Estud Saude.</i> 2005;69(29):99-104.    ^cY
#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#109#105#article#151#</font></p> 
    ^cY#2403.htm##
00566000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704031400085002000900399#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#110#106#article#151#
4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Chieffi AL, 
   Barata RB. Judicializa&ccedil;&atilde;o da pol&iacute;tica p&uacute;blica de 
   assist&ecirc;ncia farmac&ecirc;utica e equidade. <i>Cad Saude Publica.</i> 20
09;25(8):1839-49.    DOI:10.1590/S0102-311X2009000800020</font></p>     ^cY#2403
.htm##
00560000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704030800085002000900393#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#111#107#article#151#
5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Ferraz OLM, 
   Vieira FS. Direito &agrave; sa&uacute;de, recursos escassos e equidade: os ri
scos    da interpreta&ccedil;&atilde;o judicial dominante. <i>Dados</i>. 2009;52
(1):223-51.    DOI:10.1590/S0011-52582009000100007</font></p>     ^cY#2403.htm##
00507000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704025500085002000900340#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#112#108#article#151#
6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Laporte JR, 
   Capella D. Useless drugs are not placebos: lessons from flunarizine and cinna
rizine.    <i>Lancet.</i> 1986;11(2):853-4. DOI:10.1016/S0140-6736(86)92883-7</f
ont></p>     ^cY#2403.htm##
00484000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704023200085002000900317#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#113#109#article#151#
7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Machado FRS.
    Contribui&ccedil;&otilde;es ao debate da judicializa&ccedil;&atilde;o da sa&
uacute;de    no Brasil. <i>Rev Direito Sanit.</i> 2008;9(2):73-91.    ^cY#2403.h
tm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#114#110#article#151#</font></p> 
    ^cY#2403.htm##
00551000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704029900085002000900384#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#115#111#article#151#
8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Marques SB, 
   Dallari SG. Garantia do direito social &agrave; assist&ecirc;ncia farmac&ecir
c;utica    no Estado de S&atilde;o Paulo. <i>Rev Saude Publica.</i> 2007;41(1):1
01-7. DOI:10.1590/S0034-89102007000100014</font></p>     ^cY#2403.htm##
00449000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704019700085002000900282#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#116#112#article#151#
9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Marques SB. 
   Judicializa&ccedil;&atilde;o do direito &agrave; sa&uacute;de. <i>Rev Direito
    Sanit.</i> 2008;9(2):65-72.    ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#117#113#article#151#</font></p> 
    ^cY#2403.htm##
00630000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704037700086002000900463#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#118#114#article#151#
10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Messeder A
M,    Osorio-de-Castro CGS, Luiza VL. Mandados judiciais como ferramenta para ga
rantia    do acesso a medicamentos no setor p&uacute;blico: a experi&ecirc;ncia 
do Estado    do Rio de Janeiro, Brasil. <i>Cad Saude Publica.</i> 2005;21(5):525
-34. DOI:10.1590/S0102-311X2005000200019</font></p>     ^cY#2403.htm##
00639000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704038600086002000900472#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#119#115#article#151#
11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Pepe VLE, 
Ventura    M, Sant'ana JMB, Figueiredo TA, Souza VR, Simas L, et al. Caracteriza
&ccedil;&atilde;o    de demandas judiciais de fornecimento de medicamentos "esse
nciais" no Estado    do Rio de Janeiro, Brasil. <i>Cad Saude Publica.</i> 2010;2
6(3):461-471. DOI:10.1590/S0102-311X2010000300004</font></p>     ^cY#2403.htm##
00655000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704040200086002000900488#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#120#116#article#151#
12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Pereira JR
,    Santos RI, Nascimento Jr JM, Schenkel EP. An&aacute;lise das demandas judic
iais    para o fornecimento de medicamentos pela Secretaria de Estado da Sa&uacu
te;de    de Santa Catarina nos anos de 2003 e 2004. <i>Cienc Saude Coletiva.</i>
 2007;15    (Supl 3):3551-60. DOI:10.1590/S1413-81232010000900030</font></p>    
 ^cY#2403.htm##
00532000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704027900086002000900365#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#121#117#article#151#
13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Vidotti CC
F,    Castro LLC, Calil SS. New drugs in Brazil: Do they meet Brazilian public h
ealth    needs? <i>Rev Panam Salud Publica.</i> 2008;24(1):36-45. DOI: 10.1590/S
1020-49892008000700005</font></p>     ^cY#2403.htm##
00573000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704032000086002000900406#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#122#118#article#151#
14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Vieira FS,
    Zucchi P. Distor&ccedil;&otilde;es causadas pelas a&ccedil;&otilde;es judici
ais    &agrave; pol&iacute;tica de medicamentos no Brasil. <i>Rev Saude Publica.
</i>    2007;41(2):214-22. DOI: 10.1590/S0034-89102007000200007</font></p>     ^
cY#2403.htm##
00546000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029300086002000900379#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#123#119#article#151#
15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. World Heal
th    Organization. Expert Committee on the Use of Essenctial Drugs. The use of 
the    essential drugs: model list of essential drugs (seventh list). Fifth repo
rt    of the WHO Expert Committee. Geneva; 1992.    ^cY#2403.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#124#120#article#151#</font></p> 
    ^cY#2403.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#125#121#article#151#<p>&nbsp;</p
>     ^cY#2403.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#126#122#article#151#<p>&nbsp;</p
>     ^cY#2403.htm##
00454000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021600083002000900299#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#127#123#article#151#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#
top"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    <b> Cor
respond&ecirc;ncia | Correspondence:    ^cY#2403.htm##
00295000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005700083002000900140#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#128#124#article#151#<br>   </b> 
Marina Amaral de &Aacute;vila Machado    ^cY#2403.htm##
00302000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704006400083002000900147#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#129#125#article#151#<br>   R. Da
niel de Carvalho, 1551 - Apto. 301 Gutierrez    ^cY#2403.htm##
00289000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005100083002000900134#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#130#126#article#151#<br>   30430
-050 Belo Horizonte, MG, Brasil    ^cY#2403.htm##
00341000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704010300083002000900186#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#131#127#article#151#<br>   E-mai
l: <a href="mailto:marinamaam@yahoo.com.br">marinamaam@yahoo.com.br</a></font></
p>     ^cY#2403.htm##
00328000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704009000083002000900173#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#132#128#article#151#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Recebido: 30/6/2010    ^cY#24
03.htm##
00285000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004700083002000900130#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#133#129#article#151#<br>   Aprov
ado: 14/11/2010</font></p>     ^cY#2403.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#134#130#article#151#<p>&nbsp;</p
>     ^cY#2403.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#135#131#article#151#<p>&nbsp;</p
>     ^cY#2403.htm##
00453000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021500083002000900298#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#136#132#article#151#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Trabalho apresentado    no XV
III Congresso Mundial de Epidemiologia e VII Congresso Brasileiro de Epidemiolog
ia    em Porto Alegre, RS, em 2008.    ^cY#2403.htm##
00510000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704027200083002000900355#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#137#133#article#151#<br>   Artig
o baseado na disserta&ccedil;&atilde;o de mestrado de Machado MAA apresentada   
 ao Programa de P&oacute;s-Gradua&ccedil;&atilde;o em Ci&ecirc;ncias Farmac&ecir
c;uticas    da Faculdade de Farm&aacute;cia da Universidade Federal de Minas Ger
ais em 2010.    ^cY#2403.htm##
00313000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704007500083002000900158#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#138#134#article#151#<br>   Os au
tores declaram n&atilde;o haver conflitos de interesse.    ^cY#2403.htm##
00761000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704052300083002000900606#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#139#135#article#151#<br>   <a na
me="backa"></a><a href="#topa">a</a> Minist&eacute;rio da Sa&uacute;de.    A&cce
dil;&otilde;es judiciais comprometem pol&iacute;tica de sa&uacute;de. Bras&iacut
e;lia;    2008&#91;citado 2008 out 06&#93;. Dispon&iacute;vel em: <a href="http:
//portal.saude.gov.br/portal/aplicacoes/noticias/default.cfm?pg=dspDetalheNotici
a&amp;id_area=1450&amp;CO_NOTICIA=9633" target="_blank">http://portal.saude.gov.
br/portal/aplicacoes/noticias/default.cfm?pg=dspDetalheNoticia&amp;id_area=1450&
amp;CO_NOTICIA=9633</a>    ^cY#2403.htm##
00785000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704054700083002000900630#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#140#136#article#151#<br>   <a na
me="backb"></a><a href="#topb">b</a> Minist&eacute;rio da Sa&uacute;de.    Minis
t&eacute;rio defende equil&iacute;brio nas a&ccedil;&otilde;es judiciais    de s
a&uacute;de. Bras&iacute;lia; 2009&#91;citado 2010 fev 02&#93;. Dispon&iacute;ve
l    em: <a href="http://portal.saude.gov.br/portal/aplicacoes/noticias/default.
cfm?pg=dspDetalheNoticia&amp;id_area=124&amp;CO_NOTICIA=10167" target="_blank">h
ttp://portal.saude.gov.br/portal/aplicacoes/noticias/default.cfm?pg=dspDetalheNo
ticia&amp;id_area=124&amp;CO_NOTICIA=10167</a>.    ^cY#2403.htm##
00402000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704016400083002000900247#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#141#137#article#151#<br>   <a na
me="backc"></a><a href="#topc">c</a> Dados fornecidos pela Assessoria T&eacute;c
nica    da Secretaria de Estado de Sa&uacute;de de Minas Gerais.    ^cY#2403.htm
##
00534000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704029600083002000900379#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#142#138#article#151#<br>   <a na
me="backd"></a><a href="#topd">d</a> Conselho Nacional de Secret&aacute;rios    
de Sa&uacute;de. Assist&ecirc;ncia Farmac&ecirc;utica: medicamentos de dispensa&
ccedil;&atilde;o    de car&aacute;ter excepcional. Conselho Brasil. Bras&iacute;
lia; 2004. (CONASS    documenta, 5).    ^cY#2403.htm##
00470000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704023200083002000900315#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#143#139#article#151#<br>   <a na
me="backe"></a><a href="#tope">e</a> Brasil. Portaria GM/MS nº 3916 de    30 de 
outubro de 1998. Define a Pol&iacute;tica Nacional de Medicamentos. Diario    Of
icial Uniao. 10 nov 1998, Se&ccedil;&atilde;o1:18-22    ^cY#2403.htm##
00503000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704026500083002000900348#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#144#140#article#151#<br>   <a na
me="backf"></a><a href="#topf">f</a> A Portaria MS n° 2981/2009 alterou    a den
omina&ccedil;&atilde;o do Programa de Medicamentos de Dispensa&ccedil;&atilde;o 
   Excepcional para Componente Especializado da Assist&ecirc;ncia Farmac&ecirc;u
tica.    ^cY#2403.htm##
00428000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704019000083002000900273#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#145#141#article#151#<br>   <a na
me="backg"></a><a href="#topg">g</a> Faleiros DR, Guerra Jr AA, Szuster    DAC. 
A quest&atilde;o das demandas judiciais por medicamentos no SUS. Bras&iacute;lia
;    2007.    ^cY#2403.htm##
00439000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704020100083002000900284#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#146#142#article#151#<br>   <a na
me="backh"></a><a href="#toph">h</a> Por patrono da a&ccedil;&atilde;o    entend
e-se advogado/defensor p&uacute;blico/promotor de justi&ccedil;a respons&aacute;
vel    pelo processo.    ^cY#2403.htm##
00583000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704034500083002000900428#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#147#143#article#151#<br>   <a na
me="backi"></a><a href="#topi">i</a> World Health Organization. Collaborating   
 Centre for Drug and Statistics Methodology. Anatomical Therapeutic Chemical    
Classification. Geneva; 2008&#91;citado 2008 maio 22&#93;. Dispon&iacute;vel    
em: <a href="http://www.whocc.no/atcddd/" target="_blank">http://www.whocc.no/at
cddd/    ^cY#2403.htm##
00600000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704036200083002000900445#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#148#144#article#151#<br>   </a><
a name="backj"></a><a href="#topj">j</a> Ag&ecirc;ncia Nacional de Vigil&acirc;n
cia    Sanit&aacute;ria. Banco de dados de Medicamentos. Bras&iacute;lia; 2002&#
91;citado    2008 set 11&#93;. Dispon&iacute;vel em: <a href="http://www.anvisa.
gov.br/medicamentos/banco_med.htm" target="_blank">http://www.anvisa.gov.br/medi
camentos/banco_med.htm    ^cY#2403.htm##
00584000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704034600083002000900429#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#149#145#article#151#<br>   </a><
a name="backk"></a><a href="#topk">k</a> Minist&eacute;rio da Sa&uacute;de.    S
ecretaria de Ci&ecirc;ncia, Tecnologia e Insumos Estrat&eacute;gicos. Departamen
to    de Assist&ecirc;ncia Farmac&ecirc;utica Insumos Estrat&eacute;gicos. Rela&
ccedil;&atilde;o    nacional de medicamentos essenciais. 5. ed. Bras&iacute;lia;
 2007.    ^cY#2403.htm##
00589000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704035100083002000900434#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#150#146#article#151#<br>   <a na
me="backl"></a><a href="#topl">l</a> World Health Organization. WHO Model    Lis
t. Essential Medicines.15 ed. Geneva;2007&#91;citado 2007 abr 18&#93;. Dispon&ia
cute;vel    em: <a href="http://www.who.int/medicines/publications/essentialmedi
cines/en/" target="_blank">http://www.who.int/medicines/publications/essentialme
dicines/en/    ^cY#2403.htm##
00509000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704027100083002000900354#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#151#147#article#151#<br>   </a><
a name="backm"></a><a href="#topm">m</a> Minas Gerais. Secretaria de Estado    d
e Sa&uacute;de. Superintend&ecirc;ncia de Assist&ecirc;ncia Farmac&ecirc;utica. 
   Rela&ccedil;&atilde;o estadual de medicamentos de Minas Gerais. Belo Horizont
e;    2009.    ^cY#2403.htm##
00445000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704020700083002000900290#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#152#148#article#151#<br>   <a na
me="backn"></a><a href="#topn">n</a> Em Minas Gerais, o Programa de Medicamentos
    de Dispensa&ccedil;&atilde;o Excepcional &eacute; denominado Programa de Med
icamentos    de Alto Custo.    ^cY#2403.htm##
00452000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021400083002000900297#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#153#149#article#151#<br>   <a na
me="backo"></a><a href="#topo">o</a> Cochrane Library. Dispon&iacute;vel    em: 
<a href="http://cochrane.bireme.br" target="_blank">http://cochrane.bireme.br</a
>    &#91;citado 2008 out 02&#93;.    ^cY#2403.htm##
00650000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704041200083002000900495#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#154#150#article#151#<br>   <a na
me="backp"></a><a href="#topp">p</a> Bonfim JRA. O registro de produtos    farma
c&ecirc;uticos novos: crit&eacute;rios para a promo&ccedil;&atilde;o do    uso r
acional de f&aacute;rmacos no Sistema &Uacute;nico de Sa&uacute;de &#91;disserta
&ccedil;&atilde;o    de mestrado&#93;. Coordenadoria de Controle de Doen&ccedil;
as da Secretaria    de Estado da Sa&uacute;de de S&atilde;o Paulo; 2006.    ^cY#
2403.htm##
00614000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704037600083002000900459#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2403.htm#S#p#155#151#article#151#<br>   <a na
me="backq"></a><a href="#topq">q</a> Minist&eacute;rio da Sa&uacute;de.    Secre
taria de Vigil&acirc;ncia em Sa&uacute;de. Programa Nacional de DST e AIDS.    O
 Rem&eacute;dio via Justi&ccedil;a: um estudo sobre o acesso a novos medicamento
s    e exames em HIV/AIDS no Brasil por meio de a&ccedil;&otilde;es judiciais. B
ras&iacute;lia;    2005.</font></p>     ^cY#2403.htm##
00745000000000337000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100019000820100018001010100
01900119010001900138010002000157010001600177810000600193012013600199030002200335
71000020035706500090035906400050036803100030037303200050037601400080038186500090
0389002000900398#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#c#
156#1#article#15#1#^rND^sAndrade^nEIG#^rND^sMachado^nCD#^rND^sFaleiros^nDR#^rND^
sSzuster^nDAC#^rND^sGuerra Jr^nAA#^rND^sSilva^nGD#et al#A judicialização da saúd
e e a política nacional de assistência farmacêutica no Brasil: gestão da clínica
 e medicalização da justiça^lpt#Rev Med Minas Gerais.#2#20080000#2008#18#4^s4#S4
6-S50#20110000#2403.htm##
00434000000000241000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800170024000820180031001060630
00300137066001300140062000700153065000900160064000500169865000900174002000900183
#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#c#157#2#article#15
#2#British Medical Journal#Evidência clínica: conciso^lpt#11#Porto Alegre#Artmed
#20050000#2005#20110000#2403.htm##
00530000000000265000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820120090001000300
02700190710000200217065000900219064000500228031000300233032000300236014000700239
865000900246002000900255#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.
htm#S#c#158#3#article#15#3#^rND^sCarvalho^nG#Saúde: o tudo para todos que sonham
os e o tudo que nos impingem os que lucram com ela^lpt#Rev Cent Bras Estud Saude
.#2#20050000#2005#69#29#99-104#20110000#2403.htm##
00583000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100017001000120
07800117030001900195710000200214065000900216064000500225031000300230032000200233
014000800235237003200243865000900275002000900284#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2403.htm#S#c#159#4#article#15#4#^rND^sChieffi^nAL#^rND^sBarat
a^nRB#Judicialização da política pública de assistência farmacêutica e equidade^
lpt#Cad Saude Publica.#2#20090000#2009#25#8#1839-49#10.1590/S0102-311X2009000800
020#20110000#2403.htm##
00614000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100017001000120
09700117030000600214065000900220064000500229031000300234032000200237014000700239
237003200246865000900278002000900287035001000296801000600306#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2403.htm#S#c#160#5#article#15#5#^rND^sFerraz^nOLM
#^rND^sVieira^nFS#Direito à saúde, recursos escassos e equidade: os riscos da in
terpretação judicial dominante^lpt#Dados#20090000#2009#52#1#223-51#10.1590/S0011
-52582009000100007#20110000#2403.htm#0011-5258#Dados##
00567000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100017001000120
07700117030000800194710000200202065000900204064000500213031000300218032000200221
014000600223237003000229865000900259002000900268#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2403.htm#S#c#161#6#article#15#6#^rND^sLaporte^nJR#^rND^sCapel
la^nD#Useless drugs are not placebos: lessons from flunarizine and cinnarizine^l
en#Lancet.#2#19860000#1986#11#2#853-4#10.1016/S0140-6736(86)92883-7#20110000#240
3.htm##
00495000000000265000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100019000820120065001010300
01900166710000200185065000900187064000500196031000200201032000200203014000600205
865000900211002000900220#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.
htm#S#c#162#7#article#15#7#^rND^sMachado^nFRS#Contribuições ao debate da judicia
lização da saúde no Brasil^lpt#Rev Direito Sanit.#2#20080000#2008#9#2#73-91#2011
0000#2403.htm##
00585000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100018001000120
08100118030001900199710000200218065000900220064000500229031000300234032000200237
014000600239237003200245865000900277002000900286#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2403.htm#S#c#163#8#article#15#8#^rND^sMarques^nSB#^rND^sDalla
ri^nSG#Garantia do direito social à assistência farmacêutica no Estado de São Pa
ulo^lpt#Rev Saude Publica.#2#20070000#2007#41#1#101-7#10.1590/S0034-891020070001
00014#20110000#2403.htm##
00467000000000265000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820120038001000300
01900138710000200157065000900159064000500168031000200173032000200175014000600177
865000900183002000900192#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2403.
htm#S#c#164#9#article#15#9#^rND^sMarques^nSB#Judicialização do direito à saúde^l
pt#Rev Direito Sanit.#2#20080000#2008#9#2#65-72#20110000#2403.htm##
00692000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100028001030100
01600131012014600147030001900293710000200312065000900314064000500323031000300328
032000200331014000700333237003200340865000900372002000900381#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2403.htm#S#c#165#10#article#15#10#^rND^sMesseder^
nAM#^rND^sOsorio-de-Castro^nCGS#^rND^sLuiza^nVL#Mandados judiciais como ferramen
ta para garantia do acesso a medicamentos no setor público: a experiência do Est
ado do Rio de Janeiro, Brasil^lpt#Cad Saude Publica.#2#20050000#2005#21#5#525-34
#10.1590/S0102-311X2005000200019#20110000#2403.htm##
00765000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100017001000100
02000117010002100137010001600158010001500174810000600189012012200195030001900317
71000020033606500090033806400050034703100030035203200020035501400080035723700320
0365865000900397002000900406#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
403.htm#S#c#166#11#article#15#11#^rND^sPepe^nVLE#^rND^sVentura^nM#^rND^sSant'ana
^nJMB#^rND^sFigueiredo^nTA#^rND^sSouza^nVR#^rND^sSimas^nL#et al#Caracterização d
e demandas judiciais de fornecimento de medicamentos "essenciais" no Estado do R
io de Janeiro, Brasil^lpt#Cad Saude Publica.#2#20100000#2010#26#3#461-471#10.159
0/S0102-311X2010000300004#20110000#2403.htm##
00727000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100017001020100
02400119010001900143012014800162030002200310710000200332065000900334064000500343
031000300348032000400351014000800355237003200363865000900395002000900404#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#c#167#12#article#15#12#^rN
D^sPereira^nJR#^rND^sSantos^nRI#^rND^sNascimento Jr^nJM#^rND^sSchenkel^nEP#Análi
se das demandas judiciais para o fornecimento de medicamentos pela Secretaria de
 Estado da Saúde de Santa Catarina nos anos de 2003 e 2004^lpt#Cienc Saude Colet
iva.#2#20070000#2007#15#^s3#3551-60#10.1590/S1413-81232010000900030#20110000#240
3.htm##
00610000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100018001030100
01600121012006900137030002500206710000200231065000900233064000500242031000300247
032000200250014000600252237003200258865000900290002000900299#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2403.htm#S#c#168#13#article#15#13#^rND^sVidotti^n
CCF#^rND^sCastro^nLLC#^rND^sCalil^nSS#New drugs in Brazil: Do they meet Brazilia
n public health needs?^len#Rev Panam Salud Publica.#2#20080000#2008#24#1#36-45#1
0.1590/S1020-49892008000700005#20110000#2403.htm##
00587000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100016001010120
08300117030001900200710000200219065000900221064000500230031000300235032000200238
014000700240237003200247865000900279002000900288#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2403.htm#S#c#169#14#article#15#14#^rND^sVieira^nFS#^rND^sZucc
hi^nP#Distorções causadas pelas ações judiciais à política de medicamentos no Br
asil^lpt#Rev Saude Publica.#2#20070000#2007#41#2#214-22#10.1590/S0034-8910200700
0200007#20110000#2403.htm##
00535000000000229000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810170026000840180115001100620
04100225066000700266065000900273064000500282865000900287002000900296#2011nahead#
V:\SciELO\serial\rsp\2011nahead\markup\2403.htm#S#c#170#15#article#15#15#World H
ealth Organization#Expert Committee on the Use of Essenctial Drugs: The use of t
he essential drugs: model list of essential drugs^len#Fifth report of the WHO Ex
pert Committee#Geneva#19920000#1992#20110000#2403.htm##
00276000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00400102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#o#1#1#arti
cle#1#20110331#151407#1827.htm#166##
06467000000000733000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000300095121000300098049000300101158000300104030001900107
03200060012606500090013201400070014103500100014822300090015801200770016701200800
02440120078003240100026004020100026004280100025004540100025004790700111005040831
47600615085001002091085004102101085004202142085002302184085005502207083147202262
08500100373408500320374408500290377608500230380508500400382808500390386808315300
39070850010054370850037054470850043054840850023055270850057055501170008056070720
00305615112000905618111001105627114000905638113001105647058005305658060001305711
002000905724#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#h#2#1#
article#1#oa#pt#br1.1#1#4.0#ND#17#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0
#0034-8910#20110408#Propaganda de álcool e associação ao consumo de cerveja por 
adolescentes^lpt#Association between alcohol advertising and beer drinking among
 adolescents^len#Propaganda de alcohol y asociación al consumo de cerveza por ad
olescentes^les#^rND^1A01^nRoberta^sFaria#^rND^1A01^nAlan^sVendrame#^rND^1A01^nRe
beca^sSilva#^rND^1A01^nIlana^sPinsky#Universidade Federal de São Paulo^iA01^1Dep
artamento de Psiquiatria e Psicologia Médica^cSão Paulo^sSP^pBrasil#^lpt^aOBJETI
VO: Analisar a associação entre propaganda de álcool e o consumo de cerveja por 
adolescentes. MÉTODOS: Foram entrevistados 1.115 estudantes de 7º e 8º anos de t
rês escolas públicas de São Bernardo do Campo, SP, em 2006. As variáveis indepen
dentes foram: atenção prestada às propagandas de álcool, crença na veracidade da
s propagandas, resposta afetiva às propagandas, uso prévio de cigarro, entre out
ras. A variável dependente foi consumo de cerveja nos últimos 30 dias. Análises 
de regressões logísticas univariada e múltipla foram realizadas. Idade, importân
cia dada à religião e ter banheiro em casa foram utilizadas como controle. RESUL
TADOS: O consumo de cerveja nos últimos 30 dias esteve associado ao uso de cigar
ro (OR = 4,551), ter uma marca preferida de bebida alcoólica (OR = 5,150), não s
er monitorado pelos pais (OR = 2,139), achar que as festas que freqüentam parece
m-se com as de comerciais (OR = 1,712), prestar muita atenção aos comerciais (OR
 = 1,563) e acreditar que os comerciais falam a verdade (OR = 2,122). Essa assoc
iação manteve-se mesmo na presença de outras variáveis associadas ao seu consumo
. CONCLUSÕES: As propagandas de bebidas alcoólicas associam-se positivamente ao 
consumo recente de cerveja, por remetem os adolescentes à própria realidade ou p
or fazê-los acreditar em sua veracidade. Limitar a veiculação de propagandas de 
bebidas alcoólicas pode ser um dos caminhos para a prevenção do uso e abuso de á
lcool por adolescentes.#^ddecs^i1#^tm^lpt^kComportamento do Adolescente^i1#^tm^l
pt^kConsumo de Bebidas Alcoólicas^i1#^tm^lpt^kPropaganda^i1#^tm^lpt^kConheciment
os^i1^sAtitudes e Prática em Saúde#^len^aOBJECTIVE: To analyze the association b
etween alcohol advertising and beer drinking among adolescents. METHODS: A total
 of 1,115 students enrolled in the 7th and 8th grades of three public schools in
 São Bernardo do Campo, Southeastern Brazil, were interviewed in 2006. The indep
endent variables were as follows: attention paid to alcohol advertisements, beli
ef in the veracity of advertisements, affective response to advertisements and p
revious tobacco use, among others. The dependent variable was beer drinking in t
he last 30 days. Univariate and multiple logistic regression analyses were made.
 Age, importance given to religion and the presence of a bathroom in the home we
re used as control. RESULTS: Beer drinking in the last 30 days was associated wi
th tobacco use (OR = 4.551), having a favorite alcoholic beverage brand (OR = 5.
150), poor parental supervision (OR = 2.139), considering parties one goes to as
 similar to those seen in commercials (OR = 1.712), paying more attention to adv
ertisements (OR = 1.563) and believing that advertisements tell the truth (OR = 
2.122). This association remained, even in the presence of other variables assoc
iated with beer drinking. CONCLUSIONS: Alcohol advertisements are positively ass
ociated with recent beer drinking, because they remind adolescents of their own 
reality or make them believe in their veracity. Alcohol advertisement restrictio
ns can be one way to prevent alcohol use and abuse by adolescents.#^ddecs^i2#^tm
^len^kAdolescent Behavior^i2#^tm^len^kAlcohol Drinking^i2#^tm^len^kPropaganda^i2
#^tm^len^kHealth Knowledge^i2^sAttitudes#^tm^len^kHealth Knowledge^i2^sPractice#
^les^aOBJETIVO: Analizar la asociación entre propaganda de alcohol y el consumo 
de cerveza por adolescentes. MÉTODOS: Se entrevistaron 1.115 estudiantes de 6ª y
 7ª series de tres escuelas públicas de Sao Bernardo do Campo, Sureste de Brasil
, en 2006. Las variables independientes fueron: atención prestada a las propagan
das de alcohol, creencia en la veracidad de las propagandas, respuesta afectiva 
a las propagandas, uso previo de cigarro, entre otras. La variable dependiente f
ue consumo de cerveza en los últimos 30 días. Análisis de regresión logísticas u
nivariada y múltiple fueron realizadas. Edad, importancia debido a la religión y
 tener baño en casa fueron utilizadas como control. RESULTADOS: El consumo de ce
rveza en los últimos 30 días estuvo asociado al uso de cigarro (OR=4,551), tener
 una marca preferida de bebida alcohólica (OR=5,150), no ser monitoreado por los
 padres (OR=2,139), pensar que las fiestas que frecuentan se parecen con las de 
comerciales (OR=1,712), prestar mucha atención a los comerciales (OR=1,563) y cr
eer que los comerciales dicen la verdad (OR=2,122). Esa asociación se mantuvo aú
n en presencia de otras variables asociadas al consumo. CONCLUSIONES: Las propag
andas de bebidas alcohólicas se asocian positivamente al consumo reciente de cer
veza; por remitir a los adolescentes a la propia realidad o por hacerlos creer e
n su veracidad. Limitar la circulación de propagandas de bebidas alcohólicas pue
de ser uno de los caminos para la prevención del uso y abuso de alcohol por adol
escentes.#^ddecs^i3#^tm^les^kConducta del Adolescente^i3#^tm^les^kConsumo de Beb
idas Alcohólicas^i3#^tm^les^kPropaganda^i3#^tm^les^kConocimientos^i3^sActitudes 
y Práctica en Salud#vancouv#27#20091124#24/11/2009#20101018#18/10/2010#Fundação 
de Amparo à Pesquisa do Estado de São Paulo#2003/06250-7#1827.htm##
06631000000000733000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000300095121000300098049000300101158000300104030001900107
03200060012606500090013201400070014103500100014822300090015801200840016701200870
02510120085003380100026004230100026004490100025004750100025005000700111005250831
50400636085001002140085004102150085004202191085002302233085005502256083150002311
08500100381108500320382108500290385308500230388208500400390508500390394508315580
39840850010055420850037055520850043055890850023056320850057056551170008057120720
00305720112000905723111001105732114000905743113001105752058005305763060007205816
002000905888#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#f#3#1#
article#1#oa#pt#br1.1#1#4.0#ND#17#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0
#0034-8910#20110408#<b>Propaganda de álcool e associação ao consumo de cerveja p
or adolescentes</b>^lpt#<b>Association between alcohol advertising and beer drin
king among adolescents</b>^len#<b>Propaganda de alcohol y asociación al consumo 
de cerveza por adolescentes</b>^les#^rND^1A01^nRoberta^sFaria#^rND^1A01^nAlan^sV
endrame#^rND^1A01^nRebeca^sSilva#^rND^1A01^nIlana^sPinsky#Universidade Federal d
e São Paulo^iA01^1Departamento de Psiquiatria e Psicologia Médica^cSão Paulo^sSP
^pBrasil#^lpt^a<b>OBJETIVO:</b> Analisar a associação entre propaganda de álcool
 e o consumo de cerveja por adolescentes. <b>MÉTODOS:</b> Foram entrevistados 1.
115 estudantes de 7º e 8º anos de três escolas públicas de São Bernardo do Campo
, SP, em 2006. As variáveis independentes foram: atenção prestada às propagandas
 de álcool, crença na veracidade das propagandas, resposta afetiva às propaganda
s, uso prévio de cigarro, entre outras. A variável dependente foi consumo de cer
veja nos últimos 30 dias. Análises de regressões logísticas univariada e múltipl
a foram realizadas. Idade, importância dada à religião e ter banheiro em casa fo
ram utilizadas como controle. <b>RESULTADOS:</b> O consumo de cerveja nos último
s 30 dias esteve associado ao uso de cigarro (OR = 4,551), ter uma marca preferi
da de bebida alcoólica (OR = 5,150), não ser monitorado pelos pais (OR = 2,139),
 achar que as festas que freqüentam parecem-se com as de comerciais (OR = 1,712)
, prestar muita atenção aos comerciais (OR = 1,563) e acreditar que os comerciai
s falam a verdade (OR = 2,122). Essa associação manteve-se mesmo na presença de 
outras variáveis associadas ao seu consumo. <b>CONCLUSÕES:</b> As propagandas de
 bebidas alcoólicas associam-se positivamente ao consumo recente de cerveja, por
 remetem os adolescentes à própria realidade ou por fazê-los acreditar em sua ve
racidade. Limitar a veiculação de propagandas de bebidas alcoólicas pode ser um 
dos caminhos para a prevenção do uso e abuso de álcool por adolescentes.#^ddecs^
i1#^tm^lpt^kComportamento do Adolescente^i1#^tm^lpt^kConsumo de Bebidas Alcoólic
as^i1#^tm^lpt^kPropaganda^i1#^tm^lpt^kConhecimentos^i1^sAtitudes e Prática em Sa
úde#^len^a<b>OBJECTIVE:</b> To analyze the association between alcohol advertisi
ng and beer drinking among adolescents. <b>METHODS:</b> A total of 1,115 student
s enrolled in the 7th and 8th grades of three public schools in São Bernardo do 
Campo, Southeastern Brazil, were interviewed in 2006. The independent variables 
were as follows: attention paid to alcohol advertisements, belief in the veracit
y of advertisements, affective response to advertisements and previous tobacco u
se, among others. The dependent variable was beer drinking in the last 30 days. 
Univariate and multiple logistic regression analyses were made. Age, importance 
given to religion and the presence of a bathroom in the home were used as contro
l. <b>RESULTS:</b> Beer drinking in the last 30 days was associated with tobacco
 use (OR = 4.551), having a favorite alcoholic beverage brand (OR = 5.150), poor
 parental supervision (OR = 2.139), considering parties one goes to as similar t
o those seen in commercials (OR = 1.712), paying more attention to advertisement
s (OR = 1.563) and believing that advertisements tell the truth (OR = 2.122). Th
is association remained, even in the presence of other variables associated with
 beer drinking. <b>CONCLUSIONS:</b> Alcohol advertisements are positively associ
ated with recent beer drinking, because they remind adolescents of their own rea
lity or make them believe in their veracity. Alcohol advertisement restrictions 
can be one way to prevent alcohol use and abuse by adolescents.#^ddecs^i2#^tm^le
n^kAdolescent Behavior^i2#^tm^len^kAlcohol Drinking^i2#^tm^len^kPropaganda^i2#^t
m^len^kHealth Knowledge^i2^sAttitudes#^tm^len^kHealth Knowledge^i2^sPractice#^le
s^a<b>OBJETIVO:</b> Analizar la asociación entre propaganda de alcohol y el cons
umo de cerveza por adolescentes. <b>MÉTODOS:</b> Se entrevistaron 1.115 estudian
tes de 6ª y 7ª series de tres escuelas públicas de Sao Bernardo do Campo, Surest
e de Brasil, en 2006. Las variables independientes fueron: atención prestada a l
as propagandas de alcohol, creencia en la veracidad de las propagandas, respuest
a afectiva a las propagandas, uso previo de cigarro, entre otras. La variable de
pendiente fue consumo de cerveza en los últimos 30 días. Análisis de regresión l
ogísticas univariada y múltiple fueron realizadas. Edad, importancia debido a la
 religión y tener baño en casa fueron utilizadas como control. <b>RESULTADOS:</b
> El consumo de cerveza en los últimos 30 días estuvo asociado al uso de cigarro
 (OR=4,551), tener una marca preferida de bebida alcohólica (OR=5,150), no ser m
onitoreado por los padres (OR=2,139), pensar que las fiestas que frecuentan se p
arecen con las de comerciales (OR=1,712), prestar mucha atención a los comercial
es (OR=1,563) y creer que los comerciales dicen la verdad (OR=2,122). Esa asocia
ción se mantuvo aún en presencia de otras variables asociadas al consumo. <b>CON
CLUSIONES:</b> Las propagandas de bebidas alcohólicas se asocian positivamente a
l consumo reciente de cerveza; por remitir a los adolescentes a la propia realid
ad o por hacerlos creer en su veracidad. Limitar la circulación de propagandas d
e bebidas alcohólicas puede ser uno de los caminos para la prevención del uso y 
abuso de alcohol por adolescentes.#^ddecs^i3#^tm^les^kConducta del Adolescente^i
3#^tm^les^kConsumo de Bebidas Alcohólicas^i3#^tm^les^kPropaganda^i3#^tm^les^kCon
ocimientos^i3^sActitudes y Práctica en Salud#vancouv#27#20091124#24/11/2009#2010
1018#18/10/2010#Fundação de Amparo à Pesquisa do Estado de São Paulo#<span style
='font-size: 10.0pt;font-family:Verdana'>2003/06250-7</span>#1827.htm##
06574000000000745000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098121000300102049000300105158000300108030001900111
03200060013006500090013601400070014503500100015222300090016201200770017101200800
02480120078003280100026004060100026004320100025004580100025004830700113005080831
47600621085001002097085004102107085004202148085002302190085005502213083147202268
08500100374008500320375008500290378208500230381108500400383408500390387408315300
39130850010054430850037054530850043054900850023055330850057055561170008056130720
00305621112000905624111001105633114000905644113001105653058005305664060001305717
002000905730008008905739#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.
htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#17#nd#nd#Rev. saúde pública#ahead
#20110000#^f0^l0#0034-8910#20110408#Propaganda de álcool e associação ao consumo
 de cerveja por adolescentes^lpt#Association between alcohol advertising and bee
r drinking among adolescents^len#Propaganda de alcohol y asociación al consumo d
e cerveza por adolescentes^les#^rND^1A01^nRoberta^sFaria#^rND^1A01^nAlan^sVendra
me#^rND^1A01^nRebeca^sSilva#^rND^1A01^nIlana^sPinsky#^iA01^1Universidade Federal
 de São Paulo^2Departamento de Psiquiatria e Psicologia Médica^cSão Paulo^sSP^pB
rasil#^lpt^aOBJETIVO: Analisar a associação entre propaganda de álcool e o consu
mo de cerveja por adolescentes. MÉTODOS: Foram entrevistados 1.115 estudantes de
 7º e 8º anos de três escolas públicas de São Bernardo do Campo, SP, em 2006. As
 variáveis independentes foram: atenção prestada às propagandas de álcool, crenç
a na veracidade das propagandas, resposta afetiva às propagandas, uso prévio de 
cigarro, entre outras. A variável dependente foi consumo de cerveja nos últimos 
30 dias. Análises de regressões logísticas univariada e múltipla foram realizada
s. Idade, importância dada à religião e ter banheiro em casa foram utilizadas co
mo controle. RESULTADOS: O consumo de cerveja nos últimos 30 dias esteve associa
do ao uso de cigarro (OR = 4,551), ter uma marca preferida de bebida alcoólica (
OR = 5,150), não ser monitorado pelos pais (OR = 2,139), achar que as festas que
 freqüentam parecem-se com as de comerciais (OR = 1,712), prestar muita atenção 
aos comerciais (OR = 1,563) e acreditar que os comerciais falam a verdade (OR = 
2,122). Essa associação manteve-se mesmo na presença de outras variáveis associa
das ao seu consumo. CONCLUSÕES: As propagandas de bebidas alcoólicas associam-se
 positivamente ao consumo recente de cerveja, por remetem os adolescentes à próp
ria realidade ou por fazê-los acreditar em sua veracidade. Limitar a veiculação 
de propagandas de bebidas alcoólicas pode ser um dos caminhos para a prevenção d
o uso e abuso de álcool por adolescentes.#^ddecs^i1#^tm^lpt^kComportamento do Ad
olescente^i1#^tm^lpt^kConsumo de Bebidas Alcoólicas^i1#^tm^lpt^kPropaganda^i1#^t
m^lpt^kConhecimentos^i1^sAtitudes e Prática em Saúde#^len^aOBJECTIVE: To analyze
 the association between alcohol advertising and beer drinking among adolescents
. METHODS: A total of 1,115 students enrolled in the 7th and 8th grades of three
 public schools in São Bernardo do Campo, Southeastern Brazil, were interviewed 
in 2006. The independent variables were as follows: attention paid to alcohol ad
vertisements, belief in the veracity of advertisements, affective response to ad
vertisements and previous tobacco use, among others. The dependent variable was 
beer drinking in the last 30 days. Univariate and multiple logistic regression a
nalyses were made. Age, importance given to religion and the presence of a bathr
oom in the home were used as control. RESULTS: Beer drinking in the last 30 days
 was associated with tobacco use (OR = 4.551), having a favorite alcoholic bever
age brand (OR = 5.150), poor parental supervision (OR = 2.139), considering part
ies one goes to as similar to those seen in commercials (OR = 1.712), paying mor
e attention to advertisements (OR = 1.563) and believing that advertisements tel
l the truth (OR = 2.122). This association remained, even in the presence of oth
er variables associated with beer drinking. CONCLUSIONS: Alcohol advertisements 
are positively associated with recent beer drinking, because they remind adolesc
ents of their own reality or make them believe in their veracity. Alcohol advert
isement restrictions can be one way to prevent alcohol use and abuse by adolesce
nts.#^ddecs^i2#^tm^len^kAdolescent Behavior^i2#^tm^len^kAlcohol Drinking^i2#^tm^
len^kPropaganda^i2#^tm^len^kHealth Knowledge^i2^sAttitudes#^tm^len^kHealth Knowl
edge^i2^sPractice#^les^aOBJETIVO: Analizar la asociación entre propaganda de alc
ohol y el consumo de cerveza por adolescentes. MÉTODOS: Se entrevistaron 1.115 e
studiantes de 6ª y 7ª series de tres escuelas públicas de Sao Bernardo do Campo,
 Sureste de Brasil, en 2006. Las variables independientes fueron: atención prest
ada a las propagandas de alcohol, creencia en la veracidad de las propagandas, r
espuesta afectiva a las propagandas, uso previo de cigarro, entre otras. La vari
able dependiente fue consumo de cerveza en los últimos 30 días. Análisis de regr
esión logísticas univariada y múltiple fueron realizadas. Edad, importancia debi
do a la religión y tener baño en casa fueron utilizadas como control. RESULTADOS
: El consumo de cerveza en los últimos 30 días estuvo asociado al uso de cigarro
 (OR=4,551), tener una marca preferida de bebida alcohólica (OR=5,150), no ser m
onitoreado por los padres (OR=2,139), pensar que las fiestas que frecuentan se p
arecen con las de comerciales (OR=1,712), prestar mucha atención a los comercial
es (OR=1,563) y creer que los comerciales dicen la verdad (OR=2,122). Esa asocia
ción se mantuvo aún en presencia de otras variables asociadas al consumo. CONCLU
SIONES: Las propagandas de bebidas alcohólicas se asocian positivamente al consu
mo reciente de cerveza; por remitir a los adolescentes a la propia realidad o po
r hacerlos creer en su veracidad. Limitar la circulación de propagandas de bebid
as alcohólicas puede ser uno de los caminos para la prevención del uso y abuso d
e alcohol por adolescentes.#^ddecs^i3#^tm^les^kConducta del Adolescente^i3#^tm^l
es^kConsumo de Bebidas Alcohólicas^i3#^tm^les^kPropaganda^i3#^tm^les^kConocimien
tos^i3^sActitudes y Práctica en Salud#vancouv#27#20091124#24/11/2009#20101018#18
/10/2010#Fundação de Amparo à Pesquisa do Estado de São Paulo#2003/06250-7#1827.
htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102
011005000017##
00284000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704005000079002000900129#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#5#1#article#135#<html> <head> <t
itle>1827</title> </head>     ^cY#1827.htm##
00442000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704020800079002000900287#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#6#2#article#135#<p><a name="top"
></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Propaganda  
  de &aacute;lcool e associa&ccedil;&atilde;o ao consumo de cerveja por adolesce
ntes</b>    </font></p>     ^cY#1827.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#7#3#article#135#<p>&nbsp;</p>   
  ^cY#1827.htm##
00402000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704016800079002000900247#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#8#4#article#135#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Association    between alcohol
 advertising and beer drinking among adolescents</b></font></p>     ^cY#1827.htm
##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#9#5#article#135#<p>&nbsp;</p>   
  ^cY#1827.htm##
00408000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704017300080002000900253#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#10#6#article#135#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="3"><b>Propaganda de    alcohol y as
ociaci&oacute;n al consumo de cerveza por adolescentes</b></font></p>     ^cY#18
27.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#11#7#article#135#<p>&nbsp;</p>  
   ^cY#1827.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#12#8#article#135#<p>&nbsp;</p>  
   ^cY#1827.htm##
00384000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704014900080002000900229#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#13#9#article#135#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Roberta Faria;    Alan Vendra
me; Rebeca Silva; Ilana Pinsky</b></font></p>     ^cY#1827.htm##
00451000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704021500081002000900296#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#14#10#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Departamento de    Psiquiatria 
e Psicologia M&eacute;dica. Universidade Federal de S&atilde;o Paulo.    S&atild
e;o Paulo, SP, Brasil</font></p>     ^cY#1827.htm##
00380000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014400081002000900225#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#15#11#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecir
c;ncia    | Correspondence</a></font></p>     ^cY#1827.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#16#12#article#135#<p>&nbsp;</p> 
    ^cY#1827.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704004400081002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#17#13#article#135#<p>&nbsp;</p> 
<hr size="1" noshade>     ^cY#1827.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#18#14#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^c
Y#1827.htm##
00440000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020400081002000900285#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#19#15#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analisar a 
associa&ccedil;&atilde;o entre propaganda de &aacute;lcool e o consumo    de cer
veja por adolescentes.    ^cY#1827.htm##
00967000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704073100081002000900812#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#20#16#article#135#<br>   <b>M&Ea
cute;TODOS:</b> Foram entrevistados 1.115 estudantes de 7º e 8º anos    de tr&ec
irc;s escolas p&uacute;blicas de S&atilde;o Bernardo do Campo, SP, em    2006. A
s vari&aacute;veis independentes foram: aten&ccedil;&atilde;o prestada    &agrav
e;s propagandas de &aacute;lcool, cren&ccedil;a na veracidade das propagandas,  
  resposta afetiva &agrave;s propagandas, uso pr&eacute;vio de cigarro, entre   
 outras. A vari&aacute;vel dependente foi consumo de cerveja nos &uacute;ltimos 
   30 dias. An&aacute;lises de regress&otilde;es log&iacute;sticas univariada e 
   m&uacute;ltipla foram realizadas. Idade, import&acirc;ncia dada &agrave; reli
gi&atilde;o    e ter banheiro em casa foram utilizadas como controle.    ^cY#182
7.htm##
00830000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704059400081002000900675#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#21#17#article#135#<br>   <b>RESU
LTADOS:</b> O consumo de cerveja nos &uacute;ltimos 30 dias esteve associado    
ao uso de cigarro (OR = 4,551), ter uma marca preferida de bebida alco&oacute;li
ca    (OR = 5,150), n&atilde;o ser monitorado pelos pais (OR = 2,139), achar que
 as    festas que freq&uuml;entam parecem-se com as de comerciais (OR = 1,712), 
prestar    muita aten&ccedil;&atilde;o aos comerciais (OR = 1,563) e acreditar q
ue os comerciais    falam a verdade (OR = 2,122). Essa associa&ccedil;&atilde;o 
manteve-se mesmo    na presen&ccedil;a de outras vari&aacute;veis associadas ao 
seu consumo.    ^cY#1827.htm##
00702000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704046600081002000900547#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#22#18#article#135#<br>   <b>CONC
LUS&Otilde;ES:</b> As propagandas de bebidas alco&oacute;licas associam-se    po
sitivamente ao consumo recente de cerveja, por remetem os adolescentes &agrave; 
   pr&oacute;pria realidade ou por faz&ecirc;-los acreditar em sua veracidade.  
  Limitar a veicula&ccedil;&atilde;o de propagandas de bebidas alco&oacute;licas
    pode ser um dos caminhos para a preven&ccedil;&atilde;o do uso e abuso de &a
acute;lcool    por adolescentes.</font></p>     ^cY#1827.htm##
00505000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704026900081002000900350#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#23#19#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> Comport
amento do Adolescente. Consumo de Bebidas Alco&oacute;licas. Propaganda.    Conh
ecimentos, Atitudes e Pr&aacute;tica em Sa&uacute;de.</font></p> <hr size="1" no
shade>     ^cY#1827.htm##
00334000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009800081002000900179#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#24#20#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     
^cY#1827.htm##
00422000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018600081002000900267#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#25#21#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To analyze
 the association between alcohol advertising and beer drinking among    adolesce
nts.    ^cY#1827.htm##
00881000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704064500081002000900726#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#26#22#article#135#<br>   <b>METH
ODS:</b> A total of 1,115 students enrolled in the 7th and 8th grades    of thre
e public schools in S&atilde;o Bernardo do Campo, Southeastern Brazil,    were i
nterviewed in 2006. The independent variables were as follows: attention    paid
 to alcohol advertisements, belief in the veracity of advertisements, affective 
   response to advertisements and previous tobacco use, among others. The depend
ent    variable was beer drinking in the last 30 days. Univariate and multiple l
ogistic    regression analyses were made. Age, importance given to religion and 
the presence    of a bathroom in the home were used as control.    ^cY#1827.htm#
#
00761000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704052500081002000900606#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#27#23#article#135#<br>   <b>RESU
LTS:</b> Beer drinking in the last 30 days was associated with tobacco    use (O
R = 4.551), having a favorite alcoholic beverage brand (OR = 5.150), poor    par
ental supervision (OR = 2.139), considering parties one goes to as similar    to
 those seen in commercials (OR = 1.712), paying more attention to advertisements
    (OR = 1.563) and believing that advertisements tell the truth (OR = 2.122). 
   This association remained, even in the presence of other variables associated
    with beer drinking.    ^cY#1827.htm##
00559000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704032300081002000900404#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#28#24#article#135#<br>   <b>CONC
LUSIONS:</b> Alcohol advertisements are positively associated with recent    bee
r drinking, because they remind adolescents of their own reality or make    them
 believe in their veracity. Alcohol advertisement restrictions can be one    way
 to prevent alcohol use and abuse by adolescents.</font></p>     ^cY#1827.htm##
00457000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704022100081002000900302#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#29#25#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:    </b> Adolesc
ent Behavior. Alcohol Drinking. Propaganda. Health Knowledge, Attitudes,    Prac
tice.</font></p> <hr size="1" noshade>     ^cY#1827.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#30#26#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^
cY#1827.htm##
00429000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704019300081002000900274#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#31#27#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analizar la
 asociaci&oacute;n entre propaganda de alcohol y el consumo de cerveza    por ad
olescentes.    ^cY#1827.htm##
00941000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704070500081002000900786#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#32#28#article#135#<br>   <b>M&Ea
cute;TODOS:</b> Se entrevistaron 1.115 estudiantes de 6ª y 7ª series    de tres 
escuelas p&uacute;blicas de Sao Bernardo do Campo, Sureste de Brasil,    en 2006
. Las variables independientes fueron: atenci&oacute;n prestada a las    propaga
ndas de alcohol, creencia en la veracidad de las propagandas, respuesta    afect
iva a las propagandas, uso previo de cigarro, entre otras. La variable    depend
iente fue consumo de cerveza en los &uacute;ltimos 30 d&iacute;as. An&aacute;lis
is    de regresi&oacute;n log&iacute;sticas univariada y m&uacute;ltiple fueron 
realizadas.    Edad, importancia debido a la religi&oacute;n y tener ba&ntilde;o
 en casa fueron    utilizadas como control.    ^cY#1827.htm##
00801000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704056500081002000900646#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#33#29#article#135#<br>   <b>RESU
LTADOS:</b> El consumo de cerveza en los &uacute;ltimos 30 d&iacute;as    estuvo
 asociado al uso de cigarro (OR=4,551), tener una marca preferida de bebida    a
lcoh&oacute;lica (OR=5,150), no ser monitoreado por los padres (OR=2,139),    pe
nsar que las fiestas que frecuentan se parecen con las de comerciales (OR=1,712)
,    prestar mucha atenci&oacute;n a los comerciales (OR=1,563) y creer que los 
comerciales    dicen la verdad (OR=2,122). Esa asociaci&oacute;n se mantuvo a&ua
cute;n en presencia    de otras variables asociadas al consumo.    ^cY#1827.htm#
#
00663000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704042700081002000900508#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#34#30#article#135#<br>   <b>CONC
LUSIONES:</b> Las propagandas de bebidas alcoh&oacute;licas se asocian    positi
vamente al consumo reciente de cerveza; por remitir a los adolescentes    a la p
ropia realidad o por hacerlos creer en su veracidad. Limitar la circulaci&oacute
;n    de propagandas de bebidas alcoh&oacute;licas puede ser uno de los caminos 
para    la prevenci&oacute;n del uso y abuso de alcohol por adolescentes.</font>
</p>     ^cY#1827.htm##
00498000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704026200081002000900343#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#35#31#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:    </b> Conduc
ta del Adolescente. Consumo de Bebidas Alcoh&oacute;licas. Propaganda.    Conoci
mientos, Actitudes y Pr&aacute;ctica en Salud.</font></p> <hr size="1" noshade> 
    ^cY#1827.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#36#32#article#135#<p>&nbsp;</p> 
    ^cY#1827.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#37#33#article#135#<p>&nbsp;</p> 
    ^cY#1827.htm##
00350000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011400081002000900195#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#38#34#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b>
</font></p>     ^cY#1827.htm##
00646000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704041000081002000900491#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#39#35#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A inicia&ccedil;&atilde;o    do
 uso de &aacute;lcool &eacute; influenciada por fatores individuais e interpesso
ais,    incluindo aspectos familiares, biol&oacute;gicos, de temperamento e ambi
entais,    <sup>12,15,16,19</sup> dentre os quais se encontra a publicidade de b
ebidas    alco&oacute;licas. <sup>2,12,19,20,21,26</sup></font></p>     ^cY#1827
.htm##
00736000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704050000081002000900581#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#40#36#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudos indicam    que a propag
anda influencia o consumo de &aacute;lcool por adolescentes.<sup>6,16,19,</sup><
a href="#backa">ª</a>    Embora n&atilde;o haja extensas pesquisas sobre a propa
ganda de &aacute;lcool    no Brasil, essa discuss&atilde;o iniciou-se no mundo h
&aacute; mais de 20 anos.<sup>1</sup>    H&aacute; dois tipos principais de estu
dos sobre o tema: os econom&eacute;tricos    e os de consumidores.</font></p>   
  ^cY#1827.htm##
01215000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704097900081002000901060#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#41#37#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudos econom&eacute;tricos,  
  de maneira geral, analisam os gastos com propaganda (usados como aproxima&cced
il;&atilde;o    para exposi&ccedil;&atilde;o e resposta) e consumo total (usado 
como aproxima&ccedil;&atilde;o    para preju&iacute;zos relacionados ao &aacute;
lcool). Gastos com propaganda    foram tamb&eacute;m comparados a problemas rela
cionados a bebidas alco&oacute;licas,    como acidentes automobil&iacute;sticos 
e problemas cl&iacute;nicos conseq&uuml;entes    do uso cr&ocirc;nico de &aacute
;lcool.<sup>1,</sup><a href="#backa">ª</a> Snyder    et al<sup>26</sup> mostrara
m que jovens americanos de &aacute;reas com maior    gasto com propagandas conso
mem volumes maiores de bebidas alco&oacute;licas,    inclusive depois dos 20 ano
s. Pesquisas econom&eacute;tricas, entretanto, apresentam    defici&ecirc;ncias,
 como n&atilde;o diferenciar adultos e adolescentes.<sup>18</sup></font></p>    
 ^cY#1827.htm##
00777000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704054100081002000900622#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#42#38#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudos de consumidores    s&at
ilde;o aqueles que "utilizam o indiv&iacute;duo como a unidade da an&aacute;lise
",<sup>1</sup>    i.e., examinam e prev&ecirc;em respostas dos jovens a propagan
das de bebidas    alco&oacute;licas. As an&aacute;lises s&atilde;o baseadas em e
xposi&ccedil;&atilde;o    &agrave; propaganda, resposta afetiva e influ&ecirc;nc
ia nas expectativas dos    adolescentes em rela&ccedil;&atilde;o &agrave;s bebid
as.<sup>3,12,13,16,26</sup></font></p>     ^cY#1827.htm##
00789000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704055300081002000900634#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#43#39#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Alguns autores,    como Austin 
&amp; Meili,<sup>5</sup> Ellickson et al,<sup>12</sup> Collins et    al,<sup>10,
11</sup> Grube &amp; Waiters<sup>18</sup> e Fleming et al,<sup>16</sup>    explo
ram as respostas do "receptor" da propaganda como preditores de uso atual    e f
uturo. Outros autores (Stacy et al<sup>26</sup> e Snyder et al<sup>25</sup>)    
analisam a exposi&ccedil;&atilde;o de maneira quantitativa, com base nas horas  
  de exposi&ccedil;&atilde;o presumida.</font></p>     ^cY#1827.htm##
01190000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704095400081002000901035#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#44#40#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os estudos publicados    sobre 
o tema foram realizados em pa&iacute;ses desenvolvidos, cujos mercados    de beb
idas alco&oacute;licas est&atilde;o relativamente estabilizados. O Brasil    &ea
cute; um mercado com grande potencial de crescimento, em virtude de sua economia
    em expans&atilde;o e do grande contingente populacional (com elevada propor&
ccedil;&atilde;o    de adolescentes).<a href="#backb"><sup>b</sup></a> Grande pa
rte dos jovens brasileiros    n&atilde;o consome bebidas alco&oacute;licas regul
armente,<sup>24,</sup><a href="#backc"><sup>c</sup></a>    e a popula&ccedil;&at
ilde;o do Pa&iacute;s apresenta h&aacute;bitos e condi&ccedil;&otilde;es    de v
ida distintos dos pa&iacute;ses estudados. Estudos originais devem ser realizado
s    dentro da cultura brasileira para avaliar a possibilidade de comparar essa 
realidade    com dados de outros locais.</font></p>     ^cY#1827.htm##
01514000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704127800081002000901359#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#45#41#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">No Brasil, al&eacute;m    de po
ucos programas de preven&ccedil;&atilde;o ao consumo de &aacute;lcool,    h&aacu
te; poucas restri&ccedil;&otilde;es &agrave; propaganda de bebidas alco&oacute;l
icas.    O Pa&iacute;s adotou o modelo de auto-regula&ccedil;&atilde;o do Consel
ho de    Auto-Regulamenta&ccedil;&atilde;o Publicit&aacute;ria (Conar),<a name="
topd"></a><a href="#backd"><sup>d</sup></a>    e as regras relacionam-se, princi
palmente, ao conte&uacute;do e &agrave; exposi&ccedil;&atilde;o    de menores de
 idade &agrave;s pe&ccedil;as. Considerando a efic&aacute;cia dessa    auto-regu
lamenta&ccedil;&atilde;o question&aacute;vel,<sup>15</sup> o governo    brasilei
ro tentou restringir as propagandas de cerveja na televis&atilde;o em    2008 po
r meio da Ag&ecirc;ncia Nacional de Vigil&acirc;ncia Sanit&aacute;ria    (Anvisa
) e do Minist&eacute;rio da Sa&uacute;de. Entretanto, movimentos encabe&ccedil;a
dos    pelas ind&uacute;strias cervejeiras e por associa&ccedil;&otilde;es repre
sentantes    dos meios de comunica&ccedil;&atilde;o conseguiram reverter essas p
ropostas,    e atualmente n&atilde;o h&aacute; restri&ccedil;&atilde;o de hor&aa
cute;rio    para propagandas dessas bebidas.</font></p>     ^cY#1827.htm##
00453000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704021700081002000900298#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#46#42#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O objetivo deste    artigo &eac
ute; analisar a associa&ccedil;&atilde;o entre a propaganda e o consumo    de ce
rveja por adolescentes.</font></p>     ^cY#1827.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#47#43#article#135#<p>&nbsp;</p> 
    ^cY#1827.htm##
00340000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010400081002000900185#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#48#44#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p
>     ^cY#1827.htm##
00988000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704075200081002000900833#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#49#45#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Este estudo &eacute;    parte d
e um estudo longitudinal com 1.132 estudantes de 7º e 8º anos de tr&ecirc;s    e
scolas p&uacute;blicas pr&oacute;ximas &agrave; regi&atilde;o central de S&atild
e;o    Bernardo do Campo, SP, entre 2006 e 2007. S&atilde;o Bernardo do Campo po
ssui    cerca de 660.400 habitantes, com caracter&iacute;sticas demogr&aacute;fi
cas    semelhantes &agrave;s da maioria das cidades urbanas do Brasil em termos 
de    idade, renda familiar e grau de educa&ccedil;&atilde;o (IBGE 2000).<a href
="#backb"><sup>b</sup></a>    Internamente, o padr&atilde;o socioecon&ocirc;mico
 dos freq&uuml;entadores de    escola p&uacute;blica &eacute; homog&ecirc;neo.</
font></p>     ^cY#1827.htm##
00793000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704055700081002000900638#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#50#46#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As escolas selecionadas    poss
u&iacute;am 34 salas de 7º e 8º anos, com m&eacute;dia de 33 alunos por    sala.
 A op&ccedil;&atilde;o de entrevistar alunos desses anos deveu-se aos resultados
    do levantamento nacional do Centro Brasileiro de Informa&ccedil;&otilde;es s
obre    Drogas Psicotr&oacute;picas (Cebrid) de 2004,<a href="#backc"><sup>c</su
p></a>    segundo os quais o in&iacute;cio de consumo de &aacute;lcool no Brasil
 acontece    em m&eacute;dia aos 12,5 anos.</font></p>     ^cY#1827.htm##
00907000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704067100081002000900752#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#51#47#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os alunos receberam    previame
nte um folheto informativo sobre a pesquisa com o contato do coordenador    para
 que seus respons&aacute;veis pudessem consentir ou n&atilde;o sua participa&cce
dil;&atilde;o.    N&atilde;o houve recusas e todos os alunos presentes no dia da
 aplica&ccedil;&atilde;o    foram entrevistados por meio de question&aacute;rios
 confidenciais preenchidos    por eles pr&oacute;prios. As entrevistas foram rea
lizadas em dois momentos:    de agosto a novembro de 2006 e de agosto a novembro
 de 2007. Este artigo refere-se    aos resultados do primeiro per&iacute;odo.</f
ont></p>     ^cY#1827.htm##
01002000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704076600081002000900847#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#52#48#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O question&aacute;rio    aborda
va aspectos como monitora&ccedil;&atilde;o por parte dos pais,<sup>17</sup>    u
so pr&eacute;vio de cigarro, import&acirc;ncia da religi&atilde;o em suas vidas,
    entre outras. O instrumento teve por base principal o question&aacute;rio de
senvolvido    por Collins et al (2005),<sup>11</sup> al&eacute;m do de Stacy et 
al (2004)<sup>26</sup>    e de Austin et al (1994).<sup>3</sup> Tr&ecirc;s grupo
s focais foram realizados    com alunos de escolas p&uacute;blicas e particulare
s para assegurar a compreens&atilde;o    das perguntas por adolescentes de 12 a 
15 anos e a adequa&ccedil;&atilde;o do    question&aacute;rio &agrave; realidade
 dos jovens.</font></p>     ^cY#1827.htm##
00814000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704057800081002000900659#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#53#49#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Dez estudantes    preencheram o
s question&aacute;rios de maneira inadequada e, portanto, n&atilde;o    foram in
clu&iacute;dos na an&aacute;lise. Outros oito question&aacute;rios foram    excl
u&iacute;dos porque seus respondentes possu&iacute;am idades fora da idade    ha
bitual de alunos de 7º ou 8º anos (abaixo de 11 anos ou acima de 16 anos).    O 
n&uacute;mero final de question&aacute;rios analisados foi de 1.115. As perdas  
  foram desprez&iacute;veis para os efeitos das an&aacute;lises.</font></p>     
^cY#1827.htm##
00823000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704058700081002000900668#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#54#50#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os estudantes foram    question
ados sobre o consumo de cerveja na vida, no &uacute;ltimo ano e nos    &uacute;l
timos 30 dias, e esta teve a resposta mais confi&aacute;vel, j&aacute;    que ha
via inconsist&ecirc;ncias nas respostas (e.g., o estudante referiu n&atilde;o   
 ter consumido cerveja no &uacute;ltimo ano, por&eacute;m referiu ter feito uso 
   nos &uacute;ltimos 30 dias). A vari&aacute;vel resposta foi, portanto, consum
o    de cerveja nos 30 dias que antecederam a pesquisa (sim; n&atilde;o).</font>
</p>     ^cY#1827.htm##
01429000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704119300081002000901274#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#55#51#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As vari&aacute;veis    independ
entes foram sexo, idade (<u>></u> 14 anos; &lt; 14 anos), qual escola    era fre
q&uuml;entada, ter banheiro dentro de casa (sim; n&atilde;o), import&acirc;ncia 
   da religi&atilde;o (muito importante; n&atilde;o), ter marca preferida de beb
ida    alco&oacute;lica (sim; n&atilde;o), considerar que os comerciais de bebid
as    alco&oacute;licas falam a verdade (verdadeiro; falso), aludir que as festa
s    que freq&uuml;entam parecem-se com as dos comerciais de bebidas alco&oacute
;licas    (verdadeiro; falso), prestar aten&ccedil;&atilde;o aos comerciais de b
ebidas    alco&oacute;licas (sim; n&atilde;o), consumo pr&eacute;vio de cigarro 
(sim;    n&atilde;o) e se os pais costumam saber onde eles est&atilde;o, usada c
omo indica&ccedil;&atilde;o    de monitora&ccedil;&atilde;o por parte dos pais (
sim; &agrave;s vezes/nunca).    A vari&aacute;vel "ter banheiro dentro de casa" 
foi utilizada, pois nos dias    atuais n&atilde;o ter banheiro dentro de casa re
vela sobremaneira a prec&aacute;ria    condi&ccedil;&atilde;o de moradia e, por 
conseguinte, de status econ&ocirc;mico.</font></p>     ^cY#1827.htm##
00942000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704070600081002000900787#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#56#52#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Idade, a import&acirc;ncia    d
a religi&atilde;o e ter banheiro em casa mostraram-se estatisticamente diferente
s    entre as tr&ecirc;s escolas pesquisadas e optou-se por mant&ecirc;-las, com
o    controle no modelo de regress&atilde;o. As demais vari&aacute;veis independ
entes    compuseram o modelo inicial, saturado ou completo sempre que, na an&aac
ute;lise    univariada, i.e., contrastadas isoladamente com a vari&aacute;vel re
sposta,    apontassem signific&acirc;ncia estat&iacute;stica de pelo menos 10% (
p &lt;    0,10). Apenas aquelas com signific&acirc;ncia &lt; 0,05 no conjunto fo
ram mantidas    no modelo final.</font></p>     ^cY#1827.htm##
00444000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020800081002000900289#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#57#53#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As poss&iacute;veis    intera&c
cedil;&otilde;es multiplicativas foram testadas, mas n&atilde;o se revelaram    
significantes.</font></p>     ^cY#1827.htm##
00497000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704026100081002000900342#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#58#54#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O teste de Hosmer-Lemeshow    f
oi realizado para avaliar a adequa&ccedil;&atilde;o do modelo. As an&aacute;lise
s    foram realizadas com uso do programa SPSS, vers&atilde;o 15.0.</font></p>  
   ^cY#1827.htm##
00476000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704024000081002000900321#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#59#55#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O estudo foi aprovado    pelo C
omit&ecirc; de &Eacute;tica em Pesquisa da Universidade Federal de S&atilde;o   
 Paulo (Unifesp), sob o n&uacute;mero 1767/05.</font></p>     ^cY#1827.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#60#56#article#135#<p>&nbsp;</p> 
    ^cY#1827.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010000081002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#61#57#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>   
  ^cY#1827.htm##
00844000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704060800081002000900689#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#62#58#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A distribui&ccedil;&atilde;o   
 de sexo foi homog&ecirc;nea entre as escolas (53,3% de meninas) (<a href="/img/
revistas/rsp/2011nahead/1827t01.jpg">Tabela    1)</a>. Cada escola apresentou um
a caracter&iacute;stica que a diferenciasse    das outras em rela&ccedil;&atilde
;o &agrave; presen&ccedil;a de banheiro dentro    de casa, import&acirc;ncia da 
religi&atilde;o na vida e idade. A vari&aacute;vel    de cunho socioecon&ocirc;m
ico que mais diferenciou uma escola da outra foi ter    ou n&atilde;o banheiro d
entro de casa.</font></p>     ^cY#1827.htm##
00932000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704069600081002000900777#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#63#59#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Sexo e escola n&atilde;o    per
maneceram no modelo final, pois n&atilde;o se mostraram estatisticamente    asso
ciadas ao consumo de &aacute;lcool nos &uacute;ltimos 30 dias na presen&ccedil;a
    das demais vari&aacute;veis (p &gt; 0,05). As vari&aacute;veis independentes
    estiveram positivamente associadas ao consumo de cerveja nos 30 dias que ant
ecederam    a aplica&ccedil;&atilde;o do question&aacute;rio (<a href="/img/revi
stas/rsp/2011nahead/1827t01.jpg">Tabela    2</a>), mesmo ap&oacute;s controle pa
ra idade, import&acirc;ncia da religi&atilde;o    em suas vidas e presen&ccedil;
a de banheiro em casa.</font></p>     ^cY#1827.htm##
00573000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704033700081002000900418#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#64#60#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Pais saberem onde    os filhos 
se encontram quando n&atilde;o est&atilde;o com eles foi importante    fator de 
prote&ccedil;&atilde;o: n&atilde;o saber correspondeu ao <i>odds ratio</i>    (O
R) de 2,139 para consumo de cerveja no &uacute;ltimo m&ecirc;s.</font></p>     ^
cY#1827.htm##
01089000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704085300081002000900934#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#65#61#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Vari&aacute;veis    ligadas dir
etamente &agrave;s propagandas estiveram associadas ao consumo de    cerveja nos
 &uacute;ltimos 30 dias. A cren&ccedil;a de que os comerciais de    bebidas alco
&oacute;licas falam a verdade mostrou associa&ccedil;&atilde;o com    o consumo 
(OR = 2,122; p = 0,000), assim como a percep&ccedil;&atilde;o de similaridade   
 entre os comerciais e a vida real dos estudantes, definida por "as festas que  
  eu freq&uuml;ento parecem com as dos comerciais" (OR = 1,712; p = 0,009). Pres
tar    aten&ccedil;&atilde;o aos comerciais ofereceu risco aumentado de consumo 
de    bebidas (OR = 1,563, p = 0,028), mas a associa&ccedil;&atilde;o mais forte
 foi    observada em ter uma marca preferida de bebida alco&oacute;lica (OR = 5,
150;    p = 0,000).</font></p>     ^cY#1827.htm##
00443000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020700081002000900288#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#66#62#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O teste de Hosmer-Lemeshow    m
ostrou qui-quadrado de 1,835 (p = 0,934), confirmando a adequa&ccedil;&atilde;o 
   do modelo.</font></p>     ^cY#1827.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#67#63#article#135#<p>&nbsp;</p> 
    ^cY#1827.htm##
00342000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010600081002000900187#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#68#64#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font><
/p>     ^cY#1827.htm##
01539000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704130300081002000901384#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#69#65#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Este &eacute; um    estudo orig
inal no Brasil que mostra a associa&ccedil;&atilde;o das propagandas    de bebid
as alco&oacute;licas ao consumo de cerveja por alunos de ensino fundamental,    
os quais n&atilde;o atingiram a idade legal m&iacute;nima de 18 anos para beber.
    Essa associa&ccedil;&atilde;o ocorre por meio de pelo menos quatro aspectos:
    similaridade percebida entre as propagandas e suas vidas, aten&ccedil;&atild
e;o    prestada aos comerciais, cren&ccedil;a de que eles falam a verdade e prom
o&ccedil;&atilde;o    da fidelidade &agrave; marca. Isso &eacute; observado mesm
o controlando para    outros aspectos tradicionalmente associados ao consumo de 
bebidas alco&oacute;licas    em adolescentes, como idade, g&ecirc;nero, monitora
&ccedil;&atilde;o por parte    dos pais (fator protetor), classe social, consumo
 de cigarros e import&acirc;ncia    da religi&atilde;o<sup>5</sup> na vida dos e
studantes. Em rela&ccedil;&atilde;o    &agrave; religiosidade, recente estudo na
cional afirma que um indiv&iacute;duo    ser criado em um lar em que a religi&at
ilde;o n&atilde;o &eacute; relevante    aumenta a chance da ado&ccedil;&atilde;o
 de padr&atilde;o de consumo regular    de &aacute;lcool.<sup>5</sup></font></p>
     ^cY#1827.htm##
00746000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051000081002000900591#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#70#66#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Nossos resultados    s&atilde;o
 compat&iacute;veis com os de outros estudos que ligam consci&ecirc;ncia    da p
ropaganda (<i>advertising awareness</i>) e propens&atilde;o para beber.    Colli
ns et al (2005) afirmam que a aten&ccedil;&atilde;o prestada aos comerciais    &
eacute; o fator preditivo mais relevante de consci&ecirc;ncia da propaganda<sup>
9</sup>    e de consumo de bebidas alco&oacute;licas em meninos.<sup>8</sup></fo
nt></p>     ^cY#1827.htm##
01831000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704159500081002000901676#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#71#67#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A cren&ccedil;a    de que os co
merciais de bebidas alco&oacute;licas falam a verdade pode estar    associada &a
grave; percep&ccedil;&atilde;o de similaridade dos adolescentes    entre situa&c
cedil;&otilde;es de suas vidas e aquelas que aparecem nos comerciais    de bebid
as alco&oacute;licas. Se os adolescentes acreditam nisso, os comerciais    podem
 ser vistos como fontes para definir suas id&eacute;ias a respeito de "h&aacute;
bitos    normais de beber", o que nos leva &agrave; import&acirc;ncia da discuss
&atilde;o    a respeito do conte&uacute;do ao qual eles s&atilde;o expostos.<sup
>3</sup>    A habilidade de diferencia&ccedil;&atilde;o entre o que se v&ecirc; 
nos comerciais    e situa&ccedil;&otilde;es reais pode ser desenvolvida em progr
amas de preven&ccedil;&atilde;o    do uso de bebidas alco&oacute;licas, pela edu
ca&ccedil;&atilde;o dos jovens    para a m&iacute;dia. A fidelidade &agrave; mar
ca (ter uma marca preferida de    bebida alco&oacute;lica) associada ao consumo 
aumentado de cerveja contradiz    a ind&uacute;stria de bebidas alco&oacute;lica
s, que alega que mensagens de    refor&ccedil;o dessa fidelidade n&atilde;o apre
sentam impacto no consumo.<sup>6</sup>    Estudos indicam que a fidelidade &agra
ve; marca <i>per se</i> prediz consumo    inclusive em escalas maiores.<sup>6,15
</sup> A fideliza&ccedil;&atilde;o &agrave;    marca, segundo a ind&uacute;stria
 do &aacute;lcool, meta de suas propagandas,    pode ser efeito da exposi&ccedil
;&atilde;o excessiva a essa m&iacute;dia.</font></p>     ^cY#1827.htm##
01350000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704111400081002000901195#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#72#68#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Algumas atitudes    podem ser t
omadas para diminuir a influ&ecirc;ncia da propaganda de cerveja    no consumo p
or adolescentes. Uma delas, em teoria feita pelo Conar, &eacute;    o controle d
o conte&uacute;do das propagandas, que deve ser espec&iacute;fico    ao universo
 adulto e que n&atilde;o permita a percep&ccedil;&atilde;o de similaridade    en
tre a propaganda e situa&ccedil;&otilde;es de vida da maioria dos adolescentes. 
   A percep&ccedil;&atilde;o dos adolescentes sobre a semelhan&ccedil;a da propa
ganda    de cerveja com suas vidas no presente estudo sugere que as regras de au
to-regulamenta&ccedil;&atilde;o    n&atilde;o s&atilde;o eficazes para proteger 
o p&uacute;blico mais vulner&aacute;vel    no Brasil. A viola&ccedil;&atilde;o d
os c&oacute;digos de auto-regulamenta&ccedil;&atilde;o    publicit&aacute;ria pa
ra propaganda de bebidas alco&oacute;licas foi detectada    tamb&eacute;m por es
tudos australianos, americanos e europeus.<sup>2, 7, 12,23,26,</sup><a name="top
e"></a><a href="#backe"><sup>e</sup></a></font></p>     ^cY#1827.htm##
00774000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704053800081002000900619#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#73#69#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Pesquisas sugerem    que a form
a mais eficaz de controlar a influ&ecirc;ncia da propaganda sobre    o consumo d
e &aacute;lcool seria diminuir a exposi&ccedil;&atilde;o dos mais    jovens, res
tringindo a veicula&ccedil;&atilde;o de propagandas de bebidas alco&oacute;licas
,    incluindo cerveja, na televis&atilde;o e em outros meios de comunica&ccedil
;&atilde;o.<sup>27</sup>    Tal restri&ccedil;&atilde;o inexiste no Brasil para 
a propaganda de cerveja.</font></p>     ^cY#1827.htm##
00854000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704061800081002000900699#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#74#70#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Enquanto medidas    legais n&at
ilde;o s&atilde;o tomadas nesse sentido, a sociedade pode diminuir    essa influ
&ecirc;ncia agindo nos receptores das mensagens (os adolescentes)    pela educa&
ccedil;&atilde;o para a m&iacute;dia.<a href="#backf"><sup>f</sup></a>    As pro
pagandas deixariam de ser refer&ecirc;ncias para a defini&ccedil;&atilde;o    de
 "normalidade" ou "realidade" e passariam a ser vistas pelos adolescentes    com
o ferramentas para influenci&aacute;-los ao consumo de bebidas, alimentos,    ve
stu&aacute;rio e outros.</font></p>     ^cY#1827.htm##
01055000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704081900081002000900900#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#75#71#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A educa&ccedil;&atilde;o    par
a a m&iacute;dia visa compreender como as propagandas moldam o entendimento    d
os jovens sobre seu ambiente. O objetivo &eacute; fazer com que o receptor    da
 mensagem - o adolescente - desenvolva uma vis&atilde;o distante e cr&iacute;tic
a,    que o capacite a formar julgamentos a tomar decis&otilde;es pr&oacute;pria
s.<a href="#backf"><sup>f</sup></a>    A educa&ccedil;&atilde;o para a m&iacute;
dia tem sido estudada em outras quest&otilde;es    de sa&uacute;de, como h&aacut
e;bitos alimentares e comportamentos sexuais.<sup>11,14</sup>    O oferecimento 
de atividades direcionadas a essas quest&otilde;es pelas escolas    poderia abri
r espa&ccedil;o para discuss&atilde;o e orienta&ccedil;&atilde;o.</font></p>    
 ^cY#1827.htm##
01030000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079400081002000900875#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#76#72#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As limita&ccedil;&otilde;es    
deste estudo incluem a amostra de apenas uma cidade, a impossibilidade de medi&c
cedil;&atilde;o    da real for&ccedil;a de associa&ccedil;&atilde;o e a natureza
 transversal da    investiga&ccedil;&atilde;o, cuja metodologia n&atilde;o permi
te estabelecimento    da rela&ccedil;&atilde;o de causalidade, mas aponta as dir
e&ccedil;&otilde;es    a serem tomadas em estudos futuros. Os nossos resultados 
apontam maneiras pelas    quais as propagandas podem estar influenciando o consu
mo dos jovens e o que    pode ser feito para preven&ccedil;&atilde;o, pois h&aac
ute; consist&ecirc;ncia    com trabalhos anteriores e a associa&ccedil;&atilde;o
 &eacute; plaus&iacute;vel.<sup>22</sup></font></p>     ^cY#1827.htm##
01038000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704080200081002000900883#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#77#73#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A responsabilidade    pela elab
ora&ccedil;&atilde;o, codifica&ccedil;&atilde;o e apropria&ccedil;&atilde;o    d
as mensagens transmitidas pela m&iacute;dia reside tanto no produtor quanto    n
o receptor da mensagem. Certamente a m&iacute;dia n&atilde;o &eacute; causa    d
ireta de consumo de bebidas alco&oacute;licas. Por&eacute;m, h&aacute; associa&c
cedil;&atilde;o    entre essas mensagens vindas da m&iacute;dia e o comportament
o dos jovens. &Eacute;    nessa convers&atilde;o da id&eacute;ia para a pr&aacut
e;tica social que reside    uma parte da chamada "responsabilidade social" da pr
opaganda de maneira geral    e, particularmente, da ind&uacute;stria do &aacute;
lcool, que n&atilde;o pode    ser negligenciada.</font></p>     ^cY#1827.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#78#74#article#135#<p>&nbsp;</p> 
    ^cY#1827.htm##
00343000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010700081002000900188#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#79#75#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font>
</p>     ^cY#1827.htm##
00507000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704025700083002000900340#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#80#76#article#135#1#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Aitken PP, Ead
ie    DR, Leathar DS. McNeill REJ, Scott AC. Television advertisements for alcoh
olic    drinks do reinforce under-age drinking. <i>Br J Addict</i>. 1988;83(12):
1399-419.    ^cY#1827.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#81#77#article#135#</font></p>   
  ^cY#1827.htm##
00411000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704016100083002000900244#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#82#78#article#135#2#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Anderson P.   
 Is it time to ban alcohol advertising? <i>Clin Med.</i> 2009;9(2):121-4.    ^cY
#1827.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#83#79#article#135#</font></p>   
  ^cY#1827.htm##
00502000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704025200083002000900335#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#84#80#article#135#3#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Austin EW, Joh
nson    KK. Effects of general and alcohol-specific media literacy training on c
hildren's    decision making about alcohol. <i>J Health Commun</i>. 1997;2(1):17
-42.    ^cY#1827.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#85#81#article#135#</font></p>   
  ^cY#1827.htm##
00498000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704024800083002000900331#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#86#82#article#135#4#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Austin EW, Mei
li    HK. Effects of interpretations of televised alcohol portrails on children'
s    alcohol beliefs. <i>J Broadcasting Electronic Media.</i> 1994;38(4):417-35.
    ^cY#1827.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#87#83#article#135#</font></p>   
  ^cY#1827.htm##
00519000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704026900083002000900352#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#88#84#article#135#5#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Austin EW, Pin
kleton    BE, Fujioka Y. The role of interpretation processes and parental discu
ssion    in the media's effects on adolescents' use of alcohol. <i>Pediatrics.</
i> 2000;105(2):343-9.    ^cY#1827.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#89#85#article#135#</font></p>   
  ^cY#1827.htm##
00529000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704027900083002000900362#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#90#86#article#135#6#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Babor T, Caeta
no    R, Casswell S, Edwads G, Giesbrecht N. Alcohol: no ordinary commodity: res
earch    and public policy. New York: Oxford University Press; 2003. Regulating 
alcohol    promotion; p.173-88.    ^cY#1827.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#91#87#article#135#</font></p>   
  ^cY#1827.htm##
00521000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704027100083002000900354#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#92#88#article#135#7#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Babor TF, Xuan
    Z, Proctor D. Reliability of a rating procedure to monitor industry self-reg
ulation    codes governing alcohol advertising content. <i>J Stud Alcohol Drugs<
/i>. 2008;69(2):235-42.    ^cY#1827.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#93#89#article#135#</font></p>   
  ^cY#1827.htm##
00569000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704031900083002000900402#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#94#90#article#135#8#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Bastos FI, Ber
toni    N, Hacker MA. Consumo de &aacute;lcool e drogas: principais achados de p
esquisa    de &acirc;mbito nacional, Brasil 2005. <i>Rev Saude Publica.</i> 2008
;42 (Supl    1):109-17. DOI:10.1590/S0034-89102008000800013</font></p>     ^cY#1
827.htm##
00451000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704020100083002000900284#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#95#91#article#135#9#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Beccaria F.   
 Italian alcohol advertising regulation and enforcement. <i>Contemporary Drug   
 Problems.</i> 2007;34(3):347-60.    ^cY#1827.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#96#92#article#135#</font></p>   
  ^cY#1827.htm##
00531000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000300081704028000084002000900364#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#97#93#article#135#10
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Collins RL, 
   Schell Y, Ellickson PL, McCaffrey D. Predictors of beer advertising awareness
    among eighth graders. <i>Addiction.</i> 2003;98(9):1297-306. DOI:10.1046/j.1
360-0443.2003.00448.x</font></p>     ^cY#1827.htm##
00568000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000300081704031700084002000900401#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#98#94#article#135#11
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Collins RL, 
   Ellickson PL, McCaffrey DF, Hambarsoomians K. Saturated in beer: awareness of
    beer advertising in late childhood and adolescence. <i>J Adolesc Health.</i>
    2005;37(1):29-36. DOI:10.1016/j.jadohealth.2004.08.011</font></p>     ^cY#18
27.htm##
00562000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000300081704031100084002000900395#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#99#95#article#135#12
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Ellickson PL
,    Collins RL, Hambarsoomians K, McCaffrey DF. Does alcohol advertising promot
e    adolescent drinking? Results from a longitudinal assessment. <i>Addiction</
i>.    2005;100(2):235-46. DOI:10.1111/j.1360-0443.2005.00974.x.    ^cY#1827.htm
##
00257000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704002000082002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#100#96#article#135#</font></p>  
   ^cY#1827.htm##
00613000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000300082704036100085002000900446#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#101#97#article#135#1
3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Englund M M
,    Egeland B, Oliva EM, Collins WA. Childhood and adolescent predictors of hea
vy    drinking and alcohol use disorders in early adulthood: a longitudinal deve
lopmental    analysis. <i>Addiction.</i> 2008;103 (Suppl 1):23-35. DOI:10.1111/j
.1360-0443.2008.02174.x</font></p>     ^cY#1827.htm##
00555000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000300082704030300085002000900388#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#102#98#article#135#1
4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Escobar-Cha
ves    SL, Tortolero SR, Markham CM, Low BJ, Eitel P, Thickstun P. Impact of the
 media    on adolescent sexual attitudes and behaviors. <i>Pediatrics.</i> 2005;
116(1):303-26.    DOI:10.1542/peds.2005-0355D</font></p>     ^cY#1827.htm##
00568000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000300082704031600085002000900401#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#103#99#article#135#1
5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Fielder L, 
   Donovan RJ, Ouschan R. Exposure of children and adolescents to alcohol advert
ising    on Australian metropolitan free-to-air television. <i>Addiction.</i> 20
09;104(7):1157-65.    DOI:10.1111/j.1360-0443.2009.02592.x</font></p>     ^cY#18
27.htm##
00559000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704030600086002000900392#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#104#100#article#135#
16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Fleming K,
    Thorson E, Atkin CK. Alcohol advertising exposure and perceptions: links wit
h    alcohol expectancies and intentions to drink or drinking in underaged youth
    and young adults. <i>J Health Commun</i>. 2004;9(1):3-29.    ^cY#1827.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#105#101#article#135#</font></p> 
    ^cY#1827.htm##
00619000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704036600086002000900452#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#106#102#article#135#
17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Fulkerson 
JA,    Pasch KE, Perry CL, Komro K. Relationships between alcohol-related inform
al    social control, parental monitoring and adolescent problem behaviors among
 racially    diverse urban youth. <i>J Community Health.</i> 2008;33(6):425-33. 
DOI:10.1007/s10900-008-9117-5</font></p>     ^cY#1827.htm##
00533000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028000086002000900366#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#107#103#article#135#
18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Grube JW, 
Waiters    E. Alcohol in the media: content and effects on drinking beliefs and 
behaviors    among youth. <i>Adolesc Med Clin.</i> 2005;16(2):327-43. DOI:10.101
6/j.admecli.2005.02.005</font></p>     ^cY#1827.htm##
00549000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029600086002000900382#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#108#104#article#135#
19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Hastings G
,    Anderson S, Cooke E, Gordon R. Alcohol marketing and young people's drinkin
g:    a review of the research. <i>J Public Health Policy.</i> 2005;26(3):296-31
1.    DOI:10.1057/palgrave.jphp.3200039</font></p>     ^cY#1827.htm##
00548000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029500086002000900381#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#109#105#article#135#
20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Henriksen 
L,    Feighery EC, Schleicher NC, Fortmann SP. Receptivity to alcohol marketing 
predicts    initiation of alcohol use. <i>J Adolesc Health</i>, 2008;42(1):28-35
. DOI:10.1016/j.jadohealth.2007.07.005</font></p>     ^cY#1827.htm##
00511000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704025800086002000900344#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#110#106#article#135#
21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Jernigan D
H,    Ostroff J, Ross C. Alcohol advertising and youth: a measured approach. <i>
J    Public Health Policy.</i> 2005;26(3):312-25. DOI:10.1057/palgrave.jphp.3200
0</font></p>     ^cY#1827.htm##
00597000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704034400086002000900430#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#111#107#article#135#
22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Maggs JL, 
Patrick    ME, Feinstein L. Childhood and adolescent predictors of alcohol use a
nd problems    in adolescence and adulthood in the National Child Development St
udy. <i>Addiction.</i>    2008;103 (Suppl 1):7-22. DOI:10.1111/j.1360-0443.2008.
02173.x</font></p>     ^cY#1827.htm##
00660000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704040700086002000900493#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#112#108#article#135#
23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Pinsky I, 
Pavarino    Filho RV. A apologia do consumo de bebidas alco&oacute;licas e da ve
locidade    no tr&acirc;nsito no Brasil: considera&ccedil;&otilde;es sobre a pro
paganda    de dois problemas de sa&uacute;de p&uacute;blica. <i>Rev Psiquiatr Ri
o Gd Sul.</i>    2007;29(1):110-8. DOI:10.1590/S0101-81082007000100019</font></p
>     ^cY#1827.htm##
00536000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028300086002000900369#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#113#109#article#135#
24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Pinsky I, 
Sanches    M, Zaleski M, Laranjeira R, Caetano R. Patterns of alcohol use among 
Brazilian    adolescents. <i>Rev Bras Psiquiatr</i>. 2010;32(3):242-9. DOI:10.15
90/S1516-44462010005000007</font></p>     ^cY#1827.htm##
00549000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029600086002000900382#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#114#110#article#135#
25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Snyder LB,
    Milici FF, Slater M, Sun H, Strizhakova Y. Effects of alcohol advertising ex
posure    on drinking among youth. <i>Arch Pediatr Adolesc Med.</i> 2006;160(1):
18-24.    DOI:10.1001/archpedi.160.1.18</font></p>     ^cY#1827.htm##
00490000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704023700086002000900323#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#115#111#article#135#
26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Stacy AW, 
Zogg    JB, Unger JB, Dent CW. Exposure to televised alcohol ads and subsequent 
adolescent    alcohol use. <i>Am J Health Behav.</i> 2004;28(6):498-509.    ^cY#
1827.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#116#112#article#135#</font></p> 
    ^cY#1827.htm##
00654000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704040100086002000900487#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#117#113#article#135#
27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Vendrame A
,    Pinsky I, Faria R, Silva R. Aprecia&ccedil;&atilde;o de propagandas de cerv
eja    por adolescentes: rela&ccedil;&atilde;o com a exposi&ccedil;&atilde;o pr&
eacute;via    &agrave;s mesmas e o consumo de &aacute;lcool. <i>Cad Saude Public
a</i>. 2009;25(2):359-65.    DOI:10.1590/S0102-311X2009000200014</font></p>     
^cY#1827.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#118#114#article#135#<p>&nbsp;</p
>     ^cY#1827.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#119#115#article#135#<p>&nbsp;</p
>     ^cY#1827.htm##
00453000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021500083002000900298#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#120#116#article#135#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href
="#top"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    Corr
espond&ecirc;ncia | Correspondence:    ^cY#1827.htm##
00271000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003300083002000900116#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#121#117#article#135#<br>   </b> 
Roberta Faria    ^cY#1827.htm##
00293000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005500083002000900138#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#122#118#article#135#<br>   R. De
sembargador Francisco M. Santos, 79    ^cY#1827.htm##
00270000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003200083002000900115#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#123#119#article#135#<br>   Alto 
da Boa Vista    ^cY#1827.htm##
00291000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005300083002000900136#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#124#120#article#135#<br>   04741
-178 S&atilde;o Paulo, SP, Brasil    ^cY#1827.htm##
00335000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704009700083002000900180#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#125#121#article#135#<br>   E-mai
l: <a href="mailto:faria_ro@hotmail.com">faria_ro@hotmail.com</a></font></p>    
 ^cY#1827.htm##
00329000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704009100083002000900174#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#126#122#article#135#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Recebido: 24/11/2009    ^cY#1
827.htm##
00273000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003500083002000900118#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#127#123#article#135#<br>   Aprov
ado: 18/10/2010    ^cY#1827.htm##
00411000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704017300083002000900256#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#128#124#article#135#<br>   Pesqu
isa financiada pela Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa    do Est
ado de S&atilde;o Paulo (Fapesp - Processo nº: 2003/06250-7).</font></p>     ^cY
#1827.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#129#125#article#135#<p>&nbsp;</p
>     ^cY#1827.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#130#126#article#135#<p>&nbsp;</p
>     ^cY#1827.htm##
00441000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704020300083002000900286#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#131#127#article#135#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Trabalho apresentado    na 33
rd Annual Alcohol Epidemiology Symposium of the Kettil Bruun Society em    Budap
este, Hungria, em 2007.    ^cY#1827.htm##
00313000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704007500083002000900158#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#132#128#article#135#<br>   Os au
tores declaram n&atilde;o haver conflitos de interesse.    ^cY#1827.htm##
00793000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704055500083002000900638#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#133#129#article#135#<br>   <a na
me="backa"></a>a National Institute from Alcohol Abuse and Alcoholism.    10th s
pecial report to the U.S. Congress on alcohol and health: highlights from    cur
rent research from the Secretary of Health and Human Services. Washington,    DC
: US Department of Health and Human Services; 2000. Prevention research; chapter
    7, p.373-426. &#91;citado 2011 fev 28&#93;. Dispon&iacute;vel em: <a href="h
ttp://pubs.niaaa.nih.gov/publications/10report/intro.pdf" target="_blank">http:/
/pubs.niaaa.nih.gov/publications/10report/intro.pdf</a>    ^cY#1827.htm##
00564000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704032600083002000900409#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#134#130#article#135#<br>   <a na
me="backb"></a>b Instituto Brasileiro de Geografia e Estat&iacute;stica.    Cens
o 2000: IBGE cidades @. Rio de Janeiro; s.d. &#91;citado 2011 mar 8&#93;.    Dis
pon&iacute;vel em: <a href="http://www.ibge.gov.br/cidadesat/topwindow.htm?1" ta
rget="_blank">http://www.ibge.gov.br/cidadesat/topwindow.htm?1</a>    ^cY#1827.h
tm##
00795000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704055700083002000900640#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#135#131#article#135#<br>   <a na
me="backc"></a>c Universidade Federal de S&atilde;o Paulo, Centro Brasileiro    
de Informa&ccedil;&otilde;es sobre Drogas Psicotr&oacute;picas. 5º Levantamento 
   sobre drogas psicotr&oacute;picas entre estudantes do ensino fundamental e m&
eacute;dio    da rede p&uacute;blica de ensino nas 27 capitais brasileiras - 200
4. S&atilde;o    Paulo: CEBRID; 2004. &#91;citado 2011 fev 28&#93;. Dispon&iacut
e;vel em: <a href="http://www.unifesp.br/dpsicobio/cebrid/index.php" target="_bl
ank">http://www.unifesp.br/dpsicobio/cebrid/index.php</a>    ^cY#1827.htm##
00692000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704045400083002000900537#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#136#132#article#135#<br>   <a na
me="backd"></a><a href="#topd">d</a> Conselho Nacional de Autorregulamenta&ccedi
l;&atilde;o    Publicit&aacute;ria. C&oacute;digos e anexos: anexo A - bebidas a
lco&oacute;licas.    S&atilde;o Paulo; s.d. &#91;citado 2011 fev 28&#93;. Dispon
&iacute;vel em: <a href="http://www.conar.org.br/html/codigos/codigos%20e%20anex
os_cap2_anexoA.htm" target="_blank">http://www.conar.org.br/html/codigos/codigos
%20e%20anexos_cap2_anexoA.htm</a>.    ^cY#1827.htm##
00407000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704016900083002000900252#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#137#133#article#135#<br>   <a na
me="backe"></a><a href="#tope">e</a> Pinsky I, organizadora. Publicidade    de b
ebidas alco&oacute;licas e os jovens. S&atilde;o Paulo: FAPESP; 2009.    ^cY#182
7.htm##
00660000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704042200083002000900505#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#138#134#article#135#<br>   <a na
me="backf"></a>f Silverblatt A. Media literacy in the digital&nbsp;age.    Readi
ng Online. 2000 Sept &#91;citado 2009 jun 10&#93;;4(3). Dispon&iacute;vel    em:
 <a href="http://www.readingonline.org/newliteracies/lit_index.asp?HREF=/newlite
racies/silverblatt/index.html" target="_blank">http://www.readingonline.org/newl
iteracies/lit_index.asp?HREF=/newliteracies/silverblatt/index.html</a></font></p
>     ^cY#1827.htm##
00263000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002500083002000900108#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\1827.htm#S#p#139#135#article#135#</body> </ht
ml>      ^cY#1827.htm##
00622000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100016000990100
01800115012010600133030001200239065000900251064000500260031000300265032000300268
014000900271865000900280002000900289035001000298801001200308#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\1827.htm#S#c#140#1#article#27#1#^rND^sAitken^nPP#
^rND^sEadie^nDR#^rND^sLeathar^nDS#McNeill REJ, Scott AC: Television advertisemen
ts for alcoholic drinks do reinforce under-age drinking^len#Br J Addict#19880000
#1988#83#12#1399-419#20110000#1827.htm#0952-0481#Br J Addict##
00463000000000265000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820120043001000300
01000143710000200153065000900155064000500164031000200169032000200171014000600173
865000900179002000900188#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.
htm#S#c#141#2#article#27#2#^rND^sAnderson^nP#Is it time to ban alcohol advertisi
ng?^len#Clin Med.#2#20090000#2009#9#2#121-4#20110000#1827.htm##
00567000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100018000990120
11200117030001600229710000200245065000900247064000500256031000200261032000200263
014000600265865000900271002000900280#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\1827.htm#S#c#142#3#article#27#3#^rND^sAustin^nEW#^rND^sJohnson^nKK#Effect
s of general and alcohol-specific media literacy training on children's decision
 making about alcohol^len#J Health Commun#2#19970000#1997#2#1#17-42#20110000#182
7.htm##
00564000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100016000990120
09200115030003300207710000200240065000900242064000500251031000300256032000200259
014000700261865000900268002000900277#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\1827.htm#S#c#143#4#article#27#4#^rND^sAustin^nEW#^rND^sMeili^nHK#Effects 
of interpretations of televised alcohol portrails on children's alcohol beliefs^
len#J Broadcasting Electronic Media.#2#19940000#1994#38#4#417-35#20110000#1827.h
tm##
00603000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100020000990100
01700119012011900136030001200255710000200267065000900269064000500278031000400283
032000200287014000600289865000900295002000900304#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\1827.htm#S#c#144#5#article#27#5#^rND^sAustin^nEW#^rND^sPinkle
ton^nBE#^rND^sFujioka^nY#The role of interpretation processes and parental discu
ssion in the media's effects on adolescents' use of alcohol^len#Pediatrics.#2#20
000000#2000#105#2#343-9#20110000#1827.htm##
00593000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800160015000820160017000970160
01800114016001600132016002000148018006300168066000900231062002400240065000900264
064000500273014000700278865000900285002000900294#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\1827.htm#S#c#145#6#article#27#6#^rND^sBabor^nT#^rND^sCaetano^
nR#^rND^sCasswell^nS#^rND^sEdwads^nG#^rND^sGiesbrecht^nN#Alcohol: no ordinary co
mmodity: research and public policy^len#New York#Oxford University Press#2003000
0#2003#173-88#20110000#1827.htm##
00604000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100016000820100014000980100
01700112012011800129030002100247710000200268065000900270064000500279031000300284
032000200287014000700289865000900296002000900305#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\1827.htm#S#c#146#7#article#27#7#^rND^sBabor^nTF#^rND^sXuan^nZ
#^rND^sProctor^nD#Reliability of a rating procedure to monitor industry self-reg
ulation codes governing alcohol advertising content^len#J Stud Alcohol Drugs#2#2
0080000#2008#69#2#235-42#20110000#1827.htm##
00629000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100017000990100
01700116012009500133030001900228710000200247065000900249064000500258031000300263
032000400266014000700270237003200277865000900309002000900318#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\1827.htm#S#c#147#8#article#27#8#^rND^sBastos^nFI#
^rND^sBertoni^nN#^rND^sHacker^nMA#Consumo de álcool e drogas: principais achados
 de pesquisa de âmbito nacional, Brasil 2005^lpt#Rev Saude Publica.#2#20080000#2
008#42#^s1#109-17#10.1590/S0034-89102008000800013#20110000#1827.htm##
00499000000000265000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820120059001000300
02800159710000200187065000900189064000500198031000300203032000200206014000700208
865000900215002000900224#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.
htm#S#c#148#9#article#27#9#^rND^sBeccaria^nF#Italian alcohol advertising regulat
ion and enforcement^len#Contemporary Drug Problems.#2#20070000#2007#34#3#347-60#
20110000#1827.htm##
00629000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100016001020100
02000118010001900138012006600157030001100223710000200234065000900236064000500245
031000300250032000200253014000900255237003300264865000900297002000900306#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#149#10#article#27#10#^rN
D^sCollins^nRL#^rND^sSchell^nY#^rND^sEllickson^nPL#^rND^sMcCaffrey^nD#Predictors
 of beer advertising awareness among eighth graders^len#Addiction.#2#20030000#20
03#98#9#1297-306#10.1046/j.1360-0443.2003.00448.x#20110000#1827.htm##
00663000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100020001020100
02000122010002400142012008700166030001800253710000200271065000900273064000500282
031000300287032000200290014000600292237003300298865000900331002000900340#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#150#11#article#27#11#^rN
D^sCollins^nRL#^rND^sEllickson^nPL#^rND^sMcCaffrey^nDF#^rND^sHambarsoomians^nK#S
aturated in beer: awareness of beer advertising in late childhood and adolescenc
e^len#J Adolesc Health.#2#20050000#2005#37#1#29-36#10.1016/j.jadohealth.2004.08.
011#20110000#1827.htm##
00698000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100020000840100018001040100
02400122010002000146012009800166030001000264065000900274064000500283031000400288
03200020029201400070029423700330030186500090033400200090034303500100035280100100
0362#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#151#12#artic
le#27#12#^rND^sEllickson^nPL#^rND^sCollins^nRL#^rND^sHambarsoomians^nK#^rND^sMcC
affrey^nDF#Does alcohol advertising promote adolescent drinking?: Results from a
 longitudinal assessment^len#Addiction#20050000#2005#100#2#235-46#10.1111/j.1360
-0443.2005.00974.x#20110000#1827.htm#0965-2140#Addiction##
00702000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100017001030100
01600120010001800136012014200154030001100296710000200307065000900309064000500318
031000400323032000400327014000600331237003300337865000900370002000900379#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#152#13#article#27#13#^rN
D^sEnglund M^nM#^rND^sEgeland^nB#^rND^sOliva^nEM#^rND^sCollins^nWA#Childhood and
 adolescent predictors of heavy drinking and alcohol use disorders in early adul
thood: a longitudinal developmental analysis^len#Addiction.#2#20080000#2008#103#
^s1#23-35#10.1111/j.1360-0443.2008.02174.x#20110000#1827.htm##
00685000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100025000840100020001090100
01800129010001400147010001500161010001900176012006900195030001200264710000200276
06500090027806400050028703100040029203200020029601400070029823700240030586500090
0329002000900338#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#
153#14#article#27#14#^rND^sEscobar-Chaves^nSL#^rND^sTortolero^nSR#^rND^sMarkham^
nCM#^rND^sLow^nBJ#^rND^sEitel^nP#^rND^sThickstun^nP#Impact of the media on adole
scent sexual attitudes and behaviors^len#Pediatrics.#2#20050000#2005#116#1#303-2
6#10.1542/peds.2005-0355D#20110000#1827.htm##
00644000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100018001010100
01700119012011400136030001100250710000200261065000900263064000500272031000400277
032000200281014000800283237003300291865000900324002000900333#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\1827.htm#S#c#154#15#article#27#15#^rND^sFielder^n
L#^rND^sDonovan^nRJ#^rND^sOuschan^nR#Exposure of children and adolescents to alc
ohol advertising on Australian metropolitan free-to-air television^len#Addiction
.#2#20090000#2009#104#7#1157-65#10.1111/j.1360-0443.2009.02592.x#20110000#1827.h
tm##
00637000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100017001010100
01600118012015400134030001600288710000200304065000900306064000500315031000200320
032000200322014000500324865000900329002000900338#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\1827.htm#S#c#155#16#article#27#16#^rND^sFleming^nK#^rND^sThor
son^nE#^rND^sAtkin^nCK#Alcohol advertising exposure and perceptions: links with 
alcohol expectancies and intentions to drink or drinking in underaged youth and 
young adults^len#J Health Commun#2#20040000#2004#9#1#3-29#20110000#1827.htm##
00712000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100020000840100016001040100
01600120010001500136012015500151030002000306710000200326065000900328064000500337
031000300342032000200345014000700347237002600354865000900380002000900389#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#156#17#article#27#17#^rN
D^sFulkerson^nJA#^rND^sPasch^nKE#^rND^sPerry^nCL#^rND^sKomro^nK#Relationships be
tween alcohol-related informal social control, parental monitoring and adolescen
t problem behaviors among racially diverse urban youth^len#J Community Health.#2
#20080000#2008#33#6#425-33#10.1007/s10900-008-9117-5#20110000#1827.htm##
00593000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100017001000120
09200117030001800209710000200227065000900229064000500238031000300243032000200246
014000700248237003000255865000900285002000900294#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\1827.htm#S#c#157#18#article#27#18#^rND^sGrube^nJW#^rND^sWaite
rs^nE#Alcohol in the media: content and effects on drinking beliefs and behavior
s among youth^len#Adolesc Med Clin.#2#20050000#2005#16#2#327-43#10.1016/j.admecl
i.2005.02.005#20110000#1827.htm##
00642000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100018001020100
01500120010001600135012007600151030002400227710000200251065000900253064000500262
031000300267032000200270014000800272237003000280865000900310002000900319#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#158#19#article#27#19#^rN
D^sHastings^nG#^rND^sAnderson^nS#^rND^sCooke^nE#^rND^sGordon^nR#Alcohol marketin
g and young people's drinking: a review of the research^len#J Public Health Poli
cy.#2#20050000#2005#26#3#296-311#10.1057/palgrave.jphp.3200039#20110000#1827.htm
##
00644000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100019001030100
02100122010001900143012007200162030001800234710000200252065000900254064000500263
031000300268032000200271014000600273237003300279865000900312002000900321#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#159#20#article#27#20#^rN
D^sHenriksen^nL#^rND^sFeighery^nEC#^rND^sSchleicher^nNC#^rND^sFortmann^nSP#Recep
tivity to alcohol marketing predicts initiation of alcohol use^len#J Adolesc Hea
lth,#2#20080000#2008#42#1#28-35#10.1016/j.jadohealth.2007.07.005#20110000#1827.h
tm##
00589000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100017001030100
01400120012005500134030002400189710000200213065000900215064000500224031000300229
032000200232014000700234237002800241865000900269002000900278#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\1827.htm#S#c#160#21#article#27#21#^rND^sJernigan^
nDH#^rND^sOstroff^nJ#^rND^sRoss^nC#Alcohol advertising and youth: a measured app
roach^len#J Public Health Policy.#2#20050000#2005#26#3#312-25#10.1057/palgrave.j
php.32000#20110000#1827.htm##
00651000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100018001000100
01900118012013700137030001100274710000200285065000900287064000500296031000400301
014000500305237003300310865000900343002000900352#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\1827.htm#S#c#161#22#article#27#22#^rND^sMaggs^nJL#^rND^sPatri
ck^nME#^rND^sFeinstein^nL#Childhood and adolescent predictors of alcohol use and
 problems in adolescence and adulthood in the National Child Development Study^l
en#Addiction.#2#20080000#2008#103#7-22#10.1111/j.1360-0443.2008.02173.x#20110000
#1827.htm##
00673000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100025001000120
15500125030002600280710000200306065000900308064000500317031000300322032000200325
014000600327237003200333865000900365002000900374#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\1827.htm#S#c#162#23#article#27#23#^rND^sPinsky^nI#^rND^sPavar
ino Filho^nRV#A apologia do consumo de bebidas alcoólicas e da velocidade no trâ
nsito no Brasil: considerações sobre a propaganda de dois problemas de saúde púb
lica^lpt#Rev Psiquiatr Rio Gd Sul.#2#20070000#2007#29#1#110-8#10.1590/S0101-8108
2007000100019#20110000#1827.htm##
00649000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100017001000100
01700117010002000134010001700154012005600171030001900227710000200246065000900248
06400050025703100030026203200020026501400060026723700320027386500090030500200090
0314#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#163#24#artic
le#27#24#^rND^sPinsky^nI#^rND^sSanches^nM#^rND^sZaleski^nM#^rND^sLaranjeira^nR#^
rND^sCaetano^nR#Patterns of alcohol use among Brazilian adolescents^len#Rev Bras
 Psiquiatr#2#20100000#2010#32#3#242-9#10.1590/S1516-44462010005000007#20110000#1
827.htm##
00660000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100017001010100
01600118010001300134010002100147012006800168030002600236710000200262065000900264
06400050027303100040027803200020028201400060028423700260029086500090031600200090
0325#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#164#25#artic
le#27#25#^rND^sSnyder^nLB#^rND^sMilici^nFF#^rND^sSlater^nM#^rND^sSun^nH#^rND^sSt
rizhakova^nY#Effects of alcohol advertising exposure on drinking among youth^len
#Arch Pediatr Adolesc Med.#2#20060000#2006#160#1#18-24#10.1001/archpedi.160.1.18
#20110000#1827.htm##
00590000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100015001000100
01600115010001500131012007600146030001900222710000200241065000900243064000500252
031000300257032000200260014000800262865000900270002000900279#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\1827.htm#S#c#165#26#article#27#26#^rND^sStacy^nAW
#^rND^sZogg^nJB#^rND^sUnger^nJB#^rND^sDent^nCW#Exposure to televised alcohol ads
 and subsequent adolescent alcohol use^len#Am J Health Behav.#2#20040000#2004#28
#6#498-509#20110000#1827.htm##
00718000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100016001020100
01500118010001500133012012200148030001800270065000900288064000500297031000300302
03200020030501400070030723700320031486500090034600200090035503500100036480100180
0374#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\1827.htm#S#c#166#27#artic
le#27#27#^rND^sVendrame^nA#^rND^sPinsky^nI#^rND^sFaria^nR#^rND^sSilva^nR#Aprecia
ção de propagandas de cerveja por adolescentes: relação com a exposição prévia à
s mesmas e o consumo de álcool^lpt#Cad Saude Publica#20090000#2009#25#2#359-65#1
0.1590/S0102-311X2009000200014#20110000#1827.htm#0102-311X#Cad Saude Publica##
00276000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00400102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#o#1#1#arti
cle#1#20110331#154553#2331.htm#171##
08249000000000913000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000400095121000300099049000300102158000300105030001900108
03200060012706500090013301400070014203500100014922300090015901200800016801200730
02480120094003210100043004150100041004580100039004990100041005380100040005790100
04200619070009400661070011300755070012100868070010100989083176901090085001002859
08500300286908500510289908500240295008500240297408500290299808500360302708500310
30630831718030940850010048120850027048220850047048490850025048960850024049210850
02504945085003404970085003105004083183705035085001006872085003206882085005206914
08500250696608500250699108500310701608500370704708500320708411700080711607200030
71241120009071271110019071361140009071551130011071640580053071750600013072280580
06207241060002307303002000907326#2011nahead#V:\SciELO\serial\rsp\2011nahead\mark
up\2331.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#TAB#18#nd#nd#Rev. Saúde Pública#
ahead#20110000#^f0^l0#0034-8910#20110408#Áreas de vulnerabilidade para co-infecç
ão HIV-aids/TB em Ribeirão Preto, SP^lpt#Areas of vulnerability to HIV/TB co-inf
ection in Southeastern Brazil^len#Áreas de vulnerabilidad para coinfección VIH-s
ida/TB en Ribeirao Preto, Sureste de Brasil^les#^rND^1A01^nMaria Eugênia Firmino
^sBrunello#^rND^1A02^nFrancisco^sChiaravalloti Neto#^rND^1A03^nRicardo Alexandre
^sArcêncio#^rND^1A04^nRubia Laine de Paula^sAndrade#^rND^1A01^nGabriela Tavares^
sMagnabosco#^rND^1A03^nTereza Cristina Scatena^sVilla#Universidade de São Paulo^
iA01^1Escola de Enfermagem de Ribeirão Preto^cSão Paulo^sSP^pBrasil#Universidade
 de São Paulo^iA02^1Faculdade de Saúde Pública^2Departamento de Epidemiologia^cS
ão Paulo^sSP^pBrasil#Universidade de São Paulo^iA03^1EERP^2Departamento de Enfer
magem Materno-infantil e Saúde Pública^cSão Paulo^sSP^pBrasil#Universidade de Sã
o Paulo^iA04^1EERP^2Programa de Pós-Graduação Interunidades^cSão Paulo^sSP^pBras
il#^lpt^aOBJETIVO: Identificar áreas de vulnerabilidade para os casos novos de c
o-infecção HIV/tuberculose (TB). MÉTODOS: Estudo descritivo ecológico realizado 
por meio do georreferenciamento dos casos novos de HIV/TB notificados em Ribeirã
o Preto, SP, em 2006. Os dados foram obtidos do sistema de informação estadual p
aulista de notificação de TB. Os casos novos de co-infecção HIV/TB foram analisa
dos conforme características sociodemográficas e clínicas e, posteriormente, geo
rreferenciados na base cartográfica do município segundo endereço residencial. O
s setores do município foram categorizados em três níveis socioeconômicos: infer
ior, intermediário e superior, com base na análise de componentes principais das
 variáveis do censo demográfico de 2000 (renda, instrução e percentagem de domic
ílios com cinco ou mais moradores). Foi calculada a incidência da co-infecção HI
V/TB para cada nível socioeconômico. RESULTADOS: A co-infecção HIV/TB acometeu m
ais adultos do sexo masculino em idade economicamente ativa e a forma pulmonar d
a TB foi a mais comum. A distribuição espacial mostrou que as incidências nas ár
eas com níveis socioeconômicos intermediários e inferiores (8,3 e 11,5 casos por
 100 mil habitantes, respectivamente) foram superiores àquela (4,8 casos por 100
 mil habitantes) de nível socioeconômico superior. CONCLUSÕES: A taxa de incidên
cia de co-infecção HIV/TB analisada por níveis socioeconômicos mostrou padraÞo e
spacial de distribuiçaÞo não homogêneo e apresentou valores mais altos em áreas 
de maior vulnerabilidade social. O estudo diagnosticou aìreas geograìficas prior
itaìrias para o controle da co-infecção e a tecnologia do sistema de informação 
geográfica pode ser empregada no planejamento das ações em saúde pelos gestores 
municipais.#^ddecs^i1#^tm^lpt^kInfecções por HIV^i1#^tm^lpt^kSíndrome de Imunode
ficiência Adquirida^i1#^tm^lpt^kTuberculose^i1#^tm^lpt^kComorbidade^i1#^tm^lpt^k
Fatores de Risco^i1#^tm^lpt^kFatores Socioeconômicos^i1#^tm^lpt^kEstudos Ecológi
cos^i1#^len^aOBJECTIVE: To identify areas of vulnerability to new cases of HIV/t
uberculosis (TB) co-infection. METHODS: An ecological descriptive study was cond
ucted by georeferencing new HIV/TB cases reported in the city of Ribeirão Preto,
 Southeastern Brazil, in 2006. Data were obtained from the São Paulo state infor
mation system for TB notification (TB-WEB) database. New cases of HIV/TB co-infe
ction were analyzed according to sociodemographic and clinical characteristics a
nd, subsequently, georeferenced in the city's cartographic basis, based on home 
addresses. City sectors were categorized into three socioeconomic levels: lower,
 average and upper levels, based on the analysis of the main components of the 2
000 Demographic Census variables (income, level of education and percentage of h
ouseholds with five or more residents). The incidence of HIV/TB co-infection was
 calculated for each socioeconomic level. RESULTS: HIV/TB co-infection affected 
a higher number of economically active adult males and the pulmonary form of TB 
was the most frequent. Spatial distribution showed that the incidences in areas 
with average and lower socioeconomic levels (8.3 and 11.5 cases per 100,000 inha
bitants, respectively) were higher than that with a higher socioeconomic level (
4.8 cases per 100,000 inhabitants). CONCLUSIONS: The incidence rate of HIV/TB co
-infection, analyzed according to socioeconomic levels, showed a non-homogeneous
 spatial pattern of distribution and higher values in more socially vulnerable a
reas. The present study identified priority geographical areas to control co-inf
ection and revealed that the geographical information system technology can be u
sed by city managers to plan health actions.#^ddecs^i2#^tm^len^kHIV Infections^i
2#^tm^len^kAcquired Immunodeficiency Syndrome^i2#^tm^len^kTuberculosis^i2#^tm^le
n^kComorbidity^i2#^tm^len^kRisk Factors^i2#^tm^len^kSocioeconomic Factors^i2#^tm
^len^kEcological Studies^i2#^les^aOBJETIVO: Identificar áreas de vulnerabilidad 
para los casos nuevos de coinfección VIH/tuberculosis (TB). MÉTODOS: Estudio des
criptivo ecológico realizado por medio del georeferenciamiento de los casos nuev
os de VIH/TB notificados en Ribeirao Preto, Sureste de Brasil, en 2006. Los dato
s fueron obtenidos del sistema de información estatal paulista de notificación d
e TB. Los casos nuevos de coinfección VIH/TB fueron analizados conforme caracter
ísticas sociodemográficas y clínicas y, posteriormente, georeferenciados en la b
ase cartográfica del municipio según dirección residencial. Los sectores del mun
icipio fueron categorizados en tres niveles socioeconómicos: inferior, intermedi
o y superior, con base en el análisis de componentes principales de las variable
s del censo demográfico de 2000 (renta, instrucción y porcentaje de domicilios c
on cinco o más moradores). Fue calculada la incidencia de la coinfección VIH/TB 
para cada nivel socioeconómico. RESULTADOS: La coinfección VIH/TB afectó más adu
ltos del sexo masculino en edad económicamente activa y la forma pulmonar de la 
TB fue la más común. La distribución espacial mostró que las incidencias en las 
áreas con niveles socioeconómicos intermedios e inferiores (8,3 y 11,5 casos por
 100 mil habitantes, respectivamente), fueron superiores a (4,8 casos por 100 mi
l habitantes) las del nivel socioeconómico superior. CONCLUSIONES: La tasa de in
cidencia de coinfección HIV/TB analizada por niveles socioeconómicos mostró patr
ón espacial de distribución no homogéneo y presentó valores más altos en áreas d
e mayor vulnerabilidad social. El estudio diagnosticó áreas geográficas priorita
rias para el control de la coinfección la tecnología del sistema de información 
geográfica puede ser empleada en la planificación de las acciones en salud por l
os gestores municipales.#^ddecs^i3#^tm^les^kInfecciones por VIH^i3#^tm^les^kSínd
rome de Inmunodeficiencia Adquirida^i3#^tm^les^kTuberculosis^i3#^tm^les^kComorbi
lidad^i3#^tm^les^kFactores de Riesgo^i3#^tm^les^kFactores Socioeconómicos^i3#^tm
^les^kEstudios Ecológicos^i3#vancouv#24#20100607#Recebido: 7/6/2010#20101114#14/
11/2010#Fundação de Amparo à Pesquisa do Estado de São Paulo#2007/57516-8#Consel
ho Nacional de Desenvolvimento Científico e Tecnológico#25/2006 410547/ 2006-9#2
331.htm##
08470000000000913000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000400095121000300099049000300102158000300105030001900108
03200060012706500090013301400070014203500100014922300090015901200870016801200800
02550120101003350100043004360100041004790100039005200100041005590100040006000100
04200640070009400682070011300776070012100889070010101010083179701111085001002908
08500300291808500510294808500240299908500240302308500290304708500360307608500310
31120831746031430850010048890850027048990850047049260850025049730850024049980850
02505022085003405047085003105081083186505112085001006977085003206987085005207019
08500250707108500250709608500310712108500370715208500320718911700080722107200030
72291120009072321110019072411140009072601130011072690580053072800600071073330580
06207404060008107466002000907547#2011nahead#V:\SciELO\serial\rsp\2011nahead\mark
up\2331.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#TAB#18#nd#nd#Rev. Saúde Pública#
ahead#20110000#^f0^l0#0034-8910#20110408#<b>Áreas de vulnerabilidade para co-inf
ecção HIV-aids/TB em Ribeirão Preto, SP</b>^lpt#<b>Areas of vulnerability to HIV
/TB co-infection in Southeastern Brazil</b>^len#<b>Áreas de vulnerabilidad para 
coinfección VIH-sida/TB en Ribeirao Preto, Sureste de Brasil</b>^les#^rND^1A01^n
Maria Eugênia Firmino^sBrunello#^rND^1A02^nFrancisco^sChiaravalloti Neto#^rND^1A
03^nRicardo Alexandre^sArcêncio#^rND^1A04^nRubia Laine de Paula^sAndrade#^rND^1A
01^nGabriela Tavares^sMagnabosco#^rND^1A03^nTereza Cristina Scatena^sVilla#Unive
rsidade de São Paulo^iA01^1Escola de Enfermagem de Ribeirão Preto^cSão Paulo^sSP
^pBrasil#Universidade de São Paulo^iA02^1Faculdade de Saúde Pública^2Departament
o de Epidemiologia^cSão Paulo^sSP^pBrasil#Universidade de São Paulo^iA03^1EERP^2
Departamento de Enfermagem Materno-infantil e Saúde Pública^cSão Paulo^sSP^pBras
il#Universidade de São Paulo^iA04^1EERP^2Programa de Pós-Graduação Interunidades
^cSão Paulo^sSP^pBrasil#^lpt^a<b>OBJETIVO:</b> Identificar áreas de vulnerabilid
ade para os casos novos de co-infecção HIV/tuberculose (TB). <b>MÉTODOS:</b> Est
udo descritivo ecológico realizado por meio do georreferenciamento dos casos nov
os de HIV/TB notificados em Ribeirão Preto, SP, em 2006. Os dados foram obtidos 
do sistema de informação estadual paulista de notificação de TB. Os casos novos 
de co-infecção HIV/TB foram analisados conforme características sociodemográfica
s e clínicas e, posteriormente, georreferenciados na base cartográfica do municí
pio segundo endereço residencial. Os setores do município foram categorizados em
 três níveis socioeconômicos: inferior, intermediário e superior, com base na an
álise de componentes principais das variáveis do censo demográfico de 2000 (rend
a, instrução e percentagem de domicílios com cinco ou mais moradores). Foi calcu
lada a incidência da co-infecção HIV/TB para cada nível socioeconômico. <b>RESUL
TADOS:</b> A co-infecção HIV/TB acometeu mais adultos do sexo masculino em idade
 economicamente ativa e a forma pulmonar da TB foi a mais comum. A distribuição 
espacial mostrou que as incidências nas áreas com níveis socioeconômicos interme
diários e inferiores (8,3 e 11,5 casos por 100 mil habitantes, respectivamente) 
foram superiores àquela (4,8 casos por 100 mil habitantes) de nível socioeconômi
co superior. <b>CONCLUSÕES:</b> A taxa de incidência de co-infecção HIV/TB anali
sada por níveis socioeconômicos mostrou padraÞo espacial de distribuiçaÞo não ho
mogêneo e apresentou valores mais altos em áreas de maior vulnerabilidade social
. O estudo diagnosticou aìreas geograìficas prioritaìrias para o controle da co-
infecção e a tecnologia do sistema de informação geográfica pode ser empregada n
o planejamento das ações em saúde pelos gestores municipais.#^ddecs^i1#^tm^lpt^k
Infecções por HIV^i1#^tm^lpt^kSíndrome de Imunodeficiência Adquirida^i1#^tm^lpt^
kTuberculose^i1#^tm^lpt^kComorbidade^i1#^tm^lpt^kFatores de Risco^i1#^tm^lpt^kFa
tores Socioeconômicos^i1#^tm^lpt^kEstudos Ecológicos^i1#^len^a<b>OBJECTIVE:</b> 
To identify areas of vulnerability to new cases of HIV/tuberculosis (TB) co-infe
ction. <b>METHODS:</b> An ecological descriptive study was conducted by georefer
encing new HIV/TB cases reported in the city of Ribeirão Preto, Southeastern Bra
zil, in 2006. Data were obtained from the São Paulo state information system for
 TB notification (TB-WEB) database. New cases of HIV/TB co-infection were analyz
ed according to sociodemographic and clinical characteristics and, subsequently,
 georeferenced in the city's cartographic basis, based on home addresses. City s
ectors were categorized into three socioeconomic levels: lower, average and uppe
r levels, based on the analysis of the main components of the 2000 Demographic C
ensus variables (income, level of education and percentage of households with fi
ve or more residents). The incidence of HIV/TB co-infection was calculated for e
ach socioeconomic level. <b>RESULTS:</b> HIV/TB co-infection affected a higher n
umber of economically active adult males and the pulmonary form of TB was the mo
st frequent. Spatial distribution showed that the incidences in areas with avera
ge and lower socioeconomic levels (8.3 and 11.5 cases per 100,000 inhabitants, r
espectively) were higher than that with a higher socioeconomic level (4.8 cases 
per 100,000 inhabitants). <b>CONCLUSIONS:</b> The incidence rate of HIV/TB co-in
fection, analyzed according to socioeconomic levels, showed a non-homogeneous sp
atial pattern of distribution and higher values in more socially vulnerable area
s. The present study identified priority geographical areas to control co-infect
ion and revealed that the geographical information system technology can be used
 by city managers to plan health actions.#^ddecs^i2#^tm^len^kHIV Infections^i2#^
tm^len^kAcquired Immunodeficiency Syndrome^i2#^tm^len^kTuberculosis^i2#^tm^len^k
Comorbidity^i2#^tm^len^kRisk Factors^i2#^tm^len^kSocioeconomic Factors^i2#^tm^le
n^kEcological Studies^i2#^les^a<b>OBJETIVO:</b> Identificar áreas de vulnerabili
dad para los casos nuevos de coinfección VIH/tuberculosis (TB). <b>MÉTODOS:</b> 
Estudio descriptivo ecológico realizado por medio del georeferenciamiento de los
 casos nuevos de VIH/TB notificados en Ribeirao Preto, Sureste de Brasil, en 200
6. Los datos fueron obtenidos del sistema de información estatal paulista de not
ificación de TB. Los casos nuevos de coinfección VIH/TB fueron analizados confor
me características sociodemográficas y clínicas y, posteriormente, georeferencia
dos en la base cartográfica del municipio según dirección residencial. Los secto
res del municipio fueron categorizados en tres niveles socioeconómicos: inferior
, intermedio y superior, con base en el análisis de componentes principales de l
as variables del censo demográfico de 2000 (renta, instrucción y porcentaje de d
omicilios con cinco o más moradores). Fue calculada la incidencia de la coinfecc
ión VIH/TB para cada nivel socioeconómico. <b>RESULTADOS:</b> La coinfección VIH
/TB afectó más adultos del sexo masculino en edad económicamente activa y la for
ma pulmonar de la TB fue la más común. La distribución espacial mostró que las i
ncidencias en las áreas con niveles socioeconómicos intermedios e inferiores (8,
3 y 11,5 casos por 100 mil habitantes, respectivamente), fueron superiores a (4,
8 casos por 100 mil habitantes) las del nivel socioeconómico superior. <b>CONCLU
SIONES:</b> La tasa de incidencia de coinfección HIV/TB analizada por niveles so
cioeconómicos mostró patrón espacial de distribución no homogéneo y presentó val
ores más altos en áreas de mayor vulnerabilidad social. El estudio diagnosticó á
reas geográficas prioritarias para el control de la coinfección la tecnología de
l sistema de información geográfica puede ser empleada en la planificación de la
s acciones en salud por los gestores municipales.#^ddecs^i3#^tm^les^kInfecciones
 por VIH^i3#^tm^les^kSíndrome de Inmunodeficiencia Adquirida^i3#^tm^les^kTubercu
losis^i3#^tm^les^kComorbilidad^i3#^tm^les^kFactores de Riesgo^i3#^tm^les^kFactor
es Socioeconómicos^i3#^tm^les^kEstudios Ecológicos^i3#vancouv#24#20100607#Recebi
do: 7/6/2010#20101114#14/11/2010#Fundação de Amparo à Pesquisa do Estado de São 
Paulo#<span style='font-size:10.0pt;font-family:Verdana'>2007/57516-8</span>#Con
selho Nacional de Desenvolvimento Científico e Tecnológico#<span style='font-siz
e:10.0pt;font-family:Verdana'>25/2006 410547/ 2006-9</span>#2331.htm##
08377000000000937000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098038000400102121000300106049000300109158000300112
03000190011503200060013406500090014001400070014903500100015622300090016601200800
01750120073002550120094003280100043004220100041004650100039005060100041005450100
04000586010004200626070009600668070011500764070012300879070010301002083176901105
08500100287408500300288408500510291408500240296508500240298908500290301308500360
30420850031030780831718031090850010048270850027048370850047048640850025049110850
02404936085002504960085003404985085003105019083183705050085001006887085003206897
08500520692908500250698108500250700608500310703108500370706208500320709911700080
71310720003071391120009071421110019071511140009071701130011071790580053071900600
01307243058006207256060002307318002000907341008008907350#2011nahead#V:\SciELO\se
rial\rsp\2011nahead\markup\2331.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#t
ab#18#nd#nd#Rev. saúde pública#ahead#20110000#^f0^l0#0034-8910#20110408#Áreas de
 vulnerabilidade para co-infecção HIV-aids/TB em Ribeirão Preto, SP^lpt#Areas of
 vulnerability to HIV/TB co-infection in Southeastern Brazil^len#Áreas de vulner
abilidad para coinfección VIH-sida/TB en Ribeirao Preto, Sureste de Brasil^les#^
rND^1A01^nMaria Eugênia Firmino^sBrunello#^rND^1A02^nFrancisco^sChiaravalloti Ne
to#^rND^1A03^nRicardo Alexandre^sArcêncio#^rND^1A04^nRubia Laine de Paula^sAndra
de#^rND^1A01^nGabriela Tavares^sMagnabosco#^rND^1A03^nTereza Cristina Scatena^sV
illa#^iA01^1Universidade de São Paulo^2Escola de Enfermagem de Ribeirão Preto^cS
ão Paulo^sSP^pBrasil#^iA02^1Universidade de São Paulo^2Faculdade de Saúde Públic
a^3Departamento de Epidemiologia^cSão Paulo^sSP^pBrasil#^iA03^1Universidade de S
ão Paulo^2EERP^3Departamento de Enfermagem Materno-infantil e Saúde Pública^cSão
 Paulo^sSP^pBrasil#^iA04^1Universidade de São Paulo^2EERP^3Programa de Pós-Gradu
ação Interunidades^cSão Paulo^sSP^pBrasil#^lpt^aOBJETIVO: Identificar áreas de v
ulnerabilidade para os casos novos de co-infecção HIV/tuberculose (TB). MÉTODOS:
 Estudo descritivo ecológico realizado por meio do georreferenciamento dos casos
 novos de HIV/TB notificados em Ribeirão Preto, SP, em 2006. Os dados foram obti
dos do sistema de informação estadual paulista de notificação de TB. Os casos no
vos de co-infecção HIV/TB foram analisados conforme características sociodemográ
ficas e clínicas e, posteriormente, georreferenciados na base cartográfica do mu
nicípio segundo endereço residencial. Os setores do município foram categorizado
s em três níveis socioeconômicos: inferior, intermediário e superior, com base n
a análise de componentes principais das variáveis do censo demográfico de 2000 (
renda, instrução e percentagem de domicílios com cinco ou mais moradores). Foi c
alculada a incidência da co-infecção HIV/TB para cada nível socioeconômico. RESU
LTADOS: A co-infecção HIV/TB acometeu mais adultos do sexo masculino em idade ec
onomicamente ativa e a forma pulmonar da TB foi a mais comum. A distribuição esp
acial mostrou que as incidências nas áreas com níveis socioeconômicos intermediá
rios e inferiores (8,3 e 11,5 casos por 100 mil habitantes, respectivamente) for
am superiores àquela (4,8 casos por 100 mil habitantes) de nível socioeconômico 
superior. CONCLUSÕES: A taxa de incidência de co-infecção HIV/TB analisada por n
íveis socioeconômicos mostrou padraÞo espacial de distribuiçaÞo não homogêneo e 
apresentou valores mais altos em áreas de maior vulnerabilidade social. O estudo
 diagnosticou aìreas geograìficas prioritaìrias para o controle da co-infecção e
 a tecnologia do sistema de informação geográfica pode ser empregada no planejam
ento das ações em saúde pelos gestores municipais.#^ddecs^i1#^tm^lpt^kInfecções 
por HIV^i1#^tm^lpt^kSíndrome de Imunodeficiência Adquirida^i1#^tm^lpt^kTuberculo
se^i1#^tm^lpt^kComorbidade^i1#^tm^lpt^kFatores de Risco^i1#^tm^lpt^kFatores Soci
oeconômicos^i1#^tm^lpt^kEstudos Ecológicos^i1#^len^aOBJECTIVE: To identify areas
 of vulnerability to new cases of HIV/tuberculosis (TB) co-infection. METHODS: A
n ecological descriptive study was conducted by georeferencing new HIV/TB cases 
reported in the city of Ribeirão Preto, Southeastern Brazil, in 2006. Data were 
obtained from the São Paulo state information system for TB notification (TB-WEB
) database. New cases of HIV/TB co-infection were analyzed according to sociodem
ographic and clinical characteristics and, subsequently, georeferenced in the ci
ty's cartographic basis, based on home addresses. City sectors were categorized 
into three socioeconomic levels: lower, average and upper levels, based on the a
nalysis of the main components of the 2000 Demographic Census variables (income,
 level of education and percentage of households with five or more residents). T
he incidence of HIV/TB co-infection was calculated for each socioeconomic level.
 RESULTS: HIV/TB co-infection affected a higher number of economically active ad
ult males and the pulmonary form of TB was the most frequent. Spatial distributi
on showed that the incidences in areas with average and lower socioeconomic leve
ls (8.3 and 11.5 cases per 100,000 inhabitants, respectively) were higher than t
hat with a higher socioeconomic level (4.8 cases per 100,000 inhabitants). CONCL
USIONS: The incidence rate of HIV/TB co-infection, analyzed according to socioec
onomic levels, showed a non-homogeneous spatial pattern of distribution and high
er values in more socially vulnerable areas. The present study identified priori
ty geographical areas to control co-infection and revealed that the geographical
 information system technology can be used by city managers to plan health actio
ns.#^ddecs^i2#^tm^len^kHIV Infections^i2#^tm^len^kAcquired Immunodeficiency Synd
rome^i2#^tm^len^kTuberculosis^i2#^tm^len^kComorbidity^i2#^tm^len^kRisk Factors^i
2#^tm^len^kSocioeconomic Factors^i2#^tm^len^kEcological Studies^i2#^les^aOBJETIV
O: Identificar áreas de vulnerabilidad para los casos nuevos de coinfección VIH/
tuberculosis (TB). MÉTODOS: Estudio descriptivo ecológico realizado por medio de
l georeferenciamiento de los casos nuevos de VIH/TB notificados en Ribeirao Pret
o, Sureste de Brasil, en 2006. Los datos fueron obtenidos del sistema de informa
ción estatal paulista de notificación de TB. Los casos nuevos de coinfección VIH
/TB fueron analizados conforme características sociodemográficas y clínicas y, p
osteriormente, georeferenciados en la base cartográfica del municipio según dire
cción residencial. Los sectores del municipio fueron categorizados en tres nivel
es socioeconómicos: inferior, intermedio y superior, con base en el análisis de 
componentes principales de las variables del censo demográfico de 2000 (renta, i
nstrucción y porcentaje de domicilios con cinco o más moradores). Fue calculada 
la incidencia de la coinfección VIH/TB para cada nivel socioeconómico. RESULTADO
S: La coinfección VIH/TB afectó más adultos del sexo masculino en edad económica
mente activa y la forma pulmonar de la TB fue la más común. La distribución espa
cial mostró que las incidencias en las áreas con niveles socioeconómicos interme
dios e inferiores (8,3 y 11,5 casos por 100 mil habitantes, respectivamente), fu
eron superiores a (4,8 casos por 100 mil habitantes) las del nivel socioeconómic
o superior. CONCLUSIONES: La tasa de incidencia de coinfección HIV/TB analizada 
por niveles socioeconómicos mostró patrón espacial de distribución no homogéneo 
y presentó valores más altos en áreas de mayor vulnerabilidad social. El estudio
 diagnosticó áreas geográficas prioritarias para el control de la coinfección la
 tecnología del sistema de información geográfica puede ser empleada en la plani
ficación de las acciones en salud por los gestores municipales.#^ddecs^i3#^tm^le
s^kInfecciones por VIH^i3#^tm^les^kSíndrome de Inmunodeficiencia Adquirida^i3#^t
m^les^kTuberculosis^i3#^tm^les^kComorbilidad^i3#^tm^les^kFactores de Riesgo^i3#^
tm^les^kFactores Socioeconómicos^i3#^tm^les^kEstudios Ecológicos^i3#vancouv#24#2
0100607#Recebido: 7/6/2010#20101114#14/11/2010#Fundação de Amparo à Pesquisa do 
Estado de São Paulo#2007/57516-8#Conselho Nacional de Desenvolvimento Científico
 e Tecnológico#25/2006 410547/ 2006-9#2331.htm#Internet^ihttp://www.scielo.br/sc
ielo.php?script=sci_arttext&pid=S0034-89102011005000018##
00284000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704005000079002000900129#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#5#1#article#143#<html> <head> <t
itle>2331</title> </head>     ^cY#2331.htm##
00452000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704021800079002000900297#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#6#2#article#143#<p><a name="top"
></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>&Aacute;reas
    de vulnerabilidade para co-infec&ccedil;&atilde;o HIV-aids/TB em Ribeir&atil
de;o    Preto, SP</b> </font></p>     ^cY#2331.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#7#3#article#143#<p>&nbsp;</p>   
  ^cY#2331.htm##
00395000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704016100079002000900240#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#8#4#article#143#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Areas of vulnerability    to H
IV/TB co-infection in Southeastern Brazil</b></font></p>     ^cY#2331.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#9#5#article#143#<p>&nbsp;</p>   
  ^cY#2331.htm##
00434000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704019900080002000900279#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#10#6#article#143#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="3"><b>&Aacute;reas    de vulnerabil
idad para coinfecci&oacute;n VIH-sida/TB en Ribeirao Preto, Sureste    de Brasil
</b></font></p>     ^cY#2331.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#11#7#article#143#<p>&nbsp;</p>  
   ^cY#2331.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#12#8#article#143#<p>&nbsp;</p>  
   ^cY#2331.htm##
00602000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704036700080002000900447#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#13#9#article#143#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Maria Eug&ecirc;nia    Firmin
o Brunello<sup>I</sup>; Francisco Chiaravalloti Neto<sup>II</sup>; Ricardo    Al
exandre Arc&ecirc;ncio<sup>III</sup>; Rubia Laine de Paula Andrade<sup>IV</sup>;
    Gabriela Tavares Magnabosco<sup>I</sup>; Tereza Cristina Scatena Villa<sup>I
II</sup></b></font></p>     ^cY#2331.htm##
00543000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704030700081002000900388#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#14#10#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Programa    de P&oa
cute;s-Gradua&ccedil;&atilde;o em Enfermagem de Sa&uacute;de P&uacute;blica.    
Escola de Enfermagem de Ribeir&atilde;o Preto (EERP). Universidade de S&atilde;o
    Paulo (USP). S&atilde;o Paulo, SP, Brasil    ^cY#2331.htm##
00373000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704013700081002000900218#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#15#11#article#143#<br>   <sup>II
</sup>Departamento de Epidemiologia. Faculdade de Sa&uacute;de P&uacute;blica.  
  USP. S&atilde;o Paulo, SP, Brasil    ^cY#2331.htm##
00381000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014500081002000900226#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#16#12#article#143#<br>   <sup>II
I</sup>Departamento de Enfermagem Materno-infantil e Sa&uacute;de P&uacute;blica
.    EERP-USP. S&atilde;o Paulo, SP, Brasil    ^cY#2331.htm##
00379000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014300081002000900224#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#17#13#article#143#<br>   <sup>IV
</sup>Programa de P&oacute;s-Gradua&ccedil;&atilde;o Interunidades. EERP-USP.   
 S&atilde;o Paulo, SP, Brasil</font></p>     ^cY#2331.htm##
00380000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014400081002000900225#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#18#14#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecir
c;ncia    | Correspondence</a></font></p>     ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#19#15#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704004400081002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#20#16#article#143#<p>&nbsp;</p> 
<hr size="1" noshade>     ^cY#2331.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#21#17#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^c
Y#2331.htm##
00444000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020800081002000900289#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#22#18#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Identificar
 &aacute;reas de vulnerabilidade para os casos novos de co-infec&ccedil;&atilde;
o    HIV/tuberculose (TB).    ^cY#2331.htm##
01310000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704107400081002000901155#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#23#19#article#143#<br>   <b>M&Ea
cute;TODOS:</b> Estudo descritivo ecol&oacute;gico realizado por meio    do geor
referenciamento dos casos novos de HIV/TB notificados em Ribeir&atilde;o    Pret
o, SP, em 2006. Os dados foram obtidos do sistema de informa&ccedil;&atilde;o   
 estadual paulista de notifica&ccedil;&atilde;o de TB. Os casos novos de co-infe
c&ccedil;&atilde;o    HIV/TB foram analisados conforme caracter&iacute;sticas so
ciodemogr&aacute;ficas    e cl&iacute;nicas e, posteriormente, georreferenciados
 na base cartogr&aacute;fica    do munic&iacute;pio segundo endere&ccedil;o resi
dencial. Os setores do munic&iacute;pio    foram categorizados em tr&ecirc;s n&i
acute;veis socioecon&ocirc;micos: inferior,    intermedi&aacute;rio e superior, 
com base na an&aacute;lise de componentes principais    das vari&aacute;veis do 
censo demogr&aacute;fico de 2000 (renda, instru&ccedil;&atilde;o    e percentage
m de domic&iacute;lios com cinco ou mais moradores). Foi calculada    a incid&ec
irc;ncia da co-infec&ccedil;&atilde;o HIV/TB para cada n&iacute;vel    socioecon
&ocirc;mico.    ^cY#2331.htm##
00770000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704053400081002000900615#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#24#20#article#143#<br>   <b>RESU
LTADOS:</b> A co-infec&ccedil;&atilde;o HIV/TB acometeu mais adultos    do sexo 
masculino em idade economicamente ativa e a forma pulmonar da TB foi    a mais c
omum. A distribui&ccedil;&atilde;o espacial mostrou que as incid&ecirc;ncias    
nas &aacute;reas com n&iacute;veis socioecon&ocirc;micos intermedi&aacute;rios  
  e inferiores (8,3 e 11,5 casos por 100 mil habitantes, respectivamente) foram 
   superiores &agrave;quela (4,8 casos por 100 mil habitantes) de n&iacute;vel  
  socioecon&ocirc;mico superior.    ^cY#2331.htm##
00887000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704065100081002000900732#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#25#21#article#143#<br>   <b>CONC
LUS&Otilde;ES:</b> A taxa de incid&ecirc;ncia de co-infec&ccedil;&atilde;o    HI
V/TB analisada por n&iacute;veis socioecon&ocirc;micos mostrou padra&THORN;o    
espacial de distribui&ccedil;a&THORN;o n&atilde;o homog&ecirc;neo e apresentou  
  valores mais altos em &aacute;reas de maior vulnerabilidade social. O estudo  
  diagnosticou a&igrave;reas geogra&igrave;ficas priorita&igrave;rias para o con
trole    da co-infec&ccedil;&atilde;o e a tecnologia do sistema de informa&ccedi
l;&atilde;o    geogr&aacute;fica pode ser empregada no planejamento das a&ccedil
;&otilde;es    em sa&uacute;de pelos gestores municipais.</font></p>     ^cY#233
1.htm##
00558000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704032200081002000900403#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#26#22#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> Infec&c
cedil;&otilde;es por HIV. S&iacute;ndrome de Imunodefici&ecirc;ncia    Adquirida
. Tuberculose. Comorbidade. Fatores de Risco. Fatores Socioecon&ocirc;micos.    
Estudos Ecol&oacute;gicos.</font></p> <hr size="1" noshade>     ^cY#2331.htm##
00334000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009800081002000900179#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#27#23#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     
^cY#2331.htm##
00414000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017800081002000900259#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#28#24#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To identif
y areas of vulnerability to new cases of HIV/tuberculosis (TB) co-infection.    
^cY#2331.htm##
01112000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704087600081002000900957#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#29#25#article#143#<br>   <b>METH
ODS:</b> An ecological descriptive study was conducted by georeferencing    new 
HIV/TB cases reported in the city of Ribeir&atilde;o Preto, Southeastern    Braz
il, in 2006. Data were obtained from the S&atilde;o Paulo state information    s
ystem for TB notification (TB-WEB) database. New cases of HIV/TB co-infection   
 were analyzed according to sociodemographic and clinical characteristics and,  
  subsequently, georeferenced in the city's cartographic basis, based on home   
 addresses. City sectors were categorized into three socioeconomic levels: lower
,    average and upper levels, based on the analysis of the main components of t
he    2000 Demographic Census variables (income, level of education and percenta
ge    of households with five or more residents). The incidence of HIV/TB co-inf
ection    was calculated for each socioeconomic level.    ^cY#2331.htm##
00663000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704042700081002000900508#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#30#26#article#143#<br>   <b>RESU
LTS:</b> HIV/TB co-infection affected a higher number of economically    active 
adult males and the pulmonary form of TB was the most frequent. Spatial    distr
ibution showed that the incidences in areas with average and lower socioeconomic
    levels (8.3 and 11.5 cases per 100,000 inhabitants, respectively) were highe
r    than that with a higher socioeconomic level (4.8 cases per 100,000 inhabita
nts).    ^cY#2331.htm##
00690000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704045400081002000900535#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#31#27#article#143#<br>   <b>CONC
LUSIONS:</b> The incidence rate of HIV/TB co-infection, analyzed according    to
 socioeconomic levels, showed a non-homogeneous spatial pattern of distribution 
   and higher values in more socially vulnerable areas. The present study identi
fied    priority geographical areas to control co-infection and revealed that th
e geographical    information system technology can be used by city managers to 
plan health actions.</font></p>     ^cY#2331.htm##
00503000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704026700081002000900348#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#32#28#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:    </b> HIV Inf
ections. Acquired Immunodeficiency Syndrome. Tuberculosis. Comorbidity.    Risk 
Factors. Socioeconomic Factors. Ecological Studies.</font></p> <hr size="1" nosh
ade>     ^cY#2331.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#33#29#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^
cY#2331.htm##
00439000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020300081002000900284#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#34#30#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Identificar
 &aacute;reas de vulnerabilidad para los casos nuevos de coinfecci&oacute;n    V
IH/tuberculosis (TB).    ^cY#2331.htm##
01268000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704103200081002000901113#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#35#31#article#143#<br>   <b>M&Ea
cute;TODOS:</b> Estudio descriptivo ecol&oacute;gico realizado por medio    del 
georeferenciamiento de los casos nuevos de VIH/TB notificados en Ribeirao    Pre
to, Sureste de Brasil, en 2006. Los datos fueron obtenidos del sistema de    inf
ormaci&oacute;n estatal paulista de notificaci&oacute;n de TB. Los casos    nuev
os de coinfecci&oacute;n VIH/TB fueron analizados conforme caracter&iacute;stica
s    sociodemogr&aacute;ficas y cl&iacute;nicas y, posteriormente, georeferencia
dos    en la base cartogr&aacute;fica del municipio seg&uacute;n direcci&oacute;
n residencial.    Los sectores del municipio fueron categorizados en tres nivele
s socioecon&oacute;micos:    inferior, intermedio y superior, con base en el an&
aacute;lisis de componentes    principales de las variables del censo demogr&aac
ute;fico de 2000 (renta, instrucci&oacute;n    y porcentaje de domicilios con ci
nco o m&aacute;s moradores). Fue calculada    la incidencia de la coinfecci&oacu
te;n VIH/TB para cada nivel socioecon&oacute;mico.    ^cY#2331.htm##
00773000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704053700081002000900618#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#36#32#article#143#<br>   <b>RESU
LTADOS:</b> La coinfecci&oacute;n VIH/TB afect&oacute; m&aacute;s adultos    del
 sexo masculino en edad econ&oacute;micamente activa y la forma pulmonar    de l
a TB fue la m&aacute;s com&uacute;n. La distribuci&oacute;n espacial mostr&oacut
e;    que las incidencias en las &aacute;reas con niveles socioecon&oacute;micos
 intermedios    e inferiores (8,3 y 11,5 casos por 100 mil habitantes, respectiv
amente), fueron    superiores a (4,8 casos por 100 mil habitantes) las del nivel
 socioecon&oacute;mico    superior.    ^cY#2331.htm##
00858000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704062200081002000900703#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#37#33#article#143#<br>   <b>CONC
LUSIONES:</b> La tasa de incidencia de coinfecci&oacute;n HIV/TB analizada    po
r niveles socioecon&oacute;micos mostr&oacute; patr&oacute;n espacial de distrib
uci&oacute;n    no homog&eacute;neo y present&oacute; valores m&aacute;s altos e
n &aacute;reas    de mayor vulnerabilidad social. El estudio diagnostic&oacute; 
&aacute;reas geogr&aacute;ficas    prioritarias para el control de la coinfecci&
oacute;n la tecnolog&iacute;a del    sistema de informaci&oacute;n geogr&aacute;
fica puede ser empleada en la planificaci&oacute;n    de las acciones en salud p
or los gestores municipales.</font></p>     ^cY#2331.htm##
00549000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704031300081002000900394#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#38#34#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:    </b> Infecc
iones por VIH. S&iacute;ndrome de Inmunodeficiencia Adquirida. Tuberculosis.    
Comorbilidad. Factores de Riesgo. Factores Socioecon&oacute;micos. Estudios    E
col&oacute;gicos.</font></p> <hr size="1" noshade>     ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#39#35#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#40#36#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00350000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011400081002000900195#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#41#37#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b>
</font></p>     ^cY#2331.htm##
01029000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079300081002000900874#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#42#38#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Apesar do crescimento    da uti
liza&ccedil;&atilde;o do Sistema de Informa&ccedil;&atilde;o Geogr&aacute;fica  
  (SIG) na sa&uacute;de p&uacute;blica,<sup>23</sup> a incorpora&ccedil;&atilde;
o    dessa tecnologia para an&aacute;lise dos determinantes de algumas endemias,
    como a tuberculose (TB) e a aids, ainda &eacute; incipiente pelas dificuldad
es    ou desconhecimento na manipula&ccedil;&atilde;o do sistema.<sup>10</sup> A
 utiliza&ccedil;&atilde;o    do SIG tem permitido a integra&ccedil;&atilde;o de 
diferentes indicadores de    eventos em sa&uacute;de com dados socioambientais,<
sup>2</sup> fornecendo uma    vis&atilde;o mais ampla dos determinantes sociais 
do processo sa&uacute;de-doen&ccedil;a.</font></p>     ^cY#2331.htm##
01101000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704086500081002000900946#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#43#39#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A co-infec&ccedil;&atilde;o    
HIV/TB representa um grande desafio para a sa&uacute;de p&uacute;blica nas &uacu
te;ltimas    d&eacute;cadas, haja vista que a TB &eacute; a principal causa de &
oacute;bitos    em indiv&iacute;duos com aids (tr&ecirc;s &oacute;bitos em cada 
dez pessoas)    e &eacute; praticamente letal nos indiv&iacute;duos portadores d
o HIV.<sup>9</sup>    O risco de que um indiv&iacute;duo n&atilde;o-infectado po
r HIV desenvolva TB    ao longo da vida &eacute; de 5% a 10%, mas alcan&ccedil;a
 50% entre os doentes    de aids.<a href="#backa">ª</a> Dentre os soropositivos 
para HIV e portadores    de infec&ccedil;&atilde;o latente por <i>Mycobacterium 
tuberculosis</i>, o risco    aumenta 20 vezes em rela&ccedil;&atilde;o aos soron
egativos para HIV.<sup>16</sup></font></p>     ^cY#2331.htm##
01216000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704098000081002000901061#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#44#40#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As prec&aacute;rias    condi&cc
edil;&otilde;es de moradia ocasionadas pela falta de pol&iacute;tica    social e
 habitacional no cen&aacute;rio urbano, atreladas a desemprego, migra&ccedil;&at
ilde;o    para grandes centros, situa&ccedil;&atilde;o de pobreza financeira de 
parte    da popula&ccedil;&atilde;o, entre outros determinantes sociais, contrib
uem para    o surgimento de &aacute;reas vulner&aacute;veis ao desenvolvimento d
a TB.<sup>13</sup>    A vulnerabilidade dos indiv&iacute;duos &agrave; TB result
a na marginaliza&ccedil;&atilde;o    da popula&ccedil;&atilde;o em rela&ccedil;&
atilde;o aos locais de moradia, dificuldade    de acesso aos servi&ccedil;os de 
sa&uacute;de e falta de representa&ccedil;&atilde;o    social, e tais aspectos s
&atilde;o agravados pela situa&ccedil;&atilde;o socioecon&ocirc;mica    prec&aac
ute;ria do indiv&iacute;duo e da comunidade.<a href="#backa">ª</a></font></p>   
  ^cY#2331.htm##
01009000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704077300081002000900854#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#45#41#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Vulnerabilidade    para aids ou
 TB &eacute; um conceito complexo que engloba dimenso&THORN;es (individuais,    
institucionais e sociais) determinantes de suscetibilidade de indivi&igrave;duos
    ou grupos. Nessa linha de racioc&iacute;nio, considera-se que a distribui&cc
edil;a&THORN;o    de riscos de adoecer e morrer ocorre segundo formas distintas 
de inser&ccedil;a&THORN;o    ou oportunidades sociais. Esses aspectos influencia
m os padro&THORN;es de vulnerabilidade    dessa popula&ccedil;&atilde;o no proce
sso sau&igrave;de-doen&ccedil;a, articulando-o    &agrave;s condi&ccedil;&otilde
;es de vida de uma comunidade e, portanto, ao    espa&ccedil;o geo-social em que
 vivem.<sup>3</sup></font></p>     ^cY#2331.htm##
00753000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051700081002000900598#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#46#42#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Para alguns autores,<sup>11</su
p>    a compreens&atilde;o da din&acirc;mica da TB e do HIV/aids depende tanto d
as    taxas epidemiol&oacute;gicas quanto da compreens&atilde;o das rela&ccedil;
&otilde;es    e condi&ccedil;&otilde;es de vida no territ&oacute;rio em vulnerab
ilidade social,    possibilitando melhor planejamento e, conseq&uuml;entemente, 
a reorganiza&ccedil;&atilde;o    das pr&aacute;ticas e do trabalho em sa&uacute;
de.</font></p>     ^cY#2331.htm##
01304000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704106800081002000901149#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#47#43#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Ribeir&atilde;o    Preto possui
 posi&ccedil;&atilde;o econ&ocirc;mica e social favor&aacute;vel,    entre os mu
nic&iacute;pios mais pr&oacute;speros do Brasil, com &Iacute;ndice    de Desenvo
lvimento Humano (IDH) de 0,855.<a name="topb"></a><a href="#backb"><sup>b</sup><
/a>    Apesar disso, est&aacute; entre os munic&iacute;pios com a mais alta de t
axa    de co-infec&ccedil;&atilde;o HIV/TB do Estado de S&atilde;o Paulo, lidera
dos    por Santos e S&atilde;o Jos&eacute; dos Campos.<sup>17</sup> Em 2006, o p
ercentual    de casos de HIV entre os de TB foi de 30% do total de casos notific
ados,<a href="#backc"><sup>c</sup></a>    um desafio &agrave; vigil&acirc;ncia d
a sa&uacute;de, haja vista as chances    aumentadas de abandono, recidiva e &oac
ute;bito nesse grupo de pacientes. S&atilde;o    imperativos estudos sobre aspec
tos preponderantes da cadeia de transmiss&atilde;o    dessa comorbidade e sua in
tera&ccedil;&atilde;o com os determinantes sociais    no munic&iacute;pio.</font
></p>     ^cY#2331.htm##
00467000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704023100081002000900312#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#48#44#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Assim, este estudo    teve por 
objetivo identificar &aacute;reas de maior vulnerabilidade para a co-infec&ccedi
l;&atilde;o    HIV/TB no ano de 2006.</font></p>     ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#49#45#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00340000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010400081002000900185#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#50#46#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p
>     ^cY#2331.htm##
00584000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034800081002000900429#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#51#47#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Trata-se de um    estudo descri
tivo e ecol&oacute;gico no munic&iacute;pio de Ribeir&atilde;o    Preto, localiz
ado no nordeste do Estado de S&atilde;o Paulo, com popula&ccedil;&atilde;o    es
timada de 559.651 mil habitantes em 2006.<a href="#backd"><sup>d</sup></a></font
></p>     ^cY#2331.htm##
00737000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704050100081002000900582#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#52#48#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Ribeir&atilde;o    Preto &eacut
e; um dos 73 munic&iacute;pios priorit&aacute;rios para o controle    da TB que 
devem intensificar as a&ccedil;&otilde;es de controle da doen&ccedil;a.    Em 20
06, o coeficiente de incid&ecirc;ncia por TB pulmonar no munic&iacute;pio    foi
 de 37,82 por 100 mil habitantes, taxa de detec&ccedil;&atilde;o de casos    de 
40% e percentual de cura de 68,5%.<a href="#backc"><sup>c</sup></a></font></p>  
   ^cY#2331.htm##
00978000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704074200081002000900823#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#53#49#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A aten&ccedil;&atilde;o    aos 
doentes de TB e HIV/aids ocorre em servi&ccedil;os de n&iacute;vel secund&aacute
;rio,    com equipes especializadas, por&eacute;m n&atilde;o exclusivas dos prog
ramas,    constitu&iacute;das por um ou dois m&eacute;dicos e profissionais de e
nfermagem.    Os ambulat&oacute;rios de refer&ecirc;ncia com Programa de Control
e da TB (PCT)    realizam tratamento supervisionado da TB, em m&eacute;dia, a ce
rca de 77% dos    doentes. A dose supervisionada geralmente &eacute; fornecida n
os locais de prefer&ecirc;ncia    dos doentes de TB e/ou co-infectados, seja no 
ambulat&oacute;rio de refer&ecirc;ncia,    seja no domic&iacute;lio.</font></p> 
    ^cY#2331.htm##
00744000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704050800081002000900589#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#54#50#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A Unidade Especial    de Tratam
ento de Doen&ccedil;as Infecciosas do Hospital das Cl&iacute;nicas    da Faculda
de de Medicina de Ribeir&atilde;o Preto da Universidade de S&atilde;o    Paulo (
HCFMRP-USP) tamb&eacute;m integra a rede de aten&ccedil;&atilde;o aos    co-infe
ctados HIV/TB em n&iacute;vel terci&aacute;rio da aten&ccedil;&atilde;o    e ate
nde os usu&aacute;rios em regimes ambulatorial e interna&ccedil;&atilde;o.</font
></p>     ^cY#2331.htm##
00749000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051300081002000900594#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#55#51#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Foram inclu&iacute;dos    no es
tudo os casos de TB notificados como novos, com confirma&ccedil;&atilde;o    sor
ol&oacute;gica laboratorial do HIV, residentes em Ribeir&atilde;o Preto no    an
o de 2006. Entende-se por caso novo o definido como: "pacientes que nunca    se 
submeteram &agrave; terapia anti-tuberculosa, que fizeram tratamento por    meno
s de 30 dias ou h&aacute; mais de cinco anos".<a href="#backc"><sup>c</sup></a><
/font></p>     ^cY#2331.htm##
00755000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051900081002000900600#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#56#52#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os dados foram    obtidos em ab
ril de 2008, a partir do sistema estadual exclusivo para notifica&ccedil;&atilde
;o    de TB chamado de TB-WEB, implantado no Estado de S&atilde;o Paulo em 2006.
 As    informa&ccedil;&otilde;es da ficha de notifica&ccedil;&atilde;o de TB s&a
tilde;o    repassadas ao Sistema de Agravo de Notifica&ccedil;&atilde;o (Sinan) 
e ao TB-WEB,    onde s&atilde;o armazenadas em um &uacute;nico arquivo, via inte
rnet.</font></p>     ^cY#2331.htm##
00873000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704063700081002000900718#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#57#53#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As vari&aacute;veis    selecion
adas para caracteriza&ccedil;&atilde;o dos casos em &acirc;mbito individual    f
oram: sexo, data de nascimento, escolaridade (anos de estudo), endere&ccedil;o  
  do doente (TB-WEB), forma cl&iacute;nica (pulmonar, extrapulmonar, pulmonar   
 + extrapulmonar e disseminada), tipo de tratamento (supervisionado ou auto-admi
nistrado)    e tipo de encerramento de caso (cura, &oacute;bito, abandono, mudan
&ccedil;a    de diagn&oacute;stico e transfer&ecirc;ncia para outro servi&ccedil
;o de sa&uacute;de    ou munic&iacute;pio).</font></p>     ^cY#2331.htm##
00632000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704039600081002000900477#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#58#54#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os casos selecionados    para o
 estudo foram geocodificados a partir dos endere&ccedil;os dos doentes    (logra
douro e numera&ccedil;&atilde;o), utilizando-se o <i>software</i> ArcGIS,    9.1
, na base cartogr&aacute;fica digital de Ribeir&atilde;o Preto, obtida na    Com
panhia de Desenvolvimento Econ&ocirc;mico.</font></p>     ^cY#2331.htm##
01057000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704082100081002000900902#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#59#55#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Utilizaram-se como    unidade d
e an&aacute;lise os setores censit&aacute;rios definidos pelo Censo    Demogr&aa
cute;fico de 2000, do Instituto Brasileiro de Geografia e Estat&iacute;stica    
(IBGE). Os setores censit&aacute;rios s&atilde;o &aacute;reas cont&iacute;nuas  
  e homog&ecirc;neas com m&eacute;dia de 300 resid&ecirc;ncias cada.<a href="#ba
ckd"><sup>d</sup></a>    De acordo com o Censo Demogr&aacute;fico de 2000, o mun
ic&iacute;pio foi dividido    em 650 setores censit&aacute;rios. Destes, 17 fora
m exclu&iacute;dos da an&aacute;lise    por n&atilde;o possu&iacute;rem habitant
es (nove setores) e oito por se tratar    de &aacute;reas especiais, tais como h
ospitais e pres&iacute;dios, totalizando    633 setores analisados.</font></p>  
   ^cY#2331.htm##
01651000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704141500081002000901496#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#60#56#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As vari&aacute;veis    em &acir
c;mbito coletivo dos setores censit&aacute;rios selecionados foram:    renda m&e
acute;dia dos respons&aacute;veis pelos domic&iacute;lios, m&eacute;dia    de an
os de instru&ccedil;&atilde;o das pessoas respons&aacute;veis pelos domic&iacute
;lios,    renda m&eacute;dia das mulheres chefes de fam&iacute;lia, m&eacute;dia
 de anos    de instru&ccedil;&atilde;o das mulheres chefes de fam&iacute;lia e p
ropor&ccedil;&atilde;o    de mulheres analfabetas, propor&ccedil;&atilde;o de pe
ssoas analfabetas, porcentagem    de domic&iacute;lios com cinco ou mais morador
es. Essas vari&aacute;veis foram    selecionadas com base em trabalhos anteriorm
ente realizados<sup>8,22</sup> para    que pudessem representar a renda, educa&c
cedil;&atilde;o, aglomera&ccedil;&atilde;o    no domic&iacute;lio e grupos mais 
vulner&aacute;veis (mulheres). A caracteriza&ccedil;&atilde;o    socioecon&ocirc
;mica dos setores censit&aacute;rios foi realizada por meio da    an&aacute;lise
 de componentes principais, que produz fatores n&atilde;o correlacionados    ent
re si. Entre os fatores obtidos, foi escolhido aquele respons&aacute;vel    pela
 maior propor&ccedil;&atilde;o da varia&ccedil;&atilde;o total apresentada.    O
 fator, por representar aspectos socioecon&ocirc;micos, foi nomeado de fator    
socioecon&ocirc;mico.</font></p>     ^cY#2331.htm##
00919000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704068300081002000900764#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#61#57#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Foi calculado escore    que cor
responde ao valor do fator socioecon&ocirc;mico para cada setor censit&aacute;ri
o;    quanto maior seu valor, melhor o n&iacute;vel socioecon&ocirc;mico do seto
r.    Os setores foram ordenados de forma decrescente e divididos segundo tercis
,    resultando em tr&ecirc;s grupos: de n&iacute;vel socioecon&ocirc;mico super
ior    (condi&ccedil;&otilde;es socioecon&ocirc;micas mais favor&aacute;veis), i
ntermedi&aacute;rio    e inferior (menos favor&aacute;veis). A incid&ecirc;ncia 
de casos de co-infec&ccedil;&atilde;o    foi calculada para cada uma dessas &aac
ute;reas.</font></p>     ^cY#2331.htm##
00491000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704025500081002000900336#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#62#58#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O estudo foi aprovado    pelo C
omit&ecirc; de &Eacute;tica da Escola de Enfermagem de Ribeir&atilde;o    Preto 
da Universidade de S&atilde;o Paulo (protocolo nº 0762/2007).</font></p>     ^cY
#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#63#59#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010000081002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#64#60#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>   
  ^cY#2331.htm##
00665000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704042900081002000900510#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#65#61#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Dos 160 casos novos    de TB no
tificados em Ribeir&atilde;o Preto em 2006, 50 (31,2%) eram co-infectados    por
 HIV/TB. Dos casos novos de co-infec&ccedil;&atilde;o, dois foram exclu&iacute;d
os    do estudo pela inexist&ecirc;ncia do endere&ccedil;o no mapa digital do mu
nic&iacute;pio    e por pertencerem &agrave; penitenci&aacute;ria feminina.</fon
t></p>     ^cY#2331.htm##
00668000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704043200081002000900513#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#66#62#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Dos 48 casos selecionados,    3
3 (68,8%) eram homens e 15 (31,2%) eram mulheres. A <a href="#t1">Tabela 1</a>  
  mostra a distribui&ccedil;&atilde;o dos casos novos de co-infec&ccedil;&atilde
;o    em Ribeir&atilde;o Preto conforme a faixa et&aacute;ria, escolaridade, for
ma    cl&iacute;nica da TB, tipo de tratamento e tipo de encerramento de caso.</
font></p>     ^cY#2331.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#67#63#article#143#<p><a name="t1
"></a></p>     ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#68#64#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#69#65#article#143#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2331t01.jpg"></p>     ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#70#66#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
01220000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704098400081002000901065#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#71#67#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    de componen
tes principais produziu quatro fatores (<a href="#t2">Tabela 2</a>).    Entre el
es, foi escolhido o fator respons&aacute;vel por 81,9% da varia&ccedil;&atilde;o
    total, denominado de fator socioecon&ocirc;mico, que gerou escore calculado 
   para para cada setor censit&aacute;rio por meio da express&atilde;o: 0,84 x  
  (renda m&eacute;dia dos respons&aacute;veis pelos domic&iacute;lios) + 0,96   
 x (m&eacute;dia de anos de instru&ccedil;&atilde;o dos respons&aacute;veis pelo
s    domic&iacute;lios) + 0,84 x (renda m&eacute;dia das mulheres chefes de fam&
iacute;lia)    + 0,94 x (m&eacute;dia de anos de instru&ccedil;&atilde;o das mul
heres chefes    de fam&iacute;lia) - 0,84 x (propor&ccedil;&atilde;o de pessoas 
analfabetas)    - 0,86 x (propor&ccedil;&atilde;o de mulheres analfabetas) - 0,6
4 x (porcentagem    de domic&iacute;lios com cinco ou mais moradores).</font></p
>     ^cY#2331.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#72#68#article#143#<p><a name="t2
"></a></p>     ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#73#69#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#74#70#article#143#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2331t02.jpg"></p>     ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#75#71#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00722000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704048600081002000900567#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#76#72#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A <a href="/img/revistas/rsp/20
11nahead/2331t03.jpg">Tabela    3</a> apresenta, para os setores censit&aacute;r
ios agrupados segundo os n&iacute;veis    socioecon&ocirc;micos inferior, interm
edi&aacute;rio e superior, os n&uacute;meros    de casos de co-infec&ccedil;&ati
lde;o HIV/TB, os n&uacute;meros de habitantes,    as taxas de incid&ecirc;ncia, 
as &aacute;reas e as densidades demogr&aacute;ficas.</font></p>     ^cY#2331.htm
##
00871000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704063500081002000900716#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#77#73#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As taxas de incid&ecirc;ncia   
 de HIV/TB nas &aacute;reas de n&iacute;veis inferiores e intermedi&aacute;rios 
   foram, respectivamente, 140% e 73% maiores do que a taxa na &aacute;rea de me
lhor    n&iacute;vel (superior). A maior densidade demogr&aacute;fica ocorreu na
 &aacute;rea    de n&iacute;vel socioecon&ocirc;mico intermedi&aacute;rio e n&at
ilde;o no inferior,    embora esta tenha apresentado a maior incid&ecirc;ncia de
 co-infec&ccedil;&atilde;o    HIV/TB do munic&iacute;pio (<a href="/img/revistas
/rsp/2011nahead/2331f01.jpg">Figura</a>).</font></p>     ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#78#74#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00342000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010600081002000900187#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#79#75#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font><
/p>     ^cY#2331.htm##
00645000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704040900081002000900490#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#80#76#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O perfil dos casos    novos not
ificados em 2006 em Ribeir&atilde;o Preto, onde se constata um predom&iacute;nio
    do sexo masculino, escolaridade intermedi&aacute;ria e forma cl&iacute;nica 
   pulmonar, com expressivo n&uacute;mero de casos de extrapulmonar, refor&ccedi
l;a    resultados de outros estudos.<sup>15,17,18</sup></font></p>     ^cY#2331.
htm##
00695000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704045900081002000900540#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#81#77#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O baixo registro    de supervis
&atilde;o da dose medicamentosa entre os pacientes estudados pode    indicar uma
 barreira no fluxo de comunica&ccedil;&atilde;o entre os n&iacute;veis    de ass
ist&ecirc;ncia, o que muitas vezes dificulta a continuidade do cuidado    no cas
o de transfer&ecirc;ncia do co-infectado em rela&ccedil;&atilde;o ao local    de
 seguimento.<sup>24</sup></font></p>     ^cY#2331.htm##
01376000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704114000081002000901221#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#82#78#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O percentual de    cura foi rel
ativamente baixo, o que pode inferir dificuldade no tratamento dos    co-infecta
dos, que podem apresentar formas mais severas da TB.<sup>15</sup>    Em compara&
ccedil;&atilde;o com um estudo realizado no mesmo munic&iacute;pio,    em um per
&iacute;odo de quatro anos (1998 a 2003),<sup>17</sup> o percentual    de cura f
oi em torno de 53% entre os co-infectados, maior que no atual estudo.    Chama a
 aten&ccedil;&atilde;o o n&uacute;mero de casos notificados como &oacute;bito   
 por n&atilde;o TB e mudan&ccedil;a de diagn&oacute;stico entre a popula&ccedil;
&atilde;o    da pesquisa. Com base no estudo de Muniz et al<sup>14</sup> (2006) 
em compara&ccedil;&atilde;o    com o presente, observa-se diminui&ccedil;&atilde
;o nos percentuais de &oacute;bito    e de abandono, este &uacute;ltimo favoreci
do pela intensifica&ccedil;&atilde;o    da implanta&ccedil;&atilde;o do tratamen
to supervisionado. Isso mostra que essa    "ferramenta" de cuidado &eacute; um i
mportante elemento integrante no tratamento    da TB.<sup>24</sup></font></p>   
  ^cY#2331.htm##
00950000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704071400081002000900795#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#83#79#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Em muitos casos    de pacientes
 com aids, o resultado de tratamento da TB &eacute; notificado como    "mudan&cc
edil;a no diagn&oacute;stico". A variedade nas formas cl&iacute;nicas    da TB d
entre os soropositivos dificulta o diagn&oacute;stico da doen&ccedil;a    nesses
 pacientes que, muitas vezes, iniciam o tratamento sem a confirma&ccedil;&atilde
;o    do diagn&oacute;stico. Essa alternativa para o controle da TB n&atilde;o c
ausa    preju&iacute;zos aos doentes co-infectados e &eacute; uma forma de contr
ole    de poss&iacute;veis infec&ccedil;&otilde;es aos comunicantes do indiv&iac
ute;duo    com os sintomas.<sup>15</sup></font></p>     ^cY#2331.htm##
01045000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704080900081002000900890#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#84#80#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    encontrou 
forte rela&ccedil;&atilde;o entre os casos notificados e as &aacute;reas    de m
aior vulnerabilidade social, uma vez que as taxas de incid&ecirc;ncia s&atilde;o
    nitidamente maiores nas &aacute;reas de n&iacute;vel socioecon&ocirc;mico in
termedi&aacute;rio    e inferior. Tais resultados n&atilde;o coincidem com estud
os que supunham que    a distribui&ccedil;&atilde;o dos casos de co-infec&ccedil
;&atilde;o estivesse    localizada em &aacute;reas socioeconomicamente melhores 
e uniformemente distribu&iacute;da    entre as diferentes classes sociais.<sup>1
2</sup> Todavia, tal rela&ccedil;&atilde;o    deve ser investigada com outros ti
pos de delineamentos de estudos epidemiol&oacute;gicos.</font></p>     ^cY#2331.
htm##
01497000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704126100081002000901342#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#85#81#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As regi&otilde;es    identifica
das como vulner&aacute;veis no munic&iacute;pio de Ribeir&atilde;o    Preto apre
sentam densidade populacional expressiva, algumas &aacute;reas podem    ser cham
adas de "bols&otilde;es de pobreza", com presen&ccedil;a de grandes    favelas e
 assentamentos, al&eacute;m de locais com forte explora&ccedil;&atilde;o    do t
r&aacute;fico de drogas e da prostitui&ccedil;&atilde;o. Esses resultados    coi
ncidem com estudo realizado na Alemanha,<sup>13</sup> onde a TB se concentrava  
  em &aacute;reas com prec&aacute;rias condi&ccedil;&otilde;es de moradia e asso
ciada    a indicadores de pobreza, como o desemprego, baixo poder de compra, fal
ta de    suporte social e baixa qualifica&ccedil;&atilde;o para o mercado de tra
balho.    No entanto, a densidade demogr&aacute;fica do estudo alem&atilde;o n&a
tilde;o    coincide com a de Ribeir&atilde;o Preto, uma vez que, conforme aprese
ntado na    <a href="/img/revistas/rsp/2011nahead/2331t03.jpg">Tabela 3</a>, a m
aior incid&ecirc;ncia ocorreu    em uma &aacute;rea que concentra o maior n&uacu
te;mero populacional, mas n&atilde;o    a maior densidade demogr&aacute;fica (cl
asse intermedi&aacute;ria).</font></p>     ^cY#2331.htm##
00778000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704054200081002000900623#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#86#82#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudos realizados    nas regi&
otilde;es Sudeste e Nordeste do Brasil sobre a distribui&ccedil;&atilde;o    de 
casos de TB tamb&eacute;m encontraram estreita rela&ccedil;&atilde;o entre    oc
orr&ecirc;ncia da doen&ccedil;a e &aacute;reas de maior vulnerabilidade social  
  com os piores indicadores de qualidade de vida,<sup>21</sup> mostrando que os 
   problemas sociais da popula&ccedil;&atilde;o influenciam diretamente no apare
cimento    da doen&ccedil;a.</font></p>     ^cY#2331.htm##
00622000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704038600081002000900467#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#87#83#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Adicionalmente,    Rodrigues-Ju
nior et al<sup>17</sup> (2006) n&atilde;o identificaram associa&ccedil;&atilde;o
    entre os casos de aids e os locais de moradia, possivelmente porque a din&ac
irc;mica    dessa doen&ccedil;a isoladamente muito difere de quando atrelada aos
 determinantes    sociais da TB.</font></p>     ^cY#2331.htm##
01138000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704090200081002000900983#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#88#84#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O maior n&uacute;mero    de cas
os de co-infec&ccedil;&atilde;o entre as regi&otilde;es menos favorecidas    imp
lica e justifica a intensifica&ccedil;&atilde;o de atividades ligadas &agrave;  
  busca de sintom&aacute;ticos respirat&oacute;rios para detec&ccedil;&atilde;o 
   precoce dos casos. O conhecimento das &aacute;reas mais vulner&aacute;veis po
ssibilita    aten&ccedil;&atilde;o &agrave; sa&uacute;de mais sens&iacute;vel ao
 contexto    econ&ocirc;mico, pol&iacute;tico e social da comunidade. &Eacute; i
mperativo    &eacute;tico da gest&atilde;o municipal responder &agrave;s necessi
dades de    sa&uacute;de no territ&oacute;rio, e para responder &agrave;s de ori
gem social,    deve haver articula&ccedil;&atilde;o entre sujeitos de setores so
ciais e, portanto,    de saberes, poderes e vontades.<sup>5,20</sup></font></p> 
    ^cY#2331.htm##
00652000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704041600081002000900497#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#89#85#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os resultados apresentados    n
este estudo mostram o determinismo social no processo sa&uacute;de-doen&ccedil;a
    de uma comunidade, ou seja, as estruturas econ&ocirc;micas e sociais se faze
m    presentes na vida das pessoas, determinando o modo de ser, e nas suas condi
&ccedil;&otilde;es    de vida e de sa&uacute;de. <sup>20</sup></font></p>     ^c
Y#2331.htm##
01197000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704096100081002000901042#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#90#86#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A TB &eacute; uma    doen&ccedi
l;a social que emerge da iniq&uuml;idade na distribui&ccedil;&atilde;o    de ren
da. A presen&ccedil;a dessa doen&ccedil;a em uma comunidade &eacute; reflexo    
da precariedade de pol&iacute;ticas locais de desenvolvimento social, e sua    p
erman&ecirc;ncia acarreta o esgotamento da capacidade produtiva da comunidade,  
  por ser mais incidente na popula&ccedil;&atilde;o economicamente ativa. De for
ma    c&iacute;clica, a TB surge nas comunidades pobres e contribui no agravamen
to    do estado de pobreza, justamente por atingir sua classe econ&ocirc;mica pr
odutiva.<sup>4</sup>    A vantagem de utilizar os espa&ccedil;os geogr&aacute;fi
cos como indicadores    de condi&ccedil;&otilde;es de vida, em especial o local 
de moradia, &eacute;    a possibilidade de tomar a complexidade da organiza&cced
il;&atilde;o social    em seu todo.<sup>1</sup></font></p>     ^cY#2331.htm##
00805000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704056900081002000900650#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#91#87#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudo semelhante    sobre a di
stribui&ccedil;&atilde;o espacial dos casos de TB realizado no munic&iacute;pio 
   de Ribeir&atilde;o Preto em um per&iacute;odo de seis anos identificou varia&
ccedil;&atilde;o    nos locais de ocorr&ecirc;ncia dos casos da doen&ccedil;a no
 munic&iacute;pio.    Ora os casos concentravam-se em uma regi&atilde;o, ora em 
outra, mas sempre    em &aacute;reas em que as desigualdades sociais eram mais e
videntes e a vulnerabilidade    mais alta.<sup>10</sup></font></p>     ^cY#2331.
htm##
00813000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704057700081002000900658#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#92#88#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Em outros estudos,    pesquisad
ores observaram que os doentes de TB se concentravam em &aacute;reas    com alta
 densidade populacional e prec&aacute;rias condi&ccedil;&otilde;es de    saneame
nto e moradia,<sup>6,19,22</sup> contrastando com os nossos achados,    em que a
 taxa de co-infec&ccedil;&atilde;o HIV/TB n&atilde;o se apresentou sobrepujante 
   nas &aacute;reas de maior densidade; entretanto, concentrou-se nas &aacute;re
as    de n&iacute;veis socioecon&ocirc;micos menos favorecidos.</font></p>     ^
cY#2331.htm##
01524000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704128800081002000901369#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#93#89#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A co-infec&ccedil;&atilde;o    
HIV/TB &eacute; uma doen&ccedil;a de complexidade social e sua elimina&ccedil;&a
tilde;o    n&atilde;o se restringe ao setor sa&uacute;de, mas depende da gest&at
ilde;o    intersetorial, do investimento nas &aacute;reas de habita&ccedil;&atil
de;o,    transporte, alimenta&ccedil;&atilde;o, entre outros. A inabilidade de a
rticula&ccedil;&atilde;o    setorial imp&otilde;e grandes desafios &agrave; gest
&atilde;o da sa&uacute;de,    uma vez que n&atilde;o conta com conhecimentos e i
nstrumentos estruturados que    subsidiem a tomada de decis&atilde;o. Tais probl
emas evidenciam a vis&atilde;o    reducionista da setoriza&ccedil;&atilde;o da s
a&uacute;de e da autonomiza&ccedil;&atilde;o    do indiv&iacute;duo.<sup>7</sup>
 Assim, a intersetorialidade &eacute; uma das    principais medidas no enfrentam
ento dos problemas de ordem social no territ&oacute;rio,    como a co-infec&cced
il;&atilde;o HIV/TB, por estarem imbricadas a esse processo    a integra&ccedil;
&atilde;o de saberes, a mobiliza&ccedil;&atilde;o dos recursos    dos diferentes
 setores e da responsabilidade social dos distintos segmentos    da sociedade ci
vil em prol do bem-estar da coletividade.<sup>21</sup></font></p>     ^cY#2331.h
tm##
00959000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704072300081002000900804#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#94#90#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Essa disposi&ccedil;&atilde;o  
  ganha consist&ecirc;ncia quando as necessidades dos grupos populacionais, que 
   se distribuem pelo seu territo&igrave;rio, tornam-nos sujeitos do processo.<s
up>13,21</sup>    Dessa forma, deve estar atrelada &agrave; gest&atilde;o uma co
munidade empoderada,    que, consciente dos seus direitos, participa no planejam
ento local de sa&uacute;de    apontando suas necessidades reais e avaliando a of
erta e qualidade dos servi&ccedil;os    de sa&uacute;de. Um planejamento delinea
do pela realidade epidemiol&oacute;gico-social,    pautado nos seus recursos loc
ais e na conjuntura dos seus atores.<sup>21</sup></font></p>     ^cY#2331.htm##
00817000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704058100081002000900662#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#95#91#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O poder p&uacute;blico    deve 
propiciar condi&ccedil;&otilde;es para o desenvolvimento socioecon&ocirc;mico   
 local, por meio de pol&iacute;ticas sociais de inclus&atilde;o, de qualifica&cc
edil;&atilde;o    para o mercado de trabalho, melhoria das condi&ccedil;&otilde;
es de habita&ccedil;&atilde;o,    e o acesso aos servi&ccedil;os de sa&uacute;de
. Tais medidas somente ser&atilde;o    efetivas mediante participa&ccedil;&atild
e;o populacional nas inst&acirc;ncias    deliberativas.<sup>4</sup></font></p>  
   ^cY#2331.htm##
01070000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704083400081002000900915#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#96#92#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A associa&ccedil;&atilde;o    d
e co-infec&ccedil;&atilde;o HIV/TB e condi&ccedil;&atilde;o socioecon&ocirc;mica
    observada no n&iacute;vel agregado n&atilde;o necessariamente existe no n&ia
cute;vel    individual. Assim, para uma investiga&ccedil;&atilde;o que pudesse i
dentificar    tal associa&ccedil;&atilde;o nessa esfera, seriam necess&aacute;ri
os outros    tipos de estudo. O SIG mostrou-se uma tecnologia importante para en
tender a    din&acirc;mica social da co-infec&ccedil;&atilde;o HIV/TB e contribu
i na defini&ccedil;&atilde;o    das &aacute;reas priorit&aacute;rias para o inve
stimento sanit&aacute;rio. Essa    tecnologia permite o fornecimento das informa
&ccedil;&otilde;es em curto prazo    para a tomada de decis&otilde;es imediatas.
</font></p>     ^cY#2331.htm##
00952000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704071600081002000900797#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#97#93#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Apesar das limita&ccedil;&otild
e;es    apontadas, os resultados do estudo permitiram um diagn&oacute;stico da s
itua&ccedil;&atilde;o    da co-infec&ccedil;&atilde;o HIV/TB em Ribeir&atilde;o 
Preto, possibilitando,    assim, a identifica&ccedil;&atilde;o das &aacute;reas 
geogr&aacute;ficas priorit&aacute;rias    para o controle dessas doen&ccedil;as.
 Tais resultados podem ser considerados    pelos gestores no planejamento das a&
ccedil;&otilde;es em sa&uacute;de e na    defini&ccedil;&atilde;o de um plano mu
nicipal de gest&atilde;o mais pr&oacute;ximo    da realidade epidemiol&oacute;gi
ca e social do munic&iacute;pio em estudo.</font></p>     ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#98#94#article#143#<p>&nbsp;</p> 
    ^cY#2331.htm##
00343000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010700081002000900188#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#99#95#article#143#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font>
</p>     ^cY#2331.htm##
00451000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704020000084002000900284#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#100#96#article#143#1
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Barata RB. Ep
idemiologia    social. <i>Rev Bras Epidemiol.</i> 2005;8(1):7-17. DOI:10.1590/S1
415-790X2005000100002</font></p>     ^cY#2331.htm##
00589000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704033800084002000900422#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#101#97#article#143#2
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Barcellos C, 
   Sabroza PC. The place behind the case: leptospirosis risks and associated env
ironmental    conditions in a flood- related outbreak in Rio de Janeiro. <i>Cad 
Saude Publica</i>.    2001;17(Suppl):59-67. DOI:10.1590/S0102-311X2001000700014<
/font></p>     ^cY#2331.htm##
00639000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704038800084002000900472#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#102#98#article#143#3
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Bates I, Fent
on    C, Gruber J, Lalloo D, Medina Lara A, Squire SB, et al. Vulnerability to m
alaria,    tuberculosis and HIV/AIDS infection and disease. Part 1: determinants
 operating    at individual and household level. <i>Lancet Infect Di</i>s. 2004;
4(5):267-77.    DOI:10.1016/S1473-3099(04)01002-3</font></p>     ^cY#2331.htm##
00462000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704021100084002000900295#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#103#99#article#143#4
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Benatar SR,  
  Upshur R. Tuberculosis and poverty: what could (and should) be done? <i>Int   
 J Tuberc Lung Dis</i>. 2010;14(10):1215-21.    ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#104#100#article#143#</font></p> 
    ^cY#2331.htm##
00620000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704036800085002000900453#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#105#101#article#143#
5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Brunello MEF
,    Cerqueira DF, Pinto IC, Arc&ecirc;ncio RA, Gonz&aacute;les RIC, Villa TCS, 
et    al. V&iacute;nculo doente-profissional de sa&uacute;de na aten&ccedil;&ati
lde;o    &agrave; tuberculose. <i>Acta Paul Enferm</i>. 2009;22(2):176-82. DOI:1
0.1590/S0103-21002009000200010</font></p>     ^cY#2331.htm##
00557000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704030500085002000900390#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#106#102#article#143#
6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Chan-Yeung M
,    Yen AGO, Tam CM, Kam KM, Leung CC, Yew WW, et al. Socio-demographic and geo
graphic    indicators and distibution of tuberculosis in Hong Kong: a spatial an
alysis.    <i>Int J Tuberc Lung Dis</i>. 2005;9(12):1320-6.    ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#107#103#article#143#</font></p> 
    ^cY#2331.htm##
00635000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704038300085002000900468#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#108#104#article#143#
7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Gandhi NR, M
oll    A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-re
sistant    tuberculosis as a cause of death in patients co-infected with tubercu
losis and    HIV in a rural area of South Africa. <i>Lancet</i>. 2006;368(9547):
1575-80.    DOI:10.1016/S0140-6736(06)69573-1</font></p>     ^cY#2331.htm##
00702000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704045000085002000900535#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#109#105#article#143#
8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Godoy MF, Lu
cena    JM, Miquelin AR, Paiva FF, Oliveira DLQ, Augustin-Junior JL, et al. Mort
alidade    por doen&ccedil;as cardiovasculares e n&iacute;veis socioecon&ocirc;m
icos na    popula&ccedil;&atilde;o de S&atilde;o Jos&eacute; do Rio Preto, estad
o de S&atilde;o    Paulo, Brasil. <i>Arq Bras Cardiol</i>. 2007;88(2):200-6. DOI
:10.1590/S0066-782X2007000200011</font></p>     ^cY#2331.htm##
00603000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704035100085002000900436#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#110#106#article#143#
9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Hino P, Sant
os    CB, Villa TCS, Muniz JN, Monroe AA. Tuberculosis patients submitted to sup
ervised    treatment. Ribeir&atilde;o Preto - S&atilde;o Paulo - Brazil. 1998 an
d 1999.    <i>Rev Latino-Am Enferm</i>. 2005;13(1):27-31. DOI:10.1590/S0104-1169
2005000100005</font></p>     ^cY#2331.htm##
00551000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029800086002000900384#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#111#107#article#143#
10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Hino P, Vi
lla    TCS, Sassaki CM, Nogueira JA, Santos CB. Geoprocessamento aplicado &agrav
e;    &aacute;rea da sa&uacute;de. <i>Rev Latino-Am Enferm.</i> 2006;14(6):939-4
3.    DOI:10.1590/S0104-11692006000600016</font></p>     ^cY#2331.htm##
00475000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704022200086002000900308#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#112#108#article#143#
11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Kaufmann S
HE,    Parida SK. Changing funding patterns in tuberculosis. <i>Nature Med</i>. 
2007;13(3):299-303.    DOI:10.1038/nm0307-299</font></p>     ^cY#2331.htm##
00521000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704026800086002000900354#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#113#109#article#143#
12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Kistemann 
T,    Munzinger A, Dangendorf F. Spatial patterns of tuberculosis incidence in C
ologne    (Germany). <i>Soc Sci Med</i>. 2002;55(1):7-19. DOI:10.1016/S0277-9536
(01)00216-7</font></p>     ^cY#2331.htm##
00547000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029400086002000900380#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#114#110#article#143#
13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Macq J, To
rfoss    T, Getahun H. Patient empowerment in tuberculosis control: reflecting o
n past    documented experiences. <i>Trop Med Int Health</i>. 2007;12(7):873-85.
 DOI:10.1111/j.1365-3156.2007.01858.x</font></p>     ^cY#2331.htm##
00687000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704043400086002000900520#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#115#111#article#143#
14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Muniz JN, 
Ruffino-Netto    A, Villa TCS, Yamamura M, Arcencio R, Cardozo-Gonzales RI, et a
l. Aspectos epidemiol&oacute;gicos    da co-infec&ccedil;&atilde;o tuberculose e
 v&iacute;rus da imunodefici&ecirc;ncia    humana em Ribeir&atilde;o Preto (SP),
 de 1998 a 2003. <i>J Bras Pneumol</i>.    2006;32(6):529-34. DOI:10.1590/S1806-
37132006000600010</font></p>     ^cY#2331.htm##
00557000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704030400086002000900390#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#116#112#article#143#
15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Paix&atild
e;o    LMM, Gontijo ED. Perfil de casos de tuberculose notificados e fatores ass
ociados    ao abandono, Belo Horizonte, MG. <i>Rev Saude Publica</i>. 2007;41(2)
:205-13.    DOI:10.1590/S0034-89102007000200006</font></p>     ^cY#2331.htm##
00608000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704035500086002000900441#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#117#113#article#143#
16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Reid A, Sc
ano    F, Haileyesus G, Williams B, Dye C, Nunn P, et al. Towards universal acce
ss    to HIV prevention, treatment, care, and support: the role of tuberculosis/
HIV    collaboration. <i>Lancet Infec Dis</i>. 2006;6(8):483-95. DOI:10.1016/S14
73-3099(06)70549-7</font></p>     ^cY#2331.htm##
00609000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704035600086002000900442#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#118#114#article#143#
17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Rodrigues 
Jr    AL, Ruffino-Netto A, Castilho EA. Distribui&ccedil;&atilde;o espacial da c
o-infec&ccedil;&atilde;o    <i>M tuberculosis</i>/HIV no Estado de S&atilde;o Pa
ulo, 1991-2001. <i>Rev Saude    Publica</i>. 2006;40(2):265-70. DOI:10.1590/S003
4-89102006000200012</font></p>     ^cY#2331.htm##
00590000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704033700086002000900423#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#119#115#article#143#
18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Santos MLS
G,    Ponce MAZ, Vendramini SHF, Villa TCS, Santos NSGM, Wysocki AD, et al. A di
mens&atilde;o    epidemiol&oacute;gica da coinfec&ccedil;&atilde;o TB/HIV. <i>Re
v Latino-Am Enferm</i>.    2009;17(5):683-8. DOI:10.1590/S0104-11692009000500014
</font></p>     ^cY#2331.htm##
00568000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704031500086002000900401#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#120#116#article#143#
19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Santos SM,
    Noronha CP. Padr&otilde;es espaciais de mortalidade e diferenciais s&oacute;
cio-econ&ocirc;micos    na cidade do Rio de Janeiro. <i>Cad Saude Publica</i>. 2
001;17(5):1099-110.    DOI:10.1590/S0102-311X2001000500012</font></p>     ^cY#23
31.htm##
00651000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704039800086002000900484#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#121#117#article#143#
20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Scatena LM
,    Villa TCS, Ruffino-Netto A, Kritski AL, Figueiredo TMRM, Vendramini SHF, et
    al. Dificuldades de acesso a servi&ccedil;os de sa&uacute;de para diagn&oacu
te;stico    de tuberculose em munic&iacute;pios do Brasil. <i>Rev Saude Publica.
</i>2009;43(3):389-97.    DOI:10.1590/S0034-89102009005000022</font></p>     ^cY
#2331.htm##
00599000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704034600086002000900432#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#122#118#article#143#
21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Teixeira C
F.    Promo&ccedil;&atilde;o e vigil&acirc;ncia da sa&uacute;de no contexto da r
egionaliza&ccedil;&atilde;o    da assist&ecirc;ncia &agrave; sa&uacute;de no SUS
. <i>Cad Saude Publica</i>.    2002;18(Supl):S153-62. DOI:10.1590/S0102-311X2002
000700015</font></p>     ^cY#2331.htm##
00586000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704033300086002000900419#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#123#119#article#143#
22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Vendramini
    SHF, Santos MLSG, Gazetta CE, Chiaravallotti-Neto F, Ruffino-Netto A, Villa 
   TCS. Tuberculosis risks and socio-economic level: a case study of a city in  
  the Brazilian south-east, 1998-2004. <i>Int J Tuberc Lung Dis</i>. 2006;10(11)
:1231-5.    ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#124#120#article#143#</font></p> 
    ^cY#2331.htm##
00644000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704039100086002000900477#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#125#121#article#143#
23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Vieira RCA
,    Prado TN, Siqueira MG, Dietze R, Maciel ELN. Distribui&ccedil;&atilde;o esp
acial    dos casos novos de tuberculose em Vit&oacute;ria, Estado do Esp&iacute;
rito    Santo, no per&iacute;odo de 2000 e 2005. <i>Rev Soc Bras Med Trop</i>. 2
008;41(1):82-6.    DOI:10.1590/S0037-86822008000100017</font></p>     ^cY#2331.h
tm##
00555000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704030200086002000900388#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#126#122#article#143#
24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Williams G
,    Arrascue EA, Jittimanee S, Walusimbi M, Sebek M, Berga E, et al. Guidance f
or    the implementation of best practice for the care of patients with tubercul
osis.    <i>Int J Tuberc Lung Dis.</i> 2008;12(3):236-40.    ^cY#2331.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#127#123#article#143#</font></p> 
    ^cY#2331.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#128#124#article#143#<p>&nbsp;</p
>     ^cY#2331.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#129#125#article#143#<p>&nbsp;</p
>     ^cY#2331.htm##
00453000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021500083002000900298#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#130#126#article#143#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#
top"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    <b>Corr
espond&ecirc;ncia | Correspondence:    ^cY#2331.htm##
00294000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005600083002000900139#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#131#127#article#143#<br>   </b> 
Maria Eug&ecirc;nia Firmino Brunello    ^cY#2331.htm##
00279000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004100083002000900124#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#132#128#article#143#<br>   Av. d
os Bandeirantes, 3900    ^cY#2331.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004200083002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#133#129#article#143#<br>   Campu
s Universit&aacute;rio    ^cY#2331.htm##
00296000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005800083002000900141#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#134#130#article#143#<br>   14040
-902 Ribeir&atilde;o Preto, SP, Brasil    ^cY#2331.htm##
00335000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704009700083002000900180#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#135#131#article#143#<br>   E-mai
l: <a href="mailto:brunello@eerp.usp.br">brunello@eerp.usp.br</a></font></p>    
 ^cY#2331.htm##
00327000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704008900083002000900172#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#136#132#article#143#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Recebido: 7/6/2010    ^cY#233
1.htm##
00273000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003500083002000900118#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#137#133#article#143#<br>   Aprov
ado: 14/11/2010    ^cY#2331.htm##
00548000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704031000083002000900393#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#138#134#article#143#<br>   Pesqu
isa financiada pela Funda&ccedil;&atilde;o de Amparo &agrave; Pesquisa    do Est
ado de S&atilde;o Paulo (Fapesp; processo nº 2007/57516-8) e pelo Conselho    Na
cional de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;gico (CNPq/MS-SCTIE-
DECIT    - nº 25/2006 410547/ 2006-9).</font></p>     ^cY#2331.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#139#135#article#143#<p>&nbsp;</p
>     ^cY#2331.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#140#136#article#143#<p>&nbsp;</p
>     ^cY#2331.htm##
00593000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704035500083002000900438#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#141#137#article#143#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo baseado    na disserta
&ccedil;&atilde;o de mestrado de Brunello MEF apresentada ao Programa    de P&oa
cute;s-Gradua&ccedil;&atilde;o em Enfermagem em Sa&uacute;de P&uacute;blica    d
a Escola de Enfermagem de Ribeir&atilde;o Preto da Universidade de S&atilde;o   
 Paulo em 2010.    ^cY#2331.htm##
00313000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704007500083002000900158#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#142#138#article#143#<br>   Os au
tores declaram n&atilde;o haver conflitos de interesse.    ^cY#2331.htm##
00625000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704038700083002000900470#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#143#139#article#143#<br>   <a na
me="backa"></a>a World Health Organization. Addressing and poverty in TB    cont
rol: options for national TB control programmes. Geneva; 2005. (WHO/HTM/TB/2005.
352).    &#91;citado em 2009 nov 08&#93;. Dispon&iacute;vel em: <a href="http://
whqlibdoc.who.int/hq/2005/WHO_HTM_TB_2005.352.pdf" target="_blank">http://whqlib
doc.who.int/hq/2005/WHO_HTM_TB_2005.352.pdf</a>    ^cY#2331.htm##
00613000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704037500083002000900458#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#144#140#article#143#<br>   <a na
me="backb"></a><a href="#topb">b</a> Funda&ccedil;&atilde;o Sistema Estadual    
de An&aacute;lise de Dados. Perfil municipal: Adamantina. S&atilde;o Paulo:    S
EADE; 2010. &#91;citado 2011 jan 23&#93;. Dispon&iacute;vel em: <a href="http://
www.seade.gov.br/produtos/perfil/perfil.php" target="_blank">http://www.seade.go
v.br/produtos/perfil/perfil.php</a>    ^cY#2331.htm##
00844000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704060600083002000900689#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#145#141#article#143#<br>   <a na
me="backc"></a>c Minist&eacute;rio da Sa&uacute;de. Secretaria de Aten&ccedil;&a
tilde;o    &agrave; sa&uacute;de. Departamento de Aten&ccedil;&atilde;o B&aacute
;sica.    Vigil&acirc;ncia em Sa&uacute;de: Dengue, Esquistossomose, Hansen&iacu
te;ase,    Mal&aacute;ria, Tracoma e Tuberculose. 2007: (21): 150. &#91;citado 2
009 set    4&#93;. Dispon&iacute;vel em: <a href="http://www.saude.mt.gov.br/adm
inpublicacao/arquivo/caderno%20atencao%20basica%20n%2021%202007.pdf" target="_bl
ank">http://www.saude.mt.gov.br/adminpublicacao/arquivo/caderno%20atencao%20basi
ca%20n%2021%202007.pdf</a>    ^cY#2331.htm##
00738000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704050000083002000900583#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#146#142#article#143#<br>   <a na
me="backd"></a>d Instituto Brasileiro de Geografia e Estat&iacute;stica.    Cens
os demogr&aacute;ficos 2000 &#91;citado 2007 jul 15&#93;. Dispon&iacute;vel    e
m: <a href="http://www.ibge.gov.br/home/estatistica/populacao/censo2000/universo
.php?tipo=31o/tabela13_1.shtm&amp;paginaatual=1&amp;uf=35&amp;letra=R" target="_
blank">http://www.ibge.gov.br/home/estatistica/populacao/censo2000/universo.php?
tipo=31o/tabela13_1.shtm&amp;paginaatual=1&amp;uf=35&amp;letra=R</a></font></p> 
    ^cY#2331.htm##
00263000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002500083002000900108#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2331.htm#S#p#147#143#article#143#</body> </ht
ml>      ^cY#2331.htm##
00497000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820120025000990300
02000124710000200144065000900146064000500155031000200160032000200162014000500164
237003200169865000900201002000900210#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2331.htm#S#c#148#1#article#24#1#^rND^sBarata^nRB#Epidemiologia social^lpt
#Rev Bras Epidemiol.#2#20050000#2005#8#1#7-17#10.1590/S1415-790X2005000100002#20
110000#2331.htm##
00666000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100019000820100018001010120
13800119030001800257065000900275064000500284031000300289014000600292237003200298
865000900330002000900339035001000348801001800358#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2331.htm#S#c#149#2#article#24#2#^rND^sBarcellos^nC#^rND^sSabr
oza^nPC#The place behind the case: leptospirosis risks and associated environmen
tal conditions in a flood- related outbreak in Rio de Janeiro^len#Cad Saude Publ
ica#20010000#2001#17#59-67#10.1590/S0102-311X2001000700014#20110000#2331.htm#010
2-311X#Cad Saude Publica##
00776000000000349000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100015000820100016000970100
01600113010001600129010002100145010001700166810000600183012014400189030001800333
71000020035106500090035306400050036203100020036703200020036901400070037123700300
0378865000900408002000900417#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
331.htm#S#c#150#3#article#24#3#^rND^sBates^nI#^rND^sFenton^nC#^rND^sGruber^nJ#^r
ND^sLalloo^nD#^rND^sMedina Lara^nA#^rND^sSquire^nSB#et al#Vulnerability to malar
ia, tuberculosis and HIV/AIDS infection and disease: Part 1: determinants operat
ing at individual and household level^len#Lancet Infect Dis#2#20040000#2004#4#5#
267-77#10.1016/S1473-3099(04)01002-3#20110000#2331.htm##
00569000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100016001000120
06300116030002200179065000900201064000500210031000300215032000300218014000800221
865000900229002000900238035001000247801002200257#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2331.htm#S#c#151#4#article#24#4#^rND^sBenatar^nSR#^rND^sUpshu
r^nR#Tuberculosis and poverty: what could (and should) be done?^len#Int J Tuberc
 Lung Dis#20100000#2010#14#10#1215-21#20110000#2331.htm#1027-3719#Int J Tuberc L
ung Dis##
00711000000000349000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100020000820100020001020100
01600122010001900138010002000157010001700177810000600194012006600200030001700266
71000020028306500090028506400050029403100030029903200020030201400070030423700320
0311865000900343002000900352#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
331.htm#S#c#152#5#article#24#5#^rND^sBrunello^nMEF#^rND^sCerqueira^nDF#^rND^sPin
to^nIC#^rND^sArcêncio^nRA#^rND^sGonzáles^nRIC#^rND^sVilla^nTCS#et al#Vínculo doe
nte-profissional de saúde na atenção à tuberculose^lpt#Acta Paul Enferm#2#200900
00#2009#22#2#176-82#10.1590/S0103-21002009000200010#20110000#2331.htm##
00742000000000349000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100020000820100015001020100
01400117010001400131010001600145010001400161810000600175012011300181030002200294
06500090031606400050032503100020033003200030033201400070033586500090034200200090
0351035001000360801002200370#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
331.htm#S#c#153#6#article#24#6#^rND^sChan-Yeung^nM#^rND^sYen^nAGO#^rND^sTam^nCM#
^rND^sKam^nKM#^rND^sLeung^nCC#^rND^sYew^nWW#et al#Socio-demographic and geograph
ic indicators and distibution of tuberculosis in Hong Kong: a spatial analysis^l
en#Int J Tuberc Lung Dis#20050000#2005#9#12#1320-6#20110000#2331.htm#1027-3719#I
nt J Tuberc Lung Dis##
00798000000000361000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100014000990100
01600113010001800129010001800147010001600165810000600181012014600187030000700333
06500090034006400050034903100040035403200050035801400080036323700300037186500090
0401002000900410035001000419801000700429#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2331.htm#S#c#154#7#article#24#7#^rND^sGandhi^nNR#^rND^sMoll^nA#^rND^s
Sturm^nAW#^rND^sPawinski^nR#^rND^sGovender^nT#^rND^sLalloo^nU#et al#Extensively 
drug-resistant tuberculosis as a cause of death in patients co-infected with tub
erculosis and HIV in a rural area of South Africa^len#Lancet#20060000#2006#368#9
547#1575-80#10.1016/S0140-6736(06)69573-1#20110000#2331.htm#0099-5355#Lancet##
00820000000000361000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100016000820100017000980100
01900115010001600134010002000150010002600170810000600196012013700202030001700339
06500090035606400050036503100030037003200020037301400060037523700320038186500090
0413002000900422035001000431801001700441#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2331.htm#S#c#155#8#article#24#8#^rND^sGodoy^nMF#^rND^sLucena^nJM#^rND
^sMiquelin^nAR#^rND^sPaiva^nFF#^rND^sOliveira^nDLQ#^rND^sAugustin-Junior^nJL#et 
al#Mortalidade por doenças cardiovasculares e níveis socioeconômicos na populaçã
o de São José do Rio Preto, estado de São Paulo, Brasil^lpt#Arq Bras Cardiol#200
70000#2007#88#2#200-6#10.1590/S0066-782X2007000200011#20110000#2331.htm#0066-782
X#Arq Bras Cardiol##
00699000000000325000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100014000820100017000960100
01700113010001600130010001700146012011200163030002100275710000200296065000900298
06400050030703100030031203200020031501400060031723700320032386500090035500200090
0364#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#c#156#9#articl
e#24#9#^rND^sHino^nP#^rND^sSantos^nCB#^rND^sVilla^nTCS#^rND^sMuniz^nJN#^rND^sMon
roe^nAA#Tuberculosis patients submitted to supervised treatment: Ribeirão Preto 
- São Paulo - Brazil. 1998 and 1999^len#Rev Latino-Am Enferm#2#20050000#2005#13#
1#27-31#10.1590/S0104-11692005000100005#20110000#2331.htm##
00641000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100014000840100017000980100
01800115010001900133010001700152012004600169030002200215710000200237065000900239
06400050024803100030025303200020025601400070025823700320026586500090029700200090
0306#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#c#157#10#artic
le#24#10#^rND^sHino^nP#^rND^sVilla^nTCS#^rND^sSassaki^nCM#^rND^sNogueira^nJA#^rN
D^sSantos^nCB#Geoprocessamento aplicado à área da saúde^lpt#Rev Latino-Am Enferm
.#2#20060000#2006#14#6#939-43#10.1590/S0104-11692006000600016#20110000#2331.htm#
#
00534000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100020000840100017001040120
04600121030001100167710000200178065000900180064000500189031000300194032000200197
014000800199237001900207865000900226002000900235#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2331.htm#S#c#158#11#article#24#11#^rND^sKaufmann^nSHE#^rND^sP
arida^nSK#Changing funding patterns in tuberculosis^len#Nature Med#2#20070000#20
07#13#3#299-303#10.1038/nm0307-299#20110000#2331.htm##
00630000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100019001030100
02000122012006800142030001200210065000900222064000500231031000300236032000200239
014000500241237003000246865000900276002000900285035001000294801001200304#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#c#159#12#article#24#12#^rN
D^sKistemann^nT#^rND^sMunzinger^nA#^rND^sDangendorf^nF#Spatial patterns of tuber
culosis incidence in Cologne (Germany)^len#Soc Sci Med#20020000#2002#55#1#7-19#1
0.1016/S0277-9536(01)00216-7#20110000#2331.htm#0037-7856#Soc Sci Med##
00664000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100014000840100017000980100
01700115012009100132030002000223065000900243064000500252031000300257032000200260
014000700262237003300269865000900302002000900311035001000320801002000330#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#c#160#13#article#24#13#^rN
D^sMacq^nJ#^rND^sTorfoss^nT#^rND^sGetahun^nH#Patient empowerment in tuberculosis
 control: reflecting on past documented experiences^len#Trop Med Int Health#2007
0000#2007#12#7#873-85#10.1111/j.1365-3156.2007.01858.x#20110000#2331.htm#1360-22
76#Trop Med Int Health##
00782000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100023001000100
01700123010001800140010001800158010002700176810000600203012013000209030001500339
71000020035406500090035606400050036503100030037003200020037301400070037523700320
0382865000900414002000900423#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
331.htm#S#c#161#14#article#24#14#^rND^sMuniz^nJN#^rND^sRuffino-Netto^nA#^rND^sVi
lla^nTCS#^rND^sYamamura^nM#^rND^sArcencio^nR#^rND^sCardozo-Gonzales^nRI#et al#As
pectos epidemiológicos da co-infecção tuberculose e vírus da imunodeficiência hu
mana em Ribeirão Preto (SP), de 1998 a 2003^lpt#J Bras Pneumol#2#20060000#2006#3
2#6#529-34#10.1590/S1806-37132006000600010#20110000#2331.htm##
00644000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100018001020120
10000120030001800220065000900238064000500247031000300252032000200255014000700257
237003200264865000900296002000900305035001000314801001800324#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2331.htm#S#c#162#15#article#24#15#^rND^sPaixão^nL
MM#^rND^sGontijo^nED#Perfil de casos de tuberculose notificados e fatores associ
ados ao abandono, Belo Horizonte, MG^lpt#Rev Saude Publica#20070000#2007#41#2#20
5-13#10.1590/S0034-89102007000200006#20110000#2331.htm#0034-8910#Rev Saude Publi
ca##
00747000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100014000840100015000980100
02000113010001800133010001300151010001400164810000600178012012100184030001700305
71000020032206500090032406400050033303100020033803200020034001400070034223700300
0349865000900379002000900388#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
331.htm#S#c#163#16#article#24#16#^rND^sReid^nA#^rND^sScano^nF#^rND^sHaileyesus^n
G#^rND^sWilliams^nB#^rND^sDye^nC#^rND^sNunn^nP#et al#Towards universal access to
 HIV prevention, treatment, care, and support: the role of tuberculosis/HIV coll
aboration^len#Lancet Infec Dis#2#20060000#2006#6#8#483-95#10.1016/S1473-3099(06)
70549-7#20110000#2331.htm##
00679000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100023000840100023001070100
01900130012009400149030001800243065000900261064000500270031000300275032000200278
014000700280237003200287865000900319002000900328035001000337801001800347#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#c#164#17#article#24#17#^rN
D^sRodrigues Jr^nAL#^rND^sRuffino-Netto^nA#^rND^sCastilho^nEA#Distribuição espac
ial da co-infecção M tuberculosis/HIV no Estado de São Paulo, 1991-2001^lpt#Rev 
Saude Publica#20060000#2006#40#2#265-70#10.1590/S0034-89102006000200012#20110000
#2331.htm#0034-8910#Rev Saude Publica##
00701000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100017001030100
02200120010001700142010001900159010001800178810000600196012005100202030002100253
71000020027406500090027606400050028503100030029003200020029301400060029523700320
0301865000900333002000900342#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
331.htm#S#c#165#18#article#24#18#^rND^sSantos^nMLSG#^rND^sPonce^nMAZ#^rND^sVendr
amini^nSHF#^rND^sVilla^nTCS#^rND^sSantos^nNSGM#^rND^sWysocki^nAD#et al#A dimensã
o epidemiológica da coinfecção TB/HIV^lpt#Rev Latino-Am Enferm#2#20090000#2009#1
7#5#683-8#10.1590/S0104-11692009000500014#20110000#2331.htm##
00642000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100018001010120
09700119030001800216065000900234064000500243031000300248032000200251014000900253
237003200262865000900294002000900303035001000312801001800322#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2331.htm#S#c#166#19#article#24#19#^rND^sSantos^nS
M#^rND^sNoronha^nCP#Padrões espaciais de mortalidade e diferenciais sócio-econôm
icos na cidade do Rio de Janeiro^lpt#Cad Saude Publica#20010000#2001#17#5#1099-1
10#10.1590/S0102-311X2001000500012#20110000#2331.htm#0102-311X#Cad Saude Publica
##
00798000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100017001020100
02300119010001800142010002300160010002200183810000600205012010300211030001800314
06500090033206400050034103100030034603200020034901400070035123700320035886500090
0390002000900399035001000408801001800418#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2331.htm#S#c#167#20#article#24#20#^rND^sScatena^nLM#^rND^sVilla^nTCS#
^rND^sRuffino-Netto^nA#^rND^sKritski^nAL#^rND^sFigueiredo^nTMRM#^rND^sVendramini
^nSHF#et al#Dificuldades de acesso a serviços de saúde para diagnóstico de tuber
culose em municípios do Brasil^lpt#Rev Saude Publica#20090000#2009#43#3#389-97#1
0.1590/S0034-89102009005000022#20110000#2331.htm#0034-8910#Rev Saude Publica##
00597000000000277000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840120095001030300
01800198065000900216064000500225031000300230014000800233237003200241865000900273
002000900282035001000291801001800301#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2331.htm#S#c#168#21#article#24#21#^rND^sTeixeira^nCF#Promoção e vigilânci
a da saúde no contexto da regionalização da assistência à saúde no SUS^lpt#Cad S
aude Publica#20020000#2002#18#S153-62#10.1590/S0102-311X2002000700015#20110000#2
331.htm#0102-311X#Cad Saude Publica##
00760000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100022000840100019001060100
01800125010002900143010002300172010001700195012011100212030002200323065000900345
06400050035403100030035903200030036201400070036586500090037200200090038103500100
0390801002200400#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#c#
169#22#article#24#22#^rND^sVendramini^nSHF#^rND^sSantos^nMLSG#^rND^sGazetta^nCE#
^rND^sChiaravallotti-Neto^nF#^rND^sRuffino-Netto^nA#^rND^sVilla^nTCS#Tuberculosi
s risks and socio-economic level: a case study of a city in the Brazilian south-
east, 1998-2004^len#Int J Tuberc Lung Dis#20060000#2006#10#11#1231-5#20110000#23
31.htm#1027-3719#Int J Tuberc Lung Dis##
00758000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100016001020100
01900118010001600137010001800153012012100171030002200292065000900314064000500323
03100030032803200020033101400050033323700320033886500090037000200090037903500100
0388801002200398#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#c#
170#23#article#24#23#^rND^sVieira^nRCA#^rND^sPrado^nTN#^rND^sSiqueira^nMG#^rND^s
Dietze^nR#^rND^sMaciel^nELN#Distribuição espacial dos casos novos de tuberculose
 em Vitória, Estado do Espírito Santo, no período de 2000 e 2005^lpt#Rev Soc Bra
s Med Trop#20080000#2008#41#1#82-6#10.1590/S0037-86822008000100017#20110000#2331
.htm#0037-8682#Rev Soc Bras Med Trop##
00699000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100019001020100
02000121010001900141010001500160010001500175810000600190012009600196030002300292
71000020031506500090031706400050032603100030033103200020033401400070033686500090
0343002000900352#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2331.htm#S#c#
171#24#article#24#24#^rND^sWilliams^nG#^rND^sArrascue^nEA#^rND^sJittimanee^nS#^r
ND^sWalusimbi^nM#^rND^sSebek^nM#^rND^sBerga^nE#et al#Guidance for the implementa
tion of best practice for the care of patients with tuberculosis^len#Int J Tuber
c Lung Dis.#2#20080000#2008#12#3#236-40#20110000#2331.htm##
00276000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00400102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#o#1#1#arti
cle#1#20110408#160411#2289.htm#285##
05058000000000757000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000500095121000300100049000300103158000300106030001900109
03200060012806500090013401400070014303500100015022300090016001200850016901200810
02540120085003350100030004200100031004500100024004810100032005050100031005370100
02800568070005900596070010200655070009300757070010500850083089000955085001001845
08500370185508500300189208500330192208500190195508309890197408500100296308500400
29730850022030130850038030350850020030730831023030930850010041160850039041260850
02204165085003304187085002104220117000804241072000304249112000904252111001004261
114000904271113001104280002000904291#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2289.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#19#nd#nd#Rev. Saúde Púb
lica#ahead#20110000#^f0^l0#0034-8910#20110415#How many low birthweight babies in
 low- and middle-income countries are preterm?^len#Quantos dos recém-nascidos de
 baixo peso de países emergentes são pré-termo?^lpt#Cuantos de los recién nacido
s de bajo peso de países emergentes son pre-término?^les#^rND^1A01^nFernando C^s
Barros#^rND^1A02^nAluísio J D^sBarros#^rND^1A03^nJosé^sVillar#^rND^1A02^nAlicia^
sMatijasevich#^rND^1A04^nMarlos R^sDomingues#^rND^1A02^nCesar G^sVictora#Univers
idade Católica de Pelotas^iA01^cPelotas^sRS^pBrasil#Universidade Federal de Pelo
tas^iA02^1Programa de Pós-Graduação em Epidemiologia^cPelotas^sRS^pBrasil#Univer
sity of Oxford^iA03^1Nuffield Department of Obstetrics and Gynaecology^pUnited K
ingdom#UFPel^iA04^1Programa de Pós-Graduação em Educação Física^2Departamento de
 Desportos^cPelotas^sRS^pBrasil#^len^aOBJECTIVE: To assess the prevalence of pre
term birth among low birthweight babies in low and middle-income countries. METH
ODS: Major databases (PubMed, LILACS, Google Scholar) were searched for studies 
on the prevalence of term and preterm LBW babies with field work carried out aft
er 1990 in low- and middle-income countries. Regression methods were used to mod
el this proportion according to LBW prevalence levels. RESULTS: According to 47 
studies from 27 low- and middle-income countries, approximately half of all LBW 
babies are preterm rather than one in three as assumed in studies previous to th
e 1990s. CONCLUSIONS: The estimate of a substantially higher number of LBW prete
rm babies has important policy implications in view of special health care needs
 of these infants. As for earlier projections, our findings are limited by the r
elative lack of population-based studies.#^ddecs^i1#^tm^len^kInfant, Low Birth W
eight^i1#^tm^len^kInfant, Premature^i1#^tm^len^kDeveloping Countries^i1#^tm^len^
kReview^i1#^lpt^aOBJETIVO: Estimar a prevalência de recém-nascidos pré-termo ent
re os recém-nascidos de baixo peso ao nascer de países de renda média ou baixa. 
MÉTODOS: Em consulta a bases de dados (PubMed, LILACS, Google Scholar) foram pro
curados estudos sobre a prevalência de recém-nascidos a termo e pré-termo entre 
aqueles de baixo peso ao nascer conduzidos após 1990 em países emergentes. Model
os de regressão foram usados para avaliar a proporção de acordo com as prevalênc
ias de baixo peso. RESULTADOS: Com base em 47 estudos de 27 países emergentes, a
proximadamente metade de todos os recém-nascidos com baixo peso seriam prematuro
s, em vez de um a cada três, como estimado em estudos anteriores à década de 199
0. CONCLUSÕES: A estimativa de números substancialmente mais altos de prematuros
 com baixo peso tem importantes reflexos no planejamento em saúde, uma vez que e
sses recém-nascidos demandam cuidados especiais. Todavia, os achados são limitad
os pela falta de estudos populacionais.#^ddecs^i2#^tm^lpt^kRecém-Nascido de Baix
o Peso^i2#^tm^lpt^kPrematuro^i2#^tm^lpt^kPaíses em Desenvolvimento^i2#^tm^lpt^kR
evisão^i2#^les^aOBJETIVO: Estimar la prevalencia de recién nacidos pre-término e
ntre los recién nacidos de bajo peso al nacer de países de renta media o baja. M
ÉTODOS: En consulta a bases de datos (PubMed, LILACS, Google Scholar) fueron pro
curados estudios sobre la prevalencia de recién nacidos a término y pre-término 
entre aquellos de bajo peso al nacer conducidos posteriores a 1990 en países eme
rgentes. Modelos de regresión fueron usados para evaluar la proporción de acuerd
o con las prevalencias de bajo peso. RESULTADOS: Con base en 47 estudios de 27 p
aíses emergentes, aproximadamente la mitad de todos los recién nacidos con bajo 
peso serían prematuros, y no uno de cada tres, como se estimó en estudios anteri
ores a la década de 1990. CONCLUSIONES: La estimación de números sustancialmente
 más altos de prematuros con bajo peso tiene importantes consecuencias en la pla
nificación de salud, ya que tales recién nacidos demandan cuidados especiales. A
ún, los resultados son limitados por la falta de estudios poblacionales.#^ddecs^
i3#^tm^les^kRecién Nacido de Bajo Peso^i3#^tm^les^kPrematuro^i3#^tm^les^kPaíses 
en Desarrollo^i3#^tm^les^kRevisión^i3#vancouv#68#20100523#5/23/2010#20101216#12/
16/2010#2289.htm##
05163000000000757000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000500095121000300100049000300103158000300106030001900109
03200060012806500090013401400070014303500100015022300090016001200920016901200880
02610120092003490100030004410100031004710100024005020100032005260100031005580100
02800589070005900617070010200676070009300778070010500871083091800976085001001894
08500370190408500300194108500330197108500190200408310170202308500100304008500400
30500850022030900850038031120850020031500831051031700850010042210850039042310850
02204270085003304292085002104325117000804346072000304354112000904357111001004366
114000904376113001104385002000904396#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2289.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#19#nd#nd#Rev. Saúde Púb
lica#ahead#20110000#^f0^l0#0034-8910#20110415#<b>How many low birthweight babies
 in low- and middle-income countries are preterm?</b>^len#<b>Quantos dos recém-n
ascidos de baixo peso de países emergentes são pré-termo?</b>^lpt#<b>Cuantos de 
los recién nacidos de bajo peso de países emergentes son pre-término?</b>^les#^r
ND^1A01^nFernando C^sBarros#^rND^1A02^nAluísio J D^sBarros#^rND^1A03^nJosé^sVill
ar#^rND^1A02^nAlicia^sMatijasevich#^rND^1A04^nMarlos R^sDomingues#^rND^1A02^nCes
ar G^sVictora#Universidade Católica de Pelotas^iA01^cPelotas^sRS^pBrasil#Univers
idade Federal de Pelotas^iA02^1Programa de Pós-Graduação em Epidemiologia^cPelot
as^sRS^pBrasil#University of Oxford^iA03^1Nuffield Department of Obstetrics and 
Gynaecology^pUnited Kingdom#UFPel^iA04^1Programa de Pós-Graduação em Educação Fí
sica^2Departamento de Desportos^cPelotas^sRS^pBrasil#^len^a<b>OBJECTIVE:</b> To 
assess the prevalence of preterm birth among low birthweight babies in low and m
iddle-income countries. <b>METHODS:</b> Major databases (PubMed, LILACS, Google 
Scholar) were searched for studies on the prevalence of term and preterm LBW bab
ies with field work carried out after 1990 in low- and middle-income countries. 
Regression methods were used to model this proportion according to LBW prevalenc
e levels. <b>RESULTS:</b> According to 47 studies from 27 low- and middle-income
 countries, approximately half of all LBW babies are preterm rather than one in 
three as assumed in studies previous to the 1990s. <b>CONCLUSIONS:</b> The estim
ate of a substantially higher number of LBW preterm babies has important policy 
implications in view of special health care needs of these infants. As for earli
er projections, our findings are limited by the relative lack of population-base
d studies.#^ddecs^i1#^tm^len^kInfant, Low Birth Weight^i1#^tm^len^kInfant, Prema
ture^i1#^tm^len^kDeveloping Countries^i1#^tm^len^kReview^i1#^lpt^a<b>OBJETIVO:</
b> Estimar a prevalência de recém-nascidos pré-termo entre os recém-nascidos de 
baixo peso ao nascer de países de renda média ou baixa. <b>MÉTODOS:</b> Em consu
lta a bases de dados (PubMed, LILACS, Google Scholar) foram procurados estudos s
obre a prevalência de recém-nascidos a termo e pré-termo entre aqueles de baixo 
peso ao nascer conduzidos após 1990 em países emergentes. Modelos de regressão f
oram usados para avaliar a proporção de acordo com as prevalências de baixo peso
. <b>RESULTADOS:</b> Com base em 47 estudos de 27 países emergentes, aproximadam
ente metade de todos os recém-nascidos com baixo peso seriam prematuros, em vez 
de um a cada três, como estimado em estudos anteriores à década de 1990. <b>CONC
LUSÕES:</b> A estimativa de números substancialmente mais altos de prematuros co
m baixo peso tem importantes reflexos no planejamento em saúde, uma vez que esse
s recém-nascidos demandam cuidados especiais. Todavia, os achados são limitados 
pela falta de estudos populacionais.#^ddecs^i2#^tm^lpt^kRecém-Nascido de Baixo P
eso^i2#^tm^lpt^kPrematuro^i2#^tm^lpt^kPaíses em Desenvolvimento^i2#^tm^lpt^kRevi
são^i2#^les^a<b>OBJETIVO:</b> Estimar la prevalencia de recién nacidos pre-térmi
no entre los recién nacidos de bajo peso al nacer de países de renta media o baj
a. <b>MÉTODOS:</b> En consulta a bases de datos (PubMed, LILACS, Google Scholar)
 fueron procurados estudios sobre la prevalencia de recién nacidos a término y p
re-término entre aquellos de bajo peso al nacer conducidos posteriores a 1990 en
 países emergentes. Modelos de regresión fueron usados para evaluar la proporció
n de acuerdo con las prevalencias de bajo peso. <b>RESULTADOS:</b> Con base en 4
7 estudios de 27 países emergentes, aproximadamente la mitad de todos los recién
 nacidos con bajo peso serían prematuros, y no uno de cada tres, como se estimó 
en estudios anteriores a la década de 1990. <b>CONCLUSIONES:</b> La estimación d
e números sustancialmente más altos de prematuros con bajo peso tiene importante
s consecuencias en la planificación de salud, ya que tales recién nacidos demand
an cuidados especiales. Aún, los resultados son limitados por la falta de estudi
os poblacionales.#^ddecs^i3#^tm^les^kRecién Nacido de Bajo Peso^i3#^tm^les^kPrem
aturo^i3#^tm^les^kPaíses en Desarrollo^i3#^tm^les^kRevisión^i3#vancouv#68#201005
23#5/23/2010#20101216#12/16/2010#2289.htm##
05186000000000781000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098038000500102121000300107049000300110158000300113
03000190011603200060013506500090014101400070015003500100015722300090016701200850
01760120081002610120085003420100030004270100031004570100024004880100032005120100
03100544010002800575070006100603070010400664070009500768070010700863083089000970
08500100186008500370187008500300190708500330193708500190197008309890198908500100
29780850040029880850022030280850038030500850020030880831023031080850010041310850
03904141085002204180085003304202085002104235117000804256072000304264112000904267
111001004276114000904286113001104295002000904306008008904315#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2289.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4
.0#ilus#19#nd#nd#Rev. saúde pública#ahead#20110000#^f0^l0#0034-8910#20110415#How
 many low birthweight babies in low- and middle-income countries are preterm?^le
n#Quantos dos recém-nascidos de baixo peso de países emergentes são pré-termo?^l
pt#Cuantos de los recién nacidos de bajo peso de países emergentes son pre-térmi
no?^les#^rND^1A01^nFernando C^sBarros#^rND^1A02^nAluísio J D^sBarros#^rND^1A03^n
José^sVillar#^rND^1A02^nAlicia^sMatijasevich#^rND^1A04^nMarlos R^sDomingues#^rND
^1A02^nCesar G^sVictora#^iA01^1Universidade Católica de Pelotas^cPelotas^sRS^pBr
asil#^iA02^1Universidade Federal de Pelotas^2Programa de Pós-Graduação em Epidem
iologia^cPelotas^sRS^pBrasil#^iA03^1University of Oxford^2Nuffield Department of
 Obstetrics and Gynaecology^pUnited Kingdom#^iA04^1UFPel^2Programa de Pós-Gradua
ção em Educação Física^3Departamento de Desportos^cPelotas^sRS^pBrasil#^len^aOBJ
ECTIVE: To assess the prevalence of preterm birth among low birthweight babies i
n low and middle-income countries. METHODS: Major databases (PubMed, LILACS, Goo
gle Scholar) were searched for studies on the prevalence of term and preterm LBW
 babies with field work carried out after 1990 in low- and middle-income countri
es. Regression methods were used to model this proportion according to LBW preva
lence levels. RESULTS: According to 47 studies from 27 low- and middle-income co
untries, approximately half of all LBW babies are preterm rather than one in thr
ee as assumed in studies previous to the 1990s. CONCLUSIONS: The estimate of a s
ubstantially higher number of LBW preterm babies has important policy implicatio
ns in view of special health care needs of these infants. As for earlier project
ions, our findings are limited by the relative lack of population-based studies.
#^ddecs^i1#^tm^len^kInfant, Low Birth Weight^i1#^tm^len^kInfant, Premature^i1#^t
m^len^kDeveloping Countries^i1#^tm^len^kReview^i1#^lpt^aOBJETIVO: Estimar a prev
alência de recém-nascidos pré-termo entre os recém-nascidos de baixo peso ao nas
cer de países de renda média ou baixa. MÉTODOS: Em consulta a bases de dados (Pu
bMed, LILACS, Google Scholar) foram procurados estudos sobre a prevalência de re
cém-nascidos a termo e pré-termo entre aqueles de baixo peso ao nascer conduzido
s após 1990 em países emergentes. Modelos de regressão foram usados para avaliar
 a proporção de acordo com as prevalências de baixo peso. RESULTADOS: Com base e
m 47 estudos de 27 países emergentes, aproximadamente metade de todos os recém-n
ascidos com baixo peso seriam prematuros, em vez de um a cada três, como estimad
o em estudos anteriores à década de 1990. CONCLUSÕES: A estimativa de números su
bstancialmente mais altos de prematuros com baixo peso tem importantes reflexos 
no planejamento em saúde, uma vez que esses recém-nascidos demandam cuidados esp
eciais. Todavia, os achados são limitados pela falta de estudos populacionais.#^
ddecs^i2#^tm^lpt^kRecém-Nascido de Baixo Peso^i2#^tm^lpt^kPrematuro^i2#^tm^lpt^k
Países em Desenvolvimento^i2#^tm^lpt^kRevisão^i2#^les^aOBJETIVO: Estimar la prev
alencia de recién nacidos pre-término entre los recién nacidos de bajo peso al n
acer de países de renta media o baja. MÉTODOS: En consulta a bases de datos (Pub
Med, LILACS, Google Scholar) fueron procurados estudios sobre la prevalencia de 
recién nacidos a término y pre-término entre aquellos de bajo peso al nacer cond
ucidos posteriores a 1990 en países emergentes. Modelos de regresión fueron usad
os para evaluar la proporción de acuerdo con las prevalencias de bajo peso. RESU
LTADOS: Con base en 47 estudios de 27 países emergentes, aproximadamente la mita
d de todos los recién nacidos con bajo peso serían prematuros, y no uno de cada 
tres, como se estimó en estudios anteriores a la década de 1990. CONCLUSIONES: L
a estimación de números sustancialmente más altos de prematuros con bajo peso ti
ene importantes consecuencias en la planificación de salud, ya que tales recién 
nacidos demandan cuidados especiales. Aún, los resultados son limitados por la f
alta de estudios poblacionales.#^ddecs^i3#^tm^les^kRecién Nacido de Bajo Peso^i3
#^tm^les^kPrematuro^i3#^tm^les^kPaíses en Desarrollo^i3#^tm^les^kRevisión^i3#van
couv#68#20100523#5/23/2010#20101216#12/16/2010#2289.htm#Internet^ihttp://www.sci
elo.br/scielo.php?script=sci_arttext&pid=S0034-89102011005000019##
00429000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704019500079002000900274#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#5#1#article#213#<p><a name="top"
></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>How    many 
low birthweight babies in low- and middle-income countries are preterm?</b>    <
/font></p>     ^cY#2289.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#6#2#article#213#<p>&nbsp;</p>   
  ^cY#2289.htm##
00431000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704019700079002000900276#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#7#3#article#213#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Quantos dos    rec&eacute;m-na
scidos de baixo peso de pa&iacute;ses emergentes s&atilde;o pr&eacute;-termo?</b
></font></p>     ^cY#2289.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#8#4#article#213#<p>&nbsp;</p>   
  ^cY#2289.htm##
00428000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704019400079002000900273#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#9#5#article#213#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Cuantos de los    reci&eacute;
n nacidos de bajo peso de pa&iacute;ses emergentes son pre-t&eacute;rmino?</b></
font></p>     ^cY#2289.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#10#6#article#213#<p>&nbsp;</p>  
   ^cY#2289.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#11#7#article#213#<p>&nbsp;</p>  
   ^cY#2289.htm##
00531000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704029600080002000900376#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#12#8#article#213#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Fernando C Barros<sup>I</sup>
;    Alu&iacute;sio J D Barros<sup>II</sup>; Jos&eacute; Villar<sup>III</sup>; A
licia    Matijasevich<sup>II</sup>; Marlos R Domingues<sup>IV</sup>; Cesar G Vic
tora<sup>II</sup></b></font></p>     ^cY#2289.htm##
00464000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704022900080002000900309#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#13#9#article#213#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Programa    de P&oac
ute;s-Gradua&ccedil;&atilde;o em Sa&uacute;de e Comportamento. Universidade    C
at&oacute;lica de Pelotas. Pelotas, RS, Brasil    ^cY#2289.htm##
00425000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018900081002000900270#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#14#10#article#213#<br>   <sup>II
</sup>Departamento de Medicina Social. Programa de P&oacute;s-Gradua&ccedil;&ati
lde;o    em Epidemiologia. Universidade Federal de Pelotas (UFPel). Pelotas, RS,
 Brasil    ^cY#2289.htm##
00363000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704012700081002000900208#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#15#11#article#213#<br>   <sup>II
I</sup>Nuffield Department of Obstetrics and Gynaecology. University    of Oxfor
d. Oxford, United Kingdom    ^cY#2289.htm##
00420000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018400081002000900265#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#16#12#article#213#<br>   <sup>IV
</sup>Departamento de Desportos. Programa de P&oacute;s-Gradua&ccedil;&atilde;o 
   em Educa&ccedil;&atilde;o F&iacute;sica. UFPel. Pelotas, RS, Brasil</font></p
>     ^cY#2289.htm##
00353000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011700081002000900198#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#17#13#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence<
/a></font></p>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#18#14#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704004400081002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#19#15#article#213#<p>&nbsp;</p> 
<hr size="1" noshade>     ^cY#2289.htm##
00334000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009800081002000900179#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#20#16#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     
^cY#2289.htm##
00437000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020100081002000900282#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#21#17#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To assess 
the prevalence of preterm birth among low birthweight babies in low    and middl
e-income countries.    ^cY#2289.htm##
00565000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704032900081002000900410#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#22#18#article#213#<br>   <b>METH
ODS:</b> Major databases (PubMed, LILACS, Google Scholar) were searched    for s
tudies on the prevalence of term and preterm LBW babies with field work    carri
ed out after 1990 in low- and middle-income countries. Regression methods    wer
e used to model this proportion according to LBW prevalence levels.    ^cY#2289.
htm##
00457000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704022100081002000900302#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#23#19#article#213#<br>   <b>RESU
LTS:</b> According to 47 studies from 27 low- and middle-income countries,    ap
proximately half of all LBW babies are preterm rather than one in three as    as
sumed in studies previous to the 1990s.    ^cY#2289.htm##
00551000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704031500081002000900396#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#24#20#article#213#<br>   <b>CONC
LUSIONS:</b> The estimate of a substantially higher number of LBW preterm    bab
ies has important policy implications in view of special health care needs    of
 these infants. As for earlier projections, our findings are limited by the    r
elative lack of population-based studies.</font></p>     ^cY#2289.htm##
00438000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020200081002000900283#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#25#21#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:</b>    Infant, 
Low Birth Weight. Infant, Premature. Developing Countries. Review.</font></p> <h
r size="1" noshade>     ^cY#2289.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#26#22#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^c
Y#2289.htm##
00506000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704027000081002000900351#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#27#23#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Estimar a p
reval&ecirc;ncia de rec&eacute;m-nascidos pr&eacute;-termo entre    os rec&eacut
e;m-nascidos de baixo peso ao nascer de pa&iacute;ses de renda m&eacute;dia    o
u baixa.    ^cY#2289.htm##
00679000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704044300081002000900524#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#28#24#article#213#<br>   <b>M&Ea
cute;TODOS:</b> Em consulta a bases de dados (PubMed, LILACS, Google    Scholar)
 foram procurados estudos sobre a preval&ecirc;ncia de rec&eacute;m-nascidos    
a termo e pr&eacute;-termo entre aqueles de baixo peso ao nascer conduzidos    a
p&oacute;s 1990 em pa&iacute;ses emergentes. Modelos de regress&atilde;o foram  
  usados para avaliar a propor&ccedil;&atilde;o de acordo com as preval&ecirc;nc
ias    de baixo peso.    ^cY#2289.htm##
00524000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704028800081002000900369#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#29#25#article#213#<br>   <b>RESU
LTADOS:</b> Com base em 47 estudos de 27 pa&iacute;ses emergentes, aproximadamen
te    metade de todos os rec&eacute;m-nascidos com baixo peso seriam prematuros,
 em    vez de um a cada tr&ecirc;s, como estimado em estudos anteriores &agrave;
 d&eacute;cada    de 1990.    ^cY#2289.htm##
00590000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035400081002000900435#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#30#26#article#213#<br>   <b>CONC
LUS&Otilde;ES:</b> A estimativa de n&uacute;meros substancialmente mais    altos
 de prematuros com baixo peso tem importantes reflexos no planejamento    em sa&
uacute;de, uma vez que esses rec&eacute;m-nascidos demandam cuidados especiais. 
   Todavia, os achados s&atilde;o limitados pela falta de estudos populacionais.
</font></p>     ^cY#2289.htm##
00463000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704022700081002000900308#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#31#27#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Rec&eacu
te;m-Nascido de Baixo Peso. Prematuro. Pa&iacute;ses em Desenvolvimento.    Revi
s&atilde;o.</font></p> <hr size="1" noshade>     ^cY#2289.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#32#28#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^
cY#2289.htm##
00493000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704025700081002000900338#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#33#29#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Estimar la 
prevalencia de reci&eacute;n nacidos pre-t&eacute;rmino entre los    reci&eacute
;n nacidos de bajo peso al nacer de pa&iacute;ses de renta media    o baja.    ^
cY#2289.htm##
00679000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704044300081002000900524#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#34#30#article#213#<br>   <b>M&Ea
cute;TODOS:</b> En consulta a bases de datos (PubMed, LILACS, Google    Scholar)
 fueron procurados estudios sobre la prevalencia de reci&eacute;n nacidos    a t
&eacute;rmino y pre-t&eacute;rmino entre aquellos de bajo peso al nacer conducid
os    posteriores a 1990 en pa&iacute;ses emergentes. Modelos de regresi&oacute;
n    fueron usados para evaluar la proporci&oacute;n de acuerdo con las prevalen
cias    de bajo peso.    ^cY#2289.htm##
00530000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704029400081002000900375#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#35#31#article#213#<br>   <b>RESU
LTADOS:</b> Con base en 47 estudios de 27 pa&iacute;ses emergentes, aproximadame
nte    la mitad de todos los reci&eacute;n nacidos con bajo peso ser&iacute;an p
rematuros,    y no uno de cada tres, como se estim&oacute; en estudios anteriore
s a la d&eacute;cada    de 1990.    ^cY#2289.htm##
00610000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704037400081002000900455#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#36#32#article#213#<br>   <b>CONC
LUSIONES:</b> La estimaci&oacute;n de n&uacute;meros sustancialmente    m&aacute
;s altos de prematuros con bajo peso tiene importantes consecuencias    en la pl
anificaci&oacute;n de salud, ya que tales reci&eacute;n nacidos demandan    cuid
ados especiales. A&uacute;n, los resultados son limitados por la falta de    est
udios poblacionales.</font></p>     ^cY#2289.htm##
00456000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704022000081002000900301#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#37#33#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:</b>    Reci&ea
cute;n Nacido de Bajo Peso. Prematuro. Pa&iacute;ses en Desarrollo. Revisi&oacut
e;n.</font></p> <hr size="1" noshade>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#38#34#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#39#35#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00338000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010200081002000900183#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#40#36#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODUCTION</b></font></p> 
    ^cY#2289.htm##
00945000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704070900081002000900790#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#41#37#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Preterm babies    account for 2
7% of nearly 4 million neonatal deaths worldwide every year.<sup>31</sup>    Tho
se preterm babies weighing less than 2500 g are more likely to die. Infant    mo
rtality rate among preterm low birthweight (LBW) babies is five times higher    
than that of preterm babies weighing 2500 g or more,<sup>48</sup> and that of   
 term LBW babies.<sup>68</sup> The latter group comprises mostly babies with    
intra-uterine growth restriction (IUGR).<sup>30</sup> Because of this much highe
r    mortality, it is important to estimate how many LBW babies are preterm as t
hey    require special health care.</font></p>     ^cY#2289.htm##
00908000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704067200081002000900753#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#42#38#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">In low- and middle-income    co
untries (LMICs), where most infant deaths occur, nearly half of all births    ta
ke place at home without skilled care,<sup>57</sup> and newborn babies are    ne
ither weighted nor have their gestational age assessed. The United Nations    Ch
ildren's Fund (UNICEF) and the World Health Organization (WHO) have produced    
country-level LBW estimates using data from health statistics and surveys.<sup>5
6</sup>    In relation to gestational age distribution, regional estimates of th
e overall    proportion of preterm births were recently published.<sup>8</sup></
font></p>     ^cY#2289.htm##
00849000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704061300081002000900694#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#43#39#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">The prevalence    and number of
 LBW babies born who have either IUGR or are preterm in developing    countries 
have been recently estimated by scientists of different institutions    as part 
of the Maternal and Child Nutrition Study Group.<sup>10</sup> They have    estim
ated that more than two-thirds of LBW babies born in the developing world    hav
e IUGR, and the remaining one third is preterm. These estimates used a predictiv
e    equation derived from hospital studies carried out between 1964 and 1990.<s
up>9,13,59,62</sup></font></p>     ^cY#2289.htm##
01372000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704113600081002000901217#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#44#40#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">There are reasons    for questi
oning whether the equation derived from pre-1990 studies is still    valid in th
e light of global changes in LBW and preterm prevalence. UNICEF reported    a re
duction in LBW prevalence - from 18% in 1990-1994 to 16% in 1996-2006 -    in al
l LMICs, and from 23% to 17%, respectively, in the least developed countries.<su
p>55,57</sup>    In addition, selected studies indicate a decreasing prevalence 
of IUGR in some    LMICs<sup>2,7,33</sup> at the same time that others report su
bstantial increases    in preterm births.<sup>7,22,27,49</sup> Data from South A
merica suggest that    the proportion of preterm LBW babies has increased among 
LBW births from 59%    (1992) to 70% (2000) in Uruguay (PAHO/WHO Latin American 
Center for Perinatology,    unpublished observations) and from 46% (1996) to 62%
 (2004) in Brazil.<sup>47</sup>    The latter trend is confirmed in Brazilian bi
rth cohort studies in the city    of Pelotas, Southern Brazil, where this propor
tion increased from 60% in 1993    to 68% in 2004.<sup>7</sup></font></p>     ^c
Y#2289.htm##
00681000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704044500081002000900526#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#45#41#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">In view of recent    changes - 
in opposite directions - in the prevalence of preterm and term LBW    babies, we
 decided to generate a new set of predictive equations using data    obtained fr
om post-1990 studies. Therefore, the aim of this study was to assess    the prev
alence of preterm birth among low birthweight babies in low and middle-income   
 countries.</font></p>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#46#42#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#47#43#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>METHODS</b></font></p>     ^
cY#2289.htm##
01217000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704098100081002000901062#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#48#44#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">We reviewed major    databases 
(PubMed, LILACS, Google Scholar) for studies on the prevalence of    term and pr
eterm LBW babies with field work carried out after 1990 in countries    classifi
ed by the World Bank as LMICs.<a name="topa"></a><a href="#backa">ª</a>    Keywo
rds used in the review were preterm births, low birth weight, and low and    mid
dle-income countries. The authors were contacted in many instances to provide   
 further information. We also searched websites of the ministries of health in  
  countries mostly in Latin America where this information is available. Althoug
h    the best was to work with national estimates, they were rarely available an
d    we had to rely on subnational samples. Further information was obtained fro
m    randomized trials, either from baseline or endline assessments (the latter 
was    included only when there was no effect of the intervention).</font></p>  
   ^cY#2289.htm##
01137000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704090100081002000900982#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#49#45#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Studies were included    only i
f birthweight was obtained through weighing, but not by surrogates such    as re
ported size of the baby at birth or chest circumference measures, and when    es
timates of gestational age were based on at least one of the following methods: 
   last menstrual period, ultrasound before 20 weeks, or physical examination (D
ubowitz,<sup>15</sup>    Ballard,<sup>5</sup> Capurro<sup>11</sup> and Finnstrom
<sup>19</sup> methods).    Only live births were included. Low birthweight was d
efined as less than 2500    g, and preterm birth was defined as less than 37 com
pleted weeks of gestation.    All studies were conducted after 1990 with the exc
eption of a long-term community    study in Gambia over 1976-2003. LMICs were di
vided by region according to UNICEF    classification.<sup>57</sup></font></p>  
   ^cY#2289.htm##
01092000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704085600081002000900937#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#50#46#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Linear regression    and Pearso
n's correlation coefficients were used to compare our set of post-1990    studie
s with previous studies.<sup>62,59</sup> The best predictive equations    for es
timating preterm LBW from overall LBW prevalence were selected using linear    r
egression, polynomial linear regression and nonlinear models; the latter two    
were used to account for non-linearity in the relationship between the outcome  
  and low birthweight prevalence. The polynomial regression tested up to the cub
ic    terms. We also assessed non-linear models based on exponential, Gompertz a
nd    logistic functions. The models were compared in terms of goodness of fit (
Akaike    Information Criterion, AIC) and biological plausibility. The non-linea
r model    chosen was:</font></p>     ^cY#2289.htm##
00596000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704036000081002000900441#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#51#47#article#213#<p align="cent
er"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Y    = b<sub>1</
sub> / (1 + exp(-</font><font size="2">&#946;</font><font face="Verdana, Arial, 
Helvetica, sans-serif" size="2"><sub>2</sub>    × (X - </font><font size="2">&#9
46;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><sub>3</su
b>))).</font></p>     ^cY#2289.htm##
00407000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017100081002000900252#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#52#48#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">The standard error    for the p
redictions was obtained through the following expression:</font></p>     ^cY#228
9.htm##
00411000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017500081002000900256#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#53#49#article#213#<p align="cent
er"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">s.e.(prediction)
=&#91;var(Y-hat)    + var(residual)&#93;<sup>&frac12;</sup> ,</font></p>     ^cY
#2289.htm##
00407000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017100081002000900252#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#54#50#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">where Y-hat is    the fitted va
lue. Confidence intervals were obtained by the expression</font></p>     ^cY#228
9.htm##
00369000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704013300081002000900214#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#55#51#article#213#<p align="cent
er"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Y-hat    ± 1.96 
× s.e.(prediction).</font></p>     ^cY#2289.htm##
00472000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704023600081002000900317#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#56#52#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">All regression    models were w
eighted by sample size and adjusted for clustering at country level    as severa
l countries had more than one data source.</font></p>     ^cY#2289.htm##
00633000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704039700081002000900478#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#57#53#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">To assess whether    the result
s of community-based and facility-based studies presented in the Results    sect
ion below were statistically different, we used a generalized linear model    wi
th region as a fixed factor and type of study as a random factor, with the    ou
tcome prevalence as the dependent variable.</font></p>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#58#54#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#59#55#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTS</b></font></p>     ^
cY#2289.htm##
01170000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704093400081002000901015#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#60#56#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Data from 47 studies    from 27
 LMICs were studied. The <a href="/img/revistas/rsp/2011nahead/2289t.jpg">Table<
/a> shows for    each study site: country and year of study, method of gestation
al age assessment,    type of study, sample size, and prevalence of LBW, preterm
 LBW and term LBW.    Whenever available, the prevalences of preterm births and 
preterm babies weighing    2500 g or more were also presented. There were 15 stu
dies from eight Sub-Saharan    African countries, 12 studies from four South Asi
an countries, 10 studies from    eight Latin American and Caribbean countries, f
our studies from three countries    in the East Asia and Pacific, four studies f
rom three countries in the Middle    East and North Africa, and two studies from
 Turkey (Central and Eastern Europe    and the Commonwealth of Independent State
s - CEE/CIS region).</font></p>     ^cY#2289.htm##
00963000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704072700081002000900808#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#61#57#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Regarding the type    of study,
 33 were facility-based (prenatal clinics or maternity hospitals),    13 were co
mmunity-based, and only one was nationwide. Among 12 South Asian study    sites,
 seven were facility-based and five community-based. In Sub-Saharan Africa,    o
nly two of 15 studies were community-based, the remaining were all facility-base
d;    and four studies in this region were primarily related to malaria. In Lati
n    America and Caribbean, one was a national study (Argentina), three covered 
all    maternity hospitals in defined geographical areas where home births are v
ery    rare, and six were based on a single hospital.</font></p>     ^cY#2289.ht
m##
00540000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704030400081002000900385#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#62#58#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">In 19 study sites,    gestation
al age was evaluated by the use of the last menstrual period (LMP)    alone, 20 
combined LMP with physical examination and/or ultrasound, and eight    used only
 physical examination methods.</font></p>     ^cY#2289.htm##
00997000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704076100081002000900842#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#63#59#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Based on this initial    compar
ison of studies, South Asian sites presented the highest prevalence of    both t
erm LBW (unweighted mean of 21.8%) and preterm LBW (10.6%) babies. Compared    t
o South Asia, Sub-Saharan African sites had fewer term LBW and preterm LBW    ba
bies with mean prevalence of 7.1% and 6.5%, respectively. Preterm LBW mean    pr
evalence in Latin America/Caribbean, Middle East/North Africa, CEE/CIS and    Ea
st Asia/Pacific studies were 6.1%, 3.0%, 4.9% and 3.9%, respectively. As mention
ed    before, most studies were facility- or community-based, and therefore not 
representative    of the country as a whole, as this type of study is rarely ava
ilable.</font></p>     ^cY#2289.htm##
00974000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704073800081002000900819#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#64#60#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Community-based    and hospital
-based sites in Latin America/Caribbean showed similar prevalence    rates of LB
W, preterm LBW and term LBW. In South Asian sites, however, the mean    prevalen
ce of LBW and term LBW was much higher in community-based (41.6% and    30.6%) t
han in hospital-based studies (25.9% and 15.6%, respectively). For Sub-Saharan  
  Africa, there were no significant differences in LBW and preterm LBW prevalenc
es    between the two community-based and 13 hospital-based studies, but term LB
W    babies were more prevalent in community-based than in hospital-based studie
s    (mean prevalence of 11.2% and 6.5%, respectively; p=0.013).</font></p>     
^cY#2289.htm##
00583000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034700081002000900428#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#65#61#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">On the other hand,    the preva
lence of LBW was slightly higher in the four studies primarily related    to mal
aria in Sub-Saharan Africa (17.1%) compared to other non-malaria studies    (12.
4%), although the difference was not statistically significant (p=0.095).</font>
</p>     ^cY#2289.htm##
01069000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704083300081002000900914#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#66#62#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">First we regressed    the preva
lence of preterm LBW on overall LBW prevalence in the 47 sites using    a compar
able approach to that of earlier publications that serve as a basis    for curre
nt global estimates - linear regression unweighted for cluster or sample    size
. <a href="#f1">Figure 1</a> shows the regression lines from the analyses    con
ducted in 1982,<sup>62</sup> 1994<sup>59</sup> and our current estimates,    sug
gesting that the contribution of preterm LBW to LBW population has increased    
over time. Likewise, the correlation coefficients between preterm LBW and overal
l    LBW prevalence increased from 0.08 (p&gt;0.05) in the 1982 analyses to 0.59
    (p&lt;0.001) in 1994, and finally to 0.72 (p&lt;0.001) in the current data.<
/font></p>     ^cY#2289.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#67#63#article#213#<p><a name="f1
"></a></p>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#68#64#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#69#65#article#213#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2289f01.jpg"></p>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#70#66#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
01025000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704078900081002000900870#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#71#67#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Several candidate    models wer
e assessed to describe the relationship between preterm LBW and LBW    prevalenc
e, i.e., polynomial linear and nonlinear models. Simple linear models    were no
t good-fitting ones (AIC=155.8). Quadratic linear regression provided    a good 
fit (AIC=119.2), but yielded an implausible model where the predicted    prevale
nce of preterm LBW decreased after LBW prevalence reached 30% (as the    model f
its a parabola). Among the nonlinear models assessed, the one based on    the lo
gistic function provided the best fit (AIC=124.6), almost as good as the    quad
ratic model, but without the decreasing prevalence in preterm LBW for high    LB
W rates. This was the chosen model.</font></p>     ^cY#2289.htm##
00956000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704072000081002000900801#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#72#68#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A nonlinear logistic    functio
n regression model, weighted by sample size and taking into account the    clust
ering of studies by country, was used to describe how preterm LBW varied    acco
rding to overall LBW prevalence for the 47 study sites. <a href="#f2">Figure    
2</a> shows that the prevalence of preterm LBW markedly increases with LBW betwe
en    5% and 20%, slows down between 20% and 30%, and reaches a plateau of aroun
d    12% when overall LBW prevalence exceeds 30%. It should be noted that all si
tes    with LBW higher than 30% were in South Asia. The predictive equation was 
a 3-parameter    logistic function as follows:</font></p>     ^cY#2289.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#73#69#article#213#<p><a name="f2
"></a></p>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#74#70#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#75#71#article#213#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2289f02.jpg"></p>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#76#72#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00379000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014300081002000900224#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#77#73#article#213#<p align="cent
er"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Preterm    LBW =
 b1/(1 + exp(-b2*(LBW - b3)))</font></p>     ^cY#2289.htm##
00349000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011300081002000900194#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#78#74#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">where the coefficients    are:<
/font></p>     ^cY#2289.htm##
00347000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011100081002000900192#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#79#75#article#213#<p align="cent
er"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">b1    = 11.96</f
ont></p>     ^cY#2289.htm##
00346000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011000081002000900191#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#80#76#article#213#<p align="cent
er"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">b2    = 0.23</fo
nt></p>     ^cY#2289.htm##
00346000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011000081002000900191#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#81#77#article#213#<p align="cent
er"><font face="Verdana, Arial, Helvetica, sans-serif" size="2">b3    = 9.72</fo
nt></p>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#82#78#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010000081002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#83#79#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSSION</b></font></p>   
  ^cY#2289.htm##
01028000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079200081002000900873#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#84#80#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Our main finding    was that pr
eterm infants account for a larger proportion of all LBW babies than    is curre
ntly assumed.<sup>59,62</sup> Previous estimates based on pre-1990 studies    su
ggest that around one third of all LBW babies born in LMICs are preterm and    t
wo thirds are term,<sup>10,13</sup> whereas our analyses suggest that preterm   
 babies account for at least half of all LBW babies. Previous models also assume
d    a linear relationship between total LBW and preterm LBW, whereas we showed 
a    curvilinear association. Whether the differences related to earlier studies
    represent real time trends - either an increase in preterm babies or a decli
ne    in term LBW babies - is unclear.</font></p>     ^cY#2289.htm##
01289000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704105300081002000901134#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#85#81#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Our finding of    high rates of
 preterm LBW births in areas where term LBW are also highly prevalent,    as in 
South Asia and Sub-Saharan Africa, is not unexpected. In LMICs, IUGR and    pret
erm delivery share several common determinants such as low body mass index,    m
alaria, smoking, pregnancy-induced hypertension, and pre-eclampsia.<sup>25,29,51
,65</sup>    Thus, countries with high prevalence of risk factors (such as low m
aternal body    mass index and malaria) with a resulting high prevalence of term
 LBW are also    more likely to present high rates of preterm LBW births. In add
ition, a number    of studies<sup>7,23,28,45,50</sup> show that preterm births a
re more frequent    among poor populations. For these reasons, the current findi
ngs are more biologically    and epidemiologically plausible than those from ear
lier studies based on data    collected pre-1990, which showed little variation 
of preterm rates across a    wide range of LBW prevalences.</font></p>     ^cY#2
289.htm##
01065000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704082900081002000900910#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#86#82#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">When we applied    our curvilin
ear regression model to the national LBW estimates provided by UNICEF,<sup>57</s
up>    we estimated that 10.3 million of the 20.3 million LBW born each year in 
LMICs    are preterm, compared to the 6.6 million in the previous estimate. Thus
, based    on our estimates, 3.7 million babies would shift from the term to the
 preterm    LBW category.<sup>10</sup> Nevertheless, given the small number of c
ommunity-based    studies available for world regions where home birth delivery 
is the rule, any    predictions of preterm LBW based on LBW must be interpreted 
with great caution.    Also, the confidence intervals presented in <a href="#f2"
>Figure 2</a> points    to the need of careful interpretation of estimates.</fon
t></p>     ^cY#2289.htm##
00661000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704042500081002000900506#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#87#83#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Our study has limitations.    T
he data was obtained mostly from hospital-based studies, as few community-based 
   studies with information on birthweight and gestational age were available.  
  However, this was also a limitation of earlier studies<sup>9,13,59,62</sup>   
 that produced the model for the currently used estimates.<sup>10</sup></font></
p>     ^cY#2289.htm##
00944000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704070800081002000900789#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#88#84#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">In South Asia,    the world reg
ion with the lowest overall hospital coverage of deliveries (36%),<sup>57</sup> 
   the five community-based studies included in the present review showed consid
erably    higher prevalences of LBW (41.6%) than those reported in the seven fac
ility-based    studies (25.9%). In Sub-Saharan Africa, the two community-based s
tudies showed    higher prevalences of term LBW (11.3%) than those in the remain
ing 13 hospital-based    studies (6.5%). One must bear mind these important vari
abilities when applying    the results of our equation to obtain national or reg
ional estimates of preterm    LBW.</font></p>     ^cY#2289.htm##
01327000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704109100081002000901172#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#89#85#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">The datasets ranged    in size 
from a few hundred to over two million births. We were unable to find    studies
 for every country, but included more than one study from the same country    wh
en available. Among the 12 South Asian study sites, for example, five were    fr
om India, four from Bangladesh, two from Pakistan and one from Nepal. In the    
15 Sub-Saharan African studies, there were four from Tanzania and three from    
Zimbabwe. However, differences in sample sizes and clustering by country were   
 accounted for in the analyses. When the weighted mean regional LBW arising from
    our analyses was compared with UNICEF regional estimates, the differences we
re    within 10% except for Middle East/North Africa where UNICEF estimate of 14
.9%    is considerably higher than the 6.7% mean value seen in the studies inclu
ded    in this review. This difference is largely due to the fact that there wer
e no    studies from Sudan and Yemen where the estimated LBW prevalence is over 
30%.<sup>57</sup></font></p>     ^cY#2289.htm##
00807000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704057100081002000900652#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#90#86#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A second limitation    of this 
study refers to inconsistent methods for assessing gestational age.    Most stud
ies relied on the date of the last menstrual period, alone or combined    with p
hysical methods and ultrasound, while in eight sites physical examination    was
 the only method of assessment. It is known that the use of LMP alone overestima
tes    both preterm and post-term rates,<sup>26</sup> but these same limitations
 also    apply to the previous estimates.<sup>10,13</sup></font></p>     ^cY#228
9.htm##
00821000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704058500081002000900666#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#91#87#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Four of the 15    Sub-Saharan A
frican studies were primarily related to malaria, a known cause    of both LBW a
nd preterm births.<sup>51</sup> This is consistent with the present    estimates
 where the mean prevalence of both preterm LBW and term LBW was 8.6%    compared
 to 5.8% and 6.6%, respectively, in the other 11 African studies. However,    in
 a region where 80% of births are in malaria-endemic areas,<sup>57,66</sup>    i
t does not make sense to exclude these studies from regional estimates.</font></
p>     ^cY#2289.htm##
01031000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079500081002000900876#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#92#88#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Low-income countries    are unl
ikely to be able to assess the overall prevalence of LBW preterm infants    in t
he near future, as most births will continue to be at home or in short-staffed  
  health facilities. Our updated equation has considerable advantages over the  
  existing ones that assume a linear relationship. Our model based on post-1990 
   studies estimates that preterm babies account for at least half of all low bi
rthweight    babies in LMICs. This finding that preterm infants account for a hi
gher proportion    of those with LBW than currently believed has implications fo
r planning health    interventions for this infant population, including skilled
 providers, incubators,    and medicines.</font></p>     ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#93#89#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00341000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010500081002000900186#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#94#90#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>ACKNOWLEDGEMENT</b></font></
p>     ^cY#2289.htm##
00409000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017300081002000900254#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#95#91#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">We thank all colleagues    who 
kindly provided additional information about their studies.</font></p>     ^cY#2
289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#96#92#article#213#<p>&nbsp;</p> 
    ^cY#2289.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010000081002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#97#93#article#213#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFERENCES</b></font></p>   
  ^cY#2289.htm##
00534000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704028400083002000900367#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#98#94#article#213#1#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Altuncu E, Kav
uncuoglu    S, G&ouml;kmirza PO, Albayrak Z, Ardu&ccedil; A. The incidence of lo
w birth    weight in 5000 infants and the etiology of fetal risk factors. <i>Mar
mara Med    J</i>. 2006;19(2):46-51.    ^cY#2289.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#99#95#article#213#</font></p>   
  ^cY#2289.htm##
00489000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704023800084002000900322#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#100#96#article#213#2
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Antonisamy B,
    Sivaram M, Richard J, Rao PSS. Trends in intra-uterine growth of single live
    births in southern India. <i>J Trop Pediatr</i>. 1996;42(6):339-41.    ^cY#2
289.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704002000082002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#101#97#article#213#</font></p>  
   ^cY#2289.htm##
00526000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704027500084002000900359#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#102#98#article#213#3
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Arafa MA, Alk
houly    A, Youssef ME. Influence of inter-pregnancy interval on preterm deliver
y. <i>Paediatr    Perinat Epidemiol</i>. 2004;18(4):248-52. DOI:10.1111/j.1365-3
016.2004.00564.x</font></p>     ^cY#2289.htm##
00573000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704032200084002000900406#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#103#99#article#213#4
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Arifeen SE,  
  Black RE, Caulfield LE, Antelman G, Baqui AH, Nahar Q, et al. Infant growth   
 patterns in the slums of Dhaka in relation to birth weight, intrauterine growth
    retardation, and prematurity. <i>Am J Clin Nutr</i>. 2000;72(4):1010-7.    ^
cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#104#100#article#213#</font></p> 
    ^cY#2289.htm##
00504000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704025200085002000900337#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#105#101#article#213#
5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Ballard JL, 
   Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard Score, exp
anded    to include extremely premature infants. <i>J Pediatr</i>. 1991;119(3):4
17-23.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#106#102#article#213#</font></p> 
    ^cY#2289.htm##
00585000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704033300085002000900418#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#107#103#article#213#
6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Bang AT, Bai
tule    SB, Reddy HM, Deshmukh MD, Bang RA. Low birth weight and preterm neonate
s: can    they be managed at home by mother and a trained village health worker?
 <i>J    Perinatol</i>. 2005;25 (Suppl 1):S72-81. DOI:10.1038/sj.jp.7211276</fon
t></p>     ^cY#2289.htm##
00651000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704039900085002000900484#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#108#104#article#213#
7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Barros FC, V
ictora    CG, Matijasevich A, Santos IS, Horta BL, Silveira MF, et al. Preterm b
irths,    low birth weight, and intrauterine growth restriction in three birth c
ohorts    in Southern Brazil: 1982, 1993 and 2004. <i>Cad Saude Publica.</i> 200
8;24 (Suppl    3):S390-8. DOI:10.1590/S0102-311X2008001500004</font></p>     ^cY
#2289.htm##
00588000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704033600085002000900421#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#109#105#article#213#
8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Beck S, Wojd
yla    D, Say L, Betran AP, Merialdi M, Requejo JH, et al. The worldwide inciden
ce    of preterm birth: a systematic review of maternal mortality and morbidity.
 <i>Bull    World Health Organ</i>. 2010;88(1):31-8. DOI:10.2471/BLT.08.062554</
font></p>     ^cY#2289.htm##
00483000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704023100085002000900316#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#110#106#article#213#
9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Beliz&aacute
;n    JM, Lechtig A, Villar J. Distribution of low-birth weight babies in develo
ping    countries. <i>Am J Obstet Gynecol</i>. 1978;132(6):704-5.    ^cY#2289.ht
m##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#111#107#article#213#</font></p> 
    ^cY#2289.htm##
00583000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704033000086002000900416#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#112#108#article#213#
10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Black RE, 
Allen    LH, Bhutta ZA, Caulfield LE, de Onis M, Ezzati M, et al. Maternal and c
hild    undernutrition: global and regional exposures and health consequences. <
i>Lancet</i>.    2008;371(9608):243-60. DOI:10.1016/S0140-6736(07)61690-0</font>
</p>     ^cY#2289.htm##
00500000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704024700086002000900333#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#113#109#article#213#
11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Capurro H,
    Konichezky S, Fonseca D, Caldeyro-Barcia R. A simplified method for diagnosi
s    of gestational age in the newborn infant. <i>J Pediatr</i>. 1978;93(1):120-
2.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#114#110#article#213#</font></p> 
    ^cY#2289.htm##
00620000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704036700086002000900453#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#115#111#article#213#
12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Christian 
P,    Khatry SK, Katz J, Pradhan EK, LeClerq SC, Shrestha SR, et al. Effects of 
alternative    maternal micronutrient supplements on low birth weight in rural N
epal: double    blind randomised community trial. <i>BMJ</i>. 2003;326(7389):571
. DOI:10.1136/bmj.326.7389.571</font></p>     ^cY#2289.htm##
00494000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704024100086002000900327#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#116#112#article#213#
13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. de Onis M,
    Blossner M, Villar J. Levels and patterns of intrauterine growth retardation
    in developing countries. <i>Eur J ClinNutr</i>. 1998;52 (Suppl 1):S5-15.    
^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#117#113#article#213#</font></p> 
    ^cY#2289.htm##
00495000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704024200086002000900328#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#118#114#article#213#
14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Donzelli G
,    Rapisardi G, Pratesi S, Tomasini B, Zani S, Balzi D, et al. Low birth weigh
t    in a Kenyan rural hospital. <i>Prenat Neonatal Med</i>. 2000;5(4):243-7.   
 ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#119#115#article#213#</font></p> 
    ^cY#2289.htm##
00467000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704021400086002000900300#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#120#116#article#213#
15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Dubowitz L
M,    Dubowitz V, Goldberg C. Clinical assessment of gestational age in the newb
orn    infant. <i>J Pediatr.</i> 1970;77(1):1-10.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#121#117#article#213#</font></p> 
    ^cY#2289.htm##
00628000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704037500086002000900461#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#122#118#article#213#
16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Falade CO,
    Yusuf BO, Fadero FF, Mokuolu OA, Hamer DH, Salako LA. Intermittent preventiv
e    treatment with sulphadoxine-pyrimethamine is effective in preventing matern
al    and placental malaria in Ibadan, south-western Nigeria. <i>Malar J</i>. 20
07;6:88.    DOI:10.1186/1475-2875-6-88</font></p>     ^cY#2289.htm##
00561000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704030800086002000900394#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#123#119#article#213#
17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Fawzi MC, 
Msamanga    GI, Urassa W, Hertzmark E, Petraro P, Willet WC, et al. Vitamins and
 perinatal    outcomes among HIV-negative women in Tanzania. <i>N Engl J Med</i>
. 2007;356(14):1423-31.    DOI:10.1056/NEJMoa064868</font></p>     ^cY#2289.htm#
#
00606000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704035300086002000900439#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#124#120#article#213#
18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Feresu SA,
    Harlow SD, Welch K, Gillespie BW. Incidence of and socio-demographic risk fa
ctors    for stillbirth, preterm birth and low birthweight among Zimbabwean wome
n. <i>Paediatr    Perinat Epidemiol. 2</i>004;18(2):154-63. DOI:10.1111/j.1365-3
016.2003.00539.x</font></p>     ^cY#2289.htm##
00530000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704027700086002000900363#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#125#121#article#213#
19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Finnstrom 
O.    Studies on maturity in newborn infants. IX. Further observations on the us
e    of external characteristics in estimating gestational age. <i>Acta Paediatr
    Scand</i>. 1977;66(5):601-4.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#126#122#article#213#</font></p> 
    ^cY#2289.htm##
00506000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704025300086002000900339#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#127#123#article#213#
20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Fourn L, D
ucic    S, S&eacute;guin L. Facteurs associ&eacute;s &agrave; la naissance des e
nfants    de faible poids: une analyse multivari&eacute;e. <i>Sante</i>. 1999;9(
1):7-11.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#128#124#article#213#</font></p> 
    ^cY#2289.htm##
00608000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704035500086002000900441#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#129#125#article#213#
21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Friis H, G
omo    E, Nyazema N, Ndhlovu P, Krarup H, Kaestel P, et al. Effect of multimicro
nutrient    supplementation on gestational length and birth size: a randomized, 
placebo-controlled,    double-blind effectiveness trial in Zimbabwe. <i>Am J Cli
n Nutr</i>. 2004;80(1):178-84.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#130#126#article#213#</font></p> 
    ^cY#2289.htm##
00495000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704024200086002000900328#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#131#127#article#213#
22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Grandi C, 
Dipierri    JE. Tendencia secular del peso de nacimiento en Argentina (1992-2002
): un estudio    poblacional. <i>Arch Argent Pediatr</i>. 2008;106(3):219-25.   
 ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#132#128#article#213#</font></p> 
    ^cY#2289.htm##
00593000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704034000086002000900426#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#133#129#article#213#
23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Gray R, Bo
nellie    SR, Chalmers J, Greer I, Jarvis S, Williams C. Social inequalities in 
preterm    birth in Scotland 1980-2003: findings from an area-based measure of d
eprivation.    <i>BJOG</i>. 2008;115(1):82-90. DOI:10.1111/j.1471-0528.2007.0158
2.x</font></p>     ^cY#2289.htm##
00570000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704031700086002000900403#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#134#130#article#213#
24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Habib NA, 
Daltveit    AK, Bergsjo P, Shao J, Oneko O, Lie RT. Maternal HIV status and preg
nancy outcomes    in northeastern Tanzania: a registry-based study. <i>BJOG</i>.
 2008;115(5):616-24.    DOI:10.1111/j.1471-0528.2008.01672.x</font></p>     ^cY#
2289.htm##
00619000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704036600086002000900452#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#135#131#article#213#
25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Hendler I,
    Goldenberg RL, Mercer BM, Iams JD, Meis PJ, Moawad AH, et al. The Preterm Pr
ediction    Study: association between maternal body mass index and spontaneous 
and indicated    preterm birth. <i>Am J Obstet Gynecol</i>. 2005;192(3):882-6. D
OI:10.1016/j.ajog.2004.09.021</font></p>     ^cY#2289.htm##
00573000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704032000086002000900406#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#136#132#article#213#
26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Joseph KS,
    Huang L, Liu S, Ananth CV, Allen AC, Sauve R, et al. Reconciling the high ra
tes    of preterm and postterm birth in the United States. <i>Obstet Gynecol</i>
. 2007;109(4):813-22.    DOI:10.1097/01.AOG.0000255661.13792.c1</font></p>     ^
cY#2289.htm##
00515000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704026200086002000900348#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#137#133#article#213#
27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Kozlovskay
a    A, Bojko E, Odland JO, Grjibovski AM. Secular trends in pregnancy outcomes 
in    1980-1999 in the Komi Republic, Russia. <i>Int J Circumpolar Health</i>. 2
007;66(5):437-48.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#138#134#article#213#</font></p> 
    ^cY#2289.htm##
00598000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704034500086002000900431#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#139#135#article#213#
28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Kramer MS,
    Goulet L, Lydon J, S&eacute;guin L, McNamara H, Dassa C, et al. Socio-econom
ic    disparities in preterm birth: causal pathways and mechanisms. <i>Paediatr 
Perinat    Epidemiol</i>. 2001;15 (Suppl 2):104-23. DOI:10.1046/j.1365-3016.2001
.00012.x</font></p>     ^cY#2289.htm##
00524000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704027100086002000900357#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#140#136#article#213#
29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Kramer MS,
    Victora CG. Low birth weight and perinatal mortality. In: Semba RD, Bloem MW
,    editors. <i>Nutrition and health in developing countries</i>. Totowa: Human
a    Press; 2001. p.57-69.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#141#137#article#213#</font></p> 
    ^cY#2289.htm##
00450000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704019700086002000900283#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#142#138#article#213#
30#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Kramer MS.
    The epidemiology of adverse pregnancy outcomes: an overview. <i>J Nutr.</i> 
   2003;133(5 Suppl 2):1592S-6S.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#143#139#article#213#</font></p> 
    ^cY#2289.htm##
00492000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704023900086002000900325#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#144#140#article#213#
31#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Lawn JE, C
ousens    S, Zupan J. 4 million neonatal deaths: when? Where? Why? <i>Lancet.</i
> 2005;365(9462):891-900.    DOI:10.1016/S0140-6736(05)71048-5</font></p>     ^c
Y#2289.htm##
00567000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704031400086002000900400#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#145#141#article#213#
32#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Letaief M,
    Soltani MS, Salem KB, Bchir A. &Eacute;pid&eacute;miologie de l'insuffisance
    pond&eacute;rale &agrave; la naissance dans le Sahel tunisien. <i>Sante Publ
ique</i>.    2001;13(4):359-66. DOI:10.3917/spub.014.0359</font></p>     ^cY#228
9.htm##
00538000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028500086002000900371#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#146#142#article#213#
33#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Li CY, Sun
g    FC. Socio-economic inequalities in low-birth weight, full-term babies from 
singleton    pregnancies in Taiwan. <i>Public Health</i>. 2008;122(3):243-50. DO
I:10.1016/j.puhe.2007.05.011</font></p>     ^cY#2289.htm##
00481000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704022800086002000900314#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#147#143#article#213#
34#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Lin L, Liu
    Y, Zhang X, Mi J, Cao L. Sampling survey on low-birth weight in China in 199
8.    <i>Zhonghua Yu Fang Yi Xue Za Zhi</i>. 2002;36(3):149-53.    ^cY#2289.htm#
#
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#148#144#article#213#</font></p> 
    ^cY#2289.htm##
00596000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704034300086002000900429#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#149#145#article#213#
35#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Luxemburge
r    C, McGready R, Kham A, Morison L, Cho T, Chongsuphajaisiddhi T, et al. Effe
cts    of malaria during pregnancy on infant mortality in an area of low malaria
 transmission.    <i>Am J Epidemiol</i>. 2001;154(5):459-65. DOI:10.1093/aje/154
.5.459</font></p>     ^cY#2289.htm##
00608000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704035500086002000900441#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#150#146#article#213#
36#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Matijasevi
ch    A, Barros FC, D&iacute;az-Rossello JL, Bergel E, Forteza AC. Factores de r
iesgo    para muy bajo peso al nacer y peso al nacer entre 1.500-2.499g: un est&
uacute;dio    del sector p&uacute;blico de Montevideo, Uruguay. <i>Arch Pediatr 
Urug</i>.    2004;75(1):26-35.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#151#147#article#213#</font></p> 
    ^cY#2289.htm##
00549000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029600086002000900382#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#152#148#article#213#
37#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Menendez C
,    Ordi J, Ismail MR, Ventura PJ, Aponte JJ, Kahigwa E, et al. The impact of p
lacental    malaria on gestational age and birth weight. <i>J Infect Dis</i>. 20
00;181(5):1740-5.    DOI:10.1086/315449</font></p>     ^cY#2289.htm##
00570000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704031700086002000900403#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#153#149#article#213#
38#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Mockenhaup
t    FP, Bedu-Addo G, von Gaertner C, Boy&eacute; R, Fricke K, Hannibal I, et al
.    Detection and clinical manifestation of placental malaria in southern Ghana
.    <i>Malar J</i>. 2006;5:119. DOI:10.1186/1475-2875-5-119</font></p>     ^cY#
2289.htm##
00632000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704037900086002000900465#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#154#150#article#213#
39#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Mockenhaup
t    FP, Hamann L, von Gaertner C, Bedu-Addo G, von Kleinsorgen C, Schumann RR, 
et    al. Common polymorphisms of toll-like receptors 4 and 9 are associated wit
h    the clinical manifestation of malaria during pregnancy. <i>J Infect Dis</i>
.    2006;194(2):184-8. DOI:10.1086/505152</font></p>     ^cY#2289.htm##
00558000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704030500086002000900391#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#155#151#article#213#
40#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Mwanyumba 
F,    Inion I, Gaillard P, Mandaliya K, Praet M, Temmerman M. Placental inflamma
tion    and perinatal outcome. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2003;108
(2):164-70.    DOI:10.1016/S0301-2115(02)00438-4</font></p>     ^cY#2289.htm##
00450000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704019700086002000900283#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#156#152#article#213#
41#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">41. Najmi RS. 
Distribution    of birthweights of hospital born Pakistani infants. <i>J Pak Med
 Assoc</i>.    2000;50(4):121-4.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#157#153#article#213#</font></p> 
    ^cY#2289.htm##
00658000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704040500086002000900491#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#158#154#article#213#
42#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">42. Okoko BJ, 
Wesumperuma    LH, Ota MO, Pinder M, Banya W, Gomez SF, et al. The influence of 
placental malaria    infection and maternal hypergammaglobulinemia on transplace
ntal transfer of    antibodies and IgG subclasses in a rural West African popula
tion. <i>J Infect    Dis</i>. 2001;184(5):627-32. DOI:10.1086/322808</font></p> 
    ^cY#2289.htm##
00587000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704033400086002000900420#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#159#155#article#213#
43#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">43. Osendarp S
J,    van Raaij JM, Arifeen SE, Wahed M, Baqui AH, Fuchs GJ. A randomized, place
bo-controlled    trial of the effect of zinc supplementation during pregnancy on
 pregnancy outcome    in Bangladeshi urban poor. <i>Am J Clin Nutr</i>. 2000;71(
1):114-9.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#160#156#article#213#</font></p> 
    ^cY#2289.htm##
00673000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704042000086002000900506#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#161#157#article#213#
44#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">44. Osorno Cov
arrubias    L, Acosta Mass A, D&aacute;vila Velasquez J, Rodriguez Chapuz J, Esc
amilla Sosa    M, Echeverria Eguiluz M. Mortalidad neonatal em un hospital perin
atal regional    de M&eacute;rida, Yucat&aacute;n, de 1995 a 2004. I. An&aacute;
lisis de las    tasas crudas y espec&iacute;ficas. <i>Ginecol Obstet Mex</i>. 20
06;74(8):401-9.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#162#158#article#213#</font></p> 
    ^cY#2289.htm##
00508000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704025500086002000900341#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#163#159#article#213#
45#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">45. Peacock JL
,    Bland JM, Anderson HR. Preterm delivery: effects of socioeconomic factors, 
psychological    stress, smoking, alcohol, and caffeine. <i>BMJ</i>. 1995;311(70
04):531-5.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#164#160#article#213#</font></p> 
    ^cY#2289.htm##
00525000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704027200086002000900358#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#165#161#article#213#
46#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">46. Rayco-Solo
n    P, Fulford AJ, Prentice AM. Differential effects of seasonality on preterm 
birth    and intrauterine growth restriction in rural Africans. <i>Am J Clin Nut
r</i>.    2005;81(1):134-9.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#166#162#article#213#</font></p> 
    ^cY#2289.htm##
00576000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704032300086002000900409#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#167#163#article#213#
47#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">47. Rede Inter
agencial    de Informa&ccedil;ao para a Sa&uacute;de. Indicadores b&aacute;sicos
 para a    sa&uacute;de no Brasil: conceitos e aplica&ccedil;&otilde;es. 2. ed.B
rasilia,    DF: Organiza&ccedil;&atilde;o Pan-Americana da Sa&uacute;de; 2008.  
  ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#168#164#article#213#</font></p> 
    ^cY#2289.htm##
00615000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704036200086002000900448#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#169#165#article#213#
48#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">48. Santos IS,
    Menezes AMB, Mota DM, Albernaz EP, Barros AJD, Matijasevich A, et al. Infant
    mortality in three population-based cohorts in Southern Brazil: trends and d
ifferentials.    <i>Cad Saude Publica</i>. 2008;24 (Suppl 3):S451-60. DOI:10.159
0/S0102-311X2008001500011</font></p>     ^cY#2289.htm##
00558000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704030500086002000900391#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#170#166#article#213#
49#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">49. Silva AA, 
Barbieri    MA, Gomes UA, Bettiol H. Trends in low birth weight: a comparison of
 two birth    cohorts separated by a 15-year interval in Ribeir&atilde;o Preto, 
Brazil. <i>Bull    World Health Organ</i>. 1998;76(1):73-84.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#171#167#article#213#</font></p> 
    ^cY#2289.htm##
00545000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029200086002000900378#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#172#168#article#213#
50#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">50. Smith LK, 
Draper    ES, Manktelow BN, Dorling JS, Field DJ. Socioeconomic inequalities in 
very preterm    birth rates. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2007;92(1)
:F11-4. DOI:10.1136/adc.2005.090308</font></p>     ^cY#2289.htm##
00492000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704023900086002000900325#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#173#169#article#213#
51#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">51. Steketee R
W    Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in mal
aria-endemic    areas. <i>Am J Trop Med Hyg</i>. 2001;64(1/2 Suppl):28-35.    ^c
Y#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#174#170#article#213#</font></p> 
    ^cY#2289.htm##
00536000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028300086002000900369#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#175#171#article#213#
52#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">52. Ticconi C,
    Arpino C, Longo B, Mapfumo M. Prevalence and risk factors for low birth weig
ht    in Northern Zimbabwe. <i>Int J Gynaecol Obstet</i>. 2005;88(2):146-7. DOI:
10.1016/j.ijgo.2004.11.018</font></p>     ^cY#2289.htm##
00549000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029600086002000900382#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#176#172#article#213#
53#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">53. Toygar HU,
    Seydaoglu G, Kurklu S, Guzeldemir E, Arpak N. Periodontal health and adverse
    pregnancy outcome in 3,576 Turkish women. <i>J Periodontol</i>. 2007;78(11):
2081-94.    DOI:10.1902/jop.2007.070092</font></p>     ^cY#2289.htm##
00490000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704023700086002000900323#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#177#173#article#213#
54#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">54. Tripathy R
,    Parida SN, Tripathy SN, Devi PS, Das RN, Swain A. Physical status of newbor
ns    and neonatal outcome. <i>Indian J Pediatr</i>. 2002;69(12):1041-5.    ^cY#
2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#178#174#article#213#</font></p> 
    ^cY#2289.htm##
00420000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704016700086002000900253#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#179#175#article#213#
55#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">55. UNICEF. Th
e    state of the world&acute;s children 1998: focus on nutrition. New York; 199
8.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#180#176#article#213#</font></p> 
    ^cY#2289.htm##
00412000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704015900086002000900245#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#181#177#article#213#
56#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">56. UNICEF. Lo
w    birth weight: country, regional and global estimates. New York; 2004.    ^c
Y#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#182#178#article#213#</font></p> 
    ^cY#2289.htm##
00406000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704015300086002000900239#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#183#179#article#213#
57#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">57. UNICEF. St
ate    of the world's children 2008: child survival. New York; 2008.    ^cY#2289
.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#184#180#article#213#</font></p> 
    ^cY#2289.htm##
00671000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704041800086002000900504#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#185#181#article#213#
58#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">58. V&eacute;l
ez-G&oacute;mez    MP, Barros FC, Echavarr&iacute;a-Restrepo LG, Hormaza-Angel M
P. Prevalencia    de bajo peso al nacer y factores maternos asociados: Unidad de
 Atenci&oacute;n    y Protecci&oacute;n Materno Infantil de la Clinica Universit
aria Bolivariana,    Medellin, Colombia. <i>Rev Colomb Obstet Ginecol</i>. 2006;
57(4):264-70.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#186#182#article#213#</font></p> 
    ^cY#2289.htm##
00534000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028100086002000900367#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#187#183#article#213#
59#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">59. Villar J, 
Belizan    JM. The relative contribution of prematurity and fetal growth retarda
tion to    low birth weight in developing and developed societies. <i>Am J Obste
t Gynecol</i>.    1982;143(7):793-8.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#188#184#article#213#</font></p> 
    ^cY#2289.htm##
00468000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704021500086002000900301#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#189#185#article#213#
60#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">60. Villar J, 
Ezcurra    EG, de La Fuente VG, Canpodonico I. Preterm delivery syndrome: the un
met need.    <i>Res Clin Forums.</i> 1994;16:9-33.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#190#186#article#213#</font></p> 
    ^cY#2289.htm##
00624000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704037100086002000900457#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#191#187#article#213#
61#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">61. Villar J, 
Valladares    E, Wojdyla D, Zavaleta N, Carroli G, Velazco A, et al. Caesarean d
elivery rates    and pregnancy outcomes: the 2005 WHO global survey on maternal 
and perinatal    health in Latin America. <i>Lancet</i>. 2006;367(9525):1819-29.
 DOI:10.1016/S0140-6736(06)68704-7</font></p>     ^cY#2289.htm##
00599000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704034600086002000900432#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#192#188#article#213#
62#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">62. Villar J, 
Abdel-Aleem    H, Merialdi M, Mathai M, Ali MM, Zavaleta N, et al. World Health 
Organization    randomized trial of calcium supplementation among low calcium in
take pregnant    women. <i>Am J Obstet Gynecol</i>. 2006;194(3):639-49. DOI:10.1
016/ajog.2006.01.068.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#193#189#article#213#</font></p> 
    ^cY#2289.htm##
00481000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704022800086002000900314#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#194#190#article#213#
63#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">63. Wannous S,
    Arous S. Incidence and determinants of low birth weight in Syrian government
    hospitals. <i>East Mediterr Health J</i>. 2001;7(6):966-74.    ^cY#2289.htm#
#
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#195#191#article#213#</font></p> 
    ^cY#2289.htm##
00615000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704036200086002000900448#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#196#192#article#213#
64#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">64. Watson-Jon
es    D, Weiss HA, Changalucha JM, Todd J, Gumodoka B, Bulmer J, et al. Adverse 
birth    outcomes in United Republic of Tanzania: impact and prevention of mater
nal risk    factors. <i>Bull World Health Organ</i>. 2007;85(1):9-18. DOI:10.159
0/S0042-96862007000100007</font></p>     ^cY#2289.htm##
00543000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029000086002000900376#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#197#193#article#213#
65#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">65. Wen SW, Go
ldenberg    RL, Cutter GR, Hoffman HJ, Cliver SP. Intrauterine growth retardatio
n and preterm    delivery: prenatal risk factors in an indigent population. <i>A
m J Obstet Gynecol</i>.    1990;162(1):213-8.    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#198#194#article#213#</font></p> 
    ^cY#2289.htm##
00528000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704027500086002000900361#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#199#195#article#213#
66#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">66. World Heal
th    Organization. A strategic framework for malaria prevention and control dur
ing    pregnancy in the African Region. Brazzaville: WHO Regional Office for Afr
ica;    2004. (AFR/MAL/04/01).    ^cY#2289.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#200#196#article#213#</font></p> 
    ^cY#2289.htm##
00576000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704032300086002000900409#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#201#197#article#213#
67#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">67. Yangzom Y,
    Qian L, Shan M, La Y, Meiduo D, Hu X, et al. Outcome of hospital deliveries 
   of women living at high altitude: a study from Lhasa in Tibet. <i>Acta Paedia
tr</i>.    2008;97(3):317-21. DOI:10.1111/j.1651-2227.2008.00628.x</font></p>   
  ^cY#2289.htm##
00533000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028000086002000900366#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#202#198#article#213#
68#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">68. Yasmin S, 
Osrin    D, Paul E, Costello A. Neonatal mortality of low-birth-weight infants i
n Bangladesh.    <i>Bull World Health Organ</i>. 2001;79(7):608-14. DOI:10.1590/
S0042-96862001000700005</font></p>     ^cY#2289.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#203#199#article#213#<p>&nbsp;</p
>     ^cY#2289.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#204#200#article#213#<p>&nbsp;</p
>     ^cY#2289.htm##
00429000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704019100083002000900274#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#205#201#article#213#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#
top"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    <b>Corr
espondence:    ^cY#2289.htm##
00276000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003800083002000900121#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#206#202#article#213#<br>   </b> 
Fernando C. Barros    ^cY#2289.htm##
00292000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005400083002000900137#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#207#203#article#213#<br>   Unive
rsidade Cat&oacute;lica de Pelotas    ^cY#2289.htm##
00288000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005000083002000900133#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#208#204#article#213#<br>   R. Ma
rechal Deodoro, 1160 - 3º piso    ^cY#2289.htm##
00259000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002100083002000900104#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#209#205#article#213#<br>   Centr
o    ^cY#2289.htm##
00282000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004400083002000900127#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#210#206#article#213#<br>   96020
-220 Pelotas, RS, Brasil    ^cY#2289.htm##
00339000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704010100083002000900184#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#211#207#article#213#<br>   E-mai
l: <a href="mailto:fcbarros.epi@gmail.com">fcbarros.epi@gmail.com</a></font></p>
     ^cY#2289.htm##
00328000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704009000083002000900173#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#212#208#article#213#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Received: 5/23/2010    ^cY#22
89.htm##
00285000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004700083002000900130#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#213#209#article#213#<br>   Appro
ved: 12/16/2010</font></p>     ^cY#2289.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#214#210#article#213#<p>&nbsp;</p
>     ^cY#2289.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#215#211#article#213#<p>&nbsp;</p
>     ^cY#2289.htm##
00358000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704012000083002000900203#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#216#212#article#213#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">The authors declare    no con
lficts of interests.    ^cY#2289.htm##
00535000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704029700083002000900380#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2289.htm#S#p#217#213#article#213#<br>   <a na
me="backa"></a><a href="#topa">a</a> World Bank. How we classify countries.    &
#91;cited 2008 Nov 15&#93;. Available from: <a href="http://data.worldbank.org/a
bout/country-classifications" target="_blank">http://data.worldbank.org/about/co
untry-classifications</a></font></p>     ^cY#2289.htm##
00638000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100021000990100
01900120010001800139010001500157012009300172030001400265710000200279065000900281
064000500290031000300295032000200298014000600300865000900306002000900315#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#218#1#article#68#1#^rND^
sAltuncu^nE#^rND^sKavuncuoglu^nS#^rND^sGökmirza^nPO#^rND^sAlbayrak^nZ#^rND^sArdu
ç^nA#The incidence of low birth weight in 5000 infants and the etiology of fetal
 risk factors^len#Marmara Med J#2#20060000#2006#19#2#46-51#20110000#2289.htm##
00624000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100020000820100017001020100
01700119010001500136012007500151030001500226065000900241064000500250031000300255
032000200258014000700260865000900267002000900276035001000285801001500295#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#219#2#article#68#2#^rND^
sAntonisamy^nB#^rND^sSivaram^nM#^rND^sRichard^nJ#^rND^sRao^nPSS#Trends in intra-
uterine growth of single live births in southern India^len#J Trop Pediatr#199600
00#1996#42#6#339-41#20110000#2289.htm#0142-6338#J Trop Pediatr##
00651000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100016000820100018000980100
01800116012006200134030002700196065000900223064000500232031000300237032000200240
014000700242237003300249865000900282002000900291035001000300801002700310#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#220#3#article#68#3#^rND^
sArafa^nMA#^rND^sAlkhouly^nA#^rND^sYoussef^nME#Influence of inter-pregnancy inte
rval on preterm delivery^len#Paediatr Perinat Epidemiol#20040000#2004#18#4#248-5
2#10.1111/j.1365-3016.2004.00564.x#20110000#2289.htm#0269-5022#Paediatr Perinat 
Epidemiol##
00752000000000349000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100016001000100
02000116010001800136010001600154010001500170810000600185012012700191030001500318
06500090033306400050034203100030034703200020035001400070035286500090035900200090
0368035001000377801001500387#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
289.htm#S#c#221#4#article#68#4#^rND^sArifeen^nSE#^rND^sBlack^nRE#^rND^sCaulfield
^nLE#^rND^sAntelman^nG#^rND^sBaqui^nAH#^rND^sNahar^nQ#et al#Infant growth patter
ns in the slums of Dhaka in relation to birth weight, intrauterine growth retard
ation, and prematurity^len#Am J Clin Nutr#20000000#2000#72#4#1010-7#20110000#228
9.htm#0002-9165#Am J Clin Nutr##
00669000000000337000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100017001000100
01500117010001400132010002500146010001400171012007100185030001000256065000900266
06400050027503100040028003200020028401400070028686500090029300200090030203500100
0311801001000321#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
222#5#article#68#5#^rND^sBallard^nJL#^rND^sKhoury^nJC#^rND^sWedig^nK#^rND^sWang^
nL#^rND^sEilers-Walsman^nBL#^rND^sLipp^nR#New Ballard Score, expanded to include
 extremely premature infants^len#J Pediatr#19910000#1991#119#3#417-23#20110000#2
289.htm#0022-3476#J Pediatr##
00723000000000337000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100015000820100018000970100
01600115010001900131010001500150012011800165030001200283065000900295064000500304
03100030030903200040031201400070031623700220032386500090034500200090035403500100
0363801001200373#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
223#6#article#68#6#^rND^sBang^nAT#^rND^sBaitule^nSB#^rND^sReddy^nHM#^rND^sDeshmu
kh^nMD#^rND^sBang^nRA#Low birth weight and preterm neonates: can they be managed
 at home by mother and a trained village health worker?^len#J Perinatol#20050000
#2005#25#^s1#S72-81#10.1038/sj.jp.7211276#20110000#2289.htm#0743-8346#J Perinato
l##
00783000000000349000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100018000990100
02200117010001700139010001600156010001900172810000600191012013700197030001900334
71000020035306500090035506400050036403100030036903200040037201400070037623700320
0383865000900415002000900424#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
289.htm#S#c#224#7#article#68#7#^rND^sBarros^nFC#^rND^sVictora^nCG#^rND^sMatijase
vich^nA#^rND^sSantos^nIS#^rND^sHorta^nBL#^rND^sSilveira^nMF#et al#Preterm births
, low birth weight, and intrauterine growth restriction in three birth cohorts i
n Southern Brazil: 1982, 1993 and 2004^len#Cad Saude Publica.#2#20080000#2008#24
#^s3#S390-8#10.1590/S0102-311X2008001500004#20110000#2289.htm##
00771000000000361000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100014000820100017000960100
01300113010001700126010001800143010001800161810000600179012010200185030002400287
06500090031106400050032003100030032503200020032801400050033023700220033586500090
0357002000900366035001000375801002400385#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#225#8#article#68#8#^rND^sBeck^nS#^rND^sWojdyla^nD#^rND^s
Say^nL#^rND^sBetran^nAP#^rND^sMerialdi^nM#^rND^sRequejo^nJH#et al#The worldwide 
incidence of preterm birth: a systematic review of maternal mortality and morbid
ity^len#Bull World Health Organ#20100000#2010#88#1#31-8#10.2471/BLT.08.062554#20
110000#2289.htm#0042-9686#Bull World Health Organ##
00597000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100017001000100
01600117012006800133030002000201065000900221064000500230031000400235032000200239
014000600241865000900247002000900256035001000265801002000275#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2289.htm#S#c#226#9#article#68#9#^rND^sBelizán^nJM
#^rND^sLechtig^nA#^rND^sVillar^nJ#Distribution of low-birth weight babies in dev
eloping countries^len#Am J Obstet Gynecol#19780000#1978#132#6#704-5#20110000#228
9.htm#0002-9378#Am J Obstet Gynecol##
00749000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100016001000100
01700116010002000133010001700153010001600170810000600186012009300192030000700285
06500090029206400050030103100040030603200050031001400070031523700300032286500090
0352002000900361035001000370801000700380#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#227#10#article#68#10#^rND^sBlack^nRE#^rND^sAllen^nLH#^rN
D^sBhutta^nZA#^rND^sCaulfield^nLE#^rND^sde Onis^nM#^rND^sEzzati^nM#et al#Materna
l and child undernutrition: global and regional exposures and health consequence
s^len#Lancet#20080000#2008#371#9608#243-60#10.1016/S0140-6736(07)61690-0#2011000
0#2289.htm#0099-5355#Lancet##
00629000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100020001010100
01700121010002500138012007900163030001000242065000900252064000500261031000300266
032000200269014000600271865000900277002000900286035001000295801001000305#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#228#11#article#68#11#^rN
D^sCapurro^nH#^rND^sKonichezky^nS#^rND^sFonseca^nD#^rND^sCaldeyro-Barcia^nR#A si
mplified method for diagnosis of gestational age in the newborn infant^len#J Ped
iatr#19780000#1978#93#1#120-2#20110000#2289.htm#0022-3476#J Pediatr##
00783000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100017001030100
01400120010001800134010001800152010001900170810000600189012013800195030000400333
06500090033706400050034603100040035103200050035501400040036023700250036486500090
0389002000900398035001000407801000400417#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#229#12#article#68#12#^rND^sChristian^nP#^rND^sKhatry^nSK
#^rND^sKatz^nJ#^rND^sPradhan^nEK#^rND^sLeClerq^nSC#^rND^sShrestha^nSR#et al#Effe
cts of alternative maternal micronutrient supplements on low birth weight in rur
al Nepal: double blind randomised community trial^len#BMJ#20030000#2003#326#7389
#571#10.1136/bmj.326.7389.571#20110000#2289.htm#0959-8138#BMJ##
00570000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100018001010100
01600119012008300135030001500218710000200233065000900235064000500244031000300249
032000400252014000600256865000900262002000900271#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2289.htm#S#c#230#13#article#68#13#^rND^sde Onis^nM#^rND^sBlos
sner^nM#^rND^sVillar^nJ#Levels and patterns of intrauterine growth retardation i
n developing countries^len#Eur J ClinNutr#2#19980000#1998#52#^s1#S5-15#20110000#
2289.htm##
00641000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100019001020100
01700121010001800138010001400156010001500170810000600185012004800191030002000239
71000020025906500090026106400050027003100020027503200020027701400060027986500090
0285002000900294#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
231#14#article#68#14#^rND^sDonzelli^nG#^rND^sRapisardi^nG#^rND^sPratesi^nS#^rND^
sTomasini^nB#^rND^sZani^nS#^rND^sBalzi^nD#et al#Low birth weight in a Kenyan rur
al hospital^len#Prenat Neonatal Med#2#20000000#2000#5#4#243-7#20110000#2289.htm#
#
00549000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100018001030100
01800121012006500139030001100204710000200215065000900217064000500226031000300231
032000200234014000500236865000900241002000900250#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2289.htm#S#c#232#15#article#68#15#^rND^sDubowitz^nLM#^rND^sDu
bowitz^nV#^rND^sGoldberg^nC#Clinical assessment of gestational age in the newbor
n infant^len#J Pediatr.#2#19700000#1970#77#1#1-10#20110000#2289.htm##
00742000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100016001010100
01700117010001800134010001600152010001700168012016100185030000800346710000200354
06500090035606400050036503100020037001400030037223700230037586500090039800200090
0407#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#233#16#artic
le#68#16#^rND^sFalade^nCO#^rND^sYusuf^nBO#^rND^sFadero^nFF#^rND^sMokuolu^nOA#^rN
D^sHamer^nDH#^rND^sSalako^nLA#Intermittent preventive treatment with sulphadoxin
e-pyrimethamine is effective in preventing maternal and placental malaria in Iba
dan, south-western Nigeria^len#Malar J#2#20070000#2007#6#88#10.1186/1475-2875-6-
88#20110000#2289.htm##
00733000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100019001000100
01600119010001900135010001700154010001700171810000600188012007300194030001300267
06500090028006400050028903100040029403200030029801400080030123700210030986500090
0330002000900339035001000348801001300358#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#234#17#article#68#17#^rND^sFawzi^nMC#^rND^sMsamanga^nGI#
^rND^sUrassa^nW#^rND^sHertzmark^nE#^rND^sPetraro^nP#^rND^sWillet^nWC#et al#Vitam
ins and perinatal outcomes among HIV-negative women in Tanzania^len#N Engl J Med
#20070000#2007#356#14#1423-31#10.1056/NEJMoa064868#20110000#2289.htm#0028-4793#N
 Engl J Med##
00661000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100017001010100
01500118010002000133012012500153030002800278710000200306031000300308032000200311
014000700313237003300320865000900353002000900362#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2289.htm#S#c#235#18#article#68#18#^rND^sFeresu^nSA#^rND^sHarl
ow^nSD#^rND^sWelch^nK#^rND^sGillespie^nBW#Incidence of and socio-demographic ris
k factors for stillbirth, preterm birth and low birthweight among Zimbabwean wom
en^len#Paediatr Perinat Epidemiol.#2#18#2#154-63#10.1111/j.1365-3016.2003.00539.
x#20110000#2289.htm##
00612000000000277000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840120138001030300
02000241065000900261064000500270031000300275032000200278014000600280865000900286
002000900295035001000304801002000314#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2289.htm#S#c#236#19#article#68#19#^rND^sFinnstrom^nO#Studies on maturity 
in newborn infants: IX. Further observations on the use of external characterist
ics in estimating gestational age^len#Acta Paediatr Scand#19770000#1977#66#5#601
-4#20110000#2289.htm#0001-656X#Acta Paediatr Scand##
00585000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100015000840100015000990100
01600114012009000130030000600220065000900226064000500235031000200240032000200242
014000500244865000900249002000900258035001000267801000600277#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2289.htm#S#c#237#20#article#68#20#^rND^sFourn^nL#
^rND^sDucic^nS#^rND^sSéguin^nL#Facteurs associés à la naissance des enfants de f
aible poids: une analyse multivariée^lfr#Sante#19990000#1999#9#1#7-11#20110000#2
289.htm#1157-5999#SANTE##
00786000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100015000840100014000990100
01700113010001700130010001600147010001700163810000600180012016600186030001500352
06500090036706400050037603100030038103200020038401400070038686500090039300200090
0402035001000411801001500421#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
289.htm#S#c#238#21#article#68#21#^rND^sFriis^nH#^rND^sGomo^nE#^rND^sNyazema^nN#^
rND^sNdhlovu^nP#^rND^sKrarup^nH#^rND^sKaestel^nP#et al#Effect of multimicronutri
ent supplementation on gestational length and birth size: a randomized, placebo-
controlled, double-blind effectiveness trial in Zimbabwe^len#Am J Clin Nutr#2004
0000#2004#80#1#178-84#20110000#2289.htm#0002-9165#Am J Clin Nutr##
00598000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100019001000120
09400119030002000213065000900233064000500242031000400247032000200251014000700253
865000900260002000900269035001000278801002000288#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2289.htm#S#c#239#22#article#68#22#^rND^sGrandi^nC#^rND^sDipie
rri^nJE#Tendencia secular del peso de nacimiento en Argentina (1992-2002): un es
tudio poblacional^les#Arch Argent Pediatr#20080000#2008#106#3#219-25#20110000#22
89.htm#0004-0487#Arch Argent Pediatr##
00721000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100014000840100019000980100
01800117010001500135010001600150010001800166012011500184030000500299710000200304
06500090030606400050031503100040032003200020032401400060032623700330033286500090
0365002000900374#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
240#23#article#68#23#^rND^sGray^nR#^rND^sBonellie^nSR#^rND^sChalmers^nJ#^rND^sGr
eer^nI#^rND^sJarvis^nS#^rND^sWilliams^nC#Social inequalities in preterm birth in
 Scotland 1980-2003: findings from an area-based measure of deprivation^len#BJOG
#2#20080000#2008#115#1#82-90#10.1111/j.1471-0528.2007.01582.x#20110000#2289.htm#
#
00698000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100019001000100
01700119010001400136010001500150010001400165012009600179030000500275710000200280
06500090028206400050029103100040029603200020030001400070030223700330030986500090
0342002000900351#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
241#24#article#68#24#^rND^sHabib^nNA#^rND^sDaltveit^nAK#^rND^sBergsjo^nP#^rND^sS
hao^nJ#^rND^sOneko^nO#^rND^sLie^nRT#Maternal HIV status and pregnancy outcomes i
n northeastern Tanzania: a registry-based study^len#BJOG#2#20080000#2008#115#5#6
16-24#10.1111/j.1471-0528.2008.01672.x#20110000#2289.htm##
00798000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100021001010100
01700122010001500139010001500154010001700169810000600186012012300192030002000315
06500090033506400050034403100040034903200020035301400060035523700270036186500090
0388002000900397035001000406801002000416#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#242#25#article#68#25#^rND^sHendler^nI#^rND^sGoldenberg^n
RL#^rND^sMercer^nBM#^rND^sIams^nJD#^rND^sMeis^nPJ#^rND^sMoawad^nAH#et al#The Pre
term Prediction Study: association between maternal body mass index and spontane
ous and indicated preterm birth^len#Am J Obstet Gynecol#20050000#2005#192#3#882-
6#10.1016/j.ajog.2004.09.021#20110000#2289.htm#0002-9378#Am J Obstet Gynecol##
00747000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100015001010100
01300116010001700129010001600146010001500162810000600177012008200183030001500265
06500090028006400050028903100040029403200020029801400070030023700350030786500090
0342002000900351035001000360801001500370#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#243#26#article#68#26#^rND^sJoseph^nKS#^rND^sHuang^nL#^rN
D^sLiu^nS#^rND^sAnanth^nCV#^rND^sAllen^nAC#^rND^sSauve^nR#et al#Reconciling the 
high rates of preterm and postterm birth in the United States^len#Obstet Gynecol
#20070000#2007#109#4#813-22#10.1097/01.AOG.0000255661.13792.c1#20110000#2289.htm
#0029-7844#Obstet Gynecol##
00659000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100021000840100015001050100
01700120010002100137012008300158030002500241065000900266064000500275031000300280
032000200283014000700285865000900292002000900301035001000310801002500320#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#244#27#article#68#27#^rN
D^sKozlovskaya^nA#^rND^sBojko^nE#^rND^sOdland^nJO#^rND^sGrjibovski^nAM#Secular t
rends in pregnancy outcomes in 1980-1999 in the Komi Republic, Russia^len#Int J 
Circumpolar Health#20070000#2007#66#5#437-48#20110000#2289.htm#1239-9736#Int J C
ircumpolar Health##
00756000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100016001010100
01500117010001600132010001800148010001500166810000600181012008000187030002700267
06500090029406400050030303100030030801400070031123700330031886500090035100200090
0360035001000369801002700379#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
289.htm#S#c#245#28#article#68#28#^rND^sKramer^nMS#^rND^sGoulet^nL#^rND^sLydon^nJ
#^rND^sSéguin^nL#^rND^sMcNamara^nH#^rND^sDassa^nC#et al#Socio-economic dispariti
es in preterm birth: causal pathways and mechanisms^len#Paediatr Perinat Epidemi
ol#20010000#2001#15#104-23#10.1046/j.1365-3016.2001.00012.x#20110000#2289.htm#02
69-5022#Paediatr Perinat Epidemiol##
00593000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100018001010120
04500119016001600164016001600180018004900196066000700245062001300252065000900265
064000500274014000600279865000900285002000900294#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2289.htm#S#c#246#29#article#68#29#^rND^sKramer^nMS#^rND^sVict
ora^nCG#Low birth weight and perinatal mortality^len#^rND^sSemba^nRD#^rND^sBloem
^nMW#Nutrition and health in developing countries^len#Totowa#Humana Press#200100
00#2001#57-69#20110000#2289.htm##
00491000000000265000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840120064001010300
00800165710000200173065000900175064000500184031000400189032000500193014000900198
865000900207002000900216#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.
htm#S#c#247#30#article#68#30#^rND^sKramer^nMS#The epidemiology of adverse pregna
ncy outcomes: an overview^len#J Nutr.#2#20030000#2003#133#5^s2#1592S-6S#20110000
#2289.htm##
00571000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100015000840100017000990100
01500116012004900131030000800180710000200188065000900190064000500199031000400204
032000500208014000800213237003000221865000900251002000900260#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2289.htm#S#c#248#31#article#68#31#^rND^sLawn^nJE#
^rND^sCousens^nS#^rND^sZupan^nJ#4 million neonatal deaths: when? Where? Why?^len
#Lancet.#2#20050000#2005#365#9462#891-900#10.1016/S0140-6736(05)71048-5#20110000
#2289.htm##
00666000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100018001010100
01600119010001500135012008400150030001500234065000900249064000500258031000300263
03200020026601400070026823700220027586500090029700200090030603500100031580100150
0325#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#249#32#artic
le#68#32#^rND^sLetaief^nM#^rND^sSoltani^nMS#^rND^sSalem^nKB#^rND^sBchir^nA#Épidé
miologie de l'insuffisance pondérale à la naissance dans le Sahel tunisien^lfr#S
ante Publique#20010000#2001#13#4#359-66#10.3917/spub.014.0359#20110000#2289.htm#
0048-9107#Sante Publique##
00631000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100013000840100015000970120
10700112030001400219065000900233064000500242031000400247032000200251014000700253
237002700260865000900287002000900296035001000305801001400315#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2289.htm#S#c#250#33#article#68#33#^rND^sLi^nCY#^r
ND^sSung^nFC#Socio-economic inequalities in low-birth weight, full-term babies f
rom singleton pregnancies in Taiwan^len#Public Health#20080000#2008#122#3#243-50
#10.1016/j.puhe.2007.05.011#20110000#2289.htm#0033-3492#PUBLIC HEALTH##
00598000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100013000840100013000970100
01500110010001200125010001300137012005700150030003100207710000200238065000900240
064000500249031000300254032000200257014000700259865000900266002000900275#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#251#34#article#68#34#^rN
D^sLin^nL#^rND^sLiu^nY#^rND^sZhang^nX#^rND^sMi^nJ#^rND^sCao^nL#Sampling survey o
n low-birth weight in China in 1998^len#Zhonghua Yu Fang Yi Xue Za Zhi#2#2002000
0#2002#36#3#149-53#20110000#2289.htm##
00770000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100021000840100018001050100
01400123010001700137010001300154010002900167810000600196012009900202030001500301
06500090031606400050032503100040033003200020033401400070033623700220034386500090
0365002000900374035001000383801001500393#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#252#35#article#68#35#^rND^sLuxemburger^nC#^rND^sMcGready
^nR#^rND^sKham^nA#^rND^sMorison^nL#^rND^sCho^nT#^rND^sChongsuphajaisiddhi^nT#et 
al#Effects of malaria during pregnancy on infant mortality in an area of low mal
aria transmission^len#Am J Epidemiol#20010000#2001#154#5#459-65#10.1093/aje/154.
5.459#20110000#2289.htm#0002-9262#Am J Epidemiol##
00736000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100022000840100017001060100
02400123010001600147010001800163012014000181030001800321065000900339064000500348
03100030035303200020035601400060035886500090036400200090037303500100038280100180
0392#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#253#36#artic
le#68#36#^rND^sMatijasevich^nA#^rND^sBarros^nFC#^rND^sDíaz-Rossello^nJL#^rND^sBe
rgel^nE#^rND^sForteza^nAC#Factores de riesgo para muy bajo peso al nacer y peso 
al nacer entre 1.500-2.499g: un estúdio del sector público de Montevideo, Urugua
y^les#Arch Pediatr Urug#20040000#2004#75#1#26-35#20110000#2289.htm#0004-0584#Arc
h Pediatr Urug##
00721000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100014001020100
01700116010001800133010001700151010001700168810000600185012007200191030001300263
06500090027606400050028503100040029003200020029401400070029623700150030386500090
0318002000900327035001000336801001300346#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#254#37#article#68#37#^rND^sMenendez^nC#^rND^sOrdi^nJ#^rN
D^sIsmail^nMR#^rND^sVentura^nPJ#^rND^sAponte^nJJ#^rND^sKahigwa^nE#et al#The impa
ct of placental malaria on gestational age and birth weight^len#J Infect Dis#200
00000#2000#181#5#1740-5#10.1086/315449#20110000#2289.htm#0022-1899#J Infect Dis#
#
00691000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100022000840100019001060100
02200125010001400147010001600161010001800177810000600195012008000201030000800281
71000020028906500090029106400050030003100020030501400040030723700240031186500090
0335002000900344#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
255#38#article#68#38#^rND^sMockenhaupt^nFP#^rND^sBedu-Addo^nG#^rND^svon Gaertner
^nC#^rND^sBoyé^nR#^rND^sFricke^nK#^rND^sHannibal^nI#et al#Detection and clinical
 manifestation of placental malaria in southern Ghana^len#Malar J#2#20060000#200
6#5#119#10.1186/1475-2875-5-119#20110000#2289.htm##
00801000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100022000840100016001060100
02200122010001900144010002500163010001900188810000600207012013100213030001300344
06500090035706400050036603100040037103200020037501400060037723700150038386500090
0398002000900407035001000416801001300426#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#256#39#article#68#39#^rND^sMockenhaupt^nFP#^rND^sHamann^
nL#^rND^svon Gaertner^nC#^rND^sBedu-Addo^nG#^rND^svon Kleinsorgen^nC#^rND^sSchum
ann^nRR#et al#Common polymorphisms of toll-like receptors 4 and 9 are associated
 with the clinical manifestation of malaria during pregnancy^len#J Infect Dis#20
060000#2006#194#2#184-8#10.1086/505152#20110000#2289.htm#0022-1899#J Infect Dis#
#
00739000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100015001030100
01800118010001900136010001500155010001900170012004900189030003300238065000900271
06400050028003100040028503200020028901400070029123700300029886500090032800200090
0337035001000346801003300356#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
289.htm#S#c#257#40#article#68#40#^rND^sMwanyumba^nF#^rND^sInion^nI#^rND^sGaillar
d^nP#^rND^sMandaliya^nK#^rND^sPraet^nM#^rND^sTemmerman^nM#Placental inflammation
 and perinatal outcome^len#Eur J Obstet Gynecol Reprod Biol#20030000#2003#108#2#
164-70#10.1016/S0301-2115(02)00438-4#20110000#2289.htm#0301-2115#Eur J Obstet Gy
necol Reprod Biol##
00495000000000265000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840120068001000300
01600168710000200184065000900186064000500195031000300200032000200203014000600205
865000900211002000900220#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.
htm#S#c#258#41#article#68#41#^rND^sNajmi^nRS#Distribution of birthweights of hos
pital born Pakistani infants^len#J Pak Med Assoc#2#20000000#2000#50#4#121-4#2011
0000#2289.htm##
00827000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100022001000100
01400122010001600136010001500152010001600167810000600183012018000189030001300369
06500090038206400050039103100040039603200020040001400070040223700150040986500090
0424002000900433035001000442801001300452#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#259#42#article#68#42#^rND^sOkoko^nBJ#^rND^sWesumperuma^n
LH#^rND^sOta^nMO#^rND^sPinder^nM#^rND^sBanya^nW#^rND^sGomez^nSF#et al#The influe
nce of placental malaria infection and maternal hypergammaglobulinemia on transp
lacental transfer of antibodies and IgG subclasses in a rural West African popul
ation^len#J Infect Dis#20010000#2001#184#5#627-32#10.1086/322808#20110000#2289.h
tm#0022-1899#J Infect Dis##
00754000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100020001030100
01800123010001500141010001600156010001600172012014500188030001500333065000900348
06400050035703100030036203200020036501400060036786500090037300200090038203500100
0391801001500401#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
260#43#article#68#43#^rND^sOsendarp^nSJ#^rND^svan Raaij^nJM#^rND^sArifeen^nSE#^r
ND^sWahed^nM#^rND^sBaqui^nAH#^rND^sFuchs^nGJ#A randomized, placebo-controlled tr
ial of the effect of zinc supplementation during pregnancy on pregnancy outcome 
in Bangladeshi urban poor^len#Am J Clin Nutr#20000000#2000#71#1#114-9#20110000#2
289.htm#0002-9165#Am J Clin Nutr##
00806000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100028000840100021001120100
02600133010002600159010002400185010002800209012014000237030001900377065000900396
06400050040503100030041003200020041301400060041586500090042100200090043003500100
0439801001900449#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
261#44#article#68#44#^rND^sOsorno Covarrubias^nL#^rND^sAcosta Mass^nA#^rND^sDávi
la Velasquez^nJ#^rND^sRodriguez Chapuz^nJ#^rND^sEscamilla Sosa^nM#^rND^sEcheverr
ia Eguiluz^nM#Mortalidad neonatal em un hospital perinatal regional de Mérida, Y
ucatán, de 1995 a 2004: I. Análisis de las tasas crudas y específicas^lpt#Gineco
l Obstet Mex#20060000#2006#74#8#401-9#20110000#2289.htm#0300-9041#Ginecol Obstet
 Mex##
00613000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100016001020100
01900118012010900137030000400246065000900250064000500259031000400264032000500268
014000600273865000900279002000900288035001000297801000400307#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2289.htm#S#c#262#45#article#68#45#^rND^sPeacock^n
JL#^rND^sBland^nJM#^rND^sAnderson^nHR#Preterm delivery: effects of socioeconomic
 factors, psychological stress, smoking, alcohol, and caffeine^len#BMJ#19950000#
1995#311#7004#531-5#20110000#2289.htm#0959-8138#BMJ##
00638000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100021000840100018001050100
01900123012011100142030001500253065000900268064000500277031000300282032000200285
014000600287865000900293002000900302035001000311801001500321#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2289.htm#S#c#263#46#article#68#46#^rND^sRayco-Sol
on^nP#^rND^sFulford^nAJ#^rND^sPrentice^nAM#Differential effects of seasonality o
n preterm birth and intrauterine growth restriction in rural Africans^len#Am J C
lin Nutr#20050000#2005#81#1#134-9#20110000#2289.htm#0002-9165#Am J Clin Nutr##
00525000000000241000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810170046000840180071001300630
00200201066001300203062003500216065000900251064000500260865000900265002000900274
#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#264#47#article#6
8#47#Rede Interagencial de Informaçao para a Saúde#Indicadores básicos para a sa
úde no Brasil: conceitos e aplicações^lpt#2#Brasilia^eDF#Organização Pan-America
na da Saúde#20080000#2008#20110000#2289.htm##
00787000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100019001010100
01500120010001900135010001800154010002200172810000600194012010000200030001800300
06500090031806400050032703100030033203200040033501400080033923700320034786500090
0379002000900388035001000397801001800407#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#265#48#article#68#48#^rND^sSantos^nIS#^rND^sMenezes^nAMB
#^rND^sMota^nDM#^rND^sAlbernaz^nEP#^rND^sBarros^nAJD#^rND^sMatijasevich^nA#et al
#Infant mortality in three population-based cohorts in Southern Brazil: trends a
nd differentials^len#Cad Saude Publica#20080000#2008#24#^s3#S451-60#10.1590/S010
2-311X2008001500011#20110000#2289.htm#0102-311X#Cad Saude Publica##
00691000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100019001000100
01600119010001700135012012400152030002400276065000900300064000500309031000300314
032000200317014000600319865000900325002000900334035001000343801002400353#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#266#49#article#68#49#^rN
D^sSilva^nAA#^rND^sBarbieri^nMA#^rND^sGomes^nUA#^rND^sBettiol^nH#Trends in low b
irth weight: a comparison of two birth cohorts separated by a 15-year interval i
n Ribeirão Preto, Brazil^len#Bull World Health Organ#19980000#1998#76#1#73-84#20
110000#2289.htm#0042-9686#Bull World Health Organ##
00711000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100017001000100
02000117010001800137010001600155012005900171030003300230065000900263064000500272
03100030027703200020028001400060028223700240028886500090031200200090032103500100
0330801003300340#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
267#50#article#68#50#^rND^sSmith^nLK#^rND^sDraper^nES#^rND^sManktelow^nBN#^rND^s
Dorling^nJS#^rND^sField^nDJ#Socioeconomic inequalities in very preterm birth rat
es^len#Arch Dis Child Fetal Neonatal Ed#20070000#2007#92#1#F11-4#10.1136/adc.200
5.090308#20110000#2289.htm#1359-2998#Arch Dis Child Fetal Neonatal Ed##
00607000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100029000840100017001130100
01800130012006400148030001800212065000900230064000500239031000300244032000600247
014000600253865000900259002000900268035001000277801001800287#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2289.htm#S#c#268#51#article#68#51#^rND^sSteketee 
RW Nahlen^nBL#^rND^sParise^nME#^rND^sMenendez^nC#The burden of malaria in pregna
ncy in malaria-endemic areas^len#Am J Trop Med Hyg#20010000#2001#64#^s1/2#28-35#
20110000#2289.htm#0002-9637#Am J Trop Med Hyg##
00673000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100016001010100
01500117010001700132012007400149030002200223065000900245064000500254031000300259
03200020026201400060026423700270027086500090029700200090030603500100031580100220
0325#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#269#52#artic
le#68#52#^rND^sTicconi^nC#^rND^sArpino^nC#^rND^sLongo^nB#^rND^sMapfumo^nM#Preval
ence and risk factors for low birth weight in Northern Zimbabwe^len#Int J Gynaec
ol Obstet#20050000#2005#88#2#146-7#10.1016/j.ijgo.2004.11.018#20110000#2289.htm#
0020-7292#Int J Gynaecol Obstet##
00693000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100019001010100
01600120010002000136010001500156012007600171030001400247065000900261064000500270
03100030027503200030027801400080028123700240028986500090031300200090032203500100
0331801001400341#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
270#53#article#68#53#^rND^sToygar^nHU#^rND^sSeydaoglu^nG#^rND^sKurklu^nS#^rND^sG
uzeldemir^nE#^rND^sArpak^nN#Periodontal health and adverse pregnancy outcome in 
3,576 Turkish women^len#J Periodontol#20070000#2007#78#11#2081-94#10.1902/jop.20
07.070092#20110000#2289.htm#0022-3492#J Periodontol##
00662000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100017001020100
01900119010001500138010001400153010001500167012005300182030001700235065000900252
06400050026103100030026603200030026901400070027286500090027900200090028803500100
0297801001700307#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#
271#54#article#68#54#^rND^sTripathy^nR#^rND^sParida^nSN#^rND^sTripathy^nSN#^rND^
sDevi^nPS#^rND^sDas^nRN#^rND^sSwain^nA#Physical status of newborns and neonatal 
outcome^len#Indian J Pediatr#20020000#2002#69#12#1041-5#20110000#2289.htm#0019-5
456#Indian J Pediatr##
00413000000000217000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810170007000840180063000910660
00900154065000900163064000500172865000900177002000900186#2011nahead#V:\SciELO\se
rial\rsp\2011nahead\markup\2289.htm#S#c#272#55#article#68#55#UNICEF#The state of
 the world´s children 1998: focus on nutrition^len#New York#19980000#1998#201100
00#2289.htm##
00411000000000217000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810170007000840180061000910660
00900152065000900161064000500170865000900175002000900184#2011nahead#V:\SciELO\se
rial\rsp\2011nahead\markup\2289.htm#S#c#273#56#article#68#56#UNICEF#Low birth we
ight: country, regional and global estimates^len#New York#20040000#2004#20110000
#2289.htm##
00405000000000217000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810170007000840180055000910660
00900146065000900155064000500164865000900169002000900178#2011nahead#V:\SciELO\se
rial\rsp\2011nahead\markup\2289.htm#S#c#274#57#article#68#57#UNICEF#State of the
 world's children 2008: child survival^len#New York#20080000#2008#20110000#2289.
htm##
00775000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100022000840100017001060100
03000123010002400153012017800177030002600355065000900381064000500390031000300395
032000200398014000700400865000900407002000900416035001000425801002600435#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#275#58#article#68#58#^rN
D^sVélez-Gómez^nMP#^rND^sBarros^nFC#^rND^sEchavarría-Restrepo^nLG#^rND^sHormaza-
Angel^nMP#Prevalencia de bajo peso al nacer y factores maternos asociados: Unida
d de Atención y Protección Materno Infantil de la Clinica Universitaria Bolivari
ana, Medellin, Colombia^les#Rev Colomb Obstet Ginecol#20060000#2006#57#4#264-70#
20110000#2289.htm#0034-7434#Rev Colomb Obstet Ginecol##
00634000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100018001000120
13200118030002000250065000900270064000500279031000400284032000200288014000600290
865000900296002000900305035001000314801002000324#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2289.htm#S#c#276#59#article#68#59#^rND^sVillar^nJ#^rND^sBeliz
an^nJM#The relative contribution of prematurity and fetal growth retardation to 
low birth weight in developing and developed societies^len#Am J Obstet Gynecol#1
9820000#1982#143#7#793-8#20110000#2289.htm#0002-9378#Am J Obstet Gynecol##
00557000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100018001000100
02300118010002100141012004600162030001700208710000200225065000900227064000500236
031000300241014000500244865000900249002000900258#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2289.htm#S#c#277#60#article#68#60#^rND^sVillar^nJ#^rND^sEzcur
ra^nEG#^rND^sde La Fuente^nVG#^rND^sCanpodonico^nI#Preterm delivery syndrome: th
e unmet need^len#Res Clin Forums.#2#19940000#1994#16#9-33#20110000#2289.htm##
00748000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100020001000100
01700120010001800137010001700155010001700172810000600189012013000195030000700325
06500090033206400050034103100040034603200050035001400080035586500090036300200090
0372035001000381801000700391#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
289.htm#S#c#278#61#article#68#61#^rND^sVillar^nJ#^rND^sValladares^nE#^rND^sWojdy
la^nD#^rND^sZavaleta^nN#^rND^sCarroli^nG#^rND^sVelazco^nA#et al#Caesarean delive
ry rates and pregnancy outcomes: the 2005 WHO global survey on maternal and peri
natal health in Latin America^len#Lancet#20060000#2006#367#9525#1819-29#20110000
#2289.htm#0099-5355#Lancet##
00789000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100021001000100
01800121010001600139010001400155010001800169810000600187012011400193030002000307
06500090032706400050033603100040034103200020034501400070034723700250035486500090
0379002000900388035001000397801002000407#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#279#62#article#68#62#^rND^sVillar^nJ#^rND^sAbdel-Aleem^n
H#^rND^sMerialdi^nM#^rND^sMathai^nM#^rND^sAli^nMM#^rND^sZavaleta^nN#et al#World 
Health Organization randomized trial of calcium supplementation among low calciu
m intake pregnant women^len#Am J Obstet Gynecol#20060000#2006#194#3#639-49#10.10
16/ajog.2006.01.068#20110000#2289.htm#0002-9378#Am J Obstet Gynecol##
00544000000000277000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100015001010120
08200116030002300198710000200221065000900223064000500232031000200237032000200239
014000700241865000900248002000900257#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2289.htm#S#c#280#63#article#68#63#^rND^sWannous^nS#^rND^sArous^nS#Inciden
ce and determinants of low birth weight in Syrian government hospitals^len#East 
Mediterr Health J#2#20010000#2001#7#6#966-74#20110000#2289.htm##
00798000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100022000840100016001060100
02200122010001400144010001800158010001600176810000600192012010600198030002400304
06500090032806400050033703100030034203200020034501400050034723700320035286500090
0384002000900393035001000402801002400412#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#281#64#article#68#64#^rND^sWatson-Jones^nD#^rND^sWeiss^n
HA#^rND^sChangalucha^nJM#^rND^sTodd^nJ#^rND^sGumodoka^nB#^rND^sBulmer^nJ#et al#A
dverse birth outcomes in United Republic of Tanzania: impact and prevention of m
aternal risk factors^len#Bull World Health Organ#20070000#2007#85#1#9-18#10.1590
/S0042-96862007000100007#20110000#2289.htm#0042-9686#Bull World Health Organ##
00697000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100014000840100021000980100
01700119010001800136010001700154012010600171030002000277065000900297064000500306
03100040031103200020031501400060031786500090032300200090033203500100034180100200
0351#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#282#65#artic
le#68#65#^rND^sWen^nSW#^rND^sGoldenberg^nRL#^rND^sCutter^nGR#^rND^sHoffman^nHJ#^
rND^sCliver^nSP#Intrauterine growth retardation and preterm delivery: prenatal r
isk factors in an indigent population^len#Am J Obstet Gynecol#19900000#1990#162#
1#213-8#20110000#2289.htm#0002-9378#Am J Obstet Gynecol##
00515000000000229000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810170026000840180100001100660
01200210062003100222065000900253064000500262865000900267002000900276#2011nahead#
V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#283#66#article#68#66#World H
ealth Organization#A strategic framework for malaria prevention and control duri
ng pregnancy in the African Region^len#Brazzaville#WHO Regional Office for Afric
a#20040000#2004#20110000#2289.htm##
00749000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100014001010100
01400115010001200129010001600141010001200157810000600169012009700175030001400272
06500090028606400050029503100030030003200020030301400070030523700330031286500090
0345002000900354035001000363801001400373#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2289.htm#S#c#284#67#article#68#67#^rND^sYangzom^nY#^rND^sQian^nL#^rND
^sShan^nM#^rND^sLa^nY#^rND^sMeiduo^nD#^rND^sHu^nX#et al#Outcome of hospital deli
veries of women living at high altitude: a study from Lhasa in Tibet^len#Acta Pa
ediatr#20080000#2008#97#3#317-21#10.1111/j.1651-2227.2008.00628.x#20110000#2289.
htm#0001-656X#Acta Paediatr##
00672000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100015001000100
01400115010001800129012006500147030002400212065000900236064000500245031000300250
03200020025301400070025523700320026286500090029400200090030303500100031280100240
0322#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2289.htm#S#c#285#68#artic
le#68#68#^rND^sYasmin^nS#^rND^sOsrin^nD#^rND^sPaul^nE#^rND^sCostello^nA#Neonatal
 mortality of low-birth-weight infants in Bangladesh^len#Bull World Health Organ
#20010000#2001#79#7#608-14#10.1590/S0042-96862001000700005#20110000#2289.htm#004
2-9686#Bull World Health Organ##
00276000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00400102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#o#1#1#arti
cle#1#20110408#160429#2315.htm#155##
06656000000000757000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000500095038000400100121000300104049000300107158000300110
03000190011303200060013206500090013801400070014703500100015422300090016401200680
01730120067002410120070003080100032003780100036004100100040004460700071004860700
07600557070006400633083154700697085001002244085003502254085003702289085003802326
08500370236408500470240108314040244808500100385208500270386208500360388908500360
39250850032039610850047039930831599040400850010056390850035056490850037056840850
03705721085003705758085004505795117000805840072000305848112000905851111000905860
114000905869113001105878002000905889#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2315.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#20#nd#nd#Rev. Saúde
 Pública#ahead#20110000#^f0^l0#0034-8910#20110415#Aquisição de medicamentos gené
ricos em município de médio porte^lpt#Procurement of generic medicines in a medi
um size municipality^len#Adquisición de medicamentos genéricos en municipio de m
edio porte^les#^rND^1A01^nGabriela^sBevilacqua#^rND^1A01 A02^nMareni Rocha^sFari
as#^rND^1A01 A02 A03^nCarine Raquel^sBlatt#Universidade Federal de Santa Catarin
a^iA01^cFlorianópolis^sSC^pBrasil#UFSC^iA02^1Programa de Pós-Graduação em Farmác
ia^cFlorianópolis^sSC^pBrasil#Universidade do Sul de Santa Catarina^iA03^cTubarã
o^sSC^pBrasil#^lpt^aOBJETIVO: Analisar o impacto financeiro da aquisição de medi
camentos com a exigência da apresentação de testes de biodisponibilidade e/ou bi
oequivalência para o componente da Assistência Farmacêutica Básica. MÉTODOS: Est
udo retrospectivo, documental, em atas dos processos licitatórios para aquisição
 de medicamentos em município de médio porte de Santa Catarina. Foram analisadas
 licitações sem (2007) e com (2008) a exigência de testes de bioequivalência e/o
u de biodisponibilidade. Avaliaram-se o número de recursos apresentados pelos fo
rnecedores, o número de processos licitatórios anuais necessários para a aquisiç
ão de todos os medicamentos padronizados, o tempo para a finalização do processo
 licitatório, o número de itens fracassados, o custo unitário dos medicamentos e
 o valor total da aquisição. RESULTADOS: Foram observados 2,6% de itens fracassa
dos em 2007 e 56,9% em 2008. Entre os medicamentos, 60,0% tiveram acréscimo e 29
,3,0% decréscimo em 2008 em relação a 2007. Os custos totais de aquisição para 1
50 medicamentos, considerando valores unitários praticados e o consumo médio anu
al, foram de R$ 2.288.120,00 para 2007 e de R$ 4.270.425,00 para 2008. CONCLUSÕE
S: A exigência dos testes de bioequivalência e/ou de biodisponibilidade elevou e
m mais de 100% os custos com o financiamento do Componente da Assistência Farmac
êutica Básica, indicando necessidade de discussão de uma Política de Medicamento
 Genérico em consonância com a Política de Assistência Farmacêutica e com a Rela
ção Nacional de Medicamentos Essenciais.#^ddecs^i1#^tm^lpt^kMedicamentos Genéric
os^i1#^tm^lpt^kEquivalência Terapêutica^i1#^tm^lpt^kDisponibilidade Biológica^i1
#^tm^lpt^kProposta de Concorrência^i1#^tm^lpt^kAssistência Farmacêutica^i1^sEcon
omia#^len^aOBJECTIVE: To analyze the financial impact of medicine procurement wi
th the required bioavailability and or bioequivalence tests for the basic pharma
ceutical services component. METHODS: A retrospective study, based on document r
esearch of competitive bidding for medicine procurement in a medium size municip
ality of Santa Catarina state, Southern Brazil. Bids that occurred with (2007) a
nd without (2008) the requirement of bioequivalence and/or bioavailability tests
 were analyzed. The number of resources presented by providers, the number of an
nual bidding processes necessary to acquire all the standard medicines, the time
 to finalize the bidding process, the number of failing items, the per unit cost
 of medicines and the total value of procurement were evaluated. RESULTS: In 200
7 and 2008 respectively, 2.6% and 56.9% of items failed. Among medicine purchase
s, 60.0% were increased and 29.3% decreased from 2008 to 2007.The total procurem
ent costs for 150 medicines, considering per unit costs and average annual consu
mption was R$ 2,288,120.00 (2007) and R$ 4,270,425.00 (2008). CONCLUSIONS: The r
equirement for bioequivalence and/or bioavailability tests increased costs by mo
re than 100% for the basic pharmaceutical services component. There is a need to
 discuss Generic Medicine Policies to agree with Pharmaceutical Assistance Polic
ies and the National Essential Medicines Report.#^ddecs^i2#^tm^len^kDrugs, Gener
ic^i2#^tm^len^kTherapeutic Equivalency^i2#^tm^len^kBiological Availability^i2#^t
m^len^kCompetitive Bidding^i2#^tm^len^kPharmaceutical Services^i2^seconomics#^le
s^aOBJETIVO: Analizar el impacto financiero de la adquisición de medicamentos co
n la exigencia de la presentación de pruebas de biodisponibilidad y o bioequival
encia para el componente de la Asistencia Farmacéutica Básica. MÉTODOS: Estudio 
retrospectivo, documental, en actas de los procesos licitatorios para adquisició
n de medicamentos en municipio de medio porte de Santa Catarina, Sur de Brasil. 
Se analizaron licitaciones sin (2007) y con la exigencia de pruebas de bioequiva
lencia y/o biodisponibilidad (2008). Se evaluaron el número de recursos presenta
dos por los proveedores, el número de procesos licitatorios anuales necesarios p
ara la adquisición de todos los medicamentos estandarizados, el tiempo para la f
inalización del proceso licitatorio, el número de ítems fracasados, el costo uni
tario de los medicamentos y el valor total de la adquisición. RESULTADOS: Se obs
ervaron 2,6% de ítems fracasados en 2007 y 56,9% en 2008. Entre los medicamentos
, 60,0% tuvieron incremento y 29,3%, disminución en 2008 con relación a 2007. Lo
s costos totales de adquisición para 150 medicamentos, considerando valores unit
arios practicados y el consumo promedio anual, fueron de R$ 2.288.120,00 para 20
07 y de R$ 4.270.425,00 para 2008. CONCLUSIONES: La exigencia de las pruebas de 
bioequivalencia y/o biodisponibilidad elevó en más de 100% los costos con el fin
anciamiento de la Asistencia Farmacéutica Básica, indicando necesidad de discusi
ón de una Política de Medicamento Genérico en consonancia con la Política de Asi
stencia Farmacéutica y con la Relación Nacional de Medicamentos Esenciales.#^dde
cs^i3#^tm^les^kMedicamentos Genéricos^i3#^tm^les^kEquivalencia Terapéutica^i3#^t
m^les^kDisponibilidad Biológica^i3#^tm^les^kPropuestas de Licitación^i3#^tm^les^
kServicios Farmacéutico^i3^seconomía#vancouv#16#20100602#2/6/2010#20101114#14/11
/2010#2315.htm##
06761000000000757000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000500095038000400100121000300104049000300107158000300110
03000190011303200060013206500090013801400070014703500100015422300090016401200750
01730120074002480120077003220100032003990100036004310100040004670700071005070700
07600578070006400654083157500718085001002293085003502303085003702338085003802375
08500370241308500470245008314320249708500100392908500270393908500360396608500360
40020850032040380850047040700831627041170850010057440850035057540850037057890850
03705826085003705863085004505900117000805945072000305953112000905956111000905965
114000905974113001105983002000905994#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2315.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ILUS#TAB#20#nd#nd#Rev. Saúde
 Pública#ahead#20110000#^f0^l0#0034-8910#20110415#<b>Aquisição de medicamentos g
enéricos em município de médio porte</b>^lpt#<b>Procurement of generic medicines
 in a medium size municipality</b>^len#<b>Adquisición de medicamentos genéricos 
en municipio de medio porte</b>^les#^rND^1A01^nGabriela^sBevilacqua#^rND^1A01 A0
2^nMareni Rocha^sFarias#^rND^1A01 A02 A03^nCarine Raquel^sBlatt#Universidade Fed
eral de Santa Catarina^iA01^cFlorianópolis^sSC^pBrasil#UFSC^iA02^1Programa de Pó
s-Graduação em Farmácia^cFlorianópolis^sSC^pBrasil#Universidade do Sul de Santa 
Catarina^iA03^cTubarão^sSC^pBrasil#^lpt^a<b>OBJETIVO:</b> Analisar o impacto fin
anceiro da aquisição de medicamentos com a exigência da apresentação de testes d
e biodisponibilidade e/ou bioequivalência para o componente da Assistência Farma
cêutica Básica. <b>MÉTODOS:</b> Estudo retrospectivo, documental, em atas dos pr
ocessos licitatórios para aquisição de medicamentos em município de médio porte 
de Santa Catarina. Foram analisadas licitações sem (2007) e com (2008) a exigênc
ia de testes de bioequivalência e/ou de biodisponibilidade. Avaliaram-se o númer
o de recursos apresentados pelos fornecedores, o número de processos licitatório
s anuais necessários para a aquisição de todos os medicamentos padronizados, o t
empo para a finalização do processo licitatório, o número de itens fracassados, 
o custo unitário dos medicamentos e o valor total da aquisição. <b>RESULTADOS:</
b> Foram observados 2,6% de itens fracassados em 2007 e 56,9% em 2008. Entre os 
medicamentos, 60,0% tiveram acréscimo e 29,3,0% decréscimo em 2008 em relação a 
2007. Os custos totais de aquisição para 150 medicamentos, considerando valores 
unitários praticados e o consumo médio anual, foram de R$ 2.288.120,00 para 2007
 e de R$ 4.270.425,00 para 2008. <b>CONCLUSÕES:</b> A exigência dos testes de bi
oequivalência e/ou de biodisponibilidade elevou em mais de 100% os custos com o 
financiamento do Componente da Assistência Farmacêutica Básica, indicando necess
idade de discussão de uma Política de Medicamento Genérico em consonância com a 
Política de Assistência Farmacêutica e com a Relação Nacional de Medicamentos Es
senciais.#^ddecs^i1#^tm^lpt^kMedicamentos Genéricos^i1#^tm^lpt^kEquivalência Ter
apêutica^i1#^tm^lpt^kDisponibilidade Biológica^i1#^tm^lpt^kProposta de Concorrên
cia^i1#^tm^lpt^kAssistência Farmacêutica^i1^sEconomia#^len^a<b>OBJECTIVE:</b> To
 analyze the financial impact of medicine procurement with the required bioavail
ability and or bioequivalence tests for the basic pharmaceutical services compon
ent. <b>METHODS:</b> A retrospective study, based on document research of compet
itive bidding for medicine procurement in a medium size municipality of Santa Ca
tarina state, Southern Brazil. Bids that occurred with (2007) and without (2008)
 the requirement of bioequivalence and/or bioavailability tests were analyzed. T
he number of resources presented by providers, the number of annual bidding proc
esses necessary to acquire all the standard medicines, the time to finalize the 
bidding process, the number of failing items, the per unit cost of medicines and
 the total value of procurement were evaluated. <b>RESULTS:</b> In 2007 and 2008
 respectively, 2.6% and 56.9% of items failed. Among medicine purchases, 60.0% w
ere increased and 29.3% decreased from 2008 to 2007.The total procurement costs 
for 150 medicines, considering per unit costs and average annual consumption was
 R$ 2,288,120.00 (2007) and R$ 4,270,425.00 (2008). <b>CONCLUSIONS:</b> The requ
irement for bioequivalence and/or bioavailability tests increased costs by more 
than 100% for the basic pharmaceutical services component. There is a need to di
scuss Generic Medicine Policies to agree with Pharmaceutical Assistance Policies
 and the National Essential Medicines Report.#^ddecs^i2#^tm^len^kDrugs, Generic^
i2#^tm^len^kTherapeutic Equivalency^i2#^tm^len^kBiological Availability^i2#^tm^l
en^kCompetitive Bidding^i2#^tm^len^kPharmaceutical Services^i2^seconomics#^les^a
<b>OBJETIVO:</b> Analizar el impacto financiero de la adquisición de medicamento
s con la exigencia de la presentación de pruebas de biodisponibilidad y o bioequ
ivalencia para el componente de la Asistencia Farmacéutica Básica. <b>MÉTODOS:</
b> Estudio retrospectivo, documental, en actas de los procesos licitatorios para
 adquisición de medicamentos en municipio de medio porte de Santa Catarina, Sur 
de Brasil. Se analizaron licitaciones sin (2007) y con la exigencia de pruebas d
e bioequivalencia y/o biodisponibilidad (2008). Se evaluaron el número de recurs
os presentados por los proveedores, el número de procesos licitatorios anuales n
ecesarios para la adquisición de todos los medicamentos estandarizados, el tiemp
o para la finalización del proceso licitatorio, el número de ítems fracasados, e
l costo unitario de los medicamentos y el valor total de la adquisición. <b>RESU
LTADOS:</b> Se observaron 2,6% de ítems fracasados en 2007 y 56,9% en 2008. Entr
e los medicamentos, 60,0% tuvieron incremento y 29,3%, disminución en 2008 con r
elación a 2007. Los costos totales de adquisición para 150 medicamentos, conside
rando valores unitarios practicados y el consumo promedio anual, fueron de R$ 2.
288.120,00 para 2007 y de R$ 4.270.425,00 para 2008. <b>CONCLUSIONES:</b> La exi
gencia de las pruebas de bioequivalencia y/o biodisponibilidad elevó en más de 1
00% los costos con el financiamiento de la Asistencia Farmacéutica Básica, indic
ando necesidad de discusión de una Política de Medicamento Genérico en consonanc
ia con la Política de Asistencia Farmacéutica y con la Relación Nacional de Medi
camentos Esenciales.#^ddecs^i3#^tm^les^kMedicamentos Genéricos^i3#^tm^les^kEquiv
alencia Terapéutica^i3#^tm^les^kDisponibilidad Biológica^i3#^tm^les^kPropuestas 
de Licitación^i3#^tm^les^kServicios Farmacéutico^i3^seconomía#vancouv#16#2010060
2#2/6/2010#20101114#14/11/2010#2315.htm##
06912000000000781000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098038000500102038000400107121000300111049000300114
15800030011703000190012003200060013906500090014501400070015403500100016122300090
01710120068001800120067002480120070003150100032003850100036004170100040004530700
07300493070007800566070006600644083159200710085001002302085003502312085003702347
08500380238408500370242208500470245908314390250608500100394508500270395508500360
39820850036040180850032040540850047040860831649041330850010057820850035057920850
03705827085003705864085003705901085004505938117000805983072000305991112000905994
111000906003114000906012113001106021002000906032008008906041#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2315.htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4
.0#ilus#tab#20#nd#nd#Rev. saúde pública#ahead#20110000#^f0^l0#0034-8910#20110415
#Aquisição de medicamentos genéricos em município de médio porte^lpt#Procurement
 of generic medicines in a medium size municipality^len#Adquisición de medicamen
tos genéricos en municipio de medio porte^les#^rND^1A01^nGabriela^sBevilacqua#^r
ND^1A01 A02^nMareni Rocha^sFarias#^rND^1A01 A02 A03^nCarine Raquel^sBlatt#^iA01^
1Universidade Federal de Santa Catarina^cFlorianópolis^sSC^pBrasil#^iA02^1UFSC^2
Programa de Pós-Graduação em Farmácia^cFlorianópolis^sSC^pBrasil#^iA03^1Universi
dade do Sul de Santa Catarina^cTubarão^sSC^pBrasil#^lpt^aOBJETIVO: Analisar o im
pacto financeiro da aquisição de medicamentos com a exigência da apresentação de
 testes de biodisponibilidade e/ou bioequivalência para o componente da Assistên
cia Farmacêutica Básica. MÉTODOS: Estudo retrospectivo, documental, em atas dos 
processos licitatórios para aquisição de medicamentos em município de médio port
e de Santa Catarina. Foram analisadas licitações sem (2007) e com (2008) a exigê
ncia de testes de bioequivalência e/ou de biodisponibilidade. Avaliaram-se o núm
ero de recursos apresentados pelos fornecedores, o número de processos licitatór
ios anuais necessários para a aquisição de todos os medicamentos padronizados, o
 tempo para a finalização do processo licitatório, o número de itens fracassados
, o custo unitário dos medicamentos e o valor total da aquisição. RESULTADOS: Fo
ram observados 2,6 por cento de itens fracassados em 2007 e 56,9 por cento em 20
08. Entre os medicamentos, 60,0 por cento tiveram acréscimo e 29,3,0 por cento d
ecréscimo em 2008 em relação a 2007. Os custos totais de aquisição para 150 medi
camentos, considerando valores unitários praticados e o consumo médio anual, for
am de R$ 2.288.120,00 para 2007 e de R$ 4.270.425,00 para 2008. CONCLUSÕES: A ex
igência dos testes de bioequivalência e/ou de biodisponibilidade elevou em mais 
de 100 por cento os custos com o financiamento do Componente da Assistência Farm
acêutica Básica, indicando necessidade de discussão de uma Política de Medicamen
to Genérico em consonância com a Política de Assistência Farmacêutica e com a Re
lação Nacional de Medicamentos Essenciais.#^ddecs^i1#^tm^lpt^kMedicamentos Genér
icos^i1#^tm^lpt^kEquivalência Terapêutica^i1#^tm^lpt^kDisponibilidade Biológica^
i1#^tm^lpt^kProposta de Concorrência^i1#^tm^lpt^kAssistência Farmacêutica^i1^sEc
onomia#^len^aOBJECTIVE: To analyze the financial impact of medicine procurement 
with the required bioavailability and or bioequivalence tests for the basic phar
maceutical services component. METHODS: A retrospective study, based on document
 research of competitive bidding for medicine procurement in a medium size munic
ipality of Santa Catarina state, Southern Brazil. Bids that occurred with (2007)
 and without (2008) the requirement of bioequivalence and/or bioavailability tes
ts were analyzed. The number of resources presented by providers, the number of 
annual bidding processes necessary to acquire all the standard medicines, the ti
me to finalize the bidding process, the number of failing items, the per unit co
st of medicines and the total value of procurement were evaluated. RESULTS: In 2
007 and 2008 respectively, 2.6 percent and 56.9 percent of items failed. Among m
edicine purchases, 60.0 percent were increased and 29.3 percent decreased from 2
008 to 2007.The total procurement costs for 150 medicines, considering per unit 
costs and average annual consumption was R$ 2,288,120.00 (2007) and R$ 4,270,425
.00 (2008). CONCLUSIONS: The requirement for bioequivalence and/or bioavailabili
ty tests increased costs by more than 100 percent for the basic pharmaceutical s
ervices component. There is a need to discuss Generic Medicine Policies to agree
 with Pharmaceutical Assistance Policies and the National Essential Medicines Re
port.#^ddecs^i2#^tm^len^kDrugs, Generic^i2#^tm^len^kTherapeutic Equivalency^i2#^
tm^len^kBiological Availability^i2#^tm^len^kCompetitive Bidding^i2#^tm^len^kPhar
maceutical Services^i2^seconomics#^les^aOBJETIVO: Analizar el impacto financiero
 de la adquisición de medicamentos con la exigencia de la presentación de prueba
s de biodisponibilidad y o bioequivalencia para el componente de la Asistencia F
armacéutica Básica. MÉTODOS: Estudio retrospectivo, documental, en actas de los 
procesos licitatorios para adquisición de medicamentos en municipio de medio por
te de Santa Catarina, Sur de Brasil. Se analizaron licitaciones sin (2007) y con
 la exigencia de pruebas de bioequivalencia y/o biodisponibilidad (2008). Se eva
luaron el número de recursos presentados por los proveedores, el número de proce
sos licitatorios anuales necesarios para la adquisición de todos los medicamento
s estandarizados, el tiempo para la finalización del proceso licitatorio, el núm
ero de ítems fracasados, el costo unitario de los medicamentos y el valor total 
de la adquisición. RESULTADOS: Se observaron 2,6 por ciento de ítems fracasados 
en 2007 y 56,9 por ciento en 2008. Entre los medicamentos, 60,0 por ciento tuvie
ron incremento y 29,3 por ciento, disminución en 2008 con relación a 2007. Los c
ostos totales de adquisición para 150 medicamentos, considerando valores unitari
os practicados y el consumo promedio anual, fueron de R$ 2.288.120,00 para 2007 
y de R$ 4.270.425,00 para 2008. CONCLUSIONES: La exigencia de las pruebas de bio
equivalencia y/o biodisponibilidad elevó en más de 100 por ciento los costos con
 el financiamiento de la Asistencia Farmacéutica Básica, indicando necesidad de 
discusión de una Política de Medicamento Genérico en consonancia con la Política
 de Asistencia Farmacéutica y con la Relación Nacional de Medicamentos Esenciale
s.#^ddecs^i3#^tm^les^kMedicamentos Genéricos^i3#^tm^les^kEquivalencia Terapéutic
a^i3#^tm^les^kDisponibilidad Biológica^i3#^tm^les^kPropuestas de Licitación^i3#^
tm^les^kServicios Farmacéutico^i3^seconomía#vancouv#16#20100602#2/6/2010#2010111
4#14/11/2010#2315.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_artte
xt&pid=S0034-89102011005000020##
00447000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704021300079002000900292#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#5#1#article#135#<p><a name="top"
></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Aquisi&ccedi
l;&atilde;o    de medicamentos gen&eacute;ricos em munic&iacute;pio de m&eacute;
dio porte</b>    </font></p>     ^cY#2315.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#6#2#article#135#<p>&nbsp;</p>   
  ^cY#2315.htm##
00389000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704015500079002000900234#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#7#3#article#135#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Procurement    of generic medi
cines in a medium size municipality</b></font></p>     ^cY#2315.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#8#4#article#135#<p>&nbsp;</p>   
  ^cY#2315.htm##
00406000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704017200079002000900251#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#9#5#article#135#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Adquisici&oacute;n    de medic
amentos gen&eacute;ricos en municipio de medio porte</b></font></p>     ^cY#2315
.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#10#6#article#135#<p>&nbsp;</p>  
   ^cY#2315.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#11#7#article#135#<p>&nbsp;</p>  
   ^cY#2315.htm##
00438000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704020300080002000900283#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#12#8#article#135#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Gabriela Bevilacqua<sup>I</su
p>;    Mareni Rocha Farias<sup>I, II</sup>; Carine Raquel Blatt<sup>I, II, III</
sup></b></font></p>     ^cY#2315.htm##
00528000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704029300080002000900373#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#13#9#article#135#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Curso    de Especial
iza&ccedil;&atilde;o em Gest&atilde;o da Assist&ecirc;ncia Farmac&ecirc;utica.  
  Curso de Farm&aacute;cia. Universidade Federal de Santa Catarina (UFSC). Flori
an&oacute;polis,    SC, Brasil    ^cY#2315.htm##
00398000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704016200081002000900243#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#14#10#article#135#<br>   <sup>II
</sup>Programa de P&oacute;s-Gradua&ccedil;&atilde;o em Farm&aacute;cia.    Curs
o de Farm&aacute;cia. UFSC. Florian&oacute;polis, SC, Brasil    ^cY#2315.htm##
00382000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014600081002000900227#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#15#11#article#135#<br>   <sup>II
I</sup>Curso de Farm&aacute;cia e Medicina. Universidade do Sul de Santa    Cata
rina. Tubar&atilde;o, SC, Brasil</font></p>     ^cY#2315.htm##
00380000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014400081002000900225#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#16#12#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecir
c;ncia    | Correspondence</a></font></p>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#17#13#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704004400081002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#18#14#article#135#<p>&nbsp;</p> 
<hr size="1" noshade>     ^cY#2315.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#19#15#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^c
Y#2315.htm##
00592000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035600081002000900437#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#20#16#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analisar o 
impacto financeiro da aquisi&ccedil;&atilde;o de medicamentos com    a exig&ecir
c;ncia da apresenta&ccedil;&atilde;o de testes de biodisponibilidade    e/ou bio
equival&ecirc;ncia para o componente da Assist&ecirc;ncia Farmac&ecirc;utica    
B&aacute;sica.    ^cY#2315.htm##
01044000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704080800081002000900889#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#21#17#article#135#<br>   <b>M&Ea
cute;TODOS:</b> Estudo retrospectivo, documental, em atas dos processos    licit
at&oacute;rios para aquisi&ccedil;&atilde;o de medicamentos em munic&iacute;pio 
   de m&eacute;dio porte de Santa Catarina. Foram analisadas licita&ccedil;&otil
de;es    sem (2007) e com (2008) a exig&ecirc;ncia de testes de bioequival&ecirc
;ncia    e/ou de biodisponibilidade. Avaliaram-se o n&uacute;mero de recursos ap
resentados    pelos fornecedores, o n&uacute;mero de processos licitat&oacute;ri
os anuais    necess&aacute;rios para a aquisi&ccedil;&atilde;o de todos os medic
amentos padronizados,    o tempo para a finaliza&ccedil;&atilde;o do processo li
citat&oacute;rio, o n&uacute;mero    de itens fracassados, o custo unit&aacute;r
io dos medicamentos e o valor total    da aquisi&ccedil;&atilde;o.    ^cY#2315.h
tm##
00690000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704045400081002000900535#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#22#18#article#135#<br>   <b>RESU
LTADOS:</b> Foram observados 2,6% de itens fracassados em 2007 e 56,9%    em 200
8. Entre os medicamentos, 60,0% tiveram acr&eacute;scimo e 29,3,0% decr&eacute;s
cimo    em 2008 em rela&ccedil;&atilde;o a 2007. Os custos totais de aquisi&cced
il;&atilde;o    para 150 medicamentos, considerando valores unit&aacute;rios pra
ticados e o    consumo m&eacute;dio anual, foram de R$ 2.288.120,00 para 2007 e 
de R$ 4.270.425,00    para 2008.    ^cY#2315.htm##
00752000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051600081002000900597#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#23#19#article#135#<br>   <b>CONC
LUS&Otilde;ES:</b> A exig&ecirc;ncia dos testes de bioequival&ecirc;ncia    e/ou
 de biodisponibilidade elevou em mais de 100% os custos com o financiamento    d
o Componente da Assist&ecirc;ncia Farmac&ecirc;utica B&aacute;sica, indicando   
 necessidade de discuss&atilde;o de uma Pol&iacute;tica de Medicamento Gen&eacut
e;rico    em conson&acirc;ncia com a Pol&iacute;tica de Assist&ecirc;ncia Farmac
&ecirc;utica    e com a Rela&ccedil;&atilde;o Nacional de Medicamentos Essenciai
s.</font></p>     ^cY#2315.htm##
00552000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704031600081002000900397#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#24#20#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Medicame
ntos Gen&eacute;ricos. Equival&ecirc;ncia Terap&ecirc;utica. Disponibilidade    
Biol&oacute;gica. Proposta de Concorr&ecirc;ncia. Assist&ecirc;ncia Farmac&ecirc
;utica,    Economia.</font></p> <hr size="1" noshade>     ^cY#2315.htm##
00334000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009800081002000900179#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#25#21#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     
^cY#2315.htm##
00497000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704026100081002000900342#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#26#22#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To analyze
 the financial impact of medicine procurement with the required bioavailability 
   and or bioequivalence tests for the basic pharmaceutical services component. 
   ^cY#2315.htm##
00874000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704063800081002000900719#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#27#23#article#135#<br>   <b>METH
ODS:</b> A retrospective study, based on document research of competitive    bid
ding for medicine procurement in a medium size municipality of Santa Catarina   
 state, Southern Brazil. Bids that occurred with (2007) and without (2008) the  
  requirement of bioequivalence and/or bioavailability tests were analyzed. The 
   number of resources presented by providers, the number of annual bidding proc
esses    necessary to acquire all the standard medicines, the time to finalize t
he bidding    process, the number of failing items, the per unit cost of medicin
es and the    total value of procurement were evaluated.    ^cY#2315.htm##
00586000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035000081002000900431#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#28#24#article#135#<br>   <b>RESU
LTS:</b> In 2007 and 2008 respectively, 2.6% and 56.9% of items failed.    Among
 medicine purchases, 60.0% were increased and 29.3% decreased from 2008    to 20
07.The total procurement costs for 150 medicines, considering per unit    costs 
and average annual consumption was R$ 2,288,120.00 (2007) and R$ 4,270,425.00   
 (2008).    ^cY#2315.htm##
00585000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034900081002000900430#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#29#25#article#135#<br>   <b>CONC
LUSIONS:</b> The requirement for bioequivalence and/or bioavailability    tests 
increased costs by more than 100% for the basic pharmaceutical services    compo
nent. There is a need to discuss Generic Medicine Policies to agree with    Phar
maceutical Assistance Policies and the National Essential Medicines Report.</fon
t></p>     ^cY#2315.htm##
00489000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704025300081002000900334#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#30#26#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:</b>    Drugs, G
eneric. Therapeutic Equivalency. Biological Availability. Competitive    Bidding
. Pharmaceutical Services, economics.</font></p> <hr size="1" noshade>     ^cY#2
315.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#31#27#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^
cY#2315.htm##
00570000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704033400081002000900415#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#32#28#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analizar el
 impacto financiero de la adquisici&oacute;n de medicamentos con    la exigencia
 de la presentaci&oacute;n de pruebas de biodisponibilidad y o bioequivalencia  
  para el componente de la Asistencia Farmac&eacute;utica B&aacute;sica.    ^cY#
2315.htm##
00983000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704074700081002000900828#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#33#29#article#135#<br>   <b>M&Ea
cute;TODOS:</b> Estudio retrospectivo, documental, en actas de los procesos    l
icitatorios para adquisici&oacute;n de medicamentos en municipio de medio porte 
   de Santa Catarina, Sur de Brasil. Se analizaron licitaciones sin (2007) y con
    la exigencia de pruebas de bioequivalencia y/o biodisponibilidad (2008). Se 
   evaluaron el n&uacute;mero de recursos presentados por los proveedores, el n&
uacute;mero    de procesos licitatorios anuales necesarios para la adquisici&oac
ute;n de todos    los medicamentos estandarizados, el tiempo para la finalizaci&
oacute;n del proceso    licitatorio, el n&uacute;mero de &iacute;tems fracasados
, el costo unitario    de los medicamentos y el valor total de la adquisici&oacu
te;n.    ^cY#2315.htm##
00673000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704043700081002000900518#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#34#30#article#135#<br>   <b>RESU
LTADOS:</b> Se observaron 2,6% de &iacute;tems fracasados en 2007 y 56,9%    en 
2008. Entre los medicamentos, 60,0% tuvieron incremento y 29,3%, disminuci&oacut
e;n    en 2008 con relaci&oacute;n a 2007. Los costos totales de adquisici&oacut
e;n    para 150 medicamentos, considerando valores unitarios practicados y el co
nsumo    promedio anual, fueron de R$ 2.288.120,00 para 2007 y de R$ 4.270.425,0
0 para    2008.    ^cY#2315.htm##
00715000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704047900081002000900560#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#35#31#article#135#<br>   <b>CONC
LUSIONES:</b> La exigencia de las pruebas de bioequivalencia y/o biodisponibilid
ad    elev&oacute; en m&aacute;s de 100% los costos con el financiamiento de la 
Asistencia    Farmac&eacute;utica B&aacute;sica, indicando necesidad de discusi&
oacute;n de    una Pol&iacute;tica de Medicamento Gen&eacute;rico en consonancia
 con la Pol&iacute;tica    de Asistencia Farmac&eacute;utica y con la Relaci&oac
ute;n Nacional de Medicamentos    Esenciales.</font></p>     ^cY#2315.htm##
00548000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704031200081002000900393#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#36#32#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:</b>    Medicam
entos Gen&eacute;ricos. Equivalencia Terap&eacute;utica. Disponibilidad    Biol&
oacute;gica. Propuestas de Licitaci&oacute;n. Servicios Farmac&eacute;utico,    
econom&iacute;a.</font></p> <hr size="1" noshade>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#37#33#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#38#34#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00350000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011400081002000900195#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#39#35#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b>
</font></p>     ^cY#2315.htm##
01317000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704108100081002000901162#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#40#36#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Apesar de a descentraliza&ccedi
l;&atilde;o    das a&ccedil;&otilde;es de sa&uacute;de no setor p&uacute;blico t
er-se iniciado    em 1990, at&eacute; 1997 os processos de aquisi&ccedil;&atilde
;o de medicamentos    obedeceram a um modelo centralizado de gest&atilde;o, real
izados pela Central    de Medicamentos (Ceme). A extin&ccedil;&atilde;o desse &o
acute;rg&atilde;o,    aliada &agrave; publica&ccedil;&atilde;o da Pol&iacute;tic
a Nacional de Medicamentos    em 1998,<sup>6</sup> refor&ccedil;ou a pol&iacute;
tica de descentraliza&ccedil;&atilde;o    proposta para o Sistema &Uacute;nico d
e Sa&uacute;de (SUS), transferindo responsabilidades    de operacionaliza&ccedil
;&atilde;o da gest&atilde;o da assist&ecirc;ncia farmac&ecirc;utica    para os m
unic&iacute;pios.<sup>9</sup> Com isso, conforme Kornis,<sup>6</sup>    os probl
emas de gest&atilde;o e de financiamento somaram-se aos de log&iacute;stica    d
e abastecimento no quadro dos grandes desafios da assist&ecirc;ncia farmac&ecirc
;utica.</font></p>     ^cY#2315.htm##
00798000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704056200081002000900643#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#41#37#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As aquisi&ccedil;&otilde;es    
de medicamentos no servi&ccedil;o p&uacute;blico s&atilde;o realizadas mediante 
   processo licitat&oacute;rio, com concorr&ecirc;ncia entre participantes. Cont
udo,    considerando que os recursos s&atilde;o finitos, o desafio dos gestores 
p&uacute;blicos    &eacute; planejar o processo de aquisi&ccedil;&atilde;o de me
dicamentos para    que a qualidade do produto adquirido n&atilde;o seja prejudic
ada pela necessidade    de economia.<sup>8</sup></font></p>     ^cY#2315.htm##
00628000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704039200081002000900473#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#42#38#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Al&eacute;m de    transferir a 
responsabilidade de realizar a aquisi&ccedil;&atilde;o dos medicamentos    aos e
stados e munic&iacute;pios, a Pol&iacute;tica Nacional de Medicamentos<sup>6</su
p>    tamb&eacute;m adotou como prioridades o registro e utiliza&ccedil;&atilde;
o    de medicamentos gen&eacute;ricos.</font></p>     ^cY#2315.htm##
00913000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704067700081002000900758#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#43#39#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os medicamentos    gen&eacute;r
icos s&atilde;o definidos como produtos semelhantes a outros produtos    de refe
r&ecirc;ncia ou inovadores, com que podem ser intercambi&aacute;veis    e design
ados pela Denomina&ccedil;&atilde;o Comum Brasileira (DCB) ou Denomina&ccedil;&a
tilde;o    Comum Internacional (DCI).<a name="topa"></a><a href="#backa">ª</a> S
&atilde;o    geralmente produzidos ap&oacute;s o t&eacute;rmino ou ren&uacute;nc
ia da prote&ccedil;&atilde;o    patent&aacute;ria ou de outro direito de exclusi
vidade, desde que comprovadas    sua efic&aacute;cia, seguran&ccedil;a e qualida
de.</font></p>     ^cY#2315.htm##
01046000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704081000081002000900891#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#44#40#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A Pol&iacute;tica    de Medicam
entos Gen&eacute;ricos tem sido considerada nacional e internacionalmente    com
o estrat&eacute;gia para diminuir os custos e promover o acesso aos medicamentos
.<sup>3-5,16</sup>    No Brasil, a intercambialidade do medicamento gen&eacute;r
ico com o de refer&ecirc;ncia    &eacute; assegurada por testes de equival&ecirc
;ncia farmac&ecirc;utica e de    bioequival&ecirc;ncia realizados por laborat&oa
cute;rios credenciados pela Ag&ecirc;ncia    Nacional de Vigil&acirc;ncia Sanit&
aacute;ria (Anvisa), e sua qualidade, pelo    monitoramento das unidades produti
vas quanto ao atendimento das Boas Pr&aacute;ticas    de Fabrica&ccedil;&atilde;
o (BPF), de acordo com a RDC nº 210/Anvisa.<sup>12</sup></font></p>     ^cY#2315
.htm##
00878000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704064200081002000900723#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#45#41#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A Anvisa exige    comprova&cced
il;&atilde;o de equival&ecirc;ncia terap&ecirc;utica para todos    os medicament
os de uso oral e venda sob prescri&ccedil;&atilde;o m&eacute;dica,    por meio d
e demonstra&ccedil;&atilde;o de bioequival&ecirc;ncia por testes <i>in    vivo</
i> de biodisponibilidade relativa. Para os medicamentos de uso n&atilde;o    ora
l e oral de venda sem prescri&ccedil;&atilde;o m&eacute;dica, a equival&ecirc;nc
ia    terap&ecirc;utica &eacute; comprovada por testes <i>in vitro</i> de equiva
l&ecirc;ncia    farmac&ecirc;utica.<sup>13</sup></font></p>     ^cY#2315.htm##
01338000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704110200081002000901183#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#46#42#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Um estudo sobre    tend&ecirc;n
cias regulat&oacute;rias relacionadas com os medicamentos gen&eacute;ricos    em
 14 pa&iacute;ses da America Latina e Caribe apontou que os aspectos mais    fre
q&uuml;entes na regula&ccedil;&atilde;o da Pol&iacute;tica de Medicamentos    Ge
n&eacute;ricos s&atilde;o a obrigatoriedade de utilizar a DCI no r&oacute;tulo  
  dos gen&eacute;ricos (em 13 dos 14 pa&iacute;ses), a obrigatoriedade de fazer 
   a prescri&ccedil;&atilde;o em &acirc;mbito p&uacute;blico com a DCI (12 dos  
  14) e os processos de aquisi&ccedil;&atilde;o em &acirc;mbito p&uacute;blico  
  com a DCI (11 dos 14).<sup>15</sup> O Brasil preenche todos esses crit&eacute;
rios    e ainda estabelece que se d&ecirc; prefer&ecirc;ncia ao medicamento gen&
eacute;rico    nas compras p&uacute;blicas quando houver igualdade de pre&ccedil
;o e das demais    condi&ccedil;&otilde;es de aquisi&ccedil;&atilde;o, e obriga 
a Anvisa a editar    periodicamente a rela&ccedil;&atilde;o dos gen&eacute;ricos
 registrados no Pa&iacute;s.</font></p>     ^cY#2315.htm##
00820000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704058400081002000900665#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#47#43#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Contudo, essas    medidas parec
em insuficientes para garantir a disponibilidade de gen&eacute;ricos    nos serv
i&ccedil;os p&uacute;blicos, uma vez que, predominantemente, s&atilde;o    adqui
ridos medicamentos similares e n&atilde;o os gen&eacute;ricos ou os de    refer&
ecirc;ncia. Conforme estudo realizado por Miranda et al<sup>11</sup> em    difer
entes regi&otilde;es do Brasil, apenas 25% dos medicamentos dispon&iacute;veis  
  nos servi&ccedil;os p&uacute;blicos estudados eram gen&eacute;ricos.</font></p
>     ^cY#2315.htm##
00972000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704073600081002000900817#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#48#44#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Diferentes explica&ccedil;&otil
de;es    para a predomin&acirc;ncia dos similares nas compras p&uacute;blicas po
dem ser    indicadas, como problemas no cumprimento da legisla&ccedil;&atilde;o,
 desinteresse    dos ofertantes de gen&eacute;ricos em participar de compras p&u
acute;blicas    e oferta de melhores pre&ccedil;os para similares.<sup>13</sup> 
O que determina    as diferen&ccedil;as entre gen&eacute;ricos e similares n&ati
lde;o &eacute;    a exist&ecirc;ncia de boas pr&aacute;ticas de manufatura ou da
 qualidade intr&iacute;nseca,    exig&ecirc;ncia para todos, mas sim a bioequiva
l&ecirc;ncia com o produto de    refer&ecirc;ncia.<sup>6</sup></font></p>     ^c
Y#2315.htm##
01084000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704084800081002000900929#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#49#45#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os similares s&atilde;o    medi
camentos-c&oacute;pia existentes antes da Lei dos Gen&eacute;ricos que,    a par
tir de maio de 2003, devem se assemelhar a gen&eacute;ricos, mediante apresenta&
ccedil;&atilde;o    dos mesmos testes, no momento de renova&ccedil;&atilde;o do 
registro.<sup>6</sup>    Dessa maneira, os medicamentos fabricados a partir de n
ovembro de 2009 devem    comprovar equival&ecirc;ncia farmac&ecirc;utica (teste 
<i>in vitro</i>), e os    antibi&oacute;ticos, antineopl&aacute;sicos e antirret
rovirais de uso oral est&atilde;o    passando por teste de biodisponibilidade re
lativa (teste <i>in vivo</i>). At&eacute;    outubro de 2014, todas as demais cl
asses terap&ecirc;uticas de uso oral ter&atilde;o    passado pelos mesmos testes
.<sup>13</sup></font></p>     ^cY#2315.htm##
01497000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704126100081002000901342#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#50#46#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Contudo, apesar    dessas mudan
&ccedil;as, os medicamentos similares s&atilde;o vistos com desconfian&ccedil;a 
   por gestores, profissionais da sa&uacute;de e pacientes. Estudos realizados  
  no Pa&iacute;s mostraram problemas de qualidade em parte desses medicamentos. 
   Batistic et al<sup>1</sup> compilaram dados de an&aacute;lises f&iacute;sicas
    e de orienta&ccedil;&atilde;o da qualidade de comprimidos revestidos e solu&
ccedil;&otilde;es    orais de sulfato ferroso durante o per&iacute;odo de quatro
 anos e encontraram    37% das amostras em desacordo com as especifica&ccedil;&o
tilde;es de qualidade,    como inconformidade na rotulagem, teor de princ&iacute
;pio ativo (acima ou abaixo    do declarado), peso m&eacute;dio, rachaduras nos 
comprimidos e presen&ccedil;a    de precipitados em solu&ccedil;&otilde;es. Estu
do<sup>2</sup> avaliou a qualidade    de comprimidos de enalapril 10 mg e de pro
pranolol 40 mg adquiridos em processo    licitat&oacute;rio e distribu&iacute;do
s na rede p&uacute;blica de sa&uacute;de    de um munic&iacute;pio catarinense d
urante o per&iacute;odo de um ano e observou    que, de sete lotes, cinco aprese
ntaram desvio da qualidade.</font></p>     ^cY#2315.htm##
00893000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704065700081002000900738#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#51#47#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">No munic&iacute;pio    investig
ado, em 2008, ap&oacute;s ampla discuss&atilde;o entre gestores e profissionais 
   de sa&uacute;de sobre a Pol&iacute;tica Nacional de Medicamentos, a Pol&iacut
e;tica    Nacional de Assist&ecirc;ncia Farmac&ecirc;utica, a Pol&iacute;tica Na
cional    de Gen&eacute;ricos e a despeito das d&uacute;vidas em rela&ccedil;&at
ilde;o    &agrave; qualidade dos medicamentos similares, realizou-se aquisi&cced
il;&atilde;o    de medicamentos exigindo que os produtos ofertados apresentassem
 testes de bioequival&ecirc;ncia    e/ou de biodisponibilidade.</font></p>     ^
cY#2315.htm##
00615000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704037900081002000900460#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#52#48#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O objetivo deste    estudo foi 
analisar o impacto financeiro da aquisi&ccedil;&atilde;o de medicamentos    com 
a exig&ecirc;ncia da apresenta&ccedil;&atilde;o de testes de biodisponibilidade 
   e/ou bioequival&ecirc;ncia para o componente da Assist&ecirc;ncia Farmac&ecir
c;utica    B&aacute;sica.</font></p>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#53#49#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00340000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010400081002000900185#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#54#50#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p
>     ^cY#2315.htm##
00587000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035100081002000900432#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#55#51#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudo retrospectivo,    fundam
entado em pesquisa documental das atas dos processos licitat&oacute;rios    para
 aquisi&ccedil;&atilde;o de medicamentos realizados pela Secretaria Municipal   
 de Sa&uacute;de de munic&iacute;pio de m&eacute;dio porte de Santa Catarina.</f
ont></p>     ^cY#2315.htm##
00700000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704046400081002000900545#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#56#52#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O munic&iacute;pio    possu&iac
ute;a aproximadamente 170.000 habitantes e uma lista de medicamentos    do compo
nente da Assist&ecirc;ncia Farmac&ecirc;utica B&aacute;sica composta    de 171 i
tens em 2007, ampliada para 195 itens em 2008. A modalidade de aquisi&ccedil;&at
ilde;o    utilizada em ambos os anos do estudo foi o preg&atilde;o presencial co
m registro    de pre&ccedil;o.</font></p>     ^cY#2315.htm##
01250000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704101400081002000901095#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#57#53#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A coordena&ccedil;&atilde;o    
de Assist&ecirc;ncia Farmac&ecirc;utica participou da elabora&ccedil;&atilde;o  
  do edital, da an&aacute;lise t&eacute;cnica das propostas e do recebimento dos
    medicamentos. As exig&ecirc;ncias jur&iacute;dicas e econ&ocirc;mico-finance
iras    dos editais, bem como a execu&ccedil;&atilde;o do preg&atilde;o foram de
 responsabilidade    do setor de compras da Secretaria Municipal de Sa&uacute;de
, juntamente com    o setor respons&aacute;vel pelas licita&ccedil;&otilde;es da
 Secretaria Municipal    de Administra&ccedil;&atilde;o. A programa&ccedil;&atil
de;o da aquisi&ccedil;&atilde;o    de medicamentos foi feita para 12 meses e o p
rocesso licitat&oacute;rio, realizado    no primeiro trimestre. Quando os itens 
licitados n&atilde;o puderam ser adquiridos,    realizou-se novo processo licita
t&oacute;rio. Essa a&ccedil;&atilde;o repetiu-se    at&eacute; que todos os iten
s fossem adquiridos.</font></p>     ^cY#2315.htm##
00579000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034300081002000900424#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#58#54#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O ano de 2007 foi    escolhido 
porque a aquisi&ccedil;&atilde;o de medicamentos foi realizada sem    a exig&eci
rc;ncia da apresenta&ccedil;&atilde;o dos testes de biodisponibilidade    e/ou d
e bioequival&ecirc;ncia exigidos em 2008, comparando-se os dois anos.</font></p>
     ^cY#2315.htm##
00761000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704052500081002000900606#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#59#55#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Analisou-se o n&uacute;mero    
de recursos apresentados pelos fornecedores, o n&uacute;mero de processos licita
t&oacute;rios    anuais necess&aacute;rios para a aquisi&ccedil;&atilde;o de tod
os os medicamentos    padronizados, o tempo para a finaliza&ccedil;&atilde;o do 
processo licitat&oacute;rio,    a propor&ccedil;&atilde;o de itens n&atilde;o co
tados (fracassados), o custo    unit&aacute;rio e o valor total de aquisi&ccedil
;&atilde;o.</font></p>     ^cY#2315.htm##
00681000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704044500081002000900526#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#60#56#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Foram coletados    o valor unit
&aacute;rio dos medicamentos cotados e a quantidade adquirida. A    partir da di
feren&ccedil;a de valor unit&aacute;rio de cada medicamento licitado    nos dois
 anos em an&aacute;lise, determinou-se a propor&ccedil;&atilde;o de    itens com
 valores superiores e inferiores, e a m&eacute;dia das diferen&ccedil;as    em p
ercentagem.</font></p>     ^cY#2315.htm##
00842000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704060600081002000900687#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#61#57#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O impacto financeiro    total d
a aquisi&ccedil;&atilde;o de gen&eacute;ricos foi avaliado mediante a    previs&
atilde;o de consumo m&eacute;dio anual e custo unit&aacute;rio de cada    medica
mento nos anos analisados. Quando da exist&ecirc;ncia de mais de um processo    
licitat&oacute;rio para aquisi&ccedil;&atilde;o de um mesmo medicamento, o custo
    unit&aacute;rio foi calculado pela m&eacute;dia dos valores. Os medicamentos
    n&atilde;o gen&eacute;ricos adquiridos em 2008 foram exclu&iacute;dos da an&
aacute;lise.</font></p>     ^cY#2315.htm##
00581000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034500081002000900426#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#62#58#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Inclu&iacute;ram-se    na an&aa
cute;lise do custo total os medicamentos adquiridos em 2007 e os adquiridos    n
os dois primeiros preg&otilde;es de 2008, sob a exig&ecirc;ncia de medicamento  
  gen&eacute;rico ou de refer&ecirc;ncia, totalizando 150 medicamentos.</font></
p>     ^cY#2315.htm##
00469000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704023300081002000900314#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#63#59#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os valores monet&aacute;rios   
 de 2007 foram atualizados segundo o &Iacute;ndice Geral de Pre&ccedil;os - Disp
onibilidade    Interna da FGV (IGP-DI).</font></p>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#64#60#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010000081002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#65#61#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>   
  ^cY#2315.htm##
01027000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079100081002000900872#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#66#62#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Foram realizados    sete proces
sos licitat&oacute;rios, tr&ecirc;s em 2007 e quatro em 2008. Em    2007, na pri
meira licita&ccedil;&atilde;o, o percentual de itens fracassados    foi de 2,6%,
 enquanto na primeira licita&ccedil;&atilde;o de 2008 esse percentual    foi de 
56,9% (<a href="#t">Tabela</a>). Ap&oacute;s o fracasso de duas tentativas    de
 aquisi&ccedil;&atilde;o com a exig&ecirc;ncia dos gen&eacute;ricos em 2008,    
a Secretaria de Sa&uacute;de optou por realizar a aquisi&ccedil;&atilde;o sem   
 essa exig&ecirc;ncia, para n&atilde;o comprometer a disponibilidade dos medicam
entos.    O tempo para a finaliza&ccedil;&atilde;o do processo licitat&oacute;ri
o foi    de sete meses nos dois anos.</font></p>     ^cY#2315.htm##
00268000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003200081002000900113#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#67#63#article#135#<p><a name="t"
></a></p>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#68#64#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00317000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008100081002000900162#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#69#65#article#135#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2315t.jpg"></p>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#70#66#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00799000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704056300081002000900644#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#71#67#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Mesmo antes da    realiza&ccedi
l;&atilde;o do primeiro preg&atilde;o em 2008, um laborat&oacute;rio    farmac&e
circ;utico protocolou impugna&ccedil;&atilde;o ao edital e solicitou    reconsid
era&ccedil;&atilde;o quanto &agrave; exig&ecirc;ncia da apresenta&ccedil;&atilde
;o    de testes de biodisponibilidade e/ou bioequival&ecirc;ncia, e esse foi o &
uacute;nico    recurso relacionado &agrave;s exig&ecirc;ncias t&eacute;cnicas de
scrito nas    atas dos preg&otilde;es analisados.</font></p>     ^cY#2315.htm##
00586000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035000081002000900431#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#72#68#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As diferen&ccedil;as    entre o
s valores unit&aacute;rios estratificadas por aumento, diminui&ccedil;&atilde;o 
   e sem altera&ccedil;&atilde;o de valor observadas nas licita&ccedil;&otilde;e
s    de 2007 e 2008 est&atilde;o apresentadas na <a href="#f1">Figura 1</a>.</fo
nt></p>     ^cY#2315.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#73#69#article#135#<p><a name="f1
"></a></p>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#74#70#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#75#71#article#135#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2315f01.jpg"></p>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#76#72#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
01277000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704104100081002000901122#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#77#73#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Dos 150 itens analisados,    90
 apresentaram valor unit&aacute;rio de aquisi&ccedil;&atilde;o maior em 2008.   
 O aumento m&eacute;dio dos valores unit&aacute;rios foi de 246,98% (Desvio padr
&atilde;o    - DP = 4,58). A maior diferen&ccedil;a encontrada foi para o medica
mento fenobarbital    100 mg, adquirido por R$ 0,03 cada comprimido em 2007 e R$
 0,88 em 2008, resultando    em diferen&ccedil;a de 3.163%. Em 2008, 44 itens ti
veram pre&ccedil;o menor    comparados a 2007. A maior diferen&ccedil;a entre os
 valores foi de 34,0%, com    m&eacute;dia de 12,7% (DP = 0,09). Os demais medic
amentos analisados n&atilde;o    apresentaram diferen&ccedil;as entre os valores
 unit&aacute;rios de 2008 e 2007.    Em 2007, aquisi&ccedil;&atilde;o dos 150 me
dicamentos custaria R$ 2.288.120,00.    Em 2008, os mesmos medicamentos, nas mes
mas quantidades, custariam R$ 4.270.425,00,    o que corresponde a aumento de ap
roximadamente 87% (<a href="#f2">Figura 2</a>).</font></p>     ^cY#2315.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#78#74#article#135#<p><a name="f2
"></a></p>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#79#75#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#80#76#article#135#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2315f02.jpg"></p>     ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#81#77#article#135#<p>&nbsp;</p> 
    ^cY#2315.htm##
00342000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010600081002000900187#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#82#78#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font><
/p>     ^cY#2315.htm##
00762000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704052600081002000900607#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#83#79#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A distin&ccedil;&atilde;o    en
tre os dois per&iacute;odos do estudo foi a exig&ecirc;ncia de testes de biodisp
onibilidade    e/ou de bioequival&ecirc;ncia. Essa exig&ecirc;ncia foi respons&a
acute;vel pelas    diferen&ccedil;as no n&uacute;mero de recursos, no n&uacute;m
ero de processos    licitat&oacute;rios, no n&uacute;mero de itens fracassados, 
no custo unit&aacute;rio    e no total do valor de aquisi&ccedil;&atilde;o dos m
edicamentos.</font></p>     ^cY#2315.htm##
01034000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079800081002000900879#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#84#80#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A exig&ecirc;ncia    t&eacute;c
nica de apresenta&ccedil;&atilde;o de testes de biodisponibilidade    e/ou de bi
oequival&ecirc;ncia pode gerar processos de impugna&ccedil;&atilde;o    do edita
l, o que pode tornar o processo mais moroso, mas n&atilde;o desrespeita    os pr
inc&iacute;pios da licita&ccedil;&atilde;o p&uacute;blica. Devido ao elevado    
percentual de itens fracassados na primeira e na segunda licita&ccedil;&otilde;e
s    de 2008, foi necess&aacute;ria a realiza&ccedil;&atilde;o do terceiro proce
sso    licitat&oacute;rio, para o qual n&atilde;o foram exigidos os testes de bi
odisponibilidade    e/ou bioequival&ecirc;ncia devido &agrave; possibilidade de 
desabastecimento    da rede de sa&uacute;de.</font></p>     ^cY#2315.htm##
01091000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704085500081002000900936#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#85#81#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O tempo para a    finaliza&cced
il;&atilde;o do processo licitat&oacute;rio foi o mesmo para os    dois anos pes
quisados. Por&eacute;m, aproximadamente 98% dos itens de 2007 obtiveram    regis
tro de pre&ccedil;o no primeiro processo licitat&oacute;rio, enquanto aproximada
mente    25% dos itens de 2008 somente tiveram seu registro de pre&ccedil;o no &
uacute;ltimo    processo licitat&oacute;rio. Maior n&uacute;mero de itens adquir
idos no primeiro    processo licitat&oacute;rio &eacute; importante para a garan
tia do suprimento    dos medicamentos, evitando falta nas unidades de sa&uacute;
de. O n&uacute;mero    de itens em falta e o tempo de desabastecimento n&atilde;
o puderam ser estimados,    pois n&atilde;o s&atilde;o registrados no sistema de
 controle de estoque.</font></p>     ^cY#2315.htm##
00769000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704053300081002000900614#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#86#82#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A sele&ccedil;&atilde;o    da r
ela&ccedil;&atilde;o municipal de medicamentos foi baseada na Rela&ccedil;&atild
e;o    Nacional de Medicamentos Essenciais (Rename), com 70% dos itens padroniza
dos    na mesma apresenta&ccedil;&atilde;o. Contudo, a falta de cota&ccedil;&ati
lde;o    dos medicamentos gen&eacute;ricos no processo de licita&ccedil;&atilde;
o foi    expressiva e pode ser explicada por caracter&iacute;sticas do mercado d
e gen&eacute;ricos.</font></p>     ^cY#2315.htm##
00639000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704040300081002000900484#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#87#83#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Apesar do aumento    da produ&c
cedil;&atilde;o de gen&eacute;ricos no Pa&iacute;s de 2,7 milh&otilde;es    de u
nidades em junho de 2000 para 200 milh&otilde;es em dezembro de 2005, como    ap
ontam Quental et al,<sup>12</sup> boa parte desse crescimento deve-se &agrave;s 
   expensas dos medicamentos de refer&ecirc;ncia.</font></p>     ^cY#2315.htm##
01019000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704078300081002000900864#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#88#84#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Segundo Homedes    et al,<sup>4
</sup> o Brasil possu&iacute;a 1.033 medicamentos gen&eacute;ricos    em 2005, n
&uacute;mero considerado bastante expressivo em compara&ccedil;&atilde;o    a ou
tros pa&iacute;ses da Am&eacute;rica Latina. Contudo, Miranda<sup>11</sup>    ap
onta que faltam gen&eacute;ricos na lista da Rename no Pa&iacute;s. Na vers&atil
de;o    de 2006 da lista brasileira de medicamentos essenciais, dos 330 f&aacute
;rmacos    em 522 apresenta&ccedil;&otilde;es, 116 (35,2%) em 210 (40,2%) eram m
edicamentos    gen&eacute;ricos, i.e., havia 214 (64,9%) princ&iacute;pios ativo
s na Rename    para os quais n&atilde;o existiam vers&otilde;es gen&eacute;ricas
 no Pa&iacute;s.<sup>11</sup></font></p>     ^cY#2315.htm##
01198000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704096200081002000901043#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#89#85#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Conforme Miranda    et al,<sup>
11</sup> a Pol&iacute;tica Nacional de Medicamentos orienta quanto    &agrave;s 
possibilidades de integra&ccedil;&atilde;o das estrat&eacute;gias    de acesso, 
tais como produ&ccedil;&atilde;o p&uacute;blica, pol&iacute;tica    de gen&eacut
e;ricos e lista de medicamentos essenciais. Os medicamentos selecionados    por 
crit&eacute;rios de essencialidade da Rename, por atenderem &agrave;s necessidad
es    priorit&aacute;rias de aten&ccedil;&atilde;o &agrave; sa&uacute;de do Pa&i
acute;s,    deveriam tamb&eacute;m constituir a base para a produ&ccedil;&atilde
;o de gen&eacute;ricos.<sup>10</sup>    Portanto, &eacute; necess&aacute;ria uma
 interface entre a Pol&iacute;tica de    Medicamentos Gen&eacute;ricos e a Pol&i
acute;tica de Assist&ecirc;ncia Farmac&ecirc;utica,    com o incentivo para a pr
odu&ccedil;&atilde;o dos medicamentos da Rename.</font></p>     ^cY#2315.htm##
00626000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704039000081002000900471#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#90#86#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A Pol&iacute;tica    de Medicam
entos Gen&eacute;ricos deve superar duas lacunas centrais do complexo    industr
ial da sa&uacute;de: a base empresarial local de inova&ccedil;&atilde;o    e o c
omprometimento com as condi&ccedil;&otilde;es de sa&uacute;de da popula&ccedil;&
atilde;o    brasileira.<sup>12</sup></font></p>     ^cY#2315.htm##
00739000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704050300081002000900584#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#91#87#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A diferen&ccedil;a    entre os 
valores unit&aacute;rios dos medicamentos adquiridos em 2007 e os de    2008 &ea
cute; significativa. Ainda que 44 itens tenham apresentado valor unit&aacute;rio
    menor em 2008, o impacto no custo global de aquisi&ccedil;&atilde;o foi o au
mento    de mais de R$ 2 milh&otilde;es em 2008 para o munic&iacute;pio, por exi
gir os    testes de biodisponibilidade e/ou de bioequival&ecirc;ncia.</font></p>
     ^cY#2315.htm##
00544000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704030800081002000900389#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#92#88#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Esse aumento est&aacute;    rel
acionado ao fato de que os medicamentos gen&eacute;ricos s&atilde;o, em geral,  
  mais baratos que os medicamentos de refer&ecirc;ncia, mas, na maioria das veze
s,    mais caros que os similares.</font></p>     ^cY#2315.htm##
00724000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704048800081002000900569#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#93#89#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os medicamentos    gen&eacute;r
icos tendem a ser mais baratos que os medicamentos de refer&ecirc;ncia,    em gr
ande parte, por n&atilde;o reca&iacute;rem sobre eles os custos de desenvolvimen
to    e estudos cl&iacute;nicos necess&aacute;rios. Outro fator que contribui pa
ra    um custo mais baixo do gen&eacute;rico &eacute; o menor investimento em pr
opaganda    para tornar a marca conhecida.<sup>7</sup></font></p>     ^cY#2315.h
tm##
01026000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079000081002000900871#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#94#90#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">No Brasil, um estudo<sup>16</su
p>    mostrou que os gen&eacute;ricos foram introduzidos com pre&ccedil;os em m&
eacute;dia    40% menores do que os medicamentos de refer&ecirc;ncia, com tend&e
circ;ncia    de aumento da diferen&ccedil;a ao longo do tempo. Contudo, a procur
a por medicamentos    gen&eacute;ricos n&atilde;o provocou redu&ccedil;&atilde;o
 dos pre&ccedil;os    da maioria dos medicamentos de refer&ecirc;ncia. Resultado
 semelhante foi descrito    no Canad&aacute;.<sup>7</sup> Isso sugere que a perd
a de mercado dos medicamentos    de refer&ecirc;ncia para os gen&eacute;ricos n&
atilde;o foi suficiente para    for&ccedil;ar a aproxima&ccedil;&atilde;o dos pr
e&ccedil;os entre eles.<sup>16</sup></font></p>     ^cY#2315.htm##
00996000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704076000081002000900841#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#95#91#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Embora a pol&iacute;tica    de 
gen&eacute;ricos seja apontada como forma de redu&ccedil;&atilde;o de pre&ccedil
;o,    isso apenas &eacute; verdade se compararmos gen&eacute;ricos e os de refe
r&ecirc;ncia.    Os similares s&atilde;o vendidos no Brasil por pre&ccedil;o inf
erior aos gen&eacute;ricos,    principalmente nas licita&ccedil;&otilde;es p&uac
ute;blicas, de forma que os    gen&eacute;ricos n&atilde;o competem com os simil
ares em termos de pre&ccedil;o.    Uma vez que as licita&ccedil;&otilde;es s&ati
lde;o julgadas pelo menor pre&ccedil;o,    o custo do medicamento explica o baix
o percentual de gen&eacute;ricos disponibilizados    no servi&ccedil;o p&uacute;
blico.</font></p>     ^cY#2315.htm##
00932000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704069600081002000900777#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#96#92#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    das atas do
s processos licitat&oacute;rios para aquisi&ccedil;&atilde;o de medicamentos    
nos anos de abrang&ecirc;ncia do estudo n&atilde;o possibilitou estimar a propor
&ccedil;&atilde;o    de medicamentos de refer&ecirc;ncia, gen&eacute;ricos e sim
ilares adquiridos    em 2007. Isso porque os processos utilizam a DCB e n&atilde
;o h&aacute; registro    do laborat&oacute;rio fabricante e do nome comercial do
 medicamento na ata,    apenas na proposta da empresa. O sistema informatizado p
ara ger&ecirc;ncia do    estoque tamb&eacute;m n&atilde;o disponibiliza essa inf
orma&ccedil;&atilde;o.</font></p>     ^cY#2315.htm##
01291000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704105500081002000901136#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#97#93#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A elabora&ccedil;&atilde;o    d
e dois editais com especifica&ccedil;&otilde;es distintas poderia reduzir o    i
mpacto financeiro provocado pela aquisi&ccedil;&atilde;o de medicamentos gen&eac
ute;ricos    sem interferir na qualidade dos medicamentos adquiridos. A exig&eci
rc;ncia de    testes de biodisponibilidade seria necess&aacute;ria para medicame
ntos s&oacute;lidos    e suspens&otilde;es orais, com aquisi&ccedil;&atilde;o de
 medicamentos gen&eacute;ricos    ou de refer&ecirc;ncia. Para medicamentos de u
so parenteral e solu&ccedil;&otilde;es    orais, essa exig&ecirc;ncia n&atilde;o
 se faria necess&aacute;ria, uma vez que    o perfil de dissolu&ccedil;&atilde;o
 n&atilde;o interfere significativamente    no resultado terap&ecirc;utico. Se e
ssa estrat&eacute;gia fosse adotada pelo    munic&iacute;pio em estudo, haveria 
redu&ccedil;&atilde;o de aproximadamente    10% no acr&eacute;scimo de recursos 
investidos pelo munic&iacute;pio (cerca    de R$ 400.000,00).</font></p>     ^cY
#2315.htm##
00558000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704032200081002000900403#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#98#94#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A pol&iacute;tica    de medicam
entos gen&eacute;ricos &eacute; um importante componente para a gest&atilde;o   
 da assist&ecirc;ncia farmac&ecirc;utica, mas ainda est&aacute; distante da real
idade    da rede p&uacute;blica de sa&uacute;de.</font></p>     ^cY#2315.htm##
01180000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704094400081002000901025#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#99#95#article#135#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Tobar<sup>14</sup>    aponta qu
e a estrat&eacute;gia mais radical para aumentar a oferta de produtos    gen&eac
ute;ricos &eacute; habilitar todos os produtos registrados no Pa&iacute;s    par
a operar como gen&eacute;ricos, como fez a Argentina em 2002: gen&eacute;ricos  
  e similares foram equiparados e puderam competir pelo pre&ccedil;o. No Brasil,
    a nova legisla&ccedil;&atilde;o para os medicamentos similares e novos passo
u    a exigir que estes tenham os mesmos requerimentos de qualidade exigidos par
a    os gen&eacute;ricos.<a name="topb"></a><a href="#backb"><sup>b</sup></a><su
p>,</sup><a name="topc"></a><a href="#backc"><sup>c</sup></a>    Talvez esse sej
a o primeiro passo para incentivar a concorr&ecirc;ncia de pre&ccedil;o    entre
 similares e gen&eacute;ricos e para aumentar a disponibilidade destes    nos se
rvi&ccedil;os p&uacute;blicos.</font></p>     ^cY#2315.htm##
01074000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704083700082002000900919#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#100#96#article#135#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">Em conclus&atilde;o,    dispon
ibilizar medicamentos que apresentem teste de biodisponibilidade e/ou    de bioe
quival&ecirc;ncia foi uma pol&iacute;tica adotada pela gest&atilde;o    municipa
l para garantir o fornecimento de medicamentos mais eficazes e seguros    &agrav
e; popula&ccedil;&atilde;o. Por&eacute;m, a aquisi&ccedil;&atilde;o desses    me
dicamentos gerou grande impacto financeiro, com aumento de quase 100%. Diante   
 dos recursos sempre finitos e insuficientes destinados &agrave; sa&uacute;de,  
  a implanta&ccedil;&atilde;o de uma nova pol&iacute;tica de sa&uacute;de precis
a    ser racionalmente planejada, com base em crit&eacute;rios t&eacute;cnicos e
    avalia&ccedil;&otilde;es de impacto financeiro de sua implanta&ccedil;&atild
e;o.</font></p>     ^cY#2315.htm##
00259000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704002200082002000900104#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#101#97#article#135#<p>&nbsp;</p>
     ^cY#2315.htm##
00344000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704010700082002000900189#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#102#98#article#135#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font
></p>     ^cY#2315.htm##
00579000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704032800084002000900412#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#103#99#article#135#1
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Batistic MA, 
   Auricchio MT, Markman BEO. Avalia&ccedil;&atilde;o da qualidade de comprimido
s    revestidos e solu&ccedil;&otilde;es orais de sulfato ferroso utilizados no 
tratamento    da anemia ferropriva. <i>Rev Inst Adolfo Lutz.</i> 1998;57(1):25-8
.    ^cY#2315.htm##
00259000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002100083002000900104#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#104#100#article#135# </font></p>
     ^cY#2315.htm##
00798000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704054600085002000900631#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#105#101#article#135#
2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Bianchin MD,
    Blatt CR, Soares AS, Kulkamp IC. Avalia&ccedil;&atilde;o da qualidade de com
primidos    de propranolol e enalapril distribu&iacute;dos no sistema p&uacute;b
lico de    sa&uacute;de em uma cidade do sul do Brasil. <i>Cienc Saude Colet.</i
> 2010.    Dispon&iacute;vel em: <a href="http://www.abrasco.org.br/cienciaesaud
ecoletiva/artigos" target="_blank">http://www.abrasco.org.br/cienciaesaudecoleti
va/artigos    /artigo_int.php?id_artigo=5130</a></font></p>     ^cY#2315.htm##
00553000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704030100085002000900386#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#106#102#article#135#
3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Dias CRC, Ro
mano-Lieber    NS. Processo da implanta&ccedil;&atilde;o da pol&iacute;tica de m
edicamentos    gen&eacute;ricos no Brasil. <i>Cad Saude Publica.</i> 2006;22(8):
1661-9. DOI:10.1590/S0102-311X2006000800014</font></p>     ^cY#2315.htm##
00518000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704026600085002000900351#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#107#103#article#135#
4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Homedes N, U
galde    A. Multisource drug policies in Latin America: survey of 10 countries. 
<i>Bull    World Health Organ.</i> 2005;83(1):64-70. DOI:10.1590/S0042-968620050
00100016</font></p>     ^cY#2315.htm##
00470000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704021800085002000900303#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#108#104#article#135#
5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. King DR, Kan
avos    P. Encouraging the Use of generic medicines: implications for transition
 economies.    <i>Croat Med J.</i> 2002;43(4):462-9.    ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#109#105#article#135#</font></p> 
    ^cY#2315.htm##
00494000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704024200085002000900327#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#110#106#article#135#
6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Kornis GEM, 
   Braga ML, Zaire CE. Os marcos legais das Pol&iacute;ticas de Medicamentos no 
   Brasil contempor&acirc;neo (1990-2006). <i>Rev APS.</i> 2008;11(1):85-99.    
^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#111#107#article#135#</font></p> 
    ^cY#2315.htm##
00498000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704024600085002000900331#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#112#108#article#135#
7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Lexchin J. T
he    effect of generic competition on the price of brand-name drugs. <i>Health 
Policy.</i>    2004;68(1):47-54. DOI:10.1016/j.healthpol.2003.07.007</font></p> 
    ^cY#2315.htm##
00561000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704030900085002000900394#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#113#109#article#135#
8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Luiza VL, De
    Castro CGSO, Nunes JM. Aquisi&ccedil;&atilde;o de medicamentos no setor p&ua
cute;blico:    o bin&ocirc;mio qualidade-custo. <i>Cad Saude Publica.</i> 1999;1
5(4):769-76.    DOI:10.1590/S0102-311X1999000400011</font></p>     ^cY#2315.htm#
#
00596000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704034400085002000900429#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#114#110#article#135#
9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Marin N, Lui
za    VL, Os&oacute;rio de Castro CGS, Machado dos Santos S. Assist&ecirc;ncia F
armac&ecirc;utica    para gerentes municipais. Rio de Janeiro: Organiza&ccedil;&
atilde;o Mundial    da Sa&uacute;de, Organiza&ccedil;&atilde;o Panamericana da S
a&uacute;de; 2003.    ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#115#111#article#135#</font></p> 
    ^cY#2315.htm##
00640000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704038700086002000900473#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#116#112#article#135#
10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Mendis S, 
Fukino    K, Cameron A, Laing R, Filipe Jr A, Khatib O, Leowski J, Ewen M. The a
vailability    and affordability of selected essential medicines for chronic dis
eases in six    low- and middle-income countries. <i>Bull World Health Organ.</i
> 2007;85(4):279-288.    DOI:10.2471/BLT.06.033647</font></p>     ^cY#2315.htm##
00668000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704041500086002000900501#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#117#113#article#135#
11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Miranda ES
,    Pinto CBS, Reis, ALA, Emmerick ICM, Campos MR, Luiza VL, et al. Disponibili
dade    no setor p&uacute;blico e pre&ccedil;os no setor privado: um perfil de m
edicamentos    gen&eacute;ricos em diferentes regi&otilde;es do Brasil. <i>Cad S
aude Publica.</i>    2009;25(10):2147-58 . DOI:10.1590/S0102-311X2009001000006</
font></p>     ^cY#2315.htm##
00605000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704035200086002000900438#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#118#114#article#135#
12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Quental C,
    Abreu JC, Bomtempo JV, Gadelha CAG. Medicamentos gen&eacute;ricos no Brasil:
    impactos das pol&iacute;ticas p&uacute;blicas sobre a ind&uacute;stria nacio
nal.    <i>Cienc Saude Coletiva.</i> 2008;13(Supl):619-28. DOI: 10.1590/S1413-81
232008000700011</font></p>     ^cY#2315.htm##
00555000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704030200086002000900388#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#119#115#article#135#
13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Rumel D, N
ishioka    AS, Santos AM. Intercambialidade de medicamentos: abordagem cl&iacute
;nica e    o ponto de vista do consumidor. <i>Rev Saude Publica.</i> 2006;40(5):
921-7.    DOI:10.1590/S0034-89102006000600024</font></p>     ^cY#2315.htm##
00512000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704025900086002000900345#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#120#116#article#135#
14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Tobar F. E
conom&iacute;a    de los medicamentos gen&eacute;ricos en America Latina. <i>Rev
 Panam Salud Publica.</i>    2008;23(1):59-67. DOI:10.1590/S1020-498920080001000
08</font></p>     ^cY#2315.htm##
00682000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704042900086002000900515#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#121#117#article#135#
15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Vacca Gonz
&aacute;lez    CP, Fitzgerald JF, Berm&uacute;dez JAZ. Definici&oacute;n de medi
camento gen&eacute;rico:    &iquest;un fin o un medio? An&aacute;lisis de la reg
ulaci&oacute;n en 14 pa&iacute;ses    de la Regi&oacute;n de las Am&eacute;ricas
. <i>Rev Panam Salud Publica.</i>    2006;20(5):314-23. DOI: 10.1590/S1020-49892
006001000004</font></p>     ^cY#2315.htm##
00553000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704030000086002000900386#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#122#118#article#135#
16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Vieira FP,
    Zucchi P. Diferen&ccedil;as de pre&ccedil;os entre medicamentos gen&eacute;r
icos    e de refer&ecirc;ncia no Brasil. <i>Rev Saude Publica.</i> 2006;40(3):44
4-9.    DOI:10.1590/S0034-89102006000300012</font></p>     ^cY#2315.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#123#119#article#135#<p>&nbsp;</p
>     ^cY#2315.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#124#120#article#135#<p>&nbsp;</p
>     ^cY#2315.htm##
00453000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021500083002000900298#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#125#121#article#135#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#
top"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    <b>Corr
espond&ecirc;ncia | Correspondence:    ^cY#2315.htm##
00277000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003900083002000900122#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#126#122#article#135#<br>   </b> 
Carine Raquel Blatt    ^cY#2315.htm##
00290000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005200083002000900135#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#127#123#article#135#<br>   Av. J
os&eacute; Ac&aacute;cio Moreira    ^cY#2315.htm##
00292000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005400083002000900137#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#128#124#article#135#<br>   Unisu
l/Curso de Farm&aacute;cia, nº 787    ^cY#2315.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#129#125#article#135#<br>   Dehon
    ^cY#2315.htm##
00289000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005100083002000900134#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#130#126#article#135#<br>   88704
-900 Tubar&atilde;o, SC, Brasil    ^cY#2315.htm##
00339000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704010100083002000900184#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#131#127#article#135#<br>   E-mai
l: <a href="mailto:carine.blatt@unisul.br">carine.blatt@unisul.br</a></font></p>
     ^cY#2315.htm##
00327000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704008900083002000900172#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#132#128#article#135#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Recebido: 2/6/2010    ^cY#231
5.htm##
00285000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004700083002000900130#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#133#129#article#135#<br>   Aprov
ado: 14/11/2010</font></p>     ^cY#2315.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#134#130#article#135#<p>&nbsp;</p
>     ^cY#2315.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#135#131#article#135#<p>&nbsp;</p
>     ^cY#2315.htm##
00372000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704013400083002000900217#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#136#132#article#135#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Os autores declaram    n&atil
de;o haver conflitos de interesse.    ^cY#2315.htm##
00702000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704046400083002000900547#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#137#133#article#135#<br>   <a na
me="backa"></a><a href="#topa">a</a> Lei Federal nº. 9.787, de 10 de fevereiro  
  de 1999. Altera a Lei nº. 6.360, de 26 de setembro de 1976, que disp&otilde;e 
   sobre a vigil&acirc;ncia sanit&aacute;ria, estabelece o medicamento gen&eacut
e;rico,    disp&otilde;e sobre a utiliza&ccedil;&atilde;o de nomes gen&eacute;ri
cos em    produtos farmac&ecirc;uticos e d&aacute; outras provid&ecirc;ncias. <i
>Diario    Oficial Uniao.</i> 11 fev 1999:1.    ^cY#2315.htm##
00528000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704029000083002000900373#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#138#134#article#135#<br>   <a na
me="backb"></a><a href="#topb">b</a> Resolu&ccedil;&atilde;o RDC nº 133,    de 2
 de junho de 2003. Disp&otilde;e sobre o registro de Medicamentos Similares    e
 d&aacute; outras provid&ecirc;ncias. <i>Diario Oficial Uniao.</i> 10 nov 1998;S
e&ccedil;&atilde;o    1:18-22.    ^cY#2315.htm##
00517000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704027900083002000900362#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2315.htm#S#p#139#135#article#135#<br>   <a na
me="backc"></a><a href="#topc">c</a> Resolu&ccedil;&atilde;o nº 134, de    29 de
 maio de 2003. Disp&otilde;e sobre a adequa&ccedil;&atilde;o de produtos    j&aa
cute; registrados. <i>Diario Oficial Uniao.</i> 2 jun 2003;Se&ccedil;&atilde;o  
  1:22.</font></p>     ^cY#2315.htm##
00671000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100019000820100020001010100
01900121012013500140030002100275065000900296064000500305031000300310032000200313
014000500315865000900320002000900329035001000338801002100348#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2315.htm#S#c#140#1#article#16#1#^rND^sBatistic^nM
A#^rND^sAuricchio^nMT#^rND^sMarkman^nBEO#Avaliação da qualidade de comprimidos r
evestidos e soluções orais de sulfato ferroso utilizados no tratamento da anemia
 ferropriva^lpt#Rev Inst Adolfo Lutz#19980000#1998#57#1#25-8#20110000#2315.htm#0
073-9855#Rev Inst Adolfo Lutz##
00710000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100019000820100016001010100
01700117010001800134012014100152030001800293710000200311065000900313064000500322
037008700327865000900414002000900423#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2315.htm#S#c#141#2#article#16#2#^rND^sBianchin^nMD#^rND^sBlatt^nCR#^rND^s
Soares^nAS#^rND^sKulkamp^nIC#Avaliação da qualidade de comprimidos de propranolo
l e enalapril distribuídos no sistema público de saúde em uma cidade do sul do B
rasil^lpt#Cienc Saude Colet#2#20100000#2010#http://www.abrasco.org.br/cienciaesa
udecoletiva/artigos /artigo_int.php?id_artigo=5130#20110000#2315.htm##
00585000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100016000820100024000980120
07600122030001900198710000200217065000900219064000500228031000300233032000200236
014000700238237003200245865000900277002000900286#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2315.htm#S#c#142#3#article#16#3#^rND^sDias^nCRC#^rND^sRomano-
Lieber^nNS#Processo da implantação da política de medicamentos genéricos no Bras
il^lpt#Cad Saude Publica.#2#20060000#2006#22#8#1661-9#10.1590/S0102-311X20060008
00014#20110000#2315.htm##
00578000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100016000990120
07100115030002500186710000200211065000900213064000500222031000300227032000200230
014000600232237003200238865000900270002000900279#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2315.htm#S#c#143#4#article#16#4#^rND^sHomedes^nN#^rND^sUgalde
^nA#Multisource drug policies in Latin America: survey of 10 countries^len#Bull 
World Health Organ.#2#20050000#2005#83#1#64-70#10.1590/S0042-96862005000100016#2
0110000#2315.htm##
00534000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100015000820100017000970120
08400114030001300198710000200211065000900213064000500222031000300227032000200230
014000600232865000900238002000900247#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2315.htm#S#c#144#5#article#16#5#^rND^sKing^nDR#^rND^sKanavos^nP#Encouragi
ng the Use of generic medicines: implications for transition economies^len#Croat
 Med J.#2#20020000#2002#43#4#462-9#20110000#2315.htm##
00563000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100016001000100
01600116012008700132030000900219710000200228065000900230064000500239031000300244
032000200247014000600249865000900255002000900264#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2315.htm#S#c#145#6#article#16#6#^rND^sKornis^nGEM#^rND^sBraga
^nML#^rND^sZaire^nCE#Os marcos legais das Políticas de Medicamentos no Brasil co
ntemporâneo (1990-2006)^lpt#Rev APS.#2#20080000#2008#11#1#85-99#20110000#2315.ht
m##
00540000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820120071000990300
01500170710000200185065000900187064000500196031000300201032000200204014000600206
237003200212865000900244002000900253#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2315.htm#S#c#146#7#article#16#7#^rND^sLexchin^nJ#The effect of generic co
mpetition on the price of brand-name drugs^len#Health Policy.#2#20040000#2004#68
#1#47-54#10.1016/j.healthpol.2003.07.007#20110000#2315.htm##
00609000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100016000820100022000980100
01600120012007400136030001900210710000200229065000900231064000500240031000300245
032000200248014000700250237003200257865000900289002000900298#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2315.htm#S#c#147#8#article#16#8#^rND^sLuiza^nVL#^
rND^sDe Castro^nCGSO#^rND^sNunes^nJM#Aquisição de medicamentos no setor público:
 o binômio qualidade-custo^lpt#Cad Saude Publica.#2#19990000#1999#15#4#769-76#10
.1590/S0102-311X1999000400011#20110000#2315.htm##
00600000000000265000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800160015000820160016000970160
02800113016002800141018005400169066001500223062006400238065000900302064000500311
865000900316002000900325#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2315.
htm#S#c#148#9#article#16#9#^rND^sMarin^nN#^rND^sLuiza^nVL#^rND^sOsório de Castro
^nCGS#^rND^sMachado dos Santos^nS#Assistência Farmacêutica para gerentes municip
ais^lpt#Rio de Janeiro#Organização Mundial da Saúde, Organização Panamericana da
 Saúde#20030000#2003#20110000#2315.htm##
00802000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100016001000100
01700116010001500133010001900148010001600167010001700183010001400200012013200214
03000250034671000020037106500090037306400050038203100030038703200020039001400080
0392237002200400865000900422002000900431#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2315.htm#S#c#149#10#article#16#10#^rND^sMendis^nS#^rND^sFukino^nK#^rN
D^sCameron^nA#^rND^sLaing^nR#^rND^sFilipe Jr^nA#^rND^sKhatib^nO#^rND^sLeowski^nJ
#^rND^sEwen^nM#The availability and affordability of selected essential medicine
s for chronic diseases in six low- and middle-income countries^len#Bull World He
alth Organ.#2#20070000#2007#85#4#279-288#10.2471/BLT.06.033647#20110000#2315.htm
##
00775000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100017001020100
01600119010002000135010001700155010001600172810000600188012013200194030001900326
71000020034506500090034706400050035603100030036103200030036401400080036723700320
0375865000900407002000900416#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
315.htm#S#c#150#11#article#16#11#^rND^sMiranda^nES#^rND^sPinto^nCBS#^rND^sReis^n
ALA#^rND^sEmmerick^nICM#^rND^sCampos^nMR#^rND^sLuiza^nVL#et al#Disponibilidade n
o setor público e preços no setor privado: um perfil de medicamentos genéricos e
m diferentes regiões do Brasil^lpt#Cad Saude Publica.#2#20090000#2009#25#10#2147
-58#10.1590/S0102-311X2009001000006#20110000#2315.htm##
00671000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100016001010100
01900117010001900136012009700155030002200252710000200274065000900276064000500285
031000300290032000700293014000700300237003200307865000900339002000900348#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2315.htm#S#c#151#12#article#16#12#^rN
D^sQuental^nC#^rND^sAbreu^nJC#^rND^sBomtempo^nJV#^rND^sGadelha^nCAG#Medicamentos
 genéricos no Brasil: impactos das políticas públicas sobre a indústria nacional
^lpt#Cienc Saude Coletiva.#2#20080000#2008#13#^sSupl#619-28#10.1590/S1413-812320
08000700011#20110000#2315.htm##
00623000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100015000840100019000990100
01700118012009000135030001900225710000200244065000900246064000500255031000300260
032000200263014000600265237003200271865000900303002000900312#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2315.htm#S#c#152#13#article#16#13#^rND^sRumel^nD#
^rND^sNishioka^nAS#^rND^sSantos^nAM#Intercambialidade de medicamentos: abordagem
 clínica e o ponto de vista do consumidor^les#Rev Saude Publica.#2#20060000#2006
#40#5#921-7#10.1590/S0034-89102006000600024#20110000#2315.htm##
00540000000000277000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100015000840120061000990300
02500160710000200185065000900187064000500196031000300201032000200204014000600206
237003200212865000900244002000900253#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2315.htm#S#c#153#14#article#16#14#^rND^sTobar^nF#Economía de los medicame
ntos genéricos en America Latina^les#Rev Panam Salud Publica.#2#20080000#2008#23
#1#59-67#10.1590/S1020-49892008000100008#20110000#2315.htm##
00683000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100025000840100021001090100
02000130012012800150030002500278710000200303065000900305064000500314031000300319
032000200322014000700324237003200331865000900363002000900372#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2315.htm#S#c#154#15#article#16#15#^rND^sVacca Gon
zález^nCP#^rND^sFitzgerald^nJF#^rND^sBermúdez^nJAZ#Definición de medicamento gen
érico: ¿un fin o un medio? Análisis de la regulación en 14 países de la Región d
e las Américas^les#Rev Panam Salud Publica.#2#20060000#2006#20#5#314-23#10.1590/
S1020-49892006001000004#20110000#2315.htm##
00583000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100016001010120
08000117030001900197710000200216065000900218064000500227031000300232032000200235
014000600237237003200243865000900275002000900284#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2315.htm#S#c#155#16#article#16#16#^rND^sVieira^nFP#^rND^sZucc
hi^nP#Diferenças de preços entre medicamentos genéricos e de referência no Brasi
l^lpt#Rev Saude Publica.#2#20060000#2006#40#3#444-9#10.1590/S0034-89102006000300
012#20110000#2315.htm##
00276000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00400102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#o#1#1#arti
cle#1#20110408#160442#2326.htm#147##
06644000000000865000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000500095038000400100121000300104049000300107158000300110
03000190011303200060013206500090013801400070014703500100015422300090016401200890
01730120098002620120097003600100041004570100025004980100034005230700138005570700
13100695070003700826070011500863083125700978085001002235085002502245085003002270
08500510230008500240235108500240237508500330239908500350243208500350246708313560
25020850010038580850030038680850027038980850047039250850025039720850024039970850
04404021085003404065083133304099085001005432085003405442085003205476085005205508
08500250556008500250558508500330561008500390564308500380568211700080572007200030
5728112000905731111000905740114000905749113001105758002000905769#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#
ILUS#TAB#21#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0#0034-8910#20110415#Su
bnotificação da comorbidade tuberculose e aids: uma aplicação do método de linka
ge^lpt#Underreporting of the tuberculosis and AIDS comorbidity: an application o
f the linkage method^len#Subnotificación de la comorbilidad tuberculosis y sida:
 una aplicación del método de linkage^les#^rND^1A01 A02^nCarolina Novaes^sCarval
ho#^rND^1A03^nInes^sDourado#^rND^1A04^nAna Luiza^sBierrenbach#Ministério da Saúd
e^iA01^1Secretaria de Vigilância em Saúde.^2Departamento de Apoio à Gestão da Vi
gilância em Saúde^cBrasília^sDF^pBrasil#Universidade Federal da Bahia^iA02^1Inst
ituto de Saúde Coletiva^2Programa de Pós-Graduação em Saúde Coletiva^cSalvador^s
BA^pBrasil#UFBA^iA03^1ISC^cSalvador^sBA^pBrasil#Organização Mundial da Saúde^iA0
4^1STOP TB Department^2Tuberculosis Monitoring and Evaluation Unit^cGenebra^pSuí
ça#^lpt^aOBJETIVO: Analisar a subnotificação da comorbidade tuberculose (TB) e a
ids. MÉTODOS: Estudo de vigilância utilizando os registros do Sistema de Informa
ção de Agravos de Notificação de Tuberculose e de aids no Brasil de 2000 a 2005.
 Registros de TB sem informação da presença de aids foram considerados subnotifi
cações da comorbidade quando pareados a registros de aids que apresentassem ano 
de diagnóstico de aids igual ou anterior ao ano de notificação da TB, assim como
 os registros de um mesmo paciente cujos registros anteriores apresentavam essa 
informação. Criou-se um indicador: comorbidade TB-aids reconhecida, a partir dos
 registros de TB com a informação de presença de aids. RESULTADOS: A subnotifica
ção de TB-aids foi de 17,7%. Esse percentual variou entre estados. A incorporaçã
o dos registros subnotificados aos previamente reconhecidos elevou a proporção d
e TB-aids no Brasil de 6,9% para 8,4%. As maiores proporções de subnotificação f
oram observadas no Acre, Alagoas, Maranhão e Piauí (mais de 35% cada) e as menor
es em São Paulo e Goiás (cerca de 10% cada). CONCLUSÕES: A subnotificação da com
orbidade TB-aids encontrada no Brasil deve deflagrar modificações no sistema de 
vigilância para prover informações aos programas nacionais.#^ddecs^i1#^tm^lpt^kS
ub-Registro^i1#^tm^lpt^kInfecções por HIV^i1#^tm^lpt^kSíndrome de Imunodeficiênc
ia Adquirida^i1#^tm^lpt^kTuberculose^i1#^tm^lpt^kComorbidade^i1#^tm^lpt^kSistema
 de Registros^i1#^tm^lpt^kNotificação de Doenças^i1#^tm^lpt^kAnálise por Pareame
nto^i1#^len^aOBJECTIVE: To analyze the underreporting of the tuberculosis (TB) a
nd AIDS comorbidity. METHODS: Surveillance study using records from the Notifiab
le Diseases Information System - Tuberculosis and AIDS in Brazil from 2000 to 20
05. Records of TB without information on the presence of Aids were considered to
 be underreporting of the comorbidity when paired off with AIDS records in which
 the year of diagnosis of AIDS was the same or previous to the year of reporting
 of TB, as well as records from the same patient whose previous records had this
 information. An indicator was created: recognized TB-AIDS comorbidity, based on
 the TB records that had information on the presence of AIDS. RESULTS: The under
reporting of TB-AIDS was 17.7%. This percentage varied between states. The incor
poration of the underreported records into the previously recognized ones increa
sed the proportion of TB-AIDS in Brazil from 6.9% to 8.4%. The highest proportio
ns of underreporting were noted in Acre (Northern), Alagoas, Maranhão and Piauí 
(Northeastern) (more than 35% each) and the lowest in São Paulo (Southeastern) a
nd Goiás (Central-western) (around 10% each). CONCLUSIONS: The underreporting of
 the TB-AIDS comorbidity found in Brazil will probably trigger modifications in 
the surveillance system in order to provide information for the national program
s.#^ddecs^i2#^tm^len^kUnderregistration^i2#^tm^len^kHIV Infections^i2#^tm^len^kA
cquired Immunodeficiency Syndrome^i2#^tm^len^kTuberculosis^i2#^tm^len^kComorbidi
ty^i2#^tm^len^kRegistries Disease Notification^i2#^tm^len^kMatched-Pair Analysis
^i2#^les^aOBJETIVO: Analizar la subnotificación de la comorbilidad tuberculosis 
(TB) y sida. MÉTODOS: Estudio de vigilancia utilizando los registros del Sistema
 de Información de Agravios de Notificación de Tuberculosis y de sida en Brasil 
de 2000 a 2005. Registros de TB sin información de la presencia de sida fueron c
onsideradas subnotificaciones de la comorbilidad cuando se parearon a registros 
de sida que presentaron año de diagnóstico de sida igual o anterior al año de no
tificación de la TB, así como los registros de un mismo paciente cuyos registros
 anteriores presentaban esa información. Se creó un indicador: comorbilidad TB-s
ida reconocida, a partir de los registros de TB con la información de presencia 
de sida. RESULTADOS: La subnotificación de TB-sida fue de 17,7%. Este porcentaje
 varió entre estados. La incorporación de los registros subnotificados a los pre
viamente reconocidos elevó la proporción de TB-sida en Brasil de 6,9% a 8,4%. La
s mayores proporciones de subnotificación fueron observadas en Acre, Alagoas, Ma
ranhao y Piauí (más de 35% en cada uno) y las menores en Sao Paulo y Goiás (cerc
a de 10% en cada uno). CONCLUSIONES: La subnotificación de la comorbilidad TB-si
da encontrada en Brasil debe deflagrar modificaciones en el sistema de vigilanci
a para proveer informaciones a los programas nacionales.#^ddecs^i3#^tm^les^kOmis
iones de Registro^i3#^tm^les^kInfecciones por VIH^i3#^tm^les^kSíndrome de Inmuno
deficiencia Adquirida^i3#^tm^les^kTuberculosis^i3#^tm^les^kComorbilidad^i3#^tm^l
es^kSistema de Registros^i3#^tm^les^kNotificación de Enfermedad^i3#^tm^les^kAnál
isis por Apareamiento^i3#vancouv#12#20100606#6/6/2010#20101114#14/11/2010#2326.h
tm##
06784000000000865000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000500095038000400100121000300104049000300107158000300110
03000190011303200060013206500090013801400070014703500100015422300090016401201100
01730120112002830120118003950100041005130100025005540100034005790700138006130700
13100751070003700882070011500919083128501034085001002319085002502329085003002354
08500510238408500240243508500240245908500330248308500350251608500350255108313840
25860850010039700850030039800850027040100850047040370850025040840850024041090850
04404133085003404177083136104211085001005572085003405582085003205616085005205648
08500250570008500250572508500330575008500390578308500380582211700080586007200030
5868112000905871111000905880114000905889113001105898002000905909#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#
ILUS#TAB#21#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0#0034-8910#20110415#<b
>Subnotificação da comorbidade tuberculose e aids</b>: <b>uma aplicação do métod
o de <i>linkage</i></b>^lpt#<b>Underreporting of the tuberculosis and AIDS comor
bidity</b>: <b>an application of the linkage method</b>^len#<b>Subnotificación d
e la comorbilidad tuberculosis y sida</b>: <b>una aplicación del método de <i>li
nkage</i></b>^les#^rND^1A01 A02^nCarolina Novaes^sCarvalho#^rND^1A03^nInes^sDour
ado#^rND^1A04^nAna Luiza^sBierrenbach#Ministério da Saúde^iA01^1Secretaria de Vi
gilância em Saúde.^2Departamento de Apoio à Gestão da Vigilância em Saúde^cBrasí
lia^sDF^pBrasil#Universidade Federal da Bahia^iA02^1Instituto de Saúde Coletiva^
2Programa de Pós-Graduação em Saúde Coletiva^cSalvador^sBA^pBrasil#UFBA^iA03^1IS
C^cSalvador^sBA^pBrasil#Organização Mundial da Saúde^iA04^1STOP TB Department^2T
uberculosis Monitoring and Evaluation Unit^cGenebra^pSuíça#^lpt^a<b>OBJETIVO:</b
> Analisar a subnotificação da comorbidade tuberculose (TB) e aids. <b>MÉTODOS:<
/b> Estudo de vigilância utilizando os registros do Sistema de Informação de Agr
avos de Notificação de Tuberculose e de aids no Brasil de 2000 a 2005. Registros
 de TB sem informação da presença de aids foram considerados subnotificações da 
comorbidade quando pareados a registros de aids que apresentassem ano de diagnós
tico de aids igual ou anterior ao ano de notificação da TB, assim como os regist
ros de um mesmo paciente cujos registros anteriores apresentavam essa informação
. Criou-se um indicador: comorbidade TB-aids reconhecida, a partir dos registros
 de TB com a informação de presença de aids. <b>RESULTADOS:</b> A subnotificação
 de TB-aids foi de 17,7%. Esse percentual variou entre estados. A incorporação d
os registros subnotificados aos previamente reconhecidos elevou a proporção de T
B-aids no Brasil de 6,9% para 8,4%. As maiores proporções de subnotificação fora
m observadas no Acre, Alagoas, Maranhão e Piauí (mais de 35% cada) e as menores 
em São Paulo e Goiás (cerca de 10% cada). <b>CONCLUSÕES:</b> A subnotificação da
 comorbidade TB-aids encontrada no Brasil deve deflagrar modificações no sistema
 de vigilância para prover informações aos programas nacionais.#^ddecs^i1#^tm^lp
t^kSub-Registro^i1#^tm^lpt^kInfecções por HIV^i1#^tm^lpt^kSíndrome de Imunodefic
iência Adquirida^i1#^tm^lpt^kTuberculose^i1#^tm^lpt^kComorbidade^i1#^tm^lpt^kSis
tema de Registros^i1#^tm^lpt^kNotificação de Doenças^i1#^tm^lpt^kAnálise por Par
eamento^i1#^len^a<b>OBJECTIVE:</b> To analyze the underreporting of the tubercul
osis (TB) and AIDS comorbidity. <b>METHODS:</b> Surveillance study using records
 from the Notifiable Diseases Information System - Tuberculosis and AIDS in Braz
il from 2000 to 2005. Records of TB without information on the presence of Aids 
were considered to be underreporting of the comorbidity when paired off with AID
S records in which the year of diagnosis of AIDS was the same or previous to the
 year of reporting of TB, as well as records from the same patient whose previou
s records had this information. An indicator was created: recognized TB-AIDS com
orbidity, based on the TB records that had information on the presence of AIDS. 
<b>RESULTS:</b> The underreporting of TB-AIDS was 17.7%. This percentage varied 
between states. The incorporation of the underreported records into the previous
ly recognized ones increased the proportion of TB-AIDS in Brazil from 6.9% to 8.
4%. The highest proportions of underreporting were noted in Acre (Northern), Ala
goas, Maranhão and Piauí (Northeastern) (more than 35% each) and the lowest in S
ão Paulo (Southeastern) and Goiás (Central-western) (around 10% each). <b>CONCLU
SIONS:</b> The underreporting of the TB-AIDS comorbidity found in Brazil will pr
obably trigger modifications in the surveillance system in order to provide info
rmation for the national programs.#^ddecs^i2#^tm^len^kUnderregistration^i2#^tm^l
en^kHIV Infections^i2#^tm^len^kAcquired Immunodeficiency Syndrome^i2#^tm^len^kTu
berculosis^i2#^tm^len^kComorbidity^i2#^tm^len^kRegistries Disease Notification^i
2#^tm^len^kMatched-Pair Analysis^i2#^les^a<b>OBJETIVO:</b> Analizar la subnotifi
cación de la comorbilidad tuberculosis (TB) y sida. <b>MÉTODOS:</b> Estudio de v
igilancia utilizando los registros del Sistema de Información de Agravios de Not
ificación de Tuberculosis y de sida en Brasil de 2000 a 2005. Registros de TB si
n información de la presencia de sida fueron consideradas subnotificaciones de l
a comorbilidad cuando se parearon a registros de sida que presentaron año de dia
gnóstico de sida igual o anterior al año de notificación de la TB, así como los 
registros de un mismo paciente cuyos registros anteriores presentaban esa inform
ación. Se creó un indicador: comorbilidad TB-sida reconocida, a partir de los re
gistros de TB con la información de presencia de sida. <b>RESULTADOS:</b> La sub
notificación de TB-sida fue de 17,7%. Este porcentaje varió entre estados. La in
corporación de los registros subnotificados a los previamente reconocidos elevó 
la proporción de TB-sida en Brasil de 6,9% a 8,4%. Las mayores proporciones de s
ubnotificación fueron observadas en Acre, Alagoas, Maranhao y Piauí (más de 35% 
en cada uno) y las menores en Sao Paulo y Goiás (cerca de 10% en cada uno). <b>C
ONCLUSIONES:</b> La subnotificación de la comorbilidad TB-sida encontrada en Bra
sil debe deflagrar modificaciones en el sistema de vigilancia para proveer infor
maciones a los programas nacionales.#^ddecs^i3#^tm^les^kOmisiones de Registro^i3
#^tm^les^kInfecciones por VIH^i3#^tm^les^kSíndrome de Inmunodeficiencia Adquirid
a^i3#^tm^les^kTuberculosis^i3#^tm^les^kComorbilidad^i3#^tm^les^kSistema de Regis
tros^i3#^tm^les^kNotificación de Enfermedad^i3#^tm^les^kAnálisis por Apareamient
o^i3#vancouv#12#20100606#6/6/2010#20101114#14/11/2010#2326.htm##
06902000000000889000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098038000500102038000400107121000300111049000300114
15800030011703000190012003200060013906500090014501400070015403500100016122300090
01710120089001800120098002690120097003670100041004640100025005050100034005300700
14000564070013300704070003900837070011700876083130200993085001002295085002502305
08500300233008500510236008500240241108500240243508500330245908500350249208500350
25270831391025620850010039530850030039630850027039930850047040200850025040670850
02404092085004404116085003404160083138304194085001005577085003405587085003205621
08500520565308500250570508500250573008500330575508500390578808500380582711700080
58650720003058731120009058761110009058851140009058941130011059030020009059140080
08905923#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#l#4#1#arti
cle#1#^a2011#oa#pt#br1.1#1#4.0#ilus#tab#21#nd#nd#Rev. saúde pública#ahead#201100
00#^f0^l0#0034-8910#20110415#Subnotificação da comorbidade tuberculose e aids: u
ma aplicação do método de linkage^lpt#Underreporting of the tuberculosis and AID
S comorbidity: an application of the linkage method^len#Subnotificación de la co
morbilidad tuberculosis y sida: una aplicación del método de linkage^les#^rND^1A
01 A02^nCarolina Novaes^sCarvalho#^rND^1A03^nInes^sDourado#^rND^1A04^nAna Luiza^
sBierrenbach#^iA01^1Ministério da Saúde^2Secretaria de Vigilância em Saúde.^3Dep
artamento de Apoio à Gestão da Vigilância em Saúde^cBrasília^sDF^pBrasil#^iA02^1
Universidade Federal da Bahia^2Instituto de Saúde Coletiva^3Programa de Pós-Grad
uação em Saúde Coletiva^cSalvador^sBA^pBrasil#^iA03^1UFBA^2ISC^cSalvador^sBA^pBr
asil#^iA04^1Organização Mundial da Saúde^2STOP TB Department^3Tuberculosis Monit
oring and Evaluation Unit^cGenebra^pSuíça#^lpt^aOBJETIVO: Analisar a subnotifica
ção da comorbidade tuberculose (TB) e aids. MÉTODOS: Estudo de vigilância utiliz
ando os registros do Sistema de Informação de Agravos de Notificação de Tubercul
ose e de aids no Brasil de 2000 a 2005. Registros de TB sem informação da presen
ça de aids foram considerados subnotificações da comorbidade quando pareados a r
egistros de aids que apresentassem ano de diagnóstico de aids igual ou anterior 
ao ano de notificação da TB, assim como os registros de um mesmo paciente cujos 
registros anteriores apresentavam essa informação. Criou-se um indicador: comorb
idade TB-aids reconhecida, a partir dos registros de TB com a informação de pres
ença de aids. RESULTADOS: A subnotificação de TB-aids foi de 17,7 por cento. Ess
e percentual variou entre estados. A incorporação dos registros subnotificados a
os previamente reconhecidos elevou a proporção de TB-aids no Brasil de 6,9 por c
ento para 8,4 por cento. As maiores proporções de subnotificação foram observada
s no Acre, Alagoas, Maranhão e Piauí (mais de 35 por cento cada) e as menores em
 São Paulo e Goiás (cerca de 10 por cento cada). CONCLUSÕES: A subnotificação da
 comorbidade TB-aids encontrada no Brasil deve deflagrar modificações no sistema
 de vigilância para prover informações aos programas nacionais.#^ddecs^i1#^tm^lp
t^kSub-Registro^i1#^tm^lpt^kInfecções por HIV^i1#^tm^lpt^kSíndrome de Imunodefic
iência Adquirida^i1#^tm^lpt^kTuberculose^i1#^tm^lpt^kComorbidade^i1#^tm^lpt^kSis
tema de Registros^i1#^tm^lpt^kNotificação de Doenças^i1#^tm^lpt^kAnálise por Par
eamento^i1#^len^aOBJECTIVE: To analyze the underreporting of the tuberculosis (T
B) and AIDS comorbidity. METHODS: Surveillance study using records from the Noti
fiable Diseases Information System - Tuberculosis and AIDS in Brazil from 2000 t
o 2005. Records of TB without information on the presence of Aids were considere
d to be underreporting of the comorbidity when paired off with AIDS records in w
hich the year of diagnosis of AIDS was the same or previous to the year of repor
ting of TB, as well as records from the same patient whose previous records had 
this information. An indicator was created: recognized TB-AIDS comorbidity, base
d on the TB records that had information on the presence of AIDS. RESULTS: The u
nderreporting of TB-AIDS was 17.7 percent. This percentage varied between states
. The incorporation of the underreported records into the previously recognized 
ones increased the proportion of TB-AIDS in Brazil from 6.9 percent to 8.4 perce
nt. The highest proportions of underreporting were noted in Acre (Northern), Ala
goas, Maranhão and Piauí (Northeastern) (more than 35 percent each) and the lowe
st in São Paulo (Southeastern) and Goiás (Central-western) (around 10 percent ea
ch). CONCLUSIONS: The underreporting of the TB-AIDS comorbidity found in Brazil 
will probably trigger modifications in the surveillance system in order to provi
de information for the national programs.#^ddecs^i2#^tm^len^kUnderregistration^i
2#^tm^len^kHIV Infections^i2#^tm^len^kAcquired Immunodeficiency Syndrome^i2#^tm^
len^kTuberculosis^i2#^tm^len^kComorbidity^i2#^tm^len^kRegistries Disease Notific
ation^i2#^tm^len^kMatched-Pair Analysis^i2#^les^aOBJETIVO: Analizar la subnotifi
cación de la comorbilidad tuberculosis (TB) y sida. MÉTODOS: Estudio de vigilanc
ia utilizando los registros del Sistema de Información de Agravios de Notificaci
ón de Tuberculosis y de sida en Brasil de 2000 a 2005. Registros de TB sin infor
mación de la presencia de sida fueron consideradas subnotificaciones de la comor
bilidad cuando se parearon a registros de sida que presentaron año de diagnóstic
o de sida igual o anterior al año de notificación de la TB, así como los registr
os de un mismo paciente cuyos registros anteriores presentaban esa información. 
Se creó un indicador: comorbilidad TB-sida reconocida, a partir de los registros
 de TB con la información de presencia de sida. RESULTADOS: La subnotificación d
e TB-sida fue de 17,7 por ciento. Este porcentaje varió entre estados. La incorp
oración de los registros subnotificados a los previamente reconocidos elevó la p
roporción de TB-sida en Brasil de 6,9 por ciento a 8,4 por ciento. Las mayores p
roporciones de subnotificación fueron observadas en Acre, Alagoas, Maranhao y Pi
auí (más de 35 por ciento en cada uno) y las menores en Sao Paulo y Goiás (cerca
 de 10 por ciento en cada uno). CONCLUSIONES: La subnotificación de la comorbili
dad TB-sida encontrada en Brasil debe deflagrar modificaciones en el sistema de 
vigilancia para proveer informaciones a los programas nacionales.#^ddecs^i3#^tm^
les^kOmisiones de Registro^i3#^tm^les^kInfecciones por VIH^i3#^tm^les^kSíndrome 
de Inmunodeficiencia Adquirida^i3#^tm^les^kTuberculosis^i3#^tm^les^kComorbilidad
^i3#^tm^les^kSistema de Registros^i3#^tm^les^kNotificación de Enfermedad^i3#^tm^
les^kAnálisis por Apareamiento^i3#vancouv#12#20100606#6/6/2010#20101114#14/11/20
10#2326.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S00
34-89102011005000021##
00475000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704024100079002000900320#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#5#1#article#131#<p><a name="top"
></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Subnotifica&
ccedil;&atilde;o    da comorbidade tuberculose e aids: uma aplica&ccedil;&atilde
;o do m&eacute;todo    de <i>linkage</i></b> </font></p>     ^cY#2326.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#6#2#article#131#<p>&nbsp;</p>   
  ^cY#2326.htm##
00420000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704018600079002000900265#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#7#3#article#131#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Underreporting    of the tuber
culosis and AIDS comorbidity: an application of the linkage method</b></font></p
>     ^cY#2326.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#8#4#article#131#<p>&nbsp;</p>   
  ^cY#2326.htm##
00450000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704021600079002000900295#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#9#5#article#131#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Subnotificaci&oacute;n    de l
a comorbilidad tuberculosis y sida: una aplicaci&oacute;n del m&eacute;todo    d
e <i>linkage</i></b></font></p>     ^cY#2326.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#10#6#article#131#<p>&nbsp;</p>  
   ^cY#2326.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#11#7#article#131#<p>&nbsp;</p>  
   ^cY#2326.htm##
00432000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704019700080002000900277#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#12#8#article#131#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Carolina Novaes    Carvalho<s
up>I, II</sup>; Ines Dourado<sup>III</sup>; Ana Luiza Bierrenbach<sup>IV</sup></
b></font></p>     ^cY#2326.htm##
00519000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704028400080002000900364#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#13#9#article#131#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Departamento    de A
poio &agrave; Gest&atilde;o da Vigil&acirc;ncia em Sa&uacute;de. Secretaria    d
e Vigil&acirc;ncia em Sa&uacute;de. Minist&eacute;rio da Sa&uacute;de. Bras&iacu
te;lia,    DF, Brasil    ^cY#2326.htm##
00443000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020700081002000900288#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#14#10#article#131#<br>   <sup>II
</sup>Programa de P&oacute;s-Gradua&ccedil;&atilde;o em Sa&uacute;de    Coletiva
. Instituto de Sa&uacute;de Coletiva (ISC). Universidade Federal da    Bahia (UF
BA). Salvador, BA, Brasil    ^cY#2326.htm##
00295000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704005900081002000900140#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#15#11#article#131#<br>   <sup>II
I</sup>ISC-UFBA. Salvador, BA, Brasil    ^cY#2326.htm##
00423000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018700081002000900268#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#16#12#article#131#<br>   <sup>IV
</sup>Tuberculosis Monitoring and Evaluation Unit. STOP TB Department.    Organi
za&ccedil;&atilde;o Mundial da Sa&uacute;de. Genebra, Su&iacute;&ccedil;a</font>
</p>     ^cY#2326.htm##
00380000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014400081002000900225#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#17#13#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecir
c;ncia    | Correspondence</a></font></p>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#18#14#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704004400081002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#19#15#article#131#<p>&nbsp;</p> 
<hr size="1" noshade>     ^cY#2326.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#20#16#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^c
Y#2326.htm##
00406000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017000081002000900251#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#21#17#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analisar a 
subnotifica&ccedil;&atilde;o da comorbidade tuberculose (TB) e aids.    ^cY#2326
.htm##
01026000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079000081002000900871#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#22#18#article#131#<br>   <b>M&Ea
cute;TODOS:</b> Estudo de vigil&acirc;ncia utilizando os registros do    Sistema
 de Informa&ccedil;&atilde;o de Agravos de Notifica&ccedil;&atilde;o    de Tuber
culose e de aids no Brasil de 2000 a 2005. Registros de TB sem informa&ccedil;&a
tilde;o    da presen&ccedil;a de aids foram considerados subnotifica&ccedil;&oti
lde;es    da comorbidade quando pareados a registros de aids que apresentassem a
no de    diagn&oacute;stico de aids igual ou anterior ao ano de notifica&ccedil;
&atilde;o    da TB, assim como os registros de um mesmo paciente cujos registros
 anteriores    apresentavam essa informa&ccedil;&atilde;o. Criou-se um indicador
: comorbidade    TB-aids reconhecida, a partir dos registros de TB com a informa
&ccedil;&atilde;o    de presen&ccedil;a de aids.    ^cY#2326.htm##
00763000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704052700081002000900608#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#23#19#article#131#<br>   <b>RESU
LTADOS:</b> A subnotifica&ccedil;&atilde;o de TB-aids foi de 17,7%. Esse    perc
entual variou entre estados. A incorpora&ccedil;&atilde;o dos registros    subno
tificados aos previamente reconhecidos elevou a propor&ccedil;&atilde;o    de TB
-aids no Brasil de 6,9% para 8,4%. As maiores propor&ccedil;&otilde;es    de sub
notifica&ccedil;&atilde;o foram observadas no Acre, Alagoas, Maranh&atilde;o    
e Piau&iacute; (mais de 35% cada) e as menores em S&atilde;o Paulo e Goi&aacute;
s    (cerca de 10% cada).    ^cY#2326.htm##
00505000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704026900081002000900350#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#24#20#article#131#<br>   <b>CONC
LUS&Otilde;ES:</b> A subnotifica&ccedil;&atilde;o da comorbidade TB-aids    enco
ntrada no Brasil deve deflagrar modifica&ccedil;&otilde;es no sistema de    vigi
l&acirc;ncia para prover informa&ccedil;&otilde;es aos programas nacionais.</fon
t></p>     ^cY#2326.htm##
00593000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035700081002000900438#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#25#21#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Sub-Regi
stro. Infec&ccedil;&otilde;es por HIV. S&iacute;ndrome de Imunodefici&ecirc;ncia
    Adquirida. Tuberculose. Comorbidade. Sistema de Registros. Notifica&ccedil;&
atilde;o    de Doen&ccedil;as. An&aacute;lise por Pareamento.</font></p> <hr siz
e="1" noshade>     ^cY#2326.htm##
00334000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009800081002000900179#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#26#22#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     
^cY#2326.htm##
00404000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704016800081002000900249#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#27#23#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To analyze
 the underreporting of the tuberculosis (TB) and AIDS comorbidity.    ^cY#2326.h
tm##
00879000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704064300081002000900724#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#28#24#article#131#<br>   <b>METH
ODS:</b> Surveillance study using records from the Notifiable Diseases    Inform
ation System - Tuberculosis and AIDS in Brazil from 2000 to 2005. Records    of 
TB without information on the presence of Aids were considered to be underreport
ing    of the comorbidity when paired off with AIDS records in which the year of
 diagnosis    of AIDS was the same or previous to the year of reporting of TB, a
s well as    records from the same patient whose previous records had this infor
mation. An    indicator was created: recognized TB-AIDS comorbidity, based on th
e TB records    that had information on the presence of AIDS.    ^cY#2326.htm##
00767000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704053100081002000900612#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#29#25#article#131#<br>   <b>RESU
LTS:</b> The underreporting of TB-AIDS was 17.7%. This percentage varied    betw
een states. The incorporation of the underreported records into the previously  
  recognized ones increased the proportion of TB-AIDS in Brazil from 6.9% to 8.4
%.    The highest proportions of underreporting were noted in Acre (Northern), A
lagoas,    Maranh&atilde;o and Piau&iacute; (Northeastern) (more than 35% each) 
and the    lowest in S&atilde;o Paulo (Southeastern) and Goi&aacute;s (Central-w
estern)    (around 10% each).    ^cY#2326.htm##
00472000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704023600081002000900317#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#30#26#article#131#<br>   <b>CONC
LUSIONS:</b> The underreporting of the TB-AIDS comorbidity found in Brazil    wi
ll probably trigger modifications in the surveillance system in order to provide
    information for the national programs.</font></p>     ^cY#2326.htm##
00520000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704028400081002000900365#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#31#27#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:</b>    Underreg
istration. HIV Infections. Acquired Immunodeficiency Syndrome. Tuberculosis.    
Comorbidity. Registries Disease Notification. Matched-Pair Analysis.</font></p> 
<hr size="1" noshade>     ^cY#2326.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#32#28#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^
cY#2326.htm##
00406000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017000081002000900251#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#33#29#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analizar la
 subnotificaci&oacute;n de la comorbilidad tuberculosis (TB) y sida.    ^cY#2326
.htm##
01001000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704076500081002000900846#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#34#30#article#131#<br>   <b>M&Ea
cute;TODOS:</b> Estudio de vigilancia utilizando los registros del Sistema    de
 Informaci&oacute;n de Agravios de Notificaci&oacute;n de Tuberculosis y de    s
ida en Brasil de 2000 a 2005. Registros de TB sin informaci&oacute;n de la    pr
esencia de sida fueron consideradas subnotificaciones de la comorbilidad cuando 
   se parearon a registros de sida que presentaron a&ntilde;o de diagn&oacute;st
ico    de sida igual o anterior al a&ntilde;o de notificaci&oacute;n de la TB, a
s&iacute;    como los registros de un mismo paciente cuyos registros anteriores 
presentaban    esa informaci&oacute;n. Se cre&oacute; un indicador: comorbilidad
 TB-sida reconocida,    a partir de los registros de TB con la informaci&oacute;
n de presencia de sida.    ^cY#2326.htm##
00749000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051300081002000900594#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#35#31#article#131#<br>   <b>RESU
LTADOS:</b> La subnotificaci&oacute;n de TB-sida fue de 17,7%. Este porcentaje  
  vari&oacute; entre estados. La incorporaci&oacute;n de los registros subnotifi
cados    a los previamente reconocidos elev&oacute; la proporci&oacute;n de TB-s
ida en    Brasil de 6,9% a 8,4%. Las mayores proporciones de subnotificaci&oacut
e;n fueron    observadas en Acre, Alagoas, Maranhao y Piau&iacute; (m&aacute;s d
e 35% en cada    uno) y las menores en Sao Paulo y Goi&aacute;s (cerca de 10% en
 cada uno).    ^cY#2326.htm##
00476000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704024000081002000900321#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#36#32#article#131#<br>   <b>CONC
LUSIONES:</b> La subnotificaci&oacute;n de la comorbilidad TB-sida encontrada   
 en Brasil debe deflagrar modificaciones en el sistema de vigilancia para provee
r    informaciones a los programas nacionales.</font></p>     ^cY#2326.htm##
00581000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034500081002000900426#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#37#33#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:</b>    Omision
es de Registro. Infecciones por VIH. S&iacute;ndrome de Inmunodeficiencia    Adq
uirida. Tuberculosis. Comorbilidad. Sistema de Registros. Notificaci&oacute;n   
 de Enfermedad. An&aacute;lisis por Apareamiento.</font></p> <hr size="1" noshad
e>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#38#34#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#39#35#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00350000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011400081002000900195#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#40#36#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b>
</font></p>     ^cY#2326.htm##
00841000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704060500081002000900686#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#41#37#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A subnotifica&ccedil;&atilde;o 
   de agravo de notifica&ccedil;&atilde;o compuls&oacute;ria ocorre quando um ca
so    n&atilde;o &eacute; notificado ao sistema de informa&ccedil;&atilde;o ou o
corre    fora do per&iacute;odo estabelecido.<sup>9</sup> Estimativas equivocada
s da    magnitude das doen&ccedil;as podem decorrer disso, o que prejudica o pla
nejamento    de estrat&eacute;gias de preven&ccedil;&atilde;o e controle e pode 
levar &agrave;    subaloca&ccedil;&atilde;o de a&ccedil;&otilde;es e recursos.<s
up>11</sup></font></p>     ^cY#2326.htm##
01097000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704086100081002000900942#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#42#38#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O sistema de vigil&acirc;ncia  
  epidemiol&oacute;gica de doen&ccedil;as transmiss&iacute;veis no Brasil &eacut
e;    rotineiramente passivo. O desconhecimento das doen&ccedil;as a notificar e
 do    fluxo da notifica&ccedil;&atilde;o pelos profissionais de sa&uacute;de, b
em    como mudan&ccedil;as na defini&ccedil;&atilde;o de caso e a cren&ccedil;a 
de    que outro profissional notificou o caso, podem contribuir para a subnotifi
ca&ccedil;&atilde;o    de casos.<sup>3,</sup><a name="topa"></a><a href="#backa"
>ª</a> Acrescenta-se    a isso a solicita&ccedil;&atilde;o de sigilo do diagn&oa
cute;stico de doen&ccedil;as    como tuberculose (TB) e aids, por pacientes ou f
amiliares, mesmo que seja uma    informa&ccedil;&atilde;o necess&aacute;ria para
 fins oficiais.<sup>9</sup></font></p>     ^cY#2326.htm##
01135000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704089900081002000900980#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#43#39#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A co-infec&ccedil;&atilde;o    
pelo bacilo da TB e pelo v&iacute;rus da imunodefici&ecirc;ncia humana (HIV),   
 e sua m&uacute;tua interfer&ecirc;ncia na evolu&ccedil;&atilde;o de TB e aids, 
   demandou o fortalecimento da rede de vigil&acirc;ncia no Brasil. Os Programas
    Nacionais de Controle da TB (PNCT) e de doen&ccedil;as sexualmente transmiss
&iacute;veis    (DST/aids) passaram a estabelecer estrat&eacute;gias conjuntas d
e vigil&acirc;ncia    epidemiol&oacute;gica em 2004 e tornaram compuls&oacute;ri
a a oferta do teste    HIV para os casos novos de TB, com a necessidade do conse
ntimento do paciente    para a testagem. No entanto, a magnitude da associa&cced
il;&atilde;o entre essas    duas doen&ccedil;as pode n&atilde;o ser aparente se 
casos de comorbidade n&atilde;o    forem notificados.<sup>1</sup></font></p>    
 ^cY#2326.htm##
00419000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018300081002000900264#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#44#40#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O objetivo presente    foi anal
isar a subnotifica&ccedil;&atilde;o da comorbidade TB-aids no Brasil.</font></p>
     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#45#41#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00340000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010400081002000900185#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#46#42#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p
>     ^cY#2326.htm##
00920000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704068400081002000900765#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#47#43#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudo de vigil&acirc;ncia    c
om dados do Sistema de Informa&ccedil;&atilde;o de Agravos de Notifica&ccedil;&a
tilde;o    de Tuberculose (Sinan-TB) de 2000 a 2005 e do banco nacional da aids 
de 1980    a 2005. Esse banco resulta da consolida&ccedil;&atilde;o de sistemas 
de informa&ccedil;&atilde;o    como: Sistema de Informa&ccedil;&atilde;o de Agra
vos de Notifica&ccedil;&atilde;o    de aids (Sinan-aids), Sistema de Controle de
 Exames Laboratoriais (Siscel),    Sistema de Controle Log&iacute;stico de Medic
amentos (Siclom), Sistema de Informa&ccedil;&atilde;o    de Mortalidade (SIM).<s
up>7</sup></font></p>     ^cY#2326.htm##
00762000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704052600081002000900607#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#48#44#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O banco do Sinan-TB    foi extr
a&iacute;do em fevereiro de 2007 e o banco nacional da aids, em abril    de 2007
. Ambos passaram por an&aacute;lise de qualidade dos dados para o reconhecimento
,    classifica&ccedil;&atilde;o e remo&ccedil;&atilde;o de registros duplicados
    (presen&ccedil;a de mais de um registro do mesmo paciente) por meio de parea
mento    probabil&iacute;stico (<i>linkage</i>), como descrito na literatura.<su
p>2,10</sup></font></p>     ^cY#2326.htm##
01166000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704093000081002000901011#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#49#45#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O processo de depura&ccedil;&at
ilde;o    aplicado ao Sinan-TB respeitou a l&oacute;gica estrutural do Sinan, pe
la qual    deveriam ser mantidos registros de pacientes no primeiro epis&oacute;
dio de    tratamento ou em epis&oacute;dios de tratamento subseq&uuml;entes (ret
ratamentos    por reingresso ap&oacute;s abandono ou recidiva ap&oacute;s cura).
 Os registros    do mesmo paciente em um epis&oacute;dio de tratamento, mas prov
enientes de unidades    de sa&uacute;de diferentes, foram vinculados (transfer&e
circ;ncias). Os registros    do mesmo paciente em diferentes epis&oacute;dios de
 tratamento foram mantidos    no banco ordenados cronologicamente pela data de d
iagn&oacute;stico, de notifica&ccedil;&atilde;o    ou de in&iacute;cio de tratam
ento. Para o pareamento com o Sinan-aids, foi utilizado    o primeiro registro d
e cada paciente.</font></p>     ^cY#2326.htm##
00653000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704041700081002000900498#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#50#46#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Na l&oacute;gica    estrutural 
do banco nacional da aids, cada paciente deveria ter um registro.    Esse banco 
continha 419.795 registros, cada qual referente a um paciente. Do    total, 99.2
76 (23,7%) haviam morrido antes de 2000 (situa&ccedil;&atilde;o atual/data    do
 &oacute;bito) e n&atilde;o foram utilizados para o pareamento.</font></p>     ^
cY#2326.htm##
02894000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704265800081002000902739#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#51#47#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O pareamento entre    os bancos
 foi realizado em dois ciclos consecutivos, o segundo para aumentar    a sensibi
lidade de pareamento. O primeiro ciclo comportou tr&ecirc;s etapas:    pr&eacute
;-processamento do banco, pareamento probabil&iacute;stico e identifica&ccedil;&
atilde;o    de pares verdadeiros. No pr&eacute;-processamento, os bancos passara
m por reformata&ccedil;&atilde;o    das vari&aacute;veis: data de notifica&ccedi
l;&atilde;o; data de diagn&oacute;stico;    data de nascimento; e por corre&cced
il;&otilde;es nas vari&aacute;veis: nome    do paciente; nome da m&atilde;e do p
aciente. Al&eacute;m disso, foram removidos    os endere&ccedil;os mais comuns n
&atilde;o discriminat&oacute;rios, como os    de sistema penitenci&aacute;rio, o
u men&ccedil;&otilde;es de que o paciente    n&atilde;o possu&iacute;a resid&eci
rc;ncia ou que esta era desconhecida (sem    resid&ecirc;ncia, morador de rua, e
tc.). No pareamento probabil&iacute;stico,    as vari&aacute;veis usadas foram: 
nome do paciente, nome da m&atilde;e e data    de nascimento. A vari&aacute;vel 
sexo foi utilizada para repartir os bancos    de dados em blocos menores e aumen
tar a rapidez do pareamento. As probabilidades    utilizadas no pareamento foram
 extra&iacute;das por m&eacute;todo indireto.    A identifica&ccedil;&atilde;o d
e registros pareados foi realizada pelo programa    Link Plus,<a name="topb"></a
><a href="#backb"><sup>b</sup></a> que calcula a    probabilidade de concord&aci
rc;ncia e discord&acirc;ncia das vari&aacute;veis    selecionadas para o pareame
nto. Quanto maior a pontua&ccedil;&atilde;o, maior    a probabilidade de a dupla
 pareada ser referente ao mesmo indiv&iacute;duo.    O valor tr&ecirc;s foi defi
nido empiricamente como ponto de corte, acima do    qual o programa deveria list
ar as duplas pareadas. Foram considerados pares    verdadeiros os que tivessem a
mbos os registros pertencentes ao mesmo indiv&iacute;duo,    confirmados por dep
ura&ccedil;&atilde;o manual. Para tanto, foram tamb&eacute;m    consideradas inf
orma&ccedil;&otilde;es sobre idade, unidade da federa&ccedil;&atilde;o    e muni
c&iacute;pio de resid&ecirc;ncia, logradouro e n&uacute;mero do logradouro.    Q
uando em d&uacute;vida, optou-se pela alternativa conservadora de n&atilde;o    
considerar os registros pareados como pares verdadeiros. Revis&atilde;o manual  
  foi realizada em pares com pontua&ccedil;&atilde;o de tr&ecirc;s a 13,5. Aquel
es    com pontua&ccedil;&atilde;o de 13,5 at&eacute; 23,5 (maior valor encontrad
o)    foram considerados verdadeiros, sem revis&atilde;o manual.</font></p>     
^cY#2326.htm##
00975000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704073900081002000900820#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#52#48#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Havia muitos registros    no ba
nco nacional da aids com diagn&oacute;stico de TB n&atilde;o pareados ao    Sina
n-TB. Assim, foi realizado novo ciclo de pareamento desses registros com    os d
o Sinan-TB com HIV positivo e/ou agravo associado aids. Os par&acirc;metros    d
e configura&ccedil;&atilde;o do programa foram alterados, e nome do paciente    
e data de nascimento foram escolhidos como vari&aacute;veis de pareamento. Sexo 
   permaneceu como a vari&aacute;vel de blocagem e o ponto de corte foi alterado
    para 0,1. Ap&oacute;s nova depura&ccedil;&atilde;o manual, os pares verdadei
ros    foram marcados nos bancos originais do Sinan-TB e da aids.</font></p>    
 ^cY#2326.htm##
00409000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017300081002000900254#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#53#49#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os registros de    comorbidade 
identificados no Sinan-TB pertenciam a quatro tipos:</font></p> <ul>       ^cY#2
326.htm##
00438000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020200081002000900283#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#54#50#article#131#<li><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">tipo 1 - primeiro      ou &uac
ute;nico registro de cada paciente pareado a registro do banco nacional      da 
aids;</font></li>       ^cY#2326.htm##
01075000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704083900081002000900920#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#55#51#article#131#<li><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">tipo 2 - pacientes      com m&
uacute;ltiplos registros, com o primeiro pareado a registro do banco      nacion
al da aids. Em caso de pareamento entre um registro do Sinan-TB e o      banco d
a aids, todos os registros do mesmo paciente eram considerados pareados.      Se
 o ano de notifica&ccedil;&atilde;o de TB fosse anterior ao do diagn&oacute;stic
o      de aids, o registro n&atilde;o seria considerado TB-aids porque, em 2000,
      a TB pulmonar (forma mais prevalente da doen&ccedil;a) n&atilde;o era cons
iderada      condi&ccedil;&atilde;o definidora de aids no crit&eacute;rio CDC Mo
dificado;<sup>12</sup>      assim, esses registros poderiam caracterizar uma con
di&ccedil;&atilde;o de      co-infec&ccedil;&atilde;o e n&atilde;o de comorbidad
e;</font></li>       ^cY#2326.htm##
00619000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704038300081002000900464#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#56#52#article#131#<li><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">tipo 3 - agravos      associad
os &agrave; aids n&atilde;o pareados ao banco nacional da aids, i.e.,      que n
&atilde;o eram do tipo 1 ou 2. Essa vari&aacute;vel deveria ser preenchida      
com um dos valores mutuamente excludentes: aids, alcoolismo, doen&ccedil;a      
mental, diabetes e outros;</font></li>       ^cY#2326.htm##
00595000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035900081002000900440#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#57#53#article#131#<li><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">tipo 4 - sem      a informa&cc
edil;&atilde;o de agravo associado aids, n&atilde;o encontrado      por meio de 
pareamento ao banco nacional da aids, mas com informa&ccedil;&atilde;o      de a
gravo associado &agrave; aids em um dos registros anteriores do mesmo      pacie
nte.</font></li>     ^cY#2326.htm##
00250000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704001400081002000900095#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#58#54#article#131#</ul>     ^cY#
2326.htm##
00788000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704055200081002000900633#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#59#55#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os registros de    TB-aids iden
tificados (somat&oacute;ria dos registros de tipo 1 a 4) foram classificados    
em duas condi&ccedil;&otilde;es: a) comorbidade reconhecida, em que a informa&cc
edil;&atilde;o    de que o paciente tinha aids estava preenchida na vari&aacute;
vel agravos associados,    e b) subnotifica&ccedil;&atilde;o da comorbidade, em 
que a informa&ccedil;&atilde;o    de que o paciente tinha aids n&atilde;o estava
 preenchida para essa vari&aacute;vel.</font></p>     ^cY#2326.htm##
01187000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704095100081002000901032#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#60#56#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Poss&iacute;veis    associa&cce
dil;&otilde;es foram analisadas entre a comorbidade reconhecida ou    a subnotif
ica&ccedil;&atilde;o e sexo, grupo et&aacute;rio, tipo de entrada    (caso novo,
 recidiva, reingresso ap&oacute;s abandono e transfer&ecirc;ncia),    forma cl&i
acute;nica (pulmonar, extrapulmonar, pulmonar + extrapulmonar), status    de HIV
 (positivo, negativo, em andamento, n&atilde;o realizado e sem informa&ccedil;&a
tilde;o),    baciloscopia de escarro (positiva, negativa, n&atilde;o realizada) 
e situa&ccedil;&atilde;o    de encerramento (cura, abandono, &oacute;bito, trans
fer&ecirc;ncia e TB multirresistente).    Utilizou-se o teste qui-quadrado para 
avaliar diferen&ccedil;as estatisticamente    significantes entre os n&iacute;ve
is das vari&aacute;veis. A completitude das    vari&aacute;veis HIV e agravos as
sociados tamb&eacute;m foi analisada.</font></p>     ^cY#2326.htm##
00690000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704045400081002000900535#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#61#57#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os resultados obtidos    no par
eamento foram disponibilizados para profissionais de sa&uacute;de envolvidos    
em a&ccedil;&otilde;es de vigil&acirc;ncia epidemiol&oacute;gica. Dados de ident
ifica&ccedil;&atilde;o    dos indiv&iacute;duos utilizados no pareamento n&atild
e;o foram divulgados,    garantindo o sigilo e a confidencialidade dessas inform
a&ccedil;&otilde;es.</font></p>     ^cY#2326.htm##
00554000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704031800081002000900399#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#62#58#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O programa estat&iacute;stico  
  Stata 9.0 foi utilizado no pr&eacute;-processamento do banco, na depura&ccedil
;&atilde;o    manual dos pares, na marca&ccedil;&atilde;o dos pares verdadeiros 
nos bancos    originais e na an&aacute;lise.</font></p>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#63#59#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010000081002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#64#60#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>   
  ^cY#2326.htm##
00425000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018900081002000900270#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#65#61#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Foram identificados    99.262 r
egistros pareados, 32.501 classificados como pares verdadeiros (tipo    1).</fon
t></p>     ^cY#2326.htm##
00881000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704064500081002000900726#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#66#62#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Foram encontrados    5.009 regi
stros de comorbidade tipo 2, 8.460 do tipo 3 e 631 do tipo 4. De 43.404    regis
tros de comorbidade na somat&oacute;ria dos quatro tipos, 35.728 (82,3%)    eram
 de comorbidade com informa&ccedil;&atilde;o de agravo associado aids e    7.676
 (17,7%) eram subnotifica&ccedil;&otilde;es reconhecidas pelo pareamento    (16,
2%) ou por serem registros m&uacute;ltiplos de pacientes com informa&ccedil;&ati
lde;o    de agravo associado aids em registro anterior (1,5%) (<a href="/img/rev
istas/rsp/2011nahead/2326f01.jpg">Figura    1</a>).</font></p>     ^cY#2326.htm#
#
00578000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034200081002000900423#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#67#63#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Foram identificados    8.804 re
gistros no banco nacional da aids de 2000 a 2005 que apresentavam TB    no momen
to do diagn&oacute;stico, mas n&atilde;o pareados a registros do Sinan-TB    e, 
conseq&uuml;entemente, n&atilde;o considerados casos de comorbidade.</font></p> 
    ^cY#2326.htm##
00905000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704066900081002000900750#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#68#64#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A propor&ccedil;&atilde;o    de
 subnotifica&ccedil;&atilde;o teve gradual redu&ccedil;&atilde;o ao longo    de 
per&iacute;odo estudado, com m&eacute;dia de 17,7% em todo o Brasil. A propor&cc
edil;&atilde;o    de comorbidade reconhecida era de 6,9% e passou para 8,4% (acr
&eacute;scimo    de 21,4%; <a href="#t1">Tabela 1</a>). As maiores propor&ccedil
;&otilde;es de    subnotifica&ccedil;&atilde;o foram observadas no Acre, Alagoas
, Maranh&atilde;o    e Piau&iacute; (mais de 35% cada) e as menores em S&atilde;
o Paulo e Goi&aacute;s    (cerca de 10% cada) (<a href="#f2">Figura 2</a>).</fon
t></p>     ^cY#2326.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#69#65#article#131#<p><a name="t1
"></a></p>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#70#66#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#71#67#article#131#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2326t01.jpg"></p>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#72#68#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#73#69#article#131#<p><a name="f2
"></a></p>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#74#70#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#75#71#article#131#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2326f02.jpg"></p>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#76#72#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
01193000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704095700081002000901038#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#77#73#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Registros de comorbidade    rec
onhecida e de subnotifica&ccedil;&atilde;o tinham caracter&iacute;sticas    dist
intas para todas as vari&aacute;veis estudadas. Os registros de subnotifica&cced
il;&atilde;o    apresentavam idade mais avan&ccedil;ada, predom&iacute;nio de ca
sos novos, da    forma cl&iacute;nica pulmonar, de baciloscopia de escarro posit
iva, de HIV negativo    e de abandono como desfecho. Essas diferen&ccedil;as for
am mais marcantes para    status de HIV e forma cl&iacute;nica da TB: enquanto o
s registros de comorbidade    reconhecida apresentavam 93,9% (e n&atilde;o 100%)
 de resultado de HIV positivo    e 58,6% de forma cl&iacute;nica pulmonar, os re
gistros de subnotifica&ccedil;&atilde;o    de comorbidade apresentavam 58,3% de 
HIV positivo e 70,3% de forma cl&iacute;nica    pulmonar (<a href="/img/revistas
/rsp/2011nahead/2326t02.jpg">Tabela 2</a>).</font></p>     ^cY#2326.htm##
00752000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051600081002000900597#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#78#74#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Embora a propor&ccedil;&atilde;
o    de registros sem informa&ccedil;&atilde;o sobre agravos associados tenha di
minu&iacute;do    ao longo do per&iacute;odo, ainda representava a maioria dos r
egistros em 2005    (74,8%). A propor&ccedil;&atilde;o de registros sem informa&
ccedil;&atilde;o    sobre status de HIV tamb&eacute;m diminuiu ao longo do per&i
acute;odo estudado,    alcan&ccedil;ando 64% em 2005 (<a href="#t3">Tabela 3</a>
).</font></p>     ^cY#2326.htm##
00269000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704003300081002000900114#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#79#75#article#131#<p><a name="t3
"></a></p>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#80#76#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00319000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704008300081002000900164#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#81#77#article#131#<p align="cent
er"><img src="/img/revistas/rsp/2011nahead/2326t03.jpg"></p>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#82#78#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00342000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010600081002000900187#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#83#79#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font><
/p>     ^cY#2326.htm##
00550000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704031400081002000900395#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#84#80#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Este estudo estimou    17,7% de
 subnotifica&ccedil;&atilde;o da comorbidade TB-aids, um fen&ocirc;meno    j&aac
ute; descrito para TB-aids e outras doen&ccedil;as.<sup>3,7,9,</sup><a name="top
c"></a><a href="#backc"><sup>c</sup></a></font></p>     ^cY#2326.htm##
01134000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704089800081002000900979#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#85#81#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A notifica&ccedil;&atilde;o    
fidedigna de pacientes com TB-aids &eacute; essencial para o planejamento adequa
do    de medidas de controle e para o cuidado efetivo do paciente. Al&eacute;m d
isso,    &eacute; grave que a aids possa n&atilde;o ter sido identificada pelo P
NCT em    casos de n&atilde;o notifica&ccedil;&atilde;o de TB-aids. A informa&cc
edil;&atilde;o    sobre a presen&ccedil;a da comorbidade &eacute; essencial para
 o acompanhamento    diferenciado dos pacientes, uma vez que a hist&oacute;ria n
atural da TB &eacute;    modificada pela aids, com aumento da recorr&ecirc;ncia,
 assim como sua apresenta&ccedil;&atilde;o    cl&iacute;nica, dura&ccedil;&atild
e;o do tratamento e toler&acirc;ncia e resist&ecirc;ncia    &agrave;s drogas dis
pon&iacute;veis.<sup>6,8,</sup><a href="#backd"><sup>d</sup></a></font></p>     
^cY#2326.htm##
01441000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704120500081002000901286#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#86#82#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Para aumentar a    completitude
 dos agravos associados &agrave; aids, &eacute; importante aumentar    a complet
itude do status de HIV. Os profissionais de sa&uacute;de que acompanham    o cas
o e os que preenchem a ficha de acompanhamento do Sinan-TB devem atentar    para
 o preenchimento dos agravos associados &agrave; aids para os registros    de pa
cientes com HIV positivo. &Eacute; necess&aacute;rio n&atilde;o somente    garan
tir a realiza&ccedil;&atilde;o do teste para todos os que consentirem,    mas ta
mb&eacute;m garantir que os resultados sejam inseridos nos sistemas de    inform
a&ccedil;&otilde;es assim que dispon&iacute;veis. Quanto menor a propor&ccedil;&
atilde;o    de pacientes com TB testados para o HIV e de pacientes HIV positivos
 notificados    no Sinan-TB, maior a incerteza sobre a real preval&ecirc;ncia de
 HIV entre os    pacientes de TB. Segundo os dados do Sinan-TB, a preval&ecirc;n
cia de HIV seria    de 8,2% em 2005, inferior aos 14% estimados pela Organiza&cc
edil;&atilde;o Mundial    da Sa&uacute;de (OMS) para o Brasil para o mesmo ano.<
a name="tope"></a><a href="#backe"><sup>e</sup></a></font></p>     ^cY#2326.htm#
#
01281000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704104500081002000901126#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#87#83#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O PNCT tem a responsabilidade  
  de compartilhar as an&aacute;lises de dados do Sinan-TB com os profissionais  
  de sa&uacute;de que acompanham casos e que preenchem as notifica&ccedil;&otild
e;es,    para que compreendam a import&acirc;ncia do preenchimento adequado dos 
registros    e sintam-se motivados a melhorar a qualidade dos dados coletados. A
l&eacute;m    disso, &eacute; essencial que esses profissionais sejam instru&iac
ute;dos a    respeito de t&oacute;picos de epidemiologia da TB importantes para 
a execu&ccedil;&atilde;o    de seu trabalho. Por exemplo, devem ser alertados de
 que, embora os pacientes    com TB extrapulmonar tenham maior risco de desenvol
ver a comorbidade TB-aids,<sup>4</sup>    os com TB pulmonar tamb&eacute;m podem
 apresent&aacute;-la, e que portanto a    informa&ccedil;&atilde;o de comorbidad
e deve ser notificada tanto para a forma    extrapulmonar quanto para a pulmonar
, o que n&atilde;o vinha acontecendo adequadamente.</font></p>     ^cY#2326.htm#
#
00983000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704074700081002000900828#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#88#84#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A modifica&ccedil;&atilde;o    
da vari&aacute;vel "agravos associados" foi identificada como uma das medidas   
 necess&aacute;rias para a melhoria de seu preenchimento. Isso porque, como a   
 vari&aacute;vel estava estruturada, s&oacute; era poss&iacute;vel informar a   
 presen&ccedil;a de um agravo por vez. Essa modifica&ccedil;&atilde;o j&aacute; 
   foi incorporada nas &uacute;ltimas vers&otilde;es do Sinan-TB, em que cada co
morbidade    passou a ser registrada em um campo espec&iacute;fico, marcado com 
os valores    que indicam a sua presen&ccedil;a, aus&ecirc;ncia ou falta de info
rma&ccedil;&atilde;o.<a name="topf"></a><a href="#backf"><sup>f</sup></a></font>
</p>     ^cY#2326.htm##
00868000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704063200081002000900713#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#89#85#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A principal medida    para prev
enir a subnotifica&ccedil;&atilde;o da comorbidade no Sinan-TB seria    incremen
tar a colabora&ccedil;&atilde;o entre os programas de controle, tal    como reco
mendado pela OMS.<a href="#backd"><sup>d</sup></a> O interc&acirc;mbio    de inf
orma&ccedil;&otilde;es entre os dois programas deve ocorrer rotineiramente    em
 todos os n&iacute;veis administrativos para garantir o conhecimento sobre    a 
condi&ccedil;&atilde;o de comorbidade e o acesso precoce &agrave;s medidas    de
 preven&ccedil;&atilde;o e tratamento.</font></p>     ^cY#2326.htm##
01291000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704105500081002000901136#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#90#86#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O pareamento probabil&iacute;st
ico    entre os bancos do Sinan TB e banco nacional da aids pode contribuir para
 a    melhoria da qualidade de seus dados. A subnotifica&ccedil;&atilde;o de TB-
aids    por unidade federativa apresentada no presente estudo pode ser comparada
 com    a de locais que introduzam medidas aqui propostas para evitar essa subno
tifica&ccedil;&atilde;o.    A periodicidade e o n&iacute;vel administrativo resp
ons&aacute;veis pelo pareamento    devem ser definidos levando em considera&cced
il;&atilde;o a carga de ambas as    doen&ccedil;as e a disponibilidade e capacid
ade local dos recursos humanos,    tendo em vista o fato de que essa atividade d
emanda tempo e trabalho relativamente    especializado. A condi&ccedil;&atilde;o
 de comorbidade descrita pelo pareamento    em qualquer n&iacute;vel deve ser im
ediatamente transferida para as unidades    de sa&uacute;de respons&aacute;veis 
pelo acompanhamento e notifica&ccedil;&atilde;o    dos casos.</font></p>     ^cY
#2326.htm##
02114000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704187800081002000901959#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#91#87#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Em rela&ccedil;&atilde;o    &ag
rave;s limita&ccedil;&otilde;es do estudo, falsos registros de subnotifica&ccedi
l;&atilde;o    de comorbidade podem ter sido identificados se registros pareados
 foram considerados    erroneamente do mesmo paciente. Essa situa&ccedil;&atilde
;o &eacute; improv&aacute;vel,    dada a rigorosa depura&ccedil;&atilde;o manual
 realizada. Problemas na qualidade    das informa&ccedil;&otilde;es das vari&aac
ute;veis selecionadas para o pareamento    ou limita&ccedil;&otilde;es intr&iacu
te;nsecas ao programa Link Plus podem ter    comprometido a identifica&ccedil;&a
tilde;o de registros de subnotifica&ccedil;&atilde;o    de comorbidade. N&atilde
;o existe padr&atilde;o-ouro que permita averiguar a    sensibilidade desse prog
rama. Essas raz&otilde;es podem explicar ao menos parte    dos 8.804 registros n
o banco nacional da aids de 2000 a 2005 com TB quando do    diagn&oacute;stico d
e aids que n&atilde;o foram pareados ao Sinan-TB. Outra    possibilidade &eacute
; a n&atilde;o-exist&ecirc;ncia de registros correspondentes    ao banco naciona
l de aids no Sinan-TB, o que denotaria subnotifica&ccedil;&atilde;o    n&atilde;
o s&oacute; da condi&ccedil;&atilde;o de comorbidade, mas tamb&eacute;m    da no
tifica&ccedil;&atilde;o do caso de TB. Esse montante n&atilde;o foi somado    ao
 total de registros de comorbidade para evitar a duplica&ccedil;&atilde;o    dos
 casos, o que aconteceria se os registros correspondentes do Sinan-TB tamb&eacut
e;m    indicassem aids. Entretanto, se somados, a propor&ccedil;&atilde;o de com
orbidade    do total de registros de TB subiria de 6,9% para 10,1%, e a subnotif
ica&ccedil;&atilde;o    de 17,7% para 38%. A real propor&ccedil;&atilde;o de sub
notifica&ccedil;&atilde;o    de comorbidade deve estar compreendida nesse interv
alo.</font></p>     ^cY#2326.htm##
00990000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704075400081002000900835#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#92#88#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Outra poss&iacute;vel    limita
&ccedil;&atilde;o do estudo seria a n&atilde;o-utiliza&ccedil;&atilde;o    do m&
eacute;todo de captura-recaptura, que, em teoria, estimaria o total de    casos 
de TB-aids no Brasil para al&eacute;m dos que est&atilde;o contidos nos    banco
s estudados. Optamos por n&atilde;o utilizar esse m&eacute;todo pela aus&ecirc;n
cia    de uma terceira fonte de dados de TB-aids. O uso de mais de duas fontes d
e dados    &eacute; essencial para que esses estudos sejam considerados v&aacute
;lidos.    Sem isso, &eacute; imposs&iacute;vel averiguar e controlar a independ
&ecirc;ncia    entre as fontes, uma das suas premissas fundamentais.<sup>5</sup>
</font></p>     ^cY#2326.htm##
00828000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704059200081002000900673#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#93#89#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A subnotifica&ccedil;&atilde;o 
   da comorbidade TB-aids no Brasil deve deflagrar modifica&ccedil;&otilde;es no
    sistema de vigil&acirc;ncia desses agravos que ofere&ccedil;am informa&ccedi
l;&otilde;es    a programas nacionais. Essas informa&ccedil;&otilde;es s&atilde;
o essenciais    para aumentar a qualidade do sistema quanto ao desenvolvimento d
e atividades    de coleta e &agrave; an&aacute;lise de dados, al&eacute;m do mai
or incentivo    e valoriza&ccedil;&atilde;o dos profissionais de sa&uacute;de.</
font></p>     ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#94#90#article#131#<p>&nbsp;</p> 
    ^cY#2326.htm##
00343000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010700081002000900188#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#95#91#article#131#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font>
</p>     ^cY#2326.htm##
00497000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704024700083002000900330#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#96#92#article#131#1#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Balogun MA,   
 Wall PG, Noone A. Undernotification of tuberculosis in patients with AIDS. <i>I
nt    J STD AIDS.</i> 1996;7(1):58-60. DOI:10.1258/0956462961917087</font></p>  
   ^cY#2326.htm##
00632000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704038200083002000900465#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#97#93#article#131#2#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Bierrenbach   
 AL, Stevens AP, Gomes ABF, Noronha EF, Glatt R, Carvalho CN, et al. Efeito da  
  remo&ccedil;&atilde;o de notifica&ccedil;&otilde;es repetidas sobre a incid&ec
irc;ncia    de tuberculose no Brasil. <i>Rev Saude Publica.</i> 2007;41(Supl 1):
67-76. DOI:10.1590/S0034-89102007000800010</font></p>     ^cY#2326.htm##
00576000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704032600083002000900409#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#98#94#article#131#3#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Ferreira VMB, 
   Portela MC, Vasconcellos MTL. Fatores associados &agrave; subnotifica&ccedil;
&atilde;o    de pacientes com Aids no Rio de Janeiro, RJ, 1996. <i>Rev Saude Pub
lica.</i>    2000;34(2):170-7. DOI:10.1590/S0034-89102000000200011</font></p>   
  ^cY#2326.htm##
00614000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704036400083002000900447#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#99#95#article#131#4#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Getahun H, Har
rington    M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculo
sis in    people with HIV infection or AIDS in resource-constrained settings: in
forming    urgent policy changes. <i>Lancet</i>. 2007;369(9578):2042-9 DOI:10.10
16/S0140-6736(07)60284-0</font></p>     ^cY#2326.htm##
00458000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704020700084002000900291#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#100#96#article#131#5
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Hook EB, Rega
l    RR. Capture-recapture methods in epidemiology: methods and limitations. <i>
Epidemiol    Rev.</i> 1995;17(2):243-64.    ^cY#2326.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704002000082002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#101#97#article#131#</font></p>  
   ^cY#2326.htm##
00569000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704031800084002000900402#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#102#98#article#131#6
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Lima MM, Bell
uomini    M, Almeida MMMB, Arantes GR. Co-infec&ccedil;&atilde;o HIV/ tuberculos
e: necessidade    de uma vigil&acirc;ncia mais efetiva. <i>Rev Saude Publica.</i
> 1997;31(3):217-20.    DOI:10.1590/S0034-89101997000300001</font></p>     ^cY#2
326.htm##
00515000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000200082704026400084002000900348#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#103#99#article#131#7
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Lucena FDF,  
  Fonseca MGP, Sousa AIA, Coeli CM. O Relacionamento de bancos de dados na imple
menta&ccedil;&atilde;o    da vigil&acirc;ncia da AIDS. <i>Cad Saude Colet.</i> 2
006;14(2):305-12.    ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#104#100#article#131#</font></p> 
    ^cY#2326.htm##
00475000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704022300085002000900308#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#105#101#article#131#
8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Maher D, Rav
iglione    M. Global epidemiology of tuberculosis. <i>Clin Chest Med.</i> 2005;2
6(2):167-82.    DOI:10.1016/j.ccm.2005.02.009</font></p>     ^cY#2326.htm##
00594000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704034200085002000900427#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#106#102#article#131#
9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Oliveira MTD
C,    Barreira D, Santos LCO, Latorre MRDO. A subnotifica&ccedil;&atilde;o de ca
sos    de Aids em munic&iacute;pios brasileiros selecionados: uma aplica&ccedil;
&atilde;o    do m&eacute;todo de captura-recaptura. <i>Bol Epidemiol AIDST.</i> 
2004;18(1):7-11.    ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#107#103#article#131#</font></p> 
    ^cY#2326.htm##
00512000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704025900086002000900345#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#108#104#article#131#
10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Pillaye J,
    Clarke A. An evaluation of completeness of tuberculosis notification in the 
   United Kingdom. <i>BMC Public Health.</i> 2003;3:31. DOI:10.1186/1471-2458-3-
31</font></p>     ^cY#2326.htm##
00533000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028000086002000900366#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#109#105#article#131#
11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Pascom ARP
,    Lucena FDF, Medeiros MGF. Metodologia de revis&atilde;o da base de dados do
    sistema de notifica&ccedil;&atilde;o de casos de Aids - SINAN-Aids. <i>Bol E
pidemiol    AIDST.</i> 2004;1:42-5.    ^cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#110#106#article#131#</font></p> 
    ^cY#2326.htm##
00493000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704024000086002000900326#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#111#107#article#131#
12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Programa N
acional    de DST e Aids. Nova defini&ccedil;&atilde;o de caso de Aids em adulto
s e crian&ccedil;as    - 2004. <i>Bol Epidemiol AIDST.</i> 2004;1(17):1-52.    ^
cY#2326.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#112#108#article#131#</font></p> 
    ^cY#2326.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#113#109#article#131#<p>&nbsp;</p
>     ^cY#2326.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#114#110#article#131#<p>&nbsp;</p
>     ^cY#2326.htm##
00453000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021500083002000900298#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#115#111#article#131#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#
top"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    <b>Corr
espond&ecirc;ncia | Correspondence:    ^cY#2326.htm##
00282000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004400083002000900127#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#116#112#article#131#<br>   </b> 
Carolina Novaes Carvalho    ^cY#2326.htm##
00344000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704010600083002000900189#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#117#113#article#131#<br>   Depar
tamento de Apoio &agrave; Gest&atilde;o da Vigil&acirc;ncia em Sa&uacute;de    -
 DAGVS    ^cY#2326.htm##
00305000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704006700083002000900150#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#118#114#article#131#<br>   Secre
taria de Vigil&acirc;ncia em Sa&uacute;de - SVS    ^cY#2326.htm##
00286000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004800083002000900131#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#119#115#article#131#<br>   Minis
t&eacute;rio da Sa&uacute;de    ^cY#2326.htm##
00295000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005700083002000900140#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#120#116#article#131#<br>   Espla
nada dos Minist&eacute;rios - Bloco G    ^cY#2326.htm##
00294000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005600083002000900139#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#121#117#article#131#<br>   Edif&
iacute;cio sede - Sala 110 - Asa Sul    ^cY#2326.htm##
00290000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005200083002000900135#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#122#118#article#131#<br>   70058
-900 Bras&iacute;lia, DF, Brasil    ^cY#2326.htm##
00355000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704011700083002000900200#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#123#119#article#131#<br>   E-mai
l: <a href="mailto:carolina.carvalho@saude.gov.br">carolina.carvalho@saude.gov.b
r</a></font></p>     ^cY#2326.htm##
00327000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704008900083002000900172#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#124#120#article#131#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Recebido: 6/6/2010    ^cY#232
6.htm##
00285000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004700083002000900130#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#125#121#article#131#<br>   Aprov
ado: 14/11/2010</font></p>     ^cY#2326.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#126#122#article#131#<p>&nbsp;</p
>     ^cY#2326.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#127#123#article#131#<p>&nbsp;</p
>     ^cY#2326.htm##
00514000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704027600083002000900359#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#128#124#article#131#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Artigo baseado    na disserta
&ccedil;&atilde;o de mestrado de Carvalho CN, apresentada ao Programa    de P&oa
cute;s-Gradua&ccedil;&atilde;o em Sa&uacute;de Coletiva do Instituto    de Sa&ua
cute;de em 2008.    ^cY#2326.htm##
00313000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704007500083002000900158#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#129#125#article#131#<br>   Os au
tores declaram n&atilde;o haver conflito de interesses.    ^cY#2326.htm##
00582000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704034400083002000900427#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#130#126#article#131#<br>   <a na
me="backa"></a><a href="#topa">a</a> Glatt R. An&aacute;lise da qualidade    da 
base de dados de aids do Sistema de Informa&ccedil;&atilde;o de Agravos de    No
tifica&ccedil;&atilde;o (Sinan) &#91;disserta&ccedil;&atilde;o de mestrado&#93;.
    Rio de Janeiro: Escola Nacional de Sa&uacute;de P&uacute;blica da Fiocruz; 2
004.    ^cY#2326.htm##
00593000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704035500083002000900438#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#131#127#article#131#<br>   <a na
me="backb"></a><a href="#topb">b</a> Centers for Disease Control and Prevention.
    Link Plus Program. Atalanta; 2007&#91;citado 2010 fev 09&#93;. Dispon&iacute
;vel    em: <a href="http://www.cdc.gov/cancer/npcr/tools/registryplus/lp_tech_i
nfo.htm" target="_blank">http://www.cdc.gov/cancer/npcr/tools/registryplus/lp_te
ch_info.htm</a>    ^cY#2326.htm##
00535000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704029700083002000900380#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#132#128#article#131#<br>   <a na
me="backc"></a><a href="#topc">c</a> Elkhoury ANSM. Avalia&ccedil;&atilde;o    d
os registros de Morbimortalidade da Leishmaniose Visceral em Sistema de informa&
ccedil;&otilde;es    do SUS &#91;tese de doutorado&#93; Salvador: Instituto de S
a&uacute;de Coletiva    da UFBA;2005.    ^cY#2326.htm##
00574000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704033600083002000900419#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#133#129#article#131#<br>   <a na
me="backd"></a>d World Health Organization. Interim policy on collaborative    T
B/HIV activities. Geneva; 2004&#91;citado 2010 mar 06&#93;. Dispon&iacute;vel   
 em: <a href="http://whqlibdoc.who.int/hq/2004/WHO_HTM_TB_2004.330_eng.pdf" targ
et="_blank">http://whqlibdoc.who.int/hq/2004/WHO_HTM_TB_2004.330_eng.pdf</a>    
^cY#2326.htm##
00670000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704043200083002000900515#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#134#130#article#131#<br>   <a na
me="backe"></a><a href="#tope">e</a> Joint United Nations Programme on    HIV/Ai
ds. Report on the global AIDS epidemic: Executive Summary. 2006. UNAIDS/06.20E. 
   Geneva; 2006. &#91;citado 2010 mar 06&#93;. Dispon&iacute;vel em: <a href="ht
tp://data.unaids.org/pub/GlobalReport/2006/2006_gr-executivesummary_en.pdf" targ
et="_blank">http://data.unaids.org/pub/GlobalReport/2006/2006_gr-executivesummar
y_en.pdf</a>    ^cY#2326.htm##
00978000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704074000083002000900823#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2326.htm#S#p#135#131#article#131#<br>   <a na
me="backf"></a><a href="#topf">f</a> Minist&eacute;rio da Sa&uacute;de    do Bra
sil. Secretaria de vigil&acirc;ncia em Sa&uacute;de. Departamento de vigil&acirc
;ncia    epidemiol&oacute;gica. Coordena&ccedil;&atilde;o geral de doen&ccedil;a
s transmiss&iacute;veis.    Sistema de Informa&ccedil;&atilde;o de Agravos de No
tifica&ccedil;&atilde;o.    Dicion&aacute;rio de dados do Sinan Net para o agrav
o tuberculose. Bras&iacute;lia;    2004&#91;citado 2010 mar 06&#93;. Dispon&iacu
te;vel em: <a href="http://ftp.saude.ba.gov.br/dis/arquivos_pdf/dicionarios_dado
s/DIC_DADOS%20-%20Tuberculose.pdf" target="_blank">http://ftp.saude.ba.gov.br/di
s/arquivos_pdf/dicionarios_dados/DIC_DADOS%20-%20Tuberculose.pdf</a></font></p> 
    ^cY#2326.htm##
00611000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100015001000100
01500115012006000130030001500190065000900205064000500214031000200219032000200221
014000600223237002500229865000900254002000900263035001000272801001500282#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#c#136#1#article#12#1#^rND^
sBalogun^nMA#^rND^sWall^nPG#^rND^sNoone^nA#Undernotification of tuberculosis in 
patients with AIDS^len#Int J STD AIDS#19960000#1996#7#1#58-60#10.1258/0956462961
917087#20110000#2326.htm#0956-4624#Int J STD AIDS##
00774000000000361000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100022000820100018001040100
01700122010001800139010001500157010001900172810000600191012009200197030001800289
06500090030706400050031603100030032103200040032401400060032823700320033486500090
0366002000900375035001000384801001800394#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2326.htm#S#c#137#2#article#12#2#^rND^sBierrenbach^nAL#^rND^sStevens^n
AP#^rND^sGomes^nABF#^rND^sNoronha^nEF#^rND^sGlatt^nR#^rND^sCarvalho^nCN#et al#Ef
eito da remoção de notificações repetidas sobre a incidência de tuberculose no B
rasil^lpt#Rev Saude Publica#20070000#2007#41#^s1#67-76#10.1590/S0034-89102007000
800010#20110000#2326.htm#0034-8910#Rev Saude Publica##
00669000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100020000820100018001020100
02400120012009000144030001800234065000900252064000500261031000300266032000200269
014000600271237003200277865000900309002000900318035001000327801001800337#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#c#138#3#article#12#3#^rND^
sFerreira^nVMB#^rND^sPortela^nMC#^rND^sVasconcellos^nMTL#Fatores associados à su
bnotificação de pacientes com Aids no Rio de Janeiro, RJ, 1996^lpt#Rev Saude Pub
lica#20000000#2000#34#2#170-7#10.1590/S0034-89102000000200011#20110000#2326.htm#
0034-8910#Rev Saude Publica##
00736000000000325000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100020000990100
01700119010001400136012015800150030000700308065000900315064000500324031000400329
03200050033301400070033823700300034586500090037500200090038403500100039380100070
0403#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#c#139#4#articl
e#12#4#^rND^sGetahun^nH#^rND^sHarrington^nM#^rND^sO'Brien^nR#^rND^sNunn^nP#Diagn
osis of smear-negative pulmonary tuberculosis in people with HIV infection or AI
DS in resource-constrained settings: informing urgent policy changes^len#Lancet#
20070000#2007#369#9578#2042-9#10.1016/S0140-6736(07)60284-0#20110000#2326.htm#00
99-5355#Lancet##
00556000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100015000820100016000970120
07100113030001400184065000900198064000500207031000300212032000200215014000700217
865000900224002000900233035001000242801001400252#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2326.htm#S#c#140#5#article#12#5#^rND^sHook^nEB#^rND^sRegal^nR
R#Capture-recapture methods in epidemiology: methods and limitations^len#Epidemi
ol Rev#19950000#1995#17#2#243-64#20110000#2326.htm#0193-936X#Epidemiol Rev##
00680000000000325000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100015000820100020000970100
02000117010001800137012007700155030001800232065000900250064000500259031000300264
03200020026701400070026923700320027686500090030800200090031703500100032680100180
0336#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.htm#S#c#141#6#articl
e#12#6#^rND^sLima^nMM#^rND^sBelluomini^nM#^rND^sAlmeida^nMMMB#^rND^sArantes^nGR#
Co-infecção HIV/ tuberculose: necessidade de uma vigilância mais efetiva^lpt#Rev
 Saude Publica#19970000#1997#31#3#217-20#10.1590/S0034-89101997000300001#2011000
0#2326.htm#0034-8910#Rev Saude Publica##
00595000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100019001000100
01700119010001600136012007900152030001600231710000200247065000900249064000500258
031000300263032000200266014000700268865000900275002000900284#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2326.htm#S#c#142#7#article#12#7#^rND^sLucena^nFDF
#^rND^sFonseca^nMGP#^rND^sSousa^nAIA#^rND^sCoeli^nCM#O Relacionamento de bancos 
de dados na implementação da vigilância da AIDS^lpt#Cad Saude Colet#2#20060000#2
006#14#2#305-12#20110000#2326.htm##
00569000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100015000820100020000970120
04000117030001500157065000900172064000500181031000300186032000200189014000700191
237002600198865000900224002000900233035001000242801001500252#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2326.htm#S#c#143#8#article#12#8#^rND^sMaher^nD#^r
ND^sRaviglione^nM#Global epidemiology of tuberculosis^len#Clin Chest Med#2005000
0#2005#26#2#167-82#10.1016/j.ccm.2005.02.009#20110000#2326.htm#0272-5231#Clin Ch
est Med##
00648000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100021000820100018001030100
01800121010002000139012012300159030002000282710000200302065000900304064000500313
031000300318032000200321014000500323865000900328002000900337#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2326.htm#S#c#144#9#article#12#9#^rND^sOliveira^nM
TDC#^rND^sBarreira^nD#^rND^sSantos^nLCO#^rND^sLatorre^nMRDO#A subnotificação de 
casos de Aids em municípios brasileiros selecionados: uma aplicação do método de
 captura-recaptura^lpt#Bol Epidemiol AIDST#2#20040000#2004#18#1#7-11#20110000#23
26.htm##
00560000000000277000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100016001010120
08500117030001800202710000200220065000900222064000500231031000200236014000300238
237002300241865000900264002000900273#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2326.htm#S#c#145#10#article#12#11#^rND^sPillaye^nJ#^rND^sClarke^nA#An eva
luation of completeness of tuberculosis notification in the United Kingdom^len#B
MC Public Health#2#20030000#2003#3#31#10.1186/1471-2458-3-31#20110000#2326.htm##
00579000000000277000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100018001020100
02000120012010000140030002000240710000200260065000900262064000500271031000200276
014000500278865000900283002000900292#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2326.htm#S#c#146#11#article#12#10#^rND^sPascom^nARP#^rND^sLucena^nFDF#^rN
D^sMedeiros^nMGF#Metodologia de revisão da base de dados do sistema de notificaç
ão de casos de Aids - SINAN-Aids^lpt#Bol Epidemiol AIDST#2#20040000#2004#1#42-5#
20110000#2326.htm##
00510000000000265000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810110032000840120064001160300
02000180710000200200065000900202064000500211031000200216032000300218014000500221
865000900226002000900235#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2326.
htm#S#c#147#12#article#12#12#Programa Nacional de DST e Aids#Nova definição de c
aso de Aids em adultos e crianças - 2004^lpt#Bol Epidemiol AIDST#2#20040000#2004
#1#17#1-52#20110000#2326.htm##
00276000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00400102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#o#1#1#arti
cle#1#20110408#160445#2335.htm#181##
06284000000000781000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000300095121000300098049000300101158000300104030001900107
03200060012606500090013201400070014103500100014822300090015801200770016701200640
02440120078003080100037003860100049004230100027004720700089004990700072005880831
39700660085001002057085004302067085002402110085003302134085003502167085003002202
08312830223208500100351508500390352508500230356408500300358708500340361708500260
36510831442036770850010051190850042051290850024051710850033051950850035052280850
03005263117000805293072000305301112000905304111000905313114000905322113001105331
058006205342060001405404058005705418060001805475002000905493#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2335.htm#S#h#2#1#article#1#oa#pt#br1.1#1#4.0#ND#2
2#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0#0034-8910#20110415#Serviço de A
tendimento Móvel de Urgência: análise da política brasileira^lpt#Mobile Emergenc
y Care Service: analysis of Brazilian policy^len#Servicio de Atención Móvil de U
rgencia: análisis de la política brasileña^les#^rND^1A01^nCristiani Vieira^sMach
ado#^rND^1A02^nFernanda Gonçalves Ferreira^sSalvador#^rND^1A01^nGisele^sO'Dwyer#
Fundação Oswaldo Cruz^iA01^1Escola Nacional de Saúde Pública^cRio de Janeiro^sRJ
^pBrasil#Universidade Federal do Rio de Janeiro^iA02^cRio de Janeiro^sRJ^pBrasil
#^lpt^aOBJETIVO: Analisar a conformação da política de atenção móvel às urgência
s no Brasil. PROCEDIMENTOS METODOLÓGICOS: Com base no referencial da análise de 
políticas públicas, foram realizados: revisão bibliográfica, análise de document
os e dados oficiais e entrevistas com dirigentes federais relacionados à formula
ção e implantação do Serviço de Atendimento Móvel de Urgência (Samu) no Brasil n
a década de 2000. ANÁLISE DOS RESULTADOS: O Samu teve prioridade na agenda feder
al a partir de 2003. Nos primeiros anos de implantação predominaram serviços de 
abrangência municipal; em 2008, os de abrangência regional tornaram-se mais rele
vantes. A cobertura estimada alcançou 53,9% da população em 2009, residente em 2
0,5% dos municípios brasileiros. A implantação variou entre os Estados e houve m
enos ambulâncias de suporte avançado do que o recomendado, tanto no conjunto do 
País como em vários Estados. CONCLUSÕES: O Samu foi adotado nacionalmente a part
ir de 2003, com a elaboração de normas federais. A implantação da política compr
eende desafios como realização de investimentos adequados, inserção do serviço e
m uma rede articulada de atendimento de urgência, conformação de sistemas de inf
ormações apropriados, capacitação dos profissionais. O enfrentamento desses desa
fios permitirá que o Samu se configure como uma estratégia estruturante da atenç
ão à saúde no Sistema Único de Saúde.#^ddecs^i1#^tm^lpt^kServiços Médicos de Eme
rgência^i1#^tm^lpt^kAmbulâncias^i1#^tm^lpt^kPrioridades em Saúde^i1#^tm^lpt^kSis
tema Único de Saúde^i1#^tm^lpt^kPolítica de Saúde^i1#^len^aOBJECTIVE: To analyze
 the configuration of mobile emergency health care policy in Brazil. METHODOLOGI
CAL PROCEDURES: The study was based on public policy analysis. Bibliographic and
 document review, analysis of official data and interviews with federal administ
rators related to formulation and implementation of the Mobile Emergency Care Se
rvice (SAMU) in Brazil in the 2000s were performed. ANALYSIS OF RESULTS: Priorit
y was given to SAMU at the federal level since 2003. During the first years of i
mplementation, municipal level services predominated; in 2008, services with reg
ional scope became more significant. Estimated coverage reached 53.9% of the pop
ulation in 2009, in 20.5% of Brazilian municipalities. Implementation varied bet
ween States, and there were less advanced support ambulances than recommended, b
oth nationally and in several States. CONCLUSIONS: SAMU was adopted nationwide s
ince 2003 upon development of federal norms. Implementation of the policy involv
es challenges, including adequate investment, integration of the service into an
 established urgent care network, arrangement of appropriate information systems
 and personnel capacity. Addressing these challenges will allow SAMU to become a
 key health care strategy in the unified health system.#^ddecs^i2#^tm^len^kEmerg
ency Medical Services^i2#^tm^len^kAmbulances^i2#^tm^len^kHealth Priorities^i2#^t
m^len^kUnified Health System^i2#^tm^len^kHealth Policy^i2#^les^aOBJETIVO: Analiz
ar la conformación de la política de atención móvil a las urgencias en Brasil. P
ROCEDIMIENTOS METODOLÓGICOS: Con base en las referencias del análisis de polític
as públicas, se realizaron: revisión bibliográfica, análisis de documentos y dat
os oficiales y entrevistas con dirigentes federales relacionados a la formulació
n e implantación del Servicio de Atención Móvil de Urgencia (SAMU) en Brasil en 
la década de 2000. ANÁLISIS DE LOS RESULTADOS: El SAMU tuvo prioridad en la agen
da federal a partir de 2003. En los primeros años de implantación predominaron s
ervicios de cobertura municipal; en 2008, los de cobertura regional se tornaron 
más relevantes. La cobertura estimada alcanzó 53,9% de la población en 2009, res
idente en 20,5% de los municipios brasileños. La implantación varió entre los Es
tados y hubo menos ambulancias de soporte avanzado de lo recomendado, tanto en e
l conjunto del país como en varios estados. CONCLUSIONES: El SAMU fue adoptado e
n 2003, con la elaboración de normas federales. La implantación de la política c
omprende desafíos como realización de inversiones adecuadas, inserción del servi
cio en una red articulada de atención de urgencia, conformación de sistemas de i
nformaciones apropiados, capacitación de los profesionales. El enfrentamiento de
 tales desafíos permitirá que el SAMU se configure como una estrategia estructur
ada de la atención a la salud en el Sistema Único de Salud.#^ddecs^i3#^tm^les^kS
ervicios Médicos de Urgencia^i3#^tm^les^kAmbulancias^i3#^tm^les^kPrioridades en 
Salud^i3#^tm^les^kSistema Único de Salud^i3#^tm^les^kPolítica de Salud^i3#vancou
v#24#20100609#9/6/2010#20101114#14/11/2010#Conselho Nacional de Desenvolvimento 
Científico e Tecnológico#565982/2008-7#Fundação de Apoio à Pesquisa do Estado do
 Rio de Janeiro#E-26/102.283/2009#2335.htm##
06527000000000781000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000300095121000300098049000300101158000300104030001900107
03200060012606500090013201400070014103500100014822300090015801200910016701200780
02580120092003360100037004280100049004650100027005140700089005410700072006300831
42500702085001002127085004302137085002402180085003302204085003502237085003002272
08313110230208500100361308500390362308500230366208500300368508500340371508500260
37490831470037750850010052450850042052550850024052970850033053210850035053540850
03005389117000805419072000305427112000905430111000905439114000905448113001105457
058006205468060007205530058005705602060007705659002000905736#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2335.htm#S#f#3#1#article#1#oa#pt#br1.1#1#4.0#ND#2
2#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0#0034-8910#20110415#<b>Serviço d
e Atendimento Móvel de Urgência</b>: <b>análise da política brasileira</b>^lpt#<
b>Mobile Emergency Care Service</b>: <b>analysis of Brazilian policy</b>^len#<b>
Servicio de Atención Móvil de Urgencia</b>: <b>análisis de la política brasileña
</b>^les#^rND^1A01^nCristiani Vieira^sMachado#^rND^1A02^nFernanda Gonçalves Ferr
eira^sSalvador#^rND^1A01^nGisele^sO'Dwyer#Fundação Oswaldo Cruz^iA01^1Escola Nac
ional de Saúde Pública^cRio de Janeiro^sRJ^pBrasil#Universidade Federal do Rio d
e Janeiro^iA02^cRio de Janeiro^sRJ^pBrasil#^lpt^a<b>OBJETIVO:</b> Analisar a con
formação da política de atenção móvel às urgências no Brasil. <b>PROCEDIMENTOS M
ETODOLÓGICOS:</b> Com base no referencial da análise de políticas públicas, fora
m realizados: revisão bibliográfica, análise de documentos e dados oficiais e en
trevistas com dirigentes federais relacionados à formulação e implantação do Ser
viço de Atendimento Móvel de Urgência (Samu) no Brasil na década de 2000. <b>ANÁ
LISE DOS RESULTADOS:</b> O Samu teve prioridade na agenda federal a partir de 20
03. Nos primeiros anos de implantação predominaram serviços de abrangência munic
ipal; em 2008, os de abrangência regional tornaram-se mais relevantes. A cobertu
ra estimada alcançou 53,9% da população em 2009, residente em 20,5% dos municípi
os brasileiros. A implantação variou entre os Estados e houve menos ambulâncias 
de suporte avançado do que o recomendado, tanto no conjunto do País como em vári
os Estados. <b>CONCLUSÕES:</b> O Samu foi adotado nacionalmente a partir de 2003
, com a elaboração de normas federais. A implantação da política compreende desa
fios como realização de investimentos adequados, inserção do serviço em uma rede
 articulada de atendimento de urgência, conformação de sistemas de informações a
propriados, capacitação dos profissionais. O enfrentamento desses desafios permi
tirá que o Samu se configure como uma estratégia estruturante da atenção à saúde
 no Sistema Único de Saúde.#^ddecs^i1#^tm^lpt^kServiços Médicos de Emergência^i1
#^tm^lpt^kAmbulâncias^i1#^tm^lpt^kPrioridades em Saúde^i1#^tm^lpt^kSistema Único
 de Saúde^i1#^tm^lpt^kPolítica de Saúde^i1#^len^a<b>OBJECTIVE:</b> To analyze th
e configuration of mobile emergency health care policy in Brazil. <b>METHODOLOGI
CAL PROCEDURES:</b> The study was based on public policy analysis. Bibliographic
 and document review, analysis of official data and interviews with federal admi
nistrators related to formulation and implementation of the Mobile Emergency Car
e Service (SAMU) in Brazil in the 2000s were performed. <b>ANALYSIS OF RESULTS:<
/b> Priority was given to SAMU at the federal level since 2003. During the first
 years of implementation, municipal level services predominated; in 2008, servic
es with regional scope became more significant. Estimated coverage reached 53.9%
 of the population in 2009, in 20.5% of Brazilian municipalities. Implementation
 varied between States, and there were less advanced support ambulances than rec
ommended, both nationally and in several States. <b>CONCLUSIONS:</b> SAMU was ad
opted nationwide since 2003 upon development of federal norms. Implementation of
 the policy involves challenges, including adequate investment, integration of t
he service into an established urgent care network, arrangement of appropriate i
nformation systems and personnel capacity. Addressing these challenges will allo
w SAMU to become a key health care strategy in the unified health system.#^ddecs
^i2#^tm^len^kEmergency Medical Services^i2#^tm^len^kAmbulances^i2#^tm^len^kHealt
h Priorities^i2#^tm^len^kUnified Health System^i2#^tm^len^kHealth Policy^i2#^les
^a<b>OBJETIVO:</b> Analizar la conformación de la política de atención móvil a l
as urgencias en Brasil. <b>PROCEDIMIENTOS METODOLÓGICOS:</b> Con base en las ref
erencias del análisis de políticas públicas, se realizaron: revisión bibliográfi
ca, análisis de documentos y datos oficiales y entrevistas con dirigentes federa
les relacionados a la formulación e implantación del Servicio de Atención Móvil 
de Urgencia (SAMU) en Brasil en la década de 2000. <b>ANÁLISIS DE LOS RESULTADOS
:</b> El SAMU tuvo prioridad en la agenda federal a partir de 2003. En los prime
ros años de implantación predominaron servicios de cobertura municipal; en 2008,
 los de cobertura regional se tornaron más relevantes. La cobertura estimada alc
anzó 53,9% de la población en 2009, residente en 20,5% de los municipios brasile
ños. La implantación varió entre los Estados y hubo menos ambulancias de soporte
 avanzado de lo recomendado, tanto en el conjunto del país como en varios estado
s. <b>CONCLUSIONES:</b> El SAMU fue adoptado en 2003, con la elaboración de norm
as federales. La implantación de la política comprende desafíos como realización
 de inversiones adecuadas, inserción del servicio en una red articulada de atenc
ión de urgencia, conformación de sistemas de informaciones apropiados, capacitac
ión de los profesionales. El enfrentamiento de tales desafíos permitirá que el S
AMU se configure como una estrategia estructurada de la atención a la salud en e
l Sistema Único de Salud.#^ddecs^i3#^tm^les^kServicios Médicos de Urgencia^i3#^t
m^les^kAmbulancias^i3#^tm^les^kPrioridades en Salud^i3#^tm^les^kSistema Único de
 Salud^i3#^tm^les^kPolítica de Salud^i3#vancouv#24#20100609#9/6/2010#20101114#14
/11/2010#Conselho Nacional de Desenvolvimento Científico e Tecnológico#<span sty
le='font-size:10.0pt;font-family:Verdana'>565982/2008-7</span>#Fundação de Apoio
 à Pesquisa do Estado do Rio de Janeiro#<span style='font-size: 10.0pt;font-fami
ly:Verdana'>E-26/102.283/2009</span>#2335.htm##
06445000000000793000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098121000300102049000300105158000300108030001900111
03200060013006500090013601400070014503500100015222300090016201200770017101200640
02480120078003120100037003900100049004270100027004760700091005030700074005940831
41500668085001002083085004302093085002402136085003302160085003502193085003002228
08312970225808500100355508500390356508500230360408500300362708500340365708500260
36910831462037170850010051790850042051890850024052310850033052550850035052880850
03005323117000805353072000305361112000905364111000905373114000905382113001105391
058006205402060001405464058005705478060001805535002000905553008008905562#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#l#4#1#article#1#^a2011#oa#
pt#br1.1#1#4.0#22#nd#nd#Rev. saúde pública#ahead#20110000#^f0^l0#0034-8910#20110
415#Serviço de Atendimento Móvel de Urgência: análise da política brasileira^lpt
#Mobile Emergency Care Service: analysis of Brazilian policy^len#Servicio de Ate
nción Móvil de Urgencia: análisis de la política brasileña^les#^rND^1A01^nCristi
ani Vieira^sMachado#^rND^1A02^nFernanda Gonçalves Ferreira^sSalvador#^rND^1A01^n
Gisele^sO'Dwyer#^iA01^1Fundação Oswaldo Cruz^2Escola Nacional de Saúde Pública^c
Rio de Janeiro^sRJ^pBrasil#^iA02^1Universidade Federal do Rio de Janeiro^cRio de
 Janeiro^sRJ^pBrasil#^lpt^aOBJETIVO: Analisar a conformação da política de atenç
ão móvel às urgências no Brasil. PROCEDIMENTOS METODOLÓGICOS: Com base no refere
ncial da análise de políticas públicas, foram realizados: revisão bibliográfica,
 análise de documentos e dados oficiais e entrevistas com dirigentes federais re
lacionados à formulação e implantação do Serviço de Atendimento Móvel de Urgênci
a (Samu) no Brasil na década de 2000. ANÁLISE DOS RESULTADOS: O Samu teve priori
dade na agenda federal a partir de 2003. Nos primeiros anos de implantação predo
minaram serviços de abrangência municipal; em 2008, os de abrangência regional t
ornaram-se mais relevantes. A cobertura estimada alcançou 53,9 por cento da popu
lação em 2009, residente em 20,5 por cento dos municípios brasileiros. A implant
ação variou entre os Estados e houve menos ambulâncias de suporte avançado do qu
e o recomendado, tanto no conjunto do País como em vários Estados. CONCLUSÕES: O
 Samu foi adotado nacionalmente a partir de 2003, com a elaboração de normas fed
erais. A implantação da política compreende desafios como realização de investim
entos adequados, inserção do serviço em uma rede articulada de atendimento de ur
gência, conformação de sistemas de informações apropriados, capacitação dos prof
issionais. O enfrentamento desses desafios permitirá que o Samu se configure com
o uma estratégia estruturante da atenção à saúde no Sistema Único de Saúde.#^dde
cs^i1#^tm^lpt^kServiços Médicos de Emergência^i1#^tm^lpt^kAmbulâncias^i1#^tm^lpt
^kPrioridades em Saúde^i1#^tm^lpt^kSistema Único de Saúde^i1#^tm^lpt^kPolítica d
e Saúde^i1#^len^aOBJECTIVE: To analyze the configuration of mobile emergency hea
lth care policy in Brazil. METHODOLOGICAL PROCEDURES: The study was based on pub
lic policy analysis. Bibliographic and document review, analysis of official dat
a and interviews with federal administrators related to formulation and implemen
tation of the Mobile Emergency Care Service (SAMU) in Brazil in the 2000s were p
erformed. ANALYSIS OF RESULTS: Priority was given to SAMU at the federal level s
ince 2003. During the first years of implementation, municipal level services pr
edominated; in 2008, services with regional scope became more significant. Estim
ated coverage reached 53.9 percent of the population in 2009, in 20.5 percent of
 Brazilian municipalities. Implementation varied between States, and there were 
less advanced support ambulances than recommended, both nationally and in severa
l States. CONCLUSIONS: SAMU was adopted nationwide since 2003 upon development o
f federal norms. Implementation of the policy involves challenges, including ade
quate investment, integration of the service into an established urgent care net
work, arrangement of appropriate information systems and personnel capacity. Add
ressing these challenges will allow SAMU to become a key health care strategy in
 the unified health system.#^ddecs^i2#^tm^len^kEmergency Medical Services^i2#^tm
^len^kAmbulances^i2#^tm^len^kHealth Priorities^i2#^tm^len^kUnified Health System
^i2#^tm^len^kHealth Policy^i2#^les^aOBJETIVO: Analizar la conformación de la pol
ítica de atención móvil a las urgencias en Brasil. PROCEDIMIENTOS METODOLÓGICOS:
 Con base en las referencias del análisis de políticas públicas, se realizaron: 
revisión bibliográfica, análisis de documentos y datos oficiales y entrevistas c
on dirigentes federales relacionados a la formulación e implantación del Servici
o de Atención Móvil de Urgencia (SAMU) en Brasil en la década de 2000. ANÁLISIS 
DE LOS RESULTADOS: El SAMU tuvo prioridad en la agenda federal a partir de 2003.
 En los primeros años de implantación predominaron servicios de cobertura munici
pal; en 2008, los de cobertura regional se tornaron más relevantes. La cobertura
 estimada alcanzó 53,9 por ciento de la población en 2009, residente en 20,5 por
 ciento de los municipios brasileños. La implantación varió entre los Estados y 
hubo menos ambulancias de soporte avanzado de lo recomendado, tanto en el conjun
to del país como en varios estados. CONCLUSIONES: El SAMU fue adoptado en 2003, 
con la elaboración de normas federales. La implantación de la política comprende
 desafíos como realización de inversiones adecuadas, inserción del servicio en u
na red articulada de atención de urgencia, conformación de sistemas de informaci
ones apropiados, capacitación de los profesionales. El enfrentamiento de tales d
esafíos permitirá que el SAMU se configure como una estrategia estructurada de l
a atención a la salud en el Sistema Único de Salud.#^ddecs^i3#^tm^les^kServicios
 Médicos de Urgencia^i3#^tm^les^kAmbulancias^i3#^tm^les^kPrioridades en Salud^i3
#^tm^les^kSistema Único de Salud^i3#^tm^les^kPolítica de Salud^i3#vancouv#24#201
00609#9/6/2010#20101114#14/11/2010#Conselho Nacional de Desenvolvimento Científi
co e Tecnológico#565982/2008-7#Fundação de Apoio à Pesquisa do Estado do Rio de 
Janeiro#E-26/102.283/2009#2335.htm#Internet^ihttp://www.scielo.br/scielo.php?scr
ipt=sci_arttext&pid=S0034-89102011005000022##
00455000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704022100079002000900300#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#5#1#article#153#<p><a name="top"
></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Servi&ccedil
;o    de Atendimento M&oacute;vel de Urg&ecirc;ncia: an&aacute;lise da pol&iacut
e;tica    brasileira</b> </font></p>     ^cY#2335.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#6#2#article#153#<p>&nbsp;</p>   
  ^cY#2335.htm##
00386000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704015200079002000900231#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#7#3#article#153#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Mobile Emergency    Care Servi
ce: analysis of Brazilian policy</b></font></p>     ^cY#2335.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#8#4#article#153#<p>&nbsp;</p>   
  ^cY#2335.htm##
00438000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704020400079002000900283#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#9#5#article#153#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Servicio de    Atenci&oacute;n
 M&oacute;vil de Urgencia: an&aacute;lisis de la pol&iacute;tica    brasile&ntil
de;a</b></font></p>     ^cY#2335.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#10#6#article#153#<p>&nbsp;</p>  
   ^cY#2335.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#11#7#article#153#<p>&nbsp;</p>  
   ^cY#2335.htm##
00453000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704021800080002000900298#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#12#8#article#153#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Cristiani Vieira    Machado<s
up>I</sup>; Fernanda Gon&ccedil;alves Ferreira Salvador<sup>II</sup>;    Gisele 
O'Dwyer<sup>I</sup></b></font></p>     ^cY#2335.htm##
00435000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704020000080002000900280#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#13#9#article#153#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Escola    Nacional d
e Sa&uacute;de P&uacute;blica. Funda&ccedil;&atilde;o Oswaldo Cruz.    Rio de Ja
neiro, RJ, Brasil    ^cY#2335.htm##
00364000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704012800081002000900209#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#14#10#article#153#<br>   <sup>II
</sup>Curso de Medicina. Universidade Federal do Rio de Janeiro. Rio    de Janei
ro, RJ, Brasil</font></p>     ^cY#2335.htm##
00380000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014400081002000900225#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#15#11#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecir
c;ncia    | Correspondence</a></font></p>     ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#16#12#article#153#<p>&nbsp;</p> 
    ^cY#2335.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704004400081002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#17#13#article#153#<p>&nbsp;</p> 
<hr size="1" noshade>     ^cY#2335.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#18#14#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^c
Y#2335.htm##
00460000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704022400081002000900305#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#19#15#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analisar a 
conforma&ccedil;&atilde;o da pol&iacute;tica de aten&ccedil;&atilde;o    m&oacut
e;vel &agrave;s urg&ecirc;ncias no Brasil.    ^cY#2335.htm##
00708000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704047200081002000900553#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#20#16#article#153#<br>   <b>PROC
EDIMENTOS METODOL&Oacute;GICOS:</b> Com base no referencial da an&aacute;lise   
 de pol&iacute;ticas p&uacute;blicas, foram realizados: revis&atilde;o bibliogr&
aacute;fica,    an&aacute;lise de documentos e dados oficiais e entrevistas com 
dirigentes federais    relacionados &agrave; formula&ccedil;&atilde;o e implanta
&ccedil;&atilde;o do    Servi&ccedil;o de Atendimento M&oacute;vel de Urg&ecirc;
ncia (Samu) no Brasil    na d&eacute;cada de 2000.    ^cY#2335.htm##
00878000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704064200081002000900723#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#21#17#article#153#<br>   <b>AN&A
acute;LISE DOS RESULTADOS:</b> O Samu teve prioridade na agenda federal    a par
tir de 2003. Nos primeiros anos de implanta&ccedil;&atilde;o predominaram    ser
vi&ccedil;os de abrang&ecirc;ncia municipal; em 2008, os de abrang&ecirc;ncia   
 regional tornaram-se mais relevantes. A cobertura estimada alcan&ccedil;ou 53,9
%    da popula&ccedil;&atilde;o em 2009, residente em 20,5% dos munic&iacute;pio
s    brasileiros. A implanta&ccedil;&atilde;o variou entre os Estados e houve me
nos    ambul&acirc;ncias de suporte avan&ccedil;ado do que o recomendado, tanto 
no    conjunto do Pa&iacute;s como em v&aacute;rios Estados.    ^cY#2335.htm##
00963000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704072700081002000900808#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#22#18#article#153#<br>   <b>CONC
LUS&Otilde;ES:</b> O Samu foi adotado nacionalmente a partir de 2003,    com a e
labora&ccedil;&atilde;o de normas federais. A implanta&ccedil;&atilde;o    da po
l&iacute;tica compreende desafios como realiza&ccedil;&atilde;o de investimentos
    adequados, inser&ccedil;&atilde;o do servi&ccedil;o em uma rede articulada d
e    atendimento de urg&ecirc;ncia, conforma&ccedil;&atilde;o de sistemas de inf
orma&ccedil;&otilde;es    apropriados, capacita&ccedil;&atilde;o dos profissiona
is. O enfrentamento desses    desafios permitir&aacute; que o Samu se configure 
como uma estrat&eacute;gia    estruturante da aten&ccedil;&atilde;o &agrave; sa&
uacute;de no Sistema &Uacute;nico    de Sa&uacute;de.</font></p>     ^cY#2335.ht
m##
00537000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704030100081002000900382#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#23#19#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:</b>    Servi&cc
edil;os M&eacute;dicos de Emerg&ecirc;ncia. Ambul&acirc;ncias. Prioridades    em
 Sa&uacute;de. Sistema &Uacute;nico de Sa&uacute;de. Pol&iacute;tica de Sa&uacut
e;de.</font></p> <hr size="1" noshade>     ^cY#2335.htm##
00334000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009800081002000900179#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#24#20#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     
^cY#2335.htm##
00406000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017000081002000900251#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#25#21#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To analyze
 the configuration of mobile emergency health care policy in Brazil.    ^cY#2335
.htm##
00569000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704033300081002000900414#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#26#22#article#153#<br>   <b>METH
ODOLOGICAL PROCEDURES:</b> The study was based on public policy analysis.    Bib
liographic and document review, analysis of official data and interviews    with
 federal administrators related to formulation and implementation of the    Mobi
le Emergency Care Service (SAMU) in Brazil in the 2000s were performed.    ^cY#2
335.htm##
00738000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704050200081002000900583#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#27#23#article#153#<br>   <b>ANAL
YSIS OF RESULTS:</b> Priority was given to SAMU at the federal level    since 20
03. During the first years of implementation, municipal level services    predom
inated; in 2008, services with regional scope became more significant.    Estima
ted coverage reached 53.9% of the population in 2009, in 20.5% of Brazilian    m
unicipalities. Implementation varied between States, and there were less advance
d    support ambulances than recommended, both nationally and in several States.
    ^cY#2335.htm##
00702000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704046600081002000900547#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#28#24#article#153#<br>   <b>CONC
LUSIONS:</b> SAMU was adopted nationwide since 2003 upon development    of feder
al norms. Implementation of the policy involves challenges, including    adequat
e investment, integration of the service into an established urgent care    netw
ork, arrangement of appropriate information systems and personnel capacity.    A
ddressing these challenges will allow SAMU to become a key health care strategy 
   in the unified health system.</font></p>     ^cY#2335.htm##
00463000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704022700081002000900308#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#29#25#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:</b>    Emergenc
y Medical Services. Ambulances. Health Priorities. Unified Health System.    Hea
lth Policy.</font></p> <hr size="1" noshade>     ^cY#2335.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#30#26#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^
cY#2335.htm##
00442000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020600081002000900287#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#31#27#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analizar la
 conformaci&oacute;n de la pol&iacute;tica de atenci&oacute;n m&oacute;vil    a 
las urgencias en Brasil.    ^cY#2335.htm##
00696000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704046000081002000900541#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#32#28#article#153#<br>   <b>PROC
EDIMIENTOS METODOL&Oacute;GICOS:</b> Con base en las referencias del    an&aacut
e;lisis de pol&iacute;ticas p&uacute;blicas, se realizaron: revisi&oacute;n    b
ibliogr&aacute;fica, an&aacute;lisis de documentos y datos oficiales y entrevist
as    con dirigentes federales relacionados a la formulaci&oacute;n e implantaci
&oacute;n    del Servicio de Atenci&oacute;n M&oacute;vil de Urgencia (SAMU) en 
Brasil en    la d&eacute;cada de 2000.    ^cY#2335.htm##
00853000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704061700081002000900698#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#33#29#article#153#<br>   <b>AN&A
acute;LISIS DE LOS RESULTADOS:</b> El SAMU tuvo prioridad en la agenda    federa
l a partir de 2003. En los primeros a&ntilde;os de implantaci&oacute;n    predom
inaron servicios de cobertura municipal; en 2008, los de cobertura regional    s
e tornaron m&aacute;s relevantes. La cobertura estimada alcanz&oacute; 53,9%    
de la poblaci&oacute;n en 2009, residente en 20,5% de los municipios brasile&nti
lde;os.    La implantaci&oacute;n vari&oacute; entre los Estados y hubo menos am
bulancias    de soporte avanzado de lo recomendado, tanto en el conjunto del pa&
iacute;s    como en varios estados.    ^cY#2335.htm##
00877000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704064100081002000900722#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#34#30#article#153#<br>   <b>CONC
LUSIONES:</b> El SAMU fue adoptado en 2003, con la elaboraci&oacute;n    de norm
as federales. La implantaci&oacute;n de la pol&iacute;tica comprende    desaf&ia
cute;os como realizaci&oacute;n de inversiones adecuadas, inserci&oacute;n    de
l servicio en una red articulada de atenci&oacute;n de urgencia, conformaci&oacu
te;n    de sistemas de informaciones apropiados, capacitaci&oacute;n de los prof
esionales.    El enfrentamiento de tales desaf&iacute;os permitir&aacute; que el
 SAMU se configure    como una estrategia estructurada de la atenci&oacute;n a l
a salud en el Sistema    &Uacute;nico de Salud.</font></p>     ^cY#2335.htm##
00497000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704026100081002000900342#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#35#31#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:</b>    Servici
os M&eacute;dicos de Urgencia. Ambulancias. Prioridades en Salud. Sistema    &Ua
cute;nico de Salud. Pol&iacute;tica de Salud.</font></p> <hr size="1" noshade>  
   ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#36#32#article#153#<p>&nbsp;</p> 
    ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#37#33#article#153#<p>&nbsp;</p> 
    ^cY#2335.htm##
00350000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011400081002000900195#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#38#34#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b>
</font></p>     ^cY#2335.htm##
00878000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704064200081002000900723#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#39#35#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As press&otilde;es    sobre os 
servi&ccedil;os de emerg&ecirc;ncia t&ecirc;m aumentado em face de    mudan&cced
il;as demogr&aacute;ficas, epidemiol&oacute;gicas e sociais, por isso    muitos 
pa&iacute;ses organizaram sistemas para atendimento &agrave;s urg&ecirc;ncias,  
  sob modelos distintos.<sup>17,21,</sup><a name="topa"></a><a href="#backa">ª</
a>    Em geral, tais sistemas apresentam bons resultados em termos de diminui&cc
edil;&atilde;o    da morbidade e mortalidade e nenhum desses modelos &eacute; co
mprovadamente    mais eficaz.<sup>17,21,16</sup></font></p>     ^cY#2335.htm##
00597000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704036100081002000900442#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#40#36#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O modelo franc&ecirc;s    permi
te o in&iacute;cio precoce da terap&ecirc;utica, fundamental para as emerg&ecirc
;ncias    cl&iacute;nicas, mas tem sido criticado na aten&ccedil;&atilde;o ao tr
auma pelo    retardo no transporte para o local definitivo de atendimento.<sup>2
1</sup></font></p>     ^cY#2335.htm##
00658000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704042200081002000900503#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#41#37#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O modelo americano,    que tem 
influ&ecirc;ncia internacional, prop&otilde;e a remo&ccedil;&atilde;o    r&aacut
e;pida do paciente do local de atendimento.<sup>17,21</sup> A interven&ccedil;&a
tilde;o    &eacute; feita por t&eacute;cnicos em emerg&ecirc;ncias m&eacute;dica
s (<i>Emergency    Medical Technician</i>) e por param&eacute;dicos.</font></p> 
    ^cY#2335.htm##
00934000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704069800081002000900779#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#42#38#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">No Brasil, parte    expressiva 
da popula&ccedil;&atilde;o busca consultas nos pronto-socorros dos    hospitais,
 apesar da amplia&ccedil;&atilde;o da oferta de servi&ccedil;os de    aten&ccedi
l;&atilde;o b&aacute;sica desde 1990. Assim, os hospitais ainda s&atilde;o    im
portantes portas de entrada para a assist&ecirc;ncia m&eacute;dica, o que    pod
e se relacionar a dificuldades no acesso oportuno a servi&ccedil;os b&aacute;sic
os,    especializados e de apoio diagn&oacute;stico. Ademais, o sentido de urg&e
circ;ncia    para o paciente pode n&atilde;o ser o mesmo para profissionais de s
a&uacute;de.<sup>8</sup></font></p>     ^cY#2335.htm##
00900000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704066400081002000900745#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#43#39#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Para Carret et    al<sup>4</sup
> a utiliza&ccedil;&atilde;o inadequada dos servi&ccedil;os de    emerg&ecirc;nc
ia &eacute; prejudicial para os pacientes graves, que precisam    de atendimento
 oportuno, e para os n&atilde;o graves, que, ao buscarem o atendimento    hospit
alar, n&atilde;o t&ecirc;m garantido o seguimento. O acesso &agrave; aten&ccedil
;&atilde;o    b&aacute;sica reduz o uso inapropriado de servi&ccedil;os de emerg
&ecirc;ncia    apenas se o paciente tiver r&aacute;pido acesso ao atendimento de
 urg&ecirc;ncia    na aten&ccedil;&atilde;o b&aacute;sica.<sup>4</sup></font></p
>     ^cY#2335.htm##
00745000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704050900081002000900590#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#44#40#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudo de monitoramento    em p
ronto-socorros de eventos sentinela da aten&ccedil;&atilde;o b&aacute;sica    co
ncluiu que o atendimento m&eacute;dico oportuno na aten&ccedil;&atilde;o b&aacut
e;sica    &eacute; fundamental e enfatizou a necessidade de superar a defici&eci
rc;ncia    num&eacute;rica, organiza&ccedil;&atilde;o fragilizada e recursos ins
uficientes    para esse n&iacute;vel de aten&ccedil;&atilde;o.<sup>18</sup></fon
t></p>     ^cY#2335.htm##
00894000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704065800081002000900739#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#45#41#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Revis&atilde;o    da literatura
 internacional sobre interven&ccedil;&otilde;es para solucionar    a superlota&c
cedil;&atilde;o dos servi&ccedil;os de emerg&ecirc;ncia aponta    que o caminho 
para superar o modelo atual de aten&ccedil;&atilde;o nos servi&ccedil;os    de e
merg&ecirc;ncia no Brasil deve ter car&aacute;ter sist&ecirc;mico e foco    no u
su&aacute;rio, com redefini&ccedil;&atilde;o e integra&ccedil;&atilde;o    das v
oca&ccedil;&otilde;es assistenciais, reorganiza&ccedil;&atilde;o de fluxos    e 
repactua&ccedil;&atilde;o dos processos de trabalho.<sup>2</sup></font></p>     
^cY#2335.htm##
00909000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704067300081002000900754#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#46#42#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">No Brasil, o atendimento    &ag
rave;s urg&ecirc;ncias mostra defici&ecirc;ncias estruturais do sistema de    sa
&uacute;de, como: dificuldades de acesso em v&aacute;rios n&iacute;veis de    at
en&ccedil;&atilde;o, insufici&ecirc;ncia de leitos especializados, incipi&ecirc;
ncia    dos mecanismos de refer&ecirc;ncia e inadequa&ccedil;&atilde;o na forma&
ccedil;&atilde;o    dos profissionais de sa&uacute;de. Ainda assim, somente no c
ome&ccedil;o dos    anos 2000 o Minist&eacute;rio da Sa&uacute;de iniciou a estr
utura&ccedil;&atilde;o    de uma pol&iacute;tica articulada para a &aacute;rea.<
/font></p>     ^cY#2335.htm##
00642000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704040600081002000900487#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#47#43#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Diante do peso    do Executivo 
federal na defini&ccedil;&atilde;o das pol&iacute;ticas de sa&uacute;de    no Br
asil,<sup>12</sup> busca-se quais fatores influenciaram a formula&ccedil;&atilde
;o    nacional da pol&iacute;tica de aten&ccedil;&atilde;o &agrave;s urg&ecirc;n
cias    e as suas principais caracter&iacute;sticas.</font></p>     ^cY#2335.htm
##
00599000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704036300081002000900444#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#48#44#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    teve por o
bjetivo analisar a conforma&ccedil;&atilde;o da pol&iacute;tica de    aten&ccedi
l;&atilde;o pr&eacute;-hospitalar &agrave; urg&ecirc;ncia no Brasil    nos anos 
2000, com foco no Servi&ccedil;o de Atendimento M&oacute;vel de Urg&ecirc;ncia  
  (Samu).</font></p>     ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#49#45#article#153#<p>&nbsp;</p> 
    ^cY#2335.htm##
00363000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704012700081002000900208#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#50#46#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>PROCEDIMENTOS    METODOL&Oac
ute;GICOS</b></font></p>     ^cY#2335.htm##
00590000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035400081002000900435#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#51#47#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O estudo baseou-se    no refere
ncial da an&aacute;lise de pol&iacute;ticas p&uacute;blicas<sup>9,19</sup>    e 
enfocou o processo de formula&ccedil;&atilde;o, o conte&uacute;do da pol&iacute;
tica<sup>24</sup>    nacional do Samu e sua implanta&ccedil;&atilde;o no Brasil.
</font></p>     ^cY#2335.htm##
01195000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704095900081002000901040#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#52#48#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A an&aacute;lise    da entrada 
do Samu na agenda federal partiu da abordagem de Kingdon,<sup>10</sup>    em que
 "agenda" compreende o conjunto de temas que mobilizam seriamente a aten&ccedil;
&atilde;o    dos agentes governamentais ou pessoas associadas em determinado mom
ento. O estudo    considerou os tr&ecirc;s fluxos relevantes para a defini&ccedi
l;&atilde;o da    agenda: problemas (relacionado ao reconhecimento de uma quest&
atilde;o como    problema pelos governos), solu&ccedil;&otilde;es (concernente &
agrave; formula&ccedil;&atilde;o    de alternativas pelos especialistas) e pol&i
acute;tica (relativo a vari&aacute;veis    como mudan&ccedil;as de governo ou de
 equipes). Segundo essa abordagem, a converg&ecirc;ncia    entre os fluxos abre 
uma "janela de oportunidade" para que o tema entre na agenda    governamental e 
se traduza em pol&iacute;tica p&uacute;blica.</font></p>     ^cY#2335.htm##
00748000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051200081002000900593#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#53#49#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Foram definidas    como categor
ias de an&aacute;lise: inser&ccedil;&atilde;o do Samu na agenda    federal (ante
cedentes, influ&ecirc;ncias, motivos); conte&uacute;do da pol&iacute;tica    (de
senho da proposta, rela&ccedil;&atilde;o com outras estrat&eacute;gias);    e im
planta&ccedil;&atilde;o do Samu (evolu&ccedil;&atilde;o nacional dos servi&ccedi
l;os    de 2004 a julho de 2009 e sua distribui&ccedil;&atilde;o territorial).</
font></p>     ^cY#2335.htm##
01069000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704083300081002000900914#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#54#50#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As estrat&eacute;gias    metodo
l&oacute;gicas foram: revis&atilde;o bibliogr&aacute;fica; an&aacute;lise    de 
documentos e portarias federais; an&aacute;lise de dados fornecidos pelo    Mini
st&eacute;rio da Sa&uacute;de; e entrevistas com sete dirigentes federais,    se
lecionados segundo o cargo ocupado e per&iacute;odo de atua&ccedil;&atilde;o    
na pol&iacute;tica (entre 2003 e 2010), sendo: dois ministros da sa&uacute;de;  
  dois secret&aacute;rios federais de primeiro escal&atilde;o; tr&ecirc;s coorde
nadores    federais de urg&ecirc;ncias e emerg&ecirc;ncias. Na apresenta&ccedil;
&atilde;o    dos resultados, os entrevistados s&atilde;o designados somente pelo
 tipo de    cargo (respectivamente: ministro, secret&aacute;rio e coordenador).<
/font></p>     ^cY#2335.htm##
00473000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704023700081002000900318#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#55#51#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Utiliza-se no artigo    generic
amente o termo "urg&ecirc;ncias", sem diferenci&aacute;-lo de "emerg&ecirc;ncias
",    como adotado nos documentos federais.</font></p>     ^cY#2335.htm##
00532000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704029600081002000900377#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#56#52#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O projeto de investiga&ccedil;&
atilde;o    foi aprovado por Comit&ecirc; de &Eacute;tica em Pesquisa da Escola 
Nacional    de Sa&uacute;de P&uacute;blica Sergio Arouca/Fiocruz sob o n&uacute;
mero 022.0.031.000-07.</font></p>     ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#57#53#article#153#<p>&nbsp;</p> 
    ^cY#2335.htm##
00358000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704012200081002000900203#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#58#54#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>AN&Aacute;LISE    DOS RESULT
ADOS</b></font></p>     ^cY#2335.htm##
00409000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704017300081002000900254#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#59#55#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Formula&ccedil;&atilde;o    
da pol&iacute;tica: entrada na agenda e desenho do Samu</b></font></p>     ^cY#2
335.htm##
01062000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704082600081002000900907#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#60#56#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A constru&ccedil;&atilde;o    d
a pol&iacute;tica federal para aten&ccedil;&atilde;o &agrave;s urg&ecirc;ncias  
  no Brasil envolveu tr&ecirc;s momentos principais: 1998-2002 - primeiras inici
ativas    de regulamenta&ccedil;&atilde;o; 2003-2008 - formula&ccedil;&atilde;o 
e implanta&ccedil;&atilde;o    da Pol&iacute;tica Nacional de Aten&ccedil;&atild
e;o &agrave;s Urg&ecirc;ncias,    com prioriza&ccedil;&atilde;o do Samu; e a par
tir do final de 2008 - continuidade    do Samu e implanta&ccedil;&atilde;o de Un
idades de Pronto Atendimento (UPA).    A <a href="/img/revistas/rsp/2011nahead/2
335t.jpg">Tabela</a> apresenta as principais normas federais    relativas ao des
enho da pol&iacute;tica de urg&ecirc;ncias e do Samu, de 1998    a 2009.</font><
/p>     ^cY#2335.htm##
00962000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704072600081002000900807#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#61#57#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O primeiro momento    (1998-200
2) foi caracterizado pela emiss&atilde;o de normas pontuais para a    implanta&c
cedil;&atilde;o dos sistemas estaduais para atendimento de urg&ecirc;ncia    e p
ublica&ccedil;&atilde;o da primeira portaria voltada para o atendimento pr&eacut
e;-hospitalar    m&oacute;vel. Ainda que n&atilde;o existisse uma pol&iacute;tic
a nacional estruturada    para a &aacute;rea, debates subsidiaram sua formula&cc
edil;&atilde;o, como as    discuss&otilde;es sobre experi&ecirc;ncias internacio
nais, de munic&iacute;pios    espec&iacute;ficos e do Corpo de Bombeiros no aten
dimento &agrave;s urg&ecirc;ncias    no Pa&iacute;s.</font></p>     ^cY#2335.htm
##
00695000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704045900081002000900540#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#62#58#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Comunidades de    especialistas
 destacaram-se na formula&ccedil;&atilde;o de alternativas para    a &aacute;rea
, incluindo os conselhos profissionais (de Medicina e de Enfermagem)    e a Rede
 Brasileira de Coopera&ccedil;&atilde;o de Urg&ecirc;ncia e Emerg&ecirc;ncia.   
 Em documentos oficiais e nas entrevistas, foi mencionado o congresso promovido 
   por essa Rede em 2000:</font></p>     ^cY#2335.htm##
00752000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051600081002000900597#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#63#59#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"O Secret&aacute;rio    de Assi
st&ecirc;ncia &agrave; Sa&uacute;de (...) veio na abertura do congresso    e dis
se que realmente ainda n&atilde;o tinha uma pol&iacute;tica estabelecida    sobr
e as urg&ecirc;ncias no Minist&eacute;rio e que ele estava aberto a discutir    
(...) trabalhamos o congresso entusiasmados em fazer um relat&oacute;rio e tirar
    uma proposta nacional para ser levada para o Minist&eacute;rio". (Coordenado
r)</font></p>     ^cY#2335.htm##
00979000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704074300081002000900824#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#64#60#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Do congresso resultaram    deba
tes para a constru&ccedil;&atilde;o de uma pol&iacute;tica federal nos anos    s
eguintes, com o envolvimento de profissionais da &aacute;rea e o apoio de dirige
ntes,    que culminaram na publica&ccedil;&atilde;o do Regulamento do Atendiment
o dos    Sistemas Estaduais de Urg&ecirc;ncia e Emerg&ecirc;ncia em 2002, a base
 para    a estrutura&ccedil;&atilde;o subseq&uuml;ente da pol&iacute;tica. Ainda
 n&atilde;o    havia uma &aacute;rea t&eacute;cnica na estrutura do Minist&eacut
e;rio respons&aacute;vel    pela pol&iacute;tica de urg&ecirc;ncias, nem instrum
entos de financiamento para    a sua operacionaliza&ccedil;&atilde;o.</font></p>
     ^cY#2335.htm##
01037000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704080100081002000900882#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#65#61#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O segundo momento    (2003-2008
) foi marcado pela formula&ccedil;&atilde;o da Pol&iacute;tica Nacional    de At
en&ccedil;&atilde;o &agrave;s Urg&ecirc;ncias e pelo destaque na agenda    gover
namental da estrat&eacute;gia do Servi&ccedil;o de Atendimento M&oacute;vel    d
e Urg&ecirc;ncia (Samu), a ser implantado como primeiro componente dessa pol&iac
ute;tica.    As principais mudan&ccedil;as institucionais no per&iacute;odo fora
m: a formaliza&ccedil;&atilde;o    da Coordena&ccedil;&atilde;o Geral de Urg&eci
rc;ncias e Emerg&ecirc;ncias na    estrutura ministerial, a constru&ccedil;&atil
de;o das regras nacionais relativas    ao Samu e a institui&ccedil;&atilde;o de 
mecanismos de financiamento espec&iacute;ficos.</font></p>     ^cY#2335.htm##
00954000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704071800081002000900799#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#66#62#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A Pol&iacute;tica    Nacional d
e Aten&ccedil;&atilde;o &agrave;s Urg&ecirc;ncias de 2003 prop&ocirc;s    a conf
orma&ccedil;&atilde;o de sistemas de aten&ccedil;&atilde;o &agrave;s urg&ecirc;n
cias    estaduais, regionais e municipais, norteada pelos princ&iacute;pios do S
istema    &Uacute;nico de Sa&uacute;de (SUS). Essa pol&iacute;tica estruturou-se
 em cinco    eixos: promo&ccedil;&atilde;o da qualidade de vida, organiza&ccedil
;&atilde;o    em rede, opera&ccedil;&atilde;o de centrais de regula&ccedil;&atil
de;o, capacita&ccedil;&atilde;o    e educa&ccedil;&atilde;o continuada e humaniz
a&ccedil;&atilde;o da aten&ccedil;&atilde;o.</font></p>     ^cY#2335.htm##
00977000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704074100081002000900822#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#67#63#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os seguintes componentes    for
am considerados para a organiza&ccedil;&atilde;o de redes de aten&ccedil;&atilde
;o    integral &agrave;s urg&ecirc;ncias: pr&eacute;-hospitalar fixo (unidades b
&aacute;sicas    de sa&uacute;de e de sa&uacute;de da fam&iacute;lia, equipes de
 agentes comunit&aacute;rios,    ambulat&oacute;rios especializados, servi&ccedi
l;os de diagn&oacute;stico e    terapia, e unidades n&atilde;o-hospitalares de a
tendimento &agrave;s urg&ecirc;ncias);    pr&eacute;-hospitalar m&oacute;vel (Sa
mu); hospitalar; e p&oacute;s-hospitalar    (aten&ccedil;&atilde;o domiciliar, h
ospitais-dia e projetos de reabilita&ccedil;&atilde;o    integral).</font></p>  
   ^cY#2335.htm##
00728000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704049200081002000900573#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#68#64#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Segundo os entrevistados,    a 
entrada do Samu na agenda federal de prioridades em 2003 teria sido favorecida  
  pela articula&ccedil;&atilde;o anterior de especialistas, pela exist&ecirc;nci
a    de experi&ecirc;ncias municipais e de uma regulamenta&ccedil;&atilde;o naci
onal    pr&eacute;via. O apoio dos novos dirigentes federais, incluindo o Minist
ro da    Sa&uacute;de e o Presidente, teria sido decisivo:</font></p>     ^cY#23
35.htm##
00923000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704068700081002000900768#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#69#65#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"o ministro Humberto    Costa c
onhecia o pr&eacute;-hospitalar porque ele implantou em Recife (...)    foi defe
nder essa proposta de ser o primeiro componente para o Minist&eacute;rio    impl
antar na &aacute;rea de urg&ecirc;ncia e emerg&ecirc;ncia. (...) foi um    traba
lho espetacular do diretor, do secret&aacute;rio e do ministro junto ao    presi
dente Lula para que fosse priorizado esse projeto dentro da coordena&ccedil;&ati
lde;o    e que tiv&eacute;ssemos recursos para implantar esse servi&ccedil;o no 
Brasil.    Foi muito gratificante quando o presidente Lula ficou entusiasmado." 
(Coordenador)</font></p>     ^cY#2335.htm##
00571000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704033500081002000900416#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#70#66#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"Teve um idealismo    do presid
ente de dizer: eu quero isso 'pro' Pa&iacute;s. Teve um apoio pol&iacute;tico,  
  e n&atilde;o s&oacute; t&eacute;cnico, que vinha sendo discutido, para que se 
   implantasse isso 'a' n&iacute;vel nacional." (Coordenador)</font></p>     ^cY
#2335.htm##
00697000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704046100081002000900542#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#71#67#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O Samu permaneceu    na agenda 
federal de prioridades nas gest&otilde;es ministeriais subseq&uuml;entes,    o q
ue &eacute; evidenciado por: destaque como meta presidencial; presen&ccedil;a   
 nos discursos do presidente e de todos os ministros; expans&atilde;o de servi&c
cedil;os    no territ&oacute;rio; e reconhecimento por todos os entrevistados da
 pesquisa,    como na fala:</font></p>     ^cY#2335.htm##
00493000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704025700081002000900338#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#72#68#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"O presidente me    pediu: 'voc
&ecirc; d&ecirc; um jeito de atingir as metas previstas para o Samu'.    (...) E
ra uma continuidade da administra&ccedil;&atilde;o." (Ministro)</font></p>     ^
cY#2335.htm##
01116000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704088000081002000900961#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#73#69#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A defesa da implanta&ccedil;&at
ilde;o    do Samu como primeira etapa da pol&iacute;tica baseou-se no argumento 
de que    as centrais de regula&ccedil;&atilde;o seriam importantes para a organ
iza&ccedil;&atilde;o    dos fluxos de aten&ccedil;&atilde;o integral &agrave;s u
rg&ecirc;ncias, pois    poderiam exercer o papel de observat&oacute;rios das red
es de assist&ecirc;ncia    no sistema de sa&uacute;de. Dados provenientes de seu
 funcionamento seriam relevantes    para o planejamento de a&ccedil;&otilde;es, 
visando ampliar e qualificar o acesso    ao atendimento de urg&ecirc;ncia no Pa&
iacute;s. O Samu, devido a suas atribui&ccedil;&otilde;es,    constituiria uma d
as portas de entrada do sistema, ao receber demandas da popula&ccedil;&atilde;o 
   e evidenciar as defici&ecirc;ncias da rede.</font></p>     ^cY#2335.htm##
01743000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704150700081002000901588#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#74#70#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Em face da prioridade    confer
ida ao Samu, o desenho da estrat&eacute;gia se traduziu em instrumentos    de in
du&ccedil;&atilde;o, como normas federais e mecanismos financeiros. Os    Samu s
&atilde;o compostos por centrais reguladoras e por um conjunto de ambul&acirc;nc
ias,    e requerem profissionais qualificados e equipamentos adequados para o at
endimento    &agrave;s urg&ecirc;ncias. As centrais podem ser acionadas pelo n&u
acute;mero    de telefone 192 e m&eacute;dicos reguladores designam as ambul&aci
rc;ncias apropriadas    para cada atendimento. No modelo brasileiro, adotaram-se
 dois tipos principais    de ambul&acirc;ncias. As de suporte b&aacute;sico cont
am com motorista, t&eacute;cnico    de enfermagem e material b&aacute;sico para 
o primeiro atendimento &agrave;s    urg&ecirc;ncias, em casos sem risco imediato
 de vida, sob orienta&ccedil;&atilde;o    dos m&eacute;dicos das centrais. J&aac
ute; as de suporte avan&ccedil;ado incluem    motorista, m&eacute;dico e enferme
iro, al&eacute;m de equipamentos para cuidados    intensivos, nas situa&ccedil;&
otilde;es de risco iminente de vida. Foram propostos    tamb&eacute;m meios alte
rnativos de transporte, como as "ambulanchas", para    o atendimento de popula&c
cedil;&otilde;es ribeirinhas; as "motol&acirc;ncias",    para &aacute;reas remot
as ou de tr&aacute;fego intenso; e o transporte a&eacute;reo,    para situa&cced
il;&otilde;es espec&iacute;ficas.</font></p>     ^cY#2335.htm##
00486000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704025000081002000900331#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#75#71#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Segundo os entrevistados,    ap
esar de inspirado por experi&ecirc;ncias internacionais, o modelo brasileiro    
do Samu adquiriu caracter&iacute;sticas pr&oacute;prias:</font></p>     ^cY#2335
.htm##
00631000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704039500081002000900476#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#76#72#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"No modelo franc&ecirc;s,    &e
acute; 100% medicalizado. Mas n&atilde;o ter&iacute;amos condi&ccedil;&otilde;es
    de fazer isso. (...) nos espelhamos muito no modelo franc&ecirc;s, mas nosso
    Samu &eacute; um modelo brasileiro: &eacute; feito de acordo com as nossas c
ondi&ccedil;&otilde;es."    (Coordenador)</font></p>     ^cY#2335.htm##
00643000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704040700081002000900488#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#77#73#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A id&eacute;ia    do "socorrist
a", apesar de debatida no Brasil no final dos anos 1990, foi descartada    na de
fini&ccedil;&atilde;o da estrat&eacute;gia brasileira do Samu ap&oacute;s    res
ist&ecirc;ncias de conselhos profissionais e da constata&ccedil;&atilde;o    da 
inexist&ecirc;ncia desse profissional no Pa&iacute;s:</font></p>     ^cY#2335.ht
m##
00585000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704034900081002000900430#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#78#74#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"Temos aqui o enfermeiro,    o 
auxiliar de enfermagem, o t&eacute;cnico (...) que t&ecirc;m as suas &aacute;rea
s    atuantes e suas legisla&ccedil;&otilde;es. N&atilde;o temos aqui, como nos 
Estados    Unidos, a legisla&ccedil;&atilde;o do socorrista." (Coordenador)</fon
t></p>     ^cY#2335.htm##
01088000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704085200081002000900933#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#79#75#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O desenho da estrat&eacute;gia 
   do Samu previu um arranjo federativo para o financiamento e gest&atilde;o. In
centivos    federais foram adotados para investimento e custeio, com proposta de
 co-financiamento    pelas outras esferas de governo, cuja ades&atilde;o &eacute
; fundamental para    a implanta&ccedil;&atilde;o do Samu. A responsabilidade pe
la gest&atilde;o das    centrais pode ser de munic&iacute;pios ou Estados, e sua
 abrang&ecirc;ncia pode    ser municipal ou regional, a depender das condi&ccedi
l;&otilde;es institucionais    e da pactua&ccedil;&atilde;o no &acirc;mbito de c
ada Estado. No in&iacute;cio,    a ades&atilde;o de munic&iacute;pios isolados p
redominou, mas depois a preocupa&ccedil;&atilde;o    com a gest&atilde;o regiona
l do Samu cresceu:</font></p>     ^cY#2335.htm##
00738000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704050200081002000900583#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#80#76#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"Cidades que tiveram    maior c
apacidade de se organizar, as que t&ecirc;m uma popula&ccedil;&atilde;o    maior
, acabaram tendo o servi&ccedil;o. Os munic&iacute;pios menores acabaram    sem 
for&ccedil;a para se organizar. (...) Os estados que tiveram vis&atilde;o    e c
onseguiram assumir o controle dessas redes foram os estados que tiveram mais    
sucesso (...) Hoje a gente tem muitos Samu regionais." (Coordenador)</font></p> 
    ^cY#2335.htm##
00485000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704024900081002000900330#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#81#77#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"O equ&iacute;voco    do Samu &
eacute; a base municipal dele. Se ele tivesse uma base regional mais    estabele
cida, de gest&atilde;o regional..." (Secret&aacute;rio)</font></p>     ^cY#2335.
htm##
00417000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018100081002000900262#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#82#78#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"Nenhum projeto    de Samu vai 
sair a partir de agora que n&atilde;o seja regional." (Coordenador)</font></p>  
   ^cY#2335.htm##
00656000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704042000081002000900501#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#83#79#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Tamb&eacute;m foram    proposto
s comit&ecirc;s de gest&atilde;o, com o envolvimento de atores como    pol&iacut
e;cia, bombeiros, gestores da sa&uacute;de e da educa&ccedil;&atilde;o,    embor
a os entrevistados tenham reconhecido que a capacidade de articula&ccedil;&atild
e;o    interinstitucional &eacute; vari&aacute;vel no Pa&iacute;s.</font></p>   
  ^cY#2335.htm##
00787000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704055100081002000900632#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#84#80#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A compreens&atilde;o    do Samu
 como componente de uma rede de aten&ccedil;&atilde;o &agrave;s urg&ecirc;ncias 
   que requer a organiza&ccedil;&atilde;o de sistemas articulados de servi&ccedi
l;os    em determinado territ&oacute;rio, presente desde 2002, volta a ter &ecir
c;nfase    no final de 2008 no discurso e nas normas federais. O foco da pol&iac
ute;tica    deslocou-se para outras estrat&eacute;gias, com destaque para as Uni
dades de    Pronto-Atendimento (UPA):</font></p>     ^cY#2335.htm##
00968000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704073200081002000900813#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#85#81#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">"Na pol&iacute;tica    nacional
 de aten&ccedil;&atilde;o &agrave;s urg&ecirc;ncias, a gente tem outros    dois 
componentes importantes. O QualiSUS, que coloca dinheiro pras portas de    emerg
&ecirc;ncia de entrada do SUS, qualificando seu atendimento. (...) Apesar    de 
existirem no Brasil todo unidades n&atilde;o hospitalares que funcionam 24    ho
ras atendendo as urg&ecirc;ncias, de na portaria 2048 de 2002 a gente ter    des
crito as unidades n&atilde;o hospitalares de atendimento &agrave;s urg&ecirc;nci
as    (...) ela se materializou em dezembro &#91;de 2008&#93; com o nome de UPA 
24h,    como Unidade de Pronto-Atendimento." (Coordenador)</font></p>     ^cY#23
35.htm##
00594000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704035800081002000900439#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#86#82#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Um terceiro momento    parece s
e configurar a partir do final de 2008, quando a UPA ganhou destaque    como o c
omponente pr&eacute;-hospitalar fixo da aten&ccedil;&atilde;o, mobilizando    os
 esfor&ccedil;os federais nos &acirc;mbitos normativo, financeiro e pol&iacute;t
ico.</font></p>     ^cY#2335.htm##
00371000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704013500081002000900216#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#87#83#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Implanta&ccedil;&atilde;o   
 nacional do Samu</b></font></p>     ^cY#2335.htm##
00561000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704032500081002000900406#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#88#84#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O n&uacute;mero    de Samu inau
gurados no Brasil aumentou progressivamente entre janeiro de 2004    e julho de 
2009, com desacelera&ccedil;&atilde;o nesse &uacute;ltimo ano (<a href="/img/rev
istas/rsp/2011nahead/2335f01.jpg">Figura    1</a>).</font></p>     ^cY#2335.htm#
#
00848000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704061200081002000900693#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#89#85#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Quanto ao tipo    de abrang&eci
rc;ncia, em 2008 os Samu regionais ultrapassaram os municipais.    Isso pode tra
duzir o movimento de ades&atilde;o mais precoce dos grandes munic&iacute;pios   
 &agrave; estrat&eacute;gia, bem como a preocupa&ccedil;&atilde;o do Minist&eacu
te;rio    da Sa&uacute;de em estimular posteriormente a participa&ccedil;&atilde
;o dos    Estados e a organiza&ccedil;&atilde;o regionalizada dos Samu, com o ob
jetivo    de incluir munic&iacute;pios menores nas redes de atendimento &agrave;
s urg&ecirc;ncias.</font></p>     ^cY#2335.htm##
01140000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704090400081002000900985#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#90#86#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A <a href="/img/revistas/rsp/20
11nahead/2335f02.jpg">Figura    2</a> reitera essas hip&oacute;teses, ao mostrar
 que a propor&ccedil;&atilde;o    da popula&ccedil;&atilde;o abrangida &eacute; 
sempre maior do que a propor&ccedil;&atilde;o    dos munic&iacute;pios brasileir
os atendidos pelo Samu. Entre 2007 e 2008, no    entanto, a varia&ccedil;&atilde
;o na propor&ccedil;&atilde;o de munic&iacute;pios    abrangidos foi maior do qu
e a varia&ccedil;&atilde;o na popula&ccedil;&atilde;o    abrangida por esses ser
vi&ccedil;os, sugerindo a incorpora&ccedil;&atilde;o    de munic&iacute;pios de 
menor porte. Em 2009, a estrat&eacute;gia j&aacute;    estaria ao alcance de mai
s de 100 milh&otilde;es de pessoas, ou seja, mais da    metade da popula&ccedil;
&atilde;o, residente em 20,5% dos munic&iacute;pios    do Pa&iacute;s.</font></p
>     ^cY#2335.htm##
01050000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704081400081002000900895#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#91#87#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A popula&ccedil;&atilde;o    ab
rangida pelo Samu distribui-se de forma variada pelo territ&oacute;rio nacional 
   (<a href="/img/revistas/rsp/2011nahead/2335f03.jpg">Figura 3</a>). Isso se re
laciona ao fato de a    implanta&ccedil;&atilde;o descentralizada da estrat&eacu
te;gia depender da ades&atilde;o    de Estados e/ou munic&iacute;pios, que t&eci
rc;m situa&ccedil;&otilde;es diferenciadas    quanto a: distribui&ccedil;&atilde
;o populacional no territ&oacute;rio, oferta    e organiza&ccedil;&atilde;o pr&e
acute;via do sistema de sa&uacute;de, prioriza&ccedil;&atilde;o    e capacidade 
de implanta&ccedil;&atilde;o do Samu, em face das responsabilidades    de gest&a
tilde;o, co-financiamento e operacionaliza&ccedil;&atilde;o.</font></p>     ^cY#
2335.htm##
01033000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079700081002000900878#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#92#88#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A maioria das ambul&acirc;ncias
    no Pa&iacute;s era de suporte b&aacute;sico em 2009; 21,5% delas eram de sup
orte    avan&ccedil;ado. Essa propor&ccedil;&atilde;o est&aacute; pr&oacute;xima
 da    prevista na regulamenta&ccedil;&atilde;o nacional, que preconiza uma ambu
l&acirc;ncia    de suporte avan&ccedil;ado para quatro de suporte b&aacute;sico.
 No entanto,    considerando a recomenda&ccedil;&atilde;o nacional de disponibil
idade de no    m&iacute;nimo uma ambul&acirc;ncia de suporte avan&ccedil;ado por
 450 mil habitantes,    observa-se que a m&eacute;dia nacional e a de v&aacute;r
ios Estados est&atilde;o    abaixo desse par&acirc;metro (<a href="/img/revistas
/rsp/2011nahead/2335f04.jpg">Figura 4</a>).</font></p>     ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#93#89#article#153#<p>&nbsp;</p> 
    ^cY#2335.htm##
00342000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010600081002000900187#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#94#90#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font><
/p>     ^cY#2335.htm##
00700000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704046400081002000900545#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#95#91#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A aten&ccedil;&atilde;o    &agr
ave;s urg&ecirc;ncias era reconhecida como problema a ser enfrentado no    SUS e
m v&aacute;rios munic&iacute;pios brasileiros antes mesmo dos anos 2000.    Esse
s munic&iacute;pios, em face da descentraliza&ccedil;&atilde;o pol&iacute;tico-a
dministrativa,    buscaram expandir os atendimentos e implantaram experi&ecirc;n
cias locais.<sup>6,20,22</sup></font></p>     ^cY#2335.htm##
00663000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704042700081002000900508#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#96#92#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As comunidades    de especialis
tas (conselhos e redes de profissionais) constru&iacute;am alternativas    para 
a aten&ccedil;&atilde;o &agrave;s urg&ecirc;ncias e conseguiram espa&ccedil;o   
 de influ&ecirc;ncia sobre o Minist&eacute;rio da Sa&uacute;de no in&iacute;cio 
   dos anos 2000, o que resultou nas primeiras normas para a &aacute;rea.</font>
</p>     ^cY#2335.htm##
00752000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051600081002000900597#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#97#93#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Por&eacute;m, a    mudan&ccedil
;a de governo em 2003 foi decisiva para a defini&ccedil;&atilde;o    do Samu com
o prioridade na agenda federal (fluxo da pol&iacute;tica). Naquela    ocasi&atil
de;o, uma janela de oportunidade abriu-se para que as propostas em    debate se 
transformassem em pol&iacute;tica nacional, com a configura&ccedil;&atilde;o    
de instrumentos formais (normas, incentivos) para a sua implanta&ccedil;&atilde;
o.</font></p>     ^cY#2335.htm##
01027000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079100081002000900872#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#98#94#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">De certa forma,    o desenho ab
rangente da pol&iacute;tica nacional de urg&ecirc;ncias divulgada    em 2003 exp
ressa uma l&oacute;gica de depend&ecirc;ncia da trajet&oacute;ria,<sup>15</sup> 
   uma vez que &eacute; coerente com as diretrizes do SUS e favorecido pela exis
t&ecirc;ncia    de uma norma desde 2002, resultante da matura&ccedil;&atilde;o d
e debates nos    anos anteriores. Em s&iacute;ntese, para que o Samu assumisse l
ugar de destaque    na agenda federal e tivesse continuidade, tanto vari&aacute;
veis institucionais    (regras nacionais, experi&ecirc;ncias locais) como pol&ia
cute;ticas (ado&ccedil;&atilde;o    como marco de governo, valoriza&ccedil;&atil
de;o pelos atores) foram importantes.</font></p>     ^cY#2335.htm##
01016000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704078000081002000900861#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#99#95#article#153#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Dado o importante    peso do Ex
ecutivo Federal<sup>1</sup> e do Minist&eacute;rio da Sa&uacute;de    na indu&cc
edil;&atilde;o de pol&iacute;ticas no Brasil,<sup>12</sup> a implanta&ccedil;&at
ilde;o    do Samu foi expressiva no territ&oacute;rio nacional. No entanto, como
 &eacute;    esperado no contexto federativo, h&aacute; diferen&ccedil;as entre 
os Estados    quanto &agrave; abrang&ecirc;ncia populacional e caracter&iacute;s
ticas da implanta&ccedil;&atilde;o    do Samu. Tal diversidade de implanta&ccedi
l;&atilde;o requer a realiza&ccedil;&atilde;o    de estudos espec&iacute;ficos p
ara a compreens&atilde;o dos resultados da estrat&eacute;gia,    de suas possibi
lidades e de seus limites.</font></p>     ^cY#2335.htm##
01221000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704098400082002000901066#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#100#96#article#153#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">V&aacute;rios pa&iacute;ses   
 adotaram estrat&eacute;gias de atendimento pr&eacute;-hospitalar m&oacute;vel  
  como componentes dos sistemas de aten&ccedil;&atilde;o &agrave;s urg&ecirc;nci
as.<sup>17,</sup><a name="topa"></a><a href="#backa">ª</a>    A regula&ccedil;&a
tilde;o m&eacute;dica do atendimento pr&eacute;-hospitalar    pode contribuir pa
ra estruturar a rela&ccedil;&atilde;o entre os servi&ccedil;os    e os fluxos do
s pacientes, bem como para identificar os determinantes dos problemas    e auxil
iar no planejamento da assist&ecirc;ncia &agrave;s urg&ecirc;ncias.<sup>20</sup>
    No Brasil, o Samu pode favorecer a organiza&ccedil;&atilde;o de redes de ate
n&ccedil;&atilde;o,    uma vez que exige a conforma&ccedil;&atilde;o de centrais
 de regula&ccedil;&atilde;o,    que por sua vez podem impulsionar estrat&eacute;
gias de regula&ccedil;&atilde;o    assistencial em outras &aacute;reas.</font></
p>     ^cY#2335.htm##
00826000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704058900082002000900671#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#101#97#article#153#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">Pesquisas recentes    apontam 
avan&ccedil;os, mas tamb&eacute;m problemas, na implanta&ccedil;&atilde;o    do 
Samu relativos a condi&ccedil;&otilde;es estruturais,<sup>5,11,13</sup> gest&ati
lde;o,<sup>3,5,7,11</sup>    integra&ccedil;&atilde;o na rede,<sup>7,11,13</sup>
 capacita&ccedil;&atilde;o    dos profissionais<sup>5</sup> e pr&aacute;ticas de
 aten&ccedil;&atilde;o.<sup>14,23</sup>    Tais pesquisas sugerem a persist&ecir
c;ncia de lacunas tamb&eacute;m citadas    pelos entrevistados deste estudo.</fo
nt></p>     ^cY#2335.htm##
00882000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704064500082002000900727#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#102#98#article#153#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">Uma delas &eacute;    que a or
ganiza&ccedil;&atilde;o de um sistema integrado de aten&ccedil;&atilde;o    &agr
ave;s urg&ecirc;ncias requer maiores investimentos p&uacute;blicos nos diversos 
   n&iacute;veis (aten&ccedil;&atilde;o b&aacute;sica, especializada, hospitalar
),    articula&ccedil;&atilde;o de servi&ccedil;os no territ&oacute;rio e mecani
smos    efetivos de regula&ccedil;&atilde;o p&uacute;blica. A &ecirc;nfase em co
mponentes    espec&iacute;ficos da pol&iacute;tica - Samu, UPA - parece insufici
ente diante    da complexidade dessa quest&atilde;o.</font></p>     ^cY#2335.htm
##
00715000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704047800082002000900560#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#103#99#article#153#<p><font face
="Verdana, Arial, Helvetica, sans-serif" size="2">Atualmente existem    diferent
es sistemas de informa&ccedil;&otilde;es nos Estados e munic&iacute;pios,    mas
 n&atilde;o h&aacute; informa&ccedil;&otilde;es consolidadas sobre o perfil    e
 o resultado dos atendimentos realizados pelo Samu. Estas seriam &uacute;teis   
 para o planejamento das a&ccedil;&otilde;es visando &agrave; melhoria da aten&c
cedil;&atilde;o    &agrave;s urg&ecirc;ncias.</font></p>     ^cY#2335.htm##
00635000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704039700083002000900480#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#104#100#article#153#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Outra lacuna relaciona-se    
&agrave; qualifica&ccedil;&atilde;o dos profissionais que atuam nas centrais    
e nas ambul&acirc;ncias, dada a especificidade desse tipo de atendimento. Apesar
    de previstas no desenho da pol&iacute;tica, as iniciativas de forma&ccedil;&
atilde;o    ainda t&ecirc;m alcance limitado.</font></p>     ^cY#2335.htm##
00752000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704051400083002000900597#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#105#101#article#153#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">O enfrentamento    dessas lac
unas &eacute; fundamental para que o Samu se consolide como estrat&eacute;gia   
 estruturante para o SUS, componente de uma pol&iacute;tica integrada de aten&cc
edil;&atilde;o    &agrave;s urg&ecirc;ncias, e n&atilde;o somente como um progra
ma de alta visibilidade,    por&eacute;m com risco de limitada efetividade na re
solu&ccedil;&atilde;o dos    problemas de sa&uacute;de da popula&ccedil;&atilde;
o.</font></p>     ^cY#2335.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#106#102#article#153#<p>&nbsp;</p
>     ^cY#2335.htm##
00345000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704010700083002000900190#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#107#103#article#153#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></fon
t></p>     ^cY#2335.htm##
00592000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704034000085002000900425#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#108#104#article#153#
1#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Almeida MHT.
    O Estado no Brasil contempor&acirc;neo: um passeio pela hist&oacute;ria. In:
    Melo CR, S&aacute;ez MA, organizadores. A democracia brasileira: balan&ccedi
l;o    e perspectivas para o s&eacute;culo 21. Belo Horizonte: Editora UFMG; 200
7.    p.17-34.    ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#109#105#article#153#</font></p> 
    ^cY#2335.htm##
00619000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704036700085002000900452#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#110#106#article#153#
2#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Bittencourt 
   RJ, Hortale VA. Interven&ccedil;&otilde;es para solucionar a superlota&ccedil
;&atilde;o    nos servi&ccedil;os de emerg&ecirc;ncia hospitalar: uma revis&atil
de;o sistem&aacute;tica.    <i>Cad Saude Publica</i>. 2009;25(7):1439-54. DOI:10
.1590/S0102-311X2009000700002</font></p>     ^cY#2335.htm##
00625000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704037300085002000900458#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#111#107#article#153#
3#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Cabral APS, 
   Souza WV. Servi&ccedil;o de Atendimento M&oacute;vel de Urg&ecirc;ncia (Samu)
:    an&aacute;lise da demanda e sua distribui&ccedil;&atilde;o espacial em uma 
cidade    do nordeste brasileiro. <i>Rev Bras Epidemiol.</i> 2008;11(4):530-40. 
DOI:10.1590/S1415-790X2008000400002</font></p>     ^cY#2335.htm##
00560000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704030800085002000900393#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#112#108#article#153#
4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Carret MLV, 
   Fassa AG, Domingues MR. Inappropriate use of emergency services: a systematic
    review of prevalence and associated factors. <i>Cad Saude Publica</i>. 2009;
25(1):7-28.    DOI:10.1590/S0102-311X2009000100002</font></p>     ^cY#2335.htm##
00496000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704024400085002000900329#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#113#109#article#153#
5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Chomatas M. 
   Integra&ccedil;&atilde;o de saberes e pr&aacute;ticas na organiza&ccedil;&ati
lde;o    do Samu de Curitiba - PR. <i>Divulg Saude Debate</i>. 2005;(32):90-5.  
  ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#114#110#article#153#</font></p> 
    ^cY#2335.htm##
00649000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704039700085002000900482#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#115#111#article#153#
6#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Ciconet RM, 
   Marques GQ, Lima MADS. Educa&ccedil;&atilde;o em servi&ccedil;o para profissi
onais    do Servi&ccedil;o de Atendimento M&oacute;vel de Urg&ecirc;ncia (Samu):
 relato    da experi&ecirc;ncia de Porto Alegre-RS. <i>Interface (Botucatu)</i>.
 2008;12(26):659-66.    DOI:10.1590/S1414-32832008000300016</font></p>     ^cY#2
335.htm##
00696000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704044400085002000900529#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#116#112#article#153#
7#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Evangelista 
   PA, Barreto SM, Guerra HL. Central de regula&ccedil;&atilde;o de leitos do SU
S    em Belo Horizonte, Minas Gerais: avalia&ccedil;&atilde;o de seu papel pelo 
estudo    das interna&ccedil;&otilde;es por doen&ccedil;as isqu&ecirc;micas do c
ora&ccedil;&atilde;o.    <i>Cad Saude Publica</i>. 2008;24 (4):767-76. DOI:10.15
90/S0102-311X2008000400006</font></p>     ^cY#2335.htm##
00548000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704029600085002000900381#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#117#113#article#153#
8#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Giglio-Jacqu
emot    A. Urg&ecirc;ncias e emerg&ecirc;ncias em sa&uacute;de: perspectivas de 
profissionais    e usu&aacute;rios. Rio de Janeiro: Editora Fiocruz; 2005. (Cole
&ccedil;&atilde;o    Antropologia e Sa&uacute;de).    ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#118#114#article#153#</font></p> 
    ^cY#2335.htm##
00431000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000200083704017900085002000900264#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#119#115#article#153#
9#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Ham C, Hill 
   M. The policy process in the modern capitalist state. Brighton: Wheatsheaf Bo
oks;    1984.    ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#120#116#article#153#</font></p> 
    ^cY#2335.htm##
00416000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704016300086002000900249#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#121#117#article#153#
10#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Kingdon JW
.    Agendas, alternatives and public policies. 2.ed. New York: Longman; 2003.  
  ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#122#118#article#153#</font></p> 
    ^cY#2335.htm##
00655000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704040200086002000900488#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#123#119#article#153#
11#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Lima JC, R
ivera    FJU. Redes de conversa&ccedil;&atilde;o e coordena&ccedil;&atilde;o de 
a&ccedil;&otilde;es    de sa&uacute;de: estudo em um servi&ccedil;o m&oacute;vel
 regional de aten&ccedil;&atilde;o    &agrave;s urg&ecirc;ncias. <i>Cad Saude Pu
blica</i>. 2010;26(2):323-36. DOI:10.1590/S0102-311X2010000200011</font></p>    
 ^cY#2335.htm##
00538000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028500086002000900371#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#124#120#article#153#
12#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Machado CV
.    O modelo de interven&ccedil;&atilde;o do Minist&eacute;rio da Sa&uacute;de 
brasileiro    nos anos 90. <i>Cad Saude Publica</i>. 2007;23(9):2113-26. DOI:10.
1590/S0102-311X2007000900019</font></p>     ^cY#2335.htm##
00592000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704033900086002000900425#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#125#121#article#153#
13#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Minayo MCS
,    Deslandes SF. An&aacute;lise da implanta&ccedil;&atilde;o do sistema de ate
ndimento    pr&eacute;-hospitalar m&oacute;vel em cinco capitais brasileiras. <i
>Cad Saude    Publica</i>. 2008;24(8):1877-86. DOI:10.1590/S0102-311X20080008000
16</font></p>     ^cY#2335.htm##
00614000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704036100086002000900447#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#126#122#article#153#
14#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Morais DA,
    Carvalho DV, Timerman S, Gonzalez MMC. Parada cardiorrespirat&oacute;ria em 
   ambiente pr&eacute;-hospitalar: ocorr&ecirc;ncias atendidas pela Servi&ccedil
;o    de Atendimento M&oacute;vel de Urg&ecirc;ncia de Belo Horizonte. <i>Rev Br
as    Clin Med.</i> 2009;7(4):211-8.    ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#127#123#article#153#</font></p> 
    ^cY#2335.htm##
00450000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704019700086002000900283#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#128#124#article#153#
15#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Pierson P.
    Politics in time: history, institutions and social analysis. Princeton: Prin
ceton    University Press; 2004.    ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#129#125#article#153#</font></p> 
    ^cY#2335.htm##
00544000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704029100086002000900377#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#130#126#article#153#
16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Pinet LM. 
Atenci&oacute;n    prehospitalaria de urgencias en el Distrito Federal: las opor
tunidades del sistema    de salud. <i>Salud Publica Mex</i>. 2005;47(1):64-71. D
OI:10.1590/S0036-36342005000100010</font></p>     ^cY#2335.htm##
00539000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704028600086002000900372#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#131#127#article#153#
17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Pozner CN,
    Zane R, Nelson SJ, Levine M. International EMS systems: the United States: p
ast,    present and, future. <i>Resuscitation.</i> 2004;60(3):239-44. DOI:10.101
6/j.resuscitation.2003.11.004</font></p>     ^cY#2335.htm##
00585000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704033200086002000900418#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#132#128#article#153#
18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Puccini PT
,    Cornetta VK. Ocorr&ecirc;ncias em pronto-socorro: eventos sentinela para mo
nitoramento    da aten&ccedil;&atilde;o b&aacute;sica de sa&uacute;de. <i>Cad Sa
ude Publica</i>.    2008;24(9):2032-42. DOI:10.1590/S0102-311X2008000900009</fon
t></p>     ^cY#2335.htm##
00421000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704016800086002000900254#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#133#129#article#153#
19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Sabatier P
A,    editor. Theories of the policy process. 2. ed. Boulder: Westview Press; 20
07.    ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#134#130#article#153#</font></p> 
    ^cY#2335.htm##
00735000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704048200086002000900568#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#135#131#article#153#
20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Santos JS,
    Scarpelini S, Brasileiro SLL, Ferraz CA, Dallora MELV, S&aacute; MFP. Avalia
&ccedil;&atilde;o    do modelo de organiza&ccedil;&atilde;o da Unidade de Emerg&
ecirc;ncia do HCFMRP-USP,    adotando, como refer&ecirc;ncia, as pol&iacute;tica
s nacionais de aten&ccedil;&atilde;o    &agrave;s urg&ecirc;ncias e de humaniza&
ccedil;&atilde;o. <i>Medicina (Ribeirao    Preto)</i>. 2003;36(2/4):498- 515.   
 ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#136#132#article#153#</font></p> 
    ^cY#2335.htm##
00479000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704022600086002000900312#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#137#133#article#153#
21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Scarpelini
    S. A organiza&ccedil;&atilde;o do atendimento &agrave;s urg&ecirc;ncias e tr
auma.    <i>Medicina (Ribeirao Preto)</i>. 2007;40(3):315-20.    ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#138#134#article#153#</font></p> 
    ^cY#2335.htm##
00507000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704025400086002000900340#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#139#135#article#153#
22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Tannebaum 
RD,    Arnold JL, De Negri Filho A, Spadoni VS. Emergency medicine in Southern B
razil.    <i>Ann Emerg Med</i>. 2001;37(2):223-8. DOI:10.1067/mem.2001.112252</f
ont></p>     ^cY#2335.htm##
00576000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704032300086002000900409#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#140#136#article#153#
23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Vieira CMS
,    Mussi FC. A implanta&ccedil;&atilde;o do Projeto de Atendimento M&oacute;ve
l    de Urg&ecirc;ncia em Salvador/Bahia: panorama e desafios. <i>Rev Esc Enferm
    USP.</i> 2008;42(4):793-7. DOI:10.1590/S0080-62342008000400024</font></p>   
  ^cY#2335.htm##
00446000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704019300086002000900279#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#141#137#article#153#
24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Walt G. He
alth    policy: an introduction to process and power. Johannesburg: Witwatersran
d University    Press; 1994.    ^cY#2335.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#142#138#article#153#</font></p> 
    ^cY#2335.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#143#139#article#153#<p>&nbsp;</p
>     ^cY#2335.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#144#140#article#153#<p>&nbsp;</p
>     ^cY#2335.htm##
00453000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021500083002000900298#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#145#141#article#153#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#
top"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    <b>Corr
espond&ecirc;ncia | Correspondence:    ^cY#2335.htm##
00282000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004400083002000900127#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#146#142#article#153#<br>   </b> 
Cristiani Vieira Machado    ^cY#2335.htm##
00298000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704006000083002000900143#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#147#143#article#153#<br>   R. Le
opoldo Bulh&otilde;es, 1480 - Manguinhos    ^cY#2335.htm##
00289000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005100083002000900134#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#148#144#article#153#<br>   Pr&ea
cute;dio ENSP-FIOCRUZ - sl. 715    ^cY#2335.htm##
00289000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005100083002000900134#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#149#145#article#153#<br>   21041
-210 Rio de Janeiro, RJ, Brasil    ^cY#2335.htm##
00345000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704010700083002000900190#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#150#146#article#153#<br>   E-mai
l: <a href="mailto:cristiani@ensp.fiocruz.br">cristiani@ensp.fiocruz.br</a></fon
t></p>     ^cY#2335.htm##
00327000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704008900083002000900172#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#151#147#article#153#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Recebido: 9/6/2010    ^cY#233
5.htm##
00273000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003500083002000900118#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#152#148#article#153#<br>   Aprov
ado: 14/11/2010    ^cY#2335.htm##
00537000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704029900083002000900382#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#153#149#article#153#<br>   Pesqu
isa financiada pelo Conselho Nacional de Desenvolvimento Cient&iacute;fico    e 
Tecnol&oacute;gico (CNPq - Processo n. 565982/2008-7) e pela Funda&ccedil;&atild
e;o    de Apoio &agrave; Pesquisa do Estado do Rio de Janeiro (Faperj - Processo
 n.    E-26/102.283/2009). </font></p>     ^cY#2335.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#154#150#article#153#<p>&nbsp;</p
>     ^cY#2335.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#155#151#article#153#<p>&nbsp;</p
>     ^cY#2335.htm##
00400000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704016200083002000900245#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#156#152#article#153#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Salvador FGF foi    apoiada p
elo CNPq (bolsa de inicia&ccedil;&atilde;o cient&iacute;fica).    ^cY#2335.htm##
00722000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704048400083002000900567#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2335.htm#S#p#157#153#article#153#<br>   <a na
me="backa"></a><a href="#topa">a</a> Emergency Medical Services Systems    in th
e European Union: report of an assessment project coordinated by the World    He
alth Organization. Copenhagen: WHO Regional Office for Europe; 2008. &#91;citado
    2009 jul 8&#93;. Dispon&iacute;vel em: <a href="http://www.euro.who.int/__da
ta/assets/pdf_file/0016/114406/E92038.pdf" target="_blank">http://www.euro.who.i
nt/__data/assets/pdf_file/0016/114406/E92038.pdf</a></font></p>     ^cY#2335.htm
##
00607000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100019000820120063001010160
01500164016001500179018006900194066001500263062001300278065000900291064000500300
014000600305865000900311002000900320#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2335.htm#S#c#158#1#article#24#1#^rND^sAlmeida^nMHT#O Estado no Brasil con
temporâneo: um passeio pela história^lpt#^rED^sMelo^nCR#^rED^sSáez^nMA#A democra
cia brasileira: balanço e perspectivas para o século 21^lpt#Belo Horizonte#Edito
ra UFMG#20070000#2007#17-34#20110000#2335.htm##
00658000000000301000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100022000820100018001040120
11100122030001800233065000900251064000500260031000300265032000200268014000800270
237003200278865000900310002000900319035001000328801001800338#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2335.htm#S#c#159#2#article#24#2#^rND^sBittencourt
^nRJ#^rND^sHortale^nVA#Intervenções para solucionar a superlotação nos serviços 
de emergência hospitalar: uma revisão sistemática^lpt#Cad Saude Publica#20090000
#2009#25#7#1439-54#10.1590/S0102-311X2009000700002#20110000#2335.htm#0102-311X#C
ad Saude Publica##
00641000000000289000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100016001000120
13700116030002000253710000200273065000900275064000500284031000300289032000200292
014000700294237003200301865000900333002000900342#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2335.htm#S#c#160#3#article#24#3#^rND^sCabral^nAPS#^rND^sSouza
^nWV#Serviço de Atendimento Móvel de Urgência (Samu): análise da demanda e sua d
istribuição espacial em uma cidade do nordeste brasileiro^lpt#Rev Bras Epidemiol
.#2#20080000#2008#11#4#530-40#10.1590/S1415-790X2008000400002#20110000#2335.htm#
#
00672000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100016001000100
02000116012010200136030001800238065000900256064000500265031000300270032000200273
014000500275237003200280865000900312002000900321035001000330801001800340#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#161#4#article#24#4#^rND^
sCarret^nMLV#^rND^sFassa^nAG#^rND^sDomingues^nMR#Inappropriate use of emergency 
services: a systematic review of prevalence and associated factors^len#Cad Saude
 Publica#20090000#2009#25#1#7-28#10.1590/S0102-311X2009000100002#20110000#2335.h
tm#0102-311X#Cad Saude Publica##
00493000000000253000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820120077001000300
02000177710000200197065000900199064000500208032000300213014000500216865000900221
002000900230#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#162#
5#article#24#5#^rND^sChomatas^nM#Integração de saberes e práticas na organização
 do Samu de Curitiba - PR^lpt#Divulg Saude Debate#2#20050000#2005#32#90-5#201100
00#2335.htm##
00734000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100018001000100
01700118012013600135030002100271065000900292064000500301031000300306032000300309
014000700312237003200319865000900351002000900360035001000369801004100379#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#163#6#article#24#6#^rND^
sCiconet^nRM#^rND^sMarques^nGQ#^rND^sLima^nMADS#Educação em serviço para profiss
ionais do Serviço de Atendimento Móvel de Urgência (Samu): relato da experiência
 de Porto Alegre-RS^lpt#Interface (Botucatu)#20080000#2008#12#26#659-66#10.1590/
S1414-32832008000300016#20110000#2335.htm#1414-3283#Interface - Comunicação, Saú
de, Educação##
00735000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100022000820100018001040100
01700122012016000139030001800299065000900317064000500326031000300331032000200334
014000700336237003200343865000900375002000900384035001000393801001800403#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#164#7#article#24#7#^rND^
sEvangelista^nPA#^rND^sBarreto^nSM#^rND^sGuerra^nHL#Central de regulação de leit
os do SUS em Belo Horizonte, Minas Gerais: avaliação de seu papel pelo estudo da
s internações por doenças isquêmicas do coração^lpt#Cad Saude Publica#20080000#2
008#24#4#767-76#10.1590/S0102-311X2008000400006#20110000#2335.htm#0102-311X#Cad 
Saude Publica##
00480000000000229000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800160026000820180079001080660
01500187062001600202065000900218064000500227865000900232002000900241#2011nahead#
V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#165#8#article#24#8#^rND^sGig
lio-Jacquemot^nA#Urgências e emergências em saúde: perspectivas de profissionais
 e usuários^lpt#Rio de Janeiro#Editora Fiocruz#20050000#2005#20110000#2335.htm##
00463000000000241000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800160013000820160014000950180
05400109066000900163062001700172065000900189064000500198865000900203002000900212
#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#166#9#article#24
#9#^rND^sHam^nC#^rND^sHill^nM#The policy process in the modern capitalist state^
len#Brighton#Wheatsheaf Books#19840000#1984#20110000#2335.htm##
00441000000000241000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810160018000840180046001020630
00200148066000900150062000800159065000900167064000500176865000900181002000900190
#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#167#10#article#2
4#10#^rND^sKingdon^nJW#Agendas, alternatives and public policies^len#2#New York#
Longman#20030000#2003#20110000#2335.htm##
00659000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100015000840100018000990120
11800117030001800235065000900253064000500262031000300267032000200270014000700272
237003200279865000900311002000900320035001000329801001800339#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2335.htm#S#c#168#11#article#24#11#^rND^sLima^nJC#
^rND^sRivera^nFJU#Redes de conversação e coordenação de ações de saúde: estudo e
m um serviço móvel regional de atenção às urgências^lpt#Cad Saude Publica#201000
00#2010#26#2#323-36#10.1590/S0102-311X2010000200011#20110000#2335.htm#0102-311X#
Cad Saude Publica##
00589000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840120074001020300
01800176065000900194064000500203031000300208032000200211014000800213237003200221
865000900253002000900262035001000271801001800281#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2335.htm#S#c#169#12#article#24#12#^rND^sMachado^nCV#O modelo 
de intervenção do Ministério da Saúde brasileiro nos anos 90^lpt#Cad Saude Publi
ca#20070000#2007#23#9#2113-26#10.1590/S0102-311X2007000900019#20110000#2335.htm#
0102-311X#Cad Saude Publica##
00651000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100020001020120
10400122030001800226065000900244064000500253031000300258032000200261014000800263
237003200271865000900303002000900312035001000321801001800331#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2335.htm#S#c#170#13#article#24#13#^rND^sMinayo^nM
CS#^rND^sDeslandes^nSF#Análise da implantação do sistema de atendimento pré-hosp
italar móvel em cinco capitais brasileiras^lpt#Cad Saude Publica#20080000#2008#2
4#8#1877-86#10.1590/S0102-311X2008000800016#20110000#2335.htm#0102-311X#Cad Saud
e Publica##
00667000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100019001010100
01800120010002000138012014500158030001800303710000200321065000900323064000500332
031000200337032000200339014000600341865000900347002000900356#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2335.htm#S#c#171#14#article#24#14#^rND^sMorais^nD
A#^rND^sCarvalho^nDV#^rND^sTimerman^nS#^rND^sGonzalez^nMMC#Parada cardiorrespira
tória em ambiente pré-hospitalar: ocorrências atendidas pela Serviço de Atendime
nto Móvel de Urgência de Belo Horizonte^lpt#Rev Bras Clin Med#2#20090000#2009#7#
4#211-8#20110000#2335.htm##
00464000000000229000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810160017000840180064001010660
01000165062002700175065000900202064000500211865000900216002000900225#2011nahead#
V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#172#15#article#24#15#^rND^sP
ierson^nP#Politics in time: history, institutions and social analysis^len#Prince
ton#Princeton University Press#20040000#2004#20110000#2335.htm##
00616000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840120105001000300
01800205065000900223064000500232031000300237032000200240014000600242237003200248
865000900280002000900289035001000298801001800308#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2335.htm#S#c#173#16#article#24#16#^rND^sPinet^nLM#Atención pr
ehospitalaria de urgencias en el Distrito Federal: las oportunidades del sistema
 de salud^les#Salud Publica Mex#20050000#2005#47#1#64-71#10.1590/S0036-363420050
00100010#20110000#2335.htm#0036-3634#Salud Publica Mex##
00635000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100014001010100
01700115010001600132012007600148030001500224710000200239065000900241064000500250
031000300255032000200258014000700260237003600267865000900303002000900312#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#174#17#article#24#17#^rN
D^sPozner^nCN#^rND^sZane^nR#^rND^sNelson^nSJ#^rND^sLevine^nM#International EMS s
ystems: the United States: past, present and, future^len#Resuscitation.#2#200400
00#2004#60#3#239-44#10.1016/j.resuscitation.2003.11.004#20110000#2335.htm##
00645000000000301000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100019001020120
09900121030001800220065000900238064000500247031000300252032000200255014000800257
237003200265865000900297002000900306035001000315801001800325#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2335.htm#S#c#175#18#article#24#18#^rND^sPuccini^n
PT#^rND^sCornetta^nVK#Ocorrências em pronto-socorro: eventos sentinela para moni
toramento da atenção básica de saúde^lpt#Cad Saude Publica#20080000#2008#24#9#20
32-42#10.1590/S0102-311X2008000900009#20110000#2335.htm#0102-311X#Cad Saude Publ
ica##
00437000000000241000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810160019000840180035001030630
00200138066000800140062001500148065000900163064000500172865000900177002000900186
#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#176#19#article#2
4#19#^rED^sSabatier^nPA#Theories of the policy process^len#2#Boulder#Westview Pr
ess#20070000#2007#20110000#2335.htm##
00766000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100020001010100
02200121010001700143010002000160010001400180012017000194030002600364710000200390
06500090039206400050040103100030040603200040040901400090041386500090042200200090
0431#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#177#20#artic
le#24#20#^rND^sSantos^nJS#^rND^sScarpelini^nS#^rND^sBrasileiro^nSLL#^rND^sFerraz
^nCA#^rND^sDallora^nMELV#^rND^sSá^nMFP#Avaliação do modelo de organização da Uni
dade de Emergência do HCFMRP-USP, adotando, como referência, as políticas nacion
ais de atenção às urgências e de humanização^lpt#Medicina (Ribeirao Preto)#2#200
30000#2003#36#2/4#498- 515#20110000#2335.htm##
00497000000000265000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100020000840120055001040300
02600159710000200185065000900187064000500196031000300201032000200204014000700206
865000900213002000900222#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.
htm#S#c#178#21#article#24#21#^rND^sScarpelini^nS#A organização do atendimento às
 urgências e trauma^lpt#Medicina (Ribeirao Preto)#2#20070000#2007#40#3#315-20#20
110000#2335.htm##
00636000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100020000840100017001040100
02400121010001800145012004200163030001400205065000900219064000500228031000300233
03200020023601400060023823700240024486500090026800200090027703500100028680100140
0296#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#179#22#artic
le#24#22#^rND^sTannebaum^nRD#^rND^sArnold^nJL#^rND^sDe Negri Filho^nA#^rND^sSpad
oni^nVS#Emergency medicine in Southern Brazil^len#Ann Emerg Med#20010000#2001#37
#2#223-8#10.1067/mem.2001.112252#20110000#2335.htm#0196-0644#Ann Emerg Med##
00606000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100016001020120
10100118030002000219710000200239065000900241064000500250031000300255032000200258
014000600260237003200266865000900298002000900307#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2335.htm#S#c#180#23#article#24#23#^rND^sVieira^nCMS#^rND^sMus
si^nFC#A implantação do Projeto de Atendimento Móvel de Urgência em Salvador/Bah
ia: panorama e desafios^lpt#Rev Esc Enferm USP.#2#20080000#2008#42#4#793-7#10.15
90/S0080-62342008000400024#20110000#2335.htm##
00460000000000229000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810160014000840180056000980660
01300154062003100167065000900198064000500207865000900212002000900221#2011nahead#
V:\SciELO\serial\rsp\2011nahead\markup\2335.htm#S#c#181#24#article#24#24#^rND^sW
alt^nG#Health policy: an introduction to process and power^len#Johannesburg#Witw
atersrand University Press#19940000#1994#20110000#2335.htm##
00276000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00400102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#o#1#1#arti
cle#1#20110408#160449#2352.htm#169##
06536000000000805000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000300095121000300098049000300101158000300104030001900107
03200060012606500090013201400070014103500100014822300090015801200930016701200880
02600120094003480100033004420100032004750100042005070100038005490100032005870100
03900619070013800658070006800796070006300864083136800927085001002295085002402305
08500330232908500190236208500210238108500360240208314180243808500100385608500230
38660850029038890850018039180850023039360850034039590831461039930850010054540850
02405464085003305488085001905521085002105540085003705561117000805598072000305606
11200090560911100100561811400090562811300100563705800620564706000120570900200090
5721#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#h#2#1#article#
1#oa#pt#br1.1#1#4.0#ND#23#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0#0034-89
10#20110415#Determinantes do consumo de frutas e hortaliças em adolescentes por 
regressão quantílica^lpt#Determinants of fruit and vegetable intake in adolescen
ts using quantile regression^len#Determinantes del consumo de frutas y hortaliza
s en adolescentes por regresión cuantílica^les#^rND^1A01^nRoberta Schein^sBigio#
^rND^1A01^nEliseu^sVerly Junior#^rND^1A01^nMichelle Alessandra de^sCastro#^rND^1
A02^nChester Luiz Galvão^sCésar#^rND^1A03^nRegina Mara^sFisberg#^rND^1A03^nDirce
 Maria Lobo^sMarchioni#Universidade de São Paulo^iA01^1Faculdade de Saúde Públic
a^2Programa de Pós-Graduação em Nutrição em Saúde Pública^cSão Paulo^sSP^pBrasil
#USP^iA02^1FSP^2Departamento de Epidemiologia^cSão Paulo^sSP^pBrasil#USP^iA03^1F
SP^2Departamento de Nutrição^cSão Paulo^sSP^pBrasil#^lpt^aOBJETIVO: Analisar o c
onsumo de frutas, legumes e verduras (FLV) de adolescentes e identificar fatores
 associados. MÉTODOS: Estudo transversal de base populacional com amostra repres
entativa de 812 adolescentes de ambos os sexos de São Paulo, SP, em 2003. O cons
umo alimentar foi medido pelo recordatório alimentar de 24 horas. O consumo de F
LV foi descrito em percentis e para investigar a associação entre a ingestão de 
FLV e variáveis explanatórias; foram utilizados modelos de regressão quantílica.
 RESULTADOS: Dos adolescentes entrevistados, 6,4% consumiram a recomendação míni
ma de 400 g/dia de FLV e 22% não consumiram nenhum tipo de FLV. Nos modelos de r
egressão quantílica, ajustados pelo consumo energético, faixa etária e sexo, a r
enda domiciliar per capita e a escolaridade do chefe de família associaram-se po
sitivamente ao consumo de FLV, enquanto o hábito de fumar associou-se negativame
nte. Renda associou-se significativamente aos menores percentis de ingestão (p20
 ao p55); tabagismo aos percentis intermediários (p45 ao p75) e escolaridade do 
chefe de família aos percentis finais de consumo de FLV (p70 ao p95). CONCLUSÕES
: O consumo de FLV por adolescentes paulistanos mostrou-se abaixo das recomendaç
ões do Ministério da Saúde e é influenciado pela renda domiciliar per capita, pe
la escolaridade do chefe de família e pelo hábito de fumar.#^ddecs^i1#^tm^lpt^kA
dolescente^i1#^tm^lpt^kConsumo de Alimentos^i1#^tm^lpt^kFrutas^i1#^tm^lpt^kVerdu
ras^i1#^tm^lpt^kFatores Socioeconômicos^i1#^len^aOBJECTIVE: To analyze fruit and
 vegetable intake in adolescents and to identify associated factors. METHODS: A 
population-based cross-sectional study was conducted with a representative sampl
e of 812 adolescents of both sexes in the city of São Paulo, Southeastern Brazil
, in 2003. Food consumption was measured with the 24-hour dietary recall. Fruit 
and vegetable intake was described in percentiles. Quantile regression models we
re used to investigate the association between this intake and explanatory varia
bles. RESULTS: Of all adolescents interviewed, 6.4% consumed the minimum recomme
ndation of 400 g/day of fruits and vegetables and 22% did not consume any type o
f fruits and vegetables. According to quantile regression models, adjusted for e
nergy intake, age group and sex, per capita household income and head of househo
ld's level of education were positively associated with fruit and vegetable inta
ke, whereas smoking habit showed a negative association. Income was significantl
y associated with lower intake percentiles (p20 to p55); smoking, with intermedi
ate percentiles (p45 to p75); and head of household's level of education, with h
igher percentiles (p70 to 95). CONCLUSIONS: Fruit and vegetable intake among ado
lescents of São Paulo was below the Ministry of Health's recommendations and it 
is influenced by per capita household income, head of family's level of educatio
n and smoking habit.#^ddecs^i2#^tm^len^kAdolescent^i2#^tm^len^kFood Consumption^
i2#^tm^len^kFruit^i2#^tm^len^kVegetables^i2#^tm^len^kSocioeconomic Factors^i2#^l
es^aOBJETIVO: Analizar el consumo de frutas, legumbres y verduras (FLV) de adole
scentes e identificar factores asociados. MÉTODOS: Estudio transversal de base p
oblacional con muestra representativa de 812 adolescentes de ambos sexos de Sao 
Paulo, Sureste de Brasil, en 2003. El consumo alimentario fue medido por el reco
rdatorio alimentario de 24 horas. El consumo de FLV fue descrito en percentiles 
y para investigar la asociación entre la ingestión de FLV y variables explicativ
as fueron utilizados modelos de regresión cuantílica. RESULTADOS: De los adolesc
entes entrevistados, 6,4% consumieron la recomendación mínima de 400g/día de FLV
 y 22% no consumieron ningún tipo de FLV. En los modelos de regresión cuantílica
, ajustados por el consumo energético, el intervalo etario y sexo, la renta domi
ciliar per capita y la escolaridad del jefe de familia se asociaron positivament
e al consumo de FLV, mientras que el hábito de fumar se asoció negativamente. Re
nta se asoció significativamente a los menores percentiles de ingestión (p20 al 
p55); tabaquismo a los percentiles intermediarios (p45 al p75) y escolaridad del
 jefe de familia a los percentiles finales de consumo de FLV (p70 al p95). CONCL
USIONES: El consumo de FLV por adolescentes de Sao Paulo se mostró por debajo de
 las recomendaciones del Ministerio de la Salud Brasileño y es influenciado por 
la renta domiciliaria per capita, por la escolaridad del jefe de familia y por e
l hábito de fumar.#^ddecs^i3#^tm^les^kAdolescente^i3#^tm^les^kConsumo de Aliment
os^i3#^tm^les^kFrutas^i3#^tm^les^kVerduras^i3#^tm^les^kFactores Socioeconómicos^
i3#vancouv#29#20100615#15/6/2010#20101208#8/12/2010#Conselho Nacional de Desenvo
lvimento Científico e Tecnológico#402111.05-2#2352.htm##
06727000000000805000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000300095121000300098049000300101158000300104030001900107
03200060012606500090013201400070014103500100014822300090015801201000016701200950
02670120101003620100033004630100032004960100042005280100038005700100032006080100
03900640070013800679070006800817070006300885083141000948085001002358085002402368
08500330239208500190242508500210244408500360246508314460250108500100394708500230
39570850029039800850018040090850023040270850034040500831503040840850010055870850
02405597085003305621085001905654085002105673085003705694117000805731072000305739
11200090574211100100575111400090576111300100577005800620578006000700584200200090
5912#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#f#3#1#article#
1#oa#pt#br1.1#1#4.0#ND#23#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0#0034-89
10#20110415#<b>Determinantes do consumo de frutas e hortaliças em adolescentes p
or regressão quantílica</b>^lpt#<b>Determinants of fruit and vegetable intake in
 adolescents using quantile regression</b>^len#<b>Determinantes del consumo de f
rutas y hortalizas en adolescentes por regresión cuantílica</b>^les#^rND^1A01^nR
oberta Schein^sBigio#^rND^1A01^nEliseu^sVerly Junior#^rND^1A01^nMichelle Alessan
dra de^sCastro#^rND^1A02^nChester Luiz Galvão^sCésar#^rND^1A03^nRegina Mara^sFis
berg#^rND^1A03^nDirce Maria Lobo^sMarchioni#Universidade de São Paulo^iA01^1Facu
ldade de Saúde Pública^2Programa de Pós-Graduação em Nutrição em Saúde Pública^c
São Paulo^sSP^pBrasil#USP^iA02^1FSP^2Departamento de Epidemiologia^cSão Paulo^sS
P^pBrasil#USP^iA03^1FSP^2Departamento de Nutrição^cSão Paulo^sSP^pBrasil#^lpt^a<
b>OBJETIVO:</b> Analisar o consumo de frutas, legumes e verduras (FLV) de adoles
centes e identificar fatores associados. <b>MÉTODOS:</b> Estudo transversal de b
ase populacional com amostra representativa de 812 adolescentes de ambos os sexo
s de São Paulo, SP, em 2003. O consumo alimentar foi medido pelo recordatório al
imentar de 24 horas. O consumo de FLV foi descrito em percentis e para investiga
r a associação entre a ingestão de FLV e variáveis explanatórias; foram utilizad
os modelos de regressão quantílica. <b>RESULTADOS:</b> Dos adolescentes entrevis
tados, 6,4% consumiram a recomendação mínima de 400 g/dia de FLV e 22% não consu
miram nenhum tipo de FLV. Nos modelos de regressão quantílica, ajustados pelo co
nsumo energético, faixa etária e sexo, a renda domiciliar <i>per capita</i> e a 
escolaridade do chefe de família associaram-se positivamente ao consumo de FLV, 
enquanto o hábito de fumar associou-se negativamente. Renda associou-se signific
ativamente aos menores percentis de ingestão (p20 ao p55); tabagismo aos percent
is intermediários (p45 ao p75) e escolaridade do chefe de família aos percentis 
finais de consumo de FLV (p70 ao p95). <b>CONCLUSÕES:</b> O consumo de FLV por a
dolescentes paulistanos mostrou-se abaixo das recomendações do Ministério da Saú
de e é influenciado pela renda domiciliar <i>per capita,</i> pela escolaridade d
o chefe de família e pelo hábito de fumar.#^ddecs^i1#^tm^lpt^kAdolescente^i1#^tm
^lpt^kConsumo de Alimentos^i1#^tm^lpt^kFrutas^i1#^tm^lpt^kVerduras^i1#^tm^lpt^kF
atores Socioeconômicos^i1#^len^a<b>OBJECTIVE:</b> To analyze fruit and vegetable
 intake in adolescents and to identify associated factors. <b>METHODS:</b> A pop
ulation-based cross-sectional study was conducted with a representative sample o
f 812 adolescents of both sexes in the city of São Paulo, Southeastern Brazil, i
n 2003. Food consumption was measured with the 24-hour dietary recall. Fruit and
 vegetable intake was described in percentiles. Quantile regression models were 
used to investigate the association between this intake and explanatory variable
s. <b>RESULTS:</b> Of all adolescents interviewed, 6.4% consumed the minimum rec
ommendation of 400 g/day of fruits and vegetables and 22% did not consume any ty
pe of fruits and vegetables. According to quantile regression models, adjusted f
or energy intake, age group and sex, per capita household income and head of hou
sehold's level of education were positively associated with fruit and vegetable 
intake, whereas smoking habit showed a negative association. Income was signific
antly associated with lower intake percentiles (p20 to p55); smoking, with inter
mediate percentiles (p45 to p75); and head of household's level of education, wi
th higher percentiles (p70 to 95). <b>CONCLUSIONS:</b> Fruit and vegetable intak
e among adolescents of São Paulo was below the Ministry of Health's recommendati
ons and it is influenced by per capita household income, head of family's level 
of education and smoking habit.#^ddecs^i2#^tm^len^kAdolescent^i2#^tm^len^kFood C
onsumption^i2#^tm^len^kFruit^i2#^tm^len^kVegetables^i2#^tm^len^kSocioeconomic Fa
ctors^i2#^les^a<b>OBJETIVO:</b> Analizar el consumo de frutas, legumbres y verdu
ras (FLV) de adolescentes e identificar factores asociados. <b>MÉTODOS:</b> Estu
dio transversal de base poblacional con muestra representativa de 812 adolescent
es de ambos sexos de Sao Paulo, Sureste de Brasil, en 2003. El consumo alimentar
io fue medido por el recordatorio alimentario de 24 horas. El consumo de FLV fue
 descrito en percentiles y para investigar la asociación entre la ingestión de F
LV y variables explicativas fueron utilizados modelos de regresión cuantílica. <
b>RESULTADOS:</b> De los adolescentes entrevistados, 6,4% consumieron la recomen
dación mínima de 400g/día de FLV y 22% no consumieron ningún tipo de FLV. En los
 modelos de regresión cuantílica, ajustados por el consumo energético, el interv
alo etario y sexo, la renta domiciliar <i>per capita</i> y la escolaridad del je
fe de familia se asociaron positivamente al consumo de FLV, mientras que el hábi
to de fumar se asoció negativamente. Renta se asoció significativamente a los me
nores percentiles de ingestión (p20 al p55); tabaquismo a los percentiles interm
ediarios (p45 al p75) y escolaridad del jefe de familia a los percentiles finale
s de consumo de FLV (p70 al p95). <b>CONCLUSIONES:</b> El consumo de FLV por ado
lescentes de Sao Paulo se mostró por debajo de las recomendaciones del Ministeri
o de la Salud Brasileño y es influenciado por la renta domiciliaria <i>per capit
a</i>, por la escolaridad del jefe de familia y por el hábito de fumar.#^ddecs^i
3#^tm^les^kAdolescente^i3#^tm^les^kConsumo de Alimentos^i3#^tm^les^kFrutas^i3#^t
m^les^kVerduras^i3#^tm^les^kFactores Socioeconómicos^i3#vancouv#29#20100615#15/6
/2010#20101208#8/12/2010#Conselho Nacional de Desenvolvimento Científico e Tecno
lógico#<span style='font-size:10.0pt;font-family:Verdana'>402111.05-2</span>#235
2.htm##
06699000000000817000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098121000300102049000300105158000300108030001900111
03200060013006500090013601400070014503500100015222300090016201200930017101200880
02640120094003520100033004460100032004790100042005110100038005530100032005910100
03900623070014000662070007000802070006500872083138600937085001002323085002402333
08500330235708500190239008500210240908500360243008314320246608500100389808500230
39080850029039310850018039600850023039780850034040010831481040350850010055160850
02405526085003305550085001905583085002105602085003705623117000805660072000305668
11200090567111100100568011400090569011300100569905800620570906000120577100200090
5783008008905792#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#l#
4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#23#nd#nd#Rev. saúde pública#ahead#2011000
0#^f0^l0#0034-8910#20110415#Determinantes do consumo de frutas e hortaliças em a
dolescentes por regressão quantílica^lpt#Determinants of fruit and vegetable int
ake in adolescents using quantile regression^len#Determinantes del consumo de fr
utas y hortalizas en adolescentes por regresión cuantílica^les#^rND^1A01^nRobert
a Schein^sBigio#^rND^1A01^nEliseu^sVerly Junior#^rND^1A01^nMichelle Alessandra d
e^sCastro#^rND^1A02^nChester Luiz Galvão^sCésar#^rND^1A03^nRegina Mara^sFisberg#
^rND^1A03^nDirce Maria Lobo^sMarchioni#^iA01^1Universidade de São Paulo^2Faculda
de de Saúde Pública^3Programa de Pós-Graduação em Nutrição em Saúde Pública^cSão
 Paulo^sSP^pBrasil#^iA02^1USP^2FSP^3Departamento de Epidemiologia^cSão Paulo^sSP
^pBrasil#^iA03^1USP^2FSP^3Departamento de Nutrição^cSão Paulo^sSP^pBrasil#^lpt^a
OBJETIVO: Analisar o consumo de frutas, legumes e verduras (FLV) de adolescentes
 e identificar fatores associados. MÉTODOS: Estudo transversal de base populacio
nal com amostra representativa de 812 adolescentes de ambos os sexos de São Paul
o, SP, em 2003. O consumo alimentar foi medido pelo recordatório alimentar de 24
 horas. O consumo de FLV foi descrito em percentis e para investigar a associaçã
o entre a ingestão de FLV e variáveis explanatórias; foram utilizados modelos de
 regressão quantílica. RESULTADOS: Dos adolescentes entrevistados, 6,4 por cento
 consumiram a recomendação mínima de 400 g/dia de FLV e 22 por cento não consumi
ram nenhum tipo de FLV. Nos modelos de regressão quantílica, ajustados pelo cons
umo energético, faixa etária e sexo, a renda domiciliar per capita e a escolarid
ade do chefe de família associaram-se positivamente ao consumo de FLV, enquanto 
o hábito de fumar associou-se negativamente. Renda associou-se significativament
e aos menores percentis de ingestão (p20 ao p55); tabagismo aos percentis interm
ediários (p45 ao p75) e escolaridade do chefe de família aos percentis finais de
 consumo de FLV (p70 ao p95). CONCLUSÕES: O consumo de FLV por adolescentes paul
istanos mostrou-se abaixo das recomendações do Ministério da Saúde e é influenci
ado pela renda domiciliar per capita, pela escolaridade do chefe de família e pe
lo hábito de fumar.#^ddecs^i1#^tm^lpt^kAdolescente^i1#^tm^lpt^kConsumo de Alimen
tos^i1#^tm^lpt^kFrutas^i1#^tm^lpt^kVerduras^i1#^tm^lpt^kFatores Socioeconômicos^
i1#^len^aOBJECTIVE: To analyze fruit and vegetable intake in adolescents and to 
identify associated factors. METHODS: A population-based cross-sectional study w
as conducted with a representative sample of 812 adolescents of both sexes in th
e city of São Paulo, Southeastern Brazil, in 2003. Food consumption was measured
 with the 24-hour dietary recall. Fruit and vegetable intake was described in pe
rcentiles. Quantile regression models were used to investigate the association b
etween this intake and explanatory variables. RESULTS: Of all adolescents interv
iewed, 6.4 percent consumed the minimum recommendation of 400 g/day of fruits an
d vegetables and 22 percent did not consume any type of fruits and vegetables. A
ccording to quantile regression models, adjusted for energy intake, age group an
d sex, per capita household income and head of household's level of education we
re positively associated with fruit and vegetable intake, whereas smoking habit 
showed a negative association. Income was significantly associated with lower in
take percentiles (p20 to p55); smoking, with intermediate percentiles (p45 to p7
5); and head of household's level of education, with higher percentiles (p70 to 
95). CONCLUSIONS: Fruit and vegetable intake among adolescents of São Paulo was 
below the Ministry of Health's recommendations and it is influenced by per capit
a household income, head of family's level of education and smoking habit.#^ddec
s^i2#^tm^len^kAdolescent^i2#^tm^len^kFood Consumption^i2#^tm^len^kFruit^i2#^tm^l
en^kVegetables^i2#^tm^len^kSocioeconomic Factors^i2#^les^aOBJETIVO: Analizar el 
consumo de frutas, legumbres y verduras (FLV) de adolescentes e identificar fact
ores asociados. MÉTODOS: Estudio transversal de base poblacional con muestra rep
resentativa de 812 adolescentes de ambos sexos de Sao Paulo, Sureste de Brasil, 
en 2003. El consumo alimentario fue medido por el recordatorio alimentario de 24
 horas. El consumo de FLV fue descrito en percentiles y para investigar la asoci
ación entre la ingestión de FLV y variables explicativas fueron utilizados model
os de regresión cuantílica. RESULTADOS: De los adolescentes entrevistados, 6,4 p
or ciento consumieron la recomendación mínima de 400g/día de FLV y 22 por ciento
 no consumieron ningún tipo de FLV. En los modelos de regresión cuantílica, ajus
tados por el consumo energético, el intervalo etario y sexo, la renta domiciliar
 per capita y la escolaridad del jefe de familia se asociaron positivamente al c
onsumo de FLV, mientras que el hábito de fumar se asoció negativamente. Renta se
 asoció significativamente a los menores percentiles de ingestión (p20 al p55); 
tabaquismo a los percentiles intermediarios (p45 al p75) y escolaridad del jefe 
de familia a los percentiles finales de consumo de FLV (p70 al p95). CONCLUSIONE
S: El consumo de FLV por adolescentes de Sao Paulo se mostró por debajo de las r
ecomendaciones del Ministerio de la Salud Brasileño y es influenciado por la ren
ta domiciliaria per capita, por la escolaridad del jefe de familia y por el hábi
to de fumar.#^ddecs^i3#^tm^les^kAdolescente^i3#^tm^les^kConsumo de Alimentos^i3#
^tm^les^kFrutas^i3#^tm^les^kVerduras^i3#^tm^les^kFactores Socioeconómicos^i3#van
couv#29#20100615#15/6/2010#20101208#8/12/2010#Conselho Nacional de Desenvolvimen
to Científico e Tecnológico#402111.05-2#2352.htm#Internet^ihttp://www.scielo.br/
scielo.php?script=sci_arttext&pid=S0034-89102011005000023##
00458000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704022400079002000900303#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#5#1#article#136#<p><a name="top"
></a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Determinante
s    do consumo de frutas e hortali&ccedil;as em adolescentes por regress&atilde
;o    quant&iacute;lica</b> </font></p>     ^cY#2352.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#6#2#article#136#<p>&nbsp;</p>   
  ^cY#2352.htm##
00410000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704017600079002000900255#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#7#3#article#136#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Determinants    of fruit and v
egetable intake in adolescents using quantile regression</b></font></p>     ^cY#
2352.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#8#4#article#136#<p>&nbsp;</p>   
  ^cY#2352.htm##
00430000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000400075704019600079002000900275#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#9#5#article#136#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="3"><b>Determinantes    del consumo d
e frutas y hortalizas en adolescentes por regresi&oacute;n cuant&iacute;lica</b>
</font></p>     ^cY#2352.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#10#6#article#136#<p>&nbsp;</p>  
   ^cY#2352.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#11#7#article#136#<p>&nbsp;</p>  
   ^cY#2352.htm##
00573000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704033800080002000900418#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#12#8#article#136#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Roberta Schein    Bigio<sup>I
</sup>; Eliseu Verly Junior<sup>I</sup>; Michelle Alessandra de Castro<sup>I</su
p>;    Chester Luiz Galv&atilde;o C&eacute;sar<sup>II</sup>; Regina Mara Fisberg
<sup>III</sup>;    Dirce Maria Lobo Marchioni<sup>III</sup></b></font></p>     ^
cY#2352.htm##
00548000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000400076704031300080002000900393#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#13#9#article#136#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Programa    de P&oac
ute;s-Gradua&ccedil;&atilde;o em Nutri&ccedil;&atilde;o em Sa&uacute;de    P&uac
ute;blica. Faculdade de Sa&uacute;de P&uacute;blica (FSP). Universidade    de S&
atilde;o Paulo (USP). S&atilde;o Paulo, SP, Brasil    ^cY#2352.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#14#10#article#136#<br>   <sup>II
</sup>Departamento de Epidemiologia. FSP-USP. S&atilde;o Paulo, SP, Brasil    ^c
Y#2352.htm##
00357000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704012100081002000900202#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#15#11#article#136#<br>   <sup>II
I</sup>Departamento de Nutri&ccedil;&atilde;o. FSP-USP. S&atilde;o Paulo,    SP,
 Brasil</font></p>     ^cY#2352.htm##
00380000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704014400081002000900225#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#16#12#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecir
c;ncia    | Correspondence</a></font></p>     ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#17#13#article#136#<p>&nbsp;</p> 
    ^cY#2352.htm##
00280000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704004400081002000900125#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#18#14#article#136#<p>&nbsp;</p> 
<hr size="1" noshade>     ^cY#2352.htm##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009600081002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#19#15#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^c
Y#2352.htm##
00434000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704019800081002000900279#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#20#16#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analisar o 
consumo de frutas, legumes e verduras (FLV) de adolescentes e identificar    fat
ores associados.    ^cY#2352.htm##
00730000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704049400081002000900575#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#21#17#article#136#<br>   <b>M&Ea
cute;TODOS:</b> Estudo transversal de base populacional com amostra representati
va    de 812 adolescentes de ambos os sexos de S&atilde;o Paulo, SP, em 2003. O 
consumo    alimentar foi medido pelo recordat&oacute;rio alimentar de 24 horas. 
O consumo    de FLV foi descrito em percentis e para investigar a associa&ccedil
;&atilde;o    entre a ingest&atilde;o de FLV e vari&aacute;veis explanat&oacute;
rias; foram    utilizados modelos de regress&atilde;o quant&iacute;lica.    ^cY#
2352.htm##
01008000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704077200081002000900853#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#22#18#article#136#<br>   <b>RESU
LTADOS:</b> Dos adolescentes entrevistados, 6,4% consumiram a recomenda&ccedil;&
atilde;o    m&iacute;nima de 400 g/dia de FLV e 22% n&atilde;o consumiram nenhum
 tipo de    FLV. Nos modelos de regress&atilde;o quant&iacute;lica, ajustados pe
lo consumo    energ&eacute;tico, faixa et&aacute;ria e sexo, a renda domiciliar 
<i>per capita</i>    e a escolaridade do chefe de fam&iacute;lia associaram-se p
ositivamente ao consumo    de FLV, enquanto o h&aacute;bito de fumar associou-se
 negativamente. Renda associou-se    significativamente aos menores percentis de
 ingest&atilde;o (p20 ao p55); tabagismo    aos percentis intermedi&aacute;rios 
(p45 ao p75) e escolaridade do chefe de    fam&iacute;lia aos percentis finais d
e consumo de FLV (p70 ao p95).    ^cY#2352.htm##
00571000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704033500081002000900416#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#23#19#article#136#<br>   <b>CONC
LUS&Otilde;ES:</b> O consumo de FLV por adolescentes paulistanos mostrou-se    a
baixo das recomenda&ccedil;&otilde;es do Minist&eacute;rio da Sa&uacute;de    e 
&eacute; influenciado pela renda domiciliar <i>per capita,</i> pela escolaridade
    do chefe de fam&iacute;lia e pelo h&aacute;bito de fumar.</font></p>     ^cY
#2352.htm##
00447000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704021100081002000900292#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#24#20#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>DESCRITORES:</b>    Adolesce
nte. Consumo de Alimentos. Frutas. Verduras. Fatores Socioecon&ocirc;micos.</fon
t></p> <hr size="1" noshade>     ^cY#2352.htm##
00334000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009800081002000900179#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#25#21#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     
^cY#2352.htm##
00419000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704018300081002000900264#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#26#22#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJECTIVE:</b>    To analyze
 fruit and vegetable intake in adolescents and to identify associated    factors
.    ^cY#2352.htm##
00696000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704046000081002000900541#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#27#23#article#136#<br>   <b>METH
ODS:</b> A population-based cross-sectional study was conducted with    a repres
entative sample of 812 adolescents of both sexes in the city of S&atilde;o    Pa
ulo, Southeastern Brazil, in 2003. Food consumption was measured with the    24-
hour dietary recall. Fruit and vegetable intake was described in percentiles.   
 Quantile regression models were used to investigate the association between    
this intake and explanatory variables.    ^cY#2352.htm##
00946000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704071000081002000900791#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#28#24#article#136#<br>   <b>RESU
LTS:</b> Of all adolescents interviewed, 6.4% consumed the minimum recommendatio
n    of 400 g/day of fruits and vegetables and 22% did not consume any type of f
ruits    and vegetables. According to quantile regression models, adjusted for e
nergy    intake, age group and sex, per capita household income and head of hous
ehold's    level of education were positively associated with fruit and vegetabl
e intake,    whereas smoking habit showed a negative association. Income was sig
nificantly    associated with lower intake percentiles (p20 to p55); smoking, wi
th intermediate    percentiles (p45 to p75); and head of household's level of ed
ucation, with higher    percentiles (p70 to 95).    ^cY#2352.htm##
00515000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704027900081002000900360#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#29#25#article#136#<br>   <b>CONC
LUSIONS:</b> Fruit and vegetable intake among adolescents of S&atilde;o    Paulo
 was below the Ministry of Health's recommendations and it is influenced    by p
er capita household income, head of family's level of education and smoking    h
abit.</font></p>     ^cY#2352.htm##
00435000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704019900081002000900280#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#30#26#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:</b>    Adolesce
nt. Food Consumption. Fruit. Vegetables. Socioeconomic Factors.</font></p> <hr s
ize="1" noshade>     ^cY#2352.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704009700081002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#31#27#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^
cY#2352.htm##
00437000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020100081002000900282#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#32#28#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>OBJETIVO:</b>    Analizar el
 consumo de frutas, legumbres y verduras (FLV) de adolescentes e    identificar 
factores asociados.    ^cY#2352.htm##
00719000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704048300081002000900564#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#33#29#article#136#<br>   <b>M&Ea
cute;TODOS:</b> Estudio transversal de base poblacional con muestra representati
va    de 812 adolescentes de ambos sexos de Sao Paulo, Sureste de Brasil, en 200
3.    El consumo alimentario fue medido por el recordatorio alimentario de 24 ho
ras.    El consumo de FLV fue descrito en percentiles y para investigar la asoci
aci&oacute;n    entre la ingesti&oacute;n de FLV y variables explicativas fueron
 utilizados    modelos de regresi&oacute;n cuant&iacute;lica.    ^cY#2352.htm##
01026000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704079000081002000900871#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#34#30#article#136#<br>   <b>RESU
LTADOS:</b> De los adolescentes entrevistados, 6,4% consumieron la recomendaci&o
acute;n    m&iacute;nima de 400g/d&iacute;a de FLV y 22% no consumieron ning&uac
ute;n tipo    de FLV. En los modelos de regresi&oacute;n cuant&iacute;lica, ajus
tados por    el consumo energ&eacute;tico, el intervalo etario y sexo, la renta 
domiciliar    <i>per capita</i> y la escolaridad del jefe de familia se asociaro
n positivamente    al consumo de FLV, mientras que el h&aacute;bito de fumar se 
asoci&oacute; negativamente.    Renta se asoci&oacute; significativamente a los 
menores percentiles de ingesti&oacute;n    (p20 al p55); tabaquismo a los percen
tiles intermediarios (p45 al p75) y escolaridad    del jefe de familia a los per
centiles finales de consumo de FLV (p70 al p95).    ^cY#2352.htm##
00570000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704033400081002000900415#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#35#31#article#136#<br>   <b>CONC
LUSIONES:</b> El consumo de FLV por adolescentes de Sao Paulo se mostr&oacute;  
  por debajo de las recomendaciones del Ministerio de la Salud Brasile&ntilde;o 
   y es influenciado por la renta domiciliaria <i>per capita</i>, por la escolar
idad    del jefe de familia y por el h&aacute;bito de fumar.</font></p>     ^cY#
2352.htm##
00450000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704021400081002000900295#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#36#32#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:</b>    Adolesc
ente. Consumo de Alimentos. Frutas. Verduras. Factores Socioecon&oacute;micos.</
font></p> <hr size="1" noshade>     ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#37#33#article#136#<p>&nbsp;</p> 
    ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#38#34#article#136#<p>&nbsp;</p> 
    ^cY#2352.htm##
00350000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704011400081002000900195#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#39#35#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b>
</font></p>     ^cY#2352.htm##
01022000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704078600081002000900867#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#40#36#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A tr&iacute;ade    frutas, legu
mes e verduras (FLV) &eacute; amplamente reconhecida por sua relev&acirc;ncia   
 &agrave; sa&uacute;de humana<a name="topa"></a><a href="#backa">ª</a> e seu    
consumo parece exercer efeito protetor sobre o risco de obesidade,<sup>2</sup>  
  diabetes <i>mellitus</i> tipo II,<sup>2</sup> doen&ccedil;as cardiovasculares<
sup>12</sup>    e alguns tipos de c&acirc;ncer.<sup>28,29</sup> Estimativas da O
rganiza&ccedil;&atilde;o    Mundial da Sa&uacute;de (OMS) apontam que cerca de 2
,7 milh&otilde;es das mortes    mundiais registradas em 2000 poderiam ter sido e
vitadas com o consumo adequado    de FLV, o que reduziria em 1,8% a carga global
 de doen&ccedil;as.<sup>18</sup></font></p>     ^cY#2352.htm##
00627000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704039100081002000900472#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#41#37#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Como estrat&eacute;gia    de pr
even&ccedil;&atilde;o &agrave;s doen&ccedil;as cr&ocirc;nicas n&atilde;o-transmi
ss&iacute;veis,    a OMS e o Minist&eacute;rio da Sa&uacute;de do Brasil (MS) re
comendam o consumo    m&iacute;nimo de 400 g de FLV por dia (equivalente a cinco
 por&ccedil;&otilde;es).<sup>29</sup></font></p>     ^cY#2352.htm##
00755000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051900081002000900600#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#42#38#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A Pesquisa de Or&ccedil;amentos
    Familiares (POF 2002-2003) sugere que a participa&ccedil;&atilde;o cal&oacut
e;rica    de FLV na dieta seja de 2,3%.<sup>7</sup> Levy-Costa et al (2005),<sup
>17</sup>    em an&aacute;lise de tend&ecirc;ncia da disponibilidade de alimento
s nos domic&iacute;lios    brasileiros, constataram que a contribui&ccedil;&atil
de;o cal&oacute;rica do    grupo FLV tem se mantido baixa nos &uacute;ltimos 30 
anos.</font></p>     ^cY#2352.htm##
00717000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704048100081002000900562#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#43#39#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">No Brasil, as estimativas    do
 consumo de FLV entre adolescentes s&atilde;o escassas e prov&ecirc;m, em    sua
 maioria, de estudos realizados com amostras n&atilde;o-representativas.    Al&e
acute;m disso, o question&aacute;rio de freq&uuml;&ecirc;ncia alimentar,    m&ea
cute;todo de investiga&ccedil;&atilde;o usualmente empregado, n&atilde;o    forn
ece medidas acuradas do consumo.<sup>5,21</sup></font></p>     ^cY#2352.htm##
00437000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704020100081002000900282#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#44#40#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    teve por o
bjetivo analisar o consumo de FLV por adolescentes e identificar fatores    asso
ciados.</font></p>     ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#45#41#article#136#<p>&nbsp;</p> 
    ^cY#2352.htm##
00340000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010400081002000900185#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#46#42#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p
>     ^cY#2352.htm##
00961000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704072500081002000900806#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#47#43#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudo transversal    de base p
opulacional em 2003, proveniente da pesquisa multic&ecirc;ntrica denominada    "
Inqu&eacute;rito de Sa&uacute;de de S&atilde;o Paulo (ISA-Capital)". O ISA-Capit
al    foi delineado para coletar dados sobre sa&uacute;de e alimenta&ccedil;&ati
lde;o    de adolescentes, adultos e idosos do munic&iacute;pio de S&atilde;o Pau
lo, SP.    O presente estudo utilizou dados de 812 adolescentes de 12 a 19 anos.
 A amostragem    foi estratificada por conglomerados em dois est&aacute;gios: se
tor censit&aacute;rio    e domic&iacute;lio. Mais detalhes sobre a amostragem po
dem ser encontrados em    Castro et al.<sup>6</sup></font></p>     ^cY#2352.htm#
#
00567000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704033100081002000900412#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#48#44#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Entrevistadores    treinados re
alizaram inqu&eacute;rito domiciliar com question&aacute;rio estruturado    para
 investigar caracter&iacute;sticas demogr&aacute;ficas, antropom&eacute;tricas, 
   socioecon&ocirc;micas, familiares e de estilo de vida.</font></p>     ^cY#235
2.htm##
01588000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704135200081002000901433#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#49#45#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O consumo alimentar    foi medi
do pelo recordat&oacute;rio alimentar de 24 horas (R24h), aplicado segundo    o 
m&eacute;todo passo-a-passo estruturado em cinco etapas: 1) o <i>quick list</i> 
   ou listagem r&aacute;pida, na qual o entrevistado lista os alimentos e bebida
s    consumidos de forma ininterrupta; 2) <i>forgotten list</i> ou listagem de a
limentos    esquecidos, que questiona o indiv&iacute;duo sobre o consumo de alim
entos comumente    esquecidos, como doces, caf&eacute;s e refrigerantes; 3) os h
or&aacute;rios    e locais de consumo dos alimentos e bebidas; 4) o ciclo de det
alhamento, no    qual s&atilde;o descritos o modo de preparo e as quantidades co
nsumidas dos    alimentos; 5) a revis&atilde;o final, que verifica se houve algu
m alimento consumido    ao longo do dia que n&atilde;o tinha sido relatado anter
iormente.<sup>20</sup>    Esse m&eacute;todo contribui para que o indiv&iacute;d
uo se recorde dos alimentos    e bebidas consumidos no dia anterior &agrave; ent
revista e os relate de maneira    detalhada, reduzindo os erros na medida diet&e
acute;tica.<sup>24</sup> Os adolescentes    foram orientados a relatar os alimen
tos consumidos sob a forma de medidas caseiras    e a mencionar o modo de prepar
o, os temperos e as marcas comerciais.</font></p>     ^cY#2352.htm##
00747000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704051100081002000900592#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#50#46#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As informa&ccedil;&otilde;es   
 de consumo foram revistas para identificar eventuais falhas no preenchimento   
 e para converter as medidas caseiras dos alimentos e bebidas em gramas e milili
tros,    respectivamente.<sup>23</sup> Utilizou-se o programa NDS - <i>Nutrition
 Data    System for Research</i> (vers&atilde;o 2007, NCC, Universidade de Minne
sota,    Minneapolis) para a obten&ccedil;&atilde;o dos valores nutricionais.</f
ont></p>     ^cY#2352.htm##
01623000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704138700081002000901468#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#51#47#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Para criar a vari&aacute;vel   
 FLV, somou-se o consumo di&aacute;rio (em gramas) dos alimentos dos grupos frut
as,    legumes e verduras. Essa vari&aacute;vel foi constitu&iacute;da por todos
 os    tipos de frutas, legumes e verduras consumidos crus ou submetidos a difer
entes    m&eacute;todos de coc&ccedil;&atilde;o, com ou sem casca, e incluiu aqu
eles    utilizados como ingredientes de prepara&ccedil;&otilde;es. Optou-se por 
quantificar    os alimentos do grupo FLV contidos nas prepara&ccedil;&otilde;es,
 como sopas,    guarni&ccedil;&otilde;es e pratos mistos, com o objetivo de mens
urar todo e    qualquer tipo de FLV consumido, evitando-se a ingest&atilde;o sub
estimada desse    grupo alimentar. Para isso, as prepara&ccedil;&otilde;es relat
adas no recordat&oacute;rio    alimentar foram quantificadas, digitadas, e decom
postas em seus ingredientes.    Exclu&iacute;ram-se os alimentos do grupo das ra
&iacute;zes e tub&eacute;rculos    (e.g., batata, mandioca, inhame), por n&atild
e;o pertencerem &agrave; categoria    de FLV, segundo o Guia Alimentar da Popula
&ccedil;&atilde;o Brasileira.<a name="topa"></a><a href="#backa">ª</a>    Consid
erou-se adequado o consumo de FLV igual ou superior a 400 g/dia, conforme    a r
ecomenda&ccedil;&atilde;o do MS.<a name="topa"></a><a href="#backa">ª</a></font>
</p>     ^cY#2352.htm##
00714000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704047800081002000900559#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#52#48#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A classifica&ccedil;&atilde;o  
  do estado nutricional baseou-se nos pontos de corte do &iacute;ndice de massa 
   corporal (IMC) segundo sexo e idade propostos pela OMS.<sup>22</sup> Medidas 
   antropom&eacute;tricas de peso e altura auto-referidas foram utilizadas para 
   o c&aacute;lculo do IMC. Adolescentes com sobrepeso ou obesidade foram agrupa
dos    e classificados como excesso de peso.</font></p>     ^cY#2352.htm##
00609000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704037300081002000900454#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#53#49#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Adolescentes que    relataram c
onsumo de bebida alco&oacute;lica, independente do tipo, freq&uuml;&ecirc;ncia  
  e quantidade, foram classificados como etilistas. Para a defini&ccedil;&atilde
;o    dos adolescentes em tabagistas, considerou-se o h&aacute;bito de fumar atu
al    ou pregresso.</font></p>     ^cY#2352.htm##
00733000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704049700081002000900578#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#54#50#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A renda domiciliar    <i>per ca
pita</i> foi estimada pela soma da renda mensal de todos os indiv&iacute;duos   
 do domic&iacute;lio dividido pelo total de moradores. Foram definidas duas cate
gorias    de renda domiciliar <i>per capita</i> (at&eacute; um sal&aacute;rio m&
iacute;nimo;    acima de um sal&aacute;rio m&iacute;nimo), de acordo com o sal&a
acute;rio m&iacute;nimo    vigente na &eacute;poca (R$ 240,00).</font></p>     ^
cY#2352.htm##
00467000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704023100081002000900312#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#55#51#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A escolaridade    do chefe de f
am&iacute;lia foi categorizada segundo anos de estudo conclu&iacute;dos    (at&e
acute; oito anos; nove anos ou mais).</font></p>     ^cY#2352.htm##
00927000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704069100081002000900772#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#56#52#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O consumo de FLV    foi estrati
ficado por sexo e descrito na forma de percentis. Modelos de regress&atilde;o   
 quant&iacute;lica foram constru&iacute;dos para identificar a associa&ccedil;&a
tilde;o    entre a ingest&atilde;o de FLV e as vari&aacute;veis investigadas. Es
ses modelos    permitem observar o efeito de vari&aacute;veis independentes em d
iferentes pontos    da distribui&ccedil;&atilde;o da vari&aacute;vel dependente 
e s&atilde;o apropriados    quando esta &eacute; assim&eacute;trica e heteroced&
aacute;stica em rela&ccedil;&atilde;o    &agrave;s demais vari&aacute;veis do mo
delo.<sup>4</sup></font></p>     ^cY#2352.htm##
00689000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704045300081002000900534#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#57#53#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A vari&aacute;vel    dependente
 foi consumo de FLV (gramas/dia). Foram testadas como vari&aacute;veis    indepe
ndentes as vari&aacute;veis dicot&ocirc;micas escolaridade do chefe da    fam&ia
cute;lia, renda familiar <i>per capita</i>, tabagismo, etilismo, faixa    et&aac
ute;ria e as vari&aacute;veis cont&iacute;nuas: energia (kcal/dia) e escore-z   
 de IMC-para-idade.</font></p>     ^cY#2352.htm##
01642000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704140600081002000901487#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#58#54#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A modelagem foi    realizada pe
lo procedimento <i>stepwise-forward</i> e permaneceram no modelo    como vari&aa
cute;veis associadas aquelas cujo intervalo de 95% de confian&ccedil;a    n&atil
de;o continha o zero. Foram estimados, simultaneamente, coeficientes de    regre
ss&atilde;o a cada cinco percentis no intervalo dos percentis 20 a 95,    a part
ir do mesmo modelo, para analisar o efeito das vari&aacute;veis independentes   
 ao longo de toda distribui&ccedil;&atilde;o. Esse intervalo caracteriza os pont
os    da distribui&ccedil;&atilde;o em que o consumo de FLV &eacute; diferente d
e    zero. O erro-padr&atilde;o para cada um dos coeficientes estimados foi comp
utado    a partir de 400 replica&ccedil;&otilde;es utilizando a t&eacute;cnica d
e replica&ccedil;&atilde;o    <i>bootstrap</i>. Associa&ccedil;&otilde;es observ
adas em um dado percentil    podem n&atilde;o ser significantes em outro porque 
os coeficientes de regress&atilde;o    foram estimados em v&aacute;rios pontos d
a distribui&ccedil;&atilde;o. A escolha    dos modelos que obtiveram melhores aj
ustes baseou-se em dois crit&eacute;rios:    1) associa&ccedil;&atilde;o de vari
&aacute;veis explicativas no maior n&uacute;mero    de percentis e 2) menores in
tervalos de confian&ccedil;a dos coeficientes das    principais vari&aacute;veis
 associadas.</font></p>     ^cY#2352.htm##
00448000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704021200081002000900293#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#59#55#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O pacote estat&iacute;stico    
Stata (Statistics/Data Analysis, vers&atilde;o 10.1, Texas, USA) foi usado para 
   an&aacute;lise.</font></p>     ^cY#2352.htm##
00493000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704025700081002000900338#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#60#56#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O estudo foi aprovado    pelo C
omit&ecirc; de &Eacute;tica da Faculdade de Sa&uacute;de P&uacute;blica    da Un
iversidade de S&atilde;o Paulo (Processo nº 381, em 13/2/2001).</font></p>     ^
cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#61#57#article#136#<p>&nbsp;</p> 
    ^cY#2352.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010000081002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#62#58#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>   
  ^cY#2352.htm##
00735000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704049900081002000900580#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#63#59#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A preval&ecirc;ncia    de sobre
peso foi de 19%, tabagismo, 10% e ingest&atilde;o de bebidas alco&oacute;licas, 
   39%. Para cerca de 57% dos adolescentes, os chefes de fam&iacute;lia tinham  
  at&eacute; oito anos de estudo e 52% pertenciam a fam&iacute;lias com renda   
 igual ou inferior a R$ 240,00 (at&eacute; um sal&aacute;rio m&iacute;nimo) (<a 
href="/img/revistas/rsp/2011nahead/2352t01.jpg">Tabela    1</a>).</font></p>    
 ^cY#2352.htm##
00969000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704073300081002000900814#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#64#60#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Aproximadamente    20% dos adol
escentes n&atilde;o consumiram FLV no dia relatado e 6,5% apresentaram    ingest
&atilde;o adequada (<u>></u> 400 g/dia). Houve ingest&atilde;o adequada    entre
 os percentis 90 e 95 da distribui&ccedil;&atilde;o na maioria das vari&aacute;v
eis    investigadas na an&aacute;lise estratificada por sexo (<a href="/img/revi
stas/rsp/2011nahead/2352t01.jpg">Tabela    1</a>). A propor&ccedil;&atilde;o de 
indiv&iacute;duos com consumo acima dessa    recomenda&ccedil;&atilde;o foi meno
r que 10% em todos os estratos analisados,    com exce&ccedil;&atilde;o dos taba
gistas do sexo feminino, cujo percentil 90    foi de 403 g.</font></p>     ^cY#2
352.htm##
01290000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704105400081002000901135#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#65#61#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O modelo que melhor    atendeu 
aos crit&eacute;rios teve como vari&aacute;veis explicativas renda domiciliar   
 <i>per capita</i>, escolaridade do chefe da fam&iacute;lia e h&aacute;bito de  
  fumar, ajustados pelo consumo energ&eacute;tico, faixa et&aacute;ria e sexo.  
  As <a href="/img/revistas/rsp/2011nahead/2352f01.jpg">Figuras 1</a> e <a href=
"/img/revistas/rsp/2011nahead/2352f02.jpg">2</a>    mostram as mudan&ccedil;as n
os coeficientes de regress&atilde;o ao longo da    distribui&ccedil;&atilde;o em
 rela&ccedil;&atilde;o &agrave; renda e &agrave;    escolaridade do chefe de fam
&iacute;lia. Esses coeficientes expressam a diferen&ccedil;a    de consumo de FL
V em gramas entre as categorias das vari&aacute;veis independentes    analisadas
. Nesses gr&aacute;ficos, a &aacute;rea cinza representa o intervalo    de confi
an&ccedil;a de 95% dos coeficientes estimados em cada percentil. Renda    associ
ou-se positivamente ao consumo de FLV do percentil 20 ao 55.</font></p>     ^cY#
2352.htm##
00853000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704061700081002000900698#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#66#62#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Os coeficientes    mantiveram-s
e praticamente constantes entre esses percentis, indicando consumo    de aproxim
adamente 20 g a menos no grupo de menor renda. A maior escolaridade    do chefe 
de fam&iacute;lia exerceu influ&ecirc;ncia significativa a partir do    percenti
l 70, e esse efeito variou com o aumento dos percentis. A diferen&ccedil;a    de
 ingest&atilde;o de FLV entre as categorias de maior e menor escolaridade    foi
 de 63 g, no percentil 70, e de 77 g no percentil 90, independentemente das    d
emais vari&aacute;veis.</font></p>     ^cY#2352.htm##
00693000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704045700081002000900538#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#67#63#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A partir do percentil    45, o 
efeito do tabagismo sobre a ingest&atilde;o de FLV foi significante e    aumento
u gradativamente at&eacute; o percentil 75 (<a href="/img/revistas/rsp/2011nahea
d/2352f03.jpg">Figura    3</a>). O grupo de fumantes apresentou ingest&atilde;o 
de 20 g e de 65 g a menos    que o grupo de n&atilde;o-fumantes nos percentis 45
 e 75, respectivamente.</font></p>     ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#68#64#article#136#<p>&nbsp;</p> 
    ^cY#2352.htm##
00342000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010600081002000900187#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#69#65#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font><
/p>     ^cY#2352.htm##
00558000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704032200081002000900403#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#70#66#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">No presente estudo,    6,5% dos
 adolescentes atingiram a recomenda&ccedil;&atilde;o de ingest&atilde;o    de FL
V (<u>></u> 400 g/dia). Renda, escolaridade do chefe e tabagismo exerceram    in
flu&ecirc;ncia no consumo desse grupo alimentar.</font></p>     ^cY#2352.htm##
01251000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704101500081002000901096#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#71#67#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Embora existam    diferen&ccedi
l;as nos m&eacute;todos de avalia&ccedil;&atilde;o da dieta, os    resultados de
ste trabalho s&atilde;o consistentes aos de estudos nacionais com    adolescente
s. Estudos transversais que utilizaram question&aacute;rios de freq&uuml;&ecirc;
ncia    alimentar encontraram baixa ingest&atilde;o habitual de frutas e hortali
&ccedil;as    em adolescentes brasileiros.<sup>1,25</sup> Em estudo realizado pe
lo Instituto    Nacional do C&acirc;ncer (INCA), quase metade (45%) dos jovens d
e 15 a 24 anos    do munic&iacute;pio de S&atilde;o Paulo consumiam frutas, legu
mes ou verduras    menos que cinco vezes por semana.<a name="topb"></a><a href="
#backb"><sup>b</sup></a>    Em adolescentes da oitava s&eacute;rie de escolas da
 rede municipal no Rio de    Janeiro, RJ, verduras cruas e legumes cozidos foram
 consumidos ao menos cinco    vezes na semana por 20% e 16,5% dos adolescentes e
studados.<sup>5</sup></font></p>     ^cY#2352.htm##
00862000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704062600081002000900707#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#72#68#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Estudos norte-americanos    rec
entes relataram baixo consumo de FLV em adolescentes.<sup>11,15,16</sup>    Cont
udo, diferen&ccedil;as na categoriza&ccedil;&atilde;o dos grupos de alimentos,  
  como a inclus&atilde;o da batata e de outros tub&eacute;rculos no grupo FLV,  
  limitam a compara&ccedil;&atilde;o dos resultados. Dados do estudo <i>National
    Health and Nutrition Examination Survey</i> de 2003-2004 (NHANES III), por e
xemplo,    mostraram que a batata representou cerca de 41% da ingest&atilde;o to
tal de    vegetais.<sup>15</sup></font></p>     ^cY#2352.htm##
01796000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704156000081002000901641#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#73#69#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Modelos de regress&atilde;o    
quant&iacute;lica, utilizados para investigar a associa&ccedil;&atilde;o entre  
  a ingest&atilde;o de FLV e vari&aacute;veis explanat&oacute;rias, s&atilde;o  
  extensamente aplicados em econometria, por&eacute;m pouco empregados nas ci&ec
irc;ncias    da sa&uacute;de, especialmente na epidemiologia nutricional. O estu
do de Variyam    et al<sup>27</sup> sobre fatores associados &agrave; ingest&ati
lde;o de nutrientes    por meio de tais modelos &eacute; uma das exce&ccedil;&ot
ilde;es. No presente    estudo, a escolha do modelo justifica-se pela assimetria
 &agrave; direita da    curva de ingest&atilde;o de FLV e &agrave; heterocedasti
cidade da vari&aacute;vel    dependente em rela&ccedil;&atilde;o &agrave;s vari&
aacute;veis explicativas.    Nesses casos, modelos baseados pelo m&eacute;todo d
os m&iacute;nimos quadrados    geram res&iacute;duos que podem ter vari&acirc;nc
ia n&atilde;o-uniforme, conduzindo    infer&ecirc;ncias a partir de coeficientes
 enviesados. Quando n&atilde;o h&aacute;    homocedasticidade, determinados perc
entis podem ser mais influenciados pelas    vari&aacute;veis explanat&oacute;ria
s do que outros. Por fim, os modelos de    regress&atilde;o quant&iacute;lica s&
atilde;o aditivos, ou seja, os coeficientes    de regress&atilde;o s&atilde;o in
terpretados como a mudan&ccedil;a num dado    percentil da vari&aacute;vel depen
dente provocado pela mudan&ccedil;a de uma    unidade da vari&aacute;vel indepen
dente.</font></p>     ^cY#2352.htm##
00822000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704058600081002000900667#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#74#70#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">As an&aacute;lises    m&uacute;
ltiplas mostram diferen&ccedil;as na influ&ecirc;ncia da renda e da    escolarid
ade do chefe de fam&iacute;lia sobre a ingest&atilde;o de FLV de adolescentes,  
  semelhante ao observado em estudos que utilizaram modelos de regress&atilde;o 
   linear.<sup>26</sup> Renda associou-se de maneira significativa nos menores  
  percentis de ingest&atilde;o (p 20 ao 55), enquanto escolaridade associou-se  
  apenas nos percentis finais da distribui&ccedil;&atilde;o (p 70 a 95).</font><
/p>     ^cY#2352.htm##
00642000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704040600081002000900487#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#75#71#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A renda pode ser    um dos dete
rminantes entre os adolescentes que consomem pequenas quantidades    de FLV (75 
g ou menos, i.e., inferior a uma por&ccedil;&atilde;o di&aacute;ria).    Para aq
ueles com consumo maior (entre 140 g e 460 g), a escolaridade do chefe    de fam
&iacute;lia passa a atuar como um dos determinantes.</font></p>     ^cY#2352.htm
##
00936000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704070000081002000900781#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#76#72#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O papel dessas    vari&aacute;v
eis sobre o consumo de FLV tem sido investigado por diferentes    estudos.<sup>7
,26</sup> A renda influenciaria o acesso e a disponibilidade de    recursos fina
nceiros para aquisi&ccedil;&atilde;o de alimentos de maior custo,    como os do 
grupo FLV.<sup>25</sup> No presente estudo, no qual 52% dos adolescentes    poss
u&iacute;am renda domiciliar <i>per capita</i> igual ou inferior a R$ 240,00,   
 o baixo consumo de FLV pode ser atribu&iacute;do ao menor poder de compra das  
  fam&iacute;lias, o que limitaria a quantidade dispon&iacute;vel desses aliment
os    no domic&iacute;lio.</font></p>     ^cY#2352.htm##
00956000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704072000081002000900801#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#77#73#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A escolaridade,    por sua vez,
 influenciaria a escolha do alimento, por conferir ao indiv&iacute;duo    a habi
lidade de assimilar mensagens de programas de educa&ccedil;&atilde;o nutricional
    e de compreender a import&acirc;ncia da alimenta&ccedil;&atilde;o como forma
    de promo&ccedil;&atilde;o da sa&uacute;de.<sup>26</sup> No presente estudo, 
   a maior escolaridade do chefe de fam&iacute;lia poderia predispor o adolescen
te    ao maior consumo de FLV, como resultado da escolha por alimentos mais saud
&aacute;veis    pelo chefe de fam&iacute;lia, principal respons&aacute;vel pelas
 decis&otilde;es    no n&uacute;cleo familiar.</font></p>     ^cY#2352.htm##
01496000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704126000081002000901341#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#78#74#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O tabagismo exerce    influ&eci
rc;ncia sobre a ingest&atilde;o de FLV entre os percentis 45 e 75 de    ingest&a
tilde;o, independentemente dos efeitos da renda e da escolaridade do    chefe. E
sses achados sugerem que os efeitos do tabagismo sobre a ingest&atilde;o    de F
LV ocorrem tanto em n&iacute;veis baixos de ingest&atilde;o (50 g) quanto    em 
n&iacute;veis moderados de consumo (165 g). Em estudo populacional no Canad&aacu
te;,    Birkett<sup>3</sup> observou que os fumantes consumiam substancialmente 
menos    frutas e sucos naturais de frutas que os n&atilde;o-fumantes. Al&eacute
;m disso,    aqueles que consumiam maior n&uacute;mero de cigarros no dia aprese
ntavam entre    quatro e seis vezes mais chance de ingerir menos frutas que o re
comendado. Resultados    similares, por&eacute;m menos expressivos, foram encont
rados em rela&ccedil;&atilde;o    ao consumo de legumes e verduras. Os tabagista
s, no entanto, possuem necessidades    aumentadas de antioxidantes presentes no 
grupo FLV, por terem n&iacute;veis    diminu&iacute;dos de antioxidantes no plas
ma, causados pela carga excessiva    de radicais livres contidos na fuma&ccedil;
a do cigarro.<sup>14</sup></font></p>     ^cY#2352.htm##
01595000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704135900081002000901440#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#79#75#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">A ingest&atilde;o    de FLV par
a cada indiv&iacute;duo foi obtida a partir de um &uacute;nico R24h.    Esse pro
cedimento falha ao captar as varia&ccedil;&otilde;es do dia-a-dia, o    que aume
nta a vari&acirc;ncia da distribui&ccedil;&atilde;o.<sup>8</sup> O consumo    ab
aixo da mediana pode estar subestimado, enquanto o acima pode estar superestimad
o.    Considerando que a recomenda&ccedil;&atilde;o de 400 g/dia de consumo de F
LV    foi alcan&ccedil;ada nos percentis finais da distribui&ccedil;&atilde;o, &
eacute;    poss&iacute;vel que a propor&ccedil;&atilde;o de adolescentes com con
sumo abaixo    desse valor esteja subestimada. Outro efeito do aumento da vari&a
circ;ncia &eacute;    a atenua&ccedil;&atilde;o das medidas de associa&ccedil;&a
tilde;o entre o consumo    e as vari&aacute;veis explanat&oacute;rias, que impli
ca poss&iacute;vel subestimativa    dos coeficientes encontrados. Presume-se que
 as associa&ccedil;&otilde;es observadas    continuariam a existir com uso de ma
is R24h, por&eacute;m com coeficientes de    maior magnitude. Ainda que uma medi
da diet&eacute;tica reduza a precis&atilde;o    dos percentis de consumo e atenu
e os coeficientes de regress&atilde;o, sua utiliza&ccedil;&atilde;o    n&atilde;
o invalida as conclus&otilde;es deste estudo.</font></p>     ^cY#2352.htm##
00763000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704052700081002000900608#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#80#76#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O consumo de frutas,    legumes
 e verduras &eacute; um comportamento socialmente desej&aacute;vel, o    que pod
e acarretar no relato superestimado desse consumo.<sup>13,19</sup> Entretanto,  
  esse tipo de vi&eacute;s n&atilde;o parece ser fonte importante de erro na amo
stra    estudada, uma vez que pequeno percentual de adolescentes atingiu as reco
menda&ccedil;&otilde;es    (6,5%) e maior percentual n&atilde;o relatou consumo 
de FLV (20%).</font></p>     ^cY#2352.htm##
00635000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704039900081002000900480#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#81#77#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">Outra poss&iacute;vel    limita
&ccedil;&atilde;o refere-se ao peso e altura auto-referidos para o c&aacute;lcul
o    do IMC. Entretanto, o uso de &iacute;ndice antropom&eacute;trico com base e
m    medidas auto-referidas &eacute; descrito como favor&aacute;vel na popula&cc
edil;&atilde;o    adolescente.<sup>9,10</sup></font></p>     ^cY#2352.htm##
01152000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704091600081002000900997#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#82#78#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">O consumo de FLV    por adolesc
entes do munic&iacute;pio de S&atilde;o Paulo est&aacute; muito abaixo    das re
comenda&ccedil;&otilde;es atuais e &eacute; influenciado por renda, escolaridade
    do chefe de fam&iacute;lia e tabagismo. A&ccedil;&otilde;es intersetoriais d
e    incentivo ao consumo de frutas e hortali&ccedil;as e a ado&ccedil;&atilde;o
    de estilo de vida saud&aacute;vel podem melhorar esse panorama. A implanta&c
cedil;&atilde;o    de pol&iacute;ticas p&uacute;blicas de redu&ccedil;&atilde;o 
do pre&ccedil;o    de FLV, o desenvolvimento de mecanismos que promovam o increm
ento da renda familiar    e a ado&ccedil;&atilde;o de a&ccedil;&otilde;es m&uacu
te;ltiplas de educa&ccedil;&atilde;o    nutricional nas escolas s&atilde;o medid
as favor&aacute;veis ao aumento do consumo    de FLV por adolescentes brasileiro
s.</font></p>     ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002200081002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#83#79#article#136#<p>&nbsp;</p> 
    ^cY#2352.htm##
00343000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704010700081002000900188#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#84#80#article#136#<p><font face=
"Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font>
</p>     ^cY#2352.htm##
00555000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704030500083002000900388#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#85#81#article#136#1#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Andrade RG,   
 Pereira RA, Sichieri R. Consumo alimentar de adolescentes com e sem sobrepeso  
  do Munic&iacute;pio do Rio de Janeiro. <i>Cad Saude Publica</i>. 2003;19(5):14
85-95.    DOI:10.1590/S0102-311X2003000500027</font></p>     ^cY#2352.htm##
00457000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704020700083002000900290#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#86#82#article#136#2#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Bazzano LA.   
 Dietary Intake of fruit and vegetable and risk of diabetes mellitus and cardiov
ascular    diseases. Geneva: WHO; 2005.    ^cY#2352.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#87#83#article#136#</font></p>   
  ^cY#2352.htm##
00472000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704022200083002000900305#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#88#84#article#136#3#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Birkett NJ.   
 Intake of fruits and vegetables in smokers. <i>Public Health Nutr.</i> 1999;2(2
):217-22.    DOI:10.1017/S1368980099000270</font></p>     ^cY#2352.htm##
00476000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704022600083002000900309#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#89#85#article#136#4#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Buchinsky M.  
  Recent advancens in quantile regression models: a practical guideline for empi
rical    research. <i>J Hum Resour</i>. 1998;33(1):88-126.    ^cY#2352.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077704002000081002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#90#86#article#136#</font></p>   
  ^cY#2352.htm##
00656000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704040600083002000900489#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#91#87#article#136#5#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Castro IRR,   
 Cardoso LO, Engstrom EM, Levy RB, Monteiro CA. Vigil&acirc;ncia de fatores de  
  risco para doen&ccedil;as n&atilde;o transmiss&iacute;veis entre adolescentes:
    a experi&ecirc;ncia da cidade do Rio de Janeiro, Brasil. <i>Cad Saude Public
a</i>.    2008;24(10):2279-88. DOI:10.1590/S0102-311X2008001000009</font></p>   
  ^cY#2352.htm##
00573000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704032300083002000900406#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#92#88#article#136#6#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">6. Castro MA, Bar
ros    RR, Bueno MB, C&eacute;sar CLG, Fisberg RM. Trans fatty acids intake amon
g the    population of the city of S&atilde;o Paulo, Brazil. <i>Rev Saude Public
a</i>.    2009;43(6):991-7. DOI:10.1590/S0034-89102009005000084</font></p>     ^
cY#2352.htm##
00578000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704032800083002000900411#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#93#89#article#136#7#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">7. Claro RM, Carm
o    HCE do, Machado FMS, Monteiro CA. Renda, pre&ccedil;o dos alimentos e parti
cipa&ccedil;&atilde;o    de frutas e hortali&ccedil;as na dieta. <i>Rev Saude Pu
blica.</i> 2007;41(4):557-64.    DOI:10.1590/S0034-89102007000400009</font></p> 
    ^cY#2352.htm##
00591000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704034100083002000900424#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#94#90#article#136#8#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">8. Dodd KW, Guent
her    PM, Freedman LS, Subar AF, Kipnis V, Midthune D, et al. Statistical metho
ds    for estimating usual intake of nutrients and foods: a review of the theory
.    <i>J Am Diet Assoc</i>. 2006;106(10):1640-50. DOI:10.1016/j.jada.2006.07.01
1</font></p>     ^cY#2352.htm##
00584000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000200081704033400083002000900417#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#95#91#article#136#9#
<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">9. Farias J&uacut
e;nior    JC. Validade das medidas auto-referidas de peso e estatura para o diag
n&oacute;stico    do estado nutricional de adolescentes. <i>Rev Bras Saude Mater
 Infant.</i>&nbsp;2007;7(2):167-74.    DOI:10.1590/S1519-38292007000200007</font
></p>     ^cY#2352.htm##
00563000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000300081704031200084002000900396#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#96#92#article#136#10
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Fonseca H,  
  Silva AM, Matos MG, Esteves I, Costa P, Guerra A, et al. Validity of BMI based
    on self-reported weight and height in adolescents. <i>Acta Paediatr</i>. 201
0;99(1):83-8.    DOI:10.1111/j.1651-2227.2009.01518.x</font></p>     ^cY#2352.ht
m##
00548000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000300081704029700084002000900381#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#97#93#article#136#11
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Guenther PM,
    Dodd KW, Reedy J, Krebs-Smith SM. Most Americans eat much less than recommen
ded    amounts of fruits and vegetables. <i>J Am Diet Assoc.</i> 2006;106(9):137
1-9.    DOI:10.1016/j.jada.2006.06.002</font></p>     ^cY#2352.htm##
00523000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000300081704027200084002000900356#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#98#94#article#136#12
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">12. He FJ, Nowso
n    CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis
    of cohort studies. <i>Lancet.</i> 2006;367(9507):320-6. DOI:10.1016/S0140-67
36(06)68069-0</font></p>     ^cY#2352.htm##
00593000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000400077888000300081704034200084002000900426#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#99#95#article#136#13
#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Herbert JR, 
   Hurley TG, Peterson KE, Resnicow K, Thompson FE, Yaroch AL, et al. Social des
irability    trait influences on self-reported dietary measures among diverse pa
rticipants    in a multicenter multiple risk factor trial. <i>J Nutr</i>. 2008;1
38(1):226S-34S.    ^cY#2352.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704002000082002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#100#96#article#136#</font></p>  
   ^cY#2352.htm##
00480000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000300082704022800085002000900313#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#101#97#article#136#1
4#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Institute o
f    Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and
    carotenoids. Washington, DC: National Academy Press; 2000.    ^cY#2352.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078704002000082002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#102#98#article#136#</font></p>  
   ^cY#2352.htm##
00559000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000300067709000800070708000400078888000300082704030700085002000900392#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#103#99#article#136#1
5#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Kimmons J, 
   Gillespie C, Seymour J, Serdula M, Blanck HM. Fruit and vegetable intake amon
g    adolescents and adults in the United States: percentage meeting individuali
zed    recommendations. <i>Medscape J Med</i>. 2009;11(1):26.    ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#104#100#article#136#</font></p> 
    ^cY#2352.htm##
00577000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704032400086002000900410#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#105#101#article#136#
16#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Larson NI,
    Neumark-Sztainer DR, Harnack LJ, Wall MM, Story MT, Eisenberg ME. Fruit and 
   vegetable intake correlates during the transition to young adulthood. <i>Am  
  J Prev Med</i>. 2008;35(1):33-7. DOI:10.1016/j.amepre.2008.03.019</font></p>  
   ^cY#2352.htm##
00596000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704034300086002000900429#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#106#102#article#136#
17#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Levy-Costa
    RB, Sichieri R, Pontes NS, Monteiro CA. Disponibilidade domiciliar de alimen
tos    no Brasil: distribui&ccedil;&atilde;o e evolu&ccedil;&atilde;o (1974-2003
).    <i>Rev Saude Publica</i>. 2005;39(4):530-40. DOI:10.1590/S0034-89102005000
400003</font></p>     ^cY#2352.htm##
00608000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704035500086002000900441#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#107#103#article#136#
18#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Lock K, Po
merleau    J, Altmann DR, McKee M. The global burden of disease attributable to 
low consumption    of fruit and vegetables: implications for the global strategy
 on diet. <i>Bull    World Health Organ</i>. 2005;83(2):100-8. DOI:10.1590/S0042
-96862005000200010</font></p>     ^cY#2352.htm##
00574000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704032100086002000900407#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#108#104#article#136#
19#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Miller TM,
    Abdel-Msksoud MF, Crane LA, Marcus AC, Byers TE. Effects of social approval 
   bias on self-reported fruit and vegetable consumption: a randomized controlle
d    trial. <i>Nutr J</i>. 2008;7:18. DOI:10.1186/1475-2891-7-18</font></p>     
^cY#2352.htm##
00566000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704031300086002000900399#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#109#105#article#136#
20#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Moshfegh A
J,    Rhodes DG, Baer DJ, Murayi T, Clemens JC, Rumpler WV, et al. The US Depart
ment    of Agriculture automated multiple-pass method reduces bias in the collec
tion    of energy intakes. <i>Am J Clin Nutr</i>. 2008;88(2):324-32.    ^cY#2352
.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#110#106#article#136#</font></p> 
    ^cY#2352.htm##
00639000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704038600086002000900472#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#111#107#article#136#
21#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Nahas MK, 
Barros    MVG, Goldfine BD, Lopes AS, Hallal PC, Farias J&uacute;nior JC, et al.
 Physical    activity and eating habits in public high schools from different re
gions in    Brazil: the Saude na Boa Project. <i>Rev Bras Epidemiol</i>. 2009;12
(2):270-7.    DOI:10.1590/S1415-790X2009000200016</font></p>     ^cY#2352.htm##
00531000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704027800086002000900364#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#112#108#article#136#
22#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Onis M de,
    Onyango AW, Borgui E, Siyam A, Nishida C, Siekmann J. Development of a WHO g
rowth    reference for school-aged children and adolescents. <i>Bull World Healt
h Organ</i>.    2007;85(9):660-7.    ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#113#109#article#136#</font></p> 
    ^cY#2352.htm##
00511000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704025800086002000900344#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#114#110#article#136#
23#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Pinheiro A
BV,    Lacerda EMA, Benzecry EH, Gomes MCS, Costa VM. Tabela para avalia&ccedil;
&atilde;o    de consumo alimentar em medidas caseiras. 4.ed. S&atilde;o Paulo: A
theneu; 2000.    ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#115#111#article#136#</font></p> 
    ^cY#2352.htm##
00526000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704027300086002000900359#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#116#112#article#136#
24#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Raper N, P
erloff    B, Ingwersen L, Steinfeldt L, Anand J. An overview of USDA's Dietary I
ntake    Data System. <i>J Food Compost Anal</i>. 2004;17(3/4):545-55. DOI:10.10
16/j.jfca.02.013</font></p>     ^cY#2352.htm##
00594000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704034100086002000900427#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#117#113#article#136#
25#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Santos JS,
    Costa MCO, Nascimento Sobrinho CL, Silva MCM, Souza KEP, Melo BO. Perfil ant
ropom&eacute;trico    e consumo alimentar de adolescentes de Teixeira de Freitas
 - Bahia. <i>Rev Nutr</i>.    2005;18(5):623-32. DOI:10.1590/S1415-5273200500050
0005</font></p>     ^cY#2352.htm##
00568000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704031500086002000900401#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#118#114#article#136#
26#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Turrell G,
    Hewitt B, Patterson C, Oldenburg B. Measuring socio-economic position in die
tary    research: is choice of socio-economic indicator important? <i>Public Hea
lth    Nutr</i>. 2003;6(2):191-200. DOI:10.1079/PHN2002416</font></p>     ^cY#23
52.htm##
00520000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704026700086002000900353#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#119#115#article#136#
27#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Variyam JN
,    Blaylock J, Smallwood D. Characterizing the distribution of macronutrient I
ntake    among U.S. adults: a quantile regression approach. <i>Am J Agric Econ</
i>. 2002;84(2):454-66.    ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#120#116#article#136#</font></p> 
    ^cY#2352.htm##
00513000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704026000086002000900346#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#121#117#article#136#
28#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">28. World Canc
er    Research Fund; American Institute for Cancer Research. Food, nutrition, ph
ysical    activity and the prevention of cancer: a global perspective. Washingto
n, DC;    2007.    ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#122#118#article#136#</font></p> 
    ^cY#2352.htm##
00512000000000157000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079888000300083704025900086002000900345#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#123#119#article#136#
29#<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">29. World Heal
th    Organization. Diet, nutrition and prevention of chronic diseases: report o
f    a joint WHO/FAO expert consultation. Geneva; 2003. (WHO Technical Report Se
ries,    916).    ^cY#2352.htm##
00258000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002000083002000900103#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#124#120#article#136#</font></p> 
    ^cY#2352.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#125#121#article#136#<p>&nbsp;</p
>     ^cY#2352.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#126#122#article#136#<p>&nbsp;</p
>     ^cY#2352.htm##
00453000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704021500083002000900298#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#127#123#article#136#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#
top"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    <b>Corr
espond&ecirc;ncia | Correspondence:    ^cY#2352.htm##
00284000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704004600083002000900129#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#128#124#article#136#<br>   </b> 
Dirce Maria Lobo Marchioni    ^cY#2352.htm##
00300000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704006200083002000900145#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#129#125#article#136#<br>   Facul
dade de Sa&uacute;de P&uacute;blica da USP    ^cY#2352.htm##
00276000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003800083002000900121#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#130#126#article#136#<br>   Av. D
outor Arnaldo, 715    ^cY#2352.htm##
00291000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704005300083002000900136#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#131#127#article#136#<br>   01246
-904 S&atilde;o Paulo, SP, Brasil    ^cY#2352.htm##
00327000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704008900083002000900172#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#132#128#article#136#<br>   E-mai
l: <a href="mailto:marchioni@usp.br">marchioni@usp.br</a></font></p>     ^cY#235
2.htm##
00328000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704009000083002000900173#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#133#129#article#136#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Recebido: 15/6/2010    ^cY#23
52.htm##
00272000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704003400083002000900117#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#134#130#article#136#<br>   Aprov
ado: 8/12/2010    ^cY#2352.htm##
00396000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704015800083002000900241#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#135#131#article#136#<br>   Pesqu
isa financiada pelo Conselho Nacional de Desenvolvimento Cient&iacute;fico    e 
Tecnol&oacute;gico (Processo nº: 402111.05-2).</font></p>     ^cY#2352.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#136#132#article#136#<p>&nbsp;</p
>     ^cY#2352.htm##
00260000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704002200083002000900105#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#137#133#article#136#<p>&nbsp;</p
>     ^cY#2352.htm##
00372000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704013400083002000900217#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#138#134#article#136#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">Os autores declaram    n&atil
de;o haver conflitos de interesse.    ^cY#2352.htm##
00905000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704066700083002000900750#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#139#135#article#136#<br>   <a na
me="backa"></a><a href="#topa">a</a> Minist&eacute;rio da Sa&uacute;de.    Secre
taria de Aten&ccedil;&atilde;o &agrave; Sa&uacute;de. Coordena&ccedil;&atilde;o 
   Geral da Pol&iacute;tica de Alimenta&ccedil;&atilde;o e Nutri&ccedil;&atilde;
o.    Guia alimentar da popula&ccedil;&atilde;o brasileira: promovendo a aliment
a&ccedil;&atilde;o    sud&aacute;vel. Bras&iacute;lia, DF; 2005. (S&eacute;rie A
. Normas e Manuais    T&eacute;cnicos). &#91;citado 2011 jan 25&#93;. Dispon&iac
ute;vel em: <a href="http://dtr2001.saude.gov.br/editora/produtos/livros" target
="_blank">http://dtr2001.saude.gov.br/editora/produtos/livros    /pdf/05_1109_M.
pdf</a>    ^cY#2352.htm##
00514000000000145000450000400110000070200480001170500020005970600020006170000040
0063701000400067709000800071708000400079704027600083002000900359#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2352.htm#S#p#140#136#article#136#<br>   <a na
me="backb"></a><a href="#topb">b</a> Instituto Nacional de C&acirc;ncer.    Inqu
&eacute;rito domiciliar sobre comportamentos de risco e morbidade referida    de
 doen&ccedil;as e agravos n&atilde;o transmiss&iacute;veis. Rio de Janeiro;    2
005.</font></p>     ^cY#2352.htm##
00662000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100018001000100
01800118012008900136030001800225065000900243064000500252031000300257032000200260
014000800262237003200270865000900302002000900311035001000320801001800330#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#141#1#article#29#1#^rND^
sAndrade^nRG#^rND^sPereira^nRA#^rND^sSichieri^nR#Consumo alimentar de adolescent
es com e sem sobrepeso do Município do Rio de Janeiro^lpt#Cad Saude Publica#2003
0000#2003#19#5#1485-95#10.1590/S0102-311X2003000500027#20110000#2352.htm#0102-31
1X#Cad Saude Publica##
00473000000000229000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800160018000820180100001000660
00700200062000400207065000900211064000500220865000900225002000900234#2011nahead#
V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#142#2#article#29#2#^rND^sBaz
zano^nLA#Dietary Intake of fruit and vegetable and risk of diabetes mellitus and
 cardiovascular diseases^len#Geneva#WHO#20050000#2005#20110000#2352.htm##
00516000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820120047001000300
02000147710000200167065000900169064000500178031000200183032000200185014000700187
237002600194865000900220002000900229#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2352.htm#S#c#143#3#article#29#3#^rND^sBirkett^nNJ#Intake of fruits and ve
getables in smokers^len#Public Health Nutr.#2#19990000#1999#2#2#217-22#10.1017/S
1368980099000270#20110000#2352.htm##
00556000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100019000820120097001010300
01300198065000900211064000500220031000300225032000200228014000700230865000900237
002000900246035001000255801001300265#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2352.htm#S#c#144#4#article#29#4#^rND^sBuchinsky^nM#Recent advancens in qu
antile regression models: a practical guideline for empirical research^len#J Hum
 Resour#19980000#1998#33#1#88-126#20110000#2352.htm#0022-166X#J Hum Resour##
00770000000000337000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100018000820100018001000100
01900118010001500137010001900152012013700171030001800308065000900326064000500335
03100030034003200030034301400080034623700320035486500090038600200090039503500100
0404801001800414#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#
145#5#article#29#5#^rND^sCastro^nIRR#^rND^sCardoso^nLO#^rND^sEngstrom^nEM#^rND^s
Levy^nRB#^rND^sMonteiro^nCA#Vigilância de fatores de risco para doenças não tran
smissíveis entre adolescentes: a experiência da cidade do Rio de Janeiro, Brasil
^lpt#Cad Saude Publica#20080000#2008#24#10#2279-88#10.1590/S0102-311X20080010000
09#20110000#2352.htm#0102-311X#Cad Saude Publica##
00709000000000337000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100017000820100017000990100
01600116010001700132010001800149012008300167030001800250065000900268064000500277
03100030028203200020028501400060028723700320029386500090032500200090033403500100
0343801001800353#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#
146#6#article#29#6#^rND^sCastro^nMA#^rND^sBarros^nRR#^rND^sBueno^nMB#^rND^sCésar
^nCLG#^rND^sFisberg^nRM#Trans fatty acids intake among the population of the cit
y of São Paulo, Brazil^len#Rev Saude Publica#20090000#2009#43#6#991-7#10.1590/S0
034-89102009005000084#20110000#2352.htm#0034-8910#Rev Saude Publica##
00645000000000313000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100016000820100020000980100
01900118010001900137012007800156030001900234710000200253065000900255064000500264
031000300269032000200272014000700274237003200281865000900313002000900322#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#147#7#article#29#7#^rND^
sClaro^nRM#^rND^sCarmo^nHCE do#^rND^sMachado^nFMS#^rND^sMonteiro^nCA#Renda, preç
o dos alimentos e participação de frutas e hortaliças na dieta^lpt#Rev Saude Pub
lica.#2#20070000#2007#41#4#557-64#10.1590/S0034-89102007000400009#20110000#2352.
htm##
00768000000000361000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100015000820100019000970100
01900116010001600135010001600151010001800167810000600185012009900191030001600290
06500090030606400050031503100040032003200030032401400080032723700270033586500090
0362002000900371035001000380801001600390#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2352.htm#S#c#148#8#article#29#8#^rND^sDodd^nKW#^rND^sGuenther^nPM#^rN
D^sFreedman^nLS#^rND^sSubar^nAF#^rND^sKipnis^nV#^rND^sMidthune^nD#et al#Statisti
cal methods for estimating usual intake of nutrients and foods: a review of the 
theory^len#J Am Diet Assoc#20060000#2006#106#10#1640-50#10.1016/j.jada.2006.07.0
11#20110000#2352.htm#0002-8223#J Am Diet Assoc##
00605000000000277000450000400110000070200480001170500020005970600020006170000040
00637010002000677090008000697080003000771180002000800100024000820120116001060300
02800222710000200250065000900252064000500261031000200266032000200268014000700270
237003200277865000900309002000900318#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2352.htm#S#c#149#9#article#29#9#^rND^sFarias Júnior^nJC#Validade das medi
das auto-referidas de peso e estatura para o diagnóstico do estado nutricional d
e adolescentes^les#Rev Bras Saude Mater Infant#2#20070000#2007#7#2#167-74#10.159
0/S1519-38292007000200007#20110000#2352.htm##
00738000000000361000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100016001010100
01600117010001700133010001500150010001600165810000600181012007600187030001400263
06500090027706400050028603100030029103200020029401400050029623700330030186500090
0334002000900343035001000352801001400362#2011nahead#V:\SciELO\serial\rsp\2011nah
ead\markup\2352.htm#S#c#150#10#article#29#10#^rND^sFonseca^nH#^rND^sSilva^nAM#^r
ND^sMatos^nMG#^rND^sEsteves^nI#^rND^sCosta^nP#^rND^sGuerra^nA#et al#Validity of 
BMI based on self-reported weight and height in adolescents^len#Acta Paediatr#20
100000#2010#99#1#83-8#10.1111/j.1651-2227.2009.01518.x#20110000#2352.htm#0001-65
6X#Acta Paediatr##
00643000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100015001030100
01500118010002200133012008300155030001700238710000200255065000900257064000500266
031000400271032000200275014000700277237002700284865000900311002000900320#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#151#11#article#29#11#^rN
D^sGuenther^nPM#^rND^sDodd^nKW#^rND^sReedy^nJ#^rND^sKrebs-Smith^nSM#Most America
ns eat much less than recommended amounts of fruits and vegetables^len#J Am Diet
 Assoc.#2#20060000#2006#106#9#1371-9#10.1016/j.jada.2006.06.002#20110000#2352.ht
m##
00629000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100013000840100017000970100
02000114012008000134030000700214065000900221064000500230031000400235032000500239
014000600244237003000250865000900280002000900289035001000298801000700308#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#152#12#article#29#12#^rN
D^sHe^nFJ#^rND^sNowson^nCA#^rND^sMacGregor^nGA#Fruit and vegetable consumption a
nd stroke: meta-analysis of cohort studies^len#Lancet#20060000#2006#367#9507#320
-6#10.1016/S0140-6736(06)68069-0#20110000#2352.htm#0099-5355#Lancet##
00765000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100017001020100
01900119010001800138010001900156010001700175810000600192012014600198030000700344
06500090035106400050036003100040036503200020036901400090037186500090038000200090
0389035001000398801000700408#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
352.htm#S#c#153#13#article#29#13#^rND^sHerbert^nJR#^rND^sHurley^nTG#^rND^sPeters
on^nKE#^rND^sResnicow^nK#^rND^sThompson^nFE#^rND^sYaroch^nAL#et al#Social desira
bility trait influences on self-reported dietary measures among diverse particip
ants in a multicenter multiple risk factor trial^len#J Nutr#20080000#2008#138#1#
226S-34S#20110000#2352.htm#0022-3166#J Nutr##
00488000000000229000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810170022000840180082001060660
01500188062002300203065000900226064000500235865000900240002000900249#2011nahead#
V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#154#14#article#29#14#Institu
te of Medicine#Dietary reference intakes for vitamin C, vitamin E, selenium, and
 carotenoids^len#Washington^eDC#National Academy Press#20000000#2000#20110000#23
52.htm##
00674000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100019001010100
01700120010001700137010001700154012013200171030001500303710000200318065000900320
064000500329031000300334032000200337014000300339865000900342002000900351#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#155#15#article#29#15#^rN
D^sKimmons^nJ#^rND^sGillespie^nC#^rND^sSeymour^nJ#^rND^sSerdula^nM#^rND^sBlanck^
nHM#Fruit and vegetable intake among adolescents and adults in the United States
: percentage meeting individualized recommendations^len#Medscape J Med#2#2009000
0#2009#11#1#26#20110000#2352.htm##
00739000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100027001010100
01800128010001500146010001600161010002000177012008300197030001400280065000900294
06400050030303100030030803200020031101400050031323700290031886500090034700200090
0356035001000365801001400375#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
352.htm#S#c#156#16#article#29#16#^rND^sLarson^nNI#^rND^sNeumark-Sztainer^nDR#^rN
D^sHarnack^nLJ#^rND^sWall^nMM#^rND^sStory^nMT#^rND^sEisenberg^nME#Fruit and vege
table intake correlates during the transition to young adulthood^len#Am J Prev M
ed#20080000#2008#35#1#33-7#10.1016/j.amepre.2008.03.019#20110000#2352.htm#0749-3
797#Am J Prev Med##
00698000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100021000840100018001050100
01700123010001900140012009100159030001800250065000900268064000500277031000300282
03200020028501400070028723700320029486500090032600200090033503500100034480100180
0354#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#157#17#artic
le#29#17#^rND^sLevy-Costa^nRB#^rND^sSichieri^nR#^rND^sPontes^nNS#^rND^sMonteiro^
nCA#Disponibilidade domiciliar de alimentos no Brasil: distribuição e evolução (
1974-2003)^lpt#Rev Saude Publica#20050000#2005#39#4#530-40#10.1590/S0034-8910200
5000400003#20110000#2352.htm#0034-8910#Rev Saude Publica##
00744000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100014000840100019000980100
01800117010001500135012013500150030002400285065000900309064000500318031000300323
03200020032601400060032823700320033486500090036600200090037503500100038480100240
0394#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#158#18#artic
le#29#18#^rND^sLock^nK#^rND^sPomerleau^nJ#^rND^sAltmann^nDR#^rND^sMcKee^nM#The g
lobal burden of disease attributable to low consumption of fruit and vegetables:
 implications for the global strategy on diet^len#Bull World Health Organ#200500
00#2005#83#2#100-8#10.1590/S0042-96862005000200010#20110000#2352.htm#0042-9686#B
ull World Health Organ##
00673000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100024001010100
01600125010001700141010001600158012011600174030000700290710000200297065000900299
064000500308031000200313014000300315237002300318865000900341002000900350#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#159#19#article#29#19#^rN
D^sMiller^nTM#^rND^sAbdel-Msksoud^nMF#^rND^sCrane^nLA#^rND^sMarcus^nAC#^rND^sBye
rs^nTE#Effects of social approval bias on self-reported fruit and vegetable cons
umption: a randomized controlled trial^len#Nutr J#2#20080000#2008#7#18#10.1186/1
475-2891-7-18#20110000#2352.htm##
00744000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100019000840100017001030100
01500120010001600135010001800151010001800169810000600187012011700193030001500310
06500090032506400050033403100030033903200020034201400070034486500090035100200090
0360035001000369801001500379#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
352.htm#S#c#160#20#article#29#20#^rND^sMoshfegh^nAJ#^rND^sRhodes^nDG#^rND^sBaer^
nDJ#^rND^sMurayi^nT#^rND^sClemens^nJC#^rND^sRumpler^nWV#et al#The US Department 
of Agriculture automated multiple-pass method reduces bias in the collection of 
energy intakes^len#Am J Clin Nutr#20080000#2008#88#2#324-32#20110000#2352.htm#00
02-9165#Am J Clin Nutr##
00768000000000349000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100016000840100018001000100
01900118010001600137010001700153010002400170810000600194012012200200030001900322
71000020034106500090034306400050035203100030035703200020036001400060036223700320
0368865000900400002000900409#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2
352.htm#S#c#161#21#article#29#21#^rND^sNahas^nMK#^rND^sBarros^nMVG#^rND^sGoldfin
e^nBD#^rND^sLopes^nAS#^rND^sHallal^nPC#^rND^sFarias Júnior^nJC#et al#Physical ac
tivity and eating habits in public high schools from different regions in Brazil
: the Saude na Boa Project^len#Rev Bras Epidemiol#2#20090000#2009#12#2#270-7#10.
1590/S1415-790X2009000200016#20110000#2352.htm##
00707000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100018001010100
01600119010001500135010001700150010001800167012008300185030002400268065000900292
06400050030103100030030603200020030901400060031186500090031700200090032603500100
0335801002400345#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#
162#22#article#29#22#^rND^sOnis^nM de#^rND^sOnyango^nAW#^rND^sBorgui^nE#^rND^sSi
yam^nA#^rND^sNishida^nC#^rND^sSiekmann^nJ#Development of a WHO growth reference 
for school-aged children and adolescents^len#Bull World Health Organ#20070000#20
07#85#9#660-7#20110000#2352.htm#0042-9686#Bull World Health Organ##
00584000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810160020000840160019001040160
01900123016001700142016001600159018006700175063000200242066001000244062000800254
065000900262064000500271865000900276002000900285#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2352.htm#S#c#163#23#article#29#23#^rND^sPinheiro^nABV#^rND^sL
acerda^nEMA#^rND^sBenzecry^nEH#^rND^sGomes^nMCS#^rND^sCosta^nVM#Tabela para aval
iação de consumo alimentar em medidas caseiras^lpt#4#São Paulo#Atheneu#20000000#
2000#20110000#2352.htm##
00639000000000325000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100015000840100017000990100
01900116010002000135010001500155012005300170030002000223710000200243065000900245
06400050025403100030025903200040026201400070026623700220027386500090029500200090
0304#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#164#24#artic
le#29#24#^rND^sRaper^nN#^rND^sPerloff^nB#^rND^sIngwersen^nL#^rND^sSteinfeldt^nL#
^rND^sAnand^nJ#An overview of USDA's Dietary Intake Data System^len#J Food Compo
st Anal#2#20040000#2004#17#3/4#545-55#10.1016/j.jfca.02.013#20110000#2352.htm##
00715000000000337000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100017001010100
03000118010001700148010001700165010001500182012009300197030000900290710000200299
06500090030106400050031003100030031503200020031801400070032023700320032786500090
0359002000900368#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#
165#25#article#29#25#^rND^sSantos^nJS#^rND^sCosta^nMCO#^rND^sNascimento Sobrinho
^nCL#^rND^sSilva^nMCM#^rND^sSouza^nKEP#^rND^sMelo^nBO#Perfil antropométrico e co
nsumo alimentar de adolescentes de Teixeira de Freitas - Bahia^lpt#Rev Nutr#2#20
050000#2005#18#5#623-32#10.1590/S1415-52732005000500005#20110000#2352.htm##
00661000000000313000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100017000840100016001010100
01900117010001900136012010800155030001900263710000200282065000900284064000500293
031000200298032000200300014000800302237001900310865000900329002000900338#2011nah
ead#V:\SciELO\serial\rsp\2011nahead\markup\2352.htm#S#c#166#26#article#29#26#^rN
D^sTurrell^nG#^rND^sHewitt^nB#^rND^sPatterson^nC#^rND^sOldenburg^nB#Measuring so
cio-economic position in dietary research: is choice of socio-economic indicator
 important?^len#Public Health Nutr#2#20030000#2003#6#2#191-200#10.1079/PHN200241
6#20110000#2352.htm##
00601000000000289000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810100018000840100018001020100
01900120012011000139030001600249710000200265065000900267064000500276031000300281
032000200284014000700286865000900293002000900302#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2352.htm#S#c#167#27#article#29#27#^rND^sVariyam^nJN#^rND^sBla
ylock^nJ#^rND^sSmallwood^nD#Characterizing the distribution of macronutrient Int
ake among U.S. adults: a quantile regression approach^len#Am J Agric Econ#2#2002
0000#2002#84#2#454-66#20110000#2352.htm##
00506000000000217000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810170067000840180090001510660
01500241065000900256064000500265865000900270002000900279#2011nahead#V:\SciELO\se
rial\rsp\2011nahead\markup\2352.htm#S#c#168#28#article#29#28#World Cancer Resear
ch Fund^dAmerican Institute for Cancer Research#Food, nutrition, physical activi
ty and the prevention of cancer: a global perspective^len#Washington^eDC#2007000
0#2007#20110000#2352.htm##
00469000000000217000450000400110000070200480001170500020005970600020006170000040
00637010003000677090008000707080003000781180003000810170026000840180102001100660
00700212065000900219064000500228865000900233002000900242#2011nahead#V:\SciELO\se
rial\rsp\2011nahead\markup\2352.htm#S#c#169#29#article#29#29#World Health Organi
zation#Diet, nutrition and prevention of chronic diseases: report of a joint WHO
/FAO expert consultation^len#Geneva#20030000#2003#20110000#2352.htm##
00275000000000169000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750910009000770920007000860020009000937030
00300102#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2196.htm#S#o#1#1#arti
cle#1#20110411#122347#2196.htm#84##
04469000000000733000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000300095121000300098049000300101158000300104030001900107
03200060012606500090013201400070014103500100014822300090015801201020016701200850
02690120112003540100043004660100040005090700071005490700064006200700076006840830
78800760085001001548085003801558085003301596085003701629085003201666085004701698
08307160174508500100246108500400247108500230251108500320253408500290256608500470
25950830837026420850010034790850040034890850034035290850037035630850032036000850
04503632117000803677072000203685112000903687111001003696114000903706113001103715
002000903726#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2196.htm#S#h#2#1#
article#1#oa#pt#br1.1#1#4.0#ND#16#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0
#0034-8910#20110401#Consórcio intermunicipal para a aquisição de medicamentos: i
mpacto no desabastecimento e no custo^lpt#Municipal consortia for medicine procu
rement: impact on the stock-out and budget^len#Consorcio intermunicipal para la 
adquisición de medicamentos: impacto en el desabastecimiento y en el costo^les#^
rND^1A01^nSilvâni Maria Sehnem do^sAmaral#^rND^1A01 A02 A03^nCarine Raquel^sBlat
t#Universidade Federal de Santa Catarina^iA01^cFlorianópolis^sSC^pBrasil#Univers
idade do Sul de Santa Catarina^iA02^cTubarão^sSC^pBrasil#UFSC^iA03^1Programa de 
Pós-Graduação em Farmácia^cFlorianópolis^sSC^pBrasil#^lpt^aO estudo analisa o im
pacto de consórcio para a aquisição de medicamentos no desabastecimento e no cus
to dos medicamentos do Componente da Assistência Farmacêutica Básica do municípi
o de Indaial, SC. Observou-se uma redução aproximada de 12,0% de 2008 para 2007,
 e de 48,0% de 2009 para 2007 no número de itens que apresentaram falta em pelo 
menos um dia; a redução foi de 33% no custo total de aquisição quando comparada 
a aquisição pelo consórcio (2009) com a aquisição municipal (2007), e de 18% qua
ndo comparada aos valores médios do Banco de Preço em Saúde do Ministério da Saú
de/2009. A aquisição de medicamentos pelo consórcio diminuiu o desabastecimento 
e apresentou economia, possibilitando aquisição de maior quantidade de produtos 
com a mesma disponibilidade de recursos.#^ddecs^i1#^tm^lpt^kPreparações Farmacêu
ticas^i1#^tm^lpt^kPreço de Medicamento^i1#^tm^lpt^kProposta de Concorrência^i1#^
tm^lpt^kConsórcios de Saúde^i1#^tm^lpt^kAssistência Farmacêutica, economia^i1#^l
en^aThe study evaluated the impact of the consortia on the budget and shortage o
f medicines for the basic pharmaceutical assistance component in Indaial municip
ality, Southern Brazil. The number of items with a stock out for at least one da
y decreased by 12% from 2008 to 2007 and 48% from 2009 to 2007; total costs decr
eased by 33%, when comparing procurement by consortia (2009) to municipal procur
ement (2007), and by 18% when compared to the average values of the 2009 Health 
Prices Database from the Ministry of Health. The procurement of medicines by the
 consortia decreased stock outs and represented an economy of scale, allowing fo
r the procurement of a greater quantity of products with the same budget.#^ddecs
^i2#^tm^len^kPharmaceutical Preparations^i2#^tm^len^kDrug Price^i2#^tm^len^kComp
etitive Bidding^i2#^tm^len^kHealth Consortia^i2#^tm^len^kPharmaceutical Services
, economics^i2#^les^aEl estudio analiza el impacto de consorcio para la adquisic
ión de medicamentos en el desabastecimiento y en el costo de los medicamentos de
l Componente de la Asistencia Farmacéutica Básica del municipio de Indaial, Sur 
de Brasil. Hubo una reducción aproximada de 12,0% de 2008 a 2007, y de 48,0% de 
2009 a 2007 en el número de itens que presentaron falta en por lo menos un día. 
La reducción fue de 33% en el costo total de adquisición al comparar la adquisic
ión por el consorcio (2009) con la adquisición municipal (2007), y de 18% al com
parar con los valores promedios del Banco de Precio en Salud del Ministerio de l
a Salud/2009. La adquisición de medicamentos por el consorcio disminuyó el desab
astecimiento y presentó economía, posibilitando adquisición de mayor cantidad de
 productos con la misma disponibilidad de recursos.#^ddecs^i3#^tm^les^kPreparaci
ones Farmacéuticas^i3#^tm^les^kPrecio de Medicamento^i3#^tm^les^kPropuestas de L
icitación^i3#^tm^les^kConsorcios de Salud^i3#^tm^les^kServicios Farmacéutico, ec
onomía^i3#vancouv#5#20100417#17/4/2010#20101114#14/11/2010#2196.htm##
04511000000000733000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750710003000770400003000800010006000830420
00200089120000400091038000300095121000300098049000300101158000300104030001900107
03200060012606500090013201400070014103500100014822300090015801201160016701200990
02830120126003820100043005080100040005510700071005910700064006620700076007260830
78800802085001001590085003801600085003301638085003701671085003201708085004701740
08307160178708500100250308500400251308500230255308500320257608500290260808500470
26370830837026840850010035210850040035310850034035710850037036050850032036420850
04503674117000803719072000203727112000903729111001003738114000903748113001103757
002000903768#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2196.htm#S#f#3#1#
article#1#oa#pt#br1.1#1#4.0#ND#16#nd#nd#Rev. Saúde Pública#ahead#20110000#^f0^l0
#0034-8910#20110401#<b>Consórcio intermunicipal para a aquisição de medicamentos
</b>: <b>impacto no desabastecimento e no custo</b>^lpt#<b>Municipal consortia f
or medicine procurement</b>: <b>impact on the stock-out and budget</b>^len#<b>Co
nsorcio intermunicipal para la adquisición de medicamentos</b>: <b>impacto en el
 desabastecimiento y en el costo</b>^les#^rND^1A01^nSilvâni Maria Sehnem do^sAma
ral#^rND^1A01 A02 A03^nCarine Raquel^sBlatt#Universidade Federal de Santa Catari
na^iA01^cFlorianópolis^sSC^pBrasil#Universidade do Sul de Santa Catarina^iA02^cT
ubarão^sSC^pBrasil#UFSC^iA03^1Programa de Pós-Graduação em Farmácia^cFlorianópol
is^sSC^pBrasil#^lpt^aO estudo analisa o impacto de consórcio para a aquisição de
 medicamentos no desabastecimento e no custo dos medicamentos do Componente da A
ssistência Farmacêutica Básica do município de Indaial, SC. Observou-se uma redu
ção aproximada de 12,0% de 2008 para 2007, e de 48,0% de 2009 para 2007 no númer
o de itens que apresentaram falta em pelo menos um dia; a redução foi de 33% no 
custo total de aquisição quando comparada a aquisição pelo consórcio (2009) com 
a aquisição municipal (2007), e de 18% quando comparada aos valores médios do Ba
nco de Preço em Saúde do Ministério da Saúde/2009. A aquisição de medicamentos p
elo consórcio diminuiu o desabastecimento e apresentou economia, possibilitando 
aquisição de maior quantidade de produtos com a mesma disponibilidade de recurso
s.#^ddecs^i1#^tm^lpt^kPreparações Farmacêuticas^i1#^tm^lpt^kPreço de Medicamento
^i1#^tm^lpt^kProposta de Concorrência^i1#^tm^lpt^kConsórcios de Saúde^i1#^tm^lpt
^kAssistência Farmacêutica, economia^i1#^len^aThe study evaluated the impact of 
the consortia on the budget and shortage of medicines for the basic pharmaceutic
al assistance component in Indaial municipality, Southern Brazil. The number of 
items with a stock out for at least one day decreased by 12% from 2008 to 2007 a
nd 48% from 2009 to 2007; total costs decreased by 33%, when comparing procureme
nt by consortia (2009) to municipal procurement (2007), and by 18% when compared
 to the average values of the 2009 Health Prices Database from the Ministry of H
ealth. The procurement of medicines by the consortia decreased stock outs and re
presented an economy of scale, allowing for the procurement of a greater quantit
y of products with the same budget.#^ddecs^i2#^tm^len^kPharmaceutical Preparatio
ns^i2#^tm^len^kDrug Price^i2#^tm^len^kCompetitive Bidding^i2#^tm^len^kHealth Con
sortia^i2#^tm^len^kPharmaceutical Services, economics^i2#^les^aEl estudio analiz
a el impacto de consorcio para la adquisición de medicamentos en el desabastecim
iento y en el costo de los medicamentos del Componente de la Asistencia Farmacéu
tica Básica del municipio de Indaial, Sur de Brasil. Hubo una reducción aproxima
da de 12,0% de 2008 a 2007, y de 48,0% de 2009 a 2007 en el número de itens que 
presentaron falta en por lo menos un día. La reducción fue de 33% en el costo to
tal de adquisición al comparar la adquisición por el consorcio (2009) con la adq
uisición municipal (2007), y de 18% al comparar con los valores promedios del Ba
nco de Precio en Salud del Ministerio de la Salud/2009. La adquisición de medica
mentos por el consorcio disminuyó el desabastecimiento y presentó economía, posi
bilitando adquisición de mayor cantidad de productos con la misma disponibilidad
 de recursos.#^ddecs^i3#^tm^les^kPreparaciones Farmacéuticas^i3#^tm^les^kPrecio 
de Medicamento^i3#^tm^les^kPropuestas de Licitación^i3#^tm^les^kConsorcios de Sa
lud^i3#^tm^les^kServicios Farmacéutico, economía^i3#vancouv#5#20100417#17/4/2010
#20101114#14/11/2010#2196.htm##
04684000000000745000450000400110000070200480001170500020005970600020006170000020
00637010002000657090008000677080002000750640007000770710003000840400003000870010
00600090042000200096120000400098121000300102049000300105158000300108030001900111
03200060013006500090013601400070014503500100015222300090016201201020017101200850
02730120112003580100043004700100040005130700073005530700066006260700078006920830
82400770085001001594085003801604085003301642085003701675085003201712085004701744
08307440179108500100253508500400254508500230258508500320260808500290264008500470
26690830877027160850010035930850040036030850034036430850037036770850032037140850
04503746117000803791072000203799112000903801111001003810114000903820113001103829
002000903840008008903849#2011nahead#V:\SciELO\serial\rsp\2011nahead\markup\2196.
htm#S#l#4#1#article#1#^a2011#oa#pt#br1.1#1#4.0#16#nd#nd#Rev. saúde pública#ahead
#20110000#^f0^l0#0034-8910#20110401#Consórcio intermunicipal para a aquisição de
 medicamentos: impacto no desabastecimento e no custo^lpt#Municipal consortia fo
r medicine procurement: impact on the stock-out and budget^len#Consorcio intermu
nicipal para la adquisición de medicamentos: impacto en el desabastecimiento y e
n el costo^les#^rND^1A01^nSilvâni Maria Sehnem do^sAmaral#^rND^1A01 A02 A03^nCar
ine Raquel^sBlatt#^iA01^1Universidade Federal de Santa Catarina^cFlorianópolis^s
SC^pBrasil#^iA02^1Universidade do Sul de Santa Catarina^cTubarão^sSC^pBrasil#^iA
03^1UFSC^2Programa de Pós-Graduação em Farmácia^cFlorianópolis^sSC^pBrasil#^lpt^
aO estudo analisa o impacto de consórcio para a aquisição de medicamentos no des
abastecimento e no custo dos medicamentos do Componente da Assistência Farmacêut
ica Básica do município de Indaial, SC. Observou-se uma redução aproximada de 12
,0 por cento de 2008 para 2007, e de 48,0 por cento de 2009 para 2007 no número 
de itens que apresentaram falta em pelo menos um dia; a redução foi de 33 por ce
nto no custo total de aquisição quando comparada a aquisição pelo consórcio (200
9) com a aquisição municipal (2007), e de 18 por cento quando comparada aos valo
res médios do Banco de Preço em Saúde do Ministério da Saúde/2009. A aquisição d
e medicamentos pelo consórcio diminuiu o desabastecimento e apresentou economia,
 possibilitando aquisição de maior quantidade de produtos com a mesma disponibil
idade de recursos.#^ddecs^i1#^tm^lpt^kPreparações Farmacêuticas^i1#^tm^lpt^kPreç
o de Medicamento^i1#^tm^lpt^kProposta de Concorrência^i1#^tm^lpt^kConsórcios de 
Saúde^i1#^tm^lpt^kAssistência Farmacêutica, economia^i1#^len^aThe study evaluate
d the impact of the consortia on the budget and shortage of medicines for the ba
sic pharmaceutical assistance component in Indaial municipality, Southern Brazil
. The number of items with a stock out for at least one day decreased by 12 perc
ent from 2008 to 2007 and 48 percent from 2009 to 2007; total costs decreased by
 33 percent, when comparing procurement by consortia (2009) to municipal procure
ment (2007), and by 18 percent when compared to the average values of the 2009 H
ealth Prices Database from the Ministry of Health. The procurement of medicines 
by the consortia decreased stock outs and represented an economy of scale, allow
ing for the procurement of a greater quantity of products with the same budget.#
^ddecs^i2#^tm^len^kPharmaceutical Preparations^i2#^tm^len^kDrug Price^i2#^tm^len
^kCompetitive Bidding^i2#^tm^len^kHealth Consortia^i2#^tm^len^kPharmaceutical Se
rvices, economics^i2#^les^aEl estudio analiza el impacto de consorcio para la ad
quisición de medicamentos en el desabastecimiento y en el costo de los medicamen
tos del Componente de la Asistencia Farmacéutica Básica del municipio de Indaial
, Sur de Brasil. Hubo una reducción aproximada de 12,0 por ciento de 2008 a 2007
, y de 48,0 por ciento de 2009 a 2007 en el número de itens que presentaron falt
a en por lo menos un día. La reducción fue de 33 por ciento en el costo total de
 adquisición al comparar la adquisición por el consorcio (2009) con la adquisici
ón municipal (2007), y de 18 por ciento al comparar con los valores promedios de
l Banco de Precio en Salud del Ministerio de la Salud/2009. La adquisición de me
dicamentos por el consorcio disminuyó el desabastecimiento y presentó economía, 
posibilitando adquisición de mayor cantidad de productos con la misma disponibil
idad de recursos.#^ddecs^i3#^tm^les^kPreparaciones Farmacéuticas^i3#^tm^les^kPre
cio de Medicamento^i3#^tm^les^kPropuestas de Licitación^i3#^tm^les^kConsorcios d
e Salud^i3#^tm^les^kServicios Farmacéutico, economía^i3#vancouv#5#20100417#17/4/
2010#20101114#14/11/2010#2196.htm#Internet^ihttp://www.scielo.br/scielo.php?scri
pt=sci_arttext&pid=S0034-89102011005000016##
00465000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000300075704023200078002000900310#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#5#1#article#75#<p><a name="top">
</a><font face="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Cons&oacute;r
cio    intermunicipal para a aquisi&ccedil;&atilde;o de medicamentos: impacto no
 desabastecimento    e no custo</b></font></p>     ^cY#2196.htm##
00255000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000300075704002200078002000900100#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#6#2#article#75#<p>&nbsp;</p>    
 ^cY#2196.htm##
00406000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000300075704017300078002000900251#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#7#3#article#75#<p><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="3"><b>Municipal consortia    for medi
cine procurement: impact on the stock-out and budget</b></font></p>     ^cY#2196
.htm##
00255000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000300075704002200078002000900100#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#8#4#article#75#<p>&nbsp;</p>    
 ^cY#2196.htm##
00443000000000145000450000400110000070200480001170500020005970600020006170000020
0063701000200065709000800067708000300075704021000078002000900288#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#9#5#article#75#<p><font face="Ve
rdana, Arial, Helvetica, sans-serif" size="3"><b>Consorcio intermunicipal    par
a la adquisici&oacute;n de medicamentos: impacto en el desabastecimiento    y en
 el costo</b></font></p>     ^cY#2196.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000300076704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#10#6#article#75#<p>&nbsp;</p>   
  ^cY#2196.htm##
00256000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000300076704002200079002000900101#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#11#7#article#75#<p>&nbsp;</p>   
  ^cY#2196.htm##
00417000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000300076704018300079002000900262#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#12#8#article#75#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="2"><b>Silv&acirc;ni    Maria Sehnem 
do Amaral<sup>I</sup>; Carine Raquel Blatt<sup>I, II, III</sup></b></font></p>  
   ^cY#2196.htm##
00527000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000200066709000800068708000300076704029300079002000900372#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#13#9#article#75#<p><font face="V
erdana, Arial, Helvetica, sans-serif" size="2"><sup>I</sup>Curso    de Especiali
za&ccedil;&atilde;o em Gest&atilde;o da Assist&ecirc;ncia Farmac&ecirc;utica.   
 Curso de Farm&aacute;cia. Universidade Federal de Santa Catarina (UFSC). Floria
n&oacute;polis,    SC, Brasil    ^cY#2196.htm##
00368000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704013300080002000900213#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#14#10#article#75#<br>   <sup>II<
/sup>Curso de Farm&aacute;cia e Medicina. Universidade do Sul de Santa    Catari
na. Tubar&atilde;o, SC, Brasil    ^cY#2196.htm##
00410000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704017500080002000900255#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#15#11#article#75#<br>   <sup>III
</sup>Programa de P&oacute;s-Gradua&ccedil;&atilde;o em Farm&aacute;cia.    Curs
o de Farm&aacute;cia. UFSC. Florian&oacute;polis, SC, Brasil</font></p>     ^cY#
2196.htm##
00379000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704014400080002000900224#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#16#12#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><a href="#back">Correspond&ecirc
;ncia    | Correspondence</a></font></p>     ^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#17#13#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00279000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704004400080002000900124#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#18#14#article#75#<p>&nbsp;</p> <
hr size="1" noshade>     ^cY#2196.htm##
00331000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704009600080002000900176#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#19#15#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY
#2196.htm##
01336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704110100080002000901181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#20#16#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">O estudo analisa    o impacto de
 cons&oacute;rcio para a aquisi&ccedil;&atilde;o de medicamentos    no desabaste
cimento e no custo dos medicamentos do Componente da Assist&ecirc;ncia    Farmac
&ecirc;utica B&aacute;sica do munic&iacute;pio de Indaial, SC. Observou-se    um
a redu&ccedil;&atilde;o aproximada de 12,0% de 2008 para 2007, e de 48,0%    de 
2009 para 2007 no n&uacute;mero de itens que apresentaram falta em pelo menos   
 um dia; a redu&ccedil;&atilde;o foi de 33% no custo total de aquisi&ccedil;&ati
lde;o    quando comparada a aquisi&ccedil;&atilde;o pelo cons&oacute;rcio (2009)
 com    a aquisi&ccedil;&atilde;o municipal (2007), e de 18% quando comparada ao
s valores    m&eacute;dios do Banco de Pre&ccedil;o em Sa&uacute;de do Minist&ea
cute;rio    da Sa&uacute;de/2009. A aquisi&ccedil;&atilde;o de medicamentos pelo
 cons&oacute;rcio    diminuiu o desabastecimento e apresentou economia, possibil
itando aquisi&ccedil;&atilde;o    de maior quantidade de produtos com a mesma di
sponibilidade de recursos.</font></p>     ^cY#2196.htm##
00560000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704032500080002000900405#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#21#17#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descritores:    </b> Prepara&
ccedil;&otilde;es Farmac&ecirc;uticas. Pre&ccedil;o de Medicamento.    Proposta 
de Concorr&ecirc;ncia. Cons&oacute;rcios de Sa&uacute;de. Assist&ecirc;ncia    F
armac&ecirc;utica, economia.</font></p> <hr size="1" noshade>     ^cY#2196.htm##
00333000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704009800080002000900178#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#22#18#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^
cY#2196.htm##
01054000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704081900080002000900899#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#23#19#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">The study evaluated    the impac
t of the consortia on the budget and shortage of medicines for the    basic phar
maceutical assistance component in Indaial municipality, Southern    Brazil. The
 number of items with a stock out for at least one day decreased    by 12% from 
2008 to 2007 and 48% from 2009 to 2007; total costs decreased by    33%, when co
mparing procurement by consortia (2009) to municipal procurement    (2007), and 
by 18% when compared to the average values of the 2009 Health Prices    Database
 from the Ministry of Health. The procurement of medicines by the consortia    d
ecreased stock outs and represented an economy of scale, allowing for the procur
ement    of a greater quantity of products with the same budget.</font></p>     
^cY#2196.htm##
00482000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704024700080002000900327#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#24#20#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptors:    </b> Pharmace
utical Preparations. Drug Price. Competitive Bidding. Health Consortia.    Pharm
aceutical Services, economics.</font></p> <hr size="1" noshade>     ^cY#2196.htm
##
00332000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704009700080002000900177#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#25#21#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b></font></p>     ^c
Y#2196.htm##
01286000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704105100080002000901131#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#26#22#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">El estudio analiza    el impacto
 de consorcio para la adquisici&oacute;n de medicamentos en el desabastecimiento
    y en el costo de los medicamentos del Componente de la Asistencia Farmac&eac
ute;utica    B&aacute;sica del municipio de Indaial, Sur de Brasil. Hubo una red
ucci&oacute;n    aproximada de 12,0% de 2008 a 2007, y de 48,0% de 2009 a 2007 e
n el n&uacute;mero    de itens que presentaron falta en por lo menos un d&iacute
;a. La reducci&oacute;n    fue de 33% en el costo total de adquisici&oacute;n al
 comparar la adquisici&oacute;n    por el consorcio (2009) con la adquisici&oacu
te;n municipal (2007), y de 18%    al comparar con los valores promedios del Ban
co de Precio en Salud del Ministerio    de la Salud/2009. La adquisici&oacute;n 
de medicamentos por el consorcio disminuy&oacute;    el desabastecimiento y pres
ent&oacute; econom&iacute;a, posibilitando adquisici&oacute;n    de mayor cantid
ad de productos con la misma disponibilidad de recursos.</font></p>     ^cY#2196
.htm##
00528000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704029300080002000900373#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#27#23#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><b>Descriptores:    </b> Prepara
ciones Farmac&eacute;uticas. Precio de Medicamento. Propuestas de    Licitaci&oa
cute;n. Consorcios de Salud. Servicios Farmac&eacute;utico, econom&iacute;a.</fo
nt></p> <hr size="1" noshade>     ^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#28#24#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#29#25#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00349000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704011400080002000900194#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#30#26#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="3"><b>INTRODU&Ccedil;&Atilde;O</b><
/font></p>     ^cY#2196.htm##
00794000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704055900080002000900639#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#31#27#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">O processo de descentraliza&cced
il;&atilde;o    da pol&iacute;tica de sa&uacute;de no Brasil levou a um signific
ativo incremento    das atividades e da participa&ccedil;&atilde;o dos munic&iac
ute;pios na provis&atilde;o    de servi&ccedil;os de sa&uacute;de. Isso acarreto
u nova realidade para muitos    munic&iacute;pios, como inexist&ecirc;ncia de re
cursos humanos e financeiros,    dificuldade de acesso ao uso de tecnologias e f
alta de estrutura f&iacute;sica    adequada.</font></p>     ^cY#2196.htm##
00765000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704053000080002000900610#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#32#28#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Diante dessas dificuldades,    o
s cons&oacute;rcios na a&eacute;rea da sa&uacute;de encontraram condi&ccedil;&ot
ilde;es    favor&aacute;veis para se desenvolver, sobretudo em munic&iacute;pios
 de pequeno    porte, e para sanar d&eacute;ficits do processo de regionaliza&cc
edil;&atilde;o    na aten&ccedil;&atilde;o &agrave; m&eacute;dia complexidade, n
a oferta de consultas    m&eacute;dicas de especialidades, em diagnose e terapia
.<sup>2,3</sup></font></p>     ^cY#2196.htm##
00769000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704053400080002000900614#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#33#29#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Seguindo o processo    de descen
traliza&ccedil;&atilde;o do Sistema &Uacute;nico de Sa&uacute;de (SUS),    a aqu
isi&ccedil;&atilde;o dos medicamentos essenciais passou a ser de responsabilidad
e    dos munic&iacute;pios, com as mesmas dificuldades inerentes &agrave; sua op
eracionaliza&ccedil;&atilde;o.    Al&eacute;m disso, a despeito do or&ccedil;ame
nto p&uacute;blico finito, o custo    dos medicamentos tem aumentado ao longo do
s anos.<sup>5</sup></font></p>     ^cY#2196.htm##
00842000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704060700080002000900687#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#34#30#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Em 2008, os munic&iacute;pios   
 da Associa&ccedil;&atilde;o dos Munic&iacute;pios do M&eacute;dio Vale do Itaja
&iacute;    (AMMVI), no estado de Santa Catarina, passaram a utilizar o Cons&oac
ute;rcio    Intermunicipal de Sa&uacute;de (CIS-AMMVI) para a aquisi&ccedil;&ati
lde;o de    medicamentos. Esse novo modelo de aquisi&ccedil;&atilde;o tinha como
 meta a    redu&ccedil;&atilde;o dos custos operacionais dos munic&iacute;pios, 
bem como    a busca por pre&ccedil;os mais vantajosos que os obtidos em compras 
individuais.</font></p>     ^cY#2196.htm##
00574000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704033900080002000900419#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#35#31#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">O presente estudo    teve como o
bjetivo analisar o impacto da aquisi&ccedil;&atilde;o de medicamentos    pelo co
ns&oacute;rcio CIS-AMMVI no desabastecimento e no custo dos medicamentos    do c
omponente da Assist&ecirc;ncia Farmac&ecirc;utica B&aacute;sica.</font></p>     
^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#36#32#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00339000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704010400080002000900184#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#37#33#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="3"><b>M&Eacute;TODOS</b></font></p>
     ^cY#2196.htm##
00675000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704044000080002000900520#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#38#34#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Estudo retrospectivo    no munic
&iacute;pio de Indaial, SC, de 2007 a 2009, fundamentado em pesquisa    document
al. A partir de documentos das licita&ccedil;&otilde;es realizadas no    per&iac
ute;odo, identificaram-se os medicamentos adquiridos, quantidades, valores    un
it&aacute;rios, modalidades de licita&ccedil;&atilde;o e periodicidade de    com
pras.</font></p>     ^cY#2196.htm##
01050000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704081500080002000900895#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#39#35#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">As compara&ccedil;&otilde;es    
de custos e de desabastecimento foram realizadas em uma amostra dos medicamentos
    da Rela&ccedil;&atilde;o Municipal de Medicamentos. Os medicamentos comuns &
agrave;s    tr&ecirc;s listas do per&iacute;odo de estudo foram utilizados para 
a classifica&ccedil;&atilde;o    dos itens nas curvas ABC e PQR. A primeira cons
istiu na separa&ccedil;&atilde;o    dos medicamentos em tr&ecirc;s grupos, confo
rme o valor da demanda em determinado    per&iacute;odo (ponto de vista econ&oci
rc;mico); a segunda, na freq&uuml;&ecirc;ncia    de utiliza&ccedil;&atilde;o dos
 itens (classifica&ccedil;&atilde;o de popularidade).    A amostra foi composta 
por 38 medicamentos pertencentes &agrave;s classes A    e P.</font></p>     ^cY#
2196.htm##
00434000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704019900080002000900279#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#40#36#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">O impacto no desabastecimento   
 foi obtido por levantamento dos medicamentos que estavam em falta em algum mome
nto.</font></p>     ^cY#2196.htm##
00800000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704056500080002000900645#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#41#37#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Os valores unit&aacute;rios    d
os medicamentos adquiridos nas licita&ccedil;&otilde;es de 2007 (sem cons&oacute
;rcio),    2008 (mista), 2009 (cons&oacute;rcio) foram comparados quanto &agrave
; diferen&ccedil;a    percentual por item e o percentual de itens com decr&eacut
e;scimo, acr&eacute;scimo    ou sem altera&ccedil;&atilde;o no valor unit&aacute
;rio e com o valor m&eacute;dio    do Banco de Pre&ccedil;o em Sa&uacute;de/Mini
st&eacute;rio da Sa&uacute;de (BPS/MS)    em 2009.</font></p>     ^cY#2196.htm##
00593000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704035800080002000900438#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#42#38#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">O impacto no custo    das aquisi
&ccedil;&otilde;es foi obtido pela estimativa de custo de aquisi&ccedil;&atilde;
o    total para a amostra, a partir do consumo m&eacute;dio anual multiplicado p
elos    valores de custo unit&aacute;rio praticados em cada ano e pelo BPS/MS 20
09.</font></p>     ^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#43#39#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00335000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704010000080002000900180#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#44#40#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="3"><b>RESULTADOS</b></font></p>    
 ^cY#2196.htm##
00704000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704046900080002000900549#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#45#41#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Em rela&ccedil;&atilde;o    ao n
&uacute;mero de itens que apresentaram falta em pelo menos um dia, houve    uma 
redu&ccedil;&atilde;o aproximada de 12,0% em 2008 em rela&ccedil;&atilde;o    a 
2007, e de 48% em 2009 em rela&ccedil;&atilde;o a 2007. O n&uacute;mero de    me
dicamentos em falta por um per&iacute;odo superior a 90 dias foi de 11 (2007),  
  tr&ecirc;s (2008) e dois (2009).</font></p>     ^cY#2196.htm##
00762000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704052700080002000900607#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#46#42#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Os pre&ccedil;os    pagos em 200
8 para a aquisi&ccedil;&atilde;o dos medicamentos por unidade, j&aacute;    sob 
influ&ecirc;ncia do cons&oacute;rcio, foram sistematicamente mais baixos    que 
em 2007 (63% dos itens). Quando comparados os valores unit&aacute;rios de    200
9 com a aquisi&ccedil;&atilde;o dos medicamentos por meio de cons&oacute;rcio   
 com os valores de 2007, os valores unit&aacute;rios foram inferiores para 76%  
  dos itens.</font></p>     ^cY#2196.htm##
00636000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704040100080002000900481#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#47#43#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Apesar do aumento    do custo un
it&aacute;rio de alguns itens, o custo total da aquisi&ccedil;&atilde;o    de me
dicamentos por meio do cons&oacute;rcio, considerando os pre&ccedil;os    pratic
ados em 2007, 2008, 2009 e BPS 2009, seria de R$ 302.962,60, R$ 247.734,63,    R
$ 203.022,32 e R$ 247.148,44, respectivamente.</font></p>     ^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#48#44#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00341000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704010600080002000900186#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#49#45#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="3"><b>DISCUSS&Atilde;O</b></font></
p>     ^cY#2196.htm##
00617000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704038200080002000900462#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#50#46#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">A ades&atilde;o    ao cons&oacut
e;rcio para a aquisi&ccedil;&atilde;o de medicamentos possibilitou    a redu&cce
dil;&atilde;o dos custos, garantindo maior oferta de medicamentos    e diminui&c
cedil;&atilde;o do desabastecimento do componente da Assist&ecirc;ncia    Farmac
&ecirc;utica B&aacute;sica.</font></p>     ^cY#2196.htm##
00573000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704033800080002000900418#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#51#47#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Em rela&ccedil;&atilde;o    ao d
esabastecimento, houve redu&ccedil;&atilde;o na m&eacute;dia de dias por    medi
camento em falta e o n&uacute;mero de itens em falta, o que produziu impacto    
positivo na gest&atilde;o dos medicamentos no munic&iacute;pio.</font></p>     ^
cY#2196.htm##
01391000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704115600080002000901236#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#52#48#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Tal redu&ccedil;&atilde;o    pod
e ser explicada, em parte, pela nova din&acirc;mica do processo de compras    pe
lo cons&oacute;rcio, possibilitando ao farmac&ecirc;utico maior gerenciamento   
 do processo, inclusive emiss&atilde;o e envio da ordem de compra ao fornecedor,
    o que antes era realizado pelo setor de compra. Outra vantagem &eacute; o mo
delo    de contrato por ata de registro de pre&ccedil;os, com cota&ccedil;&atild
e;o    v&aacute;lida para o per&iacute;odo de 12 meses. O registro de pre&ccedil
;os    possibilita antecipar-se &agrave; demanda e racionalizar melhor a utiliza
&ccedil;&atilde;o    do or&ccedil;amento dispon&iacute;vel no momento da contrat
a&ccedil;&atilde;o    e n&atilde;o no in&iacute;cio da licita&ccedil;&atilde;o. 
Esse modelo tamb&eacute;m    diminui o n&uacute;mero de licita&ccedil;&otilde;es
, propiciando redu&ccedil;&atilde;o    de pre&ccedil;os pela economia em escala,
 agiliza o processo de aquisi&ccedil;&atilde;o,    com maior rapidez na contrata
&ccedil;&atilde;o, e permite a redu&ccedil;&atilde;o    do estoque f&iacute;sico
.</font></p>     ^cY#2196.htm##
00706000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704047100080002000900551#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#53#49#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Os pre&ccedil;os    dos medicame
ntos tendem a cair com a economia de escala e o poder de negocia&ccedil;&atilde;
o    de pre&ccedil;os aumenta com maiores volumes negociados. Segundo Ferraes &a
mp;    Cordoni Junior,<sup>1</sup> o Cons&oacute;rcio Paran&aacute; Sa&uacute;de
 foi    uma op&ccedil;&atilde;o de gerenciamento que ofereceu economia de escala
, com    pre&ccedil;os competitivos.</font></p>     ^cY#2196.htm##
00907000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704067200080002000900752#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#54#50#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Note-se que os    c&aacute;lculo
s foram realizados com 38 itens, para um munic&iacute;pio de aproximadamente    
50 mil habitantes. Na pr&aacute;tica, a diminui&ccedil;&atilde;o de custos pode 
   ser ainda maior quando calculada em percentual: redu&ccedil;&atilde;o de 33% 
   no custo total de aquisi&ccedil;&atilde;o quando comparada a compra pelo cons
&oacute;rcio    (2009) com a compra municipal (2007), e redu&ccedil;&atilde;o de
 18% no custo    total de aquisi&ccedil;&atilde;o na compra por cons&oacute;rcio
 (2009) em rela&ccedil;&atilde;o    aos valores m&eacute;dios do BPS/MS 2009.</f
ont></p>     ^cY#2196.htm##
01189000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704095400080002000901034#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#55#51#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Para aqueles munic&iacute;pios  
  que n&atilde;o disp&otilde;em de cons&oacute;rcio para a aquisi&ccedil;&atilde
;o    de medicamentos, verificaram-se algumas vantagens que podem ser adequadas 
ao    processo de compra municipal. S&atilde;o elas: altera&ccedil;&atilde;o da 
modalidade    de licita&ccedil;&atilde;o de tomada de pre&ccedil;os para preg&at
ilde;o eletr&ocirc;nico;    utiliza&ccedil;&atilde;o do sistema de registro de p
re&ccedil;os; aplica&ccedil;&atilde;o    das san&ccedil;&otilde;es permitidas em
 edital quando de seu descumprimento;    maior autonomia ao profissional farmac&
ecirc;utico para emitir e enviar as ordens    de compra. Essas modifica&ccedil;&
otilde;es provavelmente n&atilde;o propiciam    a vantagem da economia de escala
 verificada pelo cons&oacute;rcio, mas podem    dar maior agilidade &agrave;s aq
uisi&ccedil;&otilde;es de medicamentos.</font></p>     ^cY#2196.htm##
00917000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704068200080002000900762#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#56#52#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Segundo Reis &amp;    Perini,<su
p>4</sup> &eacute; essencial que se incorporem cada vez mais os modernos    conc
eitos de log&iacute;stica de materiais para evitar o desabastecimento de    medi
camentos devido a fatores internos, tais como planejamento inadequado ou    empr
ego de ferramentas gerenciais ineficientes. Al&eacute;m disso, &eacute;    neces
s&aacute;rio considerar o medicamento como um insumo diferencial durante    o pr
ocesso de licita&ccedil;&atilde;o. A falta dele compromete o servi&ccedil;o    d
e sa&uacute;de e coloca em descr&eacute;dito a gest&atilde;o municipal de sa&uac
ute;de.</font></p>     ^cY#2196.htm##
00968000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704073300080002000900813#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#57#53#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">A ades&atilde;o    ao cons&oacut
e;rcio possibilitou economia de recursos e oferta mais regular    de medicamento
s. Al&eacute;m disso, munic&iacute;pios menores puderam usufruir    do poder de 
compra e da infra-estrutura administrativa dessa forma de organiza&ccedil;&atild
e;o,    desobrigando a realiza&ccedil;&atilde;o do processo de licita&ccedil;&at
ilde;o    de medicamentos em v&aacute;rios munic&iacute;pios da mesma regi&atild
e;o. Dessa    maneira, o cons&oacute;rcio intermunicipal para a aquisi&ccedil;&a
tilde;o de    medicamentos pode ser uma importante ferramenta para a melhoria da
 gest&atilde;o    da Assist&ecirc;ncia Farmac&ecirc;utica.</font></p>     ^cY#21
96.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#58#54#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00342000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704010700080002000900187#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#59#55#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="3"><b>REFER&Ecirc;NCIAS</b></font><
/p>     ^cY#2196.htm##
00535000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077888000200080704028600082002000900368#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#60#56#article#75#1#<
p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">1. Ferraes AMB,   
 Cordoni Jr L. Cons&oacute;rcio de medicamentos no Paran&aacute;: an&aacute;lise
    de cobertura e custos. <i>Rev Adm Publica.</i> 2007;41(3):475-86. DOI:10.159
0/S0034-76122007000300005</font></p>     ^cY#2196.htm##
00504000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077888000200080704025500082002000900337#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#61#57#article#75#2#<
p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">2. Neves JA, Ribei
ro    JM. Cons&oacute;rcios de sa&uacute;de: estudo de caso exitoso. <i>Cad Saud
e    Publica.</i> 2006;22(10):2207-17. DOI:10.1590/S0102-311X2006001000027</font
></p>     ^cY#2196.htm##
00543000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077888000200080704029400082002000900376#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#62#58#article#75#3#<
p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">3. Nicoletto SCS, 
   Cordoni Jr L, Costa NR. Cons&oacute;rcios Intermunicipais de Sa&uacute;de: o 
   caso do Paran&aacute;, Brasil. <i>Cad Saude Publica.</i> 2005;21(1):29-38. DO
I:10.1590/S0102-311X2005000100004</font></p>     ^cY#2196.htm##
00538000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077888000200080704028900082002000900371#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#63#59#article#75#4#<
p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">4. Reis AMM, Perin
i    E. Desabastecimento de medicamentos: determinantes, conseq&uuml;&ecirc;ncia
s    e gerenciamento. <i>Cienc Saude Coletiva.</i> 2008:13(Supl):603-10. DOI:10.
1590/S1413-81232008000700009</font></p>     ^cY#2196.htm##
00540000000000157000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077888000200080704029100082002000900373#201
1nahead#V:\SciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#64#60#article#75#5#<
p><font face="Verdana, Arial, Helvetica, sans-serif" size="2">5. Vieira FS. Gast
o    do Minist&eacute;rio da Sa&uacute;de com medicamentos: tend&ecirc;ncia dos 
programas    de 2002 a 2007. <i>Rev Saude Publica.</i> 2009;43(4):674-81 . DOI:1
0.1590/S0034-89102009005000041</font></p>     ^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#65#61#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#66#62#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00451000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704021600080002000900296#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#67#63#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2"><a name="back"></a><a href="#top
"><img src="/img/revistas/rsp/2011nahead/seta.jpg" border="0"></a>    <b> Corres
pond&ecirc;ncia | Correspondence:    ^cY#2196.htm##
00274000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704003900080002000900119#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#68#64#article#75#<br>   </b> Car
ine Raquel Blatt    ^cY#2196.htm##
00287000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704005200080002000900132#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#69#65#article#75#<br>   Av. Jos&
eacute; Ac&aacute;cio Moreira    ^cY#2196.htm##
00289000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704005400080002000900134#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#70#66#article#75#<br>   Unisul/C
urso de Farm&aacute;cia, nº 787    ^cY#2196.htm##
00255000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002000080002000900100#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#71#67#article#75#<br>   Dehon   
 ^cY#2196.htm##
00286000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704005100080002000900131#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#72#68#article#75#<br>   88704-90
0 Tubar&atilde;o, SC, Brasil    ^cY#2196.htm##
00336000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704010100080002000900181#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#73#69#article#75#<br>   E-mail: 
<a href="mailto:carine.blatt@unisul.br">carine.blatt@unisul.br</a></font></p>   
  ^cY#2196.htm##
00325000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704009000080002000900170#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#74#70#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Recebido: 17/4/2010    ^cY#2196.
htm##
00282000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704004700080002000900127#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#75#71#article#75#<br>   Aprovado
: 14/11/2010</font></p>     ^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#76#72#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00257000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704002200080002000900102#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#77#73#article#75#<p>&nbsp;</p>  
   ^cY#2196.htm##
00369000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704013400080002000900214#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#78#74#article#75#<p><font face="
Verdana, Arial, Helvetica, sans-serif" size="2">Os autores declaram    n&atilde;
o haver conflito de interesses.    ^cY#2196.htm##
00464000000000145000450000400110000070200480001170500020005970600020006170000030
0063701000300066709000800069708000300077704022900080002000900309#2011nahead#V:\S
ciELO\serial\rsp\2011nahead\markup\2196.htm#S#p#79#75#article#75#<br>   Este art
igo teve a seguinte altera&ccedil;&atilde;o em 1/4/2011: corre&ccedil;&atilde;o 
   ortogr&aacute;fica da palavra no t&iacute;tulo em ingl&ecirc;s; onde se l&eci
rc;    Munipal, leia-se Municipal.</font></p>     ^cY#2196.htm##
00575000000000289000450000400110000070200480001170500020005970600020006170000030
00637010002000667090008000687080002000761180002000780100019000800100020000990120
07100119030001700190710000200207065000900209064000500218031000300223032000200226
014000700228237003200235865000900267002000900276#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2196.htm#S#c#80#1#article#5#1#^rND^sFerraes^nAMB#^rND^sCordon
i Jr^nL#Consórcio de medicamentos no Paraná: análise de cobertura e custos^lpt#R
ev Adm Publica.#2#20070000#2007#41#3#475-86#10.1590/S0034-76122007000300005#2011
0000#2196.htm##
00551000000000289000450000400110000070200480001170500020005970600020006170000030
00637010002000667090008000687080002000761180002000780100016000800100018000960120
04800114030001900162710000200181065000900183064000500192031000300197032000300200
014000800203237003200211865000900243002000900252#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2196.htm#S#c#81#2#article#5#2#^rND^sNeves^nJA#^rND^sRibeiro^n
JM#Consórcios de saúde: estudo de caso exitoso^lpt#Cad Saude Publica.#2#20060000
#2006#22#10#2207-17#10.1590/S0102-311X2006001000027#20110000#2196.htm##
00601000000000301000450000400110000070200480001170500020005970600020006170000030
00637010002000667090008000687080002000761180002000780100021000800100020001010100
01600121012006600137030001900203710000200222065000900224064000500233031000300238
032000200241014000600243237003200249865000900281002000900290#2011nahead#V:\SciEL
O\serial\rsp\2011nahead\markup\2196.htm#S#c#82#3#article#5#3#^rND^sNicoletto^nSC
S#^rND^sCordoni Jr^nL#^rND^sCosta^nNR#Consórcios Intermunicipais de Saúde: o cas
o do Paraná, Brasil^lpt#Cad Saude Publica.#2#20050000#2005#21#1#29-38#10.1590/S0
102-311X2005000100004#20110000#2196.htm##
00590000000000289000450000400110000070200480001170500020005970600020006170000030
00637010002000667090008000687080002000761180002000780100016000800100016000960120
08300112030002200195710000200217065000900219064000500228031000300233032000700236
014000700243237003200250865000900282002000900291#2011nahead#V:\SciELO\serial\rsp
\2011nahead\markup\2196.htm#S#c#83#4#article#5#4#^rND^sReis^nAMM#^rND^sPerini^nE
#Desabastecimento de medicamentos: determinantes, conseqüências e gerenciamento^
lpt#Cienc Saude Coletiva.#2#20080000#2008#13#^sSupl#603-10#10.1590/S1413-8123200
8000700009#20110000#2196.htm##
00562000000000277000450000400110000070200480001170500020005970600020006170000030
00637010002000667090008000687080002000761180002000780100017000800120090000970300
01900187710000200206065000900208064000500217031000300222032000200225014000700227
237003200234865000900266002000900275#2011nahead#V:\SciELO\serial\rsp\2011nahead\
markup\2196.htm#S#c#84#5#article#5#5#^rND^sVieira^nFS#Gasto do Ministério da Saú
de com medicamentos: tendência dos programas de 2002 a 2007^lpt#Rev Saude Public
a.#2#20090000#2009#43#4#674-81#10.1590/S0034-89102009005000041#20110000#2196.htm
##
